"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A3,WO 2002/019984 A3,143-537-966-823-554,2002-08-29,2002,US 0127634 W,2001-09-06,US 23142600 P,2000-09-08,STABLE EMULSIONS USEFUL FOR SKIN CARE WIPES,"The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsioncomprising: an acrylate/C10-C30 alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting of (i) a polymeric ether, (ii) a mixture of laurate esters of sorbitol and sorbital anhydrides condensed with ethylene oxide; and (iii) mixtures thereof. The invention also relates to a method for depositing salicylic acid to mammalian skin comprising topically applying the wipe product described above to the skin to be treated. The emulsion according to the invention produces an aesthetically pleasing product, capable of removing non-water proof make-up and able to deliver salicylic acid to the skin and is mild on the skin.",JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/143-537-966-823-554,Search Report,yes,1,1,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/02;;A61K8/33;;A61K8/00;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,1,0,,,"DATABASE CHEMICAL ABSTRACTS [online] XP002199761, retrieved from STN Database accession no. 115:189775",PATENTED
2,ES,T3,ES 2266252 T3,159-257-040-897-220,2007-03-01,2007,ES 01968574 T,2001-09-06,US 23142600 P,2000-09-08,EMULSIONES ESTABLES PARA TOALLITAS HUMEDAS PARA LA PIEL.,"Un producto en toallitas húmedas comprendiendo un sustrato y una emulsión, dicha emulsión constando de: (a) un emulsificante de polímero reticulado de acrilatos/acrilato de alquilo C10-C30; (b) ácido salicílico; y (c) un surfactante no iónico seleccionado del grupo que se compone de (i) un éter polímero, (ii) una mezcla de ésteres de laurato de sorbitol y anhídridos de sorbitol condensados con óxido de etileno, y (iii) mezclas de los mismos.",JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/159-257-040-897-220,Granted Patent,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
3,MX,A,MX PA03002048 A,181-535-311-661-987,2004-12-13,2004,MX PA03002048 A,2001-09-06,US 23142600 P;;US 0127634 W,2000-09-08,STABLE EMULSIONS USEFUL FOR SKIN CARE WIPES.,"The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsioncomprising: an acrylate/C10-C30 alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting of (i) a polymeric ether, (ii) a mixture of laurate esters of sorbitol and sorbital anhydrides condensed with ethylene oxide; and (iii) mixtures thereof. The invention also relates to a method for depositing salicylic acid to mammalian skin comprising topically applying the wipe product described above to the skin to be treated. The emulsion according to the invention produces an aesthetically pleasing product, capable of removing non-water proof make-up and able to deliver salicylic acid to the skin and is mild on the skin.",JOHNSON & JOHNSON,DUNN IAN,,https://lens.org/181-535-311-661-987,Patent Application,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
4,AU,A,AU 2001/088814 A,097-847-905-255-909,2002-03-22,2002,AU 2001/088814 A,2001-09-06,US 23142600 P;;US 0127634 W,2000-09-08,Stable emulsions useful for skin care wipes,,JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/097-847-905-255-909,Patent Application,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,PENDING
5,DE,T2,DE 60120775 T2,119-614-504-541-68X,2007-02-08,2007,DE 60120775 T,2001-09-06,US 23142600 P;;US 0127634 W,2000-09-08,"STABILE EMULSIONEN, DIE AUF TÜCHER FÜR DIE HAUTPFLEGE VERWENDBAR SIND",,JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/119-614-504-541-68X,Granted Patent,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
6,AT,T1,AT E329567 T1,119-772-037-350-158,2006-07-15,2006,AT 01968574 T,2001-09-06,US 23142600 P,2000-09-08,"STABILE EMULSIONEN, DIE AUF TÜCHER FÜR DIE HAUTPFLEGE VERWENDBAR SIND",,JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/119-772-037-350-158,Granted Patent,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
7,DE,D1,DE 60120775 D1,069-421-047-667-785,2006-07-27,2006,DE 60120775 T,2001-09-06,US 23142600 P;;US 0127634 W,2000-09-08,"STABILE EMULSIONEN, DIE AUF TÜCHER FÜR DIE HAUTPFLEGE VERWENDBAR SIND",,JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/069-421-047-667-785,Granted Patent,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
8,CA,A1,CA 2422199 A1,157-135-159-622-031,2002-03-14,2002,CA 2422199 A,2001-09-06,US 23142600 P;;US 0127634 W,2000-09-08,STABLE EMULSIONS USEFUL FOR SKIN CARE WIPES,"The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsioncomprising: an acrylate/C10-C30 alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting of (i) a polymeric ether, (ii) a mixture of laurate esters of sorbitol and sorbital anhydrides condensed with ethylene oxide; and (iii) mixtures thereo f. The invention also relates to a method for depositing salicylic acid to mammalian skin comprising topically applying the wipe product described abov e to the skin to be treated. The emulsion according to the invention produces an aesthetically pleasing product, capable of removing non-water proof make-up and able to deliver salicylic acid to the skin and is mild on the skin.</SDO AB>",JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/157-135-159-622-031,Patent Application,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,DISCONTINUED
9,WO,A2,WO 2002/019984 A2,173-460-603-496-22X,2002-03-14,2002,US 0127634 W,2001-09-06,US 23142600 P,2000-09-08,STABLE EMULSIONS USEFUL FOR SKIN CARE WIPES,"The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsioncomprising: an acrylate/C10-C30 alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting of (i) a polymeric ether, (ii) a mixture of laurate esters of sorbitol and sorbital anhydrides condensed with ethylene oxide; and (iii) mixtures thereof. The invention also relates to a method for depositing salicylic acid to mammalian skin comprising topically applying the wipe product described above to the skin to be treated. The emulsion according to the invention produces an aesthetically pleasing product, capable of removing non-water proof make-up and able to deliver salicylic acid to the skin and is mild on the skin.",JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/173-460-603-496-22X,Patent Application,yes,0,18,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/02;;A61K8/33;;A61K8/00;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,PATENTED
10,BR,A,BR 0113739 A,005-113-763-688-177,2003-07-22,2003,BR 0113739 A,2001-09-06,US 23142600 P;;US 0127634 W,2000-09-08,Emulsões estáveis úteis para lenços para o cuidado com a pele,"""EMULSõES ESTáVEIS úTEIS PARA LENçOS PARA O CUIDADO COM A PELE"". A invenção se refere a um produto para lenços umedecidos que compreende um substrato e uma emulsão. A emulsão compreendendo: um emulsificante de polímero reticulado de acrilato/acrilato de C~ 10~-C~ 30~ alquila; ácido salicílico; um tensoativo não-iónico; e um componente lipofílico. O tensoativo não-iónico é selecionado do grupo que consiste em (i) um éter polimérico, (ii) uma mistura de ésteres laurato de sorbitol e anidridos de sorbital condensados com óxido de etileno; e (iii) misturas dos mesmos. A invenção se refere ainda a um processo para depositar ácido salicílico na pele de mamíferos que compreende a aplicação tópica do produto para lenços descrito acima na pele que será tratada. A emulsão de acordo com a invenção produz um produto com satisfação estética, capaz de remover maquiagem que não é à prova d'água e capaz de distribuir ácido salicílico na pele e ser suave na mesma.",JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/005-113-763-688-177,Patent Application,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,DISCONTINUED
11,AU,B9,AU 2001/288814 B9,104-228-932-074-125,2006-11-23,2006,AU 2001/288814 A,2001-09-06,US 23142600 P;;US 0127634 W,2000-09-08,Stable emulsions useful for skin care wipes,,JOHNSON AND JOHNSON CONSUMER COMPANIES INC,DUNN IAN,,https://lens.org/104-228-932-074-125,Amended Patent,no,1,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61Q19/10;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
12,US,A1,US 2002/0123448 A1,026-694-484-363-468,2002-09-05,2002,US 94787701 A,2001-09-06,US 94787701 A;;US 23142600 P,2000-09-08,Stable emulsions useful for skin care wipes,"
    The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsion comprising: an acrylate/C ₁₀ -C ₃₀ alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting of (i) a polymeric ether, (ii) a mixture of laurate esters of sorbitol and sorbital anhydrides condensed with ethylene oxide; and (iii) mixtures thereof. The invention also relates to a method for depositing salicylic acid to mammalian skin comprising topically applying the wipe product described above to the skin to be treated. The emulsion according to the invention produces an aesthetically pleasing product, capable of removing non-water proof make-up and able to deliver salicylic acid to the skin and is mild on the skin. 
",DUNN IAN,DUNN IAN,JOHNSON & JOHNSON CONSUMER INC (2015-06-23);;JOHNSON & JOHNSON CONSUMER COMPANIES LLC (2015-06-23);;JOHNSON & JOHNSON CONSUMER COMPANIES INC (2001-11-20),https://lens.org/026-694-484-363-468,Patent Application,yes,0,9,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/02;;A61K8/00;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,510/421;;510/439;;510/475,0,0,,,,EXPIRED
13,AU,B2,AU 2001/288814 B2,075-784-427-058-412,2006-08-17,2006,AU 2001/288814 A,2001-09-06,US 23142600 P;;US 0127634 W,2000-09-08,Stable emulsions useful for skin care wipes,,JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/075-784-427-058-412,Granted Patent,no,1,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61Q19/10;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
14,PT,E,PT 1361855 E,103-385-845-925-131,2006-09-29,2006,PT 01968574 T,2001-09-06,US 23142600 P,2000-09-08,EMULSOES ESTAVEIS UTEIS PARA LENCOS HUMIDOS DERMICOS,,JOHNSON & JOHNSON CONSUMER,IAN DUNN,,https://lens.org/103-385-845-925-131,Granted Patent,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
15,DK,T3,DK 1361855 T3,173-790-695-809-386,2006-09-18,2006,DK 01968574 T,2001-09-06,US 23142600 P,2000-09-08,Stabile emulsioner egnede til hudplejeservietter,,JOHNSON & JOHNSON CONSUMER,DUNN IAN,,https://lens.org/173-790-695-809-386,Granted Patent,no,0,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
16,EP,B1,EP 1361855 B1,044-536-150-217-988,2006-06-14,2006,EP 01968574 A,2001-09-06,US 0127634 W;;US 23142600 P,2000-09-08,STABLE EMULSIONS USEFUL FOR SKIN CARE WIPES,,JOHNSON & JOHNSON CONSUMER,DUNN IAN,"JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (2007-10-30)",https://lens.org/044-536-150-217-988,Granted Patent,yes,1,0,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,1,0,,,"DATABASE CHEMICAL ABSTRACTS [Online] retrieved from STN Database accession no. 115:189775 XP002199761 & JP 03 070707 A (TAISHO PHARMACEUTICAL CO., LTD) 26 March 1991 (1991-03-26)",EXPIRED
17,US,B2,US 6696070 B2,118-066-118-476-719,2004-02-24,2004,US 94787701 A,2001-09-06,US 94787701 A;;US 23142600 P,2000-09-08,Stable emulsions useful for skin care wipes,"
    The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsion comprising: an acrylate/C _{ 10 } -C _{ 30 } alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting of (i) a polymeric ether, (ii) a mixture of laurate esters of sorbitol and sorbital anhydrides condensed with ethylene oxide; and (iii) mixtures thereof. The invention also relates to a method for depositing salicylic acid to mammalian skin comprising topically applying the wipe product described above to the skin to be treated. The emulsion according to the invention produces an aesthetically pleasing product, capable of removing non-water proof make-up and able to deliver salicylic acid to the skin and is mild on the skin. 
",JOHNSON & JOHNSON CONSUMER,DUNN IAN,JOHNSON & JOHNSON CONSUMER INC (2015-06-23);;JOHNSON & JOHNSON CONSUMER COMPANIES LLC (2015-06-23);;JOHNSON & JOHNSON CONSUMER COMPANIES INC (2001-11-20),https://lens.org/118-066-118-476-719,Granted Patent,yes,5,16,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,424/402;;424/400;;424/401;;424/78.03,4,0,,,"Database Chemical Abstracts Online retrieved from STN Database accession No. 115:189775 XP002199761 (JP 03 070707 A).;;""Cationic skin lotions formulated with pemulen(R) polymeric emulsifier"", Pemulen Polymeric Emulsifiers, 1995, 1-4.;;Clymans, D.R.J. et al., ""An alternative to traditional emulsifiers based on stability of multi-phase systems"", Polymeric Emulsifiers, B F Goodrich Chemical, pp 119-125.;;International Search Report for PCT/US 01/27634 datedJul. 3, 2002.",EXPIRED
18,EP,A2,EP 1361855 A2,014-433-510-826-825,2003-11-19,2003,EP 01968574 A,2001-09-06,US 0127634 W;;US 23142600 P,2000-09-08,STABLE EMULSIONS USEFUL FOR SKIN CARE WIPES,,JOHNSON & JOHNSON CONSUMER,DUNN IAN,"JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (2007-10-30)",https://lens.org/014-433-510-826-825,Patent Application,yes,0,3,22,22,0,A61K8/0208;;A61K8/8152;;A61K8/86;;A61K8/90;;A61K2800/75;;A61Q1/00;;A61Q19/00;;C11D1/66;;C11D1/667;;C11D1/72;;C11D1/825;;C11D3/2086;;C11D3/3707;;C11D3/3757;;C11D17/049;;A61K8/02;;A61K8/81;;A61K8/86;;A61K8/86;;C11D3/3757;;A61K8/8152;;C11D1/66;;C11D3/3707;;C11D3/2086;;A61K8/90;;C11D17/049;;A61Q1/00;;A61K8/0208;;A61K2800/75;;C11D1/667;;C11D1/72;;C11D1/825;;A61Q19/00,A61K8/00;;A61K8/02;;A61K8/33;;A61K8/34;;A61K8/37;;A61K8/39;;A61K8/40;;A61K8/81;;A61K8/86;;A61K8/89;;A61K8/891;;A61K8/90;;A61Q1/00;;A61Q1/02;;A61Q1/14;;A61Q19/00;;C11D1/66;;C11D1/72;;C11D1/825;;C11D3/20;;C11D3/37;;C11D17/04,,0,0,,,,EXPIRED
19,ZA,B,ZA 88575 B,103-512-207-074-669,1988-11-30,1988,ZA 88575 A,1988-01-28,ZW 2187 A,1987-02-02,APPLICATOR FOR BIOLOGICAL ACTIVE SUBSTANCE,,AGRICURA LTD,DUNN IAN MICHAEL,,https://lens.org/103-512-207-074-669,Granted Patent,no,0,0,3,3,0,A61D7/00;;A01K13/003,A01K13/00;;A61D7/00,,0,0,,,,EXPIRED
20,US,A1,US 2016/0166904 A1,193-108-419-025-965,2016-06-16,2016,US 201514967193 A,2015-12-11,US 201514967193 A;;US 201462090718 P,2014-12-11,Soccer Training Device,A training device assists soccer players to deflect a soccer ball by bouncing off a vertical wall. The vertical wall includes an anchor wall acting as a brace that extends at an angle where stakes pass through which allows the device to be anchored to ground. The device is made without moving parts as a stand-alone unit that is made by injection molding as a one-piece homogeneous construction. The device can be sold by itself or as a kit having multiple devices including a set of stakes.,BUSH IAN DUNN,BUSH IAN DUNN,,https://lens.org/193-108-419-025-965,Patent Application,yes,0,2,1,1,0,A63B69/002;;A63B69/002;;A63B69/0097;;A63B69/0097;;A63B2071/024;;A63B2071/024;;A63B2071/026;;A63B2071/026;;G09B19/0038;;G09B19/0038,A63B69/00;;G09B19/00,,0,0,,,,DISCONTINUED
21,NZ,A,NZ 714546 A,139-417-775-745-986,2021-10-29,2021,NZ 71454614 A,2014-06-04,US 2014/0040822 W;;US 201361831133 P,2013-06-04,Methods and compositions for templated assembly of nucleic acid specific heterocompounds,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/139-417-775-745-986,Patent Application,no,0,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,0,0,,,,PENDING
22,CN,A,CN 109563537 A,006-609-490-447-815,2019-04-02,2019,CN 201780038985 A,2017-05-22,US 201662339981 P;;US 2017/0033807 W,2016-05-23,METHODS FOR USING NUCLEIC ACID APTAMERS FOR DIRECTED TEMPLATED ASSEMBLY,"The present disclosure provides nucleic acid aptamers, nucleic acid aptamers hybridized to haplomers, methods of using nucleic acid aptamers to present template sequences, where the aptamers bind to target molecules unique to specific cellular targets, for the purpose of nucleic acid-templated assembly of molecules with desired functions.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/006-609-490-447-815,Patent Application,no,3,3,8,8,0,C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12N2310/531,C12Q1/6811;;C07H21/04;;C12Q1/6816,,1,0,,,"PAI等: ""Using RNA aptamers and the proximity ligation assay for the detection of cell surface antigens"", 《METHODS MOL BIOL》",ACTIVE
23,WO,A1,WO 2019/032942 A1,023-405-584-457-995,2019-02-14,2019,US 2018/0046179 W,2018-08-10,US 201762544010 P,2017-08-11,METHODS FOR GENERATING EPITOPES FOR BINDING TO RECOGNITION MOLECULES BY TEMPLATED ASSEMBLY,"The present disclosure provides polypeptides and polypeptide-nucleic acid conjugates comprising portions of epitopes, and methods of using target molecule binding components, such as aptamers, to present template sequences, where the target molecule binding components bind to target molecules unique to specific cellular targets, for the purpose of templated assembly of the epitopes for recognition molecules.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/023-405-584-457-995,Patent Application,yes,2,0,7,7,133,A61K45/06;;A61K47/549;;A61K47/66;;C07K14/001;;C07K14/001;;C07K7/00;;C07K16/1027;;C07K16/1235;;C07K16/18;;C07K16/2803;;C07K16/2863;;C07K16/32;;C07K2317/34;;C07K2317/55;;C12N15/115;;C12N15/115;;C12N2310/16;;C12N2310/16;;C12N2310/3513,C12N15/00;;A61K31/713;;C07K7/00;;C12N15/115,,1,0,,,See also references of EP 3665277A4,PENDING
24,SG,A,SG 10201710033P A,068-236-671-970-971,2018-01-30,2018,SG 10201710033P A,2014-06-04,US 201361831133 P,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/068-236-671-970-971,Unknown,no,0,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,,,0,0,,,,PENDING
25,WO,A1,WO 2018/094195 A1,065-136-240-695-544,2018-05-24,2018,US 2017/0062267 W,2017-11-17,US 201662424642 P,2016-11-21,METHODS FOR DIRECTED FOLDING ASSEMBLY OR DIMERIZATION OF PROTEINS BY TEMPLATED ASSEMBLY REACTIONS,"The present disclosure provides nucleic acid molecules, compositions, and kits comprising the same, and methods for producing templated assembly products.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/065-136-240-695-544,Patent Application,yes,2,0,8,8,54,A61K31/713;;C12N15/11;;C12N2310/3513;;C12N15/111;;C12N15/1068;;C07D401/12;;C07D401/14;;A61K31/713;;C12N15/11;;C12N2310/3513;;C12P19/34;;G01N33/50,C12N15/115;;A61K31/713,,1,0,,,See also references of EP 3541940A4,PENDING
26,EP,A1,EP 2153238 A1,076-742-827-649-933,2010-02-17,2010,EP 08750754 A,2008-05-19,GB 2008050359 W;;GB 0709475 A,2007-05-17,IMPROVEMENTS RELATING TO THE TESTING OF AN EARTH CONNECTION,,NEWSON GALE LTD,DUNN JOHN;;EDGE IAN,,https://lens.org/076-742-827-649-933,Patent Application,yes,0,1,10,10,0,G01R27/205;;G01R27/205;;G01R27/205;;H02H5/105,G01R27/20;;H05F3/02,,1,0,,,See references of WO 2008142447A1,ACTIVE
27,CN,A,CN 107208313 A,090-317-088-709-436,2017-09-26,2017,CN 201580071031 A,2015-12-02,US 201462086658 P;;US 201462086661 P;;US 2015/0063368 W,2014-12-02,Methods and kits for theranostic applications,"The present disclosure is directed to methods and kits for identifying, enriching, and evaluating templated assembly reactants. Some embodiments disclose methods for identifying templated assembly targets by synthesizing templated assembly reactants, hybridizing the templated assembly reactants to target nucleic acids, performing a templated assembly reaction, and identifying the target nucleic acids that hybridized to the templated assembly reactants. Libraries of templated assembly reactants, a kit for identifying templated assembly targets, and a pair of templated assembly targets enriched from a library of chemically-ligated oligonucleotides spatially elicited (CLOSE) products are also disclosed.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/090-317-088-709-436,Patent Application,no,13,0,12,12,0,C12N15/1093;;C12Q1/6816;;C40B20/00;;C12N15/1093;;C12Q1/6816;;C12Q2533/107;;C12Q2563/107;;C40B20/00;;C40B40/00,C40B40/00;;C12Q1/68;;C40B20/00,,1,0,,,"D HU等: ""Probing the structure of the PI-SceI-DNA complex by affinity cleavage and affinity photocross-linking"", 《J BIOL CHEM》",ACTIVE
28,EP,B1,EP 3004351 B1,097-614-724-664-298,2018-08-08,2018,EP 14807845 A,2014-06-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/097-614-724-664-298,Granted Patent,yes,7,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11;;C12N15/10;;C12Q1/68,,4,0,,,"WALDER J A ET AL: ""COMPLEMENTARY CARRIER PEPTIDE SYNTHESIS: GENERAL STRATEGY AND IMPLICATIONS FOR PREBIOTIC ORIGIN OF PEPTIDE SYNTHESIS"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 76, no. 1, 1 January 1979 (1979-01-01), pages 51-55, XP000857351, ISSN: 0027-8424, DOI: 10.1073/PNAS.76.1.51;;IMOTO S ET AL: ""DNA-templated click chemistry for creation of novel DNA binding molecules"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 20, 15 October 2008 (2008-10-15), pages 5660-5663, XP025562130, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.08.074 [retrieved on 2008-08-26];;ELLEN M. SLETTEN ET AL: ""From Mechanism to Mouse: A Tale of Two Bioorthogonal Reactions"", ACCOUNTS OF CHEMICAL RESEARCH, 1 January 2011 (2011-01-01), XP055014258, ISSN: 0001-4842, DOI: 10.1021/ar200148z;;SLETTEN ET AL.: 'From mechanism to mouse: a tale of two bioorthogonal reactions' ACC CHEM RES. vol. 44, no. 9, 15 August 2011, pages 666 - 676, XP055014258",ACTIVE
29,EP,A4,EP 3541415 A4,147-192-400-857-602,2020-10-14,2020,EP 17871984 A,2017-11-16,US 201662424689 P;;US 2017/0061907 W,2016-11-21,METHODS FOR SPLIT-PROTEIN TEMPLATE ASSEMBLY BY PROXIMITY-ENHANCED REACTIVITY,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/147-192-400-857-602,Search Report,no,6,0,7,7,0,C12N15/11;;C12N2310/3513;;A61P31/04;;A61P31/12;;A61P35/02;;A61P37/04;;A61P43/00;;C12N15/1068;;C12N15/111;;C07D257/08;;C12N15/1055;;C12N15/1068;;C12N15/1086;;C12N15/11;;C12N2310/3513;;C12N2310/531,C12N15/11;;A61K31/713;;C07D257/08;;C12N15/10,,7,6,016-207-722-887-053;;068-697-470-069-804;;026-182-044-545-082;;125-320-506-006-190;;055-673-221-473-04X;;051-153-390-690-93X,pmc4110906;;10.1016/j.bios.2011.12.055;;22386491;;18289876;;10.1016/j.pep.2008.01.009;;24898110;;10.1007/s10295-014-1466-8;;25218101;;10.1016/j.bios.2014.09.001;;10.1039/b822582f;;19462088;;10.1021/jf3027233;;23066909,"YUQING HE ET AL: ""Visual detection of single-base mismatches in DNA using hairpin oligonucleotide with double-target DNA binding sequences and gold nanoparticles"", BIOSENSORS AND BIOELECTRONICS, ELSEVIER SCIENCE LTD. UK, AMSTERDAM, NL, vol. 34, no. 1, 10 February 2012 (2012-02-10), pages 37 - 43, XP028468851, ISSN: 0956-5663, [retrieved on 20120210], DOI: 10.1016/J.BIOS.2011.12.055;;CHENG-GANG XU ET AL: ""Effect of location of the His-tag on the production of soluble and functional Buthus martensii Karsch insect toxin"", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, vol. 59, no. 1, 24 January 2008 (2008-01-24), pages 103 - 109, XP022561023, ISSN: 1046-5928, DOI: 10.1016/J.PEP.2008.01.009;;PRASHANT PYATI ET AL: ""Optimising expression of the recombinant fusion protein biopesticide [omega]-hexatoxin-Hv1a/GNA in Pichia pastoris: sequence modifications and a simple method for the generation of multi-copy strains"", JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, vol. 41, no. 8, 5 June 2014 (2014-06-05), pages 1237 - 1247, XP055171076, ISSN: 1367-5435, DOI: 10.1007/s10295-014-1466-8;;QING ZHOU: ""Synthesis of new tetrazines functionalized with photoactive and electroactive groups"", 2012. PHD THESIS. ÉCOLE NORMALE SUPÉRIEURE DE CACHAN-ENS CACHAN ZHOU, QING, 4 March 2013 (2013-03-04), XP055277966, Retrieved from the Internet <URL:https://hal.archives-ouvertes.fr/tel-00796461/document> [retrieved on 20160606];;YONG QIAN ET AL: ""A novel signal-on electrochemical DNA sensor based on target catalyzed hairpin assembly strategy"", BIOSENSORS AND BIOELECTRONICS, vol. 64, 6 September 2014 (2014-09-06), AMSTERDAM, NL, pages 177 - 181, XP055693512, ISSN: 0956-5663, DOI: 10.1016/j.bios.2014.09.001;;XUN MAO ET AL: ""Molecular beacon-functionalized gold nanoparticles as probes in dry-reagent strip biosensor for DNA analysis"", CHEMICAL COMMUNICATIONS, no. 21, 15 April 2009 (2009-04-15), pages 3065, XP055695031, ISSN: 1359-7345, DOI: 10.1039/b822582f;;XIULAN SUN ET AL: ""Electrochemical Detection of Peanut Allergen Ara h 1 Using a Sensitive DNA Biosensor Based on Stem-Loop Probe"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 60, no. 44, 15 October 2012 (2012-10-15), US, pages 10979 - 10984, XP055693567, ISSN: 0021-8561, DOI: 10.1021/jf3027233",PENDING
30,WO,A3,WO 2017/205277 A3,164-307-476-231-474,2018-01-04,2018,US 2017/0033807 W,2017-05-22,US 201662339981 P,2016-05-23,METHODS FOR USING NUCLEIC ACID APTAMERS FOR DIRECTED TEMPLATED ASSEMBLY,"The present disclosure provides nucleic acid aptamers, nucleic acid aptamers hybridized to haplomers, methods of using nucleic acid aptamers to present template sequences, where the aptamers bind to target molecules unique to specific cellular targets, for the purpose of nucleic acid-templated assembly of molecules with desired functions.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/164-307-476-231-474,Search Report,yes,1,0,8,8,13,C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12N2310/531,C12Q1/68;;C07H21/04,,1,1,038-449-181-279-185,10.1007/978-1-60327-569-9_21;;19159107,"vol. 504, 1 January 2009, ISSN: 1064-3745, article PAI ET AL.: ""Using RNA aptamers and the proximity ligation assay for the detection of cell surface antigens"", pages: 385 - 398, XP008173902, DOI: doi:10.1007/978-1-60327-569-9_21",PENDING
31,CA,A1,CA 3064197 A1,187-084-021-564-343,2017-11-30,2017,CA 3064197 A,2017-05-22,US 201662339981 P;;US 2017/0033807 W,2016-05-23,METHODS FOR USING NUCLEIC ACID APTAMERS FOR DIRECTED TEMPLATED ASSEMBLY,"The present disclosure provides nucleic acid aptamers, nucleic acid aptamers hybridized to haplomers, methods of using nucleic acid aptamers to present template sequences, where the aptamers bind to target molecules unique to specific cellular targets, for the purpose of nucleic acid-templated assembly of molecules with desired functions.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/187-084-021-564-343,Patent Application,no,0,0,8,8,13,C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12N2310/531,C12Q1/68;;C07H21/04;;C12N15/115,,0,0,,,,PENDING
32,CA,A1,CA 3072569 A1,035-746-426-671-938,2019-02-14,2019,CA 3072569 A,2018-08-10,US 201762544010 P;;US 2018/0046179 W,2017-08-11,METHODS FOR GENERATING EPITOPES FOR BINDING TO RECOGNITION MOLECULES BY TEMPLATED ASSEMBLY,"The present disclosure provides polypeptides and polypeptide-nucleic acid conjugates comprising portions of epitopes, and methods of using target molecule binding components, such as aptamers, to present template sequences, where the target molecule binding components bind to target molecules unique to specific cellular targets, for the purpose of templated assembly of the epitopes for recognition molecules.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/035-746-426-671-938,Patent Application,no,0,0,7,7,133,C07K7/00;;C07K14/001;;C12N15/115;;A61K45/06;;C12N2310/16;;C12N2310/3513;;C07K16/1027;;C07K16/1235;;C07K16/18;;C07K16/2803;;C07K16/2863;;C07K16/32;;C07K2317/34;;C07K2317/55;;A61K47/549;;A61K47/66;;C07K14/001;;C12N15/115;;C12N2310/16,C12N15/00;;A61K31/713;;C07K7/00;;C12N15/115,,0,0,,,,PENDING
33,EP,B1,EP 2153238 B1,084-706-748-206-482,2016-03-16,2016,EP 08750754 A,2008-05-19,GB 2008050359 W;;GB 0709475 A,2007-05-17,IMPROVEMENTS RELATING TO THE TESTING OF AN EARTH CONNECTION,,NEWSON GALE LTD,DUNN JOHN;;EDGE IAN,,https://lens.org/084-706-748-206-482,Granted Patent,yes,4,0,10,10,0,G01R27/205;;G01R27/205;;G01R27/205;;H02H5/105,G01R27/20;;H05F3/02,,0,0,,,,ACTIVE
34,EP,B1,EP 3227476 B1,054-015-450-429-05X,2021-02-24,2021,EP 15865336 A,2015-12-02,US 201462086658 P;;US 201462086661 P;;US 2015/0063368 W,2014-12-02,METHODS AND KITS FOR THERANOSTIC APPLICATIONS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/054-015-450-429-05X,Granted Patent,yes,1,0,12,12,0,C12N15/1093;;C12Q1/6816;;C40B20/00;;C12N15/1093;;C12Q1/6816;;C12Q2533/107;;C12Q2563/107;;C40B20/00;;C40B40/00,C12Q1/6816,,0,0,,,,ACTIVE
35,CN,A,CN 110191953 A,077-244-739-605-118,2019-08-30,2019,CN 201780084045 A,2017-11-16,US 201662424689 P;;US 2017/0061907 W,2016-11-21,METHODS FOR SPLIT-PROTEIN TEMPLATE ASSEMBLY BY PROXIMITY-ENHANCED REACTIVITY,"Compounds, composition, and kits are provided for use in methods for the assisted folding of protein fragments of a larger protein by means of induced proximity, forced by specific nucleic acid hybridizations between a target nucleic acid molecule and complementary nucleic acid molecules appended to the protein fragments of interest.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/077-244-739-605-118,Patent Application,no,7,1,7,7,0,C12N15/11;;C12N2310/3513;;A61P31/04;;A61P31/12;;A61P35/02;;A61P37/04;;A61P43/00;;C12N15/1068;;C12N15/111;;C07D257/08;;C12N15/1055;;C12N15/1068;;C12N15/1086;;C12N15/11;;C12N2310/3513;;C12N2310/531,C12N15/113;;A61K47/54;;A61K47/64;;C07D257/08;;C07K19/00,,3,0,,,"YUQING HE等: ""Visual detection of single-base mismatches in DNA using hairpin oligonucleotide with double-target DNA binding sequences and gold nanoparticles"", 《BIOSENSORS AND BIOELECTRONICS》;;YONGQIAN等: ""A novel signal-on electrochemical DNA sensor based on target catalyzed hairpin assembly strategy"", 《BIOSENSORS AND BIOELECTRONICS》;;王永红: ""基于纳米材料信号增强的电化学生物传感器研究"", 《中国博士学位论文全文数据库（电子期刊）工程科技I辑》",DISCONTINUED
36,AU,A1,AU 2014/275010 A1,189-185-652-282-313,2015-12-17,2015,AU 2014/275010 A,2014-06-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,Methods and compositions for templated assembly of nucleic acid specific heterocompounds,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/189-185-652-282-313,Patent Application,no,0,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,0,0,,,,ACTIVE
37,CA,A1,CA 2950117 A1,017-318-780-265-023,2014-12-11,2014,CA 2950117 A,2014-06-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/017-318-780-265-023,Patent Application,no,0,0,23,23,12,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,0,0,,,,PENDING
38,HK,A1,HK 1222201 A1,144-124-460-657-043,2017-06-23,2017,HK 16110443 A,2016-09-01,US 2014/0040822 W;;US 201361831133 P,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,,TRIBIOTICA LLC,IAN DUNN;;MATTHEW LAWLER,,https://lens.org/144-124-460-657-043,Patent Application,no,0,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N/,,0,0,,,,PENDING
39,CA,A1,CA 2968552 A1,196-052-499-038-326,2016-06-09,2016,CA 2968552 A,2015-12-02,US 201462086658 P;;US 201462086661 P;;US 2015/0063368 W,2014-12-02,METHODS AND KITS FOR THERANOSTIC APPLICATIONS,"The present disclosure is directed to methods and kits for identifying, enriching, and evaluating templated assembly reactants. Some embodiments disclose methods for identifying templated assembly targets by synthesizing templated assembly reactants, hybridizing the templated assembly reactants to target nucleic acids, performing a templated assembly reaction, and identifying the target nucleic acids that hybridized to the templated assembly reactants. Libraries of templated assembly reactants, a kit for identifying templated assembly targets, and a pair of templated assembly targets enriched from a library of chemically-ligated oligonucleotides spatially elicited (CLOSE) products are also disclosed.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/196-052-499-038-326,Patent Application,no,0,0,12,12,91,C12N15/1093;;C12Q1/6816;;C40B20/00;;C12N15/1093;;C12Q1/6816;;C12Q2533/107;;C12Q2563/107;;C40B20/00;;C40B40/00,C40B40/00;;C12Q1/68;;C40B20/00,,0,0,,,,PENDING
40,EP,A4,EP 3541940 A4,054-674-063-659-76X,2020-10-14,2020,EP 17871569 A,2017-11-17,US 201662424642 P;;US 2017/0062267 W,2016-11-21,METHODS FOR DIRECTED FOLDING ASSEMBLY OR DIMERIZATION OF PROTEINS BY TEMPLATED ASSEMBLY REACTIONS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/054-674-063-659-76X,Search Report,no,6,0,8,8,0,A61K31/713;;C12N15/11;;C12N2310/3513;;C12N15/111;;C12N15/1068;;C07D401/12;;C07D401/14;;A61K31/713;;C12N15/11;;C12N2310/3513;;C12P19/34;;G01N33/50,C12N15/11;;A61K31/713;;C07D207/40;;C12N15/10,,7,6,008-226-040-770-53X;;004-076-748-860-008;;112-482-603-084-027;;055-673-221-473-04X;;060-638-475-568-054;;040-681-123-017-943,22664266;;10.1016/j.nbt.2012.05.005;;pmc2651805;;19174562;;10.1093/nar/gkp020;;10.1021/ja102635c;;pmc2901626;;20550198;;10.1039/b822582f;;19462088;;8290352;;pmc310473;;10.1093/nar/21.25.5909;;10.1039/c1mb05025g;;21487580,"GUCCI JIJUAN GU ET AL: ""Protein tag-mediated conjugation of oligonucleotides to recombinant affinity binders for proximity ligation"", NEW BIOTECHNOLOGY, vol. 30, no. 2, 1 June 2012 (2012-06-01), NL, pages 144 - 152, XP055694790, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2012.05.005;;S. ZIMNIK ET AL: ""Mutually exclusive STAT1 modifications identified by Ubc9/substrate dimerization-dependent SUMOylation"", NUCLEIC ACIDS RESEARCH, vol. 37, no. 4, 18 December 2008 (2008-12-18), pages e30 - e30, XP055694776, ISSN: 0305-1048, DOI: 10.1093/nar/gkp020;;OSAMU NAKAGAWA ET AL: ""Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small-Molecule Ligands"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, no. 26, 15 June 2010 (2010-06-15), US, pages 8848 - 8849, XP055594660, ISSN: 0002-7863, DOI: 10.1021/ja102635c;;XUN MAO ET AL: ""Molecular beacon-functionalized gold nanoparticles as probes in dry-reagent strip biosensor for DNA analysis"", CHEMICAL COMMUNICATIONS, no. 21, 15 April 2009 (2009-04-15), pages 3065, XP055695031, ISSN: 1359-7345, DOI: 10.1039/b822582f;;GRYAZNOV S M AND LLOYD D H: ""Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions"", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD, vol. 21, no. 25, 25 December 1993 (1993-12-25), pages 5909 - 5915, XP002089282, ISSN: 0305-1048;;TIM SONNTAG ET AL: ""An intein-cassette integration approach used for the generation of a split TEV protease activated by conditional protein splicing"", MOLECULAR BIOSYSTEMS, vol. 7, no. 6, 12 April 2011 (2011-04-12), GB, pages 2031, XP055483931, ISSN: 1742-206X, DOI: 10.1039/c1mb05025g;;See also references of WO 2018094195A1",PENDING
41,US,A1,US 2021/0023227 A1,090-867-963-245-243,2021-01-28,2021,US 202016795968 A,2020-02-20,US 202016795968 A;;US 201514895398 A;;US 2014/0040822 W;;US 201361831133 P,2013-06-04,Methods And Compositions For Templated Assembly Of Nucleic Acid Specific Heterocompounds,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed front the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2016-01-23),https://lens.org/090-867-963-245-243,Patent Application,yes,1,0,23,23,12,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,A61K47/54;;A61K39/00;;C12N15/10;;C12N15/11;;C12N15/113,,0,0,,,,PENDING
42,ZA,B,ZA 201600024 B,191-561-066-153-71X,2019-04-24,2019,ZA 201600024 A,2016-01-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,,TRIBIOTICA LLC,IAN DUNN;;MATTHEW LAWLER,,https://lens.org/191-561-066-153-71X,Granted Patent,no,0,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,,,0,0,,,,ACTIVE
43,US,A1,US 2023/0193244 A1,038-917-265-140-759,2023-06-22,2023,US 201716462337 A,2017-11-16,US 201716462337 A;;US 201662424689 P;;US 2017/0061907 W,2016-11-21,Methods For Split-Protein Template Assembly By Proximity-Enhanced Reactivity,"Compounds, composition, and kits are provided for use in methods for the assisted folding of protein fragments of a of choice point larger protein by means of induced proximity, forced by specific nucleic acid hybridizations between a target nucleic acid molecule and complementary nucleic acid molecules appended to the protein fragments of interest.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2019-07-11),https://lens.org/038-917-265-140-759,Patent Application,yes,0,0,7,7,59,C12N15/11;;C12N2310/3513;;A61P31/04;;A61P31/12;;A61P35/02;;A61P37/04;;A61P43/00;;C12N15/1068;;C12N15/111;;C07D257/08;;C12N15/1055;;C12N15/1068;;C12N15/1086;;C12N15/11;;C12N2310/3513;;C12N2310/531,C12N15/10;;C12N15/11,,0,0,,,,PENDING
44,EP,A2,EP 3541415 A2,069-001-636-253-563,2019-09-25,2019,EP 17871984 A,2017-11-16,US 201662424689 P;;US 2017/0061907 W,2016-11-21,METHODS FOR SPLIT-PROTEIN TEMPLATE ASSEMBLY BY PROXIMITY-ENHANCED REACTIVITY,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/069-001-636-253-563,Patent Application,yes,0,0,7,7,59,C12N15/11;;C12N2310/3513;;A61P31/04;;A61P31/12;;A61P35/02;;A61P37/04;;A61P43/00;;C12N15/1068;;C12N15/111;;C07D257/08;;C12N15/1055;;C12N15/1068;;C12N15/1086;;C12N15/11;;C12N2310/3513;;C12N2310/531,A61K39/00;;A61K47/54,,0,0,,,,PENDING
45,EP,A1,EP 3541940 A1,106-671-757-943-627,2019-09-25,2019,EP 17871569 A,2017-11-17,US 201662424642 P;;US 2017/0062267 W,2016-11-21,METHODS FOR DIRECTED FOLDING ASSEMBLY OR DIMERIZATION OF PROTEINS BY TEMPLATED ASSEMBLY REACTIONS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/106-671-757-943-627,Patent Application,yes,0,0,8,8,54,A61K31/713;;C12N15/11;;C12N2310/3513;;C12N15/111;;C12N15/1068;;C07D401/12;;C07D401/14;;A61K31/713;;C12N15/11;;C12N2310/3513;;C12P19/34;;G01N33/50,C12N15/115;;A61K31/713,,0,0,,,,PENDING
46,GB,B,GB 2449285 B,013-998-950-932-092,2010-08-11,2010,GB 0709475 A,2007-05-17,GB 0709475 A,2007-05-17,Improvements relating to the testing of an earth connection,,NEWSON GALE LTD,DUNN JOHN;;EDGE IAN,,https://lens.org/013-998-950-932-092,Granted Patent,no,3,0,10,10,0,G01R27/205;;G01R27/205;;G01R27/205;;H02H5/105,G01R27/20;;H02H5/10,,0,0,,,,ACTIVE
47,WO,A1,WO 2008/142447 A1,054-528-052-614-309,2008-11-27,2008,GB 2008050359 W,2008-05-19,GB 0709475 A,2007-05-17,IMPROVEMENTS RELATING TO THE TESTING OF AN EARTH CONNECTION,"A device (10) is disclosed that is suitable for testing an earth connection (30) that is isolated from a mains electricity supply. The device (10) comprises means (14, 40) for electrically connecting the device(10) to the earth connection (30), and means (16, 32) for electrically connecting the device (10) to an electrically conductive item (20) having a capacitance relative to an adjacent surface of the earth that is within a pre-determined range of capacitances. Furthermore, the device (10) includes means for generating an AC signal and delivering the AC signal to the electrically conductive item, and means for determining whether the resistance between the earth connection (30) and earth reference potential is less than a maximum earth resistance value. This determination is achieved by comparing the frequency of the generated AC signal with a pre-determined range of frequencies.",NEWSON GALE LTD;;DUNN JOHN;;EDGE IAN,DUNN JOHN;;EDGE IAN,,https://lens.org/054-528-052-614-309,Patent Application,yes,4,0,10,10,0,G01R27/205;;G01R27/205;;G01R27/205;;H02H5/105,G01R27/20;;H05F3/02,,0,0,,,,PENDING
48,EP,A1,EP 3541952 A1,055-905-757-896-067,2019-09-25,2019,EP 17872434 A,2017-11-16,US 201662424607 P;;US 2017/0062048 W,2016-11-21,METHODS FOR PREVENTING TITRATION OF BIMOLECULAR TEMPLATED ASSEMBLY REACTIONS BY STRUCTURALLY-DETERMINED DIFFERENTIAL HYBRIDIZATIONS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/055-905-757-896-067,Patent Application,yes,0,0,6,6,24,C12Q1/6818;;C07H21/00;;C12N15/113;;C12N2310/14,C12Q1/68;;C07H21/00;;C07H21/02;;C07H21/04;;C12P19/34,,0,0,,,,DISCONTINUED
49,US,B2,US 10704084 B2,066-125-252-884-804,2020-07-07,2020,US 201515529807 A,2015-12-02,US 201515529807 A;;US 201462086658 P;;US 201462086661 P;;US 2015/0063368 W,2014-12-02,Methods and kits for theranostic applications,"The present disclosure is directed to methods and kits for identifying, enriching, and evaluating templated assembly reactants. Some embodiments disclose methods for identifying templated assembly targets by synthesizing templated assembly reactants, hybridizing the templated assembly reactants to target nucleic acids, performing a templated assembly reaction, and identifying the target nucleic acids that hybridized to the templated assembly reactants. Libraries of templated assembly reactants, a kit for identifying templated assembly targets, and a pair of templated assembly targets enriched from a library of chemically-ligated oligonucleotides spatially elicited (CLOSE) products are also disclosed.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2017-12-13),https://lens.org/066-125-252-884-804,Granted Patent,yes,33,0,12,12,126,C12N15/1093;;C12Q1/6816;;C40B20/00;;C12N15/1093;;C12Q1/6816;;C12Q2533/107;;C12Q2563/107;;C40B20/00;;C40B40/00,C12Q1/68;;C12N15/10;;C12Q1/6816;;C40B20/00;;C40B40/00,,30,22,030-948-819-976-189;;038-449-181-279-185;;164-676-346-718-413;;106-636-441-099-622;;012-853-994-047-956;;040-429-048-444-149;;028-837-355-337-456;;045-114-594-599-274;;014-906-721-248-911;;092-123-522-553-057;;057-636-778-723-958;;053-805-907-594-101;;050-799-140-429-305;;019-019-888-166-054;;040-757-070-736-108;;106-360-460-538-50X;;085-490-453-197-300;;131-237-725-144-008;;026-628-400-549-105;;036-127-074-364-531;;065-768-057-412-628;;012-782-624-537-805,10.1016/0888-7543(89)90280-2;;2744765;;10.1007/978-1-60327-569-9_21;;19159107;;21876785;;10.4061/2011/741723;;pmc3163130;;10.2174/1568026615666150330110131;;25858134;;10.1016/j.bmcl.2008.08.074;;18793850;;284368;;pmc382874;;10.1073/pnas.76.1.51;;pmc3182823;;18651678;;10.1002/anie.200705471;;17975674;;10.1172/jci32047;;pmc2045603;;16946459;;10.1107/s1744309106029125;;pmc2242885;;10.1021/ar200148z;;21838330;;pmc3184615;;10.1016/j.bmc.2008.02.047;;pmc2661128;;18314338;;pmc2851833;;17713909;;10.1021/ja073204p;;10.1021/ja073204p.s001;;10.1021/bc050283q;;16704214;;10.1021/ja309505c;;pmc3951380;;23210862;;10.1039/b809598a;;18843404;;pmc27912;;10.1073/pnas.95.18.10437;;9724721;;10.1002/cbic.200600150;;16897799;;10.1002/jmr.941;;19235144;;pmc3811213;;10.1128/aem.02033-13;;23956387;;12705589;;pmc4154785;;10.1021/ac020731c;;10.1055/s-0029-1219353;;22028936;;10.1371/journal.pone.0026691;;pmc3197676,"Wu et al, Genomics 4, 560 (1989).;;Pai et al., “Using RNA aptamers and the proximity ligation assay for the detection of cell surface antigens”, Methods Mol Biol, 2009, 504, pp. 385-398.;;Monroy-Contreras et al., “Molecular Beacons: Powerful Tools for Imaging RNA in Living Cells”, Journal of Nucleic Acids, 2011, 2011, pp. 1-15.;;Ponomarenko et al., “Recent advacnes in self-assembled fluorescent DNA structures and probes” Curr Top Med Chem, 2015, 15(13), pp. 1162-1178.;;Office Action dated Aug. 6, 2018 in U.S. Appl. No. 14/895,398.;;Restriction Requirement dated Mar. 28, 2017, issued in related U.S. Appl. No. 14/895,398.;;Imoto et al., “DNA-templated click chemistry for creation of novel DNA binding molecules” Bioorganic & Medicinal Chem Lett, 2008, 18(20), p. 5660-5663.;;Walder et al., “Complementary carrier peptide synthesis: general strategy and implications for prebiotic origin of peptide synthesis”, PNAS, 1979, 76(1), p. 51-55.;;Blanco-Canosa and Dawson, “An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation”, Angew Chem Int Ed Engl, 2008, 47(36), p. 6851-6855.;;Le Gall et al., “Protable flanking sequences modulate CTL epitope processing”, J Clin Invest 2007, 117(11), p. 3563-3575.;;Roosild et al., “Structure of anti-FLAG M2 Fab domain and its use in the stabilization of engineered membrane proteins”, Acta Crystallogr Sect F Struct Biol Cryst Commun, 2006, 62(9), p. 835-839.;;Sletten et al., “From mechanism to mouse: a tale of two bioorthogonal reactions”, Acc Chem Res, 2011, 44(9), p. 666-676.;;Tam and Raines, “Coulombic effects on the traceless Staudinger ligation in water” Bioorg Med Chem, 2009, 17(3), p. 1055-1063.;;Tam et al., “Water-souble phosphinothiols for traceless Staudinger ligation and integration with expressed protein ligation”, J Am Chem Soc, 2007, 129(37), p. 11421-11430.;;International Search Report and Written opinion for PCT/US2015/063368. (2016).;;Office Action dated Nov. 15, 2017 in related U.S. Appl. No. 14/895,398.;;Bendifallah et al., “Evaluation of Cell-Penetrating Peptides (CPPs) as Vehicles for Intracellular Delivery of Antisense Peptide Nucleic Acid (PNA)”, Bioconjugate Chem, 2006, 17, pp. 750-758.;;Kazane, et al., “Self-Assembled Antibody Multimers Through Peptide Nucleic Acid Conjugation”, JACS, 2012, 135, pp. 340-346.;;Zhao et al, “Solid-phase synthesis and evaluation of TAR RNA targeted beta-carboline-nucleoside conjugates”, Organic and Biomolecular Chemistry, 2008, 6(20), pp. 3741-3750.;;Clackson et al., “Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity”, PNAS USA, 1998, 95(18):10437-10442.;;Kalia et al., “Reactivity of Intein Thioesters: Appending a Functional Group to a Protein”, ChemBioChem, 2006, 7:1375-1383.;;Knecht et al., “Oligohis-tags: mechanisms of binding to Ni2+ surfaces”, J Mol Recognit, 2009, 22:270-279.;;Official Action dated Jun. 11, 2019 in related U.S. Appl. No. 14/895,398.;;Overkamp et al., “Benchmarking various green fluorescent protein variants in Bacillus subtilis, Streptococcus pneumoniae, and Lactococcus lactis for live cell imaging”, Appl Environ Microbiol, 2013, 79(20):6481-6490.;;Paulmurugan et al., “Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation”, Anal Chem, 2003, 75(7):1584-1589.;;Weisbrod et al., “Synthesis of Water-Soluble Phosphinophenol for Traceless Staudinger Ligation”, Synlett, 2010, 5:787-789.;;Official Action dated Aug. 6, 2018 in related U.S. Appl. No. 14/895,398.;;Niwayama et al., “A Pyrene Maleimide with a Flexible Linker for Sampling of Longer Inter-Thiol Distances by Excimer Formation”, PLoS One, 2011, 6(10), e26691.;;Notice of Allowance dated Nov. 21, 2019 related U.S. Appl. No. 14/895,398.;;Office Action dated Dec. 11, 2019 related U.S. Appl. No. 15/601,449.",ACTIVE
50,US,A1,US 2010/0301881 A1,152-294-716-561-11X,2010-12-02,2010,US 60020608 A,2008-05-19,GB 0709475 A;;GB 2008050359 W,2007-05-17,IMPROVEMENTS RELATING TO THE TESTING OF AN EARTH CONNECTION,"A device ( 10 ) is disclosed that is suitable for testing an earth connection ( 30 ) that is isolated from a mains electricity supply. The device ( 10 ) comprises means ( 14, 40 ) for electrically connecting the device ( 10 ) to the earth connection ( 30 ), and means ( 16, 32 ) for electrically connecting the device ( 10 ) to an electrically conductive item ( 20 ) having a capacitance relative to an adjacent surface of the earth that is within a pre-determined range of capacitances. Furthermore, the device ( 10 ) includes means for generating an AC signal and delivering the AC signal to the electrically conductive item, and means for determining whether the resistance between the earth connection ( 30 ) and earth reference potential is less than a maximum earth resistance value. This determination is achieved by comparing the frequency of the generated AC signal with a pre-determined range of frequencies.",NEWSON GALE LTD,DUNN JOHN;;EDGE IAN,NEWSON GALE LIMITED (2009-12-10),https://lens.org/152-294-716-561-11X,Patent Application,yes,6,3,10,10,0,G01R27/205;;G01R27/205;;G01R27/205;;H02H5/105,G01R27/08,324/691,0,0,,,,ACTIVE
51,US,A1,US 2021/0087612 A1,038-801-928-898-612,2021-03-25,2021,US 202016887497 A,2020-05-29,US 202016887497 A;;US 201715529807 A;;US 2015/0063368 W;;US 201462086658 P;;US 201462086661 P,2014-12-02,Methods And Kits For Theranostic Applications,"The present disclosure is directed to methods and kits for identifying, enriching, and evaluating templated assembly reactants. Some embodiments disclose methods for identifying templated assembly targets by synthesizing templated assembly reactants, hybridizing the templated assembly reactants to target nucleic acids, performing a templated assembly reaction, and identifying the target nucleic acids that hybridized to the templated assembly reactants. Libraries of templated assembly reactants, a kit for identifying templated assembly targets, and a pair of templated assembly targets enriched from a library of chemically-ligated oligonucleotides spatially elicited (CLOSE) products are also disclosed.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2017-12-13),https://lens.org/038-801-928-898-612,Patent Application,yes,0,0,12,12,126,C12N15/1093;;C12Q1/6816;;C40B20/00;;C12N15/1093;;C12Q1/6816;;C12Q2533/107;;C12Q2563/107;;C40B20/00;;C40B40/00,C12Q1/6816;;C12N15/10,,3,3,006-934-116-945-207;;004-443-663-444-082;;021-930-365-263-122,23076879;;10.1039/c2ob26163d;;10.4161/adna.27896;;25483841;;pmc4014522;;23775794;;10.1093/nar/gkt540;;pmc3753649,"Percivalle(Org. Biomol. Chem., 2013, 11, 16);;Litovchick (Artificial DNA: PNA & XNA 5, e27896; January; © 2014);;Seckute (Nucleic Acids Research, 2013, Vol. 41, No. 15 e148)",PENDING
52,US,A1,US 2022/0387471 A1,029-116-094-144-774,2022-12-08,2022,US 202217569792 A,2022-01-06,US 202217569792 A;;US 201916462332 A;;US 2017/0062267 W;;US 201662424642 P,2016-11-21,Methods For Directed Folding Assembly Or Dimerization Of Proteins By Templated Assembly Reactions,"The present disclosure provides nucleic acid molecules, compositions, and kits comprising the same, and methods for producing templated assembly products.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2019-07-11),https://lens.org/029-116-094-144-774,Patent Application,yes,0,0,8,8,54,A61K31/713;;C12N15/11;;C12N2310/3513;;C12N15/111;;C12N15/1068;;C07D401/12;;C07D401/14;;A61K31/713;;C12N15/11;;C12N2310/3513;;C12P19/34;;G01N33/50,A61K31/713;;C12N15/11;;C12P19/34;;G01N33/50,,0,0,,,,PENDING
53,CA,C,CA 2950117 C,095-188-596-254-910,2023-02-14,2023,CA 2950117 A,2014-06-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/095-188-596-254-910,Granted Patent,no,0,0,23,23,12,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,0,0,,,,PENDING
54,US,B2,US 8476913 B2,100-167-880-980-510,2013-07-02,2013,US 60020608 A,2008-05-19,GB 0709475 A;;GB 2008050359 W,2007-05-17,Improvements relating to the testing of an earth connection,"A device ( 10 ) is disclosed that is suitable for testing an earth connection ( 30 ) that is isolated from a mains electricity supply. The device ( 10 ) comprises means ( 14, 40 ) for electrically connecting the device ( 10 ) to the earth connection ( 30 ), and means ( 16, 32 ) for electrically connecting the device ( 10 ) to an electrically conductive item ( 20 ) having a capacitance relative to an adjacent surface of the earth that is within a pre-determined range of capacitances. Furthermore, the device ( 10 ) includes means for generating an AC signal and delivering the AC signal to the electrically conductive item, and means for determining whether the resistance between the earth connection ( 30 ) and earth reference potential is less than a maximum earth resistance value. This determination is achieved by comparing the frequency of the generated AC signal with a pre-determined range of frequencies.",DUNN JOHN;;EDGE IAN;;NEWSON GALE LTD,DUNN JOHN;;EDGE IAN,NEWSON GALE LIMITED (2009-12-10),https://lens.org/100-167-880-980-510,Granted Patent,yes,26,2,10,10,0,G01R27/205;;G01R27/205;;G01R27/205;;H02H5/105,G01R31/14;;H02H3/00,324/707;;324/509;;361/42,8,0,,,"International Search Report for International Patent Application No. PCT/GB2008/050359 (May 19, 2008).;;UK Search Report for Application No. GB0709475.8 (Apr. 29, 2008).;;""Earth-Rite Plus Dual mode (ATEX Specification) Static Ground Indicator and Interlock System for Road Tankers"" (English), Newson Gale Ltd, Nottingham, United Kingdom (Sep. 26, 2006).;;""Earth-Rite Plus with EExd IIB enclosure and 2-pole cable reel"", Installation and Operating Instructions, Newson Gale Ltd, Nottingham, United Kingdom(Feb. 24, 2006).;;""Earth-Rite Plus with EExd IIB enclosure and spiral cable"", Installation and Operating Instructions, Newson Gale Ltd, Nottingham, United Kingdom (Feb. 24, 2006).;;""Earth-Rite Plus with EExd IIC enclosure and spiral cable"", Installation and Operating Instructions, Newson Gale Ltd, Nottingham, United Kingdom, (Feb. 24, 2006).;;""Earth-Rite Plus Dual mode"" (USA), Newson Gale Ltd, Nottingham, United Kingdom, (Jul. 11, 2006).;;""Earth-Rite Plus Static Ground Indicator and Interlock System"" (UK Version), Newson Gale Ltd, Nottingham, United Kingdom (Jul. 11, 2006).",ACTIVE
55,CN,B,CN 101743483 B,132-089-277-843-650,2014-01-15,2014,CN 200880020795 A,2008-05-19,GB 2008050359 W;;GB 0709475 A,2007-05-17,Improvements relating to the testing of an earth connection,,NEWSON GALE LTD,DUNN JOHN;;EDGE IAN,,https://lens.org/132-089-277-843-650,Granted Patent,no,0,0,10,10,0,G01R27/205;;G01R27/205;;G01R27/205;;H02H5/105,G01R27/20;;H05F3/02,,0,0,,,,ACTIVE
56,EP,A2,EP 3464632 A2,129-031-459-902-949,2019-04-10,2019,EP 17803363 A,2017-05-22,US 201662339981 P;;US 2017/0033807 W,2016-05-23,METHODS FOR USING NUCLEIC ACID APTAMERS FOR DIRECTED TEMPLATED ASSEMBLY,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/129-031-459-902-949,Patent Application,yes,0,0,8,8,28,C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12N2310/531,C12Q1/68;;C07H21/04,,0,0,,,,PENDING
57,EP,A4,EP 3004351 A4,165-197-504-191-396,2016-12-21,2016,EP 14807845 A,2014-06-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/165-197-504-191-396,Search Report,no,1,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11;;C12N15/10;;C12Q1/68,,4,3,040-429-048-444-149;;012-853-994-047-956;;092-123-522-553-057,284368;;pmc382874;;10.1073/pnas.76.1.51;;10.1016/j.bmcl.2008.08.074;;18793850;;10.1021/ar200148z;;21838330;;pmc3184615,"WALDER J A ET AL: ""COMPLEMENTARY CARRIER PEPTIDE SYNTHESIS: GENERAL STRATEGY AND IMPLICATIONS FOR PREBIOTIC ORIGIN OF PEPTIDE SYNTHESIS"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 76, no. 1, 1 January 1979 (1979-01-01), pages 51 - 55, XP000857351, ISSN: 0027-8424, DOI: 10.1073/PNAS.76.1.51;;IMOTO S ET AL: ""DNA-templated click chemistry for creation of novel DNA binding molecules"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 20, 15 October 2008 (2008-10-15), pages 5660 - 5663, XP025562130, ISSN: 0960-894X, [retrieved on 20080826], DOI: 10.1016/J.BMCL.2008.08.074;;ELLEN M. SLETTEN ET AL: ""From Mechanism to Mouse: A Tale of Two Bioorthogonal Reactions"", ACCOUNTS OF CHEMICAL RESEARCH, 1 January 2011 (2011-01-01), XP055014258, ISSN: 0001-4842, DOI: 10.1021/ar200148z;;See also references of WO 2014197547A1",ACTIVE
58,US,B2,US 11186839 B2,179-176-102-149-49X,2021-11-30,2021,US 201716462324 A,2017-11-16,US 201716462324 A;;US 201662424607 P;;US 2017/0062048 W,2016-11-21,Methods for preventing titration of bimolecular templated assembly reactions by structurally-determined differential hybridizations,"The present disclosure provides nucleic acid molecules, and kits comprising the same, for producing templated assembly products for a cell.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2019-07-11),https://lens.org/179-176-102-149-49X,Granted Patent,yes,45,0,6,6,24,C12Q1/6818;;C07H21/00;;C12N15/113;;C12N2310/14,C12N15/113;;C07H21/00,,52,40,016-983-896-478-390;;021-719-120-620-511;;152-924-955-371-878;;008-226-040-770-53X;;016-207-722-887-053;;093-746-935-439-145;;060-638-475-568-054;;055-673-221-473-04X;;112-482-603-084-027;;026-182-044-545-082;;125-320-506-006-190;;040-681-123-017-943;;051-153-390-690-93X;;068-697-470-069-804;;023-068-910-964-278;;004-076-748-860-008;;012-782-624-537-805;;050-799-140-429-305;;028-837-355-337-456;;106-360-460-538-50X;;030-948-819-976-189;;012-853-994-047-956;;085-490-453-197-300;;019-019-888-166-054;;131-237-725-144-008;;045-114-594-599-274;;164-676-346-718-413;;026-628-400-549-105;;038-449-181-279-185;;036-127-074-364-531;;106-636-441-099-622;;014-906-721-248-911;;092-123-522-553-057;;057-636-778-723-958;;053-805-907-594-101;;040-429-048-444-149;;065-768-057-412-628;;040-757-070-736-108;;077-950-844-586-930;;024-218-233-248-166,10.1021/cr050266u;;17944519;;10.1016/j.cbpa.2012.05.198;;22704981;;10.1039/b901971p;;20309492;;22664266;;10.1016/j.nbt.2012.05.005;;pmc4110906;;10.1016/j.bios.2011.12.055;;22386491;;10.1039/c5an00566c;;25909387;;8290352;;pmc310473;;10.1093/nar/21.25.5909;;10.1039/b822582f;;19462088;;10.1021/ja102635c;;pmc2901626;;20550198;;24898110;;10.1007/s10295-014-1466-8;;25218101;;10.1016/j.bios.2014.09.001;;10.1039/c1mb05025g;;21487580;;10.1021/jf3027233;;23066909;;18289876;;10.1016/j.pep.2008.01.009;;27162146;;10.1016/j.bios.2016.05.010;;pmc2651805;;19174562;;10.1093/nar/gkp020;;22028936;;10.1371/journal.pone.0026691;;pmc3197676;;10.1021/bc050283q;;16704214;;pmc3182823;;18651678;;10.1002/anie.200705471;;pmc27912;;10.1073/pnas.95.18.10437;;9724721;;10.1016/0888-7543(89)90280-2;;2744765;;10.1016/j.bmcl.2008.08.074;;18793850;;10.1002/cbic.200600150;;16897799;;10.1021/ja309505c;;pmc3951380;;23210862;;10.1002/jmr.941;;19235144;;17975674;;10.1172/jci32047;;pmc2045603;;21876785;;10.4061/2011/741723;;pmc3163130;;pmc3811213;;10.1128/aem.02033-13;;23956387;;10.1007/978-1-60327-569-9_21;;19159107;;12705589;;pmc4154785;;10.1021/ac020731c;;10.2174/1568026615666150330110131;;25858134;;16946459;;10.1107/s1744309106029125;;pmc2242885;;10.1021/ar200148z;;21838330;;pmc3184615;;10.1016/j.bmc.2008.02.047;;pmc2661128;;18314338;;pmc2851833;;17713909;;10.1021/ja073204p;;10.1021/ja073204p.s001;;284368;;pmc382874;;10.1073/pnas.76.1.51;;10.1055/s-0029-1219353;;10.1039/b809598a;;18843404;;10.1016/j.molimm.2004.11.003;;15829301;;25699094;;pmc4329498;;10.7150/thno.10257,"Kaur et al., Chem Rev. 107 :4672 (Year: 2007).;;Pinheiro et al., Current Opinion in Chemical Biology 16 :245 (Year: 2012).;;El-Sagheer et al., “Click chemistry with DNA”, Chemical Society Reviews, 2010, 39(4), pp. 1388.;;Gu et al., “Protein tag-mediated conjugation of oligonucleotides to recombinant affinity binders for proximity ligation”, New Biotechnology, 2012, 30(2), pp. 144-152.;;He et al., “Visual detection of single-base mismatches in DNA using hairpin oligonucleotide with double-target DNA binding sequences and gold nanoparticles”, Biosensors and Bioelectronics, 2012, 34(1), pp. 37-43.;;Hu et al., “Simple and fast electrochemical detection of sequence-specific DNA via click chemistry-mediated labeling of hairpin DNA probes with ethylnylferrocene”, Analyst, 2015, 140(12), pp. 4154-4161.;;Lloyd et al., “Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions”, Nucleic Acids Research, 1993, 21(5), pp. 5909-5915.;;Mao et al., “Molecular beacon-functionalized gold nanoparticles as probes in dry-reagent strip biosensor for DNA analysis”, Chemical Communications, 2009, 21, pp. 3065.;;Nakagawa et al., “Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small-Molecule Ligands”, JACS, 2010, 132(26), pp. 8848-8849.;;Pyati et al., “Optimising expression of the recombinant fusion protein biopesticide [omega]-hexatoxin-Hv1a/GNA in Pichia pastoris: sequence modifications and a simple method for the generation of multi-copy strains”, Journal of Industrial Microbiology & Biotechnology, 2014, 41(8), pp. 1237-1247.;;Qian et al., “A novel signal-on electrochemical DNA sensor based on target catalyzed hairpin assembly strategy”, Biosensors and Bioelectronics, 2014, 64, pp. 177-181.;;Sonntag et al., “An intein-cassette integration approach used for the generation of a split TEV protease activated by conditional protein splicing”, Molecular Biosystems, 2011, 7(6), pp. 2031.;;Sun et al., “Electrochemical Detection of Peanut Allergan Ara h 1 Using a Sensitive DNA Biosensor Based on Stem-Loop Probe”, Journal of Agricultural and Food Chemistry, 2012, 60(44), p. 10979-10984.;;Xu et al., “Effect of location of the His-tag on the production of soluble and functional Buthus martensii Karsch insect toxin”, Protein Expression and Purification, 2008, 59(1), pp. 103-109.;;Yaqin et al., “Tenison promoted circular probe for highly selective microRNA detection and imaging”, Biosensors and Bioelectronics, 2016, 85, pp. 151-156.;;Zhou, “Synthesis of new tetrazines functionalized with photoactive and electroactive groups”, 2012, PhD Thesis, Ecole normale superieure de Cachan-ENS Cachan.;;Zimnik et al., “Mutually exclusive STAT1 modifications identified by Ubc9/substrate dimerization-dependent SUMOylation”, Nucleic Acids Research, 2008, 37(4), pp. e30.;;Final Official Action dated Jul. 28, 2020 in related U.S. Appl. No. 15/601,449.;;Official Action dated Dec. 11, 2019 in related U.S. Appl. No. 15/601,449.;;Official Action dated Dec. 6, 2019 in related U.S. Appl. No. 15/529,807.;;Notice of Allowance dated Nov. 21, 2019 in related U.S. Appl. No. 14/895,398.;;Niwayama et al., “A Pyrene Maleimide with a Flexible Linker for Sampling of Longer Inter-Thiol Distances by Excimer Formation”, PLoS ONE, 2011, 6(10), e26691.;;Bendifallah et al., “Evaluation of Cell-Penetrating Peptides (CPPs) as Vehicles for Intracellular Delivery of Antisense Peptide Nucleic Acid (PNA)”, Bioconjugate Chem., 2006, 17:750-758.;;Blanco-Canosa and Dawson, “An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation”, Angew Chem Int Ed Engl, 2008, 47(36):6851-6855.;;Clackson et al., “Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity”, PNAS USA, 1998, 95(18):10437-10442.;;D.Y. Wu and B. Wallace “The Ligation Amplification Reaction (LAR)—Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation”, Genomics, 1989, 4:560-569.;;Imoto et al., “DNA-template click chemistry for creation of novel DNA binding molecules”, Bioorganic & Medicinal Chem Lett, 2008, 18(20):5660-5663.;;International Search Report and Written Opinion for PCT/US2015/063368.;;Kalia et al., “Reactivity of Intein Thioesters: Appending a Functional Group to a Protein”, ChemBioChem, 2006, 7:1375-1383.;;Kazane et al., “Self-Assembled Antibody Multimers Through Peptide Nucleic Acid Conjugation”, JACS, 2012, 135:340-346.;;Knecht et al., “Oligohis-tags: mechanisms of binding to Ni2+ surfaces”, J Mol Recognit, 2009, 22:270-279.;;LeGall et al., “Protable flanking sequences modulate CTL epitope processing”, J Clin Invest, 2007, 117(11):3563-3575.;;Monroy-Contreras et al., “Molecular Beacons: Powerful Tools For Imaging RNA in Living Cells”, J Nuc Acids, 2011, 5-6.;;Official Action dated Aug. 6, 2018 in U.S. Appl. No. 14/895,398.;;Official Action dated Jun. 11, 2019 in related U.S. Appl. No. 14/895,398.;;Official Action dated Mar. 6, 2019 in related U.S. Appl. No. 15/529,807.;;Official Action dated Nov. 15, 2017 in related U.S. Appl. No. 14/895,398.;;Overkamp et al., “Benchmarking various green fluorescent protein variants in Bacillus subtilis, Streptococcus pneumoniae, and Lactococcus lactis for live cell imaging”, Appl Environ Microbiol, 2013, 79(20):6481-6490.;;Pai et al., “Using RNA aptamers and the proximity ligation assay for the detection of cell surface antigens”, Methods Mol Biol, 2009, 504:385-398.;;Paulmurugan et al., “Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation”, Anal Chem, 2003, 75(7):1584-1589.;;Ponomarenko et al., “Recent advances in self-assembled fluorescent DNA structures and probes”, Curr Top Med Chem, 2015, 15(13):1162-1178.;;Restriction Requirement dated Mar. 28, 2017, issued in related U.S. Appl. No. 14/895,398.;;Roosild et al., “Structure of anti-FLAG M2 Fab domain and its use in the stabilization of engineered membrane proteins”, Acta Crystallogr Sect F Struct Biol Cryst Commun, 2006, 62(9):835-839.;;Sletten et al., “From mechanism to mouse: a tale of two bioorthogonal reactions”, Acc Chem Res, 2011, 44(9):666-676.;;Tam and Raines, “Coulombic effects on the traceless Staudinger ligation in water”, Bioorg Med Chem, 2009, 17(3):1055-1063.;;Tam et al., “Water-soluble phosphinothiols for traceless Staudinger ligation and integration with expressed protein ligation”, J Am Chem Soc, 2007, 129(37):11421-11430.;;Walder et al., “Complementary carrier peptide synthesis: general strategy and implications for prebiotic origin of peptide synthesis”, PNAS, 1979, 76(1):51-55.;;Weisbrod et al., “Synthesis of Water-Soluble Phosphinophenol for Traceless Staudinger Ligation”, Synlett, 2010, 5:787-789.;;Zhao et al., “Solid-phase synthesis and evaluation of TAR RNA targeted beta-carboline-nucleoside conjugates”, Organic and Biomolecular Chemistry, 2008, 6(20):3741-3750.;;Notice of Allowance dated Mar. 2, 2020 in related U.S. Appl. No. 15/529,807.;;Riemer et al., “Matching of trastuzumab (Herceptin158 (R)) epitope mimics onto the surface of Her-2/neu—a new method of epitope definition”, Pergamon, 2005, 42(9), pp. 1121-1124.;;Wu et al., “Aptmpers: Active Targeting Ligands for Cancer Diagnosis and Therapy”, Theranostics, 2015, 5(4), pp. 322-344.",ACTIVE
59,WO,A1,WO 2018/094070 A1,037-847-752-020-669,2018-05-24,2018,US 2017/0062048 W,2017-11-16,US 201662424607 P,2016-11-21,METHODS FOR PREVENTING TITRATION OF BIMOLECULAR TEMPLATED ASSEMBLY REACTIONS BY STRUCTURALLY-DETERMINED DIFFERENTIAL HYBRIDIZATIONS,"The present disclosure provides nucleic acid molecules, and kits comprising the same, for producing templated assembly products for a cell.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/037-847-752-020-669,Patent Application,yes,0,0,6,6,24,C12Q1/6818;;C07H21/00;;C12N15/113;;C12N2310/14,C12Q1/68;;C07H21/00;;C07H21/02;;C07H21/04;;C12P19/34,,3,2,106-636-441-099-622;;164-676-346-718-413,10.2174/1568026615666150330110131;;25858134;;21876785;;10.4061/2011/741723;;pmc3163130,"PONOMARENKO ET AL.: ""Recent advances in self-assembled fluorescent DNA structures and Probes"", CURR TOP MED CHEM., vol. 15, no. 13, 2015, pages 1162 - 1178, XP055489118;;MONROY-CONTRERAS ET AL.: ""Molecular Beacons: Powerful Tools for Imaging RNA in Living Cells"", JOURNAL OF NUCLEIC ACIDS 2011, vol. 2011, no. ID 741723, XP055048718;;See also references of EP 3541952A4",PENDING
60,EP,A4,EP 3665277 A4,069-417-011-586-455,2021-05-12,2021,EP 18843336 A,2018-08-10,US 201762544010 P;;US 2018/0046179 W,2017-08-11,METHODS FOR GENERATING EPITOPES FOR BINDING TO RECOGNITION MOLECULES BY TEMPLATED ASSEMBLY,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/069-417-011-586-455,Search Report,no,1,0,7,7,0,A61K45/06;;A61K47/549;;A61K47/66;;C07K14/001;;C07K14/001;;C07K7/00;;C07K16/1027;;C07K16/1235;;C07K16/18;;C07K16/2803;;C07K16/2863;;C07K16/32;;C07K2317/34;;C07K2317/55;;C12N15/115;;C12N15/115;;C12N2310/16;;C12N2310/16;;C12N2310/3513,C12N15/00;;A61K31/713;;C07K7/00;;C12N15/115,,4,3,038-449-181-279-185;;077-950-844-586-930;;024-218-233-248-166,10.1007/978-1-60327-569-9_21;;19159107;;10.1016/j.molimm.2004.11.003;;15829301;;25699094;;pmc4329498;;10.7150/thno.10257,"PAI SUPRIYA S ET AL: ""Using RNA Aptamers and the Proximity Ligation Assay for the Detection of Cell Surface Antigens"", 1 January 2009, BIOSENSORS AND BIODETECTIONMETHODS IN MOLECULAR BIOLOGY; [METHODS IN MOLECULAR BIOLOGY; ISSN 1064-3745; VOL. 504], HUMANA PRESS, US, PAGE(S) 385 - 398, ISBN: 978-1-60327-568-2, XP008173902;;RIEMER A B ET AL: ""Matching of trastuzumab (Herceptin^(R)) epitope mimics onto the surface of Her-2/neu - a new method of epitope definition"", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 42, no. 9, 1 May 2005 (2005-05-01), pages 1121 - 1124, XP027635008, ISSN: 0161-5890, [retrieved on 20050501];;XU WU ET AL: ""Aptamers: Active Targeting Ligands for Cancer Diagnosis and Therapy"", THERANOSTICS, vol. 5, no. 4, 20 January 2015 (2015-01-20), AU, pages 322 - 344, XP055322092, ISSN: 1838-7640, DOI: 10.7150/thno.10257;;See also references of WO 2019032942A1",PENDING
61,EP,A4,EP 3464632 A4,065-120-789-004-337,2020-04-22,2020,EP 17803363 A,2017-05-22,US 201662339981 P;;US 2017/0033807 W,2016-05-23,METHODS FOR USING NUCLEIC ACID APTAMERS FOR DIRECTED TEMPLATED ASSEMBLY,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/065-120-789-004-337,Search Report,no,2,0,8,8,0,C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12N2310/531,C12Q1/68;;C07H21/04,,1,1,038-449-181-279-185,10.1007/978-1-60327-569-9_21;;19159107,"PAI SUPRIYA S ET AL: ""Using RNA Aptamers and the Proximity Ligation Assay for the Detection of Cell Surface Antigens"", 1 January 2009, BIOSENSORS AND BIODETECTIONMETHODS IN MOLECULAR BIOLOGY; [METHODS IN MOLECULAR BIOLOGY; ISSN 1064-3745; VOL. 504], HUMANA PRESS, US, PAGE(S) 385 - 398, ISBN: 978-1-60327-568-2, XP008173902",PENDING
62,US,B2,US 11253536 B2,108-049-163-820-85X,2022-02-22,2022,US 201716462332 A,2017-11-17,US 201716462332 A;;US 201662424642 P;;US 2017/0062267 W,2016-11-21,Methods for directed folding assembly or dimerization of proteins by templated assembly reactions,"The present disclosure provides nucleic acid molecules, compositions, and kits comprising the same, and methods for producing templated assembly products.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2019-07-11),https://lens.org/108-049-163-820-85X,Granted Patent,yes,46,0,8,8,54,A61K31/713;;C12N15/11;;C12N2310/3513;;C12N15/111;;C12N15/1068;;C07D401/12;;C07D401/14;;A61K31/713;;C12N15/11;;C12N2310/3513;;C12P19/34;;G01N33/50,A61K31/713;;C12N15/11;;C12P19/34;;G01N33/50,,69,49,002-131-277-090-356;;003-505-801-081-350;;152-924-955-371-878;;008-226-040-770-53X;;016-207-722-887-053;;093-746-935-439-145;;060-638-475-568-054;;055-673-221-473-04X;;112-482-603-084-027;;026-182-044-545-082;;125-320-506-006-190;;040-681-123-017-943;;051-153-390-690-93X;;068-697-470-069-804;;023-068-910-964-278;;004-076-748-860-008;;016-983-896-478-390;;021-719-120-620-511;;012-782-624-537-805;;077-950-844-586-930;;024-218-233-248-166;;050-799-140-429-305;;028-837-355-337-456;;106-360-460-538-50X;;030-948-819-976-189;;012-853-994-047-956;;085-490-453-197-300;;019-019-888-166-054;;131-237-725-144-008;;045-114-594-599-274;;164-676-346-718-413;;026-628-400-549-105;;038-449-181-279-185;;036-127-074-364-531;;106-636-441-099-622;;014-906-721-248-911;;092-123-522-553-057;;057-636-778-723-958;;053-805-907-594-101;;040-429-048-444-149;;065-768-057-412-628;;040-757-070-736-108;;094-711-958-775-578;;031-617-921-795-958;;001-344-857-157-767;;054-989-796-679-916;;012-349-780-054-648;;127-894-804-785-749;;001-843-305-790-552,26777239;;10.1016/j.jbiosc.2015.12.004;;20359299;;10.2144/000113354;;10.1039/b901971p;;20309492;;22664266;;10.1016/j.nbt.2012.05.005;;pmc4110906;;10.1016/j.bios.2011.12.055;;22386491;;10.1039/c5an00566c;;25909387;;8290352;;pmc310473;;10.1093/nar/21.25.5909;;10.1039/b822582f;;19462088;;10.1021/ja102635c;;pmc2901626;;20550198;;24898110;;10.1007/s10295-014-1466-8;;25218101;;10.1016/j.bios.2014.09.001;;10.1039/c1mb05025g;;21487580;;10.1021/jf3027233;;23066909;;18289876;;10.1016/j.pep.2008.01.009;;27162146;;10.1016/j.bios.2016.05.010;;pmc2651805;;19174562;;10.1093/nar/gkp020;;10.1021/cr050266u;;17944519;;10.1016/j.cbpa.2012.05.198;;22704981;;22028936;;10.1371/journal.pone.0026691;;pmc3197676;;10.1016/j.molimm.2004.11.003;;15829301;;25699094;;pmc4329498;;10.7150/thno.10257;;10.1021/bc050283q;;16704214;;pmc3182823;;18651678;;10.1002/anie.200705471;;pmc27912;;10.1073/pnas.95.18.10437;;9724721;;10.1016/0888-7543(89)90280-2;;2744765;;10.1016/j.bmcl.2008.08.074;;18793850;;10.1002/cbic.200600150;;16897799;;10.1021/ja309505c;;pmc3951380;;23210862;;10.1002/jmr.941;;19235144;;17975674;;10.1172/jci32047;;pmc2045603;;21876785;;10.4061/2011/741723;;pmc3163130;;pmc3811213;;10.1128/aem.02033-13;;23956387;;10.1007/978-1-60327-569-9_21;;19159107;;12705589;;pmc4154785;;10.1021/ac020731c;;10.2174/1568026615666150330110131;;25858134;;16946459;;10.1107/s1744309106029125;;pmc2242885;;10.1021/ar200148z;;21838330;;pmc3184615;;10.1016/j.bmc.2008.02.047;;pmc2661128;;18314338;;pmc2851833;;17713909;;10.1021/ja073204p;;10.1021/ja073204p.s001;;284368;;pmc382874;;10.1073/pnas.76.1.51;;10.1055/s-0029-1219353;;10.1039/b809598a;;18843404;;pmc5572134;;28146093;;10.3390/molecules22020215;;10.1371/journal.pone.0022471;;pmc3139652;;21811618;;27258484;;10.1016/j.biomaterials.2016.05.035;;10.1158/1078-0432.ccr-12-2067;;23460536;;29711117;;10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.3.co;2-v;;10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.0.co;2-3;;10.1093/nar/24.4.707;;8604314;;pmc145693;;10.1038/nbt1366;;18176556,"Inobe et al, Rapamycin-induced oligomer formation system of FRB-FKBP fusion proteins, 2016, Journal of Bioscience and Bioengineering, 122,40-46 (Year: 2016).;;Gajadhar et al , A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases, 2009, Biotechniques, 48, 145-152 (Year: 2009).;;Official Action dated Dec. 11, 2019 in related U.S. Appl. No. 15/601,449.;;Official Action dated Dec. 6, 2019 in related U.S. Appl. No. 15/529,807.;;Notice of Allowance dated Nov. 21, 2019 in related U.S. Appl. No. 14/895,398.;;El-Sagheer et al., “Click chemistry with DNA”, Chemical Society Reviews, 2010, 39(4), pp. 1388.;;Gu et al., “Protein tag-mediated conjugation of oligonucleotides to recombinant affinity binders for proximity ligation”, New Biotechnology, 2012, 30(2), pp. 144-152.;;He et al., “Visual detection of single-base mismatches in DNA using hairpin oligonucleotide with double-target DNA binding sequences and gold nanoparticles”, Biosensors and Bioelectronics, 2012, 34(1), pp. 37-43.;;Hu et al., “Simple and fast electrochemical detection of sequence-specific DNA via click chemistry-mediated labeling of hairpin DNA probes with ethylnylferrocene”, Analyst, 2015, 140(12), pp. 4154-4161.;;Lloyd et al., “Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions”, Nucleic Acids Research, 1993, 21(5), pp. 5909-5915.;;Mao et al., “Molecular beacon-functionalized gold nanoparticles as probes in dry-reagent strip biosensor for DNA analysis”, Chemical Communications, 2009, 21, pp. 3065.;;Nakagawa et al., “Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small-Molecule Ligands”, JACS, 2010, 132(26), pp. 8848-8849.;;Pyati et al., “Optimising expression of the recombinant fusion protein biopesticide [omega]-hexatoxin-Hv1a/GNA in Pichia pastoris: sequence modifications and a simple method for the generation of multi-copy strains”, Journal of Industrial Microbiology & Biotechnology, 2014, 41(8), pp. 1237-1247.;;Qian et al., “A novel signal-on electrochemical DNA sensor based on target catalyzed hairpin assembly strategy”, Biosensors and Bioelectronics, 2014, 64, pp. 177-181.;;Sonntag et al., “An intein-cassette integration approach used for the generation of a split TEV protease activated by conditional protein splicing”, Molecular Biosystems, 2011, 7(6), pp. 2031.;;Sun et al., “Electrochemical Detection of Peanut Allergan Ara h 1 Using a Sensitive DNA Biosensor Based on Stem-Loop Probe”, Journal of Agricultural and Food Chemistry, 2012, 60(44), pp. 10979-10984.;;Xu et al., “Effect of location of the His-tag on the production of soluble and functional Buthus martensii Karsch insect toxin”, Protein Expression and Purification, 2008, 59(1), pp. 103-109.;;Yaqin et al., “Tenison promoted circular probe for highly selective microRNA detection and imaging”, Biosensors and Bioelectronics, 2016, 85, pp. 151-156.;;Zhou, “Synthesis of new tetrazines functionalized with photoactive and electroactive groups”, 2012, PhD Thesis, Ecole normale superieure de Cachan-ENS Cachan.;;Zimnik et al., “Mutually exclusive STAT1 modifications identified by Ubc9/substrate dimerization-dependent SUMOylation”, Nucleic Acids Research, 2008, 37(4), pp. e30.;;Final Official Action dated Jul. 28, 2020 in related U.S. Appl. No. 15/601,449.;;Kaur et al., “Perspectives on Chemistry and Therapeutic Applications of Locked Nucleic Acid (LNA)”, Chem Rev, 2007, 107, pp. 4672-4697.;;Pinheiro et al., “The XNA world: progress towards replication and evolution of synthetic genetic polymers”, Current Opinion in Chemical Biology, 2012, 16, pp. 245-252.;;Non-Final Office Action dated Dec. 22, 2020 in related U.S. Appl. No. 16/462,324.;;Niwayama et al., “A Pyrene Maleimide with a Flexible Linker for Sampling of Longer Inter-Thiol Distances by Excimer Formation”, PLoS ONE, 2011, 6(10), e26691.;;Notice of Allowance dated Mar. 2, 2020 in related U.S. Appl. No. 15/529,807.;;Riemer et al., “Matching of trastuzumab (Herceptin∧(R)) epitope mimics onto the surface of Her-2/neu—a new method of epitope definition”, Pergamon, 2005, 42(9), pp. 1121-1124.;;Wu et al., “Aptmpers: Active Targeting Ligands for Cancer Diagnosis and Therapy”, Theranostics, 2015, 5(4), pp. 322-344.;;Bendifallah et al., “Evaluation of Cell-Penetrating Peptides (CPPs) as Vehicles for Intracellular Delivery of Antisense Peptide Nucleic Acid (PNA)”, Bioconjugate Chem., 2006, 17:750-758.;;Blanco-Canosa and Dawson, “An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation”, Angew Chem Int Ed Engl, 2008, 47(36):6851-6855.;;Clackson et al., “Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity”, PNAS USA, 1998, 95(18):10437-10442.;;D.Y. Wu and B. Wallace “The Ligation Amplification Reaction (LAR)—Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation”, Genomics, 1989, 4:560-569.;;Imoto et al., “DNA-template click chemistry for creation of novel DNA binding molecules”, Bioorganic & Medicinal Chem Lett, 2008, 18(20):5660-5663.;;International Search Report and Written Opinion for PCT/US2015/063368.;;Kalia et al., “Reactivity of Intein Thioesters: Appending a Functional Group to a Protein”, ChemBioChem, 2006, 7:1375-1383.;;Kazane et al., “Self-Assembled Antibody Multimers Through Peptide Nucleic Acid Conjugation”, JACS, 2012, 135:340-346.;;Knecht et al., “Oligohis-tags: mechanisms of binding to Ni2+ surfaces”, J Mol Recognit, 2009, 22:270-279.;;LeGall et al., “Protable flanking sequences modulate CTL epitope processing”, J Clin Invest, 2007, 117(11):3563-3575.;;Monroy-Contreras et al., “Molecular Beacons: Powerful Tools For Imaging RNA in Living Cells”, J Nuc Acids, 2011, 5-6.;;Official Action dated Aug. 6, 2018 in U.S. Appl. No. 14/895,398.;;Official Action dated Jun. 11, 2019 in related U.S. Appl. No. 14/895,398.;;Official Action dated Mar. 6, 2019 in related U.S. Appl. No. 15/529,807.;;Official Action dated Nov. 15, 2017 in related U.S. Appl. No. 14/895,398.;;Overkamp et al., “Benchmarking various green fluorescent protein variants in Bacillus subtilis, Streptococcus pneumoniae, and Lactococcus lactis for live cell imaging”, Appl Environ Microbiol, 2013, 79(20):6481-6490.;;Pai et al., “Using RNA aptamers and the proximity ligation assay for the detection of cell surface antigens”, Methods Mol Biol, 2009, 504:385-398.;;Paulmurugan et al., “Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation”, Anal Chem, 2003, 75(7):1584-1589.;;Ponomarenko et al., “Recent advances in self-assembled fluorescent DNA structures and probes”, Curr Top Med Chem, 2015, 15(13):1162-1178.;;Restriction Requirement dated Mar. 28, 2017, issued in related U.S. Appl. No. 14/895,398.;;Roosild et al., “Structure of anti-FLAG M2 Fab domain and its use in the stabilization of engineered membrane proteins”, Acta Crystallogr Sect F Struct Biol Cryst Commun, 2006, 62(9):835-839.;;Sletten et al., “From mechanism to mouse: a tale of two bioorthogonal reactions”, Acc Chem Res, 2011, 44(9):666-676.;;Tam and Raines, “Coulombic effects on the traceless Staudinger ligation in water”, Bioorg Med Chem, 2009, 17(3):1055-1063.;;Tam et al., “Water-soluble phosphinothiols fortraceless Staudinger ligation and integration with expressed protein ligation”, J Am Chem Soc, 2007, 129(37):11421-11430.;;Walder et al., “Complementary carrier peptide synthesis: general strategy and implications for prebiotic origin of peptide synthesis”, PNAS, 1979, 76(1):51-55.;;Weisbrod et al., “Synthesis of Water-Soluble Phosphinophenol for Traceless Staudinger Ligation”, Synlett, 2010, 6:787-789.;;Zhao et al., “Solid-phase synthesis and evaluation of TAR RNA targeted beta-carboline-nucleoside conjugates”, Organic and Biomolecular Chemistry, 2008, 6(20):3741-3750.;;Notice of Allowance dated Jul. 27, 2021 in related U.S. Appl. No. 16/462,324.;;Non-Final Office Action dated May 26, 2021 in related U.S. Appl. No. 16/637,858.;;GenBank entry KQ142094, uploaded 2015.;;Desai et al., “Geologists discover new extremophiles in anartic ice self”, blog “the swaddle”, http://theswaddle.com/geologists-discover-new-extremophiles-in-antarctic-ice-shelf/#:˜:text=Geologists%20have%20discovered%20a%20new, The%20discover%20was%20accidental., posted Feb. 2021.;;Mallikaratchy et al., “Evolution of complex target selex to identify aptamers against mammalian cell surface antigens”, Molecules, 2017, 22(215), pp. 1-12.;;Reynolds et al., “A functional proteomic method for biomarker discovery”, PLoS ONE, 2011, 6(7), pp. e22471.;;Park et al., “Hybridization based aptamer labeling using complementary oligonucleotide platform for PET and optical imaging”, Biomaterials, 2016, 100, pp. 143-151.;;Gilboa et al., “Use of oligonucleotide aptamer ligands to modulate the function of immune receptors”, Clin Canc Res, 2013, 19(5), pp. 1054-1063.;;Mammen et al., “Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors”, Angew Chem Int Ed, 1998, 37, pp. 2754-2494.;;Non-Final Office Action dated Aug. 17, 2021 in related U.S. Appl. No. 15/601,449.;;Final Office Action dated Oct. 5, 2021 in related U.S. Appl. No. 16/637,858.;;Ke et al., “The thermal stability of DNA fragments with tandem mismatches at a d(CXYG-d(CY′X′G) site”, Nucleic Acids Research, 1996, 24(4), pp. 707-712.;;Henke et al., “Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regular in vivo”. Nature Biotechnology, 2008, 26(1), pp. 91-100.;;Advisory Action dated Dec. 15, 2021 in related U.S. Appl. No. 16/637,858.",ACTIVE
63,US,A1,US 2019/0316131 A1,114-786-424-178-162,2019-10-17,2019,US 201716462324 A,2017-11-16,US 201716462324 A;;US 201662424607 P;;US 2017/0062048 W,2016-11-21,Methods For Preventing Titration Of Bimolecular Templated Assembly Reactions By Structurally-Determined Differential Hybridizations,"The present disclosure provides nucleic acid molecules, and kits comprising the same, for producing templated assembly products for a cell.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2019-07-11),https://lens.org/114-786-424-178-162,Patent Application,yes,0,1,6,6,24,C12Q1/6818;;C07H21/00;;C12N15/113;;C12N2310/14,C12N15/113,,0,0,,,,ACTIVE
64,WO,A3,WO 2018/093978 A3,026-657-626-578-606,2018-09-20,2018,US 2017/0061907 W,2017-11-16,US 201662424689 P,2016-11-21,METHODS FOR SPLIT-PROTEIN TEMPLATE ASSEMBLY BY PROXIMITY-ENHANCED REACTIVITY,"Compounds, composition, and kits are provided for use in methods for the assisted folding of protein fragments of a larger protein by means of induced proximity, forced by specific nucleic acid hybridizations between a target nucleic acid molecule and complementary nucleic acid molecules appended to the protein fragments of interest.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/026-657-626-578-606,Search Report,yes,2,0,7,7,59,C12N15/11;;C12N2310/3513;;A61P31/04;;A61P31/12;;A61P35/02;;A61P37/04;;A61P43/00;;C12N15/1068;;C12N15/111;;C07D257/08;;C12N15/1055;;C12N15/1068;;C12N15/1086;;C12N15/11;;C12N2310/3513;;C12N2310/531,A61K39/00;;A61K47/54,,2,2,019-019-888-166-054;;050-799-140-429-305,10.1021/ja309505c;;pmc3951380;;23210862;;10.1021/bc050283q;;16704214,"KAZANE, SA ET AL.: ""Self-Assembled Antibody Multimers Through Peptide Nucleic Acid Conjugation"", J. AM. CHEM. SOC., vol. 135, 4 December 2012 (2012-12-04), pages 340 - 346, XP055550671;;BENDIFALLAH, N ET AL.: ""Evaluation of Cell -Penetrating Peptides (CPPs) as Vehicles for Intracellular Delivery of Antisense Peptide Nucleic Acid (PNA"", BIOCONJUGATE CHEM, vol. 17, 22 March 2008 (2008-03-22), pages 750 - 758, XP002499767",PENDING
65,CN,A,CN 101743483 A,029-154-653-918-690,2010-06-16,2010,CN 200880020795 A,2008-05-19,GB 2008050359 W;;GB 0709475 A,2007-05-17,Improvements relating to the testing of an earth connection,"A device (10) is disclosed that is suitable for testing an earth connection (30) that is isolated from a mains electricity supply. The device (10) comprises means (14, 40) for electrically connecting the device(10) to the earth connection (30), and means (16, 32) for electrically connecting the device (10) to an electrically conductive item (20) having a capacitance relative to an adjacent surface of the earth that is within a pre-determined range of capacitances. Furthermore, the device (10) includes means for generating an AC signal and delivering the AC signal to the electrically conductive item, and means for determining whether the resistance between the earth connection (30) and earth reference potential is less than a maximum earth resistance value. This determination is achieved by comparing the frequency of the generated AC signal with a pre-determined range of frequencies.",NEWSON GALE LTD,JOHN DUNN;;IAN EDGE,,https://lens.org/029-154-653-918-690,Patent Application,no,0,5,10,10,0,G01R27/205;;G01R27/205;;G01R27/205;;H02H5/105,G01R27/20;;H05F3/02,,0,0,,,,ACTIVE
66,US,A1,US 2022/0106597 A1,051-686-198-854-377,2022-04-07,2022,US 202117509561 A,2021-10-25,US 202117509561 A;;US 201916462324 A;;US 2017/0062048 W;;US 201662424607 P,2016-11-21,Methods For Preventing Titration Of Bimolecular Templated Assembly Reactions By Structurally-Determined Differential Hybridizations,"The present disclosure provides nucleic acid molecules, and kits comprising the same, for producing templated assembly products for a cell.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2019-07-11),https://lens.org/051-686-198-854-377,Patent Application,yes,0,0,6,6,24,C12Q1/6818;;C07H21/00;;C12N15/113;;C12N2310/14,C12N15/113,,0,0,,,,PENDING
67,AU,B2,AU 2020/256386 B2,046-995-539-481-846,2023-07-27,2023,AU 2020/256386 A,2020-10-15,AU 2020/256386 A;;AU 2014/275010 A;;US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/046-995-539-481-846,Granted Patent,no,3,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,0,0,,,,ACTIVE
68,WO,A2,WO 2017/205277 A2,046-259-446-116-203,2017-11-30,2017,US 2017/0033807 W,2017-05-22,US 201662339981 P,2016-05-23,METHODS FOR USING NUCLEIC ACID APTAMERS FOR DIRECTED TEMPLATED ASSEMBLY,"The present disclosure provides nucleic acid aptamers, nucleic acid aptamers hybridized to haplomers, methods of using nucleic acid aptamers to present template sequences, where the aptamers bind to target molecules unique to specific cellular targets, for the purpose of nucleic acid-templated assembly of molecules with desired functions.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/046-259-446-116-203,Patent Application,yes,0,4,8,8,13,C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12N2310/531,C12N15/10;;C12N15/115,,0,0,,,,PENDING
69,SG,A,SG 11201509882W A,086-812-715-430-113,2016-01-28,2016,SG 11201509882W A,2014-06-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/086-812-715-430-113,Unknown,no,0,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,0,0,,,,PENDING
70,US,A1,US 2017/0335314 A1,096-761-023-239-436,2017-11-23,2017,US 201715601449 A,2017-05-22,US 201715601449 A;;US 201662339981 P,2016-05-23,Methods For Using Nucleic Acid Aptamers For Directed Templated Assembly,"The present disclosure provides nucleic acid aptamers, nucleic acid aptamers hybridized to haplomers, methods of using nucleic acid aptamers to present template sequences, where the aptamers bind to target molecules unique to specific cellular targets, for the purpose of nucleic acid-templated assembly of molecules with desired functions.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2017-06-23),https://lens.org/096-761-023-239-436,Patent Application,yes,1,5,8,8,13,C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12Q1/6811;;C12Q1/6816;;A61K31/713;;C12N15/1048;;C12N15/115;;C12N2310/16;;C12N2310/531,C12N15/10;;A61K31/713;;C12N15/115,,1,1,138-663-578-315-095,10.1002/anie.201403463;;25065762,"Liu et al (Angew. Chem. Int. Ed., Vol. 53, pages 10049-10055 (2014)). (Year: 2014)",DISCONTINUED
71,US,A1,US 2020/0247851 A1,151-715-084-101-911,2020-08-06,2020,US 201816637858 A,2018-08-10,US 201816637858 A;;US 201762544010 P;;US 2018/0046179 W,2017-08-11,Methods For Generating Epitopes For Binding To Recognition Molecules By Templated Assembly,"The present disclosure provides polypeptides and polypeptide-nucleic acid conjugates comprising portions of epitopes, and methods of using target molecule binding components, such as aptamers, to present template sequences, where the target molecule binding components bind to target molecules unique to specific cellular targets, for the purpose of templated assembly of the epitopes for recognition molecules.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2022-03-11),https://lens.org/151-715-084-101-911,Patent Application,yes,0,0,7,7,133,C07K7/00;;C07K14/001;;C12N15/115;;A61K45/06;;C12N2310/16;;C12N2310/3513;;C07K16/1027;;C07K16/1235;;C07K16/18;;C07K16/2803;;C07K16/2863;;C07K16/32;;C07K2317/34;;C07K2317/55;;A61K47/549;;A61K47/66;;C07K14/001;;C12N15/115;;C12N2310/16,C07K14/00;;C12N15/115,,3,2,093-098-539-502-648;;041-443-502-851-113,8413605;;10.1038/365520a0;;10.4061/2011/967098;;pmc3142669;;21822475,"Kim, Joseph L. et al; ""Co-crystal structure of tbp recognizing the minor groove of a tata element."" Nature (1993) 365 p520-527;;Nakano, Shu-ichi et al; ""Use of nucleic acid analogs for the study of nucleic acid interactions."" J. Nucleic Acids (2011) article ID 967098;;Lowe, Derek; ""Not alphafold's fault."" Blog “In the pipeline” entry of 7 Sept, 2022",PENDING
72,WO,A2,WO 2018/093978 A2,180-352-765-914-370,2018-05-24,2018,US 2017/0061907 W,2017-11-16,US 201662424689 P,2016-11-21,METHODS FOR SPLIT-PROTEIN TEMPLATE ASSEMBLY BY PROXIMITY-ENHANCED REACTIVITY,"Compounds, composition, and kits are provided for use in methods for the assisted folding of protein fragments of a larger protein by means of induced proximity, forced by specific nucleic acid hybridizations between a target nucleic acid molecule and complementary nucleic acid molecules appended to the protein fragments of interest.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/180-352-765-914-370,Patent Application,yes,0,4,7,7,59,C12N15/11;;C12N2310/3513;;A61P31/04;;A61P31/12;;A61P35/02;;A61P37/04;;A61P43/00;;C12N15/1068;;C12N15/111;;C07D257/08;;C12N15/1055;;C12N15/1068;;C12N15/1086;;C12N15/11;;C12N2310/3513;;C12N2310/531,,,0,0,,,,PENDING
73,CN,A,CN 110121559 A,162-771-382-427-472,2019-08-13,2019,CN 201780080921 A,2017-11-17,US 201662424642 P;;US 2017/0062267 W,2016-11-21,METHODS FOR DIRECTED FOLDING ASSEMBLY OR DIMERIZATION OF PROTEINS BY TEMPLATED ASSEMBLY REACTIONS,"The present disclosure provides nucleic acid molecules, compositions, and kits comprising the same, and methods for producing templated assembly products.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/162-771-382-427-472,Patent Application,no,6,0,8,8,0,A61K31/713;;C12N15/11;;C12N2310/3513;;C12N15/111;;C12N15/1068;;C07D401/12;;C07D401/14;;A61K31/713;;C12N15/11;;C12N2310/3513;;C12P19/34;;G01N33/50,C12N15/115;;A61K31/713,,3,0,,,"周孟华等: ""“G蛋白偶联受体的二聚化及其意义”"", 《现代医药卫生》;;AARON GAJADHAR等: ""“A proximity ligation assay using transiently transfected,epitope-tagged proteins:application for in situ detection of dimerized receptor tyrosine kinases”"", 《BIOTECHNIQUES》;;SUSAN ZIMNIK等: ""“Mutually exclusive STAT1 modifications identified by Ubc9/substrate dimerization-dependent SUMOylation”"", 《NUCLEIC ACIDS RES》",DISCONTINUED
74,US,A1,US 2018/0023123 A1,027-418-320-119-704,2018-01-25,2018,US 201515529807 A,2015-12-02,US 201515529807 A;;US 201462086658 P;;US 201462086661 P;;US 2015/0063368 W,2014-12-02,Methods And Kits For Theranostic Applications,"The present disclosure is directed to methods and kits for identifying, enriching, and evaluating templated assembly reactants. Some embodiments disclose methods for identifying templated assembly targets by synthesizing templated assembly reactants, hybridizing the templated assembly reactants to target nucleic acids, performing a templated assembly reaction, and identifying the target nucleic acids that hybridized to the templated assembly reactants. Libraries of templated assembly reactants, a kit for identifying templated assembly targets, and a pair of templated assembly targets enriched from a library of chemically-ligated oligonucleotides spatially elicited (CLOSE) products are also disclosed.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2017-12-13),https://lens.org/027-418-320-119-704,Patent Application,yes,2,2,12,12,91,C12N15/1093;;C12Q1/6816;;C40B20/00;;C12N15/1093;;C12Q1/6816;;C12Q2533/107;;C12Q2563/107;;C40B20/00;;C40B40/00,C12N15/10;;C12Q1/68,,0,0,,,,ACTIVE
75,EP,A1,EP 3004351 A1,047-914-034-792-816,2016-04-13,2016,EP 14807845 A,2014-06-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/047-914-034-792-816,Patent Application,yes,0,0,23,23,21,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11;;C12N15/10;;C12Q1/68,,0,0,,,,ACTIVE
76,AU,A1,AU 2020/256386 A1,066-736-249-145-413,2020-11-12,2020,AU 2020/256386 A,2020-10-15,AU 2020/256386 A;;AU 2014/275010 A;;US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/066-736-249-145-413,Patent Application,no,0,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,0,0,,,,ACTIVE
77,MX,A,MX 2015016371 A,139-904-570-767-602,2017-02-15,2017,MX 2015016371 A,2014-06-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS.,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,IAN DUNN;;MATTHEW LAWLER,,https://lens.org/139-904-570-767-602,Patent Application,no,0,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,0,0,,,,PENDING
78,EP,A4,EP 3227476 A4,047-331-695-299-821,2018-10-10,2018,EP 15865336 A,2015-12-02,US 201462086658 P;;US 201462086661 P;;US 2015/0063368 W,2014-12-02,METHODS AND KITS FOR THERANOSTIC APPLICATIONS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/047-331-695-299-821,Search Report,no,2,0,12,12,0,C12N15/1093;;C12Q1/6816;;C40B20/00;;C12N15/1093;;C12Q1/6816;;C12Q2533/107;;C12Q2563/107;;C40B20/00;;C40B40/00,C12Q1/68;;C40B20/00;;C40B40/00,,3,1,038-449-181-279-185,10.1007/978-1-60327-569-9_21;;19159107,"PAI SUPRIYA S ET AL: ""Using RNA Aptamers and the Proximity Ligation Assay for the Detection of Cell Surface Antigens"", 1 January 2009, BIOSENSORS AND BIODETECTIONMETHODS IN MOLECULAR BIO; [METHODS IN MOLECULAR BIOLOGY; ISSN 1064-3745; VOL. 504], HUMANA PRESS, US, PAGE(S) 385 - 398, ISBN: 978-1-60327-568-2, XP008173902;;PENG ZHAO ET AL: ""Solid-phase synthesis and evaluation of TAR RNA targeted β-carboline-nucleoside conjugates"", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 6, no. 20, 1 January 2008 (2008-01-01), pages 3741, XP055260950, ISSN: 1477-0520, DOI: 10.1039/b809598a;;See also references of WO 2016089958A1",ACTIVE
79,WO,A1,WO 2016/089958 A1,043-794-684-850-476,2016-06-09,2016,US 2015/0063368 W,2015-12-02,US 201462086658 P;;US 201462086661 P,2014-12-02,METHODS AND KITS FOR THERANOSTIC APPLICATIONS,"The present disclosure is directed to methods and kits for identifying, enriching, and evaluating templated assembly reactants. Some embodiments disclose methods for identifying templated assembly targets by synthesizing templated assembly reactants, hybridizing the templated assembly reactants to target nucleic acids, performing a templated assembly reaction, and identifying the target nucleic acids that hybridized to the templated assembly reactants. Libraries of templated assembly reactants, a kit for identifying templated assembly targets, and a pair of templated assembly targets enriched from a library of chemically-ligated oligonucleotides spatially elicited (CLOSE) products are also disclosed.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/043-794-684-850-476,Patent Application,yes,3,6,12,12,91,C12N15/1093;;C12Q1/6816;;C40B20/00;;C12N15/1093;;C12Q1/6816;;C12Q2533/107;;C12Q2563/107;;C40B20/00;;C40B40/00,C12Q1/68;;C40B40/00;;C40B20/00,,1,0,,,See also references of EP 3227476A4,PENDING
80,EP,A1,EP 3665277 A1,069-384-581-212-027,2020-06-17,2020,EP 18843336 A,2018-08-10,US 201762544010 P;;US 2018/0046179 W,2017-08-11,METHODS FOR GENERATING EPITOPES FOR BINDING TO RECOGNITION MOLECULES BY TEMPLATED ASSEMBLY,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/069-384-581-212-027,Patent Application,yes,0,0,7,7,133,A61K45/06;;A61K47/549;;A61K47/66;;C07K14/001;;C07K14/001;;C07K7/00;;C07K16/1027;;C07K16/1235;;C07K16/18;;C07K16/2803;;C07K16/2863;;C07K16/32;;C07K2317/34;;C07K2317/55;;C12N15/115;;C12N15/115;;C12N2310/16;;C12N2310/16;;C12N2310/3513,C12N15/00;;A61K31/713;;C07K7/00;;C12N15/115,,0,0,,,,PENDING
81,EP,A1,EP 3227476 A1,092-607-474-103-086,2017-10-11,2017,EP 15865336 A,2015-12-02,US 201462086658 P;;US 201462086661 P;;US 2015/0063368 W,2014-12-02,METHODS AND KITS FOR THERANOSTIC APPLICATIONS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/092-607-474-103-086,Patent Application,yes,0,0,12,12,91,C12N15/1093;;C12Q1/6816;;C40B20/00;;C12N15/1093;;C12Q1/6816;;C12Q2533/107;;C12Q2563/107;;C40B20/00;;C40B40/00,C40B40/00;;C12Q1/68;;C40B20/00,,0,0,,,,ACTIVE
82,WO,A1,WO 2014/197547 A1,160-027-041-590-636,2014-12-11,2014,US 2014/0040822 W,2014-06-04,US 201361831133 P,2013-06-04,METHODS AND COMPOSITIONS FOR TEMPLATED ASSEMBLY OF NUCLEIC ACID SPECIFIC HETEROCOMPOUNDS,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/160-027-041-590-636,Patent Application,yes,6,9,23,23,12,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,2,1,092-123-522-553-057,10.1021/ar200148z;;21838330;;pmc3184615,"SLETTEN ET AL.: ""From mechanism to mouse: a tale of two bioorthogonal reactions"", ACC CHEM RES., vol. 44, no. 9, 15 August 2011 (2011-08-15), pages 666 - 676, XP055014258;;See also references of EP 3004351A4",PENDING
83,US,B2,US 10603385 B2,187-706-206-828-02X,2020-03-31,2020,US 201414895398 A,2014-06-04,US 201414895398 A;;US 201361831133 P;;US 2014/0040822 W,2013-06-04,Methods and compositions for templated assembly of nucleic acid specific heterocompounds,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2016-01-23),https://lens.org/187-706-206-828-02X,Granted Patent,yes,32,0,23,23,12,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,A61K47/54;;A61K39/00;;C12N15/10;;C12N15/11;;C12N15/113,,25,22,028-837-355-337-456;;045-114-594-599-274;;014-906-721-248-911;;092-123-522-553-057;;057-636-778-723-958;;053-805-907-594-101;;012-853-994-047-956;;040-429-048-444-149;;038-449-181-279-185;;030-948-819-976-189;;050-799-140-429-305;;019-019-888-166-054;;164-676-346-718-413;;106-636-441-099-622;;040-757-070-736-108;;012-782-624-537-805;;106-360-460-538-50X;;085-490-453-197-300;;131-237-725-144-008;;065-768-057-412-628;;026-628-400-549-105;;036-127-074-364-531,pmc3182823;;18651678;;10.1002/anie.200705471;;17975674;;10.1172/jci32047;;pmc2045603;;16946459;;10.1107/s1744309106029125;;pmc2242885;;10.1021/ar200148z;;21838330;;pmc3184615;;10.1016/j.bmc.2008.02.047;;pmc2661128;;18314338;;pmc2851833;;17713909;;10.1021/ja073204p;;10.1021/ja073204p.s001;;10.1016/j.bmcl.2008.08.074;;18793850;;284368;;pmc382874;;10.1073/pnas.76.1.51;;10.1007/978-1-60327-569-9_21;;19159107;;10.1016/0888-7543(89)90280-2;;2744765;;10.1021/bc050283q;;16704214;;10.1021/ja309505c;;pmc3951380;;23210862;;21876785;;10.4061/2011/741723;;pmc3163130;;10.2174/1568026615666150330110131;;25858134;;10.1039/b809598a;;18843404;;22028936;;10.1371/journal.pone.0026691;;pmc3197676;;pmc27912;;10.1073/pnas.95.18.10437;;9724721;;10.1002/cbic.200600150;;16897799;;10.1002/jmr.941;;19235144;;10.1055/s-0029-1219353;;pmc3811213;;10.1128/aem.02033-13;;23956387;;12705589;;pmc4154785;;10.1021/ac020731c,"Blanco-Canosa and Dawson, An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation, Angew Chem Int Ed Engl 2008 47(36):6851-6855.;;Le Gall et al., Protable flanking sequences modulate CTL epitope processing, J Clin Invest 2007 117(11):3563-3575.;;Roosild et al., Structure of anti-FLAG M2 Fab domain and its use in the stabilization of engineered membrane proteins, Acta Crystallogr Sect F Struct Biol Cryst Commun 2006 62(9):835-839.;;Sletten et al., From mechanism to mouse: a tale of two bioorthogonal reactions, Acc Chem Res 2011 44(9):666-76.;;Tam and Raines, Coulombic effects on the traceless Staudinger ligation in water, Bioorg Med Chem 2009 17 (3):1055-1063.;;Tam et al., Water-soluble phosphinothiols for traceless Staudinger ligation and integration with expressed protein ligation, J Am Chem Soc 2007 129(37):11421-11430.;;Imoto et al., DNA-templated click chemistry for creation of novel DNA binding molecules, Bioorganic & Medicinal Chem Lett 2008 18(20):5660-5663.;;Walder et al., Complementary carrier peptide synthesis: general strategy and implications for prebiotic origin of peptide synthesis, PNAS 1979 76(1):51-55.;;Pai et al., “Using RNA aptamers and the proximity ligation assay for the detection of cell surface antigens”, Methods Mol Biol, 2009, 504, pp. 385-398.;;Official Action dated Mar. 6, 2019 in related U.S. Appl. No. 15/529,807.;;D.Y. Wu and B. Wallace “The Ligation Amplification Reaction (LAR)—Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation”, Genomics, 1989, 4:560-569.;;Bendifallah et al., “Evaluation of Cell-Penetrating Peptides (CPPs) as Vehicles for Intracellular Delivery of Antisense Peptide Nucleic Acid (PNA)”, Bioconjugate Chem, 2006, 17, pp. 750-758.;;Kazane, et al., “Self-Assembled Antibody Multimers Through Peptide Nucleic Acid Conjugation”, JACS, 2012, 135, pp. 340-346.;;Monroy-Contreras et al., “Molecular Beacons: Powerful Tools for Imaging RNA in Living Cells”, J Nuc Acids, 2011, pp. 5-6.;;Ponomarenko et al., “Recent advances in self-assembled fluorescent DNA structures and probes”, Curr Top Med Chem, 2015, 15(13), pp. 1162-1178.;;Zhao et al, “Solid-phase synthesis and evaluation of TAR RNA targeted beta-carboline-nucleoside conjugates”, Organic and Biomolecular Chemistry, 2008, 6(20), pp. 3741-3750.;;Niwayama et al., “A Pyrene Maleimide with a Flexible Linker for Sampling of Longer Inter-Thiol Distances by Excimer Formation”, PLoS ONE, 2011, 6(10), e26691.;;Clackson et al., “Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity”, PNAS USA, 1998, 95(18):10437-10442.;;Kalia et al., “Reactivity of Intein Thioesters: Appending a Functional Group to a Protein”, ChemBioChem, 2006, 7:1375-1383.;;Knecht et al., “Oligohis-tags: mechanisms of binding to Ni2+ surfaces”, J Mol Recognit, 2009, 22:270-279.;;Weisbrod et al., “Synthesis of Water-Soluble Phosphinophenol for Traceless Staudinger Ligation”, Synlett, 2010, 5:787-789.;;Overkamp et al., “Benchmarking various green fluorescent protein variants in Bacillus subtilis, Streptococcus pneumoniae, and Lactococcus lactis for live cell imaging”, Appl Environ Microbiol, 2013, 79(20):6481-6490.;;Paulmurugan et al., “Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation”, Anal Chem, 2003, 75(7):1584-1589.;;Official Action dated Dec. 6, 2019 in related U.S. Appl. No. 15/529,807.;;Official Action dated Dec. 11, 2019 in related U.S. Appl. No. 15/601,449.",ACTIVE
84,CN,A,CN 105358691 A,033-833-483-261-938,2016-02-24,2016,CN 201480038772 A,2014-06-04,US 2014/0040822 W;;US 201361831133 P,2013-06-04,Methods and compositions for templated assembly of nucleic acid specific heterocompounds,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/033-833-483-261-938,Patent Application,no,3,2,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,1,1,040-429-048-444-149,284368;;pmc382874;;10.1073/pnas.76.1.51,"WALDER J A ET AL.: ""COMPLEMENTARY CARRIER PEPTIDE SYNTHESIS：GENERAL STRATEGY AND IMPLICATIONS FOR PREBIOTIC ORIGIN OF PEPTIDE SYNTHESIs"", 《PNAS》",PENDING
85,CN,A,CN 111133104 A,082-126-934-992-591,2020-05-08,2020,CN 201880059858 A,2018-08-10,US 201762544010 P;;US 2018/0046179 W,2017-08-11,METHODS FOR GENERATING EPITOPES FOR BINDING TO RECOGNITION MOLECULES BY TEMPLATED ASSEMBLY,"The present disclosure provides polypeptides and polypeptide-nucleic acid conjugates comprising portions of epitopes, and methods of using target molecule binding components, such as aptamers, to present template sequences, where the target molecule binding components bind to target molecules unique to specific cellular targets, for the purpose of templated assembly of the epitopes for recognitionmolecules.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/082-126-934-992-591,Patent Application,no,5,0,7,7,0,C07K7/00;;C07K14/001;;C12N15/115;;A61K45/06;;C12N2310/16;;C12N2310/3513;;C07K16/1027;;C07K16/1235;;C07K16/18;;C07K16/2803;;C07K16/2863;;C07K16/32;;C07K2317/34;;C07K2317/55;;A61K47/549;;A61K47/66;;C07K14/001;;C12N15/115;;C12N2310/16,C12N15/00;;A61K31/713;;C07K7/00;;C12N15/115,,0,0,,,,DISCONTINUED
86,US,A1,US 2016/0106854 A1,122-905-257-800-813,2016-04-21,2016,US 201414895398 A,2014-06-04,US 201414895398 A;;US 201361831133 P;;US 2014/0040822 W,2013-06-04,Methods And Compositions For Templated Assembly Of Nucleic Acid Specific Heterocompounds,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2016-01-23),https://lens.org/122-905-257-800-813,Patent Application,yes,6,8,23,23,12,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,A61K47/48;;A61K39/00,,0,0,,,,ACTIVE
87,US,A1,US 2019/0314397 A1,126-049-828-816-090,2019-10-17,2019,US 201716462332 A,2017-11-17,US 201716462332 A;;US 201662424642 P;;US 2017/0062267 W,2016-11-21,Methods For Directed Folding Assembly Or Dimerization Of Proteins By Templated Assembly Reactions,"The present disclosure provides nucleic acid molecules, compositions, and kits comprising the same, and methods for producing templated assembly products.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,TRIBIOTICA LLC (2019-07-11),https://lens.org/126-049-828-816-090,Patent Application,yes,0,1,8,8,54,A61K31/713;;C12N15/11;;C12N2310/3513;;C12N15/111;;C12N15/1068;;C07D401/12;;C07D401/14;;A61K31/713;;C12N15/11;;C12N2310/3513;;C12P19/34;;G01N33/50,A61K31/713;;C12N15/11;;C12P19/34;;G01N33/50,,0,0,,,,ACTIVE
88,EP,A4,EP 3541952 A4,132-389-921-704-489,2020-06-24,2020,EP 17872434 A,2017-11-16,US 201662424607 P;;US 2017/0062048 W,2016-11-21,METHODS FOR PREVENTING TITRATION OF BIMOLECULAR TEMPLATED ASSEMBLY REACTIONS BY STRUCTURALLY-DETERMINED DIFFERENTIAL HYBRIDIZATIONS,,TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/132-389-921-704-489,Search Report,no,5,0,6,6,0,C12Q1/6818;;C07H21/00;;C12N15/113;;C12N2310/14,C12Q1/6818;;A61K31/7088;;C07H21/00;;C07H21/02;;C07H21/04;;C12P19/34,,6,5,106-636-441-099-622;;164-676-346-718-413;;093-746-935-439-145;;023-068-910-964-278;;152-924-955-371-878,10.2174/1568026615666150330110131;;25858134;;21876785;;10.4061/2011/741723;;pmc3163130;;10.1039/c5an00566c;;25909387;;27162146;;10.1016/j.bios.2016.05.010;;10.1039/b901971p;;20309492,"PONOMARENKO A.I. ET AL: ""Recent Advances in Self-Assembled Fluorescent DNA Structures and Probes"", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 15, 1 January 2015 (2015-01-01), pages 1162 - 1178, XP055489118, ISSN: 1832-5492;;RICARDO MONROY-CONTRERAS ET AL: ""Molecular Beacons: Powerful Tools for Imaging RNA in Living Cells"", JOURNAL OF NUCLEIC ACIDS, vol. 32, no. 6, Art. e57, 1 January 2011 (2011-01-01), pages 474 - 15, XP055048718, ISSN: 2090-0201, DOI: 10.4061/2011/741723;;QIONG HU ET AL: ""Simple and fast electrochemical detection of sequence-specific DNA via click chemistry-mediated labeling of hairpin DNA probes with ethynylferrocene"", ANALYST, vol. 140, no. 12, 1 January 2015 (2015-01-01), UK, pages 4154 - 4161, XP055696125, ISSN: 0003-2654, DOI: 10.1039/C5AN00566C;;TANG YAQIN ET AL: ""Tension promoted circular probe for highly selective microRNA detection and imaging"", BIOSENSORS AND BIOELECTRONICS, ELSEVIER SCIENCE LTD. UK, AMSTERDAM, NL, vol. 85, 3 May 2016 (2016-05-03), pages 151 - 156, XP029680578, ISSN: 0956-5663, DOI: 10.1016/J.BIOS.2016.05.010;;AFAF H. EL-SAGHEER ET AL: ""Click chemistry with DNA"", CHEMICAL SOCIETY REVIEWS, vol. 39, no. 4, 1 January 2010 (2010-01-01), pages 1388, XP055084878, ISSN: 0306-0012, DOI: 10.1039/b901971p;;See also references of WO 2018094070A1",DISCONTINUED
89,AU,B2,AU 2014/275010 B2,144-134-561-570-966,2020-10-29,2020,AU 2014/275010 A,2014-06-04,US 201361831133 P;;US 2014/0040822 W,2013-06-04,Methods and compositions for templated assembly of nucleic acid specific heterocompounds,"The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.",TRIBIOTICA LLC,DUNN IAN;;LAWLER MATTHEW,,https://lens.org/144-134-561-570-966,Granted Patent,no,4,0,23,23,0,C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12N15/111;;C12N15/1131;;A61K39/0011;;A61K2039/5158;;C12Q1/6811;;C12N15/1068;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/111;;A61K2039/5158;;A61K2039/6025;;A61K39/0011;;A61K47/549;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/02;;C12N15/1068;;C12N15/1131;;C12N2310/351;;C12N2310/3513;;C12N2310/3517;;C12N2320/30;;C12Q1/6811;;A61K39/0011;;A61K47/549;;C12N15/1131;;C12N2310/351;;C12N2320/30;;C12N2310/3513;;C12N15/111;;C12N2310/3517;;C12N15/1068;;A61K2039/6025,C12N15/11,,0,0,,,,ACTIVE
90,GB,A,GB 2449285 A,174-728-799-969-332,2008-11-19,2008,GB 0709475 A,2007-05-17,GB 0709475 A,2007-05-17,Testing an earth connection,"An earth connection 30, that is isolated from a mains electricity supply, is tested by a device 10 connected to a conductive item 20 such as a vehicle that has a capacitance relative to an adjacent surface of the earth. Whether the earth resistance is less than a maximum value is determined by comparing the frequency of an AC signal generated by an oscillator (fig 9) with a range of frequencies. The device may be used to test an earth connection for a truck or road tanker containing flammable material and may connect to a grounding rod or structural metalwork by a clamp (fig 3) and serves to dissipate static electrostatic charge. Additional capacitance can be supplied by a metal plate (fig 2, 70) insulated from the earth. The device may be mounted on the conductive item or on the earth connection, have pass and fail indicator lamps 13,15, can automatically connect the item to earth via an electronic switch and enable an action such as the transfer of liquid from the vehicle when the frequency falls within the frequency range.",NEWSON GALE LTD,DUNN JOHN;;EDGE IAN,,https://lens.org/174-728-799-969-332,Patent Application,no,3,4,10,10,0,G01R27/205;;G01R27/205;;G01R27/205;;H02H5/105,G01R27/20;;H02H5/10,,0,0,,,,ACTIVE
91,CN,A,CN 1951117 A,045-505-975-611-626,2007-04-18,2007,CN 200580014399 A,2005-04-01,US 2005/0011366 W;;US 81653704 A,2004-04-01,Virtual flip chart method and apparatus,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,DUNN MICHAEL H HUTCHINSON IAN,STEELCASE INC. (2014-09-03),https://lens.org/045-505-975-611-626,Patent Application,no,0,1,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,H04N7/15;;G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00,,0,0,,,,INACTIVE
92,US,B2,US 7552903 B2,117-402-481-456-468,2009-06-30,2009,US 30143005 A,2005-12-13,US 30143005 A,2005-12-13,Machine mounting system,"A gas turbine engine assembly includes a gas turbine engine mounted on a three-point mounting frame. The three-point mounting frame includes an engine support structure having first and second beams in a V-configuration, and a secondary support structure that is positioned about the engine support structure and has a rectangular footprint. The frame may include a Y-configuration that includes the V-configuration, and may be implemented in a machine mounting system, such as in a marine vessel.",SOLAR TURBINES INC,DUNN JEFFREY H;;BROWN IAN T,CATERPILLAR INC (2005-12-08);;SOLAR TURBINES INC (2005-12-08),https://lens.org/117-402-481-456-468,Granted Patent,yes,20,147,6,6,0,B63H21/16;;B63H21/30;;F01D15/04;;F01D25/28;;F16M5/00;;F16M5/00;;F01D25/28;;B63H21/30;;B63H21/16;;F01D15/04,F16M1/00,248/678;;248/637;;60/797,1,0,,,"""Genetech: P.T.O. generators 16-69 kVA"" [online] Oct. 24, 2002 p. 1-2, XP002421122 http://web.archive.org/web/20021024163556/http://www.genetech.se/pdf/Ti-20077E.pdf.",INACTIVE
93,WO,A3,WO 2022/099062 A3,185-128-435-969-876,2022-06-09,2022,US 2021/0058322 W,2021-11-05,US 202063111450 P,2020-11-09,ANTIBODIES AND SINGLE-CHAIN VARIABLE REGION PROTEINS RECOGNIZING CLICK PRODUCTS,"The present disclosure is directed, at least in part, to click-product binding molecules for recognition of templated assembly products defined by bioorthogonal click groups. Such molecules can be used for therapeutic and diagnostic purposes, including kits for the same.",MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES;;DUNN IAN;;LAWLER MATTHEW,,https://lens.org/185-128-435-969-876,Search Report,yes,3,0,3,3,96,C07K16/44;;C07K2317/622;;C07K2317/21;;C07K2317/33;;C07K2317/52;;C07K2317/92;;C07K16/44;;C07K2317/21;;C07K2317/33;;C07K2317/622;;C07K2317/92;;G01N33/5308,C07K16/00;;C07K14/315;;C07K16/28;;C07K16/30;;C07K16/32,,1,1,094-672-900-707-32X,pmc3716466;;10.1039/c2ib20110k;;22836343,"MILLWARD ET AL.: ""In situ click chemistry: from small molecule discovery to synthetic antibodies"", INTEGR. BIOL., vol. 5, no. 1, 2013, pages 87 - 95, XP055300677, DOI: 10.1039/C2IB20110K",PENDING
94,EP,A1,EP 1960706 A1,037-189-349-992-976,2008-08-27,2008,EP 06816874 A,2006-10-13,US 2006/0040111 W;;US 30143005 A,2005-12-13,MACHINE MOUNTING SYSTEM,,SOLAR TURBINES INC,DUNN JEFFREY H;;BROWN IAN T,,https://lens.org/037-189-349-992-976,Patent Application,yes,0,0,6,6,0,B63H21/16;;B63H21/30;;F01D15/04;;F01D25/28;;F16M5/00;;F16M5/00;;F01D25/28;;B63H21/30;;B63H21/16;;F01D15/04,F16M5/00;;B63B3/70;;F01D25/28,,0,0,,,,DISCONTINUED
95,US,B2,US 7445399 B2,063-982-805-801-480,2008-11-04,2008,US 95059904 A,2004-09-28,US 95059904 A,2004-09-28,Low profile gimbal,"A gimbal includes a first lug housing. The first lug housing includes a first base plate and a first lug protruding from the second surface of the first base plate. The gimbal also includes a second lug housing. The second lug housing includes a second base plate and a second lug protruding from the second surface of the second base plate. In addition, the gimbal includes a shaft passing through the first and second lugs, thereby connecting the first lug housing to the second lug housing, such that the first base plate is facing the second base plate. The gimbal also includes a first void in the second base plate, opposite the first lug, such that the first lug extends into the first void of the second base plate.",SOLAR TURBINES INC,DUNN JEFFREY HAROLD;;BROWN IAN TREVOR,SOLAR TURBINES INCORPORATION (2004-09-22),https://lens.org/063-982-805-801-480,Granted Patent,yes,23,31,5,5,0,F16C11/0614;;F16C11/0614;;F16M11/125;;F16M11/125;;Y10T403/32606;;Y10T403/32606;;Y10T403/32631;;Y10T403/32631;;Y10T403/32655;;Y10T403/32655;;Y10T403/32861;;Y10T403/32861,F16D1/12,403/150;;403/119;;403/125,0,0,,,,ACTIVE
96,WO,A2,WO 2022/099062 A2,107-998-213-474-050,2022-05-12,2022,US 2021/0058322 W,2021-11-05,US 202063111450 P,2020-11-09,ANTIBODIES AND SINGLE-CHAIN VARIABLE REGION PROTEINS RECOGNIZING CLICK PRODUCTS,"The present disclosure is directed, at least in part, to click-product binding molecules for recognition of templated assembly products defined by bioorthogonal click groups. Such molecules can be used for therapeutic and diagnostic purposes, including kits for the same.",MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES;;DUNN IAN;;LAWLER MATTHEW,,https://lens.org/107-998-213-474-050,Patent Application,yes,0,0,3,3,96,C07K16/44;;C07K2317/622;;C07K2317/21;;C07K2317/33;;C07K2317/52;;C07K2317/92;;C07K16/44;;C07K2317/21;;C07K2317/33;;C07K2317/622;;C07K2317/92;;G01N33/5308,,,0,0,,,,PENDING
97,CN,A,CN 101395913 A,167-453-618-287-786,2009-03-25,2009,CN 200680027837 A,2006-06-02,US 2006/0021233 W;;US 68738905 P;;US 77190806 P,2005-06-02,Virtual flip chart method and apparatus,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G,STEELCASE INC. (2014-09-10),https://lens.org/167-453-618-287-786,Patent Application,no,0,6,3,15,0,,H04N7/15;;G09G5/00,,0,0,,,,INACTIVE
98,CA,A,CA 1042966 A,146-322-585-874-703,1978-11-21,1978,CA 225683 A,1975-04-28,GB 1867574 A,1974-04-29,COMPOSITE RING FOR A ROLLING ELEMENT BEARING,"A composite ring for a rolling element bearing comprises a relatively thin metal track member, a relatively thin metal support and a resilient packing bonded to both the track member and the support.",RANSOME HOFFMANN POLLARD,DUNN IAN A;;POON SIU Y,,https://lens.org/146-322-585-874-703,Granted Patent,no,0,0,6,6,0,F16C27/066;;F16C19/06;;F16C19/46;;F16C33/588;;F16C33/60;;F16C35/067,F16C27/06;;F16C33/58;;F16C33/60,308-29,0,0,,,,EXPIRED
99,AT,T1,AT E488957 T1,184-935-233-278-422,2010-12-15,2010,AT 05733062 T,2005-04-01,US 81653704 A;;US 2005/0011366 W,2004-04-01,VERFAHREN UND VORRICHTUNG FÜR EINE VIRTUELLE FLIP-CHART,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,DUNN MICHAEL;;HUTCHINSON IAN;;HILDEBRANDT PETER,,https://lens.org/184-935-233-278-422,Granted Patent,no,0,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,G06F3/033;;G06F3/042;;G09G5/00;;H04N7/15,,0,0,,,,INACTIVE
100,GB,A,GB 2446291 A,150-241-143-949-667,2008-08-06,2008,GB 0801797 A,2008-01-31,GB 0701838 A,2007-01-31,MODULAR CAR PARK DECK,"The invention relates to a raised car parking deck and comprises a plurality of deck modules 16. Each module includes a support structure 14 and (20 figure 2) and deck panelling (12a figure 2) supported on the support structure. The deck panelling has a bonded, grit-coated top surface, and a leak-proof seal (62 figure 9, 162 figure 12) provided between adjacent modules. Later embodiments relate to a car parking module comprising a deck and a support means characterised by a unitary support section and first and second connection means; a car parking deck module comprising a deck and a support means characterised by a support member movably coupled a movable deck; a car parking deck module characterised by an extendable leg portion with geared adjusting means; a car parking deck module comprising a deck characterised by a deck which may be raised and has a foldable perimeter barrier; a ramp for use in a modular raised car parking system; a deck structure for use in a raised car parking deck characterised by a sub structure; and a deck module suitable for use in a raised car park system characterised by lighting on the underside of the deck surface.",HILL & SMITH INFRASTRUCTURE PR,DARLINGTON IAN;;SMYTHE PAUL;;DUNN STEVE,,https://lens.org/150-241-143-949-667,Patent Application,no,3,9,5,5,0,E04B1/34331;;E04H6/10;;E04H6/10,E04H6/10;;E04B1/343,,0,0,,,,DISCONTINUED
101,DE,T2,DE 69128141 T2,043-295-005-139-695,1998-05-28,1998,DE 69128141 T,1991-01-08,AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A;;AU 2006/091000 W,1990-01-08,FEUERLÖSCH-SYSTEM,"An apparatus and system for storing and supplying liquid CO2 at low pressure for extinguishing fires. The apparatus comprises a pressure vessel (13) for storing liquid CO2 at low pressure, a cooling means (29) in contact with gaseous CO2 in the vessel to maintain the low pressure, an inlet (24) and outlet (32) to fill the vessel and a supply conduit (17) communicating with a lower portion of the interior of the vessel to allow liquid CO2 to pass from the vessel and into a reticulation system. A number of pressure vessels can be coupled together through a manifold (165) to provide the required amount of liquid CO2 to a risk site. Supply valves (18) or manifold valves (173, 174) can be operated by a sensor (175, 176) in a risk site and a logic processor (177) can be used to regulate the valves and thereby the liquid CO2. The apparatus and system is particularly designed as a replacement for current halon systems which cause damage to the ozone layer.",PYROZONE PTY LTD,ALLISON JAMES;;TRONC IAN;;DUNN PETER,,https://lens.org/043-295-005-139-695,Granted Patent,no,0,1,10,13,0,A62C35/15;;A62C35/62;;F17C7/02;;F17C2201/0109;;F17C2201/032;;F17C2203/0333;;F17C2203/0629;;F17C2205/0332;;F17C2205/0335;;F17C2221/013;;F17C2223/0153;;F17C2223/035;;F17C2223/047;;F17C2250/032;;F17C2250/036;;F17C2250/061;;F17C2270/0754,A62C35/15;;A62C35/62;;F17C7/02,,0,0,,,,EXPIRED
102,WO,A2,WO 2008/093081 A2,179-981-284-146-506,2008-08-07,2008,GB 2008000311 W,2008-01-31,GB 0701838 A,2007-01-31,MODULAR CAR PARK DECK,"A raised car parking deck comprises a plurality of deck modules (16). Each module includes a support structure (14, 20) and deck panelling (12a) supported on the support structure. The deck panelling has a bonded, grit-coated top surface, and a leak-proof seal (62, 162) is provided between adjacent modules.",HILL & SMITH INFRASTRUCTURE PR;;DARLINGTON IAN;;SMYTHE PAUL;;DUNN STEVE,DARLINGTON IAN;;SMYTHE PAUL;;DUNN STEVE,,https://lens.org/179-981-284-146-506,Patent Application,yes,0,1,5,5,0,E04B1/34331;;E04H6/10;;E04H6/10,,,0,0,,,,PENDING
103,US,A1,US 2006/0088371 A1,027-067-833-284-738,2006-04-27,2006,US 95059904 A,2004-09-28,US 95059904 A,2004-09-28,Low profile gimbal,"A gimbal includes a first lug housing. The first lug housing includes a first base plate and a first lug protruding from the second surface of the first base plate. The gimbal also includes a second lug housing. The second lug housing includes a second base plate and a second lug protruding from the second surface of the second base plate. In addition, the gimbal includes a shaft passing through the first and second lugs, thereby connecting the first lug housing to the second lug housing, such that the first base plate is facing the second base plate. The gimbal also includes a first void in the second base plate, opposite the first lug, such that the first lug extends into the first void of the second base plate.",SOLAR TURBINES INC,DUNN JEFFREY H;;BROWN IAN T,SOLAR TURBINES INCORPORATION (2004-09-22),https://lens.org/027-067-833-284-738,Patent Application,yes,19,6,5,5,0,F16C11/0614;;F16C11/0614;;F16M11/125;;F16M11/125;;Y10T403/32606;;Y10T403/32606;;Y10T403/32631;;Y10T403/32631;;Y10T403/32655;;Y10T403/32655;;Y10T403/32861;;Y10T403/32861,F16C11/00,403/122,0,0,,,,ACTIVE
104,ES,T3,ES 2399749 T3,108-870-786-913-413,2013-04-03,2013,ES 03749229 T,2003-08-29,US 40749202 P;;US 0327125 W,2002-08-29,Composiciones farmacéuticas que comprenden Interferón beta para su uso en el tratamiento de melanoma,"Agonista del receptor de interferón-b (IFN-b) y antígeno asociado a tumor (AAT) para su uso en el tratamiento deun melanoma en un sujeto, siendo el agonista del receptor de IFN-b un polipéptido, y consistiendo el polipéptido enbeta-interferón-1a humano recombinante o beta-interferón-1b humano recombinante.",CYTOCURE LLC,DURDA PAUL;;KURNICK JAMES;;DUNN IAN,,https://lens.org/108-870-786-913-413,Granted Patent,no,0,0,14,14,0,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61K38/21;;A61B19/00;;A61K/;;A61K35/00;;A61K39/00;;A61K39/395;;A61P35/00;;C07K16/30;;G01N33/50,,0,0,,,,EXPIRED
105,DE,A1,DE 2518789 A1,116-299-409-308-752,1975-11-20,1975,DE 2518789 A,1975-04-28,GB 1867574 A,1974-04-29,WAELZLAGER,,RANSOME HOFFMANN POLLARD,DUNN IAN ASHLEY;;POON SIU YUN,,https://lens.org/116-299-409-308-752,Patent Application,no,0,19,6,6,0,F16C27/066;;F16C19/06;;F16C19/46;;F16C33/588;;F16C33/60;;F16C35/067,F16C27/06;;F16C33/58;;F16C33/60,,0,0,,,,PENDING
106,US,S,US D0958006 S,012-474-321-674-779,2022-07-19,2022,US 202129814968 F,2021-11-10,US 202129814968 F;;US 202029743786 F,2020-07-24,All-terrain vehicle,,POLARIS INC,DUNN IAN M;;FLICK BRIAN N,POLARIS INDUSTRIES INC (2020-07-23),https://lens.org/012-474-321-674-779,Design Right,no,203,0,5,5,0,,,1211;;D12/107,14,0,,,"“2020 Fourtrax Recon” Honda., posted date Jun. 22, 2019 [online], [retrieved on Jul. 13, 2021]. Retrieved from the Internet <URL: https://powersports.honda.com/atv/recutility/fourtrax-recon?year=2020> (Year: 2019).;;“Sportsman 850” Polaris., posted date Jun. 29, 2017 [online], [retrieved on Jul. 13, 2021]. Retrieved from the Internet <URL: https://atv.polaris.com/en-us/sportsman-850/> (Year: 2017).;;“2019 Polaris Sportsman 850” Polaris., posted date Jul. 23, 2019 [online], [retrieved on Jul. 13, 2021]. Retrieved from the Internet <URL: http://atvillustrated.com/content/2019-polaris-sportsman-850-sp-premium-review> (Year: 2019).;;International Preliminary Report on Patentability issued by the European Patent Office, dated Mar. 15, 2011, for International Patent Application No. PCT/US2009/059535; 6 pages.;;International Preliminary Report on Patentability issued by the European Patent Office, dated May 11, 2009, for International Patent Application No. PCT/US2008/003483; 20 pages.;;International Preliminary Report on Patentability issued by the European Patent Office, dated Jan. 27, 2011, for International Patent Application No. PCT/US2009/049799; 13 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Aug. 27, 2008, for International Patent Application No. PCT/US2008/003485; 11 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Jan. 6, 2010, for International Patent Application No. PCT/US2009/059535; 10 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Oct. 2, 2008; for International Patent Application No. PCT/US2008/003483; 15 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Sep. 1, 2008, for International Patent Application No. PCT/US2008/003480; 17 pages.;;International Search Report and Written Opinion issued by the International Searching Authority, dated Sep. 19, 2016, for International Patent Application No. PCT/US2016/031992; 20 pages.;;International Search Report issued by the European Patent Office, dated Feb. 24, 2010, for International Patent Application No. PCT/US2009/049799; 6 pages.;;The Council of the European Communities, “Council Directive on the approximation of the laws of the Member States relating to the driver's seat on wheeled agricultural or forestry tractors (78/764/EEC) (OJL 255, 18.9, 1978)”, Jul. 25, 1978, 69 pages, available at http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1978L0764:20070101:EN.pdf.;;Written Opinion issued by the International Searching Authority, dated Feb. 24, 2010, for International Patent Application No. PCT/US2009/049799; 7 pages.",ACTIVE
107,DE,D1,DE 69128141 D1,026-552-355-684-00X,1997-12-11,1997,DE 69128141 T,1991-01-08,AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A;;AU 2006/091000 W,1990-01-08,FEUERLÖSCH-SYSTEM,"An apparatus and system for storing and supplying liquid CO2 at low pressure for extinguishing fires. The apparatus comprises a pressure vessel (13) for storing liquid CO2 at low pressure, a cooling means (29) in contact with gaseous CO2 in the vessel to maintain the low pressure, an inlet (24) and outlet (32) to fill the vessel and a supply conduit (17) communicating with a lower portion of the interior of the vessel to allow liquid CO2 to pass from the vessel and into a reticulation system. A number of pressure vessels can be coupled together through a manifold (165) to provide the required amount of liquid CO2 to a risk site. Supply valves (18) or manifold valves (173, 174) can be operated by a sensor (175, 176) in a risk site and a logic processor (177) can be used to regulate the valves and thereby the liquid CO2. The apparatus and system is particularly designed as a replacement for current halon systems which cause damage to the ozone layer.",PYROZONE PTY LTD,ALLISON JAMES;;TRONC IAN;;DUNN PETER,,https://lens.org/026-552-355-684-00X,Granted Patent,no,0,0,10,13,0,A62C35/15;;A62C35/62;;F17C7/02;;F17C2201/0109;;F17C2201/032;;F17C2203/0333;;F17C2203/0629;;F17C2205/0332;;F17C2205/0335;;F17C2221/013;;F17C2223/0153;;F17C2223/035;;F17C2223/047;;F17C2250/032;;F17C2250/036;;F17C2250/061;;F17C2270/0754,A62C35/15;;A62C35/62;;F17C7/02,,0,0,,,,EXPIRED
108,ES,T3,ES 2356845 T3,169-413-903-235-156,2011-04-13,2011,ES 06771804 T,2006-06-02,US 68738905 P,2005-06-02,PROCEDIMIENTO Y APARATO DE ROTAFOLIO VIRTUAL.,"Sistema de presentación para presentar un conjunto de imágenes de sesión, comprendiendo el sistema: - una unidad (30) de presentación maestra que incluye un espacio maestro; - al menos una unidad (22) de presentación esclava con una pluralidad de distintos espacios de presentación esclavos o una pluralidad de distintas unidades (22) de presentación esclavas cada uno con al menos un espacio de presentación esclavo mediante lo cual las unidades de presentación esclavas son distintas entre sí; - un procesador (80); - una interfaz (30) de control configurada para recibir entradas de control de un usuario y proporcionar órdenes de control para el procesador (80); - una red que vincula el procesador (80), la interfaz, la unidad (30) de presentación maestra y la al menos una unidad (22) de presentación esclava o la pluralidad de unidades (22) de presentación esclavas; en el que el procesador (80) está programado para: - presentar el espacio maestro que comprende al menos una parte (1002, 1056) y una parte (1004) de área de espacio de trabajo; - presentar representaciones (1082-1092) de imagen de sesión para una pluralidad de imágenes de sesión simultáneamente en la parte (1002, 1056) del espacio maestro; - presentar una de las imágenes de sesión en la parte (1004) de área de espacio de trabajo del espacio maestro simultáneamente con las representaciones (1082-1092) de imagen de sesión en la parte (1002, 1056) en el que la imagen presentada en la parte (1004) de área de espacio de trabajo puede editarse usando una interfaz y en el que las representaciones (1082-1092) de imagen de sesión incluyen una representación (1082-1092) de imagen correspondiente a la imagen de sesión presentada en la parte (1004) de área de espacio de trabajo; - presentar diferentes imágenes de sesión mediante los espacios de presentación esclavos; y - distinguir visualmente las representaciones (1082-1092) de imagen de sesión asociadas con las imágenes presentadas mediante los espacios de presentación esclavos de las otras representaciones (1082-1092) de imagen de sesión en la parte del espacio maestro.",POLYVISION CORP,DUNN MICHAEL;;HUTCHINSON IAN;;HILDEBRANDT PETER,,https://lens.org/169-413-903-235-156,Granted Patent,no,0,0,3,15,0,,H04N7/15;;G09G5/00,,0,0,,,,ACTIVE
109,WO,A3,WO 2007/008215 A3,176-442-376-395-479,2007-03-08,2007,US 2005/0026295 W,2005-07-22,US 95059904 A,2004-09-28,LOW PROFILE GIMBAL,"An electroless method of forming high aspect ratio metal particles includes the steps of mixing a metal or metal salt with at least one acid to fou i an acidified metal halide salt solution, and mixing the solution with a supersaturated sol to form a sol comprising solution. Metal cations provided by the acidified metal salt are reduced to form a plurality of high aspect ratio metal particles. Instead of using a sol, an organic compound can be oxidized to generate the reducing agent. A metal comprising particle assembly includes a plurality of high aspect ratio metal platelets having an aspect ratio of a major dimension averaging from 10 to 200 times a nanoscale minor dimension of the platelet. The platelets can be used for nail polish, eye liner or the cores for medical delivery vehicles.",SOLAR TURBINES INC;;DUNN JEFFREY H;;BROWN IAN T,DUNN JEFFREY H;;BROWN IAN T,,https://lens.org/176-442-376-395-479,Search Report,yes,4,0,5,5,0,F16C11/0614;;F16C11/0614;;F16M11/125;;F16M11/125;;Y10T403/32606;;Y10T403/32606;;Y10T403/32631;;Y10T403/32631;;Y10T403/32655;;Y10T403/32655;;Y10T403/32861;;Y10T403/32861,F16C11/06;;F16M11/14,,0,0,,,,PENDING
110,GB,B,GB 2215121 B,133-190-903-260-296,1991-03-13,1991,GB 8802996 A,1988-02-10,GB 8802996 A,1988-02-10,MULTI-LAYER INTEGRATED CIRCUIT DEVICES,,PLESSEY CO PLC;;MARCONI GEC LTD,DUNN MICHAEL SIDNEY FRANCIS;;MITCHELL IAN,,https://lens.org/133-190-903-260-296,Granted Patent,no,0,0,3,3,0,H01L23/5226;;H01L2924/0002,H01L23/522,H1K KGF           GF;;H1K K1AA9         GF;;H1K K1CA          GF;;H1K K11C1A        GF;;H1K K11D          GF;;H1K K4C1U         GF;;H1K K4C11         GF;;H1K K4C14         GF;;H1K K4C2A         GF,0,0,,,,EXPIRED
111,ES,T3,ES 2356844 T3,034-430-051-548-708,2011-04-13,2011,ES 05733062 T,2005-04-01,US 81653704 A,2004-04-01,PROCEDIMIENTO Y APARATO DE ROTAFOLIO VIRTUAL.,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,DUNN MICHAEL;;HUTCHINSON IAN;;HILDEBRANDT PETER,,https://lens.org/034-430-051-548-708,Granted Patent,no,0,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,H04N7/15;;G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00,,0,0,,,,ACTIVE
112,WO,A1,WO 2007/070158 A1,081-979-118-017-489,2007-06-21,2007,US 2006/0040111 W,2006-10-13,US 30143005 A,2005-12-13,MACHINE MOUNTING SYSTEM,"A gas turbine engine assembly (8) includes a gas turbine engine (12) mounted on a three-point mounting frame (10). The three-point mounting frame (10) includes an engine support structure (18) having first and second beams (22a, 22b) in a V-configuration, and a secondary support structure (24) that is positioned about the engine support structure (18) and has a rectangular footprint. The frame (10) may include a Y-configuration that includes the V-configuration, and may be implemented in a machine mounting system, such as in a marine vessel (50).",SOLAR TURBINES INC;;DUNN JEFFREY H;;BROWN IAN T,DUNN JEFFREY H;;BROWN IAN T,,https://lens.org/081-979-118-017-489,Patent Application,yes,4,2,6,6,0,B63H21/16;;B63H21/30;;F01D15/04;;F01D25/28;;F16M5/00;;F16M5/00;;F01D25/28;;B63H21/30;;B63H21/16;;F01D15/04,F16M5/00;;B63B3/70;;F01D25/28,,1,0,,,"GENETECH: ""P.T.O. generators 16-60 kVA"", 24 October 2002 (2002-10-24), Internet, pages 1 - 2, XP002421122, Retrieved from the Internet <URL:http://web.archive.org/web/20021024163556/http://www.genetech.se/pdf/Ti-20077E.PDF> [retrieved on 20070220]",PENDING
113,CN,B,CN 101356399 B,112-041-805-655-509,2012-08-22,2012,CN 200680050924 A,2006-10-13,US 2006/0040111 W;;US 30143005 A,2005-12-13,"Assembly of three-point frame, mount frame and gas turbine engine and ship","A gas turbine engine assembly (8) includes a gas turbine engine (12) mounted on a three-point mounting frame (10). The three-point mounting frame (10) includes an engine support structure (18) having first and second beams (22a, 22b) in a V-configuration, and a secondary support structure (24) that is positioned about the engine support structure (18) and has a rectangular footprint. The frame (10) may include a Y-configuration that includes the V-configuration, and may be implemented in a machine mounting system, such as in a marine vessel (50).",SOLAR TURBINES INC,DUNN JEFFREY H;;BROWN IAN T,,https://lens.org/112-041-805-655-509,Granted Patent,no,0,0,6,6,0,B63H21/16;;B63H21/30;;F01D15/04;;F01D25/28;;F16M5/00;;F16M5/00;;F01D25/28;;B63H21/30;;B63H21/16;;F01D15/04,F16M5/00;;B63B3/70;;F01D25/28,,0,0,,,,INACTIVE
114,WO,A3,WO 2008/093081 A3,180-585-863-034-307,2008-12-24,2008,GB 2008000311 W,2008-01-31,GB 0701838 A,2007-01-31,MODULAR CAR PARK DECK,"A raised car parking deck comprises a plurality of deck modules (16). Each module includes a support structure (14, 20) and deck panelling (12a) supported on the support structure. The deck panelling has a bonded, grit-coated top surface, and a leak-proof seal (62, 162) is provided between adjacent modules.",HILL & SMITH INFRASTRUCTURE PR;;DARLINGTON IAN;;SMYTHE PAUL;;DUNN STEVE,DARLINGTON IAN;;SMYTHE PAUL;;DUNN STEVE,,https://lens.org/180-585-863-034-307,Search Report,yes,4,0,5,5,0,E04B1/34331;;E04H6/10;;E04H6/10,E04H6/10,,0,0,,,,PENDING
115,US,S,US D0937710 S,071-087-362-540-697,2021-12-07,2021,US 202029743786 F,2020-07-24,US 202029743786 F,2020-07-24,All-terrain vehicle,,POLARIS INC,DUNN IAN M;;FLICK BRIAN N,POLARIS INDUSTRIES INC (2020-07-23),https://lens.org/071-087-362-540-697,Design Right,no,218,2,5,5,0,,,1211;;D12/107;;D12/87,17,0,,,"“2020 Fourtrax Recon” Honda., posted date Jun. 22, 2019 [online], [retrieved on Jul. 13, 2021]. Retrieved from the Internet <URL: https://powersports.honda.com/atv/recutility/fourtrax-recon?year=2020> (Year: 2019).;;“Sportsman 850” Polaris., posted date Jun. 29, 2017 [online], [retrieved on Jul. 13, 2021]. Retrieved from the Internet <URL: https://atv.polaris.com/en-us/sportsman-850/> (Year: 2017).;;“2019 Polaris Sportsman 850” Polaris., posted date Jul. 23, 2019 [online], [retrieved on Jul. 13, 2021]. Retrieved from the Internet <URL: http://atvillustrated.com/content/2019-polaris-sportsman-850-sp-premium-review> (Year: 2019).;;International Preliminary Report on Patentability issued by the European Patent Office, dated Mar. 15, 2011, for International Patent Application No. PCT/US2009/059535; 6 pages.;;International Preliminary Report on Patentability issued by the European Patent Office, dated May 11, 2009, for International Patent Application No. PCT/US2008/003483; 20 pages.;;International Preliminary Report on Patentability issued by the European Patent Office, dated Jan. 27, 2011, for International Patent Application No. PCT/US2009/049799; 13 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Aug. 27, 2008, for International Patent Application No. PCT/US2008/003485; 11 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Jan. 6, 2010, for International Patent Application No. PCT/US2009/059535; 10 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Oct. 2, 2008; for International Patent Application No. PCT/US2008/003483; 15 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Sep. 1, 2008, for International Patent Application No. PCT/US2008/003480; 17 pages.;;International Search Report and Written Opinion issued by the International Searching Authority, dated Sep. 19, 2016, for International Patent Application No. PCT/US2016/031992; 20 pages.;;International Search Report issued by the European Patent Office, dated Feb. 24, 2010, for International Patent Application No. PCT/US2009/049799; 6 pages.;;The Council of the European Communities, “Council Directive on the approximation of the laws of the Member States relating to the driver's seat on wheeled agricultural or forestry tractors (78/764/EEC) (OJL 255, 18.9, 1978)”, Jul. 25, 1978, 69 pages, available at http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1978L0764:20070101:EN.pdf.;;Written Opinion issued by the International Searching Authority, dated Feb. 24, 2010, for International Patent Application No. PCT/US2009/049799; 7 pages.;;""2020 FOURTRAX RECON"" Honda., posted date 22 June 2019 [online], [retrieved on 13 July 2021]. Retrieved from the Internet <URL: https://powersports.honda.com/atv/recutility/fourtrax-recon?year=2020> (Year: 2019);;""Sportsman 850"" Polaris., posted date 29 June 2017 [online], [retrieved on 13 July 2021]. Retrieved from the Internet <URL: https://atv.polaris.com/en-us/sportsman-850/> (Year: 2017);;""2019 POLARIS SPORTSMAN 850"" Polaris., posted date 23 July 2019 [online], [retrieved on 13 July 2021]. Retrieved from the Internet <URL: http://atvillustrated.com/content/2019-polaris-sportsman-850-sp-premium-review> (Year: 2019)",ACTIVE
116,US,A1,US 2007/0131839 A1,161-020-062-001-620,2007-06-14,2007,US 30143005 A,2005-12-13,US 30143005 A,2005-12-13,Machine mounting system,"A gas turbine engine assembly includes a gas turbine engine mounted on a three-point mounting frame. The three-point mounting frame includes an engine support structure having first and second beams in a V-configuration, and a secondary support structure that is positioned about the engine support structure and has a rectangular footprint. The frame may include a Y-configuration that includes the V-configuration, and may be implemented in a machine mounting system, such as in a marine vessel.",DUNN JEFFREY H;;BROWN IAN T,DUNN JEFFREY H;;BROWN IAN T,CATERPILLAR INC (2005-12-08);;SOLAR TURBINES INC (2005-12-08),https://lens.org/161-020-062-001-620,Patent Application,yes,19,37,6,6,0,B63H21/16;;B63H21/30;;F01D15/04;;F01D25/28;;F16M5/00;;F16M5/00;;F01D25/28;;B63H21/30;;B63H21/16;;F01D15/04,F16M5/00,248/637;;267/140.12,0,0,,,,INACTIVE
117,WO,A2,WO 2007/008215 A2,133-644-650-029-945,2007-01-18,2007,US 2005/0026295 W,2005-07-22,US 95059904 A,2004-09-28,LOW PROFILE GIMBAL,"An electroless method of forming high aspect ratio metal particles includes the steps of mixing a metal or metal salt with at least one acid to fou i an acidified metal halide salt solution, and mixing the solution with a supersaturated sol to form a sol comprising solution. Metal cations provided by the acidified metal salt are reduced to form a plurality of high aspect ratio metal particles. Instead of using a sol, an organic compound can be oxidized to generate the reducing agent. A metal comprising particle assembly includes a plurality of high aspect ratio metal platelets having an aspect ratio of a major dimension averaging from 10 to 200 times a nanoscale minor dimension of the platelet. The platelets can be used for nail polish, eye liner or the cores for medical delivery vehicles.",SOLAR TURBINES INC;;DUNN JEFFREY H;;BROWN IAN T,DUNN JEFFREY H;;BROWN IAN T,,https://lens.org/133-644-650-029-945,Patent Application,yes,0,0,5,5,0,F16C11/0614;;F16C11/0614;;F16M11/125;;F16M11/125;;Y10T403/32606;;Y10T403/32606;;Y10T403/32631;;Y10T403/32631;;Y10T403/32655;;Y10T403/32655;;Y10T403/32861;;Y10T403/32861,F16C11/06;;F16M11/14,,0,0,,,,PENDING
118,AT,T1,AT E488958 T1,030-673-466-653-762,2010-12-15,2010,AT 06771804 T,2006-06-02,US 68738905 P;;US 77190806 P;;US 2006/0021233 W,2005-06-02,VERFAHREN UND VORRICHTUNG FÜR EINE VIRTUELLE FLIP-CHART,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLYVISION CORP,DUNN MICHAEL;;HUTCHINSON IAN;;HILDEBRANDT PETER,,https://lens.org/030-673-466-653-762,Granted Patent,no,0,0,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,,,0,0,,,,INACTIVE
119,GB,A,GB 2215121 A,036-554-648-877-077,1989-09-13,1989,GB 8802996 A,1988-02-10,GB 8802996 A,1988-02-10,Multilayer interconnect integrated circuit,"A multi-layer integrated circuit device comprises a plurality of superimposed insulating layers (1, 2, 3, 4) which carry signal tracks (S, SS) and power supply tracks (P, G) and a substrate (e.g. silicon) (5) which carries the superimposed insulating layers and the various circuit components of the device. Each layer of an adjacent pair of insulating layers (3, 4) carries relatively long signal tracks (S) interspersed in parallel relationship with power and ground tracks (P and G) with the tracks in the respective layers (3, 4) are disposed orthogonally relative to one another. The intersection points (7) of the effective power supply grid defined by the power and ground tracks (P, G) in the two layers (3, 4) are appropriately connected to the circuit components carried by the substrate (5) of the device. <IMAGE>",PLESSEY CO PLC,DUNN MICHAEL SIDNEY FRANCIS;;MITCHELL IAN,,https://lens.org/036-554-648-877-077,Patent Application,no,0,8,3,3,0,H01L23/5226;;H01L2924/0002,H01L23/522,H1K KGF           GF;;H1K K1AA9         GF;;H1K K1CA          GF;;H1K K11C1A        GF;;H1K K11D          GF;;H1K K4C1U         GF;;H1K K4C11         GF;;H1K K4C14         GF;;H1K K4C2A         GF,0,0,,,,EXPIRED
120,US,S,US D0962823 S,148-039-247-943-082,2022-09-06,2022,US 202129814970 F,2021-11-10,US 202129814970 F;;US 202029743786 F,2020-07-24,Combination center and side lamps for all-terrain vehicle,,POLARIS INC,DUNN IAN M;;FLICK BRIAN N,POLARIS INDUSTRIES INC (2020-07-23),https://lens.org/148-039-247-943-082,Design Right,no,212,0,5,5,0,,,1208;;D12/87,17,0,,,"“2022 Polaris Sportsman 450 H.O.” Polaris., posted date Jun. 3, 2021 [online], [retrieved on May 4, 2022], Retrieved from the Internet <URL: https://premierpolaris.com/ATVs-Polaris-Sportsman-450-H-O-2022-Monroe-WA-e328a734-ecca-4aeb-ae9b-ad75007216abG> (Year: 2021).;;“LED Light Kit” Polaris., posted date Apr. 11, 2014 [online], [retrieved on May 4, 2022], Retrieved from the Internet <URL: https://atv.polaris.com/en-us/shop/accessories/lights/2884859/?utm_source=gmc&utm_medium=product_feed&utm_term=LED_Light_Kit> (Year: 2014).;;“2022 TRX250X” Honda., posted date Feb. 8, 2022 [online], [retrieved on May 4, 2022], Retrieved from the Internet <URL: https://powersports.honda.com/atv/sport/trx250x> (Year: 2022).;;“2019 Polaris Sportsman 850” Polaris., posted date Jul. 23, 2019 [online], [retrieved on Jul. 13, 2021], Retrieved from the Internet <URL: http://atvillustrated.com/content/2019-polaris-sportsman-850-sp-premium-review> (Year 2019).;;“2020 Fourtrax Recon” Honda., posted date Jun. 22, 2019 [online], [retrieved on Jul. 13, 2021], Retrieved from the Internet <URL: https://powersports.honda.com/atv/recutility/fourtrax-recon?year=2020> (Year: 2019).;;“Sportsman 850” Polaris., posted date Jun. 29, 2017 [online], [retrieved on Jul. 13, 2021], Retrieved from the Internet <URL: https://atv.polaris.com/en-us/sportsman-850/> (Year: 2017).;;International Preliminary Report on Patentability issued by the European Patent Office, dated Mar. 15, 2011, for International Patent Application No. PCT/US2009/059535; 6 pages.;;International Preliminary Report on Patentability issued by the European Patent Office, dated May 11, 2009, for International Patent Application No. PCT/US2008/003483; 20 pages.;;International Preliminary Report on Patentability issued by the European Patent Office, dated Jan. 27, 2011, for International Patent Application No. PCT/US2009/049799; 13 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Aug. 27, 2008, for International Patent Application No. PCT/US2008/003485; 11 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Jan. 6, 2010, for International Patent Application No. PCT/US2009/059535; 10 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Oct. 2, 2008; for International Patent Application No. PCT/US2008/003483; 15 pages.;;International Search Report and Written Opinion issued by the European Patent Office, dated Sep. 1, 2008, for International Patent Application No. PCT/US2008/003480; 17 pages.;;International Search Report and Written Opinion issued by the International Searching Authority, dated Sep. 19, 2016, for International Patent Application No. PCT/US2016/031992; 20 pages.;;International Search Report issued by the European Patent Office, dated Feb. 24, 2010, for International Patent Application No. PCT/US2009/049799; 6 pages.;;The Council of the European Communities, “Council Directive on the approximation of the laws of the Member States relating to the driver's seat on wheeled agricultural or forestry tractors (78/764/EEC) (OJL 255, 18.9, 1978)”, Jul. 25, 1978, 69 pages, available at http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1978L0764:20070101:EN.pdf.;;Written Opinion issued by the International Searching Authority, dated Feb. 24, 2010, for International Patent Application No. PCT/US2009/049799; 7 pages.",ACTIVE
121,AU,A,AU 1999/024038 A,178-733-172-925-047,1999-08-16,1999,AU 1999/024038 A,1999-01-28,AU PP161698 A;;AU 1963/099000 W;;AU 1999/024038 A,1998-02-02,Transgenic mouse model,,LUDWIG INST CANCER RES;;UNIV MELBOURNE;;INST MEDICAL W & E HALL,ERNST MATTHIAS;;DUNN ASHLEY;;WARING PAUL;;WICKS IAN;;CAMPBELL IAN,,https://lens.org/178-733-172-925-047,Patent Application,no,0,0,1,3,0,,A01K67/027;;A61K48/00;;C12N5/10;;C12N15/19;;G01N33/68,,0,0,,,,DISCONTINUED
122,WO,A1,WO 1999/038377 A1,160-602-193-274-024,1999-08-05,1999,AU 1963/099000 W,1999-01-28,AU PP161698 A,1998-02-02,TRANSGENIC MOUSE MODEL,"This invention provides targeted gene disruption, and in particular to disruption of a portion of the gp130 gene which encodes the binding motif for the latent STAT transcription factors. Transgenic mice carrying this disruption exhibit a variety of pathological features, including joint abnormalities, decreased mucosal immunity, gastrointestinal ulceration, and female infertility associated with failure of blastocyst implantation, and are useful as models of disease. The invention provides transgenic animals and methods and targeting vectors for their production methods of identification and testing of therapeutic agents, and methods of diagnosis and treatment of conditions associated with mutation in the gp130 locus.",LUDWIG INST CANCER RES;;UNIV MELBOURNE;;WALTER AND ELIZA HALL INST FOR;;ERNST MATTHIAS;;DUNN ASHLEY;;WARING PAUL;;WICKS IAN;;CAMPBELL IAN,ERNST MATTHIAS;;DUNN ASHLEY;;WARING PAUL;;WICKS IAN;;CAMPBELL IAN,,https://lens.org/160-602-193-274-024,Patent Application,yes,0,1,2,3,0,A01K67/0276;;A01K2217/072;;A01K2217/075;;A01K2227/105;;A01K2267/03;;C07K14/70503;;C12N15/8509;;C12N2840/203;;G01N33/6893,C07K14/705;;C12N15/85;;G01N33/68,,5,5,102-699-327-632-940;;009-576-180-097-160;;050-087-390-855-977;;025-956-188-805-154;;082-804-293-996-09X,pmc451995;;8670868;;10.1002/j.1460-2075.1996.tb00734.x;;pmc450065;;10.1002/j.1460-2075.1996.tb00500.x;;8612579;;8934572;;10.1016/s1074-7613(00)80501-4;;1602143;;10.1016/s0888-7543(05)80166-1;;1427893,"THE EMBO JOURNAL, 1996, Vol. 15(14), NAKAJIMA K. et al., ""A Central Role for STAT3 in Il-6-Induced Regulation of Growth and Differentiation in M1 Leukemia Cells"", pages 3651-3658.;;THE EMBO JOURNAL, 1996, Vol. 15(7), YAMANAKA Y. et al., ""Differentiation and Growth Arrest Signals are Generated Through the Cytoplasmic Region of gp130 that is Essential for STAT3 Activation"", pages 1557-1565.;;IMMUNITY, Nov. 1996, Vol. 5(5), FUKADA T. et al., ""Two Signals are Necessary for Cell Proliferation Induced by a Cytokine Receptor gp130: Involvement of STAT3 in Anti-Apoptosis"", pages 449-460.;;J. IMMUNOLOGY, 1992, Vol. 148, SAITO M. et al., ""Molecular Cloning of a Murine IL-6 Receptor-Associated Signal Transducer, gp130 and its Regulated Expression In Vivo"", pages 4066-4071.;;GENOMICS, 1992, Vol. 14, WANG Y. et al., ""Molecular Cloning and Characterization of the Rat Liver IL-6 Signal Transducer Molecule, gp130"", pages 666-672.",PENDING
123,US,B2,US 9609087 B2,138-975-127-980-179,2017-03-28,2017,US 201514685221 A,2015-04-13,US 201514685221 A;;US 201213554679 A;;US 201161626692 P,2011-10-01,Sending and receiving configurable buckets of communications,A method of sending and receiving configurable buckets of communication is disclosed. A request to send a communication from an application executing on a client to an application executing on a server is received. The communication has a first priority. A request to send an additional communication from the application executing on the client to the application executing on the server is received. The additional communication has a second priority. The communication is placed into a bucket of communications based on the communication having the first priority. A determination is made to send the bucket of communications to the application executing on the server. The additional communication is placed into the bucket of communications based on a determination that the bucket of communications is not full. The bucket of communications is sent to the application executing on the server.,ZYNGA INC,DUNN IAN;;JONES ROBERT AARON;;RACANELLI DAN,ZYNGA INC (2012-07-30),https://lens.org/138-975-127-980-179,Granted Patent,yes,3,3,3,3,0,H04L47/2433;;H04L67/131;;H04L47/2433;;H04L67/01,G06F15/16;;H04L12/851;;H04L29/06,,3,0,,,"“U.S. Appl. No. 13/554,679, Non Final Office Action mailed Jul. 17, 2014”, 23 pgs.;;“U.S. Appl. No. 13/554,679, Notice of Allowance mailed Jan. 12, 2015”, 13 pgs.;;“U.S. Appl. No. 13/554,679, Response filed Oct. 17, 2014 to Non-Final Office Action dated Jul. 17, 2014”, 12 pgs.",ACTIVE
124,DE,D1,DE 69114421 D1,184-042-964-607-826,1995-12-14,1995,DE 69114421 T,1991-09-06,GB 9019897 A,1990-09-12,Vorrichtung zur Infrarot-Detektion bei mehreren Wellenlängen.,,MARCONI GEC LTD,BAKER IAN MARTIN;;DUNN WILLIAM ANDREW ERNEST,,https://lens.org/184-042-964-607-826,Granted Patent,no,0,0,10,10,0,H01L27/14669;;H01L27/14669,H01L27/146;;H01L27/14,,0,0,,,,EXPIRED
125,EP,A1,EP 0475525 A1,156-431-339-536-704,1992-03-18,1992,EP 91202283 A,1991-09-06,GB 9019897 A,1990-09-12,Plural-wavelength infrared detector devices.,"An infrared detector device for viewing an object or scene at plural wavelengths, e.g. in the 3 to 5 micron and 8 to 14 micron wavebands, comprises detector elements (10 and 20) formed in two or more infrared-sensitive materials with different bandgaps, e.g. in cadmium mercury telluride. These materials may be provided side-by-side in a single level on a substrate (3) or preferably as different levels (1 and 2) on the substrate (3). Each detector element (10 and 20) comprises a p-n junction (11 and 21) between opposite conductivity type regions (12,13 and 22,23). Electrical connections (15,25,24) extend from these regions to the substrate (3). A degree of versatility and freedom in the design and fabrication of the device is obtained by adopting a connection structure in accordance with the invention, in which one connection (25) of the longer-wavelength response element (20) contacts both the semiconductor material (2) of that element (20) and the larger-bandgap material (1) of the shorter-wavelength response element (10), at a side-wall (42) of both materials. The larger-bandgap material (1) comprises a further region (18) which adjoins the side-wall (42) and which forms a further p-n junction (19) electrically in parallel with the p-n junction (21) of the longer-wavelength detector element (20). This further p-n junction (19) has a higher impedance than the element p-n junction (21) due to the difference in bandgap, and so the output signal in this connection (25) is dominated by the photo-current generated in the longer-wavelength detector element (20).",PHILIPS ELECTRONICS UK LTD;;PHILIPS NV,BAKER IAN MARTIN;;DUNN WILLIAM ANDREW ERNEST,GEC-MARCONI LIMITED (1993-10-06);;N.V. PHILIPS' GLOEILAMPENFABRIEKEN (1992-04-22);;PHILIPS ELECTRONICS UK LIMITED (1992-04-22),https://lens.org/156-431-339-536-704,Patent Application,yes,5,17,10,10,0,H01L27/14669;;H01L27/14669,H01L27/146;;H01L27/14,,0,0,,,,EXPIRED
126,GB,A,GB 2247985 A,068-662-180-687-671,1992-03-18,1992,GB 9019897 A,1990-09-12,GB 9019897 A,1990-09-12,PLURAL-WAVELENGTH INFRARED DETECTOR DEVICES,,PHILIPS ELECTRONIC ASSOCIATED,BAKER IAN MARTIN;;DUNN WILLIAM ANDREW ERNEST,,https://lens.org/068-662-180-687-671,Patent Application,no,2,4,10,10,0,H01L27/14669;;H01L27/14669,H01L27/146;;H01L27/14,H1K KECA          ECA;;H1K K1EB          ECA;;H1K K11B1         ECA;;H1K K11C1A        ECA;;H1K K11D          ECA;;H1K K11D1         ECA;;H1K K4C11         ECA;;H1K K4C2A         ECA;;H1K K5BX          ECA;;H1K K5B3          ECA;;H1K K5B4          ECA;;H1K K9B1          ECA;;H1K K9B1A         ECA;;H1K K9E           ECA,0,0,,,,DISCONTINUED
127,US,B1,US 9032022 B1,187-490-787-385-297,2015-05-12,2015,US 201213554679 A,2012-07-20,US 201213554679 A;;US 201161626692 P,2011-10-01,Sending and receiving configurable buckets of communications,A method of sending and receiving configurable buckets of communication is disclosed. A request to send a communication from an application executing on a client to an application executing on a server is received. The communication has a first priority. A request to send an additional communication from the application executing on the client to the application executing on the server is received. The additional communication has a second priority. The communication is placed into a bucket of communications based on the communication having the first priority. A determination is made to send the bucket of communications to the application executing on the server. The additional communication is placed into the bucket of communications based on a determination that the bucket of communications is not full. The bucket of communications is sent to the application executing on the server.,DUNN IAN;;JONES ROBERT AARON;;RACANELLI DAN;;ZYNGA INC,DUNN IAN;;JONES ROBERT AARON;;RACANELLI DAN,ZYNGA INC (2012-07-30),https://lens.org/187-490-787-385-297,Granted Patent,yes,2,10,3,3,0,H04L47/2433;;H04L67/131;;H04L47/2433;;H04L67/01,G06F15/16;;H04L29/06,709/203;;709/201,0,0,,,,ACTIVE
128,US,B1,US 9223599 B1,016-133-343-492-511,2015-12-29,2015,US 201213436356 A,2012-03-30,US 201213436356 A,2012-03-30,Client-side server for client-side scripting languages,"A method of executing a cross-platform application on a system is disclosed. An instruction pertaining to an execution of the cross-platform application on the system is received. Based on a determination that the instruction pertains to a rendering of an element of a user interface of the cross-platform application on the system, the instruction is sent across a bridge to an engine executing in the native layer to process the instruction at the native layer. Alternatively, based on a determination that the instruction does not pertain to a rendering of the element of the user interface of the cross-platform application on the system, the instruction is sent to an engine executing in the cross-platform layer of the system to process the instruction at the cross-platform layer.",RACANELLI DAN;;DUNN IAN;;JONES ROBERT AARON;;ZYNGA INC,RACANELLI DAN;;DUNN IAN;;JONES ROBERT AARON,ZYNGA INC (2012-03-28),https://lens.org/016-133-343-492-511,Granted Patent,yes,19,23,1,1,0,G06F9/45512;;G06F9/45512,G06F9/44;;G06F9/45;;G06F9/455,,0,0,,,,ACTIVE
129,DE,T2,DE 69114421 T2,018-914-072-025-886,1996-03-21,1996,DE 69114421 T,1991-09-06,GB 9019897 A,1990-09-12,Vorrichtung zur Infrarot-Detektion bei mehreren Wellenlängen.,,MARCONI GEC LTD,BAKER IAN MARTIN;;DUNN WILLIAM ANDREW ERNEST,,https://lens.org/018-914-072-025-886,Granted Patent,no,0,0,10,10,0,H01L27/14669;;H01L27/14669,H01L27/146;;H01L27/14,,0,0,,,,EXPIRED
130,AU,B2,AU 631403 B2,049-930-408-012-021,1992-11-26,1992,AU 1990/051392 A,1990-03-16,AU PJ749289 A,1989-11-20,NOVEL MAIZE PRODUCTS,,GOODMAN FIELDER WATTIE AUSTRALIA LIMITED,CHARLES DUNN;;KENNETH MCWHIRTER;;IAN LEWIS BROWN,PENFORD AUSTRALIA LIMITED (2003-10-30),https://lens.org/049-930-408-012-021,Granted Patent,no,2,2,2,2,0,A23L23/00;;A23L29/212;;A23P20/12;;C08B30/044;;C08B30/20,A23L23/00;;A23L29/212;;A23P20/12;;C08B30/04;;C08B30/20,,0,0,,,,EXPIRED
131,US,A1,US 2015/0288784 A1,191-338-908-935-813,2015-10-08,2015,US 201514685221 A,2015-04-13,US 201514685221 A;;US 201213554679 A;;US 201161626692 P,2011-10-01,SENDING AND RECEIVING CONFIGURABLE BUCKETS OF COMMUNICATIONS,A method of sending and receiving configurable buckets of communication is disclosed. A request to send a communication from an application executing on a client to an application executing on a server is received. The communication has a first priority. A request to send an additional communication from the application executing on the client to the application executing on the server is received. The additional communication has a second priority. The communication is placed into a bucket of communications based on the communication having the first priority. A determination is made to send the bucket of communications to the application executing on the server. The additional communication is placed into the bucket of communications based on a determination that the bucket of communications is not full. The bucket of communications is sent to the application executing on the server.,ZYNGA INC,DUNN IAN;;JONES ROBERT AARON;;RACANELLI DAN,ZYNGA INC (2012-07-30),https://lens.org/191-338-908-935-813,Patent Application,yes,2,1,3,3,0,H04L47/2433;;H04L67/131;;H04L47/2433;;H04L67/01,H04L29/06,,0,0,,,,ACTIVE
132,AU,A,AU 1990/051392 A,005-124-273-385-935,1991-05-23,1991,AU 1990/051392 A,1990-03-16,AU PJ749289 A,1989-11-20,NOVEL MAIZE PRODUCTS,,NAT STARCH LLC,DUNN CHARLES;;MCWHIRTER KENNETH;;BROWN IAN LEWIS,PENFORD AUSTRALIA LIMITED (2003-10-30),https://lens.org/005-124-273-385-935,Patent Application,no,0,0,2,2,0,C08B30/044;;C08B30/20;;A23P20/12;;A23L29/212;;A23L23/00,A23L23/00;;A23L29/212;;A23P20/12;;C08B30/04;;C08B30/20,,0,0,,,,EXPIRED
133,US,A,US 5185648 A,040-166-474-970-115,1993-02-09,1993,US 75738091 A,1991-09-10,GB 9019897 A,1990-09-12,PLURAL-WAVELENGTH INFRARED DETECTOR DEVICES,"An infrared detector device for at least two wavelengths, i.e. 3 to 5 microns and 8 to 14 microns, comprises detector elements (10 and 20) formed in two or more infrared-sensitive materials with different badgaps, e.g. in cadmium mercury telluride. These materials may be provided side-by-side in a single level on a substrate (3) or preferably as different levels (1 and 2) on the substrate (3). Each detector element (10 and 20) comprises a p-n junction (11 and 21) between opposite conductivity type regions (12,13 and 22,23). Electrical connections (15,25,24) extend from these regions to the substrate (3). Freedom in design and fabrication is obtained by a connection structure in which one connection (25) of the longer-wavelength response element (20) contacts both the semiconductor material (2) of that element (20) and the larger-bandgap material (1) of the shorter-wavelength response element (10), at a side-wall (42) of both materials. The larger-bandgap material (1) comprises a further region (18) which adjoins the side-wall (42) and which forms a further p-n junction (19) electrically in parallel with the p-n junction (21) of the longer-wavelength detector element (20).",PHILIPS CORP,BAKER IAN M;;DUNN WILLIAM A E,GEC-MARCONI LIMITED (1993-06-07);;U.S. PHILIPS CORPORATION A CORP. OF DE (1991-07-16),https://lens.org/040-166-474-970-115,Granted Patent,yes,8,38,10,10,0,H01L27/14669;;H01L27/14669,H01L27/146;;H01L27/14,257/189;;257/442;;257/448;;257/446;;257/441;;257/466,0,0,,,,EXPIRED
134,EP,B1,EP 0511230 B1,168-857-431-748-957,1997-11-05,1997,EP 91901651 A,1991-01-08,AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A;;AU 2006/091000 W,1990-01-08,SYSTEM FOR EXTINGUISHING OF FIRES,"An apparatus and system for storing and supplying liquid CO2 at low pressure for extinguishing fires. The apparatus comprises a pressure vessel (13) for storing liquid CO2 at low pressure, a cooling means (29) in contact with gaseous CO2 in the vessel to maintain the low pressure, an inlet (24) and outlet (32) to fill the vessel and a supply conduit (17) communicating with a lower portion of the interior of the vessel to allow liquid CO2 to pass from the vessel and into a reticulation system. A number of pressure vessels can be coupled together through a manifold (165) to provide the required amount of liquid CO2 to a risk site. Supply valves (18) or manifold valves (173, 174) can be operated by a sensor (175, 176) in a risk site and a logic processor (177) can be used to regulate the valves and thereby the liquid CO2. The apparatus and system is particularly designed as a replacement for current halon systems which cause damage to the ozone layer.",PYROZONE PTY LTD,ALLISON JAMES HENRY;;TRONC IAN ROBERT;;DUNN PETER,,https://lens.org/168-857-431-748-957,Granted Patent,yes,0,0,10,13,0,A62C35/15;;A62C35/62;;F17C7/02;;F17C2201/0109;;F17C2201/032;;F17C2203/0333;;F17C2203/0629;;F17C2205/0332;;F17C2205/0335;;F17C2221/013;;F17C2223/0153;;F17C2223/035;;F17C2223/047;;F17C2250/032;;F17C2250/036;;F17C2250/061;;F17C2270/0754,A62C35/15;;A62C35/62;;F17C7/02,,8,0,,,EP-A- 0 107 837;;GB-A- 0 232 750;;GB-A- 0 509 101;;GB-A- 0 586 291;;GB-A- 0 784 734;;US-A- 2 482 778;;US-A- 2 529 127;;US-A- 2 544 016,EXPIRED
135,AU,B2,AU 659077 B2,098-791-813-021-175,1995-05-11,1995,AU 1991/070463 A,1991-01-08,AU 1991/070463 A;;AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A;;AU 2006/091000 W,1990-01-08,Apparatus and system for the storage and supply of liquid CO2 at low pressure for extinguishing of fires,,PYROZONE PTY LTD,ALLISON JAMES HENRY;;TRONC IAN ROBERT;;DUNN PETER,,https://lens.org/098-791-813-021-175,Granted Patent,no,2,0,2,13,0,,A62C35/15;;A62C35/62;;F17C7/02,,0,0,,,,EXPIRED
136,EP,A1,EP 0511230 A1,004-306-056-649-587,1992-11-04,1992,EP 91901651 A,1991-01-08,AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A;;AU 2006/091000 W,1990-01-08,APPARATUS AND SYSTEM FOR THE STORAGE AND SUPPLY OF LIQUID CO 2? AT LOW PRESSURE FOR EXTINGUISHING OF FIRES.,"An apparatus and system for storing and supplying liquid CO2 at low pressure for extinguishing fires. The apparatus comprises a pressure vessel (13) for storing liquid CO2 at low pressure, a cooling means (29) in contact with gaseous CO2 in the vessel to maintain the low pressure, an inlet (24) and outlet (32) to fill the vessel and a supply conduit (17) communicating with a lower portion of the interior of the vessel to allow liquid CO2 to pass from the vessel and into a reticulation system. A number of pressure vessels can be coupled together through a manifold (165) to provide the required amount of liquid CO2 to a risk site. Supply valves (18) or manifold valves (173, 174) can be operated by a sensor (175, 176) in a risk site and a logic processor (177) can be used to regulate the valves and thereby the liquid CO2. The apparatus and system is particularly designed as a replacement for current halon systems which cause damage to the ozone layer.",PYROZONE PTY LTD,ALLISON JAMES HENRY;;TRONC IAN ROBERT;;DUNN PETER,,https://lens.org/004-306-056-649-587,Patent Application,yes,0,1,10,13,0,A62C35/15;;A62C35/62;;F17C7/02;;F17C2201/0109;;F17C2201/032;;F17C2203/0333;;F17C2203/0629;;F17C2205/0332;;F17C2205/0335;;F17C2221/013;;F17C2223/0153;;F17C2223/035;;F17C2223/047;;F17C2250/032;;F17C2250/036;;F17C2250/061;;F17C2270/0754,A62C35/15;;A62C35/62;;F17C7/02,,0,0,,,,EXPIRED
137,US,A1,US 2004/0253235 A1,076-751-790-670-652,2004-12-16,2004,US 65161603 A,2003-08-29,US 65161603 A;;US 40749202 P,2002-08-29,Methods for up-regualting antigen expression of tumors,"
   The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against a tumor cell. Methods include administering to a subject with a tumor an amount of IFN- receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell. 
",DURDA PAUL;;KURNICK JAMES T.;;DUNN IAN S.,DURDA PAUL;;KURNICK JAMES T;;DUNN IAN S,CYTOCURE LLC (2004-04-12),https://lens.org/076-751-790-670-652,Patent Application,yes,9,17,14,14,28,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61B19/00;;A61K/;;A61K38/21;;A61K39/00;;A61K39/395;;C07K16/30;;G01N33/50,424/143.1,0,0,,,,EXPIRED
138,US,B2,US 8071321 B2,109-217-223-350-80X,2011-12-06,2011,US 65161603 A,2003-08-29,US 65161603 A;;US 40749202 P,2002-08-29,Methods for up-regulating antigen expression in tumors,"The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against a tumor cell. Methods include administering to a subject with a tumor an amount of IFN-β receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.",DURDA PAUL;;KURNICK JAMES T;;DUNN IAN S;;CYTOCURE LLC,DURDA PAUL;;KURNICK JAMES T;;DUNN IAN S,CYTOCURE LLC (2004-04-12),https://lens.org/109-217-223-350-80X,Granted Patent,yes,12,0,14,14,30,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61K39/395;;A61B19/00;;A61K/;;A61K38/21;;A61K39/00;;C07K16/30;;G01N33/50,435/7.23;;424/143.1,106,104,050-636-149-346-788;;034-891-431-823-507;;032-854-664-208-42X;;018-564-556-191-197;;064-252-779-422-330;;146-892-709-279-821;;003-069-172-605-853;;024-708-521-475-63X;;005-115-074-264-765;;152-236-741-903-024;;030-471-063-843-654;;012-063-847-650-863;;064-314-454-152-652;;029-129-985-153-386;;068-747-774-839-428;;013-733-057-290-943;;001-236-298-393-975;;029-457-014-702-20X;;015-050-824-887-450;;036-939-239-601-958;;010-471-035-015-83X;;066-674-928-861-824;;006-650-069-475-059;;128-588-287-691-509;;081-264-681-794-624;;073-001-983-461-708;;014-977-169-455-383;;039-122-901-560-787;;009-020-417-635-665;;024-671-083-184-915;;007-890-695-685-714;;035-976-778-643-686;;138-793-470-009-657;;066-220-614-804-177;;005-541-752-859-39X;;035-886-219-820-704;;040-111-549-307-150;;157-738-588-555-159;;085-407-027-879-720;;096-274-815-644-917;;096-368-415-142-755;;014-580-892-851-347;;121-132-127-566-194;;071-790-243-452-314;;030-377-777-338-368;;038-643-698-122-85X;;094-188-421-623-781;;018-004-761-934-29X;;038-389-934-017-103;;025-681-331-930-215;;069-436-282-814-513;;068-926-172-082-45X;;017-337-523-761-986;;152-236-741-903-024;;013-562-399-053-178;;096-675-965-150-514;;039-518-641-312-613;;076-997-125-144-345;;086-568-467-867-938;;124-486-603-151-676;;133-344-830-073-594;;021-275-890-060-157;;079-527-914-865-260;;069-504-103-122-880;;085-547-782-448-769;;082-239-944-047-658;;030-383-921-769-180;;023-951-067-124-058;;001-032-316-580-180;;168-622-529-554-249;;028-471-251-046-466;;049-783-945-967-926;;045-463-909-612-791;;198-883-931-557-417;;017-981-364-818-638;;138-049-927-174-594;;074-573-889-329-575;;062-455-214-476-160;;042-060-698-565-589;;134-012-734-800-849;;054-875-434-329-219;;157-340-086-544-951;;001-202-479-189-134;;040-419-173-387-324;;076-296-402-888-296;;127-769-191-559-032;;052-752-897-747-174;;007-025-899-057-588;;039-456-596-424-788;;007-323-091-709-235;;145-102-337-092-357;;079-394-017-103-139;;004-740-182-961-805;;015-157-310-611-561;;072-035-342-031-360;;024-031-601-353-024;;039-650-520-672-071;;038-608-207-579-131;;092-764-883-182-167;;134-143-182-401-486;;145-774-848-623-334;;022-675-958-576-600;;090-720-794-700-316;;032-325-608-259-827,14519650;;10.1038/442739a;;16915261;;16760006;;10.1007/s12094-006-0177-7;;14643925;;10.1016/s0304-419x(03)00032-5;;10586214;;pmc1484849;;16725231;;10.1016/j.vaccine.2006.04.059;;15800663;;10.1038/sj.gt.3302490;;16951315;;10.4049/jimmunol.177.6.3564;;14636243;;10.1046/j.0818-9641.2003.01189.x;;10.1158/1078-0432.ccr-13-17-cor1;;14752422;;10.1016/j.jtcvs.2003.08.034;;10.1002/ijc.20331;;15252850;;17689283;;10.1016/j.cytogfr.2007.06.022;;pmc2682546;;10.1089/107999003772084860;;14769151;;16410805;;10.1038/sj.cdd.4401829;;18844238;;10.1002/jcp.21602;;10.1056/nejmoa053007;;16481638;;17693125;;10.1016/j.cytogfr.2007.06.020;;16904983;;10.1016/j.surg.2006.05.005;;10.1007/s00403-008-0841-6;;18324409;;16928243;;10.1111/j.1610-0387.2006.06054.x;;10.1016/j.gie.2006.05.032;;17643724;;10.1111/j.1540-9740.2006.05678.x;;17085993;;10.1111/j.1468-1331.2007.01989.x;;18171383;;16052229;;10.1038/sj.cgt.7700878;;10.1111/j.1572-0241.2005.00323.x;;16405555;;10.1002/jcp.1041370105;;2459141;;10.1158/1078-0432.ccr-08-0846;;pmc2762274;;18794103;;18545995;;10.1007/s00251-008-0303-5;;10.1159/000086973;;16020961;;14629628;;10.1046/j.1365-3083.2003.01324.x;;10.1097/00008390-200308000-00003;;12883360;;11507073;;14633712;;10.2174/138945008783954970;;18393827;;10.1089/jir.1985.5.11;;3989332;;10.1016/s0006-291x(81)80248-3;;6168262;;18754879;;10.1111/j.1349-7006.2008.00850.x;;10.1016/j.cyto.2008.04.010;;pmc2582834;;18511292;;18386001;;10.1007/s00262-008-0466-9;;10.1186/1471-2407-8-12;;pmc2242792;;18199340;;17962723;;10.1159/000110424;;17965534;;10.1272/jnms.74.377;;10.4161/cbt.6.9.4569;;10.1021/bc050237q;;16417267;;10.1097/00008390-200512000-00001;;16314732;;16204058;;10.1158/0008-5472.can-05-1387;;15946236;;10.1111/j.0906-6705.2005.00305.x;;pmc2175172;;10.1097/00002371-200501000-00007;;15614045;;14646625;;10.1097/00008390-200312000-00011;;10.1097/01.cmr.0000056285.15046.ff;;10.1067/mge.2003.219;;12739558;;10.1001/archderm.139.3.273;;12622616;;12498390;;10.1023/a:1020923326441;;10.1158/1078-0432.ccr-13-17-cor1;;10.1056/nejme058307;;16481646;;10.1016/s0065-2776(06)90007-8;;16730266;;10.1182/blood-2007-12-128843;;18509084;;pmc2532803;;18779394;;10.1182/blood-2008-06-163006;;19935776;;10.1038/mt.2009.275;;pmc2839441;;10.1021/pr800174k;;18698805;;10.4049/jimmunol.174.8.5092;;15814740;;10.1007/s11060-007-9488-y;;17975708;;2064311;;9216712;;10.1038/sj.onc.1207043;;14576832;;18384130;;10.1002/gcc.20567;;9176405;;pmc1858329;;17886559;;10.3171/jns-07/09/0586;;2596269;;10.1007/bf00294380;;20043222;;10.1007/s00262-009-0811-7;;17164780;;10.1038/sj.mt.6300003;;19183173;;10.1111/j.1365-2133.2008.09001.x;;19066887;;10.1007/s00262-008-0634-y;;10.2741/3237;;19074888;;10.1158/0008-5472.can-08-2149;;pmc2605679;;15328877;;10.4049/jimmunol.179.4.2134;;17675472;;12479262;;10.1034/j.1600-0625.2002.110402.x;;12190937;;19861461;;10.1158/1078-0432.ccr-08-2801;;10.1002/pmic.200800228;;18690647;;10.1007/s11064-008-9659-z;;18357521;;19659607;;10.1111/j.1349-7006.2009.01269.x;;pmc3680099;;10.1023/a:1006428529637;;10930098;;10.1007/s002620000163;;11258793;;7796403;;8631027;;10.1111/j.1349-7006.2008.01072.x;;19154416;;16888034;;10.4049/jimmunol.177.4.2717;;10.1038/sj.onc.1208900;;16007121;;10.1034/j.1600-0749.2000.130408.x;;10952394;;10.1046/j.1365-2133.2003.05171.x;;12653746;;10.2210/pdb1au1/pdb;;10.1073/pnas.94.22.11813;;9342320;;pmc23607;;10.1097/00002371-199807000-00001;;9672845;;pmc2836041;;10.1074/jbc.m109.066092;;20018898;;10.1038/onc.2008.364;;18820707;;10.1002/1097-0215(20000520)89:3<251::aid-ijc7>3.0.co;2-5;;10861501;;12187957;;10.1023/a:1016218117251;;pmc3312613;;10.1158/1055-9965.epi-07-2729;;18398036;;10.1023/a:1010680920087;;11508811;;11466335;;10.4049/jimmunol.167.3.1204;;19308988;;10.1002/jcb.22138;;10.1016/j.cancergencyto.2009.03.002;;19480934;;10.1046/j.1365-2133.2003.05301.x;;12828737,"Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).;;Dennis (Nature 442:739-741 (2006)).;;Cespdes et al. (Clin. Transl. Oncol. 8(5):318-329 (2006)).;;Mocellin et al. (Biochem. Biophys. Acta 1653:61-71 (2003)).;;American Cancer Society, Cancer reference information: ""How is melanoma skin cancer staged?"", pp. 1-7 (May 14, 2009).;;American Cancer Society, Cancer reference information: ""How are brain and spinal tumors in adults staged?"", p. 1 (Aug. 28, 2009).;;Bordignon et al (Haematologica 84:1110-1149 (1999)).;;Leitner et al., ""Type I Interferons are essential for the efficacy of replicase-based DNA vaccines"", Vaccine 24:24 , 5110-5118 (2006).;;Zhang et al., ""A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte"", Gene Ther. 12:13, 1049-1057 (2005).;;Shibata et al., ""Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene"", J. Immunol. 177:6, 3564-3576 (2006).;;Dezfouli et al., ""Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells"", Immunol. Cell Biol. 81 :6, 459-471 (2003).;;Sterman et al., ""A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses"", Clin. Cancer Res. 13 :15, 4456-4466 (2007).;;Kruklitis et al., ""Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma"", J. Thorac. Cardiovasc. Surg. 127 :1, 123-130 (2004).;;Saito et al., ""Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma"", Int. J. Cancer 111: 5, 777-782 (2004).;;Borden, ""Augmentatio n of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma"", Cytokine. Growth Factor Rev. 18:5-6, 491-501 (2007).;;Learman et al., ""Novel growth and death related interferon-stimulated gene s (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2"", J. Interferon Cytokine. Res. 23: 12, 745-756 (2003).;;Sarkar et al., ""Defining the mechanism by which IFN-beta dowregulates c-myc expression in human melan oma cells: pivotal role of human polynucleotide phosphorylase (hPNPaseold-35)"", Cell Death Differ. 13 :9, 1541-1553 (2006).;;Staudt et al., ""Model cell culture system for defining the molecular and biochemical events mediating terminal differentiation of human melanoma cells"", J. Cell. Physiol. online (Oct. 9, 2008).;;Gogas et al., ""Prognostic significance of autoimmunity during treatment of melanoma with interferon"", N. Engl . J. Med. 354:7, 709-718 (2006).;;Moschos et al., ""Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma"", Cytokine. Growth Factor Rev. 18:5-6, 451-458 (2007).;;Brown et al., ""Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitutmor effects"", Surgery 140 :2, 297-306 (2006).;;Kubo et al., ""Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells"", Arch. Dermatol. Res. 300:6, 297-301 (2008).;;Rapprich et al., ""Intralesional therapy of metastatic spreading melanoma with beta-interferon"", J. Dtsch. Dermatol. Ges. 4 :9, 743-746 (2006).;;Kawada et al., ""Local injection of interferon beta in malignan t melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival"", Gastrointest. Endosc. 66 :2, 408-410 (2007).;;Voelter-Mahlknecht et al., ""Phase 2 trial of the continuou s IV administration of interferon-beta in patients with disseminated malignant melanoma"", Skinmed. 5:6, 271-276 (2006).;;Gibbs et al., ""Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta"", Eur. J. Neurol. 15:1, e4-EOA (2008).;;Streck et al., ""Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta"", Cancer Gene Ther. 13:1, 99-106 (2006).;;Gurguta et al., ""Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C"", Am. J. Gastroenterol. 101:1, 197-198 (2006).;;Kameyama et al., ""Expression of melanocyte stimulating hormone receptors correlates with mammalian pigmentation, and ca n be modulated by interferons"", J. Cell. Physiol. 137:1, 35-44 (1988).;;Zimmerer et al., ""Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha"", Clin. Cancer Res. 14:18, 5900-5906 (2008).;;Carretero et al., ""Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy"", Immunogenetics 60:8, 439-447 (2008).;;Domingo-Domenech et al., ""Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon-comparison with tyrosinase rt-PCR"", Oncology 68:4-6, 341-349 (2005).;;Terheyden et al., ""Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression"", Scand . J. Immunol. 58 :5, 566-571 (2003).;;Ryuke et al., ""Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy"", Melanoma Res. 13:4, 349-356 (2003).;;Odaka et al., ""Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity"", Cancer Res. 61 :16, 6201-6212 (2001).;;DeLong et al., ""Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy"", Cancer Res. 63:22, 7845-7852 (2003).;;Birlea et al., ""Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigment ation"", Curr. Drug Targets 9:4, 345-359 (2008).;;Fisher et al., ""Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells"", J. Interferon Res. 5 :1, 11-22 (1985).;;Fisher et al., ""Interferon inhibits m elanogenesis in B-16 mouse melanoma cells"", Biochem. Biophys. Res. Commun. 100 :2, 823-830 (1981).;;Takahashi et al., ""Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumo r cells"", Cancer Sci. 99:8, 1650-1655 (2008).;;Ekmekcioglu et al., ""Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24"", Cytokine. 43:1, 34-44 (2008).;;Wang et al., ""Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma"", Cancer Immunol. Immunother. 57 :9, 1315-1321 (2008).;;Jiang et al., ""Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway"", BMC Cancer. 8:12, 1-8 (2008).;;Domingo-Domenech et al., ""Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients"", Tumour Biol. 28:5, 264-272 (2007).;;Seya et al., ""Case of rectal malignan t melanoma showing immunohistochemical variability in a tumor"", J. Nippon Med. Sch. 74 :5, 377-381 (2007).;;Kumar et al., ""Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells"", Cancer Biol. Ther. 6:9, 1437-1441 (2007).;;Baker et al., ""N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model"", Bioconjug. Chem. 17:1, 179-188 (2006).;;Kovarik et al., ""Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines"", Melanoma Res. 15 :6, 481-488 (2005).;;Gollob et al., ""Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma"", Cancer Res. 65:19, 8869-8877 (2005).;;Jrosevic et al., ""Expression of melanoma-associated antigens in melanoma cell cultures"", Exp. Dermatol. 14 :7, 491-497 (2005).;;Zhou et al., ""Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy"", J. Immunother. 28 :1, 53-62 (2005).;;Paul et al., ""Treatment of locoregional metastases of malignan t melanomas with radiotherapy and intralesional beta-interferon injection"", Melanoma Res. 13:6, 611-617 (2003).;;Sakamoto et al., ""Treatment of primary malignant melanoma of the esophagus with endoscopic injection of interferon-beta combined with systemic chemotherapy: a case report"", Gastrointest. Endosc. 57 :6, 773-777 (2003).;;Wolf et al., ""Topical imiquimod in the treatment of metastatic melanoma to skin"", Arch. Dermatol. 139 :3, 273-276 (2003).;;McCarty et al., ""Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms"", Clin. Exp. Metastasis 19 :7, 609-615 (2002).;;Kanther, ""Erratum of ""A phase I clinical trial of si ngle-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses"""", Clin. Cancer. Res. 13:17, 5226-EOA (2007).;;Koon et al., ""Autoimmunity and immunotherap y for cancer"", N. Engl. J. Med. 354:7, 758-760 (2006).;;Slingluff et al., ""Immunity to melanoma antigens: from self-tolerance to immunotherapy"", Adv. Immunol. 90, 243-295 (2006).;;Till et al., ""Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically autologous CD20-specific T cells"", Blood, 112:6, 2261-2271 (2008).;;Cooper, ""Test-driving CARs"", Blood, 112:6, 2172-2173 (2008).;;Adamina et al., ""Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma,"" Mol. Ther. 18:651-659, 2010. [Epub ahead of print: Nov. 24, 2009.];;Al-Ghoul et al., ""Comparative Proteomic Analysis of Matched Primary and Metastatic Melanoma Cell Lines,"" J. Proteome Res. 7:4107-4118, 2008.;;Ayyoub et al., ""CD4+ T Cell Responses to SSX-4 in Melanoma Patients,"" J. Immunol. 174:5092-5099, 2005.;;Bassi et al., ""HMGB1 as an Autocrine Stimulus in Human T98G Glioblastoma Cells: Role in Cell Growth and Migration,"" J. Neurooncol. 87:23-33, 2008. [Epub Nov. 2, 2007.];;Bilzer et al., ""Antigen Variation in a Human Glioblastoma: From the Primary Tumor to the Second Recurrence, Permanent Cell Line and Xenotransplantation Tumors,"" Anticancer Res. 11:547-553, 1991. (Abstract Only).;;Bodey et al., ""Immunocytochemical Detection of Prostate Specific Antigen Expression in Human Primary and Metastatic Melanomas,"" Anticancer Res. 17:2343-2346, 1997. (Abstract Only).;;Boon et al., ""Comparison of Medulloblastoma and Normal Neural Transcriptomes Identifies a Restricted Set of Activated Genes,"" Oncogene 22:7687-7694, 2003.;;Castiglia et al., ""Concomitant Activation of Wnt Pathway and Loss of Mismatch Repair Function in Human Melanoma,"" Genes Chromosomes Cancer 47:614-624, 2008. (Abstract Only).;;Chi et al., ""Molecular Detection of Tumor-Associated Antigens Shared by Human Cutaneous Melanomas and Gliomas,"" Am. J. Pathol. 150:2143-2152, 1997.;;Clark et al., ""Wilms Tumor 1 Expression in Malignant Gliomas and Correlation of +KTS Isoforms with p53 Status,"" J. Neurosurg. 107:586-592, 2007.;;Cruz-Sanchez et al., ""Medulloblastoma. An Immunohistological Study of 50 Cases,"" Acta Neuropathol. 79:205-210, 1989. (Abstract Only).;;Dangoor et al., ""Clinical and Immunological Responses in Metastatic Melanoma Patients Vaccinated with a High-Dose Poly-Epitope Vaccine,"" Cancer Immunol. Immunother. (p. 1-11) [Epub ahead of print: Dec. 31, 2009.];;Dardousis et al., ""Identification of Differentially Expressed Genes Involved in the Formation of Multicellular Tumor Spheroids by HT-29 Colon Carcinoma Cells,"" Mol. Ther. 15:94-102, 2007.;;De Panfilis et al., ""Cytoplasmic beta-Catenin is Lacking in a Subset of Melanoma-Associated Naevi, But is Detectable in Naevus-Associated Melanomas: Potential Implications for Melanoma Tumorigenesis?"" Br. J. Dermatol. 160:600-608, 2009.;;Diaz et al., ""Anti-Ganglioside Anti-Idiotypic Monoclonal Antibody-Based Cancer Vaccine Induces Apoptosis and Antiangiogenic Effect in a Metastatic Lung Carcinoma,"" Cancer Immunol. Immunother. 58:1117-1128, 2009a. [Epub ahead of print: Dec. 10, 2008.];;Diaz et al., ""Epidermal Growth Factor Receptor Modulates the Tumorigenic Potential of Melanoma,"" Front. Biosci. 14:159-166, 2009b.;;Dissanayake et al., ""Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation,"" Cancer Res. 68:10205-10214, 2008.;;du Plessis et al., ""Phenotypic and Genotypic Characterization of Glioblastoma Multiforme with Epithelial Differentiation and Adenoid Formations,"" Clin. Neuropathol. 23:141-148, 2004. (Abstract Only).;;Dunn et al., ""Enhancement of Human Melanoma Antigen Expression by IFN-beta,"" J. Immunol. 179:2134-2142, 2007.;;Egland et al., ""Characterization of Overlapping XAGE-1 Transcripts Encoding a Cancer Testis Antigen Expressed in Lung, Breast, and Other Types of Cancers,"" Mol. Cancer Ther. 1:441-450, 2002.;;Eichmüller et al., ""mRNA Expression of Tumor-Associated Antigens in Melanoma Tissues and Cell Lines,"" Exp. Dermatol. 11:292-301, 2002.;;Felsberg et al., ""Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients,"" Clin. Cancer Res. 15:6683-6693, 2009. [Epub Oct. 27, 2009.];;Furukawa et al., ""Molecules in the Signaling Pathway Activated by Gangliosides can be Targets of Therapeutics for Malignant Melanomas,"" Proteomics 8:3312-3316, 2008.;;George et al., ""Bcl-2 siRNA Augments Taxol Mediated Apoptotic Death in Human Glioblastoma U138MG and U251MG Cells,"" Neurochem. Res. 34:66-78, 2009. [Epub Mar. 21, 2008.];;Graner et al., ""Heat Shock Protein 70-Binding Protein 1 is Highly Expressed in High-Grade Gliomas, Interacts with Multiple Heat Shock Protein 70 Family Members, and Specifically Binds Brain Tumor Cell Surfaces,"" Cancer Sci. 100:1870-1879, 2009. [Epub Jul. 1, 2009.] (Abstract Only).;;Harada et al., ""Growth Inhibition of Human Glioma Cells by Transfection-Induced P21 and its Effects on Telomerase Activity,"" J. Neurooncol. 47:39-46, 2000. (Abstract Only).;;Heinzel et al., ""The Self Peptide Annexin II (208-223) Presented by Dendritic Cells Sensitizes Autologous CD4+ T Lymphocytes to Recognize Melanoma Cells,"" Cancer Immunol Immunother. 49:671-678, 2001.;;Helling et al., ""GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients after Administration with Immunological Adjuvant QS-21,"" Cancer Res. 55:2783-2788, 1995.;;Ishiguro et al., ""Identification of Genes Differentially Expressed in B16 Murine Melanoma Sublines with Different Metastatic Potentials,"" Cancer Res. 56:875-879, 1996.;;Ito et al., ""Inhibition of Heat Shock Protein 90 Sensitizes Melanoma Cells to Thermosensitive Ferromagnetic Particle-Mediated Hyperthermia with Low Curie Temperature,"" Cancer Sci. 100:558-564, 2009.;;Janjic et al., ""Spontaneous CD4+ T Cell Responses Against TRAG-3 in Patients with Melanoma and Breast Cancers,"" J. Immunol. 177:2717-2727, 2006.;;Javelaud et al., ""Stable Overexpression of Smad7 in Human Melanoma Cells Inhibits Their Tumorigenicity In Vitro and In Vivo,"" Oncogene 24:7624-7629, 2005.;;Jouneau et al., ""Plasticity of Cadherin-Catenin Expression in the Melanocyte Lineage,"" Pigment Cell Res. 13:260-272, 2000.;;Kageshita et al., ""Widespread Expression of Parathyroid Hormone-Related Peptide in Melanocytic Cells,"" Br. J. Dermatol. 148:533-538, 2003.;;Karpusas et al., ""The Crystal Structure of Human Interferon beta at 2.2-Å Resolution,"" Proc. Natl. Acad. Sci. USA 94:11813-11818, 1997.;;Kawakami et al., ""The Use of Melanosomal Proteins in the Immunotherapy of Melanoma,"" J. Immunother. 21:237-246, 1998. (Abstract Only).;;Kesavan et al., ""Annexin A2 Is a Molecular Target for TM601, a Peptide with Tumor-Targeting and Anti-Angiogenic Effects,"" J. Biol. Chem. 285:4366-4374, 2010. [Epub Dec. 15, 2009.];;Kim et al., ""Ubiquitin C-Terminal Hydrolase-L1 is a Key Regulator of Tumor Cell Invasion and Metastasis,"" Oncogene 28:117-127, 2009.;;Kjellman et al., ""Expression of TGF-beta Isoforms, TGF-beta Receptors, and SMAD Molecules at Different Stages of Human Glioma,"" Int. J. Cancer 89:251-258, 2000.;;Korshunov et al., ""Immunohistochemical Markers for Prognosis of Cerebral Glioblastomas,"" J. Neurooncol. 58:217-236, 2002.;;Kreizenbeck et al., ""Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma,"" Cancer Epidemiol. Biomarkers Prev. 17:949-958, 2008.;;Krex et al., ""Identification of Uncommon Chromosomal Aberrations in the Neuroglioma Cell Line H4 by Spectral Karyotyping,"" J. Neurooncol. 52:119-128, 2001. (Abstract Only).;;Kurnick et al., ""A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein that Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of its Promoter,"" J. Immunol. 167:1204-1211, 2001.;;Lo et al., ""Control Mechanisms of Differential Translation of Hsp90 Isoforms in 9L Rat Gliosarcoma Cells,"" J. Cell. Biochem. 107:418-427, 2009. (Abstract Only).;;Lueth et al., ""Somatic Mitochondrial Mutations in Pilocytic Astrocytoma,"" Cancer Genet. Cytogenet. 192:30-35, 2009.;;Maellaro et al., ""Different Effects of Interferon-alpha on Melanoma Cell Lines: A Study on Telomerase Reverse Transcriptase, Telomerase Activity and Apoptosis,"" Br. J. Dermatol. 148:1115-1124, 2003.",INACTIVE
139,EP,A4,EP 0511230 A4,022-433-364-936-62X,1994-04-13,1994,EP 91901651 A,1991-01-08,AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A;;AU 2006/091000 W,1990-01-08,EP 0511230 A4,"An apparatus and system for storing and supplying liquid CO2 at low pressure for extinguishing fires. The apparatus comprises a pressure vessel (13) for storing liquid CO2 at low pressure, a cooling means (29) in contact with gaseous CO2 in the vessel to maintain the low pressure, an inlet (24) and outlet (32) to fill the vessel and a supply conduit (17) communicating with a lower portion of the interior of the vessel to allow liquid CO2 to pass from the vessel and into a reticulation system. A number of pressure vessels can be coupled together through a manifold (165) to provide the required amount of liquid CO2 to a risk site. Supply valves (18) or manifold valves (173, 174) can be operated by a sensor (175, 176) in a risk site and a logic processor (177) can be used to regulate the valves and thereby the liquid CO2. The apparatus and system is particularly designed as a replacement for current halon systems which cause damage to the ozone layer.",PYROZONE PTY. LTD.,"ALLISON, JAMES, HENRY;;TRONC, IAN, ROBERT;;DUNN, PETER",,https://lens.org/022-433-364-936-62X,Search Report,no,1,0,10,13,0,A62C35/15;;A62C35/62;;F17C7/02;;F17C2201/0109;;F17C2201/032;;F17C2203/0333;;F17C2203/0629;;F17C2205/0332;;F17C2205/0335;;F17C2221/013;;F17C2223/0153;;F17C2223/035;;F17C2223/047;;F17C2250/032;;F17C2250/036;;F17C2250/061;;F17C2270/0754,A62C35/15;;A62C35/62;;F17C7/02,,0,0,,,,EXPIRED
140,WO,A1,WO 1991/010477 A1,138-128-767-945-569,1991-07-25,1991,AU 2006/091000 W,1991-01-08,AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A,1990-01-08,APPARATUS AND SYSTEM FOR THE STORAGE AND SUPPLY OF LIQUID CO2 AT LOW PRESSURE FOR EXTINGUISHING OF FIRES,"An apparatus and system for storing and supplying liquid CO2 at low pressure for extinguishing fires. The apparatus comprises a pressure vessel (13) for storing liquid CO2 at low pressure, a cooling means (29) in contact with gaseous CO2 in the vessel to maintain the low pressure, an inlet (24) and outlet (32) to fill the vessel and a supply conduit (17) communicating with a lower portion of the interior of the vessel to allow liquid CO2 to pass from the vessel and into a reticulation system. A number of pressure vessels can be coupled together through a manifold (165) to provide the required amount of liquid CO2 to a risk site. Supply valves (18) or manifold valves (173, 174) can be operated by a sensor (175, 176) in a risk site and a logic processor (177) can be used to regulate the valves and thereby the liquid CO2. The apparatus and system is particularly designed as a replacement for current halon systems which cause damage to the ozone layer.",PYROZONE PTY LTD,ALLISON JAMES HENRY;;TRONC IAN ROBERT;;DUNN PETER,,https://lens.org/138-128-767-945-569,Patent Application,yes,7,5,10,13,0,A62C35/15;;A62C35/62;;F17C7/02;;F17C2201/0109;;F17C2201/032;;F17C2203/0333;;F17C2203/0629;;F17C2205/0332;;F17C2205/0335;;F17C2221/013;;F17C2223/0153;;F17C2223/035;;F17C2223/047;;F17C2250/032;;F17C2250/036;;F17C2250/061;;F17C2270/0754,A62C35/15;;A62C35/62;;F17C7/02,,0,0,,,,PATENTED
141,AT,T1,AT E159862 T1,036-588-762-395-288,1997-11-15,1997,AT 91901651 T,1991-01-08,AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A,1990-01-08,FEUERLÖSCH-SYSTEM,"An apparatus and system for storing and supplying liquid CO2 at low pressure for extinguishing fires. The apparatus comprises a pressure vessel (13) for storing liquid CO2 at low pressure, a cooling means (29) in contact with gaseous CO2 in the vessel to maintain the low pressure, an inlet (24) and outlet (32) to fill the vessel and a supply conduit (17) communicating with a lower portion of the interior of the vessel to allow liquid CO2 to pass from the vessel and into a reticulation system. A number of pressure vessels can be coupled together through a manifold (165) to provide the required amount of liquid CO2 to a risk site. Supply valves (18) or manifold valves (173, 174) can be operated by a sensor (175, 176) in a risk site and a logic processor (177) can be used to regulate the valves and thereby the liquid CO2. The apparatus and system is particularly designed as a replacement for current halon systems which cause damage to the ozone layer.",PYROZONE PTY LTD,ALLISON JAMES HENRY;;TRONC IAN ROBERT;;DUNN PETER,,https://lens.org/036-588-762-395-288,Granted Patent,no,0,0,10,13,0,A62C35/15;;A62C35/62;;F17C7/02;;F17C2201/0109;;F17C2201/032;;F17C2203/0333;;F17C2203/0629;;F17C2205/0332;;F17C2205/0335;;F17C2221/013;;F17C2223/0153;;F17C2223/035;;F17C2223/047;;F17C2250/032;;F17C2250/036;;F17C2250/061;;F17C2270/0754,A62C35/15;;A62C35/62;;F17C7/02,,0,0,,,,DISCONTINUED
142,AU,A,AU 1991/070463 A,175-607-046-534-92X,1991-08-05,1991,AU 1991/070463 A,1991-01-08,AU 1991/070463 A;;AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A;;AU 2006/091000 W,1990-01-08,APPARATUS AND SYSTEM FOR THE STORAGE AND SUPPLY OF LIQUID CO2 AT LOW PRESSURE FOR EXTINGUISHING OF FIRES,,PYROZONE PTY LTD,ALLISON JAMES HENRY;;TRONC IAN ROBERT;;DUNN PETER,,https://lens.org/175-607-046-534-92X,Patent Application,no,0,3,2,13,0,,A62C35/15;;A62C35/62;;F17C7/02,,0,0,,,,EXPIRED
143,US,A,US 5850876 A,144-189-580-289-828,1998-12-22,1998,US 72582196 A,1996-10-07,US 72582196 A;;AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A;;AU 2006/091000 W;;US 46255395 A;;US 92050592 A,1990-01-08,Apparatus and system for the storage and supply of liquid CO2 at low pressure for extinguishing of fires,"An apparatus and system stores and supplies liquid CO.sub.2 at low pressure for extinguishing fires. The apparatus comprises a pressure vessel (13) for storing liquid CO.sub.2 at low pressure, a cooling device (29) in contact with gaseous CO.sub.2 in the vessel to maintain the low pressure, an inlet (24) and outlet (32) to fill the vessel and a supply conduit (17) communicating with a lower portion of the interior of the vessel to allow liquid CO.sub.2 to pass from the vessel and into a reticulation system. A number of pressure vessels can be coupled together through a manifold (165) to provide the required amount of liquid CO.sub.2 to a risk site. Supply valves (18) or manifold valves (173, 174) can be operated by a sensor (175, 176) in a risk site and a logic processor (177) can be used to regulate the valves and thereby the liquid CO.sub.2. The apparatus and system is particularly designed as a replacement for current halon systems which cause damage to the ozone layer.",PYROZONE PTY LTD,ALLISON JAMES H;;TRONC IAN R;;DUNN PETER,,https://lens.org/144-189-580-289-828,Granted Patent,yes,17,23,1,13,0,A62C35/15;;A62C35/62;;F17C7/02;;F17C2201/0109;;F17C2201/032;;F17C2201/056;;F17C2203/0333;;F17C2205/0111;;F17C2205/0146;;F17C2205/0314;;F17C2205/0332;;F17C2205/0335;;F17C2221/013;;F17C2221/014;;F17C2221/016;;F17C2223/0123;;F17C2223/0153;;F17C2223/033;;F17C2223/035;;F17C2227/0107;;F17C2250/032;;F17C2250/036;;F17C2260/036;;F17C2270/0754;;A62C35/15;;F17C7/02;;A62C35/62;;F17C2205/0111;;F17C2201/0109;;F17C2221/013;;F17C2223/0123;;F17C2250/036;;F17C2221/014;;F17C2260/036;;F17C2223/0153;;F17C2227/0107;;F17C2205/0335;;F17C2221/016;;F17C2205/0332;;F17C2223/035;;F17C2201/032;;F17C2270/0754;;F17C2250/032;;F17C2203/0333;;F17C2223/033;;F17C2205/0314;;F17C2205/0146;;F17C2201/056,A62C35/15;;A62C35/62;;F17C7/02,169/61;;169/11,0,0,,,,EXPIRED
144,HK,A1,HK 1004594 A1,139-837-517-658-784,1998-11-27,1998,HK 98103690 A,1998-04-30,AU PJ811890 A;;AU PJ993390 A;;AU PK026290 A;;AU 2006/091000 W,1990-01-08,System for extinguishing of fires,"An apparatus and system for storing and supplying liquid CO2 at low pressure for extinguishing fires. The apparatus comprises a pressure vessel (13) for storing liquid CO2 at low pressure, a cooling means (29) in contact with gaseous CO2 in the vessel to maintain the low pressure, an inlet (24) and outlet (32) to fill the vessel and a supply conduit (17) communicating with a lower portion of the interior of the vessel to allow liquid CO2 to pass from the vessel and into a reticulation system. A number of pressure vessels can be coupled together through a manifold (165) to provide the required amount of liquid CO2 to a risk site. Supply valves (18) or manifold valves (173, 174) can be operated by a sensor (175, 176) in a risk site and a logic processor (177) can be used to regulate the valves and thereby the liquid CO2. The apparatus and system is particularly designed as a replacement for current halon systems which cause damage to the ozone layer.",PYROZONE PTY LTD,ALLISON JAMES HENRY;;TRONC IAN ROBERT;;DUNN PETER,,https://lens.org/139-837-517-658-784,Patent Application,no,0,0,10,13,0,A62C35/15;;A62C35/62;;F17C7/02;;F17C2201/0109;;F17C2201/032;;F17C2203/0333;;F17C2203/0629;;F17C2205/0332;;F17C2205/0335;;F17C2221/013;;F17C2223/0153;;F17C2223/035;;F17C2223/047;;F17C2250/032;;F17C2250/036;;F17C2250/061;;F17C2270/0754,A62C35/15;;A62C35/62;;F17C7/02,,0,0,,,,EXPIRED
145,IN,B,IN 178094 B,011-403-880-700-721,1997-03-08,1997,IN 627MA1990 A,1990-08-01,CA 609315 A,1989-08-24,An optical fiber sensing system,,AT & T CORP,DUNN LAWRENCE RUSSELL;;WHITE IAN ARTHUR;;WHITE WILLARD CHANDLER,,https://lens.org/011-403-880-700-721,Granted Patent,no,0,0,1,1,0,,G01J9/02,,0,0,,,,EXPIRED
146,US,B2,US 11386604 B2,038-662-969-817-404,2022-07-12,2022,US 201917275046 A,2019-09-24,US 201917275046 A;;US 201862737771 P;;US 2019/0052585 W,2018-09-27,Moving an avatar based on real-world data,"In some implementations, a method is performed by a device including a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, the method includes obtaining user movement information. In some implementations, the user movement information characterizes a first body pose of the user at a first time and a second body pose of the user at a second time. In some implementations, the method includes determining whether a transition from the first body pose to the second body pose satisfies an acceptability threshold. In some implementations, the method includes in response to determining that the transition from the first body pose to the second body pose satisfies the acceptability threshold, generating a sequence of movements for a synthesized reality (SR) representation of the user.",APPLE INC,RICHTER IAN M;;DUNN CAMERON J;;RUSSELL JOHN C,,https://lens.org/038-662-969-817-404,Granted Patent,yes,14,0,6,6,0,G06F3/011;;G06F3/017;;G06T7/10;;G06T7/73;;G06F3/011;;G06T13/40,G06T13/40;;G06F3/01;;G06T7/10;;G06T7/73,,4,3,049-751-473-374-981;;010-530-238-020-409;;044-237-327-395-721,10.1109/tpami.2015.2439257;;27030844;;10.1109/iccv.2017.137;;10.1016/j.patcog.2014.08.011,"Boulbaba Ben Amor et al.; “Action Recognition Using Rate-Invariant Analysis of Skeletal Shape Trajectories;” IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 38, No. 1, Jan. 2016; 13 pages (Year: 2016).;;Y. Chen, C. Shen, X.-S. Wei, L. Liu and J. Yang, “Adversarial PoseNet: A Structure-Aware Convolutional Network for Human Pose Estimation,” 2017 IEEE International Conference on Computer Vision (ICCV), 2017, pp. 1221-1230, doi: 10.1109/ICCV.2017.137. (Year: 2017).;;Slama, et al.;“Accurate 3D action recognition using learning on the Grassmann manifold;” Pattern Recognition, vol. 28 (2015), pp. 556-567; Elsevier Ltd—(Year: 2015).;;PCT International Search Report and Written Opinion dated Feb. 4, 2020, International Application No. PCT/US2019/052585, pp. 1-16.",ACTIVE
147,WO,A2,WO 2004/019886 A2,044-013-903-192-074,2004-03-11,2004,US 0327125 W,2003-08-29,US 40749202 P,2002-08-29,METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS,"The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against tumor cell. Methods include administering to a subject with a tumor an amount of IFN-&bgr; receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.",CYTOCURE LLC;;DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/044-013-903-192-074,Patent Application,yes,8,5,14,14,0,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61B19/00;;A61K/;;A61K38/21;;A61K39/00;;A61K39/395;;C07K16/30;;G01N33/50,,27,23,035-749-405-495-801;;057-189-430-968-67X;;025-949-626-822-857;;089-035-646-012-860;;030-955-335-211-791;;083-006-623-922-975;;057-101-417-637-391;;003-020-623-577-007;;009-038-716-796-026;;030-938-317-406-451;;017-930-164-900-143;;042-204-626-457-327;;022-023-983-891-895;;010-157-107-750-37X;;039-004-732-914-566;;012-520-130-035-581;;022-340-704-416-08X;;032-603-425-099-899;;004-272-966-072-139;;016-660-079-907-443;;018-020-177-526-297;;060-824-980-876-559;;041-075-859-668-69X,10.1002/(sici)1097-0215(19960410)66:2<162::aid-ijc4>3.0.co;2-0;;10.1002/(sici)1097-0215(19960410)66:2<162::aid-ijc4>3.3.co;2-k;;8603805;;10.1073/pnas.220413497;;11027314;;pmc17318;;9935203;;10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s;;10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.3.co;2-j;;10.1002/(sici)1097-0215(19960703)67:1<54::aid-ijc11>3.0.co;2-c;;8690525;;10.1038/nm0398-321;;9500606;;pmc2064864;;9072306;;pmc2597550;;10537339;;11313806;;10.1038/sj.gt.3301396;;10.4049/jimmunol.167.12.7150;;11739538;;11691814;;10.1038/nri774;;12001994;;3127726;;10.1038/332323a0;;10.1016/0161-5890(91)90163-e;;1905784;;10.1093/protein/7.6.805;;7937712;;8302875;;pmc521435;;10.1073/pnas.91.3.969;;10.1021/bi00005a036;;7849039;;9535709;;10.1006/prep.1997.0844;;10.1089/dna.1993.12.441;;7686011;;10.1038/nbt832;;12778055;;10.1016/s0092-8674(00)81725-0;;9875855;;9486653;;10.1038/35888;;10.1126/science.1076514;;pmc1764179;;12242449;;12427970;;pmc138583;;10.1073/pnas.242600099,"JAEGER ET AL., INT J CANCER, vol. 66, 1996, pages 162;;JAGER ET AL., PROC NATL ACAD SCI USA, vol. 97, 2000, pages 12198;;MARCHAND ET AL., INT J CANCER., vol. 80, 1999, pages 219;;JÄGER ET AL., INT J CANCER, vol. 67, 1996, pages 54;;ROSENBERG ET AL., NAT MED, vol. 4, 1998, pages 321;;CORMIER ET AL., CANCER J SCI AM., vol. 3, 1997, pages 37;;WANG ET AL., CLIN CANCER RES., vol. 5, 1999, pages 2756;;CHEN, GENE THER, vol. 8, 2001, pages 316;;FONG ET AL., J IMMUNOL, vol. 167, 2001, pages 7150;;THEMER ET AL., J EXP MED, vol. 190, 1999, pages 1669;;TSO, CANCER RES, vol. 61, 2001, pages 7925;;PARDOLL, NATURE REV IMMUNOL, vol. 2, 2002, pages 227;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323;;PADLAN, MOLECULAR IMMUNOL., vol. 28, 1991, pages 489;;STUDNICKA ET AL., PROTEIN ENGINEERING, vol. 7, 1994, pages 805;;ROGUSKA. ET AL., PROC. NATT. ACAD. SCI. USA, vol. 91, 1994, pages 969;;SPATOLA, CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS, PEPTIDES AND PROTEINS, vol. 7, 1983, pages 267 - 357;;""Peptide and Backbone Modifications"", MARCEL DECKER;;WILLIAMS, BIOCHEMISTRY, vol. 34, 1995, pages 1787;;DOBELI, PROTEIN EXPR. PURIF., vol. 12, 1998, pages 404;;KROLL, DNA CELL. BIOL., vol. 12, 1993, pages 441;;DORONINA ET AL., NAT BIOTECHNOL, vol. 21, 2003, pages 778;;KENNERDELL, CELL, vol. 95, 1998, pages 1017;;FIRE, NATURE, vol. 391, 1998, pages 806;;DUDLEY ET AL., SCIENCE, vol. 298, 2002, pages 850;;YEE ET AL., PNAS, vol. 99, 2002, pages 16168;;See also references of EP 1542609A4",PENDING
148,AU,B2,AU 2002/301584 B2,056-392-048-636-209,2007-09-20,2007,AU 2002/301584 A,2002-10-22,US 2462501 A,2001-12-18,Suture welding system and method,,DEPUY MITEK INC,DUNN DOUGLAS W;;MCRURY IAN D;;CAULDWELL NATHAN S,"DEPUY MITEK, INC. (2007-09-13)",https://lens.org/056-392-048-636-209,Granted Patent,no,2,0,11,11,0,A61B17/0487;;A61B17/06166;;A61B2017/0619;;A61B17/0487;;A61B2017/0619;;A61B17/06166,A61B17/04;;A61B17/06;;B29C65/04;;B29C65/06;;B29C65/08,,0,0,,,,EXPIRED
149,US,A1,US 2014/0006976 A1,060-951-521-195-30X,2014-01-02,2014,US 201313968931 A,2013-08-16,US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"An assembly for sharing information in a conference space comprising a contiguous large presentation display assembly including a large contiguous presentation surface, a processor programmed to perform the steps of dividing the large surface into a plurality of adjacent presentation sub-spaces including at least one master sub-space and a plurality of slave sub-spaces and enabling an interface that allows images to be presented via the sub-spaces and that enables moving images among the different sub-spaces, wherein, upon an image being moved from the master sub-space to one of the slave sub-spaces, the master presentation sub-space is left blank to receive another image.",HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2013-11-13),https://lens.org/060-951-521-195-30X,Patent Application,yes,11,18,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/0481;;G06F3/0486,715/753,0,0,,,,ACTIVE
150,EP,B1,EP 1733557 B1,096-565-335-949-199,2010-11-17,2010,EP 05733062 A,2005-04-01,US 2005/0011366 W;;US 81653704 A,2004-04-01,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,"STEELCASE INC., GRAND RAPIDS, US (2014-08-28);;STEELCASE INC., US (2015-04-20)",https://lens.org/096-565-335-949-199,Granted Patent,yes,1,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,H04N7/15;;G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00,,3,0,,,"PATENT ABSTRACTS OF JAPAN vol. 011, no. 152 (E-507), 16 May 1987 (1987-05-16) & JP 61 288655 A (FUJITSU LTD), 18 December 1986 (1986-12-18);;PATENT ABSTRACTS OF JAPAN vol. 012, no. 024 (E-576), 23 January 1988 (1988-01-23) & JP 62 179268 A (MITA IND CO LTD), 6 August 1987 (1987-08-06);;PATENT ABSTRACTS OF JAPAN vol. 2000, no. 25, 12 April 2001 (2001-04-12) & JP 2001 217977 A (RICOH CO LTD), 10 August 2001 (2001-08-10)",ACTIVE
151,EP,A3,EP 2281897 A3,165-350-445-419-589,2011-11-30,2011,EP 10186056 A,2004-11-17,EP 04798619 A;;GB 0326798 A;;US 54130804 P,2003-11-17,Oncolytic mutant Herpes Simplex virus,"An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.
",CRUSADE LAB LTD;;SLOAN KETTERING INST CANCER,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (2011-12-28);;VIRTTU BIOLOGICS LIMITED (2011-12-28),https://lens.org/165-350-445-419-589,Search Report,yes,4,0,20,35,6,A01K2267/0331;;A61K35/13;;A61K48/00;;A61K2039/5256;;C12N7/00;;C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;C12N15/1135;;C12N2710/16643;;A01K2267/0331;;C12N7/00;;A61K2039/5256;;C12N15/86;;A61K48/00;;C12N2840/203;;A61K35/13,C12N15/869;;A61K35/13;;A61K35/76;;A61K39/00;;A61K48/00;;C07K14/82;;C12N7/00;;C12N7/01;;C12N15/113,,1,1,043-647-202-086-226,10.2741/2823;;17981691,"TOMOKI TODO: ""Oncolytic virus therapy using genetically engineered herpes simplex viruses"", FRONTIERS IN BIOSCIENCE, vol. 13, no. 13, 1 September 2002 (2002-09-01), pages 2060 - 159, XP055009778, ISSN: 1093-9946, DOI: 10.2741/2823",DISCONTINUED
152,US,A1,US 2017/0142370 A1,024-859-859-462-877,2017-05-18,2017,US 201715417317 A,2017-01-27,US 201715417317 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 77190806 P;;US 68738905 P,2005-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A method and assembly for sharing information in a conference space, the assembly comprising a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the surface area including at least first and second adjacent presentation sub-spaces, a processor programmed to perform the steps of presenting an interface on the surface area useable to generate session images within at least one of the sub-spaces, the interface including a panel section in which a separate panel icon for each of the session images created during a session is presented, the interface further including a separate space on the surface area associated with each of the sub-spaces, the interface facilitating selection and dragging of panel icons to locations associated with the sub-spaces to control the images presented in each of the sub-spaces, wherein, when a panel icon is dragged to a space, an image currently associated with the sub-space is replaced at the sub-space.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/024-859-859-462-877,Patent Application,yes,11,1,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,H04N7/15;;G06F3/0481;;G06F3/0486;;G06F3/0488;;G09B5/06;;G09B5/08,,0,0,,,,ACTIVE
153,EP,A2,EP 1321103 A2,037-107-538-377-487,2003-06-25,2003,EP 02257966 A,2002-11-19,US 2462501 A,2001-12-18,Surgical suture welding system and method,"A suture welding system (10) for fixedly attaching a first length of suture to a second length of suture includes an electro surgical energy source (32) and a suture welding device (12). The suture welding device has a working end (20), a suture contacting element (18) disposed on the working end, a first electrode (26) electrically coupled to the electrosurgical energy source, and a second electrode (28) electrically coupled to the electrosurgical energy source. The first electrode is disposed on the suture contacting element for providing electrical energy to the first and second lengths of suture, and the second electrode is disposable proximate to the suture welding site for providing a return electrical energy path to the electrosurgical energy source. When electrical energy is provided by the first electrode to the first and second lengths of suture welds, the first and second lengths of suture are welded into a fixed attachment.",ETHICON INC,MCRURY IAN D;;DUNN DOUGLAS W;;CAULDWELL NATHAN S,"DEPUY MITEK, INC. (2008-11-12)",https://lens.org/037-107-538-377-487,Patent Application,yes,0,3,11,11,0,A61B17/0487;;A61B17/0487;;A61B17/06166;;A61B17/06166;;A61B2017/0619;;A61B2017/0619,A61B17/04;;A61B17/06,,0,0,,,,EXPIRED
154,WO,A1,WO 2006/130750 A1,047-438-104-500-459,2006-12-07,2006,US 2006/0021233 W,2006-06-02,US 68738905 P;;US 77190806 P,2005-06-02,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP;;DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/047-438-104-500-459,Patent Application,yes,5,17,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,G06F3/033;;H04N7/15;;G09G5/00,,4,0,,,"PATENT ABSTRACTS OF JAPAN vol. 011, no. 152 (E - 507) 16 May 1987 (1987-05-16);;PATENT ABSTRACTS OF JAPAN vol. 012, no. 024 (E - 576) 23 January 1988 (1988-01-23);;PATENT ABSTRACTS OF JAPAN vol. 2000, no. 25 12 April 2001 (2001-04-12);;PATENT ABSTRACTS OF JAPAN vol. 011, (1 - 152)<152> 16 May 1987 (1987-05-16)",PENDING
155,DE,D1,DE 602006018291 D1,068-509-657-420-149,2010-12-30,2010,DE 602006018291 T,2006-06-02,US 68738905 P;;US 77190806 P;;US 2006/0021233 W,2005-06-02,VERFAHREN UND VORRICHTUNG FÜR EINE VIRTUELLE FLIP-CHART,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLYVISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/068-509-657-420-149,Granted Patent,no,0,0,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,H04N7/15;;G06F3/033;;G09G5/00,,0,0,,,,ACTIVE
156,US,B2,US 9116656 B2,136-930-289-760-636,2015-08-25,2015,US 201313968935 A,2013-08-16,US 201313968935 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,Portable presentation system and methods for use therewith,"An assembly for sharing information in a conference space, the assembly comprising a single large presentation display assembly including a single and contiguous large presentation surface juxtaposed within the conference space for viewing by an audience, a processor linked to the display assembly and programmed to perform the steps of presenting a master sub-space on the presentation surface wherein the master sub-space includes only a portion of the presentation surface, enabling an interface that allows movement of an image from the master sub-space to another location outside the master sub-space, wherein, upon movement of an image from the master presentation sub-space to another space outside the master presentation sub-space on the presentation surface, the processor creates a slave presentation space proximate the another location for presenting the image moved from the master presentation sub-space.",HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H;;STEELCASE INC,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2014-02-10),https://lens.org/136-930-289-760-636,Granted Patent,yes,102,13,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04N7/15;;H04N9/31,,4,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no. date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, Oct. 12, 2006.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, Jun. 5, 2008.",INACTIVE
157,US,A1,US 2013/0339888 A1,187-091-825-993-501,2013-12-19,2013,US 201313968945 A,2013-08-16,US 201313968945 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A method and assembly for sharing information in a conference space, the assembly comprising a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the surface area including at least first and second adjacent presentation sub-spaces, a processor programmed to perform the steps of presenting an interface on the surface area useable to generate session images within at least one of the sub-spaces, the interface including a panel section in which a separate panel icon for each of the session images created during a session is presented, the interface further including a separate space on the surface area associated with each of the sub-spaces, the interface facilitating selection and dragging of panel icons to locations associated with the sub-spaces to control the images presented in each of the sub-spaces, wherein, when a panel icon is dragged to a space, an image currently associated with the sub-space is replaced at the sub-space.",HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2014-02-10),https://lens.org/187-091-825-993-501,Patent Application,yes,12,17,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/0484,715/769,0,0,,,,ACTIVE
158,US,A1,US 2003/0114864 A1,014-335-036-923-695,2003-06-19,2003,US 2462501 A,2001-12-18,US 2462501 A,2001-12-18,Suture welding system and method,"
   A suture welding system for fixedly attaching a first length of suture to a second length of suture includes an electrosurgical energy source and a suture welding device. The suture welding device has a working end, a suture contacting element disposed on the working end, a first electrode electrically coupled to the electrosurgical energy source, and a second electrode electrically coupled to the electrosurgical energy source. The first electrode is disposed on the suture contacting element for providing electrical energy to the first and second lengths of suture, and the second electrode is disposable proximate to the suture welding site for providing a return electrical energy path to the electrosurgical energy source. When electrical energy is provided by the first electrode to the first and second lengths of suture welds, the first and second lengths of suture are welded into a fixed attachment. 
",MCRURY IAN D.;;DUNN DOUGLAS W.;;CAULDWELL NATHAN S.,MCRURY IAN D;;DUNN DOUGLAS W;;CAULDWELL NATHAN S,DEPUY SYNTHES SALES INC (2014-12-29);;DEPUY MITEK HOLDING CORPORATION (2014-12-29);;ETHICON INC (2002-03-19);;DEPUY MITEK LLC (2012-06-13);;DEPUY SPINE LLC (2014-12-29);;DEPUY SYNTHES PRODUCTS INC (2014-12-29);;SYNTHES USA LLC (2014-12-19),https://lens.org/014-335-036-923-695,Patent Application,yes,25,11,11,11,0,A61B17/0487;;A61B17/0487;;A61B17/06166;;A61B17/06166;;A61B2017/0619;;A61B2017/0619,A61B17/04;;A61B17/06,606/148,0,0,,,,EXPIRED
159,WO,A2,WO 2005/049846 A2,076-261-908-254-653,2005-06-02,2005,GB 2004004908 W,2004-11-17,GB 0326798 A;;US 54130804 P,2003-11-17,MUTANT VIRUSES,An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN;;CRUSADE LAB LTD;;SLOANE KETTERING INST FOR CANC,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,,https://lens.org/076-261-908-254-653,Patent Application,yes,0,9,9,35,6,C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61K38/00;;A61P35/00;;C12N2710/16643;;C12N2840/203;;C12N15/86;;C12N15/1135;;A61K38/00,C12N15/113;;C12N15/869,,0,0,,,,PENDING
160,AT,T1,AT E484596 T1,127-250-129-464-154,2010-10-15,2010,AT 04798619 T,2004-11-17,GB 0326798 A;;US 54130804 P;;GB 2004004908 W,2003-11-17,MUTANTES HERPES-SIMPLEX-VIRUS UND VERWENDUNG DAVON BEI DER BEHANDLUNG VON PLATTENEPITHELKARZINOM,An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.,CRUSADE LAB LTD;;SLOAN KETTERING INST CANCER,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,,https://lens.org/127-250-129-464-154,Granted Patent,no,0,0,20,35,0,A01K2267/0331;;A61K35/13;;A61K48/00;;A61K2039/5256;;C12N7/00;;C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;C12N15/1135;;C12N2710/16643;;A01K2267/0331;;C12N7/00;;A61K2039/5256;;C12N15/86;;A61K48/00;;C12N2840/203;;A61K35/13,A61K35/13;;A61K35/76;;A61K39/00;;A61K48/00;;C12N7/00;;C12N15/113;;C12N15/869,,0,0,,,,INACTIVE
161,EP,A1,EP 1891808 A1,156-676-620-941-977,2008-02-27,2008,EP 06771804 A,2006-06-02,US 2006/0021233 W;;US 68738905 P;;US 77190806 P,2005-06-02,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLYVISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,"STEELCASE, INC., GRAND RAPIDS, US (2017-06-19);;STEELCASE, INC., US (2017-11-08)",https://lens.org/156-676-620-941-977,Patent Application,yes,0,0,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,H04N7/15;;G06F3/033;;G09G5/00,,0,0,,,,ACTIVE
162,WO,A2,WO 2012/166617 A2,167-269-456-555-820,2012-12-06,2012,US 2012/0039628 W,2012-05-25,US 201161490935 P,2011-05-27,"METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER","The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.",CYTOCURE LLC;;GEN HOSPITAL CORP;;HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S,HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/167-269-456-555-820,Patent Application,yes,0,31,7,7,0,A61K39/395;;C07K16/3053;;A61K38/215;;A61K38/217;;A61K45/06;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4178;;A61K31/495;;A61P35/00;;A61K39/464491;;A61K2239/57;;A61K39/464492;;A61K39/4611;;A61K2239/47;;A61K39/4632;;A61K45/06;;A61K38/215;;A61K38/217;;A61K35/17;;A61K39/395;;C07K16/3053;;A61K35/15;;A61K31/495;;A61K31/4178;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4965;;A61K35/14;;A61K39/3955,A61K39/395,,0,0,,,,PENDING
163,WO,A2,WO 2007/029213 A2,176-790-944-227-360,2007-03-15,2007,IB 2006053190 W,2006-09-08,US 71502805 P,2005-09-08,DEREGULATED BACTERIA WITH IMPROVED POLYHYDROXYALKANOATE PRODUCTION,Mutant bacteria with improved poly-3-hydroxylalkanoate (PHA)-producing characteristics and methods of producing and using them are provided.,PROCTER & GAMBLE;;GREEN PHILLIP RICHARD;;JOHNSON ROBERT IAN;;DUNN STUART ANTONY,GREEN PHILLIP RICHARD;;JOHNSON ROBERT IAN;;DUNN STUART ANTONY,,https://lens.org/176-790-944-227-360,Patent Application,yes,0,7,9,9,0,C12N1/00;;C12N1/36;;C12N1/36;;C12N1/205;;C12N1/205;;C12N1/38;;C12N1/38;;C12P7/625;;C12P7/625;;C12R2001/01;;C12R2001/01,,,0,0,,,,PENDING
164,EP,B1,EP 1891808 B1,196-162-077-791-155,2010-11-17,2010,EP 06771804 A,2006-06-02,US 2006/0021233 W;;US 68738905 P;;US 77190806 P,2005-06-02,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLYVISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,"STEELCASE, INC., GRAND RAPIDS, US (2017-06-19);;STEELCASE, INC., US (2017-11-08)",https://lens.org/196-162-077-791-155,Granted Patent,yes,4,0,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,H04N7/15;;G06F3/033;;G09G5/00,,3,0,,,"PATENT ABSTRACTS OF JAPAN vol. 011, no. 152 (E-507), 16 May 1987 (1987-05-16) & JP 61 288655 A (FUJITSU LTD), 18 December 1986 (1986-12-18);;PATENT ABSTRACTS OF JAPAN vol. 012, no. 024 (E-576), 23 January 1988 (1988-01-23) & JP 62 179268 A (MITA IND CO LTD), 6 August 1987 (1987-08-06);;PATENT ABSTRACTS OF JAPAN vol. 2000, no. 25, 12 April 2001 (2001-04-12) & JP 2001 217977 A (RICOH CO LTD), 10 August 2001 (2001-08-10)",ACTIVE
165,US,B2,US 7582097 B2,035-592-228-623-83X,2009-09-01,2009,US 2462501 A,2001-12-18,US 2462501 A,2001-12-18,Suture welding system and method,"A suture welding system for fixedly attaching a first length of suture to a second length of suture includes an electrosurgical energy source and a suture welding device. The suture welding device has a working end, a suture contacting element disposed on the working end, a first electrode electrically coupled to the electrosurgical energy source, and a second electrode electrically coupled to the electrosurgical energy source. The first electrode is disposed on the suture contacting element for providing electrical energy to the first and second lengths of suture, and the second electrode is disposable proximate to the suture welding site for providing a return electrical energy path to the electrosurgical energy source. When electrical energy is provided by the first electrode to the first and second lengths of suture welds, the first and second lengths of suture are welded into a fixed attachment.",ETHICON INC,MCRURY IAN D;;DUNN DOUGLAS W;;CAULDWELL NATHAN S,DEPUY MITEK HOLDING CORPORATION (2014-12-29);;DEPUY SYNTHES SALES INC (2014-12-29);;ETHICON INC (2002-03-19);;DEPUY MITEK LLC (2012-06-13);;DEPUY SPINE LLC (2014-12-29);;DEPUY SYNTHES PRODUCTS INC (2014-12-29);;SYNTHES USA LLC (2014-12-19),https://lens.org/035-592-228-623-83X,Granted Patent,yes,28,25,11,11,0,A61B17/0487;;A61B17/0487;;A61B17/06166;;A61B17/06166;;A61B2017/0619;;A61B2017/0619,A61B17/04;;A61B17/06,606/148;;606/139;;606/144,1,0,,,"JP Office Action dated Jan. 13, 2009, from corresponding JP Appl No. 2002-365673, w/English translation.",EXPIRED
166,WO,A3,WO 2004/019886 A3,063-422-148-717-733,2004-09-10,2004,US 0327125 W,2003-08-29,US 40749202 P,2002-08-29,METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS,"The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against tumor cell. Methods include administering to a subject with a tumor an amount of IFN-&bgr; receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.",CYTOCURE LLC;;DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/063-422-148-717-733,Search Report,yes,2,0,14,14,0,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61B19/00;;A61K/;;A61K38/21;;A61K39/00;;A61K39/395;;C07K16/30;;G01N33/50,,1,0,,,See also references of EP 1542609A4,PENDING
167,EP,A4,EP 1542609 A4,050-784-499-454-548,2010-08-11,2010,EP 03749229 A,2003-08-29,US 0327125 W;;US 40749202 P,2002-08-29,METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS,,CYTOCURE LLC,DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,CYTOCURE LLC (2013-02-20),https://lens.org/050-784-499-454-548,Search Report,no,3,0,14,14,0,A61K35/15;;A61K38/215;;A61K39/0011;;A61K2039/55522;;C07K16/3053;;G01N33/5011;;A61P35/00;;A61P35/04;;A61K39/001152;;A61K39/001188;;A61K39/001191;;A61K39/001156;;A61K39/001192;;A61K39/001186;;C07K16/3053;;A61K2039/55522;;A61K39/0011;;G01N33/5011;;A61K35/15;;A61K38/215;;A61K39/001192;;A61K39/001152;;A61K39/001156;;A61K39/001186;;A61K39/001191;;A61K39/001188,A61B19/00;;A61K/;;A61K38/21;;A61K39/00;;A61K39/395;;C07K16/30;;G01N33/50,,8,7,138-793-470-009-657;;055-055-354-359-453;;125-335-020-145-504;;056-878-502-654-504;;066-217-716-524-224;;042-400-301-819-754;;029-914-882-799-241,11507073;;10029078;;3567933;;pmc41759;;10.1073/pnas.92.12.5674;;7777568;;10.1073/pnas.91.9.3515;;8170938;;pmc43610;;10491010;;pmc2228215;;9413942;;10.1038/bjc.1997.597,"MAKOTO ODAKA ET AL: ""Eradication of Intraperitoneal and Distant Tumor by Adenovirus-mediated Interferon-ß Gene Therapy Is Attributable to Induction of Systemic Immunity"", CANCER RESEARCH, vol. 61, 15 August 2001 (2001-08-15), pages 6201 - 6212, XP002586103;;ZHONGYUN DONG ET AL.: ""Suppression of Angiogenesis, Tumorigenicity, and Metastasis by Human Prostate Cancer Cells Engineered to Produce Interferon-ß"", CANCER RESEARCH, vol. 59, 10 February 1999 (1999-02-10), pages 872 - 879, XP002586104;;JOHN J. RINEHART ET AL.: ""Phase I/II Trial of Interferon-ß-Serine in Patients with Renal Cell Carcinoma; Immunological and Biological Effects"", CANCER RESEARCH, vol. 47, 1 May 1987 (1987-05-01), pages 2481 - 2485, XP002586105;;SENSI MARIALUISA ET AL: ""Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.92.12.5674, vol. 92, no. 12, 1 January 1995 (1995-01-01), pages 5674 - 5678, XP002143225, ISSN: 0027-8424;;KAWAKAMI Y ET AL: ""CLONING OF THE GENE CODING FOR A SHARED HUMAN MELANOMA ANTIGEN RECOGNIZED BY AUTOLOGOUS T CELLS INFILTRATING INTO TUMOR"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.91.9.3515, vol. 91, no. 9, 26 April 1994 (1994-04-26), pages 3515 - 3519, XP000770221, ISSN: 0027-8424;;MATEO ET AL: ""An HLA-A2 polyepitope vaccine for melanoma immunotherapy"", J IMMUNOL., vol. 7, no. 1, October 1999 (1999-10-01), pages 4058 - 4063, XP002587571;;BROUWENSTIJN N ET AL.: ""Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage."", BR J CANCER, vol. 12, 1997, pages 1562 - 1566, XP002587572;;See also references of WO 2004019886A2",EXPIRED
168,WO,A3,WO 2012/166617 A3,088-500-695-255-02X,2014-05-08,2014,US 2012/0039628 W,2012-05-25,US 201161490935 P,2011-05-27,"METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER","The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.",CYTOCURE LLC;;GEN HOSPITAL CORP;;HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S,HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/088-500-695-255-02X,Search Report,yes,1,0,7,7,0,A61K39/395;;C07K16/3053;;A61K38/215;;A61K38/217;;A61K45/06;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4178;;A61K31/495;;A61P35/00;;A61K39/464491;;A61K2239/57;;A61K39/464492;;A61K39/4611;;A61K2239/47;;A61K39/4632;;A61K45/06;;A61K38/215;;A61K38/217;;A61K35/17;;A61K39/395;;C07K16/3053;;A61K35/15;;A61K31/495;;A61K31/4178;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4965;;A61K35/14;;A61K39/3955,A61K39/395;;A61K38/21;;A61P35/00,,1,1,055-528-658-721-105,10.1158/0008-5472.can-08-4511;;19690146;;pmc2745213,"KAWABE, M. ET AL.: ""Heat Shock Protein 90 Inhibitor 17-Dimethylaminoethylamino-17- Demethoxygeldanamycin Enhances EphA2+ Tumor Cell Recognition by Specific CD8+ T Cells."", CANCER RESEARCH., vol. 69, 18 August 2009 (2009-08-18), pages 6995 - 7003, XP055140144",PENDING
169,EP,A2,EP 1542609 A2,136-260-904-534-324,2005-06-22,2005,EP 03749229 A,2003-08-29,US 0327125 W;;US 40749202 P,2002-08-29,Pharmaceutical compositions comprising Interferon beta for use in treating melanoma,,CYTOCURE LLC,DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,CYTOCURE LLC (2013-02-20),https://lens.org/136-260-904-534-324,Patent Application,yes,0,0,14,14,28,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61K38/21;;A61B19/00;;A61K/;;A61K35/00;;A61K39/00;;A61K39/395;;A61P35/00;;C07K16/30;;G01N33/50,,0,0,,,,EXPIRED
170,US,A1,US 2013/0339861 A1,157-381-133-968-353,2013-12-19,2013,US 201313968943 A,2013-08-16,US 201313968943 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"An assembly including a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the presentation surface area including at least first and second adjacent sub-spaces, a first processor linked to the display assembly and programmed to perform the steps of enabling a first interface that allows images to be presented via and moved among the sub-spaces by selecting images in the sub-spaces on the surface area and moving the images to different locations and a hand held device including a device display and a second processor programmed to present a second interface that presents instances of each image presented via the sub-spaces and enabling movement of the images among the different sub-spaces by moving representations of the images to locations on the device display, the second processor communicating wirelessly with the first processor to synchronize images.",HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2014-02-10),https://lens.org/157-381-133-968-353,Patent Application,yes,15,15,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/0481,715/730,0,0,,,,ACTIVE
171,WO,A3,WO 2007/029213 A3,171-831-751-038-818,2007-10-18,2007,IB 2006053190 W,2006-09-08,US 71502805 P,2005-09-08,DEREGULATED BACTERIA WITH IMPROVED POLYHYDROXYALKANOATE PRODUCTION,Mutant bacteria with improved poly-3-hydroxylalkanoate (PHA)-producing characteristics and methods of producing and using them are provided.,PROCTER & GAMBLE;;GREEN PHILLIP RICHARD;;JOHNSON ROBERT IAN;;DUNN STUART ANTONY,GREEN PHILLIP RICHARD;;JOHNSON ROBERT IAN;;DUNN STUART ANTONY,,https://lens.org/171-831-751-038-818,Search Report,yes,2,0,9,9,0,C12N1/00;;C12N1/36;;C12N1/36;;C12N1/205;;C12N1/205;;C12N1/38;;C12N1/38;;C12P7/625;;C12P7/625;;C12R2001/01;;C12R2001/01,C12N15/52;;C12N15/74;;C12P7/62;;C12R1/01,,8,8,144-557-453-058-222;;032-322-740-758-11X;;011-539-396-474-438;;125-194-069-220-783;;065-740-089-628-971;;022-410-357-978-328;;044-140-586-209-507;;040-408-359-695-831,10.1016/s0141-3910(97)00176-6;;10.1139/m95-176;;10.1007/s002530051241;;10.1023/a:1021959100432;;12882285;;10.1023/a:1013898504895;;10.1128/aem.63.8.3003-3009.1997;;pmc168600;;9251189;;10486129;;10.1002/(sici)1097-0290(19991105)65:3<306::aid-bit8>3.0.co;2-0;;10.1002/(sici)1097-0290(19991105)65:3<306::aid-bit8>3.3.co;2-s;;11733115;;10.1016/s0169-409x(01)00218-6,"LEE, CHOI: ""Effect of fermentation performance on the economics of poly(3-hydroxybutyrate) production by Alcaligenus latus"", POLYMER DEGRADATION AND STABILITY, vol. 59, 1998, pages 387 - 393, XP002430851;;PAGE WILLIAM J ET AL: ""The role of beta-oxidation of short-chain alkanoates in polyhydroxyalkanoate copolymer synthesis in Azotobacter vinelandii UWD"", CANADIAN JOURNAL OF MICROBIOLOGY, vol. 41, no. SUPPL. 1, 1995, pages 106 - 114, XP009082406, ISSN: 0008-4166;;REN Q ET AL: ""Mutants of Pseudomonas putida affected in poly-3-hydroxyalkanoate synthesis"", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 49, no. 6, June 1998 (1998-06-01), pages 743 - 750, XP002430852, ISSN: 0175-7598;;LAKSHMAN KSHAMA ET AL: ""Enhanced biosynthesis of polyhydroxyalkanoates in a mutant strain of Rhizobium meliloti."", BIOTECHNOLOGY LETTERS, vol. 25, no. 2, January 2003 (2003-01-01), pages 115 - 119, XP002430853, ISSN: 0141-5492;;BEOM SOO KIM: ""PRODUCTION OF MEDIUM CHAIN LENGTH POLYHYDROXYALKANOATES BY FED-BATCH CULTURE OF PSEUDOMONAS OLEOVORANS"", BIOTECHNOLOGY LETTERS, KEW, SURREY, GB, vol. 24, no. 2, 2002, pages 125 - 130, XP008014350, ISSN: 0141-5492;;KRANZ R G ET AL: ""POLYHYDROXYALKANOATE PRODUCTION IN RHODOBACTER CAPSULATUS: GENES, MUTANTS, EXPRESSION, AND PHYSIOLOGY"", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, WASHINGTON,DC, US, vol. 63, no. 8, August 1997 (1997-08-01), pages 3003 - 3009, XP000867233, ISSN: 0099-2240;;KELLERHALS M B ET AL: ""Closed-loop control of bacterial high-cell-density fed-batch cultures: Production of mcl-PHAs by Pseudomonas putida KT2442 under single-substrate and cofeeding conditions"", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 65, no. 3, 5 November 1999 (1999-11-05), pages 306 - 315, XP002255465, ISSN: 0006-3592;;ZINN M ET AL: ""Occurrence, synthesis and medical application of bacterial polyhydroxyalkanoate"", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 53, no. 1, 3 December 2001 (2001-12-03), pages 5 - 21, XP003000228, ISSN: 0169-409X",PENDING
172,CA,A1,CA 2413662 A1,174-748-856-243-270,2003-06-18,2003,CA 2413662 A,2002-11-29,US 2462501 A,2001-12-18,SUTURE WELDING SYSTEM AND METHOD,"A suture welding system for fixedly attaching a first length of suture to a second length of suture includes an electrosurgical energy source and a suture welding device. The suture welding device has a working end, a suture contacting element disposed on the working end, a first electrode electrically coupled to the electrosurgic al energy source, and a second electrode electrically coupled to the electrosurgical energy source. The first electrode is disposed on the suture contacting element for providi ng electrical energy to the first and second lengths of suture, and the second electrode i s disposable proximate to the suture welding site for providing a return electrical energ y path to the electrosurgical energy source. When electrical energy is provided by the fir st electrode to the first and second lengths of suture welds, the first and second length s of suture are welded into a fixed attachment.",ETHICON INC,DUNN DOUGLAS W;;MCRURY IAN D;;CAULDWELL NATHAN S,,https://lens.org/174-748-856-243-270,Patent Application,no,0,0,11,11,0,A61B17/0487;;A61B17/0487;;A61B17/06166;;A61B17/06166;;A61B2017/0619;;A61B2017/0619,A61B17/04;;A61B17/06,,0,0,,,,EXPIRED
173,EP,A2,EP 2126075 A2,185-704-788-297-895,2009-12-02,2009,EP 08713162 A,2008-01-16,US 2008/0000601 W;;US 88516007 P,2007-01-16,METHODS OF ISOLATING AND PURIFYING NUCLEIC ACID-BINDING BIOMOLECULES AND COMPOSITIONS INCLUDING SAME,,CYTOCURE INC,LAWLER MATTHEW M;;HAGGERTY TIMOTHY J;;DUNN IAN S,,https://lens.org/185-704-788-297-895,Patent Application,yes,0,0,5,5,0,C12N15/1006;;C12Q1/6804;;C12N15/1006;;C12Q1/6804,C12N15/10;;C12Q1/68,,0,0,,,,DISCONTINUED
174,US,B2,US 10455193 B2,197-084-795-323-159,2019-10-22,2019,US 201715836508 A,2017-12-08,US 201715836508 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,Portable presentation system and methods for use therewith,"A method and assembly for sharing information in a conference space, the assembly comprising a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the surface area including at least first and second adjacent presentation sub-spaces, a processor programmed to perform the steps of presenting an interface on the surface area useable to generate session images within at least one of the sub-spaces, the interface including a panel section in which a separate panel icon for each of the session images created during a session is presented, the interface further including a separate space on the surface area associated with each of the sub-spaces, the interface facilitating selection and dragging of panel icons to locations associated with the sub-spaces to control the images presented in each of the sub-spaces, wherein, when a panel icon is dragged to a space, an image currently associated with the sub-space is replaced at the sub-space.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2007-01-09);;STEELCASE INC (2014-02-10),https://lens.org/197-084-795-323-159,Granted Patent,yes,271,0,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,H04N7/15;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G06F3/0488;;G06F3/14;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04L29/06;;H04N7/14;;H04N9/31,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, dated Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, dated Oct. 12, 2006.;;PCT International Search Report, Application No. PCT/US2006/021233, dated Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, dated Dec. 6, 2007.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, dated Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2007/012671, dated Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, dated Dec. 3, 2008.",INACTIVE
175,WO,A9,WO 2005/049846 A9,006-319-302-698-997,2006-10-19,2006,GB 2004004908 W,2004-11-17,GB 0326798 A;;US 54130804 P,2003-11-17,MUTANT HERPES SIMPLEX VIRUS AND USE THEREOF IN THE TREATMENT OF SQUAMOUS CELL CANCER,An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.,CRUSADE LAB LTD;;SLOAN KETTERING INST CANCER;;BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,,https://lens.org/006-319-302-698-997,Patent Application,no,0,0,9,35,0,C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61K38/00;;A61P35/00;;C12N2710/16643;;C12N2840/203;;C12N15/86;;C12N15/1135;;A61K38/00,C12N15/113;;C12N15/869,,0,0,,,,PENDING
176,US,A1,US 2017/0139570 A1,027-669-885-610-791,2017-05-18,2017,US 201715417320 A,2017-01-27,US 201715417320 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A distributed digital content collaboration method and system, the method comprising the steps of storing collaboration session data for at least one collaboration session, the collaboration data including data objects displayable on display surfaces, identifying unused display surfaces associated a collaboration system, sending display identifiers to at least a subset of the unused display surfaces, wherein the display identifiers are presented on the display surfaces as display identification codes for associated surfaces, receiving user input via a user interface identifying at least one of the display identifiers associated with a first display surface, determining that the identified display identifier matches the display identifier sent to the first display surface and, in response to the determination, configuring the first display surface with the processor to facilitate content collaboration.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/027-669-885-610-791,Patent Application,yes,19,1,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/0481;;G06F3/0488;;G09B5/08;;H04L29/06,,0,0,,,,ACTIVE
177,US,A1,US 2023/0414764 A1,039-870-223-159-524,2023-12-28,2023,US 202118035912 A,2021-11-05,US 202118035912 A;;US 202063111401 P;;US 2021/0058314 W,2020-11-09,Template Assembly by Proximity-Enhanced Reactivity via Metabolic Labeling,"The present disclosure provides methods of metabolically labeling cells to provide a substrate for assembly of desired molecules, and to bifunctional compounds used in such methods.",MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/039-870-223-159-524,Patent Application,yes,0,0,2,2,84,A61K31/70;;A61K31/713;;A61K31/7105;;A61K47/549;;A61K47/549,A61K47/54,,0,0,,,,PENDING
178,US,A1,US 2024/0002908 A1,062-466-828-052-833,2024-01-04,2024,US 202118036008 A,2021-11-05,US 202118036008 A;;US 202063111443 P;;US 2021/0058318 W,2020-11-09,METHODS OF DETERMINING SURFACE GLYCAN DENSITY,The present disclosure provides methods of determining surface glycan density of a cell.,MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/062-466-828-052-833,Patent Application,yes,0,0,2,2,40,C12Q1/6816;;C12Q1/6816;;C12Q2600/166,C12Q1/6816,,0,0,,,,PENDING
179,US,B2,US 9465573 B2,084-602-763-294-293,2016-10-11,2016,US 201313968943 A,2013-08-16,US 201313968943 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,Portable presentation system and methods for use therewith,"An assembly including a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the presentation surface area including at least first and second adjacent sub-spaces, a first processor linked to the display assembly and programmed to perform the steps of enabling a first interface that allows images to be presented via and moved among the sub-spaces by selecting images in the sub-spaces on the surface area and moving the images to different locations and a hand held device including a device display and a second processor programmed to present a second interface that presents instances of each image presented via the sub-spaces and enabling movement of the images among the different sub-spaces by moving representations of the images to locations on the device display, the second processor communicating wirelessly with the first processor to synchronize images.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,STEELCASE INC (2014-02-10),https://lens.org/084-602-763-294-293,Granted Patent,yes,114,15,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04N7/15;;H04N9/31,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, Oct. 12, 2006.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2006/021233, Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, Dec. 6, 2007.;;PCT International Search Report, Application No. PCT/US2007/012671, Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, Dec. 3, 2008.",ACTIVE
180,US,A1,US 2024/0002536 A1,078-380-670-413-910,2024-01-04,2024,US 202118035982 A,2021-11-05,US 202118035982 A;;US 202063111450 P;;US 2021/0058322 W,2020-11-09,Antibodies and Single-Chain Variable Region Proteins Recognizing Click Products,"The present disclosure is directed, at least in part, to click-product binding molecules for recognition of templated assembly products defined by bioorthogonal click groups. Such molecules can be used for therapeutic and diagnostic purposes, including kits for the same.",MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/078-380-670-413-910,Patent Application,yes,0,0,3,3,96,C07K16/44;;C07K2317/622;;C07K2317/21;;C07K2317/33;;C07K2317/52;;C07K2317/92;;C07K16/44;;C07K2317/21;;C07K2317/33;;C07K2317/622;;C07K2317/92;;G01N33/5308,C07K16/44;;G01N33/53,,0,0,,,,PENDING
181,US,B2,US 10051236 B2,094-713-225-367-074,2018-08-14,2018,US 201715417313 A,2017-01-27,US 201715417313 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,Portable presentation system and methods for use therewith,"A content sharing system for sharing content among attendees comprising a communication network, a first content sharing configuration including at least a first large common display screen having at least a first display surface, a first processor and a first interface, a second content sharing configuration including at least a second large common display screen having at least a second display surface, a second processor and a second interface, wherein the first and second processors are linked via the network and programmed to present substantially identical content on the at least a first display surface and the at least a second display surface as the first and second interfaces are used to alter content on the first and second display surfaces.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/094-713-225-367-074,Granted Patent,yes,251,6,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,H04N7/15;;G06F3/0488;;G06F3/14;;H04L12/18;;H04L29/06;;H04N7/14;;H04N9/31,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, dated Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, dated Oct. 12, 2006.;;PCT International Search Report, Application No. PCT/US2006/021233, dated Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, dated Dec. 6, 2007.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, dated Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2007/012671, dated Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, dated Dec. 3, 2008.",ACTIVE
182,US,A1,US 2020/0007820 A1,121-159-575-102-262,2020-01-02,2020,US 201916566225 A,2019-09-10,US 201916566225 A;;US 201715836508 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A method and assembly for sharing information in a conference space, the assembly comprising a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the surface area including at least first and second adjacent presentation sub-spaces, a processor programmed to perform the steps of presenting an interface on the surface area useable to generate session images within at least one of the sub-spaces, the interface including a panel section in which a separate panel icon for each of the session images created during a session is presented, the interface further including a separate space on the surface area associated with each of the sub-spaces, the interface facilitating selection and dragging of panel icons to locations associated with the sub-spaces to control the images presented in each of the sub-spaces, wherein, when a panel icon is dragged to a space, an image currently associated with the sub-space is replaced at the sub-space.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2007-01-09);;STEELCASE INC (2014-02-10),https://lens.org/121-159-575-102-262,Patent Application,yes,10,1,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,H04N7/15;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G06F3/0488;;G06F3/14;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04L29/06;;H04N7/14;;H04N9/31,,0,0,,,,ACTIVE
183,GB,A,GB 2444848 A,172-180-639-619-92X,2008-06-18,2008,GB 0724202 A,2007-12-12,GB 0624932 A,2006-12-14,Battery life monitor,"A smart secondary battery 1 comprises a data storage device 5 and a data display 7 for displaying maximum charge capacity as a proportion of original charge capacity. The battery is connected to an external device such as a smart charger 3, which reads information stored on the battery, calculates the maximum charge capacity as a proportion of original charge capacity, and transmits it to the battery where it is recorded. The maximum charge capacity may be updated when the battery is charged and indicated by the display 7 on the battery when a button is pressed, and by lights that can be coloured green, amber and red. The battery state of charge may also be displayed. An external device is provided which calculates the charge capacity compared to the theoretical original charge capacity to indicate the remaining life of the battery in terms of the number of charge cycles available before the charge capacity falls to an unacceptable level. The battery may be used to power a mobile phone, a GPS receiver, a computer, a power tool or an electric vehicle.",ABSL POWER SOLUTIONS LTD,LIDDELL THOMAS MARK;;LEISTEN JOSEPH MICHAEL;;DUNN WILLIAM IAN,,https://lens.org/172-180-639-619-92X,Patent Application,no,2,0,5,5,0,H02J7/00036;;H01M10/48;;H02J7/00036;;H02J7/00047;;Y02E60/10,G01R31/36;;H01M10/48;;H02J7/00,,0,0,,,,INACTIVE
184,CA,A1,CA 2611084 A1,191-125-710-522-344,2006-12-07,2006,CA 2611084 A,2006-06-02,US 68738905 P;;US 77190806 P;;US 2006/0021233 W,2005-06-02,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,HUTCHINSON IAN G;;DUNN MICHAEL H;;HILDEBRANDT PETER W,,https://lens.org/191-125-710-522-344,Patent Application,no,0,0,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,H04N7/15;;G06F3/033;;G09G5/00,,0,0,,,,INACTIVE
185,AU,C1,AU 2003/268275 C1,190-404-592-285-311,2010-04-01,2010,AU 2003/268275 A,2003-08-29,US 40749202 P;;US 0327125 W,2002-08-29,Methods for up-regulating antigen expression in tumors,,CYTOCURE LLC,KURNICK JAMES T;;DURDA PAUL J;;DUNN IAN S,,https://lens.org/190-404-592-285-311,Amended Patent,no,1,0,14,14,0,A61K35/15;;A61K38/215;;A61K39/0011;;A61K2039/55522;;C07K16/3053;;G01N33/5011;;A61P35/00;;A61P35/04;;A61K39/001152;;A61K39/001188;;A61K39/001191;;A61K39/001156;;A61K39/001192;;A61K39/001186;;C07K16/3053;;A61K2039/55522;;A61K39/0011;;G01N33/5011;;A61K35/15;;A61K38/215;;A61K39/001192;;A61K39/001152;;A61K39/001156;;A61K39/001186;;A61K39/001191;;A61K39/001188,A61K38/21;;A61B19/00;;A61K/;;A61K39/00;;A61K39/395;;C07K16/30;;G01N33/50,,0,0,,,,EXPIRED
186,AU,A,AU 1989/040906 A,193-858-627-721-570,1990-03-08,1990,AU 1989/040906 A,1989-08-30,US 23881088 A,1988-08-31,METHODS OF AND SYSTEMS FOR OPTICAL FIBER SENSING,,AMERICAN TELEPHONE & TELEGRAPH,DUNN LAWRENCE RUSSELL;;WHITE WILLARD CHANDLER;;WHITE IAN ARTHUR,,https://lens.org/193-858-627-721-570,Patent Application,no,0,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,EXPIRED
187,WO,A9,WO 2008/088839 A9,125-806-642-390-908,2008-10-16,2008,US 2008/0000601 W,2008-01-16,US 88516007 P,2007-01-16,METHODS OF ISOLATING AND PURIFYING NUCLEIC ACID-BINDING BIOMOLECULES AND COMPOSITIONS INCLUDING SAME,"The invention provides methods for isolating or purifying a biomolecule directly or indirectly bound to a region of interest of a nucleic acid in a cell, and methods for isolating or purifying a biomolecule that directly or indirectly binds to a region of interest of a nucleic acid in a cell. The invention further provides substantially cell free, isolated and purified biomolecule(s) that are fixed or cross-linked to a region of interest of a nucleic acid, which optionally reflects the interaction of the biomolecule(s) with the nucleic acid in the cell (e.g., in native chromatin) when fixed or cross-linked to the region of interest. Substantially cell free, isolated and purified biomolecules that are fixed or cross-linked to a region of interest of a nucleic acid can remain fixed or cross-linked to the region of interest of the nucleic acid when heated or treated with denaturing compounds or agents.",CYTOCURE INC;;LAWLER MATTHEW M;;HAGGERTY TIMOTHY J;;DUNN IAN S,LAWLER MATTHEW M;;HAGGERTY TIMOTHY J;;DUNN IAN S,,https://lens.org/125-806-642-390-908,Patent Application,no,0,0,5,5,0,C12N15/1006;;C12Q1/6804;;C12N15/1006;;C12Q1/6804,C12Q1/68;;C12N15/10,,0,0,,,,PENDING
188,US,B2,US 9904462 B2,125-526-360-932-792,2018-02-27,2018,US 201715417871 A,2017-01-27,US 201715417871 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 77190806 P;;US 68738905 P,2005-06-02,Portable presentation system and methods for use therewith,"A system and method for content collaboration, the system comprising a first collaboration configuration including at least a first display having a first display surface, a second collaboration configuration including a least a second display having a second display surface, a processor maintaining a session dataset including a plurality of objects arranged in a relative juxtaposition with respect to each other, the processor presenting first and second different views of the session via the at the least first and second display surfaces, respectively, wherein at least some of the first view overlaps with some of the second view and indicating, via the at least a first display surface, content presented in the second view that is not presented in the first view.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/125-526-360-932-792,Granted Patent,yes,248,8,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/0488;;G06F3/0481;;G06F3/14;;H04L29/06,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, dated Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, dated Oct. 12, 2006.;;PCT International Search Report, Application No. PCT/US2006/021233, dated Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, dated Dec. 6, 2007.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, dated Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2007/012671, dated Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, dated Dec. 3, 2008.",ACTIVE
189,CN,B,CN 1951117 B,143-868-451-571-307,2010-06-09,2010,CN 200580014399 A,2005-04-01,US 2005/0011366 W;;US 81653704 A,2004-04-01,Virtual flip chart method and apparatus,"A presentation method and system for presenting information to an audience within a space that mimics a flip chart assembly, the system including a control interface, a communication network and a master presentation unit including a processor and a master display screen, the master screen juxtaposed within the space so as to be viewable by the audience within the space, the processor operable totransmit an image displayed on the master screen over the network upon user command and a slave presentation unit including a slave presenter operable to receive and present an image to the audience within the space that is transmitted by the master unit to the slave unit over the network such that the master unit can be used to create a new image while the first image is simultaneously presented.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,STEELCASE INC. (2014-09-03),https://lens.org/143-868-451-571-307,Granted Patent,no,0,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,H04N7/15;;G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00,,0,0,,,,INACTIVE
190,EP,A2,EP 1951875 A2,138-482-769-992-360,2008-08-06,2008,EP 06795977 A,2006-09-08,IB 2006053190 W;;US 71502805 P,2005-09-08,DEREGULATED BACTERIA WITH IMPROVED POLYHYDROXYALKANOATE PRODUCTION,,MEREDIAN INC,GREEN PHILLIP RICHARD;;JOHNSON ROBERT IAN;;DUNN STUART ANTONY,,https://lens.org/138-482-769-992-360,Patent Application,yes,0,0,9,9,0,C12N1/00;;C12N1/36;;C12N1/36;;C12N1/205;;C12N1/205;;C12N1/38;;C12N1/38;;C12P7/625;;C12P7/625;;C12R2001/01;;C12R2001/01,C12N15/52;;C12N15/74;;C12P7/62;;C12R1/01,,1,0,,,See references of WO 2007029213A3,DISCONTINUED
191,AU,A1,AU 2006/252490 A1,171-174-002-191-711,2006-12-07,2006,AU 2006/252490 A,2006-06-02,US 77190806 P;;US 68738905 P;;US 2006/0021233 W,2005-06-02,Virtual flip chart method and apparatus,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,HILDEBRANDT PETER W;;DUNN MICHAEL H;;HUTCHINSON IAN G,,https://lens.org/171-174-002-191-711,Patent Application,no,0,0,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,H04N7/15;;G06F3/033;;G09G5/00,,0,0,,,,DISCONTINUED
192,CN,B,CN 101395913 B,192-554-553-650-781,2011-11-09,2011,CN 200680027837 A,2006-06-02,US 2006/0021233 W;;US 68738905 P;;US 77190806 P,2005-06-02,Virtual flip chart method and apparatus,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;DUNN MICHAEL H,STEELCASE INC. (2014-09-10),https://lens.org/192-554-553-650-781,Granted Patent,no,0,0,3,15,0,,H04N7/15;;G09G5/00,,0,0,,,,INACTIVE
193,US,A1,US 2007/0106950 A1,002-844-921-757-351,2007-05-10,2007,US 58575206 A,2006-10-24,US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,Portable presentation system and methods for use therewith,A presentation system and method for presenting information to an audience within a space hat includes a plurality of mobile projectors and a master presentation unit that can be moved into a presentation space and associated where the projectors and master unit are quickly linkable via a network and where the master unit expedites the system configuration process to allow the system user to manipulate images presented by all of the projectors.,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2014-02-10),https://lens.org/002-844-921-757-351,Patent Application,yes,73,188,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G09G5/00,715/761;;715/769;;345/1.1,0,0,,,,INACTIVE
194,EP,A4,EP 2714081 A4,069-483-735-887-400,2015-09-09,2015,EP 12792958 A,2012-05-25,US 201161490935 P;;US 2012/0039628 W,2011-05-27,"METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER",,CYTOCURE LLC;;GEN HOSPITAL CORP,HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/069-483-735-887-400,Search Report,no,1,0,7,7,0,A61K39/395;;C07K16/3053;;A61K38/215;;A61K38/217;;A61K45/06;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4178;;A61K31/495;;A61P35/00;;A61K39/464491;;A61K2239/57;;A61K39/464492;;A61K39/4611;;A61K2239/47;;A61K39/4632;;A61K45/06;;A61K38/215;;A61K38/217;;A61K35/17;;A61K39/395;;C07K16/3053;;A61K35/15;;A61K31/495;;A61K31/4178;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4965;;A61K35/14;;A61K39/3955,A61K39/395;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4178;;A61K31/495;;A61K31/4965;;A61K35/00;;A61K35/14;;A61K38/21;;A61K45/06,,9,8,037-185-577-801-15X;;058-444-026-470-193;;052-397-863-910-371;;092-742-253-239-635;;048-459-344-050-337;;100-041-294-232-313;;069-930-892-673-109;;017-758-293-460-701,10.1158/1078-0432.ccr-09-0213;;19671844;;18048823;;10.1200/jco.2007.11.7960;;10.1016/j.imlet.2005.11.018;;16384610;;16618741;;10.1158/0008-5472.can-05-3778;;20669973;;pmc2992603;;10.1021/mp900321a;;10.1155/2010/956304;;pmc2864912;;20467460;;pmc2688867;;10.1073/pnas.0903392106;;19416831;;pmc2947224;;10.1172/jci42442;;20852385,"BOELL BORIS ET AL: ""Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-kB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell-Mediated Cytotoxicity"", CLINICAL CANCER RESEARCH, vol. 15, no. 16, August 2009 (2009-08-01), pages 5108 - 5116, XP002742707, ISSN: 1078-0432;;MODI S ET AL: ""Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study"", JOURNAL OF CLINICAL ONCOLOGY 20071201 US, vol. 25, no. 34, 1 December 2007 (2007-12-01), pages 5410 - 5417, XP002736522, ISSN: 0732-183X;;ZSEBIK B ET AL: ""Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1"", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 104, no. 1-2, 15 April 2006 (2006-04-15), pages 146 - 155, XP024999226, ISSN: 0165-2478, [retrieved on 20060415], DOI: 10.1016/J.IMLET.2005.11.018;;SCHMITT ELISE ET AL: ""Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma."", CANCER RESEARCH 15 APR 2006, vol. 66, no. 8, 15 April 2006 (2006-04-15), pages 4191 - 4197, XP002469637, ISSN: 0008-5472;;ZHANG TAO ET AL: ""MEK Inhibition Potentiates the Activity of Hsp90 Inhibitor 17-AAG against Pancreatic Cancer Cells"", MOLECULAR PHARMACEUTICS, vol. 7, no. 5, September 2010 (2010-09-01), pages 1576 - 1584, XP002736524, ISSN: 1543-8384;;""A Ph1 Open-Label,Dose-Escalation,Safety,PK & PD Study of CNF2024 as a Single-Agent Treatment in Subjects w/HER2- Adv Breast Cancer or in Combo w/Trastuzumab in Subjects w/HER2+ Advanced Breast Cancer"", 6 January 2011 (2011-01-06), XP002742708, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT00412412/2011_01_06> [retrieved on 20150724];;CARTELLIERI MARC ET AL: ""Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer"", JOURNAL OF BIOMEDICINE & BIOTECHNOLOGY, 2010, XP002736525, ISSN: 1110-7243;;E. CALDAS-LOPES ET AL: ""Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 20, 19 May 2009 (2009-05-19), pages 8368 - 8373, XP055138872, ISSN: 0027-8424, DOI: 10.1073/pnas.0903392106;;SACHIE MARUBAYASHI ET AL: ""HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans"", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 120, no. 10, 1 October 2010 (2010-10-01), pages 3578 - 3593, XP002674766, ISSN: 0021-9738, Retrieved from the Internet <URL:http://www.jci.org/articles/view/42442> [retrieved on 20100913], DOI: 10.1172/JCI42442",DISCONTINUED
195,WO,A1,WO 2022/099055 A1,068-012-525-897-478,2022-05-12,2022,US 2021/0058314 W,2021-11-05,US 202063111401 P,2020-11-09,TEMPLATE ASSEMBLY BY PROXIMITY-ENHANCED REACTIVITY VIA METABOLIC LABELING,"The present disclosure provides methods of metabolically labeling cells to provide a substrate for assembly of desired molecules, and to bifunctional compounds used in such methods.",MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/068-012-525-897-478,Patent Application,yes,4,0,2,2,84,A61K31/70;;A61K31/713;;A61K31/7105;;A61K47/549;;A61K47/549,A61K31/70;;A61K31/7088;;A61K31/713;;A61K47/54;;C07H21/02;;C12N15/11,,1,1,076-509-804-969-853,10.1073/pnas.0707090104;;pmc2040404;;17942682,"BASKIN ET AL.: ""Copper-free click chemistry for dynamic in vivo imaging"", PROC NATL ACAD SCI USA, vol. 104, 23 October 2007 (2007-10-23), pages 16793 - 7, XP055938023",PENDING
196,US,B2,US 7834819 B2,072-522-456-978-403,2010-11-16,2010,US 81653704 A,2004-04-01,US 81653704 A,2004-04-01,Virtual flip chart method and apparatus,"A presentation method and system for presenting information to an audience within a space that mimics a flip chart assembly, the system including a control interface, a communication network and a master presentation unit including a processor and a master display screen, the master screen juxtaposed within the space so as to be viewable by the audience within the space, the processor operable to transmit an image displayed on the master screen over the network upon user command and a slave presentation unit including a slave presenter operable to receive and present an image to the audience within the space that is transmitted by the master unit to the slave unit over the network such that the master unit can be used to create a new image while the first image is simultaneously presented.",POLYVISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2007-12-21);;STEELCASE DEVELOPMENT CORPORATION (2004-03-26);;STEELCASE INC (2014-02-10),https://lens.org/072-522-456-978-403,Granted Patent,yes,106,26,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,G06F3/033;;G09G5/00;;G06F3/042;;G06F3/0484;;H04N7/15,345/1.1;;715/761,6,0,,,"Wilkhahn + Hahne GmbH + Co; InterWall.ConsulTable.ConAction range; 12 pages, no date.;;Request for Restriction/Election, mailed Nov. 3, 2009, for U.S. Appl. No. 11/585,752.;;Non-Final Rejection, mailed Feb. 22, 2010, for U.S. Appl. No. 11/585,752.;;Request for Restriction/Election, mailed Nov. 26, 2008, for U.S. Appl. No. 11/446,019.;;Non-Final Rejection, mailed Apr. 15, 2009, for U.S. Appl. No. 11/446,019.;;Final Rejection, mailed Dec. 2, 2009, for U.S. Appl. No. 11/446,019.",ACTIVE
197,WO,A2,WO 2007/142931 A2,095-381-279-415-201,2007-12-13,2007,US 2007/0012671 W,2007-05-30,US 44601906 A,2006-06-02,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",STEELCASE DEV CORP;;DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/095-381-279-415-201,Patent Application,yes,0,0,3,3,0,G06F3/03547;;G06F3/03547;;H04N7/15;;H04N7/15,,,0,0,,,,PENDING
198,AU,A1,AU 2006/288684 A1,129-818-088-440-288,2007-03-15,2007,AU 2006/288684 A,2006-09-08,US 71502805 P;;IB 2006053190 W,2005-09-08,Deregulated bacteria with improved polyhydroxyalkanoate production,,PROCTER & GAMBLE,JOHNSON ROBERT IAN;;GREEN PHILLIP RICHARD;;DUNN STUART ANTONY,,https://lens.org/129-818-088-440-288,Patent Application,no,0,0,9,9,0,C12N1/00;;C12N1/36;;C12N1/36;;C12N1/205;;C12N1/205;;C12N1/38;;C12N1/38;;C12P7/625;;C12P7/625;;C12R2001/01;;C12R2001/01,C12N15/52;;C12N15/74;;C12P7/62;;C12R1/01,,0,0,,,,DISCONTINUED
199,EP,A3,EP 1321103 A3,122-115-905-799-544,2004-03-31,2004,EP 02257966 A,2002-11-19,US 2462501 A,2001-12-18,Surgical suture welding system and method,"A suture welding system (10) for fixedly attaching a first length of suture to a second length of suture includes an electro surgical energy source (32) and a suture welding device (12). The suture welding device has a working end (20), a suture contacting element (18) disposed on the working end, a first electrode (26) electrically coupled to the electrosurgical energy source, and a second electrode (28) electrically coupled to the electrosurgical energy source. The first electrode is disposed on the suture contacting element for providing electrical energy to the first and second lengths of suture, and the second electrode is disposable proximate to the suture welding site for providing a return electrical energy path to the electrosurgical energy source. When electrical energy is provided by the first electrode to the first and second lengths of suture welds, the first and second lengths of suture are welded into a fixed attachment.",ETHICON INC,MCRURY IAN D;;DUNN DOUGLAS W;;CAULDWELL NATHAN S,"DEPUY MITEK, INC. (2008-11-12)",https://lens.org/122-115-905-799-544,Search Report,yes,2,0,11,11,0,A61B17/0487;;A61B17/06166;;A61B2017/0619;;A61B17/0487;;A61B2017/0619;;A61B17/06166,A61B17/04;;A61B17/06,,0,0,,,,EXPIRED
200,WO,A1,WO 2022/099058 A1,147-848-725-809-472,2022-05-12,2022,US 2021/0058318 W,2021-11-05,US 202063111443 P,2020-11-09,METHODS OF DETERMINING SURFACE GLYCAN DENSITY,The present disclosure provides methods of determining surface glycan density of a cell.,MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/147-848-725-809-472,Patent Application,yes,4,0,2,2,40,C12Q1/6816;;C12Q1/6816;;C12Q2600/166,C12Q1/6811;;C12N15/11;;C12Q1/6816;;C12Q1/6818;;G01N33/50;;G01N33/53,,0,0,,,,PENDING
201,WO,A3,WO 2007/142931 A3,191-157-380-925-533,2008-03-13,2008,US 2007/0012671 W,2007-05-30,US 44601906 A,2006-06-02,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",STEELCASE DEV CORP;;DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/191-157-380-925-533,Search Report,yes,5,0,3,3,0,G06F3/03547;;G06F3/03547;;H04N7/15;;H04N7/15,H04N7/15;;G06F3/033;;G09G5/00,,3,0,,,"PATENT ABSTRACTS OF JAPAN vol. 011, no. 152 (E - 507) 16 May 1987 (1987-05-16);;PATENT ABSTRACTS OF JAPAN vol. 012, no. 024 (E - 576) 23 January 1988 (1988-01-23);;PATENT ABSTRACTS OF JAPAN vol. 2000, no. 25 12 April 2001 (2001-04-12)",PENDING
202,WO,A1,WO 2022/099043 A1,006-816-156-982-320,2022-05-12,2022,US 2021/0058299 W,2021-11-05,US 202063111269 P,2020-11-09,BIFUNCTIONAL COMPOUNDS AND METHODS OF USING THE SAME,The present disclosure provides bifunctional compounds and methods of labeling a cell having an azide-modified sugar on its surface by contacting the cell with a bifunctional compound.,MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/006-816-156-982-320,Patent Application,yes,5,0,4,4,0,C07D401/12;;C07D211/60;;G01N33/582;;C07D211/32;;C07D401/12,A61K47/54;;A61K49/00;;C07D211/60;;C07D401/12,,1,1,035-563-484-401-520,10.1021/acs.jmedchem.5b00785;;26419422,"FENG ET AL.: ""Structure-Affinity Relationship Analysis of Selective FKBP51 Ligands"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, 2015, pages 7796 - 7806, XP055510638, DOI: 10.1021/acs.jmedchem.5b00785",PENDING
203,CA,A1,CA 2624966 A1,020-010-724-088-226,2007-03-15,2007,CA 2624966 A,2006-09-08,US 71502805 P;;IB 2006053190 W,2005-09-08,DEREGULATED BACTERIA WITH IMPROVED POLYHYDROXYALKANOATE PRODUCTION,,MEREDIAN INC,DUNN STUART ANTONY;;GREEN PHILLIP RICHARD;;JOHNSON ROBERT IAN,,https://lens.org/020-010-724-088-226,Patent Application,no,0,0,9,9,0,C12N1/00;;C12N1/36;;C12N1/36;;C12N1/205;;C12N1/205;;C12N1/38;;C12N1/38;;C12P7/625;;C12P7/625;;C12R2001/01;;C12R2001/01,C12N15/52;;C12N15/74;;C12P7/62,,0,0,,,,DISCONTINUED
204,US,B2,US 9430181 B2,039-389-753-687-42X,2016-08-30,2016,US 201313968941 A,2013-08-16,US 201313968941 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,Portable presentation system and methods for use therewith,"A method and assembly for use with a display configuration including a master sub-space and a plurality of slave sub-spaces, the assembly for controlling an information sharing session, the assembly comprising a processor linked to the display configuration and programmed to perform the steps of obtaining identification information from information sources usable to generate images on the sub-spaces during a session, presenting an interface via the master sub-space, the interface including a master workspace area for presenting images via the master sub-space and a tool area including source icons and panel icons associated with session images wherein each of the source and panel icons is selectable to create images within the master workspace area.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,STEELCASE INC (2014-02-10),https://lens.org/039-389-753-687-42X,Granted Patent,yes,116,16,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04N7/15;;H04N9/31,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, Oct. 12, 2006.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2006/021233, Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, Dec. 6, 2007.;;PCT International Search Report, Application No. PCT/US2007/012671, Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, Dec. 3, 2008.",ACTIVE
205,EP,A2,EP 1694852 A2,046-740-409-358-052,2006-08-30,2006,EP 04798619 A,2004-11-17,GB 2004004908 W;;GB 0326798 A;;US 54130804 P,2003-11-17,MUTANT HERPES SIMPLEX VIRUS AND USE THEREOF IN THE TREATMENT OF SQUAMOUS CELL CANCER,,CRUSADE LAB LTD;;SLOAN KETTERING INST CANCER,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,,https://lens.org/046-740-409-358-052,Patent Application,yes,0,0,9,35,0,C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61K38/00;;A61P35/00;;C12N2710/16643;;C12N2840/203;;C12N15/86;;C12N15/1135;;A61K38/00,C12N15/869;;A61K35/76;;A61K48/00;;C07K14/82;;C12N7/01;;C12N15/113,,0,0,,,,ACTIVE
206,CN,A,CN 112654951 A,080-664-688-341-229,2021-04-13,2021,CN 201980058189 A,2019-09-24,US 201862737771 P;;US 2019/0052585 W,2018-09-27,MOVING AN AVATAR BASED ON REAL-WORLD DATA,"In some implementations, a method is performed by a device including a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, the method includes obtaining user movement information. In some implementations, the user movement information characterizes a first body pose of the user at a first time and a second body pose of the user at a second time. In some implementations, the method includes determining whether a transition from the first body pose to the second body pose satisfies an acceptability threshold. In some implementations, the method includes in response to determining that the transition from the first body pose to the second body pose satisfies the acceptability threshold, generating a sequence of movements for a synthesized reality (SR) representation of the user.",APPLE INC,RICHTER IAN M;;C J DUNN;;J C RUSSELL,,https://lens.org/080-664-688-341-229,Patent Application,no,0,0,6,6,0,G06F3/011;;G06F3/017;;G06T7/10;;G06T7/73;;G06F3/011;;G06T13/40,G06F3/01,,0,0,,,,PENDING
207,WO,A3,WO 2008/051958 A3,129-711-861-651-382,2008-08-07,2008,US 2007/0082202 W,2007-10-23,US 58575206 A,2006-10-24,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,A presentation system and method for presenting information to an audience within a space hat includes a plurality of mobile projectors and a master presentation unit that can be moved into a presentation space and associated where the projectors and master unit are quickly linkable via a network and where the master unit expedites the system configuration process to allow the system user to manipulate images presented by all of the projectors.,POLY VISION CORP;;HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,,https://lens.org/129-711-861-651-382,Search Report,yes,3,0,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G09B5/06,,0,0,,,,PENDING
208,US,A1,US 2023/0406839 A1,176-545-229-745-178,2023-12-21,2023,US 202118035904 A,2021-11-05,US 202118035904 A;;US 202063111269 P;;US 2021/0058299 W,2020-11-09,Bifunctional Compounds And Methods Of Using The Same,The present disclosure provides bifunctional compounds and methods of labeling a cell having an azide-modified sugar on its surface by contacting the cell with a bifunctional compound.,MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,THE GENERAL HOSPITAL CORPORATION (2023-08-28),https://lens.org/176-545-229-745-178,Patent Application,yes,0,0,4,4,0,C07D401/12;;C07D211/60;;G01N33/582;;C07D211/32;;C07D401/12,C07D401/12;;C07D211/32,,0,0,,,,PENDING
209,MX,A,MX PA06011363 A,039-686-715-387-515,2007-05-07,2007,MX PA06011363 A,2005-04-01,US 81653704 A;;US 2005/0011366 W,2004-04-01,VIRTUAL FLIP CHART METHOD AND APPARATUS.,"A presentation method and system for presenting information to an audience within a space that mimics a flip chart assembly, the system including a control interface, a communication network and a master presentation unit including a processor and a master display screen, the master screen juxtaposed within the space so as to be viewable by the audience within the space, the processor operable to transmit an image displayed on the master screen over the network upon user command and a slave presentation unit including a slave presenter operable to receive and present an image to the audience within the space that is transmitted by the master unit to the slave unit over the network such that the master unit can be used to create a new image while the first image is simultaneously presented.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/039-686-715-387-515,Patent Application,no,0,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,G09G5/00;;G06F3/00;;G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00;;H04N7/00;;H04N7/15,,0,0,,,,ACTIVE
210,KR,A,KR 20070040331 A,043-205-586-802-800,2007-04-16,2007,KR 20067022825 A,2006-10-31,US 81653704 A,2004-04-01,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/043-205-586-802-800,Patent Application,no,0,3,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00;;H04N7/15,,0,0,,,,DISCONTINUED
211,US,B2,US 11836842 B2,045-534-351-424-665,2023-12-05,2023,US 202217837490 A,2022-06-10,US 202217837490 A;;US 202117275046 A;;US 2019/0052585 W;;US 201862737771 P,2018-09-27,Moving an avatar based on real-world data,"In some implementations, a method is performed by a device including a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, the method includes obtaining user movement information. In some implementations, the user movement information characterizes a first body pose of the user at a first time and a second body pose of the user at a second time. In some implementations, the method includes determining whether a transition from the first body pose to the second body pose satisfies an acceptability threshold. In some implementations, the method includes in response to determining that the transition from the first body pose to the second body pose satisfies the acceptability threshold, generating a sequence of movements for a synthesized reality (SR) representation of the user.",APPLE INC,RICHTER IAN M;;DUNN CAMERON J;;RUSSELL JOHN C,,https://lens.org/045-534-351-424-665,Granted Patent,yes,14,0,6,6,0,G06F3/011;;G06F3/017;;G06T7/10;;G06T7/73;;G06F3/011;;G06T13/40,G06T13/40;;G06F3/01;;G06T7/10;;G06T7/73,,4,3,049-751-473-374-981;;010-530-238-020-409;;044-237-327-395-721,10.1109/tpami.2015.2439257;;27030844;;10.1109/iccv.2017.137;;10.1016/j.patcog.2014.08.011,"PCT International Search Report and Written Opinion dated Feb. 4, 2020, International Application No. PCT/US2019/052585, pp. 1-16.;;Boulbaba Ben Amor et al., “Action Recognition Using Rate-Invariant Analysis of Skeletal Shape Trajectories,” IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 38, No. 1, Jan. 2016, pp. 1-13.;;Y. Chen et al., “Adversial PoseNet: A Structure-Aware Convolutional Network for Human Pose Estimation,” IEEE International Conference on Computer Vision (ICCV), 2017, pp. 1221-1230.;;Slama et al., “Accurate 3D Action Recognition Using Learning on the Grassmann Manifold,” Pattern Recognition, vol. 28, 2015, pp. 556-567.",ACTIVE
212,AU,B2,AU 2003/268275 B2,079-643-184-852-545,2009-12-03,2009,AU 2003/268275 A,2003-08-29,US 40749202 P;;US 0327125 W,2002-08-29,Methods for up-regulating antigen expression in tumors,,CYTOCURE LLC,KURNICK JAMES T;;DURDA PAUL J;;DUNN IAN S,,https://lens.org/079-643-184-852-545,Granted Patent,no,1,0,14,14,0,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61K38/21;;A61B19/00;;A61K/;;A61K39/00;;A61K39/395;;C07K16/30;;G01N33/50,,0,0,,,,EXPIRED
213,US,B2,US 9727207 B2,093-123-067-583-057,2017-08-08,2017,US 201715417320 A,2017-01-27,US 201715417320 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,Portable presentation system and methods for use therewith,"A distributed digital content collaboration method and system, the method comprising the steps of storing collaboration session data for at least one collaboration session, the collaboration data including data objects displayable on display surfaces, identifying unused display surfaces associated a collaboration system, sending display identifiers to at least a subset of the unused display surfaces, wherein the display identifiers are presented on the display surfaces as display identification codes for associated surfaces, receiving user input via a user interface identifying at least one of the display identifiers associated with a first display surface, determining that the identified display identifier matches the display identifier sent to the first display surface and, in response to the determination, configuring the first display surface with the processor to facilitate content collaboration.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/093-123-067-583-057,Granted Patent,yes,249,11,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/0481;;G06F3/0488;;G09B5/08;;H04L29/06,,7,0,,,"PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, Oct. 12, 2006.;;PCT International Search Report, Application No. PCT/U52006/021233, Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, Dec. 6, 2007.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/U52007/012671, Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, Dec. 3, 2008.",ACTIVE
214,CN,A,CN 101300354 A,109-754-829-300-181,2008-11-05,2008,CN 200680041297 A,2006-09-08,US 71502805 P,2005-09-08,Deregulated bacteria with improved polyhydroxyalkanoate production,Mutant bacteria with improved poly-3-hydroxylalkanoate (PHA)-producing characteristics and methods of producing and using them are provided.,PROCTER & GAMBLE,RICHARD GREEN PHILLIP;;IAN JOHNSON ROBERT;;ANTONY DUNN STUART,,https://lens.org/109-754-829-300-181,Patent Application,no,0,2,9,9,0,C12N1/00;;C12N1/36;;C12N1/36;;C12N1/205;;C12N1/205;;C12N1/38;;C12N1/38;;C12P7/625;;C12P7/625;;C12R2001/01;;C12R2001/01,C12N15/52;;C12N15/74;;C12P7/62;;C12R1/01,,0,0,,,,DISCONTINUED
215,US,A1,US 2024/0016933 A1,127-114-811-677-455,2024-01-18,2024,US 202118036047 A,2021-11-05,US 202118036047 A;;US 202063111188 P;;US 2021/0058295 W,2020-11-09,Methods of Anchoring or Reconstituting Active Molecules on Metabolically Labeled Cells,"The present disclosure provides methods of anchoring active molecules on the surface of a cell, methods of anchoring at least two active molecules on the surface of a cell, and methods of enhancing an immune response to a target cell in a human.",MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/127-114-811-677-455,Patent Application,yes,0,0,2,2,100,A61K35/17;;Y02A50/30;;A61K38/00;;G01N33/582;;G01N33/56972;;A61K2239/13;;A61K39/4631;;A61K35/17;;C07H15/12;;C07K16/1018;;C07K16/1027;;C07K16/2803;;C07K16/2863;;C07K16/3015;;C12N5/0636,A61K39/00;;A61K35/17;;C07H15/12;;C07K16/10;;C07K16/28;;C07K16/30;;C12N5/0783,,0,0,,,,PENDING
216,US,A1,US 2005/0219225 A1,015-528-736-270-880,2005-10-06,2005,US 81653704 A,2004-04-01,US 81653704 A,2004-04-01,Virtual flip chart method and apparatus,"A presentation method and system for presenting information to an audience within a space that mimics a flip chart assembly, the system including a control interface, a communication network and a master presentation unit including a processor and a master display screen, the master screen juxtaposed within the space so as to be viewable by the audience within the space, the processor operable to transmit an image displayed on the master screen over the network upon user command and a slave presentation unit including a slave presenter operable to receive and present an image to the audience within the space that is transmitted by the master unit to the slave unit over the network such that the master unit can be used to create a new image while the first image is simultaneously presented.",DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2007-12-21);;STEELCASE DEVELOPMENT CORPORATION (2004-03-26);;STEELCASE INC (2014-02-10),https://lens.org/015-528-736-270-880,Patent Application,yes,83,13,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00;;H04N7/15,345/173;;345/105;;345/179;;345/178;;434/408;;434/411;;434/412;;434/416;;434/428;;178/18.03;;178/18.07;;382/103,0,0,,,,ACTIVE
217,EP,B8,EP 1542609 B8,039-898-173-360-469,2013-02-20,2013,EP 03749229 A,2003-08-29,US 0327125 W;;US 40749202 P,2002-08-29,Pharmaceutical compositions comprising Interferon beta for use in treating melanoma,,CYTOCURE LLC,DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,CYTOCURE LLC (2013-02-20),https://lens.org/039-898-173-360-469,Amended Patent,yes,5,0,14,14,0,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61K38/21;;A61B19/00;;A61K/;;A61K35/00;;A61K39/00;;A61K39/395;;A61P35/00;;C07K16/30;;G01N33/50,,9,0,,,"MAKOTO ODAKA ET AL: ""Eradication of Intraperitoneal and Distant Tumor by Adenovirus-mediated Interferon-ß Gene Therapy Is Attributable to Induction of Systemic Immunity"" CANCER RESEARCH, vol. 61, 15 August 2001 (2001-08-15), pages 6201-6212, XP002586103;;ZHONGYUN DONG ET AL.: ""Suppression of Angiogenesis, Tumorigenicity, and Metastasis by Human Prostate Cancer Cells Engineered to Produce Interferon-ß"" CANCER RESEARCH, vol. 59, 10 February 1999 (1999-02-10), pages 872-879, XP002586104;;JOHN J. RINEHART ET AL.: ""Phase I/II Trial of Interferon-ß-Serine in Patients with Renal Cell Carcinoma; Immunological and Biological Effects"" CANCER RESEARCH, vol. 47, 1 May 1987 (1987-05-01), pages 2481-2485, XP002586105;;SENSI MARIALUISA ET AL: ""Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.92.12.5674, vol. 92, no. 12, 1 January 1995 (1995-01-01), pages 5674-5678, XP002143225 ISSN: 0027-8424;;KAWAKAMI Y ET AL: ""CLONING OF THE GENE CODING FOR A SHARED HUMAN MELANOMA ANTIGEN RECOGNIZED BY AUTOLOGOUS T CELLS INFILTRATING INTO TUMOR"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.91.9.3515, vol. 91, no. 9, 26 April 1994 (1994-04-26) , pages 3515-3519, XP000770221 ISSN: 0027-8424;;MATEO ET AL: ""An HLA-A2 polyepitope vaccine for melanoma immunotherapy"" J IMMUNOL., vol. 7, no. 1, October 1999 (1999-10), pages 4058-4063, XP002587571;;BROUWENSTIJN N ET AL.: ""Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage."" BR J CANCER, vol. 12, 1997, pages 1562-1566, XP002587572;;MASCI PAUL ET AL: ""Malignant melanoma: treatments emerging, but early detection is still key."", CLEVELAND CLINIC JOURNAL OF MEDICINE JUL 2002 LNKD- PUBMED:12109636, vol. 69, no. 7, July 2002 (2002-07), pages 529 , 533-534 , 536, ISSN: 0891-1150;;SMITS A: ""Low-grade gliomas: clinical and pathobiological aspects."", HISTOLOGY AND HISTOPATHOLOGY JAN 2002 LNKD- PUBMED:11813876, vol. 17, no. 1, January 2002 (2002-01), pages 253-260, ISSN: 0213-3911",EXPIRED
218,EP,A2,EP 2078298 A2,030-214-403-757-115,2009-07-15,2009,EP 07854327 A,2007-10-23,US 2007/0082202 W;;US 58575206 A,2006-10-24,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,,POLY VISION CORP,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,,https://lens.org/030-214-403-757-115,Patent Application,yes,0,0,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G09B5/06,,0,0,,,,DISCONTINUED
219,US,B2,US 9471269 B2,027-839-346-985-550,2016-10-18,2016,US 201313968931 A,2013-08-16,US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,Portable presentation system and methods for use therewith,"An assembly for sharing information in a conference space comprising a contiguous large presentation display assembly including a large contiguous presentation surface, a processor programmed to perform the steps of dividing the large surface into a plurality of adjacent presentation sub-spaces including at least one master sub-space and a plurality of slave sub-spaces and enabling an interface that allows images to be presented via the sub-spaces and that enables moving images among the different sub-spaces, wherein, upon an image being moved from the master sub-space to one of the slave sub-spaces, the master presentation sub-space is left blank to receive another image.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,STEELCASE INC (2013-11-13),https://lens.org/027-839-346-985-550,Granted Patent,yes,110,17,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04N7/15;;H04N9/31,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, Oct. 12, 2006.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2006/021233, Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, Dec. 6, 2007.;;PCT International Search Report, Application No. PCT/US2007/012671, Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, Dec. 3, 2008.",ACTIVE
220,WO,A2,WO 2008/051958 A2,035-791-524-008-323,2008-05-02,2008,US 2007/0082202 W,2007-10-23,US 58575206 A,2006-10-24,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,A presentation system and method for presenting information to an audience within a space hat includes a plurality of mobile projectors and a master presentation unit that can be moved into a presentation space and associated where the projectors and master unit are quickly linkable via a network and where the master unit expedites the system configuration process to allow the system user to manipulate images presented by all of the projectors.,POLY VISION CORP;;HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,,https://lens.org/035-791-524-008-323,Patent Application,yes,0,4,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,,,0,0,,,,PENDING
221,EP,A1,EP 4240421 A1,085-926-513-223-270,2023-09-13,2023,EP 21890173 A,2021-11-05,US 202063111269 P;;US 2021/0058299 W,2020-11-09,BIFUNCTIONAL COMPOUNDS AND METHODS OF USING THE SAME,,MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/085-926-513-223-270,Patent Application,yes,0,0,4,4,0,C07D401/12;;C07D211/60;;G01N33/582;;C07D211/32;;C07D401/12,A61K47/54;;A61K49/00;;C07D211/60;;C07D401/12,,0,0,,,,PENDING
222,US,B2,US 9448759 B2,089-904-720-253-585,2016-09-20,2016,US 201313968945 A,2013-08-16,US 201313968945 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,Portable presentation system and methods for use therewith,"A method and assembly for sharing information in a conference space, the assembly comprising a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the surface area including at least first and second adjacent presentation sub-spaces, a processor programmed to perform the steps of presenting an interface on the surface area useable to generate session images within at least one of the sub-spaces, the interface including a panel section in which a separate panel icon for each of the session images created during a session is presented, the interface further including a separate space on the surface area associated with each of the sub-spaces, the interface facilitating selection and dragging of panel icons to locations associated with the sub-spaces to control the images presented in each of the sub-spaces, wherein, when a panel icon is dragged to a space, an image currently associated with the sub-space is replaced at the sub-space.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,STEELCASE INC (2014-02-10),https://lens.org/089-904-720-253-585,Granted Patent,yes,111,14,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04N7/15;;H04N9/31,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, Oct. 12, 2006.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2006/021233, Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, Dec. 6, 2007.;;PCT International Search Report, Application No. PCT/US2007/012671, Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, Dec. 3, 2008.",ACTIVE
223,EP,A2,EP 2281897 A2,108-267-372-462-847,2011-02-09,2011,EP 10186056 A,2004-11-17,EP 04798619 A;;GB 0326798 A;;US 54130804 P,2003-11-17,Oncolytic mutant Herpes Simplex virus,"An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.
",CRUSADE LAB LTD;;SLOAN KETTERING INST CANCER,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (2011-12-28);;VIRTTU BIOLOGICS LIMITED (2011-12-28),https://lens.org/108-267-372-462-847,Patent Application,yes,3,1,20,35,6,A01K2267/0331;;A61K35/13;;A61K48/00;;A61K2039/5256;;C12N7/00;;C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;C12N15/1135;;C12N2710/16643;;A01K2267/0331;;C12N7/00;;A61K2039/5256;;C12N15/86;;A61K48/00;;C12N2840/203;;A61K35/13,C12N15/869;;A61K35/13;;A61K35/76;;A61K39/00;;A61K48/00;;C07K14/82;;C12N7/00;;C12N7/01;;C12N15/113,,26,22,007-109-900-887-158;;137-001-293-527-925;;000-268-257-213-800;;038-569-628-511-46X;;123-034-227-453-14X;;084-612-955-028-685;;127-499-456-300-150;;024-275-489-946-890;;048-752-205-714-116;;050-045-355-254-863;;053-774-110-438-540;;171-779-087-610-971;;092-067-236-045-728;;067-771-158-307-587;;026-525-020-729-284;;009-470-098-709-978;;027-892-815-690-396;;070-078-336-964-196;;013-328-341-455-013;;105-421-325-180-293;;038-521-351-570-287;;138-036-512-631-113,10.1038/sj.gt.3301885;;12595888;;1321882;;10.1099/0022-1317-73-4-971;;10.1126/science.2173860;;2173860;;8908502;;8151292;;10.1099/0022-1317-75-4-733;;10.1099/0022-1317-74-11-2493;;8245868;;9253508;;12796399;;10690381;;10.1023/a:1008330026617;;10873352;;10.1053/ejso.1999.0895;;10741699;;10.1038/78638;;10932224;;9176490;;10.1038/nm0697-639;;1848598;;10.1099/0022-1317-72-3-631;;8077935;;10.1099/0022-1317-75-9-2367;;10.1038/bjc.1996.431;;pmc2074706;;8795577;;7645240;;10.1006/viro.1995.1382;;8806577;;10.1006/viro.1996.0493;;10.1097/00005072-199612000-00010;;8957450;;9012475;;10.1111/1523-1747.ep12295238;;9182825;;10845724;;10.1038/sj.gt.3301184,"SAMBROOK ET AL.: ""Molecular Cloning, A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;BL LIU; M ROBINSON; Z-Q HAN; RH BRANSTON; C ENGLISH; PREAY; Y MCGRATH; SK THOMAS; M THORNTON; P BULLOCK, GENE THERAPY, vol. 10, 2003, pages 292 - 303;;A DOLAN; E MCKIE; AR MACLEAN; DJ MCGEOCH, JOURNAL OF GENERAL VIROLOGY, vol. 73, 1992, pages 971 - 973;;AIDAN DOLAN; FIONA E JAMIESON; CHARLES CUNNIGHAM; BARBARA C BARNETT; DUNCAN J MCGEOCH, JOURNAL OF VIROLOGY, March 1998 (1998-03-01), pages 2010 - 2021;;JOANY CHOU; EARL R KERN; RICHARD J WHITLEY; BERNARD ROIZMAN, SCIENCE, vol. 250, 1990, pages 1262 - 1265;;COFFIN RS; MACLEAN AR; LATCHMAN DS; BROWN SM, GENE THERAPY, vol. 3, no. 10, October 1996 (1996-10-01), pages 886 - 91;;MCKIE EA; HOPE RG; BROWN SM; MACLEAN AR, JOURNAL OF GENERAL VIROLOGY, vol. 75, April 1994 (1994-04-01), pages 733 - 41;;MCKAY EM; MCVEY B; MARSDEN HS; BROWN SM; MACLEAN AR, JOURNAL OF GENERAL VIROLOGY, vol. 74, November 1993 (1993-11-01), pages 2493 - 7;;JOANY CHOU; BERNARD ROIZMAN, JOURNAL OF VIROLOGY, March 1990 (1990-03-01), pages 1014 - 1020;;GREEN, N.K.; YOUNGS, D.J; J.P. NEOPTOLEMOS; F. FRIEDLOS; R.J. KNOX; C.J. SPRINGER; G.M. ANLEZARK; N.P. MICHAEL; R.G. MELTON; M.J., CANCER GENE THERAPY, vol. 4, 1997, pages 229 - 238;;CHERRY L. ESTILO; PORNCHAI 0-CHAROENRAT; IVAN NAGAI; SNEHAL G. PATEL; PABBATHI G. REDDY; SU DAO; ASHOK R. SHAHA; DENNIS H. KRAUS;, CLINICAL CANCER RESEARCH, vol. 9, June 2003 (2003-06-01), pages 2300 - 2306;;GANLY I; KAYE SB: ""Recurrent head and neck cancer- current therapy and future prospects"", ANNALS OF ONCOLOGY, vol. 11, 2000, pages 1 - 6;;GANLY I; SOUTAR DS; KAYE SB: ""Current role of gene therapy in head and neck cancer"", EUROPEAN J OF SURGICAL ONCOLOGY, vol. 26, 2000, pages 338 - 343;;GANLY I; KIRN D; SOUTAR D; ECKARDT G; OTTO R; ROBERTSON AG; PARK 0; HEISE C; VON HOFF DD; KAYE SB: ""A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumourally in patients with recurrent tumours of the head and neck"", CLINICAL CANCER RESEARCH, vol. 6, 2000, pages 798 - 806;;KHURI F; NEMUNAITIS J; GANLY I; ARSENEAU J; TANNOCK I; ROMEL L; GORE M; IRONSIDE J; HEISE C; RANDLEY B: ""Controlled trial of intratumoural ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer"", NATURE MEDICINE, vol. 6, no. 8, 2000, pages 879 - 885;;HEISE C; SAMPSON-JOHANNES A; WILLIAMS A; MCCORMICK F; VON HOFF D; KIRN DH.: ""Onyx -015 an E1B gene attenuated adenovirus causes tumour specific cytolysis and antitumoural dfficacy that canb e augmented by standard chemotherpeutic agents"", NATURE MEDICINE, vol. 3, pages 639 - 645;;MACLEAN AR; FAREED MU; ROBERTSON L; HARLAND J; BROWN SM: ""Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate early gene 1 and the Aa' sequence"", JOURNAL OF GENERAL VIROLOGY, vol. 72, 1991, pages 631 - 639;;BROWN SM; HARLAND J; MACLEAN AR; PODLECH J; CLEMENTS JB: ""Cell type and cell state determine differentiated in vitro growth of non-neurovirulent ICP34.5 negative herpes simplex virus"", JOURNAL OF GENERAL VIROLOGY, vol. 75, 1994, pages 2367 - 2377;;MCKIE EA; MACLEAN AR; LEWIS AD; CRUICKSHANK G; RAMPLING R; BARNETT SC; KENNEDY PGE; BROWN SM: ""Selective in vitro replication of herpes simplex virus type 1 (HSV1), ICP34.5 null mutants in primary human CNS tumours-evaluation of a potentially effective clinical therapy"", BRITISH JOURNAL OF CANCER, vol. 74, 1996, pages 745 - 752;;RANDAZZO B; KESARI S; MACLEAN AR; BROWN SM.; FRASER NW.: ""Treatment of experimental intracranial murine melanoma with the neuroattenuated HSV1 mutant 1716"", VIROLOGY, vol. 211, 1995, pages 94 - 101;;KESARI S; RANDAZZO BP; VALYI-NAGY T; HUANG QS; BROWN SM; MACLEAN AR; LEE VM-Y; TROJANOWSKI JQ; FRASER NW.: ""A mutant herpes simplex virus replicates in brain tumours but not in neurons derived from a human embryonal carcinoma cell line"", LABORATORY INVESTIGATION, vol. 73, 1995, pages 636 - 648;;RANDAZZO BP; KUCHARCZUK JC; LITZKY LA; KAISER LR; BROWN SM; MACLEAN AR; ALBELDA SM.; FRASER NW.: ""Herpes simplex 1716 - an ICP34.5 mutant is severely replication restricted in human skin xenografts in vivo"", VIROLOGY, vol. 223, 1996, pages 392 - 396;;LASNER TM; KESARI S; BROWN SM; LEE VM-Y; FRASER NW.; TROJANOWSKI JQ.: ""Herpes simplex virus type 1 (HSV1) mutants for the treatment of childhood brain tumours"", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, vol. 55, 1996, pages 1259 - 1269;;KUCHARCZUK JC; RANDAZZO B; CHANG MY; AMIN KM; ELSHAMI AA; STERMAN DH; RIZK NP; MOLNAR-KIMBER KL; BROWN SM; MACLEAN AR: ""Use of a ""replication restricted"" herpes virus to treat experimental human malignant mesothelioma"", CANCER RESEARCH, vol. 57, 1997, pages 466 - 471;;RANDAZZO BP; BHAT MG; KESARI S; FRASER NW.; BROWN SM.: ""Treatment of experimental subcutaneous human melanoma with a replication restricted herpes simplex virus mutant"", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 108, 1997, pages 933 - 937;;RAMPLING R; CRUICKSHANK G; PAPANASTASSIOU V; NICOLL J; HADLEY D; PETTY R; MACLEAN A; HARLAND J; MCKIE E; MABBS R.: ""Toxicity evaluation of replication competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma"", GENE THERAPY, vol. 7, 2000, pages 859 - 866",DISCONTINUED
224,WO,A1,WO 2022/099040 A1,102-315-073-300-587,2022-05-12,2022,US 2021/0058295 W,2021-11-05,US 202063111188 P,2020-11-09,METHODS OF ANCHORING OR RECONSTITUTING ACTIVE MOLECULES ON METABOLICALLY LABELED CELLS,"The present disclosure provides methods of anchoring active molecules on the surface of a cell, methods of anchoring at least two active molecules on the surface of a cell, and methods of enhancing an immune response to a target cell in a human.",MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/102-315-073-300-587,Patent Application,yes,3,0,2,2,100,A61K35/17;;Y02A50/30;;A61K38/00;;G01N33/582;;G01N33/56972;;A61K2239/13;;A61K39/4631;;A61K35/17;;C07H15/12;;C07K16/1018;;C07K16/1027;;C07K16/2803;;C07K16/2863;;C07K16/3015;;C12N5/0636,A61K31/015;;A61K31/70;;A61K35/17;;A61K47/54;;C07H1/00;;C12Q1/00,,2,2,076-509-804-969-853;;011-465-284-080-910,10.1073/pnas.0707090104;;pmc2040404;;17942682;;20886827;;10.1021/bc100272z;;pmc3014321,"BASKIN JEREMY M., PRESCHER JENNIFER A., LAUGHLIN SCOTT T., AGARD NICHOLAS J., CHANG PAMELA V., MILLER ISAAC A., LO ANDERSON, CODEL: ""Copper-free click chemistry for dynamic in vivo imaging"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 104, no. 43, 23 October 2007 (2007-10-23), pages 16793 - 16797, XP055938023, ISSN: 0027-8424, DOI: 10.1073/pnas.0707090104;;VU HONG, NICOLE F. STEINMETZ, MARIANNE MANCHESTER, M. G. FINN: ""Labeling Live Cells by Copper-Catalyzed Alkyne−Azide Click Chemistry"", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 21, no. 10, 20 October 2010 (2010-10-20), US , pages 1912 - 1916, XP055305664, ISSN: 1043-1802, DOI: 10.1021/bc100272z",PENDING
225,WO,A1,WO 2005/099263 A1,177-059-579-620-570,2005-10-20,2005,US 2005/0011366 W,2005-04-01,US 81653704 A,2004-04-01,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation method and system for presenting information to an audience within a space that mimics a flip chart assembly, the system including a control interface, a communication network and a master presentation unit including a processor and a master display screen, the master screen juxtaposed within the space so as to be viewable by the audience within the space, the processor operable to transmit an image displayed on the master screen over the network upon user command and a slave presentation unit including a slave presenter operable to receive and present an image to the audience within the space that is transmitted by the master unit to the slave unit over the network such that the master unit can be used to create a new image while the first image is simultaneously presented.",POLY VISION CORP;;DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/177-059-579-620-570,Patent Application,yes,1,18,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00;;H04N7/15,,3,0,,,"PATENT ABSTRACTS OF JAPAN vol. 011, no. 152 (E - 507) 16 May 1987 (1987-05-16);;PATENT ABSTRACTS OF JAPAN vol. 012, no. 024 (E - 576) 23 January 1988 (1988-01-23);;PATENT ABSTRACTS OF JAPAN vol. 2000, no. 25 12 April 2001 (2001-04-12)",PENDING
226,US,A1,US 2012/0195855 A1,001-592-016-522-304,2012-08-02,2012,US 201113276783 A,2011-10-19,US 201113276783 A;;US 65161603 A;;US 40749202 P,2002-08-29,METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS,"The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against a tumor cell. Methods include administering to a subject with a tumor an amount of IFN-β receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.",DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S;;CYTOCURE LLC,DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/001-592-016-522-304,Patent Application,yes,0,0,14,14,30,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61K38/21;;A61B19/00;;A61K/;;A61K39/00;;A61K39/395;;A61P35/00;;A61P35/04;;C07K16/30;;G01N33/50,424/85.6,1,0,,,"1.132 declaration of Dr. Kurnick dated 9/20/10 (U.S. Application No. 10/651,616 (USPN 8071321))",DISCONTINUED
227,WO,A3,WO 2005/049846 A3,001-179-685-120-450,2005-10-06,2005,GB 2004004908 W,2004-11-17,GB 0326798 A;;US 54130804 P,2003-11-17,MUTANT HERPES SIMPLEX VIRUS AND USE THEREOF IN THE TREATMENT OF SQUAMOUS CELL CANCER,An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN;;CRUSADE LAB LTD;;SLOANE KETTERING INST FOR CANC,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,,https://lens.org/001-179-685-120-450,Search Report,yes,3,0,9,35,0,C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61K38/00;;A61P35/00;;C12N2710/16643;;C12N2840/203;;C12N15/86;;C12N15/1135;;A61K38/00,C12N15/113;;C12N15/869,,3,2,008-222-704-204-090;;024-275-489-946-890,12133274;;10.1089/104303402320138998;;12796399,"WONG R J ET AL: ""Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases"", HUMAN GENE THERAPY, vol. 13, 1 July 2002 (2002-07-01), pages 1213 - 1223, XP002971610, ISSN: 1043-0342;;ESTILO CHERRY L ET AL: ""The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JUN 2003, vol. 9, no. 6, June 2003 (2003-06-01), pages 2300 - 2306, XP002335918, ISSN: 1078-0432;;DATABASE EMBL [online] 22 February 2002 (2002-02-22), ""Homo sapiens leucine zipper protein (SCRO) mRNA, complete cds."", XP002335921, retrieved from EBI accession no. EM_HUM:AF456425 Database accession no. AF456425",PENDING
228,CA,C,CA 2611084 C,002-835-987-767-208,2014-07-08,2014,CA 2611084 A,2006-06-02,US 68738905 P;;US 77190806 P;;US 2006/0021233 W,2005-06-02,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/002-835-987-767-208,Granted Patent,no,0,0,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,H04N7/15;;B43L1/00;;G06F3/0481;;G06F3/0484;;G06F3/14;;G09B5/02;;G09B5/12;;G09F9/00,,0,0,,,,INACTIVE
229,AU,A1,AU 2003/268275 A1,034-084-110-410-831,2004-03-19,2004,AU 2003/268275 A,2003-08-29,US 40749202 P;;US 0327125 W,2002-08-29,METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS,,CYTOCURE LLC,DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/034-084-110-410-831,Patent Application,no,0,0,14,14,0,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61B19/00;;A61K/;;A61K38/21;;A61K39/00;;A61K39/395;;C07K16/30;;G01N33/50,,0,0,,,,EXPIRED
230,US,A1,US 2007/0044028 A1,034-602-169-072-459,2007-02-22,2007,US 44601906 A,2006-06-02,US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,Virtual flip chart method and apparatus,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2007-12-21);;STEELCASE DEVELOPMENT CORPORATION (2006-08-17);;STEELCASE INC (2014-02-10),https://lens.org/034-602-169-072-459,Patent Application,yes,88,51,3,3,0,G06F3/03547;;G06F3/03547;;H04N7/15;;H04N7/15,G09G5/00,715/761;;345/1.1,0,0,,,,DISCONTINUED
231,US,A1,US 2018/0107444 A1,122-086-825-220-440,2018-04-19,2018,US 201715836508 A,2017-12-08,US 201715836508 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A method and assembly for sharing information in a conference space, the assembly comprising a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the surface area including at least first and second adjacent presentation sub-spaces, a processor programmed to perform the steps of presenting an interface on the surface area useable to generate session images within at least one of the sub-spaces, the interface including a panel section in which a separate panel icon for each of the session images created during a session is presented, the interface further including a separate space on the surface area associated with each of the sub-spaces, the interface facilitating selection and dragging of panel icons to locations associated with the sub-spaces to control the images presented in each of the sub-spaces, wherein, when a panel icon is dragged to a space, an image currently associated with the sub-space is replaced at the sub-space.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2007-01-09);;STEELCASE INC (2014-02-10),https://lens.org/122-086-825-220-440,Patent Application,yes,0,22,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14;;G09B5/08;;G09G3/00;;H04N9/31,,0,0,,,,INACTIVE
232,AU,A1,AU 2005/232057 A1,128-807-687-130-046,2005-10-20,2005,AU 2005/232057 A,2005-04-01,US 81653704 A;;US 2005/0011366 W,2004-04-01,Virtual flip chart method and apparatus,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;DUNN MICHAEL H,,https://lens.org/128-807-687-130-046,Patent Application,no,0,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00;;H04N7/15,,0,0,,,,DISCONTINUED
233,US,A1,US 2005/0235215 A1,130-006-608-964-838,2005-10-20,2005,US 9696905 A,2005-04-01,US 9696905 A;;US 81653704 A,2004-04-01,Virtual flip chart method and apparatus,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2007-12-21);;STEELCASE DEVELOPMENT CORPORATION (2005-06-23);;STEELCASE INC (2014-02-10),https://lens.org/130-006-608-964-838,Patent Application,yes,86,32,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00;;H04N7/15,715/740;;345/156;;345/158;;715/751;;709/208,0,0,,,,DISCONTINUED
234,CA,A1,CA 2874998 A1,159-503-169-429-891,2012-12-06,2012,CA 2874998 A,2012-05-25,US 201161490935 P;;US 2012/0039628 W,2011-05-27,"METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER","The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-ß receptor agonist or an IFN-? receptor agonist, for the treatment of cancer.",CYTOCURE LLC;;GEN HOSPITAL CORP,HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/159-503-169-429-891,Patent Application,no,0,0,7,7,6,A61K39/395;;C07K16/3053;;A61K38/215;;A61K38/217;;A61K45/06;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4178;;A61K31/495;;A61P35/00;;A61K39/464491;;A61K2239/57;;A61K39/464492;;A61K39/4611;;A61K2239/47;;A61K39/4632;;A61K45/06;;A61K38/215;;A61K38/217;;A61K35/17;;A61K39/395;;C07K16/3053;;A61K35/15;;A61K31/495;;A61K31/4178;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4965;;A61K35/14;;A61K39/3955,A61K39/395;;A61K38/21;;A61P35/00,,0,0,,,,DISCONTINUED
235,US,B2,US 8530437 B2,173-819-278-392-408,2013-09-10,2013,US 43638209 A,2009-05-06,US 43638209 A;;GB 0326798 A;;US 57962206 A;;GB 2004004908 W;;US 54130804 P,2003-11-17,Methods for treating cancer using herpes simplex virus expressing antisense to the squamous cell carcinoma related oncogene,An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN;;SLOAN KETTERING INST CANCER;;VIRTTU BIOLOG LTD,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (2005-10-24);;VIRTTU BIOLOGICS LIMITED (2003-12-19),https://lens.org/173-819-278-392-408,Granted Patent,yes,32,1,9,35,6,C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61K38/00;;A61P35/00;;C12N2710/16643;;C12N2840/203;;C12N15/86;;C12N15/1135;;A61K38/00,A61K38/00;;C07H21/04;;C12N15/113;;C12N15/869;;C12Q1/68,514 44A;;536/24.5;;435/6.1,34,33,012-371-128-627-856;;128-026-296-127-614;;039-782-238-537-460;;072-019-227-632-54X;;054-461-303-829-766;;020-453-173-222-929;;024-275-489-946-890;;112-035-421-628-981;;051-952-864-434-139;;003-800-478-645-25X;;059-683-470-085-915;;092-013-207-791-752;;017-154-282-632-363;;014-861-355-687-159;;060-428-864-213-243;;138-036-512-631-113;;058-718-990-903-695;;081-927-774-063-93X;;006-917-095-635-749;;053-180-227-973-776;;071-892-836-895-759;;013-144-318-118-08X;;019-901-032-598-798;;008-222-704-204-090;;097-912-636-376-769;;039-782-238-537-460;;029-114-817-824-206;;029-811-397-217-20X;;070-512-052-508-753;;089-750-637-636-623;;052-340-525-809-716;;034-919-546-033-179;;057-123-167-179-128,10.1177/154405910308200104;;12508038;;10.1089/104454902762053864;;12573050;;10389942;;11426651;;10.1038/sj.onc.1204093;;10.1128/jvi.78.9.4684-4699.2004;;15078951;;pmc387725;;10.1128/jvi.73.9.7153-7164.1999;;pmc104239;;10438802;;12796399;;pmc136990;;10.1128/jvi.76.17.8560-8571.2002;;12163576;;10.1038/sj.cgt.7700339;;11571534;;12864992;;10.1016/s0165-5728(03)00208-x;;10.1089/10430340360535823;;12639307;;10.1186/1743-422x-4-47;;17547759;;pmc1892547;;3031658;;pmc304554;;10.1073/pnas.84.7.1926;;pmc114023;;11152490;;10.1128/jvi.75.3.1172-1185.2001;;12899642;;10.2165/00063030-200317040-00004;;10845724;;10.1038/sj.gt.3301184;;10.1128/jvi.46.2.498-512.1983;;6302315;;pmc255152;;pmc2447072;;10.1128/jvi.00137-08;;18448541;;7645253;;10.1006/viro.1995.1431;;1695257;;pmc249684;;10.1128/jvi.64.8.3882-3894.1990;;1311370;;10.1099/0022-1317-73-2-467;;10.1128/jvi.61.7.2198-2207.1987;;3035220;;pmc283683;;10609661;;10.1089/10430349950016410;;12133274;;10.1089/104303402320138998;;20836854;;pmc2944180;;10.1186/1471-2407-10-486;;10389942;;8794366;;10.1128/jvi.70.10.7190-7197.1996;;pmc190772;;3523478;;pmc323828;;10.1073/pnas.83.13.4794;;10.1016/j.pain.2003.08.006;;14659519;;19019961;;10.1128/jvi.01723-08;;pmc2620902;;9574551;;10.1097/01.anes.0000267603.32634.03;;17525595;;pmc2666538;;18596690;;10.1038/nature07103,"Xi et al., Gene therapy for the treatment of oral squamous cell carcinoma, 2003, Journal of Dental Research, vol. 82, pp. 11-16.;;Burton, Edward A., et al., ""Gene Delivery Using Herpes Simplex Virus Vectors,"" DNA and Cell Biology, vol. 21, No. 12, 2002, pp. 915-936.;;Coukos et al., ""Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer,"" Clinical Cancer Research, Jun. 1999, vol. 5, pp. 1523-1537.;;Crooke, Stanley T., ""Potential roles of antisense technology in cancer chemotherapy,"" Oncogene, 2000, vol. 19, pp. 6651-6659.;;Doepker, Rosalyn C. et al., ""Herpes Simplex Virus Virion Host Shutoff Protein Is Stimulated by Translation Initiation Factors eIF4B and eIF4H,"" Journal of Virology, May 2004, pp. 4684-4699.;;Elgadi, Mabrouk M. et al., ""The Herpes Simplex Virus vhs Protein Induces Endoribonucleolytic Cleavage of Target RNAs in Cell Extracts,"" Journal of Virology, Sep. 1999, pp. 7153-7164.;;EMBL Accession No. AF456425, ""Homo sapiens leucine zipper protein (SCRO) mRNA, complete cds,"" (2002).;;Estilo, et al., ""The Role of Novel Oncogenes Squamous Cell Carcinoma-related Oncogene and Phosphatidylinositol 3-Kinase p110a in Squamous Cell Carcinoma of the Oral Tongue,"" Clinical Cancer Research, 2003, vol. 9, pp. 2300-2306.;;Everly et al., ""mRNA Degradation by the Virion Host Shutoff (Vhs) Protein of Herpes Simplex Virus: Genetic and Biochemical Evidence that Vhs is a Nuclease"", Journal of Virology, 2002, vol. 76, pp. 8560-8571.;;Glenn, Gary M., and Chatterjee, Subhendra, ""Generation of Adenoviruses Encoding the Herpes Simplex Virus vhs gene: A Novel Strategy to Generate Adenoviruses Expressing Genes Toxic to Producer Cells,"" Cancer Gene Therapy, vol. 8, No. 8, 2001, pp. 566-572.;;Gomez-Lira, et al., ""CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers,"" Journal of Neuroimmunology, 2003, vol. 140, pp. 216-221.;;Jacobs, et al., ""Improved herpes simplex virus type 1 amplicon vector for proportional coexpression of positron emission tomography marker and therapeutic genes,"" Gene Therapy, 2003, vol. 14, pp. 277-297.;;Karl, Ilkka et al., ""Antisense RNA Directed to the Human Papillomavirus type 16 E7 mRNA From Herpes Simplex Virus Type I Derived Vectors is Expressed in CaSki Cells and Downregulates E7 mRNA,"" Virology Journal, Jun. 2007, 11 pages.;;Kwong, Ann D. and Frenkel, Niza, ""Herpes Simplex Virus-Infected Cells Contain a Functions(s) That Destabilizes Both Host and Viral mRNAs,"" Proc. National Academy of Sciences USA, Apr. 1987, vol. 83, pp. 1926-1930.;;Lu, Patricia et al., ""Herpes Simplex Virus Virion Host Shutoff Protein Requires a Mammalian Factor for Efficient In Vitro Endoribonuclease Activity,"" Journal of Virology, Feb. 2001, pp. 1172-1185.;;Nemunaitis, J., ""Selective replicating viral vectors: potential for use in cancer gene therapy,"" Biodrugs, 2003, vol. 17, pp. 251-262.;;Rampling, R., et al., ""Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma,"" Gene Therapy, 2000, vol. 7, pp. 259-866.;;Read, G. Sullivan and Frenkel, Niza, ""Herpes Simplex Virus Mutants Defective in the Virion-Associated Shutoff of Host Polypeptide Synthesis and Exhibiting Abnormal Synthesis of alpha (Immediate Early) Viral Polypeptides,"" Journal of Virology, May 1983, pp. 498-512.;;Sarma, Nandini et al., ""Small Interfering RNAs That Deplete the Cellular Translation Factor eIF4H Impeded mRNA Degradation by the Virion Host Shutoff Protein of Herpes Simplex Virus,"" Journal of Virology, Jul. 2008, pp. 6600-6609.;;Schmidt Pak, Annette et al., ""The Virion Host Shutoff Protein of Herpes Simplex Virus Inhibits Reporter Gene Expression in the Absence of Other Viral Gene Products,"" Virology, vol. 211, 1995, pp. 491-506.;;Smibert, Craig A. and Smiley, James R., ""Differential Regulation of Endogenous and Transduced beta-Globin Genes During Infection of Erythroid Cells with a Herpes Simplex Virus Type 1 Recombinant,"" Journal of Virology, Aug. 1990, pp. 3882-3894.;;Smibert, Craig A. et al., ""Identification and Characterization of the Virion-Induced Host Shutoff Product of Herpes Simplex Virus Gene UL41,"" Journal of General Virology, 1992, vol. 73, pp. 467-470.;;Strom, Ted and Frenkel, Niza, ""Effects of Herpes Simplex Virus on mRNA Stability,"" Journal of Virology, Jul. 1987, pp. 2198-2207.;;Toyoizumi et al., ""Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer,"" Human Gene Therapy, 1999, vol. 10, pp. 3013-3029.;;Wong, et al., ""Oncolytic Herpesvirus Effectively Treats Murine Squamous Cell Carcinoma and Spreads by Natural Lymphatics to Treat Sites of Lymphatic Metastases,"" Human Gene Therapy, 2002, vol. 13, pp. 1213-1223.;;Anesti et al. (2010) BMC Cancer 10:486, ""Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo"".;;Coukos et al. (1999) Clinical Cancer Research, 5:1523-1537, ""Use of Carrier Cells to Deliver a Replication-selective Herpes Simplex Virus-1 Mutant for the Intraperitoneal Therapy of Epithelial Ovarian Cancer1"".;;Fraefel et al. (1996) Journal of Virology, 70(10):7190-7197, ""Helper Virus-Free Transfer of Herpes Simplex Virus Type 1 Plasmid Vectors into Neural Cells"".;;Holt et al. (1986) Proc. Natl. Acad. Sci, USA 83:4794-4798, ""Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation"".;;Jones et al. (2003) Pain 106: 365-371, ""Afferent fiber-selective shift in opiate potency following targeted opioid receptor knockdown"".;;Tang et al. (2009) Journal of Virology 83(3):1433-1442, ""Novel Less-Abundant Viral MicroRNAs Encoded by Herpes Simplex Virus 2 Latency-Associated Transcript and Their Roles in Regulating ICP34.5 and ICPO mRNAs"".;;Toda et al. (1998) The Journal of Immunology, 160:4457-4464, ""In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity"".;;Tzabazis et al. (2007) Anesthesiology, 106:1196-1203, ""Antihyperalgesic Effect of a Recombinant Herpes Virus Encoding Antisense for Calcitonin Gene-related Peptide"".;;Umbach et al (2008) Nature, 454(7205):780-783, ""MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs"".",ACTIVE
236,US,B2,US 9870195 B2,178-953-413-177-700,2018-01-16,2018,US 201514958438 A,2015-12-03,US 201514958438 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,Portable presentation system and methods for use therewith,"A system and method for establishing a conference session between a plurality of presentation devices including at least first and second presentation devices, the method comprising the steps of creating a conference session involving the first presentation device and at least one other presentation device, the first presentation device comprising at least one first display device on which content to be shared is displayed, for at least the second presentation device that includes at least one second display device, upon successful joining to the conference session, automatically sharing content displayed on the first display device with the second presentation device for display on the second display device and displaying a representation on the first display device identifying the other presentation devices that are successfully joined to the conference session.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,STEELCASE INC (2015-12-10),https://lens.org/178-953-413-177-700,Granted Patent,yes,243,8,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04N7/15;;H04N9/31,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, dated Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, dated Oct. 12, 2006.;;PCT International Search Report, Application No. PCT/US2006/021233, dated Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, dated Dec. 6, 2007.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, dated Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2007/012671, dated Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, dated Dec. 3, 2008.",ACTIVE
237,JP,A,JP 2003210468 A,183-953-452-161-817,2003-07-29,2003,JP 2002365673 A,2002-12-17,US 2462501 A,2001-12-18,SUTURE WELDING SYSTEM AND ITS APPLICATION METHOD,"<P>PROBLEM TO BE SOLVED: To provide a system that can weld a suture formed of a widely-used material such as polydioxanone (PDS) for fixing one portion of the suture to the other portion of the suture without requiring a knot, and to provide its application method. <P>SOLUTION: The system has a working end part 20; a suture contact element 18 arranged at the working end part 20; a first electrode 26 electrically connected to an energy source 32 for electrosurgery; and a second electrode 28 electrically connected to the energy source 32 for electrosurgery. The first electrode 26 is arranged at the suture contact element 18 to supply electric energy to a first portion of the suture and a second portion of the suture, and the second electrode 28 is arranged near a suture weld portion to provide a return line of electric energy to the energy source for electrosurgery. When the electric energy is supplied to the first portion of the suture and the second portion of the suture by the first electrode 26, the first portion of the suture and the second portion of the suture are welded and stuck. <P>COPYRIGHT: (C)2003,JPO",ETHICON INC,MCRURY IAN D;;DUNN DOUGLAS W;;CAULDWELL NATHAN S,,https://lens.org/183-953-452-161-817,Patent Application,no,0,3,11,11,0,A61B17/0487;;A61B17/0487;;A61B17/06166;;A61B17/06166;;A61B2017/0619;;A61B2017/0619,A61B17/04;;A61B17/06,,0,0,,,,EXPIRED
238,AU,A1,AU 2012/262520 A1,184-897-422-906-470,2014-01-23,2014,AU 2012/262520 A,2012-05-25,US 201161490935 P;;US 2012/0039628 W,2011-05-27,"Methods, compositions, and kits for the treatment of cancer","The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.",CYTOCURE LLC;;MASSACHUSETTS GEN HOSPITAL,HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/184-897-422-906-470,Patent Application,no,0,0,7,7,0,A61K39/395;;C07K16/3053;;A61K38/215;;A61K38/217;;A61K45/06;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4178;;A61K31/495;;A61P35/00;;A61K39/464491;;A61K2239/57;;A61K39/464492;;A61K39/4611;;A61K2239/47;;A61K39/4632;;A61K45/06;;A61K38/215;;A61K38/217;;A61K35/17;;A61K39/395;;C07K16/3053;;A61K35/15;;A61K31/495;;A61K31/4178;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4965;;A61K35/14;;A61K39/3955,A61K39/395,,0,0,,,,DISCONTINUED
239,CN,A,CN 116113895 A,199-214-505-569-042,2023-05-12,2023,CN 202180062879 A,2021-08-27,EP 20196314 A;;EP 2021073741 W,2020-09-15,Control of technical system using artificial intelligence computing unit,"The invention relates to a computer-implemented method for controlling a technical system, comprising the following steps: reading (S1) hardware configuration parameters of a control unit and values required by the control unit in real time, reading (S2) hardware configuration parameters of an artificial intelligence computing unit (NPU), reading (S3) a control application for controlling the technical system, wherein the control application is configured to generate an input value for the control unit according to artificial intelligence,-determining (S4) a processing time of the control application for executing the control application on the artificial intelligence computing unit, taking into account hardware configuration parameters of the control unit and hardware configuration parameters of the artificial intelligence computing unit, checking (S5) the determined processing time as a function of a value requested in real time by the control unit and outputting a checking result, and outputting (S6) the control application as a function of the checking result in order to control the technical system.",SIEMENS AG,POTERO HALBLAUB ANDRES;;SCHENK TOBIAS;;DUNN IAN;;WINCHELINGER CHRISTIAN,,https://lens.org/199-214-505-569-042,Patent Application,no,0,0,7,7,0,G05B13/027;;G05B19/05;;G05B13/027;;G05B19/05;;G05B13/027;;G06N3/082,G05B19/05,,0,0,,,,PENDING
240,CA,A1,CA 2561816 A1,189-585-364-723-375,2005-10-20,2005,CA 2561816 A,2005-04-01,US 81653704 A;;US 2005/0011366 W,2004-04-01,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation method and system for presenting information to an audience within a space that mimics a flip chart assembly, the system including a control interface, a communication network and a master presentation unit including a processor and a master display screen, the master screen juxtaposed within the space so as to be viewable by the audience within the space, the processor operable to transmit an image displayed on the master screen over the network upon user command and a slave presentation unit including a slave presenter operable to receive and present an image to the audience within the space that is transmitted by the master unit to the slav e unit over the network such that the master unit can be used to create a new image while the first image is simultaneously presented.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/189-585-364-723-375,Patent Application,no,0,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,H04N7/15;;G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00,,0,0,,,,INACTIVE
241,KR,A,KR 20080053368 A,194-462-797-975-982,2008-06-12,2008,KR 20087008454 A,2008-04-08,US 71502805 P,2005-09-08,DEREGULATED BACTERIA WITH IMPROVED POLYHYDROXYALKANOATE PRODUCTION,Mutant bacteria with improved poly-3-hydroxylalkanoate (PHA)-producing characteristics and methods of producing and using them are provided.,MEREDIAN INC,GREEN PHILLIP RICHARD;;JOHNSON ROBERT IAN;;DUNN STUART ANTONY,,https://lens.org/194-462-797-975-982,Patent Application,no,0,0,9,9,0,C12N1/00;;C12N1/36;;C12N1/36;;C12N1/205;;C12N1/205;;C12N1/38;;C12N1/38;;C12P7/625;;C12P7/625;;C12R2001/01;;C12R2001/01,C12N1/00,,0,0,,,,DISCONTINUED
242,EP,B1,EP 1694852 B1,035-598-460-658-639,2010-10-13,2010,EP 04798619 A,2004-11-17,GB 2004004908 W;;GB 0326798 A;;US 54130804 P,2003-11-17,MUTANT HERPES SIMPLEX VIRUS AND USE THEREOF IN THE TREATMENT OF SQUAMOUS CELL CANCER,,CRUSADE LAB LTD;;SLOAN KETTERING INST CANCER,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,,https://lens.org/035-598-460-658-639,Granted Patent,yes,3,0,9,35,0,C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61K38/00;;A61P35/00;;C12N2710/16643;;C12N2840/203;;C12N15/86;;C12N15/1135;;A61K38/00,C12N15/869;;A61K35/76;;A61K48/00;;C07K14/82;;C12N7/01;;C12N15/113,,3,0,,,"WONG R J ET AL: ""Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases"" HUMAN GENE THERAPY, vol. 13, 1 July 2002 (2002-07-01), pages 1213-1223, XP002971610 ISSN: 1043-0342;;ESTILO CHERRY L ET AL: ""The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue."" CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JUN 2003, vol. 9, no. 6, June 2003 (2003-06), pages 2300-2306, XP002335918 ISSN: 1078-0432;;DATABASE EMBL [Online] 22 February 2002 (2002-02-22), ""Homo sapiens leucine zipper protein (SCRO) mRNA, complete cds."" XP002335921 retrieved from EBI accession no. EM_HUM:AF456425 Database accession no. AF456425",ACTIVE
243,US,A1,US 2011/0279350 A1,072-451-253-455-551,2011-11-17,2011,US 201113087085 A,2011-04-14,US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A,2004-04-01,Portable Presentation System and Methods For Use Therewith,"A method and system for configuring electronic presentation units for cooperative activities, the method comprising the steps of providing a plurality of presentation units in a conferencing space including a master unit and other units, electronically identifying the other units present in the conferencing space, enabling a configuration interface for identifying a sub-set of the other units as slave units, receiving input via the configuration interface identifying the slave unit sub-set and enabling a control interface for transferring images from the master unit to each of the slave units in the selected sub-set.",HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2014-02-10),https://lens.org/072-451-253-455-551,Patent Application,yes,11,44,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G09G5/00,345/1.1,0,0,,,,ACTIVE
244,US,B2,US 7332607 B2,076-176-929-183-309,2008-02-19,2008,US 84058604 A,2004-05-06,US 84058604 A;;US 75711304 A;;US 4349802 A;;US 67000500 A;;US 26647199 A;;US 26629899 P;;US 15519798 P,1998-03-13,"Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol","The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by the following scheme:",AVENTIS HOLDINGS INC;;SANOFI AVENTIS DEUTSCHLAND,STOLZ-DUNN SANDRA K;;EVANS JONATHAN;;TOMLINSON IAN A,AVENTIS HOLDINGS INC (2001-12-28);;MARION MERRELL S.A (1999-08-02);;SYNCOM B.V (1999-02-09);;THE DOW CHEMICAL COMPANY (1999-02-09);;AVENTIS PHARMACEUTICALS INC (1999-12-13);;AVENTIS PHARMA DEUTSCHLAND GMBH (1999-02-10);;HMR PHARMA INC (2001-12-28),https://lens.org/076-176-929-183-309,Granted Patent,yes,41,0,6,8,0,C07D211/32;;C07D211/32;;C07D211/22;;C07D211/22,C07C211/22;;A61K31/445;;C07D211/20;;C07D211/22;;C07D211/32,546/225;;546/314,11,8,077-295-491-167-117;;189-748-148-589-38X;;159-298-915-459-890;;082-212-859-841-769;;131-268-337-121-519;;022-138-021-142-447;;066-193-295-374-147;;040-931-696-791-898,10.1002/0471220574;;10.1016/s0957-4166(00)80136-6;;2284309;;10.1021/jm00174a007;;2258899;;10.1007/bf00562664;;1233237;;1360026;;10.1021/jm00101a012;;10.1016/0960-894x(96)00148-5;;10.1248/cpb.42.1902,"Greene ""Protective groups in Organic Synthesis"" (1982) p. 10-11.;;Chi-Hsin R. King et al., Immobilization of Substrates in Enzyme-Catalyzed Hydrolysis, Tetrahedron: Asymmetry vol. 4, No. 5 pp. 943-946 1993.;;Doepke, W. Schwertner et al., The resolution of racemates of the .beta. -receptor blocking agent propranolol, Chem. pp. 673-675 vol. 45 (9).;;Efange, S.M.N. et al., Flexible N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Analogues; Synthesis and Monoamine Oxidase Catalyzed Bioactivation, J. Med. Chem. pp. 3133-3138, vol. 33, 1990.;;Herbert A. Lieberman et al., Pharmaceutical Dosage Forms, Marcel Dekker, Inc. 1989 vol. 2.;;Jounela A.J. et al., Effect of Particle Size on The Bioavailability of Digoxin , Eur. J. Clin. Pharmacol. 1975, 8/5 365-370.;;Paul J. Gilligan et al., Novel Piperidine o Receptor Ligands as Potential Antipsychotic Drugs, J. Med. Chem. 1992, vol. 35, pp. 4344-4361.;;Sauter, Fritz, Synthese Substituierter Pheny-pyridinyl- und Phenyl-pyrimidinyl-methanone, J. Chem. Research, pp. 2001-2009.;;Timothy P. Burkholder et al., Identification and Chemical Synthesis of MDL 105,212, a Non-Peptide Tachykinin Antagonist with High Affinity for NK1 and NK2 Receptors, Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 8, pp. 951-956 1996.;;Villari A. et al., Methods for the Particle-Size Analysis of Pharmaceutical Powders I, Journal Farm Ed Prat vol. 42, Issue 10, year 1987 pp. 253-260.;;Matsumura M. et al., Computer Optimization for the Formulation of Controlled Release Theophylline Tablet Made of Micronized Low-substituted Hydroxypropylcellulose and Methylcellulose, Chemical & Pharmaceutical Bulletin, vol. 42, Issue 9 , 1999, pp. 1902-1908.",EXPIRED
245,US,A1,US 2007/0003520 A1,097-307-332-249-95X,2007-01-04,2007,US 57962206 A,2006-05-16,US 57962206 A;;GB 0326798 A;;US 54130804 P;;GB 2004004908 W,2003-11-17,Mutant viruses,An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.,BROWN SUSANNE M;;SINGH BHUVANESH;;GANLY IAN;;DUNN PAUL,BROWN SUSANNE M;;SINGH BHUVANESH;;GANLY IAN;;DUNN PAUL,SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (2005-10-24);;CRUSADE LABORATORIES LIMITED (2003-12-19),https://lens.org/097-307-332-249-95X,Patent Application,yes,6,1,9,35,6,C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61K38/00;;A61P35/00;;C12N2710/16643;;C12N2840/203;;C12N15/86;;C12N15/1135;;A61K38/00,C12N7/00;;A61K48/00;;C12N15/113;;C12N15/869,424/93.2;;424/93.6;;435/235.1,0,0,,,,DISCONTINUED
246,US,A1,US 2016/0162250 A1,108-326-439-042-669,2016-06-09,2016,US 201514958438 A,2015-12-03,US 201514958438 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A method and assembly for sharing information in a conference space, the assembly comprising a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the surface area including at least first and second adjacent presentation sub-spaces, a processor programmed to perform the steps of presenting an interface on the surface area useable to generate session images within at least one of the sub-spaces, the interface including a panel section in which a separate panel icon for each of the session images created during a session is presented, the interface further including a separate space on the surface area associated with each of the sub-spaces, the interface facilitating selection and dragging of panel icons to locations associated with the sub-spaces to control the images presented in each of the sub-spaces, wherein, when a panel icon is dragged to a space, an image currently associated with the sub-space is replaced at the sub-space.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,STEELCASE INC (2015-12-10),https://lens.org/108-326-439-042-669,Patent Application,yes,15,15,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G09G3/00;;H04N7/15;;H04N9/31,,0,0,,,,ACTIVE
247,EP,B1,EP 1542609 B1,129-637-216-397-235,2012-11-14,2012,EP 03749229 A,2003-08-29,US 0327125 W;;US 40749202 P,2002-08-29,Pharmaceutical compositions comprising Interferon beta for use in treating melanoma,,CYTOCURE LLC,DURDA PAUL J;;KURNICK JAMES T;;DUNN IAN S,CYTOCURE LLC (2013-02-20),https://lens.org/129-637-216-397-235,Granted Patent,yes,0,0,14,14,0,A61K35/15;;A61K38/215;;A61K39/0011;;A61K2039/55522;;C07K16/3053;;G01N33/5011;;A61P35/00;;A61P35/04;;A61K39/001152;;A61K39/001188;;A61K39/001191;;A61K39/001156;;A61K39/001192;;A61K39/001186;;C07K16/3053;;A61K2039/55522;;A61K39/0011;;G01N33/5011;;A61K35/15;;A61K38/215;;A61K39/001192;;A61K39/001152;;A61K39/001156;;A61K39/001186;;A61K39/001191;;A61K39/001188,A61K38/21;;A61B19/00;;A61K/;;A61K35/00;;A61K39/00;;A61K39/395;;A61P35/00;;C07K16/30;;G01N33/50,,2,2,048-337-508-764-075;;064-006-751-039-299,10.3949/ccjm.69.7.529;;12109636;;11813876;;10.14670/hh-17.253,"MASCI PAUL ET AL: ""Malignant melanoma: treatments emerging, but early detection is still key."", CLEVELAND CLINIC JOURNAL OF MEDICINE JUL 2002 LNKD- PUBMED:12109636, vol. 69, no. 7, July 2002 (2002-07-01), pages 529 , 533 - 534 , 536, ISSN: 0891-1150;;SMITS A: ""Low-grade gliomas: clinical and pathobiological aspects."", HISTOLOGY AND HISTOPATHOLOGY JAN 2002 LNKD- PUBMED:11813876, vol. 17, no. 1, January 2002 (2002-01-01), pages 253 - 260, ISSN: 0213-3911",EXPIRED
248,US,A1,US 2022/0058847 A1,150-458-797-861-987,2022-02-24,2022,US 201917275046 A,2019-09-24,US 201917275046 A;;US 201862737771 P;;US 2019/0052585 W,2018-09-27,MOVING AN AVATAR BASED ON REAL-WORLD DATA,"In some implementations, a method is performed by a device including a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, the method includes obtaining user movement information. In some implementations, the user movement information characterizes a first body pose of the user at a first time and a second body pose of the user at a second time. In some implementations, the method includes determining whether a transition from the first body pose to the second body pose satisfies an acceptability threshold. In some implementations, the method includes in response to determining that the transition from the first body pose to the second body pose satisfies the acceptability threshold, generating a sequence of movements for a synthesized reality (SR) representation of the user.",APPLE INC,RICHTER IAN M;;DUNN CAMERON J;;RUSSELL JOHN C,,https://lens.org/150-458-797-861-987,Patent Application,yes,0,0,6,6,0,G06F3/011;;G06F3/017;;G06T7/10;;G06T7/73;;G06F3/011;;G06T13/40,G06T13/40;;G06F3/01;;G06T7/10;;G06T7/73,,0,0,,,,ACTIVE
249,CA,A1,CA 3201418 A1,161-299-075-349-520,2022-05-12,2022,CA 3201418 A,2021-11-05,US 202063111269 P;;US 2021/0058299 W,2020-11-09,BIFUNCTIONAL COMPOUNDS AND METHODS OF USING THE SAME,The present disclosure provides bifunctional compounds and methods of labeling a cell having an azide-modified sugar on its surface by contacting the cell with a bifunctional compound.,MASSACHUSETTS GEN HOSPITAL,KURNICK JAMES T;;DUNN IAN SEYMOUR;;LAWLER MATTHEW M,,https://lens.org/161-299-075-349-520,Patent Application,no,0,0,4,4,0,C07D401/12;;C07D211/60;;G01N33/582;;C07D211/32;;C07D401/12,A61K47/54;;A61K49/00;;C07D211/60;;C07D401/12,,0,0,,,,PENDING
250,US,B2,US 8610641 B2,160-063-490-652-474,2013-12-17,2013,US 201113087085 A,2011-04-14,US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A,2004-04-01,Portable presentation system and methods for use therewith,"A method and system for configuring electronic presentation units for cooperative activities, the method comprising the steps of providing a plurality of presentation units in a conferencing space including a master unit and other units, electronically identifying the other units present in the conferencing space, enabling a configuration interface for identifying a sub-set of the other units as slave units, receiving input via the configuration interface identifying the slave unit sub-set and enabling a control interface for transferring images from the master unit to each of the slave units in the selected sub-set.",HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H;;STEELCASE INC,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2014-02-10),https://lens.org/160-063-490-652-474,Granted Patent,yes,110,22,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G09G5/00,345/1.1;;715/761;;353/74;;353/94,61,0,,,"European Patent Office, Communication, Application No. 06771804.9, Jun. 3, 2009.;;Response to European Patent Office Jun. 3, 2009 Communication, Application No. 06771804.9, Mar. 3, 2010.;;Government of India Patent Office, First Examination Report, Application No. 3162/KOLNP/2006, May 31, 2010.;;Response to India Patent Office May 31, 2010 First Examination Report, Application No. 3162/KOLNP/2006, Jun. 19, 2010.;;Japan, Office Action, Application No. 2007-506359, Mar. 29, 2011.;;Korean Intellectual Property Office, Notice to File a Response, Application No. 10-2006-7022825, Mar. 31, 2011.;;General Translation of Mexican Patent Office, Official Action, Application No. PA/a/2006/011363, 2009.;;Mexican Patent Office, Letters Patent, Application No. PA/a/2006/011363, Patent No. 269554, Aug. 27, 2009.;;Intellectual Property Office of New Zealand, Examination Report, Patent Application No. 550415, Oct. 24, 2008.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, Oct. 12, 2006.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, Jun. 5, 2008.;;Wilkhahn + Hahne GmbH + Co., InterWall.ConsulTable.ConAction range, 12 pages, no date.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 10/816,537, May 27, 2008.;;Applicant, Amendment (Response to May 27, 2008 Office Action), U.S. Appl. No. 10/816,537, Oct. 27, 2008.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 10/816,537, Feb. 12, 2009.;;Applicant, Amendment (Response to Feb. 12, 2009 Office Action), U.S. Appl. No. 10/816,537, Jun. 10, 2009.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 10/816,537, Aug. 4, 2009.;;Applicant, Amendment (Response to Aug. 4, 2009 Office Action), U.S. Appl. No. 10/816,537, Dec. 17, 2009.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/585,752, Nov. 3, 2009.;;Applicant, Response to Restriction Requirement (dated Nov. 3, 2009), U.S. Appl. No. 11/585,752, Dec. 15, 2009.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/585,752, Feb. 22, 2010.;;Applicant, Amendment (Response to Feb. 22, 2010 Office Action), U.S. Appl. No. 11/585,752, Jun. 21, 2010.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/446,019, Nov. 26, 2008.;;Applicant, Response to Restriction Requirement (Response to Nov. 26, 2008 Office Action), U.S. Appl. No. 11/446,019, Dec. 17, 2008.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/446,019, Apr. 15, 2009.;;Applicant, Amendment (Response to Apr. 15, 2009 Office Action), U.S. Appl. No. 11/446,019, Aug. 7, 2009.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/446,019, Dec. 2, 2009.;;Applicant, Request for Continued Examination and Amendment/Reply, U.S. Appl. No. 11/446,019, May 3, 2010.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/096,969, Apr. 14, 2008.;;Applicant, Amendment (Response to Apr. 14, 2008 Office Action), U.S. Appl. No. 11/096,969, Aug. 28, 2008.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/096,969, Jan. 23, 2009.;;Applicant, Amendment (Response to Jan. 23, 2009 Office Action), U.S. Appl. No. 11/096,969, Mar. 23, 2009.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/096,969, Jun. 12, 2009.;;Applicant, Request for Continued Examination and Amendment (Response to Jun. 12, 2009 Office Action), U.S. Appl. No. 11/096,969, Aug. 7, 2009.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/096,969, Oct. 28, 2009.;;Applicant, Amendment (Response to Oct. 28, 2009 Office Action), U.S. Appl. No. 11/096,969, Jan. 28, 2010.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/096,969, May 12, 2010.;;Applicant, Request for Continued Examination and Amendment (Response to May 12, 2010 Office Action), U.S. Appl. No. 11/096,969, Nov. 9, 2010.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/096,969, Jan. 20, 2011.;;Applicant, Amendment (Response to Jan. 20, 2011 Office Action), U.S. Appl. No. 11/096,969, Mar. 9, 2011.;;United States Patent and Trademark Office, Office Action, U.S. Appl. No. 11/096,969, May 26, 2011.;;IP Australia, Examiner's First Report, Application No. 2005232057, Sep. 17, 2009.;;IP Australia, Examiner's First Report, Application No. 2006252490, Sep. 9, 2009.;;The Patent Office of the State Intellectual Property Office of the People's Republic of China, First Office Action, Application No. 200580014399.8, Nov. 7, 2008.;;Response to First Office Action, China Application No. 200580014399.8, May 21, 2009.;;The Patent Office of the State Intellectual Property Office of the People's Republic of China, Second Office Action, Application No. 200580014399.8, Jul. 24, 2009.;;Response to Second Office Action, China Application No. 200580014399.8, Nov. 25, 2009.;;The Patent Office of the State Intellectual Property Office of the People's Republic of China, Patent Certification for Invention, Application No. 200580014399.8, Jun. 9, 2010.;;The State Intellectual Property Office of the People's Republic of China, First Office Action, Application No. 200680027837.9, Jun. 28, 2010.;;Response to First Office Action, China, Application No. 200680027837.9, Jan. 13, 2011 [includes English instructions for preparation of response].;;European Patent Office, Examination Report, Application No. 05733062.3, Sep. 14, 2007.;;Response to European Patent Office Sep. 14, 2007 Examination Report, Application No. 05733062.3, Mar. 17, 2008.;;European Patent Office, Examination Report, Application No. 05733062.3, Sep. 18, 2008.;;Response to European Patent Office Sep. 18, 2008 Examination Report, Application No. 05733062.3, Jan. 14, 2009.;;European Patent Office, Report, Application No. 05733062.3, Mar. 27, 2009.;;Response to European Patent Office Summons to Attend Oral Proceedings, Application No. 05733062.3, Mar. 26, 2010.;;European Patent Office, Minutes of the Oral Proceedings, Application No. 05733062.3, May 19, 2010.;;European Patent Office, Granting of Patent, Application No. 05733062.3, May 25, 2010.;;European Patent Office, Communication, Application No. 06771804.9, Aug. 7, 2008.;;Response to European Patent Office Aug. 7, 2008 Communication, Application No. 06771804.9, May 14, 2009.",ACTIVE
251,CA,A1,CA 2497151 A1,188-451-488-348-36X,2004-03-11,2004,CA 2497151 A,2003-08-29,US 40749202 P;;US 0327125 W,2002-08-29,METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS,"The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against tumor cell. Methods include administering to a subje ct with a tumor an amount of IFN-.beta. receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor ce ll.",CYTOCURE LLC,DUNN IAN S;;DURDA PAUL J;;KURNICK JAMES T,,https://lens.org/188-451-488-348-36X,Patent Application,no,0,0,14,14,30,A61K35/15;;A61K35/15;;A61K38/215;;A61K38/215;;A61K39/0011;;A61K39/0011;;A61K39/001152;;A61K39/001152;;A61K39/001156;;A61K39/001156;;A61K39/001186;;A61K39/001186;;A61K39/001188;;A61K39/001188;;A61K39/001191;;A61K39/001191;;A61K39/001192;;A61K39/001192;;A61K2039/55522;;A61K2039/55522;;A61P35/00;;A61P35/04;;C07K16/3053;;C07K16/3053;;G01N33/5011;;G01N33/5011,A61B19/00;;A61K/;;A61K38/21;;A61K39/00;;A61K39/395;;C07K16/30;;G01N33/50,,0,0,,,,DISCONTINUED
252,US,B2,US 7948448 B2,001-452-140-096-82X,2011-05-24,2011,US 58575206 A,2006-10-24,US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,Portable presentation system and methods for use therewith,A presentation system and method for presenting information to an audience within a space hat includes a plurality of mobile projectors and a master presentation unit that can be moved into a presentation space and associated where the projectors and master unit are quickly linkable via a network and where the master unit expedites the system configuration process to allow the system user to manipulate images presented by all of the projectors.,POLYVISION CORP,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2014-02-10),https://lens.org/001-452-140-096-82X,Granted Patent,yes,101,72,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G09G5/00,345/1.1;;715/761;;353/74;;353/94,39,0,,,"Wilkhahn + Hahne GMBG + CO, InterWall.Consul.Table.ConAction range; product brochure, 12 pages, no date.;;Non-Final Rejection, mailed May 27, 2008, for U.S. Appl. No. 10/816,537.;;Final Rejection, mailed Feb. 12, 2009, for U.S. Appl. No. 10/816,537.;;Non-Final Rejection, mailed Aug. 4, 2009, for U.S. Appl. No. 10/816,537.;;Non-Final Rejection, mailed Apr. 14, 2008, for U.S. Appl. No. 11/096,969.;;Final Rejection, mailed Jun. 12, 2009, for U.S. Appl. No. 11/096,969.;;Non-Final Rejection, mailed Oct. 28, 2009, for U.S. Appl. No. 11/096,969.;;Final Rejection, mailed May 12, 2010, for U.S. Appl. No. 11/096,969.;;Request for Restriction/Election, mailed Nov. 26, 2008, for U.S. Appl. No. 11/446,019.;;Non-Final Rejection, mailed Apr. 15, 2009, for U.S. Appl. No. 11/446,019.;;Final Rejection, mailed Dec. 2, 2009, for U.S. Appl. No. 11/446,019.;;IP Australia, Examiner's First Report, Application No. 2005232057, Sep. 17, 2009.;;IP Australia, Examiner's First Report, Application No. 2006252490, Sep. 9, 2009.;;The Patent Office of the State Intellectual Property Office of the People's Republic of China, First Office Action, Application No. 200580014399.8, Nov. 7, 2008.;;Response to First Office Action, China Application No. 200580014399.8, May 21, 2009.;;The Patent Office of the State Intellectual Property Office of the People's Republic of China, Second Office Action, Application No. 200580014399.8, Jul. 24, 2009.;;Response to Second Office Action, China Application No. 200580014399.8, Nov. 25, 2009.;;The Patent Office of the State Intellectual Property Office of the People's Republic of China, Patent Certification for Invention, Application No. 200580014399.8, Jun. 9, 2010.;;The State Intellectual Property Office of the People's Republic of China, First Office Action, Application No. 200680027837.9, Jun. 28, 2010.;;European Patent Office, Examination Report, Application No. 05733062.3, Sep. 14, 2007.;;Response to European Patent Office Sep. 14, 2007 Examination Report, Application No. 05733062.3, Mar. 17, 2008.;;European Patent Office, Examination Report, Application No. 05733062.3, Sep. 18, 2008.;;Response to European Patent Office Sep. 18, 2008 Examination Report, Application No. 05733062.3, Jan. 14, 2009.;;European Patent Office, Report, Application No. 05733062.3, Mar. 27, 2009.;;Response to European Patent Office Summons to Attend Oral Proceedings, Application No. 05733062.3, Mar. 26, 2010.;;European Patent Office, Minutes of the Oral Proceedings, Application No. 05733062.3, May 19, 2010.;;European Patent Office, Granting of Patent, Application No. 05733062.3, May 25, 2010.;;European Patent Office, Communication, Application No. 06771804.9, Aug. 7, 2008.;;Response to European Patent Office Aug. 7, 2008 Communication, Application No. 06771804.9, May 14, 2009.;;European Patent Office, Communication, Application No. 06771804.9, Jun. 3, 2009.;;Response to European Patent Office Jun. 3, 2009 Communication, Application No. 06771804.9, Mar. 3, 2010.;;Government of India Patent Office, First Examination Report, Application No. 3162/KOLNP12006, May 31, 2010.;;Response to India Patent Office May 31, 2010 First Examination Report, Application No. 3162/KOLNP/2006, Jun. 19, 2010.;;General Translation of Mexican Patent Office, Official Action, Application No. PA/a/2006/011363, 2009.;;Mexican Patent Office, Letters Patent, Application No. PA/a/2006/011363, Patent No. 269554, Aug. 27, 2009.;;Intellectual Property Office of New Zealand, Examination Report, Patent Application No. 550415, Oct. 24, 2008.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, Oct. 12, 2006.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, Jun. 5, 2008.",INACTIVE
253,WO,A3,WO 2008/088839 A3,000-288-602-383-615,2008-12-04,2008,US 2008/0000601 W,2008-01-16,US 88516007 P,2007-01-16,METHODS OF ISOLATING AND PURIFYING NUCLEIC ACID-BINDING BIOMOLECULES AND COMPOSITIONS INCLUDING SAME,"The invention provides methods for isolating or purifying a biomolecule directly or indirectly bound to a region of interest of a nucleic acid in a cell, and methods for isolating or purifying a biomolecule that directly or indirectly binds to a region of interest of a nucleic acid in a cell. The invention further provides substantially cell free, isolated and purified biomolecule(s) that are fixed or cross-linked to a region of interest of a nucleic acid, which optionally reflects the interaction of the biomolecule(s) with the nucleic acid in the cell (e.g., in native chromatin) when fixed or cross-linked to the region of interest. Substantially cell free, isolated and purified biomolecules that are fixed or cross-linked to a region of interest of a nucleic acid can remain fixed or cross-linked to the region of interest of the nucleic acid when heated or treated with denaturing compounds or agents.",CYTOCURE INC;;LAWLER MATTHEW M;;HAGGERTY TIMOTHY J;;DUNN IAN S,LAWLER MATTHEW M;;HAGGERTY TIMOTHY J;;DUNN IAN S,,https://lens.org/000-288-602-383-615,Search Report,yes,3,0,5,5,0,C12N15/1006;;C12Q1/6804;;C12N15/1006;;C12Q1/6804,C12Q1/68;;C12N15/10,,1,1,001-541-462-114-60X,16315372;;10.2144/000112014,"DAVID E. NOWAK, BINGTIAN, AND ALLAN R. BRASIER: ""Two-step cross-linking method for identification of NF-?B gene network by chromatin immunoprecipitation"", BIOTECHNIQUES, vol. 39, no. 5, November 2005 (2005-11-01) - November 2005 (2005-11-01), pages 715 - 725, XP002493139",PENDING
254,US,A1,US 2017/0205984 A1,025-249-341-094-49X,2017-07-20,2017,US 201715417871 A,2017-01-27,US 201715417871 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 77190806 P;;US 68738905 P,2005-06-02,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A system and method for content collaboration, the system comprising a first collaboration configuration including at least a first display having a first display surface, a second collaboration configuration including a least a second display having a second display surface, a processor maintaining a session dataset including a plurality of objects arranged in a relative juxtaposition with respect to each other, the processor presenting first and second different views of the session via the at the least first and second display surfaces, respectively, wherein at least some of the first view overlaps with some of the second view and indicating, via the at least a first display surface, content presented in the second view that is not presented in the first view.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/025-249-341-094-49X,Patent Application,yes,0,2,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/0488;;G06F3/0481;;H04L29/06,,0,0,,,,ACTIVE
255,WO,A1,WO 2008/072015 A1,195-096-457-715-622,2008-06-19,2008,GB 2007050753 W,2007-12-12,GB 0624932 A,2006-12-14,BATTERY LIFE MONITOR,"A method for displaying maximum charge capacity as a proportion of original charge capacity on a smart secondary battery comprising a data storage device and a data display device connected to the storage device, which method comprises: connecting the battery to an external device, calculating the maximum charge capacity as a proportion of original charge capacity from information stored on the battery using the external device, transmitting data representing the maximum charge capacity as a proportion of original charge capacity to the data storage device on the battery, recording said data in the data storage device, and displaying maximum charge capacity as a proportion of original charge capacity on the display device.",ABSL POWER SOLUTIONS LTD;;LIDDELL THOMAS MARK;;LEISTEN JOSEPH MICHAEL;;DUNN WILLIAM IAN,LIDDELL THOMAS MARK;;LEISTEN JOSEPH MICHAEL;;DUNN WILLIAM IAN,,https://lens.org/195-096-457-715-622,Patent Application,yes,6,14,5,5,0,H02J7/00036;;H01M10/48;;H02J7/00036;;H02J7/00047;;Y02E60/10,H02J7/00,,0,0,,,,PENDING
256,DE,D1,DE 602004029608 D1,034-228-608-733-355,2010-11-25,2010,DE 602004029608 T,2004-11-17,GB 0326798 A;;US 54130804 P;;GB 2004004908 W,2003-11-17,MUTANTES HERPES-SIMPLEX-VIRUS UND VERWENDUNG DAVON BEI DER BEHANDLUNG VON PLATTENEPITHELKARZINOM,An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.,CRUSADE LAB LTD;;SLOAN KETTERING INST CANCER,BROWN SUSANNE MOIRA;;DUNN PAUL;;SINGH BHUVANESH;;GANLY IAN,,https://lens.org/034-228-608-733-355,Granted Patent,no,0,0,20,35,0,A01K2267/0331;;A61K35/13;;A61K48/00;;A61K2039/5256;;C12N7/00;;C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;C12N15/1135;;C12N2710/16643;;A01K2267/0331;;C12N7/00;;A61K2039/5256;;C12N15/86;;A61K48/00;;C12N2840/203;;A61K35/13,C12N15/869;;A61K35/13;;A61K35/76;;A61K39/00;;A61K48/00;;C07K14/82;;C12N7/00;;C12N7/01;;C12N15/113,,0,0,,,,ACTIVE
257,US,A1,US 2023/0162422 A1,095-348-806-957-914,2023-05-25,2023,US 202217837490 A,2022-06-10,US 202217837490 A;;US 202117275046 A;;US 2019/0052585 W;;US 201862737771 P,2018-09-27,MOVING AN AVATAR BASED ON REAL-WORLD DATA,"In some implementations, a method is performed by a device including a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, the method includes obtaining user movement information. In some implementations, the user movement information characterizes a first body pose of the user at a first time and a second body pose of the user at a second time. In some implementations, the method includes determining whether a transition from the first body pose to the second body pose satisfies an acceptability threshold. In some implementations, the method includes in response to determining that the transition from the first body pose to the second body pose satisfies the acceptability threshold, generating a sequence of movements for a synthesized reality (SR) representation of the user.",APPLE INC,RICHTER IAN M;;DUNN CAMERON J;;RUSSELL JOHN C,,https://lens.org/095-348-806-957-914,Patent Application,yes,1,0,6,6,0,G06F3/011;;G06F3/017;;G06T7/10;;G06T7/73;;G06F3/011;;G06T13/40,G06T13/40;;G06F3/01;;G06T7/10;;G06T7/73,,0,0,,,,ACTIVE
258,WO,A2,WO 2008/088839 A2,104-708-587-334-426,2008-07-24,2008,US 2008/0000601 W,2008-01-16,US 88516007 P,2007-01-16,METHODS OF ISOLATING AND PURIFYING NUCLEIC ACID-BINDING BIOMOLECULES AND COMPOSITIONS INCLUDING SAME,"The invention provides methods for isolating or purifying a biomolecule directly or indirectly bound to a region of interest of a nucleic acid in a cell, and methods for isolating or purifying a biomolecule that directly or indirectly binds to a region of interest of a nucleic acid in a cell. The invention further provides substantially cell free, isolated and purified biomolecule(s) that are fixed or cross-linked to a region of interest of a nucleic acid, which optionally reflects the interaction of the biomolecule(s) with the nucleic acid in the cell (e.g., in native chromatin) when fixed or cross-linked to the region of interest. Substantially cell free, isolated and purified biomolecules that are fixed or cross-linked to a region of interest of a nucleic acid can remain fixed or cross-linked to the region of interest of the nucleic acid when heated or treated with denaturing compounds or agents.",CYTOCURE INC;;LAWLER MATTHEW M;;HAGGERTY TIMOTHY J;;DUNN IAN S,LAWLER MATTHEW M;;HAGGERTY TIMOTHY J;;DUNN IAN S,,https://lens.org/104-708-587-334-426,Patent Application,yes,0,8,5,5,6,C12N15/1006;;C12Q1/6804;;C12N15/1006;;C12Q1/6804,C12N15/09,,0,0,,,,PENDING
259,US,B2,US 9858033 B2,148-046-725-885-645,2018-01-02,2018,US 201615078494 A,2016-03-23,US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 77190806 P,2006-02-09,Portable presentation system and methods for use therewith,"A collaboration system comprising a first large display screen supported within the conference space and a processor linked to the large display screen and providing an interface thereon that includes a presentation space for presenting session content and a device icon section, the device icon section including a separate attendee icon for each attendee linked to the session via a portable computing device, wherein any one of the portable computing devices is useable to control content presented in the presentation space, the processor programmed to perform the steps of receiving a command to alter the content in the presentation space from any one of the portable computing devices, in response to receiving the command, altering the content in the presentation space and visually distinguishing the attendee icon associated with the portable computing device most recently used to change the content in the presentation space, wherein the portable computing devices are used in an egalitarian fashion.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/148-046-725-885-645,Granted Patent,yes,245,7,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04N7/15;;H04N9/31,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, dated Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, dated Oct. 12, 2006.;;PCT International Search Report, Application No. PCT/US2006/021233, dated Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, dated Dec. 6, 2007.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, dated Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2007/012671, dated Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, dated Dec. 3, 2008.",ACTIVE
260,DE,D1,DE 60230107 D1,170-308-544-315-656,2009-01-15,2009,DE 60230107 T,2002-11-19,US 2462501 A,2001-12-18,Chirurgische Näh-Schweiss-Vorrichtung und Verfahren,,DEPUY MITEK INC,MCRURY IAN D;;DUNN DOUGLAS W;;CAULDWELL NATHAN S,,https://lens.org/170-308-544-315-656,Granted Patent,no,0,0,11,11,0,A61B17/0487;;A61B17/0487;;A61B17/06166;;A61B17/06166;;A61B2017/0619;;A61B2017/0619,A61B17/04;;A61B17/06,,0,0,,,,EXPIRED
261,EP,A2,EP 2714081 A2,181-260-962-387-58X,2014-04-09,2014,EP 12792958 A,2012-05-25,US 201161490935 P;;US 2012/0039628 W,2011-05-27,"METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER",,CYTOCURE LLC;;GEN HOSPITAL CORP,HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/181-260-962-387-58X,Patent Application,yes,0,0,7,7,6,A61K39/395;;C07K16/3053;;A61K38/215;;A61K38/217;;A61K45/06;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4178;;A61K31/495;;A61P35/00;;A61K39/464491;;A61K2239/57;;A61K39/464492;;A61K39/4611;;A61K2239/47;;A61K39/4632;;A61K45/06;;A61K38/215;;A61K38/217;;A61K35/17;;A61K39/395;;C07K16/3053;;A61K35/15;;A61K31/495;;A61K31/4178;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4965;;A61K35/14;;A61K39/3955,A61K39/395;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4178;;A61K31/495;;A61K31/4965;;A61K35/00;;A61K35/14;;A61K35/15;;A61K35/17;;A61K38/21;;A61K45/06,,0,0,,,,DISCONTINUED
262,US,A1,US 2014/0335050 A1,184-054-725-241-95X,2014-11-13,2014,US 201214122531 A,2012-05-25,US 201214122531 A;;US 201161490935 P;;US 2012/0039628 W,2011-05-27,"METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER","The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.",HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S;;GEN HOSPITAL CORP;;CYTOCURE LLC,HAGGERTY TIMOTHY J;;KURNICK JAMES T;;DUNN IAN S,,https://lens.org/184-054-725-241-95X,Patent Application,yes,1,40,7,7,6,A61K39/395;;C07K16/3053;;A61K38/215;;A61K38/217;;A61K45/06;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4178;;A61K31/495;;A61P35/00;;A61K39/464491;;A61K2239/57;;A61K39/464492;;A61K39/4611;;A61K2239/47;;A61K39/4632;;A61K45/06;;A61K38/215;;A61K38/217;;A61K35/17;;A61K39/395;;C07K16/3053;;A61K35/15;;A61K31/495;;A61K31/4178;;A61K31/045;;A61K31/122;;A61K31/192;;A61K31/4965;;A61K35/14;;A61K39/3955,A61K35/14;;A61K31/4965;;A61K38/21;;A61K39/395;;A61K45/06,424/85.5;;424/85.6;;424/158.1;;424/174.1;;424/93.7,5,4,044-110-124-628-291;;055-528-658-721-105;;022-263-839-249-307;;025-703-839-391-480,pmc3427921;;10.4049/jimmunol.181.11.7721;;19017961;;10.1158/0008-5472.can-08-4511;;19690146;;pmc2745213;;10.2214/ajr.123.1.114;;1119645;;9815768,"Wesa et al (The Journal of Immunology, 2008, 181: 7721-7727);;Kawabe et al (Cancer Research, 2009, 69: 6995-7003);;Griffiths et al (Natl Cancer Inst Monogr, 1975, Abstract);;Rubin et al (Am J Roentgenol Ther Nucl Med, 1975, 123(1): Abstract);;Lindner et al (Clinical Cancer Research, 1997, 3: 931-937)",DISCONTINUED
263,US,A1,US 2009/0274728 A1,193-739-652-520-496,2009-11-05,2009,US 43638209 A,2009-05-06,US 43638209 A;;GB 0326798 A;;US 57962206 A;;GB 2004004908 W;;US 54130804 P,2003-11-17,Mutant Viruses,An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.,CRUSADE LAB LTD;;SLOAN KETTERING INST CANCER,BROWN SUSANNE MOIRA;;SINGH BHUVANESH;;GANLY IAN;;DUNN PAUL,SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (2005-10-24);;VIRTTU BIOLOGICS LIMITED (2003-12-19),https://lens.org/193-739-652-520-496,Patent Application,yes,8,50,9,35,6,C12N15/1135;;C12N15/86;;C12N2710/16643;;C12N2840/203;;A61K38/00;;A61P35/00;;C12N2710/16643;;C12N2840/203;;C12N15/86;;C12N15/1135;;A61K38/00,A61K39/245;;A61K35/76;;C12N7/01;;C12N15/113;;C12N15/66;;C12N15/869,424/231.1;;435/235.1;;424/93.6;;435/91.41,0,0,,,,ACTIVE
264,AU,A2,AU 2006/252490 A2,019-961-387-615-416,2008-04-17,2008,AU 2006/252490 A,2006-06-02,US 77190806 P;;US 68738905 P;;US 2006/0021233 W,2005-06-02,Virtual flip chart method and apparatus,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,HILDEBRANDT PETER W;;DUNN MICHAEL H;;HUTCHINSON IAN G,,https://lens.org/019-961-387-615-416,Patent Application,no,0,0,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,H04N7/15;;G06F3/033;;G09G5/00,,0,0,,,,DISCONTINUED
265,GB,B,GB 2444848 B,035-282-926-917-954,2010-03-31,2010,GB 0724202 A,2007-12-12,GB 0624932 A,2006-12-14,Battery life monitor,,ABSL POWER SOLUTIONS LTD,LIDDELL THOMAS MARK;;LEISTEN JOSEPH MICHAEL;;DUNN WILLIAM IAN,,https://lens.org/035-282-926-917-954,Granted Patent,no,2,0,5,5,0,H02J7/00036;;H01M10/48;;H02J7/00036;;H02J7/00047;;Y02E60/10,G01R31/36;;H01M10/48;;H02J7/00,,0,0,,,,INACTIVE
266,US,A1,US 2016/0202878 A1,040-991-814-463-671,2016-07-14,2016,US 201615078494 A,2016-03-23,US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 77190806 P,2006-02-09,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A collaboration system comprising a first large display screen supported within the conference space and a processor linked to the large display screen and providing an interface thereon that includes a presentation space for presenting session content and a device icon section, the device icon section including a separate attendee icon for each attendee linked to the session via a portable computing device, wherein any one of the portable computing devices is useable to control content presented in the presentation space, the processor programmed to perform the steps of receiving a command to alter the content in the presentation space from any one of the portable computing devices, in response to receiving the command, altering the content in the presentation space and visually distinguishing the attendee icon associated with the portable computing device most recently used to change the content in the presentation space, wherein the portable computing devices are used in an egalitarian fashion.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/040-991-814-463-671,Patent Application,yes,9,3,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/0481,,0,0,,,,ACTIVE
267,CA,C,CA 2413662 C,061-797-107-043-101,2006-08-15,2006,CA 2413662 A,2002-11-29,US 2462501 A,2001-12-18,SUTURE WELDING SYSTEM AND METHOD,"A suture welding system for fixedly attaching a first length of suture to a second length of suture includes an electrosurgical energy source and a suture welding device. The suture welding device has a working end, a suture contacting element disposed on the working end, a first electrode electrically coupled to the electrosurgic al energy source, and a second electrode electrically coupled to the electrosurgical energy source. The first electrode is disposed on the suture contacting element for providi ng electrical energy to the first and second lengths of suture, and the second electrode i s disposable proximate to the suture welding site for providing a return electrical energ y path to the electrosurgical energy source. When electrical energy is provided by the fir st electrode to the first and second lengths of suture welds, the first and second length s of suture are welded into a fixed attachment.",ETHICON INC,CAULDWELL NATHAN S;;MCRURY IAN D;;DUNN DOUGLAS W,,https://lens.org/061-797-107-043-101,Granted Patent,no,0,0,11,11,0,A61B17/0487;;A61B17/0487;;A61B17/06166;;A61B17/06166;;A61B2017/0619;;A61B2017/0619,A61B17/04;;A61B17/06,,0,0,,,,EXPIRED
268,US,A1,US 2013/0339880 A1,066-155-373-087-489,2013-12-19,2013,US 201313968941 A,2013-08-16,US 201313968941 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A method and assembly for use with a display configuration including a master sub-space and a plurality of slave sub-spaces, the assembly for controlling an information sharing session, the assembly comprising a processor linked to the display configuration and programmed to perform the steps of obtaining identification information from information sources usable to generate images on the sub-spaces during a session, presenting an interface via the master sub-space, the interface including a master workspace area for presenting images via the master sub-space and a tool area including source icons and panel icons associated with session images wherein each of the source and panel icons is selectable to create images within the master workspace area.",HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2014-02-10),https://lens.org/066-155-373-087-489,Patent Application,yes,16,17,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/0481;;G06F3/0482;;G06F3/0486,715/753,0,0,,,,ACTIVE
269,US,A1,US 2017/0230617 A1,090-720-371-976-644,2017-08-10,2017,US 201715417313 A,2017-01-27,US 201715417313 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"A content sharing system for sharing content among attendees comprising a communication network, a first content sharing configuration including at least a first large common display screen having at least a first display surface, a first processor and a first interface, a second content sharing configuration including at least a second large common display screen having at least a second display surface, a second processor and a second interface, wherein the first and second processors are linked via the network and programmed to present substantially identical content on the at least a first display surface and the at least a second display surface as the first and second interfaces are used to alter content on the first and second display surfaces.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/090-720-371-976-644,Patent Application,yes,0,6,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,H04N7/15;;G06F3/0488;;G06F3/14;;H04L12/18;;H04L29/06;;H04N7/14;;H04N9/31,,0,0,,,,ACTIVE
270,DE,D1,DE 602005024781 D1,097-254-633-827-817,2010-12-30,2010,DE 602005024781 T,2005-04-01,US 81653704 A;;US 2005/0011366 W,2004-04-01,VERFAHREN UND VORRICHTUNG FÜR EINE VIRTUELLE FLIP-CHART,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/097-254-633-827-817,Granted Patent,no,0,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,H04N7/15;;G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00,,0,0,,,,ACTIVE
271,KR,A,KR 20080026138 A,129-219-182-577-104,2008-03-24,2008,KR 20077031038 A,2007-12-31,US 68738905 P;;US 77190806 P,2005-06-02,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space. ® KIPO & WIPO 2008",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/129-219-182-577-104,Patent Application,no,0,10,12,15,0,H04N7/15;;H04N7/15;;G06F3/0481,G06F3/01;;G06F3/033;;G06F3/048;;G09G5/00,,0,0,,,,ACTIVE
272,US,A1,US 2015/0356943 A1,155-198-706-202-85X,2015-12-10,2015,US 201514827963 A,2015-08-17,US 201514827963 A;;US 9696905 A;;US 81653704 A,2004-04-01,Virtual Flip Chart Method and Apparatus,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2007-12-21);;STEELCASE DEVELOPMENT CORPORATION (2005-06-23);;STEELCASE INC (2014-02-10),https://lens.org/155-198-706-202-85X,Patent Application,yes,0,13,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,G06F3/033;;G09G5/00;;G06F3/041;;G06F3/042;;G06F3/0484;;G06T3/60;;H04N7/15,,0,0,,,,DISCONTINUED
273,US,B2,US 10958873 B2,154-607-318-566-73X,2021-03-23,2021,US 201916566225 A,2019-09-10,US 201916566225 A;;US 201715836508 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 77190806 P;;US 68738905 P,2004-04-01,Portable presentation system and methods for use therewith,"A method and assembly for sharing information in a conference space, the assembly comprising a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the surface area including at least first and second adjacent presentation sub-spaces, a processor programmed to perform the steps of presenting an interface on the surface area useable to generate session images within at least one of the sub-spaces, the interface including a panel section in which a separate panel icon for each of the session images created during a session is presented, the interface further including a separate space on the surface area associated with each of the sub-spaces, the interface facilitating selection and dragging of panel icons to locations associated with the sub-spaces to control the images presented in each of the sub-spaces, wherein, when a panel icon is dragged to a space, an image currently associated with the sub-space is replaced at the sub-space.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2007-01-09);;STEELCASE INC (2014-02-10),https://lens.org/154-607-318-566-73X,Granted Patent,yes,273,1,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,H04N7/15;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0486;;G06F3/0488;;G06F3/14;;G09B5/06;;G09B5/08;;G09G3/00;;H04L12/18;;H04L29/06;;H04N7/14;;H04N9/31,,8,0,,,"Wilkhahn + Hahne GmbH + Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, dated Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, dated Oct. 12, 2006.;;PCT International Search Report, Application No. PCT/US2006/021233, dated Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, dated Dec. 6, 2007.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, dated Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2007/012671, dated Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, dated Dec. 3, 2008.",ACTIVE
274,CA,C,CA 2561816 C,174-983-065-038-131,2013-12-24,2013,CA 2561816 A,2005-04-01,US 81653704 A;;US 2005/0011366 W,2004-04-01,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation method and system for presenting information to an audience within a space that mimics a flip chart assembly, the system including a control interface, a communication network and a master presentation unit including a processor and a master display screen, the master screen juxtaposed within the space so as to be viewable by the audience within the space, the processor operable to transmit an image displayed on the master screen over the network upon user command and a slave presentation unit including a slave presenter operable to receive and present an image to the audience within the space that is transmitted by the master unit to the slave unit over the network such that the master unit can be used to create a new image while the first image is simultaneously presented.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/174-983-065-038-131,Granted Patent,no,0,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,H04N7/15;;G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00,,0,0,,,,INACTIVE
275,US,A1,US 2009/0215029 A1,183-389-972-315-395,2009-08-27,2009,US 1523008 A,2008-01-16,US 1523008 A;;US 88516007 P,2007-01-16,METHODS OF ISOLATING AND PURIFYING NUCLEIC ACID-BINDING BIOMOLECULES AND COMPOSITIONS INCLUDING SAME,"The invention provides methods for isolating or purifying a biomolecule directly or indirectly bound to a region of interest of a nucleic acid in a cell, and methods for isolating or purifying a biomolecule that directly or indirectly binds to a region of interest of a nucleic acid in a cell. The invention further provides substantially cell free, isolated and purified biomolecule(s) that are fixed or cross-linked to a region of interest of a nucleic acid, which optionally reflects the interaction of the biomolecule(s) with the nucleic acid in the cell (e.g., in native chromatin) when fixed or cross-linked to the region of interest. Substantially cell free, isolated and purified biomolecules that are fixed or cross-linked to a region of interest of a nucleic acid can remain fixed or cross-linked to the region of interest of the nucleic acid when heated or treated with denaturing compounds or agents.",CYTOCURE INC,LAWLER MATTHEW M;;HAGGERTY TIMOTHY J;;DUNN IAN S,CYTOCURE INC (2008-05-08),https://lens.org/183-389-972-315-395,Patent Application,yes,5,6,5,5,6,C12N15/1006;;C12Q1/6804;;C12N15/1006;;C12Q1/6804,C12N13/00;;C12Q1/70;;C12Q1/68,435/5;;435/6;;435/173.9;;435/239,5,5,027-547-176-368-925;;013-471-678-877-299;;093-842-026-107-661;;037-768-874-272-455;;083-105-288-025-33X,10.1016/0076-6879(89)70058-6;;2770546;;10.1016/j.jmmm.2005.01.040;;10.1385/1-59259-816-1:147;;15173614;;17406543;;10.1038/nprot.2006.383;;10.2144/04376rv01;;15597545,"Mirzabekov, et al. Mapping DNA-Protein Interactions by Cross-Linking. Meth. Enzymology. 1989; 170:386-408.;;del Campo, et al. del Campo, et al. Multifunctional magnetite and silica-magnetite nanoparticles: Synthesis, surface activation and applications in life sciences. J. Magn. Magn. Mat. 2005; 293:33-40.;;Kuras Characterization of protein-DNA association in vivo by chromatin immunoprecipitation. Methods in molecular biology. 2004; 284: 147-62.;;Sandmann, et al. (Chip-on-chip protocol for genome-wide analysis on transcription factor binding in Drosophila melanogaster embryos. Nature Protocols. 2006; 1(6): (2839-2855).;;Das, et al. Chromatin immunoprecipitation assay. BioTechniques. 2004; 37:961-969.",DISCONTINUED
276,EP,B1,EP 1321103 B1,036-635-246-589-528,2008-12-03,2008,EP 02257966 A,2002-11-19,US 2462501 A,2001-12-18,Surgical suture welding system and method,,DEPUY MITEK INC,MCRURY IAN D;;DUNN DOUGLAS W;;CAULDWELL NATHAN S,"DEPUY MITEK, INC. (2008-11-12)",https://lens.org/036-635-246-589-528,Granted Patent,yes,2,1,11,11,0,A61B17/0487;;A61B17/0487;;A61B17/06166;;A61B17/06166;;A61B2017/0619;;A61B2017/0619,A61B17/04;;A61B17/06,,0,0,,,,EXPIRED
277,AU,A1,AU 2007/309007 A1,044-618-834-534-713,2008-05-02,2008,AU 2007/309007 A,2007-10-23,US 58575206 A;;US 2007/0082202 W,2006-10-24,Portable presentation system and methods for use therewith,,POLY VISION CORP,DUNN MICHAEL H;;HILDEBRANDT PETER W;;HUTCHINSON IAN G,,https://lens.org/044-618-834-534-713,Patent Application,no,0,0,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G09B5/06,,0,0,,,,DISCONTINUED
278,US,B2,US 9866794 B2,059-854-252-321-610,2018-01-09,2018,US 201715417317 A,2017-01-27,US 201715417317 A;;US 201615078494 A;;US 201313968931 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 77190806 P;;US 68738905 P,2005-04-01,Portable presentation system and methods for use therewith,"A method and assembly for sharing information in a conference space, the assembly comprising a display configuration including presentation surface area juxtaposed within the conference space for viewing by an audience, the surface area including at least first and second adjacent presentation sub-spaces, a processor programmed to perform the steps of presenting an interface on the surface area useable to generate session images within at least one of the sub-spaces, the interface including a panel section in which a separate panel icon for each of the session images created during a session is presented, the interface further including a separate space on the surface area associated with each of the sub-spaces, the interface facilitating selection and dragging of panel icons to locations associated with the sub-spaces to control the images presented in each of the sub-spaces, wherein, when a panel icon is dragged to a space, an image currently associated with the sub-space is replaced at the sub-space.",STEELCASE INC,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/059-854-252-321-610,Granted Patent,yes,244,7,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,H04N7/15;;G06F3/0481;;G06F3/0486;;G06F3/0488;;G09B5/06;;G09B5/08,,8,0,,,"Wilkhahn+Hahne GmbH+Co., InterWall. ConsulTable. ConAction range, 12 page brochure, no date.;;PCT International Search Report and Written Opinion, Application No. PCT/US2005/011366, dated Aug. 4, 2005.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2005/011366, dated Oct. 12, 2006.;;PCT International Search Report, Application No. PCT/US2006/021233, dated Oct. 6, 2006.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2006/021233, dated Dec. 6, 2007.;;PCT International Search Report and Written Opinion, Application No. PCT/US2007/082202, dated Jun. 5, 2008.;;PCT International Search Report, Application No. PCT/US2007/012671, dated Jan. 3, 2008.;;PCT International Preliminary Report on Patentability, Application No. PCT/US2007/0012671, dated Dec. 3, 2008.",ACTIVE
279,US,A1,US 2014/0085166 A1,133-658-369-661-68X,2014-03-27,2014,US 201313968935 A,2013-08-16,US 201313968935 A;;US 201113087085 A;;US 58575206 A;;US 44601906 A;;US 9696905 A;;US 81653704 A;;US 68738905 P;;US 77190806 P,2004-04-01,PORTABLE PRESENTATION SYSTEM AND METHODS FOR USE THEREWITH,"An assembly for sharing information in a conference space, the assembly comprising a single large presentation display assembly including a single and contiguous large presentation surface juxtaposed within the conference space for viewing by an audience, a processor linked to the display assembly and programmed to perform the steps of presenting a master sub-space on the presentation surface wherein the master sub-space includes only a portion of the presentation surface, enabling an interface that allows movement of an image from the master sub-space to another location outside the master sub-space, wherein, upon movement of an image from the master presentation sub-space to another space outside the master presentation sub-space on the presentation surface, the processor creates a slave presentation space proximate the another location for presenting the image moved from the master presentation sub-space.",HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DUNN MICHAEL H,STEELCASE INC (2014-02-10),https://lens.org/133-658-369-661-68X,Patent Application,yes,3,8,36,36,0,G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04N7/15;;H04L65/75;;G09B5/067;;G09B5/08;;G09G3/002;;G09G2370/04;;H04L12/1813;;H04N9/3102;;H04N9/3147;;H04L65/75;;H04N7/15;;H04N9/3197;;G06F3/0481;;G06F3/04845;;G06F3/04817;;G06F3/0482;;G06F3/0486;;G06F3/1454;;G06F3/0488;;H04L12/1831;;H04L65/403;;H04N7/147;;H04N9/3141;;H04L65/4015,G06F3/14,345/2.2,0,0,,,,INACTIVE
280,EP,A1,EP 1733557 A1,150-026-227-368-796,2006-12-20,2006,EP 05733062 A,2005-04-01,US 2005/0011366 W;;US 81653704 A,2004-04-01,VIRTUAL FLIP CHART METHOD AND APPARATUS,"A presentation system for presenting information to an audience within a space, the system comprising a control interface, a master presentation unit including a flat panel display screen and a processor, the screen including a master space and a slave presentation assembly including a slave presentation surface and a first projector for projecting images on the slave presentation surface, the master unit processor linkable to the interface to receive commands therefrom, the processor programmed to monitor for a command from the interface to flip an image from the master space to the slave space and, when a command to flip an image is received, causing the image from the master space to be presented in the slave space.",POLY VISION CORP,DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,"STEELCASE INC., GRAND RAPIDS, US (2014-08-28);;STEELCASE INC., US (2015-04-20)",https://lens.org/150-026-227-368-796,Patent Application,yes,0,0,19,19,0,G09B5/02;;G09B5/06;;G06F3/03;;G06F3/0354;;H04N7/15;;G09G5/00;;G09G5/006;;G06F3/041;;G06T3/60;;G09B5/02;;G09B5/06,H04N7/15;;G06F3/033;;G06F3/042;;G06F3/0484;;G09G5/00,,0,0,,,,ACTIVE
281,DK,D0,DK 427189 D0,169-338-559-693-424,1989-08-30,1989,DK 427189 A,1989-08-30,US 23881088 A,1988-08-31,LYSLEDEROVERVAAGNINGSSYSTEM OG FREMGANGSMAADE TIL AT OVERVAAGE EN LYSLEDER,,AMERICAN TELEPHONE & TELEGRAPH,WHITE IAN ARTHUR;;WHITE III WILLARD CHANDLER;;DUNN LAWRENCE RUSSELL,,https://lens.org/169-338-559-693-424,Patent Application,no,0,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,DISCONTINUED
282,KR,B1,KR 0139547 B1,190-597-541-408-581,1998-07-01,1998,KR 890012383 A,1989-08-30,US 23881088 A,1988-08-31,METHOD AND SYSTEM FOR OPTICAL FIBER SENSING,,AT & T BELL LAB,DUNN LAWRENCE RUSSELL;;WHITE IAN ARTHUR;;WHITE WILLARD CHANDIER III,,https://lens.org/190-597-541-408-581,Granted Patent,no,0,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,EXPIRED
283,EP,A2,EP 0364093 A2,136-138-387-635-899,1990-04-18,1990,EP 89308620 A,1989-08-24,US 23881088 A,1988-08-31,Methods of and systems for optical fiber sensing.,"An optical fiber sensing system for detecting intrusion of optical fiber or optical fiber cables includes an interferometric arrangement. Two ports (28, 30) of a four port splitter (25) are connected to a source (26) of optical power such as a laser, for example, and to a detector (32). The other two ports (46,48) are connected to ends of a length (50) of monitoring optical fiber. An input signal to the splitter is split with one subsignal being directed in one direction around the length of optical fiber which serves as a common path between the two ports. The other signal is caused to travel around the common path in an opposite direction. The split signals are recombined in the splitter and their phase difference measured as a detectable pattern by the detector. Should there be intrusion of the optical fiber or a cable containing the monitoring optical fiber, the pattern which is detected will change a significant amount.  ",AMERICAN TELEPHONE & TELEGRAPH,DUNN LAWRENCE RUSSELL;;WHITE IAN ARTHUR;;WHITE WILLARD CHANDLER III,AT&T CORP. (1994-06-22),https://lens.org/136-138-387-635-899,Patent Application,yes,0,7,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,EXPIRED
284,DE,T2,DE 68923671 T2,168-345-432-620-753,1996-01-18,1996,DE 68923671 T,1989-08-24,US 23881088 A,1988-08-31,Verfahren und System zum Ueberwachen optischer Leitungen.,,AT & T CORP,DUNN LAWRENCE RUSSELL;;WHITE IAN ARTHUR;;WHITE WILLARD CHANDLER III,,https://lens.org/168-345-432-620-753,Granted Patent,no,0,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,EXPIRED
285,US,B1,US 7486196 B1,000-081-967-397-907,2009-02-03,2009,US 10253308 A,2008-04-14,US 10253308 A,2008-04-14,Using audio to detect changes to the performance of an application,"A method for monitoring the performance of an application comprises determining an output of an application that requires monitoring, assigning an audible sound to the output, running the application and allowing the application to reach a state of equilibrium, determining a baseline for the output when the application is in the state of equilibrium, monitoring the output to detect a change relative to the baseline, emitting the audible sound assigned to the output when the detected change varies from the baseline by a predetermined amount, and adjusting configurable parameters of the audible sound to indicate the existence of the detected change, the magnitude of the detected change relative to the baseline, and the degree of deviation from the baseline. The amplitude of the audible sound may be adjusted to indicate the magnitude of the detected change from the baseline, and the pitch of the audible sound may be adjusted to indicate a positive change or a negative change from the baseline.",IBM,BICHENO RICHARD M;;DUNN TIM;;HURWORTH IAN P;;ZHANG XIAOMING,INTERNATIONAL BUSINESS MACHINES CORPORATION (2008-03-27),https://lens.org/000-081-967-397-907,Granted Patent,yes,17,3,2,2,0,G06F11/324;;G06F11/3409;;G06F2201/81;;G06F11/324;;G06F11/3409;;G06F2201/81,G08B5/00,340/691.3;;340/328;;340/514;;340/384.1;;709/207;;709/224;;714/47;;X714E1118;;X714E11192;;717/127,9,1,010-103-392-248-798,10.1109/shpcc.1992.232662,"Informationweek, n679, pp. 8A-22A, Apr. 27, 1998, Fournier, Roger.;;CommunicationsWeek, n565, p. 39, Jul. 10, 1995.;;A Windows 2000 RAID. (Product Information) http://findarticles.com/p/articles/mi-m0FOX/is-4-5/ai-60805622.;;Call Center Roundup. (Buyers Guide) Teleconnect, 16, 12, 78(1), Dec. 1998.;;AMS-2000 Altitude Alert System (8900) http://www.edmo.com/index.php?module=products&func=display&prod-id=17093.;;Audio Emergency Warning Systems http://www.magnalabs.com/audiofacts1.htm.;;3-D Audio Traffic Alert and Collision Avoidance System http://human-factors.arc.nasa.gov/ihh/spatial/research/Begault-3d-collision-avoidance.html.;;Audio Dementia http://www.audiodementia.com/ad.htm.;;""Visual-Aural Representations of Performance for a Scalable application Program"" Scalable High Performance Computing Conference, 1992. SHPCC-92, Proceedings. Apr. 26-29, 1992; pp. 430-440. Francioni, J.M.; Rover, D.T.",INACTIVE
286,US,B1,US 7557728 B1,152-106-571-221-526,2009-07-07,2009,US 24968008 A,2008-10-10,US 24968008 A;;US 10253308 A,2008-04-14,Using audio to detect changes to the performance of an application,"A system for monitoring the performance of an application comprises a computer system having one or more speakers and means for running an application, the computer system being configured to perform the steps of determining an output of an application that requires monitoring, assigning an audible sound to the output, running the application and allowing the application to reach a state of equilibrium, determining a baseline for the output when the application is in the state of equilibrium, monitoring the output to detect a change relative to the baseline, emitting the audible sound assigned to the output through at least one of the one or more speakers when the detected change varies from the baseline by a predetermined amount, and adjusting configurable parameters of the audible sound to indicate the existence of the detected change, the magnitude of the detected change relative to the baseline, and the degree of deviation from the baseline.",IBM,BICHENO RICHARD M;;DUNN TIM;;HURWORTH IAN P;;ZHANG XIAOMING,,https://lens.org/152-106-571-221-526,Granted Patent,yes,17,16,2,2,0,G06F11/324;;G06F11/3409;;G06F2201/81;;G06F11/324;;G06F11/3409;;G06F2201/81,G08B5/00,340/691.3;;340/328;;340/514;;340/384.1;;709/207;;709/224;;714/47;;X714E1118;;X714E11192;;717/127,9,1,010-103-392-248-798,10.1109/shpcc.1992.232662,"Informationweek, n679, pp. 8A-22A, Apr. 27, 1998, Fournier, Roger.;;CommunicationsWeek, n565, p. 39, Jul. 10, 1995.;;A Windows 2000 RAID. (Product Information) http://findarticles.com/p/articles/mi'm0FOX/is-4-5/ai-60805622.;;Call Center Roundup. (Buyers Guide) Teleconnect, 16, 12, 78(1), Dec. 1998.;;AMS-2000 Altitude Alert System (8900) http://www.edmo.com/index.php?module=products&func=display&prod-id=17093.;;Audio Emergency Warning Systems http://www.magnalabs.com/audiofacts1.htm.;;3-D Audio Traffic Alert and Collision Avoidance System http://human-factors.arc.nasa.gov/ihh/spatial/research/Begault-3d-collision-avoidance.html.;;Audio Dementia http://www.audiodementia.com/ad.htm.;;""Visual-Aural Representations of Performance for a Scalable application Program"" Scalable High Performance Computing Conference, 1992. SHPCC-92. Proceedings. Apr. 26-29, 1992; pp. 433-440. Francioni, J.M.; Rover, D.T.",INACTIVE
287,WO,A1,WO 2023/014429 A1,150-736-151-162-965,2023-02-09,2023,US 2022/0031822 W,2022-06-01,US 202163229656 P,2021-08-05,MEDICAL DEVICE BIO-FIREWALL,"A system for providing a bio-firewall for a medical device. The system includes a bio-firewall electronic processor configured to receive a processed network command from a device electronic processor. The bio-firewall electronic processor is also configured to determine whether the processed network command is associated with a cyberattack based on at least one rule. The bio-firewall electronic processor is also configured to, in response to determining that the processed network command is not associated with the cyberattack, enable transmission, via a non-networked communication interface, of the processed network command to a non¬ networked component. The bio-firewall electronic processor is also configured to, in response to determining that the processed network command is associated with a cyberattack, prevent transmission, via the non-networked communication interface, of the processed network command to the non-networked component.",UNIV NEBRASKA,REDWOOD WILLIAM;;DUNN JEFF;;HESTER RILEY;;TRENT IAN;;WRIGHT ERIC,,https://lens.org/150-736-151-162-965,Patent Application,yes,3,0,1,1,0,G16H40/63;;G16H40/67;;G06F21/554,H04L9/40;;G06F21/55;;G16H40/63,,0,0,,,,PENDING
288,US,A,US 4904050 A,174-973-302-472-494,1990-02-27,1990,US 23881088 A,1988-08-31,US 23881088 A,1988-08-31,Methods of and systems for optical fiber sensing,"An optical fiber sensing system for detecting intrusion of optical fiber or optical fiber cables includes an interferometric arrangement. Two ports (28, 30) of a four port splitter (25) are connected to a source (26) of optical power such as a laser, for example, and to a detector (32). The other two ports (46, 48) are connected to ends of a length (50) of monitoring optical fiber. An input signal to the splitter is split with one subsignal being directed in one direction around the length of optical fiber which serves as a common path between the two ports. The other signal is caused to travel around the common path in an opposite direction. The split signals are recombined in the splitter and their phase difference measured as a detectable pattern by the detector. Should there be intrusion of the optical fiber or a cable containing the monitoring optical fiber, the pattern which is detected will change a significant amount.",AMERICAN TELEPHONE & TELEGRAPH,DUNN LAWRENCE R;;WHITE IAN A;;WHITE III WILLARD C,AMERICAN TELEPHONE AND TELEGRAPH COMPANY 550 MADISON AVENUE NEW YORK NEW YORK 10022-3201 A CORP. OF NY (1988-08-31);;FITEL USA CORPORATION (2001-11-16);;BELL TELEPHONE LABORATORIES INCORPORATED 600 MOUNTAIN AVENUE MURRAY HILL NEW JERSEY 07974-2070 A CORP. OF NY (1988-08-31);;LUCENT TECHNOLOGIES INC (1996-03-29),https://lens.org/174-973-302-472-494,Granted Patent,yes,3,29,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G02B6/00;;G01M11/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,350/96.29;;250/227,2,0,,,"Article entitled Integrated Communication and Sensing System Using One Single Mode Optical Fiber , vol. 24, No. 13 of Electronic Letters, 6/23/88.;;Article entitled Use of Fiber for Security , Jun. 1988 issue of Lightwave Magazine.",EXPIRED
289,EP,B1,EP 0364093 B1,113-515-758-816-813,1995-08-02,1995,EP 89308620 A,1989-08-24,US 23881088 A,1988-08-31,Methods of and systems for optical fiber sensing.,,AT & T CORP,DUNN LAWRENCE RUSSELL;;WHITE IAN ARTHUR;;WHITE WILLARD CHANDLER III,AT&T CORP. (1994-06-22),https://lens.org/113-515-758-816-813,Granted Patent,yes,2,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,EXPIRED
290,HK,A,HK 34096 A,074-491-113-258-66X,1996-03-08,1996,HK 34096 A,1996-02-29,US 23881088 A,1988-08-31,Methods of and systems for optical fiber sensing,,AT & T CORP,DUNN LAWRENCE RUSSELL;;WHITE IAN ARTHUR;;WHITE WILLARD CHANDLER III,,https://lens.org/074-491-113-258-66X,Granted Patent,no,0,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,EXPIRED
291,CA,C,CA 1316235 C,095-112-752-931-346,1993-04-13,1993,CA 609315 A,1989-08-24,US 23881088 A,1988-08-31,METHODS OF AND SYSTEMS FOR OPTICAL FIBER SENSING,"An optical fiber sensing system for detecting intrusion of optical fiber or optical fiber cables includes an interferometric arrangement. Two ports of a four port splitter are connected to a source of optical power such as a laser, for example, and to a detector. The other two ports are connected to ends of a length of monitoring optical fiber. An input signal to the splitter is split with one subsignal being directed in one direction around the length of optical fiber which serves as a common path between the two ports. The other signal is caused to travel around the common path in an opposite direction. The split signals are recombined in the splitter and their phase difference measured as a detectable pattern by the detector. Should there be intrusion of the optical fiber or a cable containing the monitoring optical fiber, the pattern which is detected will change a significant amount.",AMERICAN TELEPHONE & TELEGRAPH,DUNN LAWRENCE R;;WHITE IAN A;;WHITE WILLARD C III,,https://lens.org/095-112-752-931-346,Granted Patent,no,0,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,D434001244   M,0,0,,,,EXPIRED
292,DE,D1,DE 68923671 D1,116-820-528-393-018,1995-09-07,1995,DE 68923671 T,1989-08-24,US 23881088 A,1988-08-31,Verfahren und System zum Ueberwachen optischer Leitungen.,,AT & T CORP,DUNN LAWRENCE RUSSELL;;WHITE IAN ARTHUR;;WHITE WILLARD CHANDLER III,,https://lens.org/116-820-528-393-018,Granted Patent,no,0,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,EXPIRED
293,US,A1,US 2005/0010051 A1,062-487-841-168-809,2005-01-13,2005,US 84058604 A,2004-05-06,US 84058604 A;;US 75711304 A;;US 4349802 A;;US 67000500 A;;US 26647199 A;;US 26629899 P;;US 15519798 P,1998-03-13,"Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol","The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by the following scheme:",AVENTIS PHARMA INC;;AVENTIS PHARMA GMBH,EVANS JONATHAN C;;STOLZ-DUNN SANDRA K;;TOMLINSON IAN A,AVENTIS HOLDINGS INC (2001-12-28);;MARION MERRELL S.A (1999-08-02);;SYNCOM B.V (1999-02-09);;THE DOW CHEMICAL COMPANY (1999-02-09);;AVENTIS PHARMACEUTICALS INC (1999-12-13);;AVENTIS PHARMA DEUTSCHLAND GMBH (1999-02-10);;HMR PHARMA INC (2001-12-28),https://lens.org/062-487-841-168-809,Patent Application,yes,25,1,6,8,0,C07D211/32;;C07D211/32;;C07D211/22;;C07D211/22,A61K31/445;;C07D211/20;;C07D211/22;;C07D211/32,546/237,0,0,,,,EXPIRED
294,AU,B2,AU 598718 B2,058-255-300-988-348,1990-06-28,1990,AU 1989/040906 A,1989-08-30,US 23881088 A,1988-08-31,METHODS OF AND SYSTEMS FOR OPTICAL FIBER SENSING,,AMERICAN TELEPHONE & TELEGRAPH,DUNN LAWRENCE RUSSELL;;WHITE WILLARD CHANDLER III;;WHITE IAN ARTHUR,,https://lens.org/058-255-300-988-348,Granted Patent,no,3,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,EXPIRED
295,DK,A,DK 427189 A,006-267-756-080-110,1990-03-01,1990,DK 427189 A,1989-08-30,US 23881088 A,1988-08-31,LYSLEDEROVERVAAGNINGSSYSTEM OG FREMGANGSMAADE TIL AT OVERVAAGE EN LYSLEDER,,AMERICAN TELEPHONE & TELEGRAPH,WHITE IAN ARTHUR;;WHITE III WILLARD CHANDLER;;DUNN LAWRENCE RUSSELL,,https://lens.org/006-267-756-080-110,Patent Application,no,0,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,DISCONTINUED
296,ES,T3,ES 2075052 T3,189-839-915-484-866,1995-10-01,1995,ES 89308620 T,1989-08-24,US 23881088 A,1988-08-31,METODOS Y SISTEMAS PARA DETECCION DE FIBRAS OPTICAS.,"UN SISTEMA SENSOR DE FIBRA OPTICA PARA DETECTAR INTRUSIONES DE FIBRA OPTICA O DE CABLES DE FIBRA OPTICA INCLUYE UN DISPOSITIVO INTERFEROMETRICO. DOS LUMBRERAS (28, 30) DE UN DIVISOR (25) SE CONECTAN A UNA FUENTE (26) DE ENERGIA OPTICA TAL COMO UN LASER, POR EJEMPLO, Y A UN DETECTOR (32). LAS OTRAS DOS LUMBRERAS (46, 48) SE CONECTAN A LOS EXTREMOS DE UNA LONGITUD (50) DE FIBRA OPTICA PARA EL CONTROL. UNA SEÑAL DE ENTRADA AL DIVISOR SE DIVIDE DIRIGIENDOSE UNA SUBSEÑAL EN UNA DIRECCION ALREDEDOR DE LA LONGITUD DE FIBRA OPTICA QUE SIRVE DE VIA COMUN ENTRE LAS DOS LUMBRERAS. LA OTRA SEÑAL VIAJA ALREDEDOR DEL RECORRIDO COMUN PERO EN SENTIDO OPUESTO. LAS SEÑALES PARTIDAS SE RECOMBINAN EN EL DIVISOR Y SU DIFERENCIA DE FASE SE MIDE A MODO DE PATRON DETECTABLE POR EL DETECTOR. SI HUBIERA INTRUSION DE LA FIBRA OPTICA O DEL CABLE QUE CONTIENE LA FIBRA OPTICA DE CONTROL, EL PATRON DETECTADO CAMBIARA EN UNA FORMA SIGNIFICATIVA.",AT & T CORP,DUNN LAWRENCE RUSSELL;;WHITE IAN ARTHUR;;WHITE WILLARD CHANDLER III,,https://lens.org/189-839-915-484-866,Granted Patent,no,0,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,0,0,,,,EXPIRED
297,US,B1,US 4904050 B1,010-001-590-457-50X,1992-07-28,1992,US 23881088 A,1988-08-31,US 23881088 A,1988-08-31,US 4904050 B1,,BELL TELEPHONE LABOR INC;;AMERICAN TELEPHONE & TELEGRAPH,LAWRENCE R DUNN;;IAN A WHITE;;WILLARD C WHITE III,AMERICAN TELEPHONE AND TELEGRAPH COMPANY 550 MADISON AVENUE NEW YORK NEW YORK 10022-3201 A CORP. OF NY (1988-08-31);;FITEL USA CORPORATION (2001-11-16);;BELL TELEPHONE LABORATORIES INCORPORATED 600 MOUNTAIN AVENUE MURRAY HILL NEW JERSEY 07974-2070 A CORP. OF NY (1988-08-31);;LUCENT TECHNOLOGIES INC (1996-03-29),https://lens.org/010-001-590-457-50X,Granted Patent,no,0,1,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;G01M11/00;;H04B10/12,,0,0,,,,EXPIRED
298,EP,A3,EP 0364093 A3,144-353-874-314-322,1991-04-24,1991,EP 89308620 A,1989-08-24,US 23881088 A,1988-08-31,METHODS OF AND SYSTEMS FOR OPTICAL FIBER SENSING,"An optical fiber sensing system for detecting intrusion of optical fiber or optical fiber cables includes an interferometric arrangement. Two ports (28, 30) of a four port splitter (25) are connected to a source (26) of optical power such as a laser, for example, and to a detector (32). The other two ports (46,48) are connected to ends of a length (50) of monitoring optical fiber. An input signal to the splitter is split with one subsignal being directed in one direction around the length of optical fiber which serves as a common path between the two ports. The other signal is caused to travel around the common path in an opposite direction. The split signals are recombined in the splitter and their phase difference measured as a detectable pattern by the detector. Should there be intrusion of the optical fiber or a cable containing the monitoring optical fiber, the pattern which is detected will change a significant amount.  ",AMERICAN TELEPHONE AND TELEGRAPH COMPANY,"DUNN, LAWRENCE RUSSELL;;WHITE, IAN ARTHUR;;WHITE, WILLARD CHANDLER III",AT&T CORP. (1994-06-22),https://lens.org/144-353-874-314-322,Search Report,yes,1,0,20,20,0,G01M11/083;;G01M11/331;;G02B6/4469;;H04B10/85;;H04B10/032;;H04B10/07;;H04B10/85;;G02B6/4469;;G01M11/331;;G01M11/083,G01M11/00;;G02B6/00;;G02B6/44;;G08B13/186;;H04B10/08;;H04B10/12,,1,1,098-461-369-953-678,10.1049/el:19880537,"ELECTRONICS LETTERS. vol. 24, no. 13, 23 June 1988, ENAGE GB pages 790 - 792; K.Y.Chen et al.: ""Integrated communication and sensing system using one single-mode optical fibre""",EXPIRED
299,US,B1,US 7552396 B1,168-699-352-170-690,2009-06-23,2009,US 9810608 A,2008-04-04,US 9810608 A,2008-04-04,Associating screen position with audio location to detect changes to the performance of an application,"A method for monitoring the performance of an application comprises determining an output of an application that requires monitoring, assigning an audible sound to the output, positioning an output display window at a desired location on a performance monitoring screen, determining a baseline for the output when the application is in the state of equilibrium, monitoring the output to detect a change relative to the baseline, emitting the audible sound assigned to the output from the sound location and bringing the display window into focus on the performance monitoring screen when the detected change varies from the baseline by a predetermined amount, and adjusting the configurable parameters of the audible sound to indicate the existence of the detected change, the magnitude of the detected change relative to the baseline, and the degree of deviation from the baseline, wherein an amplitude of the audible sound is adjusted to indicate the magnitude of the detected change from the baseline, and wherein a pitch of the audible sound is adjusted to indicate a positive change or a negative change from the baseline.",IBM,BICHENO RICHARD M;;DUNN TIM;;HURWORTH IAN P;;PICKERING JOHN B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2008-03-27),https://lens.org/168-699-352-170-690,Granted Patent,yes,56,23,1,1,0,G06F11/324;;G06F11/324;;G06F3/165;;G06F3/165;;G06F11/3409;;G06F11/3409;;G06F2201/81;;G06F2201/81,G06F3/048,715/766;;715/736;;715/772;;717/127,6,1,010-103-392-248-798,10.1109/shpcc.1992.232662,"http://www.usatoday.com/travel/columnist/getline/2006-01-16-ask-the-captain-x.htm.;;""Visual-Aural Representations of Performance for a Scalable Application Program,"" Scalable High Performance Computing Conference, 1992. SHPCC-92. Proceedings, Apr. 26-29, 1992; pp. 433-440. Francioni, J.M.; Rover, D.T.;;AMS-2000 Altitude Alert System (8900) http://www.edmo.com/index.php?module=products&func=display&prod-id=17093, Mar. 27, 2008.;;Audio Emergency Warning Systems http://www.magnalabs.com/audiofacts.1.htm, Mar. 27, 2008.;;3-D Audio Traffic Alert and Collision Avoidance System http://human-factors.arc.nasa.gov/ihh/spatial/research/Begault-3d-collision-avoidance.html, Mar. 27, 2008.;;http://en.wikipedia.org/wiki/Ground-proximity-warning-system, Mar. 27, 2008.",INACTIVE
300,GB,A,GB 2446055 A,141-833-554-510-627,2008-07-30,2008,GB 0801226 A,2008-01-24,GB 0701467 A;;GB 0711133 A,2007-01-26,Connection unit for connecting a secondary battery to a smart charger,"A connection unit 1 connectable between a smart charger 6 and a secondary battery 7, which connection unit comprises a battery recognition and detection unit 4, a control system 2, a charging current measurement circuit 8, a charging voltage measurement circuit 9 and a smart battery interface 3. The secondary battery may not be a smart battery.",ABSL POWER SOLUTIONS LTD,WATSON PETER;;LEISTEN MICHAEL JOSEPH;;PIGGOTT ALEXANDER ANTHONY;;DUNN WILLIAM IAN,,https://lens.org/141-833-554-510-627,Patent Application,no,1,0,3,5,0,H01M10/44;;H02J7/00036;;H02J7/0045;;H02J7/0045;;H02J7/00036;;H02J7/00047;;Y02E60/10,H02J7/00;;H01M10/44,,0,0,,,,DISCONTINUED
301,EP,B1,EP 3528458 B1,012-064-155-243-970,2020-09-23,2020,EP 19158035 A,2019-02-19,US 201862632623 P,2018-02-20,A CYBER SECURITY APPLIANCE FOR A CLOUD INFRASTRUCTURE,,DARKTRACE LTD,WOODFORD ANDREW STEWART;;ARAIZA JACOB OWAIN;;MARKHAM ALEX IAN;;DUNN MATTHEW,"DARKTRACE HOLDINGS LIMITED, CAMBRIDGE, GB (2022-06-03);;DARKTRACE LIMITED (2020-09-16)",https://lens.org/012-064-155-243-970,Granted Patent,yes,3,1,62,155,0,H04L63/1425;;H04L63/1441;;G06F21/554;;G06F21/556;;H04L67/12;;H04L51/18;;H04L51/212;;G06N20/10;;H04L63/1425;;G06N20/00;;H04L63/1416;;H04L63/20;;G06N20/20;;H04L63/14;;G06F21/36;;H04L43/045;;H04L63/101;;H04L63/1441;;G06F16/2455;;G06F3/04842;;G06F3/0486;;H04L41/22;;H04L63/0209;;H04L63/0428;;H04L63/1433;;H04L63/1483;;H04L51/42;;H04L51/212;;G06F21/554;;G06F21/556;;G06F18/23;;G06F18/232;;G06F40/40;;G06V30/10;;H04L51/224,H04L29/06;;G06F21/55;;H04L12/58,,0,0,,,,ACTIVE
302,DK,T3,DK 3800856 T3,114-773-676-857-599,2023-08-28,2023,DK 20197380 T,2019-02-19,US 201862632623 P;;EP 19158035 A,2018-02-20,Cybersikkerhedsindretning til en cloud-infrastruktur,,DARKTRACE HOLDINGS LTD,WOODFORD ANDREW STEWART;;ARAIZA JACOB OWAIN;;MARKHAM ALEX IAN;;DUNN MATTHEW,,https://lens.org/114-773-676-857-599,Granted Patent,no,0,0,62,155,0,H04L63/1425;;H04L63/1441;;G06F21/554;;G06F21/556;;H04L67/12;;H04L51/18;;H04L51/212;;G06N20/10;;H04L63/1425;;G06N20/00;;H04L63/1416;;H04L63/20;;G06N20/20;;H04L63/14;;G06F21/36;;H04L43/045;;H04L63/101;;H04L63/1441;;G06F16/2455;;G06F3/04842;;G06F3/0486;;H04L41/22;;H04L63/0209;;H04L63/0428;;H04L63/1433;;H04L63/1483;;H04L51/42;;H04L51/212;;G06F21/554;;G06F21/556;;G06F18/23;;G06F18/232;;G06F40/40;;G06V30/10;;H04L51/224,H04L9/40;;G06F21/55;;H04L51/212;;H04L67/12,,0,0,,,,ACTIVE
303,WO,A1,WO 2008/090378 A1,195-542-670-718-395,2008-07-31,2008,GB 2008050044 W,2008-01-22,GB 0701467 A;;GB 0711133 A,2007-01-26,BATTERY CONNECTION UNIT,"A connection unit connectable between a smart charger and a secondary battery, which connection unit comprises a battery recognition and detection unit, a control system, a charging current measurement circuit, a charging voltage measurement circuit and a smart battery interface.",ABSL POWER SOLUTIONS LTD;;WATSON PETER;;LEISTEN MICHAEL JOSEPH;;PIGGOTT ALEXANDER ANTHONY;;DUNN WILLIAM IAN,WATSON PETER;;LEISTEN MICHAEL JOSEPH;;PIGGOTT ALEXANDER ANTHONY;;DUNN WILLIAM IAN,,https://lens.org/195-542-670-718-395,Patent Application,yes,3,16,3,5,0,H01M10/44;;H02J7/00036;;H02J7/0045;;H02J7/0045;;H02J7/00036;;H02J7/00047;;Y02E60/10,H02J7/00,,0,0,,,,PENDING
304,EP,A1,EP 3800856 A1,085-256-480-413-747,2021-04-07,2021,EP 20197380 A,2019-02-19,US 201862632623 P;;EP 19158035 A,2018-02-20,A CYBER SECURITY APPLIANCE FOR A CLOUD INFRASTRUCTURE,"A cyber security appliance (100) has modules that utilize probes to interact with entities in a cloud infrastructure environment (CIE). A cloud module can 1) use the information about relevant changes in the CIE fed from the probes, and 2) use machine learning models that are trained on a normal behavior of at least a first entity associated with the CIE; and thus, indicate when a behavior of the first entity falls outside of being a normal pattern of life. A cyber threat module can use machine learning models trained on cyber threats in the CIE and examine at least the behaviors of the first entity falling outside of the normal pattern of life to determine what is a likelihood of 'a chain of unusual behaviors under analysis that fall outside of being the normal behavior' is a cyber threat. An autonomous response module can cause actions to contain the cyber threat.
",DARKTRACE LTD,WOODFORD ANDREW STEWART;;ARAIZA JACOB OWAIN;;MARKHAM ALEX IAN;;DUNN MATTHEW,DARKTRACE HOLDINGS LIMITED (2022-07-06),https://lens.org/085-256-480-413-747,Patent Application,yes,5,2,62,155,0,H04L63/1425;;H04L63/1441;;G06F21/554;;G06F21/556;;H04L67/12;;H04L51/18;;H04L51/212;;G06N20/10;;H04L63/1425;;G06N20/00;;H04L63/1416;;H04L63/20;;G06N20/20;;H04L63/14;;G06F21/36;;H04L43/045;;H04L63/101;;H04L63/1441;;G06F16/2455;;G06F3/04842;;G06F3/0486;;H04L41/22;;H04L63/0209;;H04L63/0428;;H04L63/1433;;H04L63/1483;;H04L51/42;;H04L51/212;;G06F21/554;;G06F21/556;;G06F18/23;;G06F18/232;;G06F40/40;;G06V30/10;;H04L51/224,H04L29/06,,0,0,,,,ACTIVE
305,EP,B1,EP 3800856 B1,170-865-060-632-18X,2023-07-05,2023,EP 20197380 A,2019-02-19,US 201862632623 P;;EP 19158035 A,2018-02-20,A CYBER SECURITY APPLIANCE FOR A CLOUD INFRASTRUCTURE,,DARKTRACE HOLDINGS LTD,WOODFORD ANDREW STEWART;;ARAIZA JACOB OWAIN;;MARKHAM ALEX IAN;;DUNN MATTHEW,DARKTRACE HOLDINGS LIMITED (2022-07-06),https://lens.org/170-865-060-632-18X,Granted Patent,yes,5,0,62,155,0,H04L63/1425;;H04L63/1441;;G06F21/554;;G06F21/556;;H04L67/12;;H04L51/18;;H04L51/212;;G06N20/10;;H04L63/1425;;G06N20/00;;H04L63/1416;;H04L63/20;;G06N20/20;;H04L63/14;;G06F21/36;;H04L43/045;;H04L63/101;;H04L63/1441;;G06F16/2455;;G06F3/04842;;G06F3/0486;;H04L41/22;;H04L63/0209;;H04L63/0428;;H04L63/1433;;H04L63/1483;;H04L51/42;;H04L51/212;;G06F21/554;;G06F21/556;;G06F18/23;;G06F18/232;;G06F40/40;;G06V30/10;;H04L51/224,G06F21/55;;H04L9/40;;H04L51/212;;H04L67/12,,0,0,,,,ACTIVE
306,EP,A2,EP 1716558 A2,035-161-681-271-727,2006-11-02,2006,EP 05705541 A,2005-01-12,US 2005/0000930 W;;US 76115204 A,2004-01-20,INTERACTIVE DISPLAY SYSTEMS,,POLYVISION CORP,ORNER EDWARD E;;DUNN MICAHEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/035-161-681-271-727,Patent Application,yes,0,3,9,9,0,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;F16M11/18;;F16M2200/027;;F16M2200/08;;G09F19/18;;F16M11/42;;A47B97/04;;F16M11/26;;F16M11/18;;F16M2200/027;;F16M2200/08,G09G5/00;;A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18,,0,0,,,,DISCONTINUED
307,AU,A,AU 1995/011035 A,126-422-070-171-104,1995-06-19,1995,AU 1995/011035 A,1994-11-30,AU PM270693 A;;AU 1941/094007 W;;AU 1995/011035 A,1993-11-30,Immunoassay for cervical cancer,,UNIV QUEENSLAND,FRAZER IAN HECTOR;;DUNN LINDA ANN;;TINDLE ROBERT WILLIAM;;FERNANDO GERMAIN JITHENDRA,,https://lens.org/126-422-070-171-104,Patent Application,no,0,0,1,2,0,,G01N33/531;;G01N33/574,,0,0,,,,PENDING
308,DE,T2,DE 60032623 T2,007-028-973-444-273,2007-10-11,2007,DE 60032623 T,2000-10-13,US 16080499 P;;US 21371800 P;;EP 0010077 W,1999-10-21,ALKYLAMINO-SUBSTITUIERTE BICYCLISCHE HETEROCYCLEN ALS P38 PROTEIN-KINASE-INHIBITOREN,,HOFFMANN LA ROCHE,DUNN JAMES;;GOLDSTEIN DAVID;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA,,https://lens.org/007-028-973-444-273,Granted Patent,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
309,WO,A1,WO 1995/015497 A1,015-780-217-034-32X,1995-06-08,1995,AU 1941/094007 W,1994-11-30,AU PM270693 A,1993-11-30,IMMUNOASSAY FOR CERVICAL CANCER,A method of stabilising HPVE7 protein in a sample by boiling the sample and/or treating the sample with a denaturing agent which may be sodium dodecyl sulphate which may also be employed in a final concentration of between 0.01-0.1 %. The sample may be also boiled for 10-15 mins. prior to treatment by sodium dodecyl sulphate.,UNIV QUEENSLAND;;FRAZER IAN HECTOR;;DUNN LINDA ANN;;TINDLE ROBERT WILLIAM;;FERNANDO GERMAIN JITHENDRA,FRAZER IAN HECTOR;;DUNN LINDA ANN;;TINDLE ROBERT WILLIAM;;FERNANDO GERMAIN JITHENDRA,,https://lens.org/015-780-217-034-32X,Patent Application,yes,3,3,1,2,0,C07K16/3069;;G01N33/57411;;G01N33/56983;;G01N2333/025,C07K16/30;;G01N33/569;;G01N33/574,,0,0,,,,PENDING
310,US,A1,US 2006/0100569 A1,008-220-035-747-995,2006-05-11,2006,US 90445604 A,2004-11-11,US 90445604 A,2004-11-11,METHODS AND DEVICES FOR SELECTIVE BULK REMOVAL AND PRECISION SCULPTING OF TISSUE,"Various surgical fluid jet cutting instruments for selective bulk removal and precision sculpting of tissue are provided. In an exemplary embodiment, the instrument includes a fluid delivery tube having a nozzle for forming a high pressure fluid jet, and an evacuation tube having an evacuation port or jet-receiving opening opposite to and spaced apart from the nozzle for receiving the high pressure fluid jet. In use, the fluid jet and/or the evacuation port can be moved relative to one another to allow the device to be selectively used for bulk removal of tissue and for precision sculpting of tissue.",DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;RANUCCI KEVIN J;;DUNN DOUGLAS W,DEPUY MITEK INC (2004-11-17),https://lens.org/008-220-035-747-995,Patent Application,yes,11,34,6,6,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648;;A61B2217/005;;A61B2217/005,A61B17/20,604/22,0,0,,,,DISCONTINUED
311,CA,A1,CA 2529014 A1,112-769-608-288-887,2006-06-13,2006,CA 2529014 A,2005-12-06,US 90504404 A,2004-12-13,INTERCHANGEABLE TISSUE MACERATING AND SCULPTING METHODS AND DEVICES,"Various surgical fluid jet cutting instruments for selective bulk removal a nd precision sculpting of tissue are provided. In one exemplary embodiment, the instrument can include a fluid delivery tube having a nozzle for forming a high pressure fluid jet, and at least two evacuation tubes that are adapted to be selectively and removably coupled to the fluid delivery tube. Each evacuation tube can have an evacuation port or jet-receiving opening that is adapted to be positioned opposite to and spaced apart from the nozzle for receiving the high pressure fluid jet. Each evacuation tube can also be adapted for a specific use. For example, the instrument can include a first evacuation tube that is adapted to allow bulk removal of tissue, and a second evacuation tube that is adapted to allow precision sculpting of tissue.</SDO AB>",DEPUY MITEK INC,RANUCCI KEVIN J;;SENGUN MEHMET Z;;MCRURY IAN D;;DUNN DOUGLAS W,,https://lens.org/112-769-608-288-887,Patent Application,no,0,0,8,8,0,A61B17/3203;;A61B17/3203;;A61B17/32037;;A61B17/32037,A61B17/3203;;B24C5/02,,0,0,,,,INACTIVE
312,US,A1,US 2006/0129086 A1,039-233-366-809-22X,2006-06-15,2006,US 90504404 A,2004-12-13,US 90504404 A,2004-12-13,INTERCHANGEABLE TISSUE MACERATING AND SCULPTING METHODS AND DEVICES,"Various surgical fluid jet cutting instruments for selective bulk removal and precision sculpting of tissue are provided. In one exemplary embodiment, the instrument can include a fluid delivery tube having a nozzle for forming a high pressure fluid jet, and at least two evacuation tubes that are adapted to be selectively and removably coupled to the fluid delivery tube. Each evacuation tube can have an evacuation port or jet-receiving opening that is adapted to be positioned opposite to and spaced apart from the nozzle for receiving the high pressure fluid jet. Each evacuation tube can also be adapted for a specific use. For example, the instrument can include a first evacuation tube that is adapted to allow bulk removal of tissue, and a second evacuation tube that is adapted to allow precision sculpting of tissue.",DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;RANUCCI KEVIN J;;DUNN DOUGLAS W,DEPUY MITEK INC (2004-12-14),https://lens.org/039-233-366-809-22X,Patent Application,yes,13,13,8,8,0,A61B17/3203;;A61B17/3203;;A61B17/32037;;A61B17/32037,A61B17/20,604/22,0,0,,,,DISCONTINUED
313,JP,A,JP 2006167461 A,109-642-721-292-830,2006-06-29,2006,JP 2005358072 A,2005-12-12,US 90504404 A,2004-12-13,INTERCHANGEABLE TISSUE MACERATING AND SCULPTING METHODS AND DEVICES,"<P>PROBLEM TO BE SOLVED: To provide a surgical fluid jet cutting instruments for selective bulk removal and precision sculpting of tissue. <P>SOLUTION: In one exemplary embodiment, the surgical fluid jet cutting instrument (10) can include a fluid delivery tube (12) having a nozzle (18) for forming a high pressure fluid jet, and at least two evacuation tubes (14, 16) that are adapted to be selectively and removably coupled to the fluid delivery tube. Each evacuation tube can have an evacuation port or jet-receiving opening (14a, 16a) that is adapted to be positioned opposite to and spaced apart from the nozzle for receiving the high pressure fluid jet (22). Each evacuation tube can also be adapted for a specific use. For example, the instrument can include a first evacuation tube (14) that is adapted to allow bulk removal of tissue, and a second evacuation tube (16) that is adapted to allow precision sculpting of tissue. <P>COPYRIGHT: (C)2006,JPO&NCIPI",DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/109-642-721-292-830,Patent Application,no,0,5,8,8,0,A61B17/3203;;A61B17/3203;;A61B17/32037;;A61B17/32037,A61B17/32,,0,0,,,,DISCONTINUED
314,US,A1,US 2005/0156952 A1,089-558-984-715-879,2005-07-21,2005,US 76115204 A,2004-01-20,US 76115204 A,2004-01-20,Interactive display systems,"An interactive display system is provided including a support frame having a vertical positioning element that counterbalances the weight of an attached interactive display, for example a touch-sensitive display. The support frame optionally includes a power supply increasing the range of mobility of the interactive display system by eliminating the need for power cord and power outlet connections. One exemplary support frame for an interactive display includes a base element, at least one support extending vertically from the base element, and a positioning element housed within the at least one support. The positioning element counterbalances the weight of the interactive display allowing vertical repositioning of the interactive display with a force of less than about 25 pounds.",ORNER EDWARD E.;;DUNN MICHAEL H.;;HUTCHINSON IAN G.;;HILDEBRANDT PETER W.,ORNER EDWARD E;;DUNN MICHAEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,POLYVISION CORPORATION (2005-08-02),https://lens.org/089-558-984-715-879,Patent Application,yes,24,30,9,9,0,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;F16M11/18;;F16M2200/027;;F16M2200/08;;G09F19/18;;F16M11/42;;A47B97/04;;F16M11/26;;F16M11/18;;F16M2200/027;;F16M2200/08,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;G09G5/00,345/905,0,0,,,,DISCONTINUED
315,DE,D1,DE 60032623 D1,050-140-806-225-988,2007-02-08,2007,DE 60032623 T,2000-10-13,US 16080499 P;;US 21371800 P;;EP 0010077 W,1999-10-21,ALKYLAMINO-SUBSTITUIERTE BICYCLISCHE HETEROCYCLEN ALS P38 PROTEIN KINASE INHIBITOREN,,HOFFMANN LA ROCHE,DUNN PATRICK;;GOLDSTEIN MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH ROSANNE,,https://lens.org/050-140-806-225-988,Granted Patent,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
316,CA,A1,CA 2553526 A1,129-473-261-303-826,2005-08-11,2005,CA 2553526 A,2005-01-12,US 76115204 A;;US 2005/0000930 W,2004-01-20,INTERACTIVE DISPLAY SYSTEMS,"An interactive display system is provided including a support frame having a vertical positioning element that counterbalances the weight of an attached interactive display, for example a touch-sensitive display. The support fram e optionally includes a power supply increasing the range of mobility of the interactive display system by eliminating the need for power cord and power outlet connections. One exemplary support frame for an interactive display includes a base element, at least one support extending vertically from the base element, and a positioning element housed within the at least one support. The positioning element counterbalances the weight of the interacti ve display allowing vertical repositioning of the interactive display with a force of less than about 25 pounds.",POLYVISION CORP,DUNN MICHAEL H;;ORNER EDWARD E;;HILDEBRANDT PETER W;;HUTCHINSON IAN G,,https://lens.org/129-473-261-303-826,Patent Application,no,0,0,9,9,0,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;F16M11/18;;F16M2200/027;;F16M2200/08;;G09F19/18;;F16M11/42;;A47B97/04;;F16M11/26;;F16M11/18;;F16M2200/027;;F16M2200/08,F16M11/24;;A47B97/04;;F16M11/26;;F16M11/42;;F16M13/00;;G06F1/16;;G09F19/18;;G09G5/00,,0,0,,,,DISCONTINUED
317,WO,A3,WO 2005/072504 A3,154-994-399-159-329,2006-12-28,2006,US 2005/0000930 W,2005-01-12,US 76115204 A,2004-01-20,INTERACTIVE DISPLAY SYSTEMS,"An interactive display system is provided including a support frame (600) having vertical positioning element that counterbalances the weight of an attached interactive display (201), for example a touch-sensitive display. The support frame (600) optionally includes a power supply increasing the range of mobility of the interactive display system by eliminating the need for power cord and power outlet connections. One exemplary support frame for an interactive display (201) includes a base element, at least one support extending vertically (603) from the base element, and a positioning element housed within the at least one support. The positioning element counterbalances the weight of the interactive display allowing vertical repositioning of the interactive display with a force of less than about 25 pounds.",POLYVISION CORP;;ORNER EDWARD E;;DUNN MICAHEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,ORNER EDWARD E;;DUNN MICAHEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/154-994-399-159-329,Search Report,yes,3,0,9,9,0,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;F16M11/18;;F16M2200/027;;F16M2200/08;;G09F19/18;;F16M11/42;;A47B97/04;;F16M11/26;;F16M11/18;;F16M2200/027;;F16M2200/08,G09G5/00;;A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18,,0,0,,,,PENDING
318,AU,B2,AU 2005/242152 B2,002-549-166-118-828,2008-10-16,2008,AU 2005/242152 A,2005-12-07,US 90504404 A,2004-12-13,Interchangeable tissue macerating and sculpting methods and devices,,DEPUY MITEK INC,MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W;;SENGUN MEHMET Z,,https://lens.org/002-549-166-118-828,Granted Patent,no,5,0,8,8,0,A61B17/3203;;A61B17/3203;;A61B17/32037;;A61B17/32037,A61B17/3203,,0,0,,,,INACTIVE
319,AU,A1,AU 2005/242152 A1,165-819-263-214-529,2006-06-29,2006,AU 2005/242152 A,2005-12-07,US 90504404 A,2004-12-13,Interchangeable tissue macerating and sculpting methods and devices,,DEPUY MITEK INC,MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W;;SENGUN MEHMET Z,,https://lens.org/165-819-263-214-529,Patent Application,no,0,0,8,8,0,A61B17/3203;;A61B17/3203;;A61B17/32037;;A61B17/32037,A61B17/3203,,0,0,,,,INACTIVE
320,CA,C,CA 2529014 C,061-756-769-725-143,2009-10-13,2009,CA 2529014 A,2005-12-06,US 90504404 A,2004-12-13,INTERCHANGEABLE TISSUE MACERATING AND SCULPTING METHODS AND DEVICES,"Various surgical fluid jet cutting instruments for selective bulk removal a nd precision sculpting of tissue are provided. In one exemplary embodiment, the instrument can include a fluid delivery tube having a nozzle for forming a high pressure fluid jet, and at least two evacuation tubes that are adapted to be selectively and removably coupled to the fluid delivery tube. Each evacuation tube can have an evacuation port or jet-receiving opening that is adapted to be positioned opposite to and spaced apart from the nozzle for receiving the high pressure fluid jet. Each evacuation tube can also be adapted for a specific use. For example, the instrument can include a first evacuation tube that is adapted to allow bulk removal of tissue, and a second evacuation tube that is adapted to allow precision sculpting of tissue.",DEPUY MITEK INC,SENGUN MEHMET Z;;DUNN DOUGLAS W;;MCRURY IAN D;;RANUCCI KEVIN J,,https://lens.org/061-756-769-725-143,Granted Patent,no,0,0,8,8,0,A61B17/3203;;A61B17/3203;;A61B17/32037;;A61B17/32037,A61B17/3203;;B24C5/02,,0,0,,,,INACTIVE
321,AU,A1,AU 2005/208489 A1,080-127-036-124-196,2005-08-11,2005,AU 2005/208489 A,2005-01-12,US 76115204 A;;US 2005/0000930 W,2004-01-20,Interactive display systems,,POLYVISION CORP,HILDEBRANDT PETER W;;DUNN MICAHEL H;;HUTCHINSON IAN G;;ORNER EDWARD E,,https://lens.org/080-127-036-124-196,Patent Application,no,0,0,9,9,0,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;F16M11/18;;F16M2200/027;;F16M2200/08;;G09F19/18;;F16M11/42;;A47B97/04;;F16M11/26;;F16M11/18;;F16M2200/027;;F16M2200/08,G09G5/00;;A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18,,0,0,,,,DISCONTINUED
322,JP,A,JP 2006136727 A,189-356-095-046-185,2006-06-01,2006,JP 2005326441 A,2005-11-10,US 90445604 A,2004-11-11,METHOD AND DEVICE FOR SELECTIVE BULK REMOVAL AND PRECISION SCULPTING OF TISSUE,"<P>PROBLEM TO BE SOLVED: To provide a fluid jet cutting instruments for selective bulk removal and precision sculpting of tissue. <P>SOLUTION: Various surgical fluid jet cutting instruments for selective bulk removal and precision sculpting of tissue are provided. The instrument 10 includes a fluid delivery tube 12 having a nozzle 18 for forming a high pressure fluid jet 22, and an evacuation tube 14 having an evacuation port 20 or jet-receiving opening opposite to and spaced apart from the nozzle 18 for receiving the high pressure fluid jet 22. In use, the fluid jet 22 and/or the evacuation port 20 can be moved relative to one another to allow the device to be selectively used for bulk removal of tissue and for precision sculpting of tissue. <P>COPYRIGHT: (C)2006,JPO&NCIPI",DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/189-356-095-046-185,Patent Application,no,0,1,6,6,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648;;A61B2217/005;;A61B2217/005,A61B17/32;;B26F3/00,,0,0,,,,DISCONTINUED
323,AU,A1,AU 2010/202227 A1,007-811-786-155-286,2010-06-24,2010,AU 2010/202227 A,2010-05-31,AU 2005/208489 A;;AU 2010/202227 A;;US 76115204 A;;US 2005/0000930 W,2004-01-20,Interactive display systems,,POLYVISION CORP,ORNER EDWARD E;;HUTCHINSON IAN G;;DUNN MICAHEL H;;HILDEBRANDT PETER W,,https://lens.org/007-811-786-155-286,Patent Application,no,0,0,9,9,0,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;F16M11/18;;F16M2200/027;;F16M2200/08;;G09F19/18;;F16M11/42;;A47B97/04;;F16M11/26;;F16M11/18;;F16M2200/027;;F16M2200/08,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;G09G5/00,,0,0,,,,DISCONTINUED
324,WO,A2,WO 2005/072504 A2,182-412-824-408-772,2005-08-11,2005,US 2005/0000930 W,2005-01-12,US 76115204 A,2004-01-20,INTERACTIVE DISPLAY SYSTEMS,"An interactive display system is provided including a support frame (600) having vertical positioning element that counterbalances the weight of an attached interactive display (201), for example a touch-sensitive display. The support frame (600) optionally includes a power supply increasing the range of mobility of the interactive display system by eliminating the need for power cord and power outlet connections. One exemplary support frame for an interactive display (201) includes a base element, at least one support extending vertically (603) from the base element, and a positioning element housed within the at least one support. The positioning element counterbalances the weight of the interactive display allowing vertical repositioning of the interactive display with a force of less than about 25 pounds.",POLYVISION CORP;;ORNER EDWARD E;;DUNN MICAHEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,ORNER EDWARD E;;DUNN MICAHEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/182-412-824-408-772,Patent Application,yes,0,3,9,9,0,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;F16M11/18;;F16M2200/027;;F16M2200/08;;G09F19/18;;F16M11/42;;A47B97/04;;F16M11/26;;F16M11/18;;F16M2200/027;;F16M2200/08,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;G09G5/00,,0,0,,,,PENDING
325,US,B1,US 6523417 B1,177-621-557-272-793,2003-02-25,2003,US 37572699 A,1999-08-17,US 37572699 A,1999-08-17,End of line seat function and motion tester,"
    An end of line seat tester for adjustable seats, comprising an array of optical sensors for sensing and measuring the physical adjustment of seat components such as a headrest, seatback or seat cushion. In a preferred form the optical sensor array is combined in closed-loop fashion with an internal function tester connected through a powered seat control module by tether to monitor the internal function of the power adjustment mechanisms. The external, optical sensing of the seat adjustments can be used to verify the internal testing of the seat adjustment mechanisms, both as to static adjusted positions and real time adjustment motion. 
",ELECTRICAL POWER & DESIGN INC,DONAHUE THOMAS J;;POHLMAN DUANE S;;BONZA LISA M;;DUNN IAN R,ELECTRICAL POWER & DESIGN INC (1999-08-16),https://lens.org/177-621-557-272-793,Granted Patent,yes,8,33,1,1,0,B60N2/0224;;B60N2/0272;;B60N2/0224;;B60N2/0272,B60N2/02,73/800;;250/221,0,0,,,,EXPIRED
326,EP,A3,EP 1671595 A3,026-930-942-421-680,2006-07-12,2006,EP 05257636 A,2005-12-13,US 90504404 A,2004-12-13,Interchangeable tissue macerating and sculpting devices.,"Various surgical fluid jet cutting instruments for selective bulk removal and precision sculpting of tissue are provided. In one exemplary embodiment, the instrument (10) can include a fluid delivery tube (12) having a nozzle (18) for forming a high pressure fluid jet (22), and at least two evacuation tubes (16) that are adapted to be selectively and removably coupled to the fluid delivery tube. Each evacuation tube can have an evacuation port (16a) or jet-receiving opening that is adapted to be positioned opposite to and spaced apart from the nozzle for receiving the high pressure fluid jet. Each evacuation tube can also be adapted for a specific use. For example, the instrument can include a first evacuation tube that is adapted to allow bulk removal of tissue, and a second evacuation tube that is adapted to allow precision sculpting of tissue.
",DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/026-930-942-421-680,Search Report,yes,5,0,8,8,0,A61B17/3203;;A61B17/32037;;A61B17/3203;;A61B17/32037,A61B17/32,,0,0,,,,DISCONTINUED
327,CA,A1,CA 2526514 A1,050-399-095-921-815,2006-05-11,2006,CA 2526514 A,2005-11-10,US 90445604 A,2004-11-11,METHODS AND DEVICES FOR SELECTIVE BULK REMOVAL AND PRECISIONSCULPTING OF TISSUE,"Various surgical fluid jet cutting instruments for selective bulk removal a nd precision sculpting of tissue are provided. In an exemplary embodiment, the instrument includes a fluid delivery tube having a nozzle for forming a high pressure fluid jet, and an evacuation tube having an evacuation port or jet-receiving opening opposi te to and spaced apart from the nozzle for receiving the high pressure fluid jet. In use, the fluid jet and/or the evacuation port can be moved relative to one another to allow the device to be selectively used for bulk removal of tissue and for precision sculpting of tissue.",DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/050-399-095-921-815,Patent Application,no,0,0,6,6,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648;;A61B2217/005;;A61B2217/005,B24C5/02;;A61B17/3203;;B24C3/32,,0,0,,,,DISCONTINUED
328,AU,B2,AU 2005/229679 B2,094-251-319-680-690,2007-12-06,2007,AU 2005/229679 A,2005-11-02,US 90445604 A,2004-11-11,Methods and devices for selective bulk removal and precision sculpting of tissue,,DEPUY MITEK INC,SENGUN MEHMET Z;;RANUCCI KEVIN J;;MCRURY IAN D;;DUNN DOUGLAS W,,https://lens.org/094-251-319-680-690,Granted Patent,no,1,0,6,6,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648;;A61B2217/005;;A61B2217/005,A61B17/32;;B24C1/04;;B26F3/00,,0,0,,,,INACTIVE
329,AU,A1,AU 2005/229679 A1,134-377-895-885-144,2006-05-25,2006,AU 2005/229679 A,2005-11-02,US 90445604 A,2004-11-11,Methods and devices for selective bulk removal and precision sculpting of tissue,,DEPUY MITEK INC,SENGUN MEHMET Z;;RANUCCI KEVIN J;;MCRURY IAN D;;DUNN DOUGLAS W,,https://lens.org/134-377-895-885-144,Patent Application,no,0,0,6,6,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648;;A61B2217/005;;A61B2217/005,A61B17/32;;B24C1/04;;B26F3/00,,0,0,,,,INACTIVE
330,EP,A2,EP 1671595 A2,166-644-780-347-455,2006-06-21,2006,EP 05257636 A,2005-12-13,US 90504404 A,2004-12-13,Interchangeable tissue macerating and sculpting devices.,"Various surgical fluid jet cutting instruments for selective bulk removal and precision sculpting of tissue are provided. In one exemplary embodiment, the instrument can include a fluid delivery tube having a nozzle for forming a high pressure fluid jet, and at least two evacuation tubes that are adapted to be selectively and removably coupled to the fluid delivery tube. Each evacuation tube can have an evacuation port or jet-receiving opening that is adapted to be positioned opposite to and spaced apart from the nozzle for receiving the high pressure fluid jet. Each evacuation tube can also be adapted for a specific use. For example, the instrument can include a first evacuation tube that is adapted to allow bulk removal of tissue, and a second evacuation tube that is adapted to allow precision sculpting of tissue.
",DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/166-644-780-347-455,Patent Application,yes,0,0,8,8,0,A61B17/3203;;A61B17/3203;;A61B17/32037;;A61B17/32037,A61B17/32,,0,0,,,,DISCONTINUED
331,MX,A,MX PA06008160 A,038-720-004-570-196,2007-01-30,2007,MX PA06008160 A,2005-01-12,US 76115204 A;;US 2005/0000930 W,2004-01-20,INTERACTIVE DISPLAY SYSTEMS.,"An interactive display system is provided including a support frame having a vertical positioning element that counterbalances the weight of an attached interactive display, for example a touch-sensitive display. The support frame optionally includes a power supply increasing the range of mobility of the interactive display system by eliminating the need for power cord and power outlet connections. One exemplary support frame for an interactive display includes a base element, at least one support extending vertically from the base element, and a positioning element housed within the at least one support. The positioning element counterbalances the weight of the interactive display allowing vertical repositioning of the interactive display with a force of less than about 25 pounds.",POLYVISION CORP,ORNER EDWARD E;;DUNN MICAHEL H;;HUTCHINSON IAN G;;HILDEBRANDT PETER W,,https://lens.org/038-720-004-570-196,Patent Application,no,0,3,9,9,0,A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;F16M11/18;;F16M2200/027;;F16M2200/08;;G09F19/18;;F16M11/42;;A47B97/04;;F16M11/26;;F16M11/18;;F16M2200/027;;F16M2200/08,G09B5/06;;A47B97/04;;F16M11/26;;F16M11/42;;G09F19/18;;G09G5/00,,0,0,,,,DISCONTINUED
332,EP,A1,EP 1656894 A1,144-736-181-831-376,2006-05-17,2006,EP 05256936 A,2005-11-10,US 90445604 A,2004-11-11,Devices for selectively macerating and sculpting tissue,"Various surgical fluid jet cutting instruments for selective bulk removal and precision sculpting of tissue are provided. In an exemplary embodiment, the instrument (10) includes a fluid delivery tube (12) having a nozzle (18) for forming a high pressure fluid jet (22), and an evacuation tube (14) having an evacuation port (20) or jet-receiving opening (20) opposite to and spaced apart from the nozzle (18) for receiving the high pressure fluid jet (22). In use, the fluid jet (22) and/or the evacuation port (20) can be moved relative to one another to allow the device to be selectively used for bulk removal of tissue and for precision sculpting of tissue.
",DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/144-736-181-831-376,Patent Application,yes,3,0,6,6,0,A61B17/1644;;A61B17/3203;;A61B17/32037;;A61B2017/1648;;A61B2217/005;;A61B17/3203;;A61B17/32037;;A61B2217/005;;A61B17/1644;;A61B2017/1648,A61B17/32;;A61B17/16;;A61B17/22,,0,0,,,,DISCONTINUED
333,CA,A1,CA 2189956 A1,092-587-187-796-953,1996-11-16,1996,CA 2189956 A,1995-03-20,GB 9409211 A;;GB 9501629 A;;GB 9500606 W;;GB 9504426 A,1994-05-10,INVALID HOIST,"The invalid hoist comprises a mobile chassis, a lifting column upstanding from the chassis and a lifting arm supported by the lifting column. The chassis comprises a main portion extending transversely of the hoist and side members which are movable between a first in use position in which they project forwardly from the main portion and a second storage position (as shown) in which they extend parallel or substantially parallel to the lifting column. Releasable means may be provided for holding the lifting arm in an operative position and for releasing the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively an extensible, retractable device (see figure 5) may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/092-587-187-796-953,Patent Application,no,0,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
334,EP,B1,EP 0475525 B1,120-041-089-484-947,1995-11-08,1995,EP 91202283 A,1991-09-06,GB 9019897 A,1990-09-12,Plural-wavelength infrared detector devices.,,MARCONI GEC LTD,BAKER IAN MARTIN C O PHILIPS I;;DUNN WILLIAM ANDREW ERNEST C O,GEC-MARCONI LIMITED (1993-10-06);;N.V. PHILIPS' GLOEILAMPENFABRIEKEN (1992-04-22);;PHILIPS ELECTRONICS UK LIMITED (1992-04-22),https://lens.org/120-041-089-484-947,Granted Patent,yes,5,0,10,10,0,H01L27/14669;;H01L27/14669,H01L27/146;;H01L27/14,,0,0,,,,EXPIRED
335,JP,A,JP 2004002392 A,135-528-124-422-792,2004-01-08,2004,JP 2003113685 A,2003-04-18,EP 02008230 A,2002-04-18,POLYMERIZABLE COMPOUND CONTAINING CINNAMIC ACID GROUP AND ACETYLENE GROUP,"<P>PROBLEM TO BE SOLVED: To provide a polymerizable mesogen compound usable especially for the production of an oriented LC polymer film or as a compound in an active layer of a switchable LC device as a mixture with a low-molecular weight LC medium. <P>SOLUTION: The invention relates to a new polymerizable mesogen or liquid crystal compound containing cinnamic acid group and acetylene group, a mixture of the polymerizable mesogen or liquid crystal, an anisotropic polymer and the use of the compound, mixture and polymer in an optical, electrooptical and electronic device for decorative and security use. <P>COPYRIGHT: (C)2004,JPO",MERCK PATENT GMBH,SIMON GREENFIELD;;HARDING RICHARD;;VAUGHAN-SPICKERS JULIAN;;SMITH ASHLEY;;HASSALL IAN;;DUNN CHRISTOPHER,,https://lens.org/135-528-124-422-792,Patent Application,no,0,10,6,6,0,C07D213/55;;C09B69/109;;C09K19/0403;;C09K19/3405;;C09K19/3444;;C09K19/3461;;C09K19/3491;;C09K19/3497;;C09K2019/0407;;C09K2019/0444;;C09K2019/0459;;C09K2219/03;;C09K2019/0448;;C07C69/734;;C07C69/736;;C07D213/55;;C09K19/18,G02B5/30;;C07C69/017;;C07C69/734;;C07D213/55;;C08F20/10;;C09K19/04;;C09K19/18;;C09K19/20;;C09K19/28;;C09K19/32;;C09K19/34;;C09K19/38;;G02F1/13;;G02F1/1335;;H01L51/05;;H01L51/30,,0,0,,,,PENDING
336,NO,B1,NO 307026 B1,165-296-089-466-754,2000-01-31,2000,NO 964761 A,1996-11-08,GB 9500606 W;;GB 9409211 A;;GB 9501629 A;;GB 9504426 A,1994-05-10,Invalideheis,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/165-296-089-466-754,Granted Patent,no,0,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
337,EP,A1,EP 0758878 A1,032-455-363-157-026,1997-02-26,1997,EP 95911437 A,1995-03-20,GB 9500606 W;;GB 9409211 A;;GB 9501629 A;;GB 9504426 A,1994-05-10,INVALID HOIST,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/032-455-363-157-026,Patent Application,yes,0,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
338,GB,B,GB 2289259 B,109-401-719-194-097,1997-06-11,1997,GB 9504427 A,1995-03-06,GB 9409212 A,1994-05-10,An actuating device,,ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/109-401-719-194-097,Granted Patent,no,4,0,7,7,0,A61G7/1017;;A61G7/1046;;A61G7/1067,A61G7/10,B8H HEX           HEX;;B8H H323          HEX;;B8H H410          HEX;;F2E EU            EU;;F2Y YSL           SL;;F2Y Y3201         SL;;U1S S1872,0,0,,,,EXPIRED
339,AU,A,AU 1995/019007 A,170-224-047-260-027,1995-11-29,1995,AU 1995/019007 A,1995-03-20,GB 9409212 A;;GB 9500605 W,1994-05-10,An actuating device,,ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/170-224-047-260-027,Patent Application,no,0,0,7,7,0,A61G7/1017;;A61G7/1046;;A61G7/1067,A61G7/10,,0,0,,,,PENDING
340,TW,B,TW I278506 B,019-167-449-325-281,2007-04-11,2007,TW 90124300 A,2001-10-02,EP 00124365 A,2000-11-20,Chiral photoisomerizable compounds,"The invention relates to chiral photoisomerizable compounds of formula I, wherein X1, X2, X3, X4, X5 and X6 have the meanings given in claim 1, to liquid crystalline mixtures and polymers containing them, and to the use of chiral photoisomerizable compounds, liquid crystalline mixtures and polymers containing them in optical and electrooptical devices like liquid crystal displays or projection systems, in optical elements like polarizers, retardation films, compensators, colour filters or holographic elements, in liquid crystal pigments and coloured films or coatings for decorative or security applications, cosmetic and pharmaceutical compositions, in nonlinear optics and optical information storage.",MERCK PATENT GMBH,DUNN CHRISTOPHER J;;GREENFIELD SIMON;;HARDING RICHARD;;HASSALL IAN V E;;JENKINS TONY,,https://lens.org/019-167-449-325-281,Granted Patent,no,0,0,13,13,0,C09K19/2028;;C09K19/586;;C09K2219/03;;C09K2323/00;;C09K19/58;;C09K19/2028;;C09K2219/03;;C09K19/586;;C09K2323/00,G02B5/30;;C07C69/767;;C09K19/38;;C09K19/54;;G02F1/13;;G02F1/1335,,0,0,,,,EXPIRED
341,AU,A,AU 1995/019008 A,109-706-146-542-951,1995-11-29,1995,AU 1995/019008 A,1995-03-20,GB 9409211 A;;GB 9501629 A;;GB 9500606 W;;GB 9504426 A,1994-05-10,Invalid hoist,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO MED AKTIEBOLAG LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,ARJO MED.AKTIEBOLAG LIMITED (2003-05-29),https://lens.org/109-706-146-542-951,Patent Application,no,0,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
342,GB,A,GB 2289457 A,154-565-712-410-562,1995-11-22,1995,GB 9504426 A,1995-03-06,GB 9409211 A;;GB 9501629 A;;GB 9504426 A,1994-05-10,Invalid hoist,"The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two legs 14 which are movable between an in use position (as shown) and a second storage position in which they extend parallel to the lifting column. Releasable means e.g. stay 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively an extendible, retractable device (30, Figure 5) may be connected between the lifting arm and the lifting column at positions remote from their pivot axis so that the lifting arm can be moved between its operative position storage positions. <IMAGE>",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/154-565-712-410-562,Patent Application,no,7,4,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,B8H HCB           HCB;;B8H H410          HCB;;B8H H553          HCB,0,0,,,,EXPIRED
343,GB,A,GB 2388600 A,168-883-914-699-706,2003-11-19,2003,GB 0308987 A,2003-04-17,EP 02008230 A,2002-04-18,Polymerisable mesogenic or liquid crystalline compounds comprising a cinnamic acid residue and an acetylene group,"Polymerisable compounds comprising a cinnamic acid residue, an acetylene group and a polymerisable group. In particular, polymerisable compounds of formula I in which P is a polymerisable group, Sp is a spacer group or a single bond, X, Z<1> and Z<2> are each independently various residues or a single bond, A<1> and A<2> are each independently aliphatic or aromatic, optionally substituted carbocyclic or heterocyclic groups, m1 and m2 are each independently 0, 1, 2 or 3 with m1+m2<5, R is H or one of various substituent groups, including a group X-Sp-P, L is F, Cl, Br, I, CN, NO2 or alkyl, alkoxy, alkylcarbonyl or alkylcarbonyloxy in which one or more H atoms may be substituted by F or Cl and r is 0, 1, 2, 3 or 4. Preferably, the polymerisable group P is a vinyl group, an acrylate group, a methacrylate group, a propenyl ether group or an epoxy group. The compounds may be mesogenic or liquid crystalline compounds and the compounds, or polymers thereof, have various uses including in liquid crystal displays, as electrode materials in batteries and in electrophotographic recording. <EMI ID=1.1 HE=24 WI=121 LX=515 LY=1317 TI=CF>",MERCK PATENT GMBH,GREENFIELD SIMON;;HARDING RICHARD;;VAUGHAN-SPICKERS JULIAN;;SMITH ASHLEY;;HASSALL IAN;;DUNN CHRISTOPHER,,https://lens.org/168-883-914-699-706,Patent Application,no,4,8,6,6,0,C07C69/734;;C07C69/736;;C07D213/55;;C09B69/109;;C09K19/18;;C07D213/55;;C09K19/0403;;C09K19/3405;;C09K19/3444;;C09K19/3461;;C09K19/3491;;C09K19/3497;;C09K2019/0407;;C09K2019/0444;;C09K2019/0448;;C09K2019/0459;;C09K2219/03,G02B5/30;;C07C69/017;;C07C69/734;;C07D213/55;;C08F20/10;;C09K19/04;;C09K19/18;;C09K19/20;;C09K19/28;;C09K19/32;;C09K19/34;;C09K19/38;;G02F1/13;;G02F1/1335;;H01L51/05;;H01L51/30,C2C CAA;;U1S S1346;;U1S S1387,0,0,,,,EXPIRED
344,WO,A1,WO 1995/030400 A1,184-276-864-937-58X,1995-11-16,1995,GB 9500606 W,1995-03-20,GB 9409211 A;;GB 9501629 A;;GB 9504426 A,1994-05-10,INVALID HOIST,"The invalid hoist comprises a mobile chassis (10), a lifting column (11) upstanding from the chassis and a lifting arm (12) supported by the lifting column. The chassis comprises a main portion (13) extending transversely of the hoist and two side members (14) which are movable between a first in use position in which they project forwardly from the main portion and a second storage position (as shown) in which they extend parallel or substantially parallel to the lifting column. Releasable means (22) may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively an extensible, retractable device (see figure 5) may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD;;DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/184-276-864-937-58X,Patent Application,yes,9,2,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,PATENTED
345,GB,B,GB 2388841 B,079-983-277-751-023,2006-03-15,2006,GB 0308990 A,2003-04-17,EP 02008231 A,2002-04-18,Polymerisable heterocyclic acetylenes,,MERCK PATENT GMBH,GREENFIELD SIMON;;HARDING RICHARD;;VAUGHAN-SPICKERS JULIAN;;SMITH ASHLEY;;HASSALL IAN;;DUNN CHRISTOPHER,,https://lens.org/079-983-277-751-023,Granted Patent,no,4,0,3,3,0,C07D213/30;;C07D307/68;;C07D333/38;;C07D213/30;;C07D307/68;;C07D333/38;;C09K19/3405;;C09K19/3411;;C09K19/3444;;C09K19/3461;;C09K19/3491;;C09K19/3497;;C09K2219/03,C07D213/30;;C07D307/68;;C07D333/38;;C09K19/34,C2C CAA;;U1S S1346;;U1S S1387,10,0,,,"CAPLUS Abstract Accession No. 2003:36481 & JP 2003012762 A;;CAPLUS Abstract Accession No. 2001:705631 & Liquid Crystals Volume 28, No. 9, 2001, pages 1361-1367;;CAPLUS Abstract Accession No. 2000:236119 & JP 2000103781 A;;CAPLUS Abstract Accession No. 1999:112403 & Liquid Crystals Volume 26, No. 2, 1999, pages 241-250;;CAPLUS Abstract Accession No. 1996:335958 & JP 08059521 A;;CAPLUS Abstract Accession No. 1995:969456 & JP 07206715 A;;CAPLUS Abstract Accession No. 1995:680663 & JP 06293689 A;;CAPLUS Abstract Accession No. 1995:406609 & JP 06312948 A;;CAPLUS Abstract Accession No. 1992:592371 & Front. Polym. Res., (Proc. Int. Conf.), 1st, 1991, pages 233-238;;CAPLUS Abstract Accession No. 1992:591860 & JP 04145072 A",EXPIRED
346,CA,C,CA 2189956 C,065-754-260-361-646,2005-08-02,2005,CA 2189956 A,1995-03-20,GB 9409211 A;;GB 9501629 A;;GB 9500606 W;;GB 9504426 A,1994-05-10,INVALID HOIST,"The invalid hoist comprises a mobile chassis, a lifting column upstanding from the chassis and a lifting arm supported by the lifting column. The chassis comprises a main portion extending transversely of the hoist and side members which are movably between a first in use position in which they project forwardly from the main portion and a second storage position (as shown) in which they extend parallel or substantially parallel to the lifting column. Releasable means may be provided for holding the lifting arm in an operative position and for releasing the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively an extensible, retractable device (see figure 5) may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/065-754-260-361-646,Granted Patent,no,0,1,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
347,NO,L,NO 964761 L,198-443-256-623-273,1997-01-09,1997,NO 964761 A,1996-11-08,GB 9500606 W;;GB 9409211 A;;GB 9501629 A;;GB 9504426 A,1994-05-10,Invalideheis,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/198-443-256-623-273,Abstract,no,0,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
348,US,A,US 5784729 A,021-064-548-267-021,1998-07-28,1998,US 73753196 A,1996-11-25,GB 9409211 A;;GB 9501629 A;;GB 9500606 W;;GB 9504426 A,1994-05-10,Invalid hoist,"The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,ARJO. MED. AKTIEBOLAG LIMITED (2003-03-14);;ARJO LIMITED (1996-11-18),https://lens.org/021-064-548-267-021,Granted Patent,yes,19,23,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,5/86.1;;5/83.1,0,0,,,,EXPIRED
349,GB,B,GB 2388600 B,058-437-442-921-971,2006-03-15,2006,GB 0308987 A,2003-04-17,EP 02008230 A,2002-04-18,Polymerisable compounds comprising a cinnamic acid group and an acetylene group,,MERCK PATENT GMBH,GREENFIELD SIMON;;HARDING RICHARD;;VAUGHAN-SPICKERS JULIAN;;SMITH ASHLEY;;HASSALL IAN;;DUNN CHRISTOPHER,,https://lens.org/058-437-442-921-971,Granted Patent,no,4,0,6,6,0,C07C69/734;;C07C69/736;;C07D213/55;;C09B69/109;;C09K19/18;;C07D213/55;;C09K19/0403;;C09K19/3405;;C09K19/3444;;C09K19/3461;;C09K19/3491;;C09K19/3497;;C09K2019/0407;;C09K2019/0444;;C09K2019/0448;;C09K2019/0459;;C09K2219/03,C07C69/734;;G02B5/30;;C07C69/017;;C07C69/736;;C07D213/55;;C08F20/10;;C09K19/04;;C09K19/18;;C09K19/20;;C09K19/28;;C09K19/32;;C09K19/34;;C09K19/38;;G02F1/13;;G02F1/1335;;H01L51/05;;H01L51/30,C2C CAA;;U1S S1346;;U1S S1387,0,0,,,,EXPIRED
350,NO,D0,NO 964761 D0,145-753-421-427-630,1996-11-08,1996,NO 964761 A,1996-11-08,GB 9500606 W;;GB 9409211 A;;GB 9501629 A;;GB 9504426 A,1994-05-10,Invalideheis,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/145-753-421-427-630,Patent Application,no,0,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
351,GB,A,GB 2388841 A,002-694-528-177-595,2003-11-26,2003,GB 0308990 A,2003-04-17,EP 02008231 A,2002-04-18,Polymerisable mesogenic or liquid crystalline compounds comprising an acetylene group and a heterocyclic group,"Polymerisable compounds of formula I in which P is a polymerisable group, Sp is a spacer group or a single bond, X, Z<1> and Z<2> are each independently various residues or a single bond, A<1> and A<2> are each independently aliphatic or aromatic, optionally substituted carbocyclic or heterocyclic groups, m1 and m2 are each independently 0, 1, 2, 3, 4 or 5 with m1+m2=1, 2, 3, 4 or 5 and R is H or one of various substituent groups, including a group X-Sp-P. The compounds contain at least one heterocyclic group A<1> or A<2>. Preferably, the polymerisable group P is a vinyl group, an acrylate group, a methacrylate group, a propenyl ether group or an epoxy group. The compounds may be mesogenic or liquid crystalline compounds and the compounds, or polymers thereof, have various uses including in liquid crystal displays, as electrode materials in batteries and in electrophotographic recording. <EMI ID=1.1 HE=9 WI=102 LX=637 LY=1365 TI=CF>",MERCK PATENT GMBH,GREENFIELD SIMON;;HARDING RICHARD;;VAUGHAN-SPICKERS JULIAN;;SMITH ASHLEY;;HASSALL IAN;;DUNN CHRISTOPHER,,https://lens.org/002-694-528-177-595,Patent Application,no,2,6,3,3,0,C07D213/30;;C07D307/68;;C07D333/38;;C07D213/30;;C07D307/68;;C07D333/38;;C09K19/3405;;C09K19/3411;;C09K19/3444;;C09K19/3461;;C09K19/3491;;C09K19/3497;;C09K2219/03,C07D213/30;;C07D307/68;;C07D333/38;;C09K19/34,C2C CAA;;U1S S1346;;U1S S1387,10,0,,,"CAPLUS Abstract Accession No. 2003:36481 & JP 2003012762 A;;CAPLUS Abstract Accession No. 2001:705631 & Liquid Crystals Volume 28, No. 9, 2001, pages 1361-1367;;CAPLUS Abstract Accession No. 2000:236119 & JP 2000103781 A;;CAPLUS Abstract Accession No. 1999:112403 & Liquid Crystals Volume 26, No. 2, 1999, pages 241-250;;CAPLUS Abstract Accession No. 1996:335958 & JP 08059521 A;;CAPLUS Abstract Accession No. 1995:969456 & JP 07206715 A;;CAPLUS Abstract Accession No. 1995:680663 & JP 06293689 A;;CAPLUS Abstract Accession No. 1995:406609 & JP 06312948 A;;CAPLUS Abstract Accession No. 1992:592371 & Front. Polym. Res., (Proc. Int. Conf.), 1st, 1991, pages 233-238;;CAPLUS Abstract Accession No. 1992:591860 & JP 04145072 A",EXPIRED
352,WO,A1,WO 1995/030399 A1,052-739-082-384-847,1995-11-16,1995,GB 9500605 W,1995-03-20,GB 9409212 A,1994-05-10,AN ACTUATING DEVICE,"An actuating device comprises a fixed circular or part circular gear (10), a holder (13) mounted for angular movement about the axis of the fixed gear, a movable part circular gear (14) slidably supported by the holder for movement into and out of engagement with the fixed gear, a spring (22) urging the movable gear into engagement with the fixed gear, and at least one operating member (24, 25) supported by the holder and movable relative thereto in one direction to initially disengage the movable gear from the fixed gear and to then angularly displace the holder relative to the fixed gear.",ARJO LTD;;DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/052-739-082-384-847,Patent Application,yes,4,0,7,7,0,A61G7/1017;;A61G7/1046;;A61G7/1067,A61G7/10,,0,0,,,,PENDING
353,AU,B2,AU 689556 B2,039-546-282-922-791,1998-04-02,1998,AU 1995/019008 A,1995-03-20,GB 9409211 A;;GB 9501629 A;;GB 9500606 W;;GB 9504426 A,1994-05-10,Invalid hoist,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,ARJO MED.AKTIEBOLAG LIMITED (2003-05-29),https://lens.org/039-546-282-922-791,Granted Patent,no,1,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
354,EP,B1,EP 0758878 B1,131-907-932-568-663,1998-05-13,1998,EP 95911437 A,1995-03-20,GB 9500606 W;;GB 9409211 A;;GB 9501629 A;;GB 9504426 A,1994-05-10,INVALID HOIST,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/131-907-932-568-663,Granted Patent,yes,9,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
355,ZA,B,ZA 952398 B,085-292-663-470-961,1995-12-18,1995,ZA 952398 A,1995-03-24,GB 9409211 A,1994-05-10,Invalid hoist,,ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/085-292-663-470-961,Granted Patent,no,0,0,2,40,0,,A61F/;;A61G/;;A61H/,,0,0,,,,EXPIRED
356,ZA,B,ZA 952399 B,093-654-293-986-826,1995-12-18,1995,ZA 952399 A,1995-03-24,GB 9409212 A,1994-05-10,An actuating device,,ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/093-654-293-986-826,Granted Patent,no,0,0,7,7,0,A61G7/1017;;A61G7/1046;;A61G7/1067,A61G7/10,,0,0,,,,EXPIRED
357,DK,T3,DK 0758878 T3,184-429-497-580-965,1998-10-07,1998,DK 95911437 T,1995-03-20,GB 9409211 A;;GB 9501629 A;;GB 9500606 W;;GB 9504426 A,1994-05-10,Handicapkran,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/184-429-497-580-965,Granted Patent,no,0,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,EXPIRED
358,GB,A,GB 2289259 A,028-119-640-450-451,1995-11-15,1995,GB 9504427 A,1995-03-06,GB 9409212 A,1994-05-10,An actuating device,"An actuating device comprises a fixed circular or part circular gear 10, a holder 13 mounted for angular movement about the axis of the fixed gear, a movable part circular gear 14 slidably supported by the holder for movement into and out of engagement with the fixed gear, a spring 22 urging the movable gear into engagement with the fixed gear, and at least one operating member 24, 25 supported by the holder and movable relative thereto in one direction to initially disengage the movable gear from the fixed gear and to thereafter angularly displace the holder relative to the fixed gear until released. Preferably two members 24, 25 are provided operating in opposite directions. Preferably the member(s) 24, 25 are foot operated. Preferably the mechanism is provided as part of an invalid hoist (Figs 3 - 5) moving its support legs (34). <IMAGE>",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/028-119-640-450-451,Patent Application,no,4,2,7,7,0,A61G7/1017;;A61G7/1046;;A61G7/1067,A61G7/10,B8H HEX           HEX;;B8H H323          HEX;;B8H H410          HEX;;F2E EU            EU;;F2Y YSL           SL;;F2Y Y3201         SL;;U1S S1872,0,0,,,,EXPIRED
359,GB,B,GB 2289457 B,151-431-342-724-202,1997-11-19,1997,GB 9504426 A,1995-03-06,GB 9409211 A;;GB 9501629 A;;GB 9504426 A,1994-05-10,Invalid hoist,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/151-431-342-724-202,Granted Patent,no,8,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,B8H HCB           HCB;;B8H H410          HCB;;B8H H553          HCB,0,0,,,,EXPIRED
360,ES,T3,ES 2553251 T3,026-914-781-385-817,2015-12-07,2015,ES 11755574 T,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,Sistema de diagnóstico,"Un sistema de diagnóstico compuesto desechable adaptado para sujetarse manualmente y que comprende un miembro (142) de soporte que tiene: un elemento (149) de penetración de membrana; un punto (156) de recogida de fluidos corporales colocado sobre el exterior del miembro de soporte para recoger un fluido corporal liberado por la aplicación del elemento de penetración de membrana en el cuerpo de un usuario; un material (162) de análisis colocado en una abertura dentro del miembro de soporte, de modo que en uso, el fluido corporal entre operativamente en contacto con el material (162) de análisis a través del punto (156) de recogida de fluidos corporales; un depósito (159) interno situado dentro del miembro (142) de soporte y adaptado para contener una solución fisiológicamente aceptable para su uso con el material (162) de análisis; y un accionador (160) de suministro de solución, en el que en uso, el accionamiento del accionador de suministro de solución haga que la solución fisiológicamente aceptable sea liberada del depósito (159) y entre en contacto con el material (162) de análisis después de que el fluido corporal se haya puesto en contacto con el material (162) de análisis.",ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN;;SIU ERIC;;NORCOTT ALISON;;DUNN CHRISTOPHER;;JOHNSON IAN;;HUESO ERNESTO;;SOKOLOV RICHARD,,https://lens.org/026-914-781-385-817,Granted Patent,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61B5/145;;A61B5/15;;A61B5/157;;A61J1/05;;B01L3/00,,0,0,,,,ACTIVE
361,EP,B1,EP 1676535 B1,064-520-795-551-595,2010-12-08,2010,EP 05258077 A,2005-12-28,US 90535104 A,2004-12-29,Surgical abrasive cutting system,,DEPUY MITEK INC,SENGUN MEHMET Z;;HENEBERRY ELIZABETH;;MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/064-520-795-551-595,Granted Patent,yes,6,1,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/16;;A61B17/32,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1998, no. 02, 30 January 1998 (1998-01-30) & JP 09 276292 A (HORIGUCHI SHOJI), 28 October 1997 (1997-10-28)",ACTIVE
362,DE,T2,DE 69610341 T2,066-056-358-933-305,2001-04-05,2001,DE 69610341 T,1996-01-30,GB 9501832 A,1995-01-31,3-D-Bildertexturierung und -schattierung,,IMAGINATION TECH LTD,FENNEY SIMON J;;OVERLIESE IAN J;;YASSAIE HOSSEIN;;DUNN MARK E;;LEABACK PETER D,,https://lens.org/066-056-358-933-305,Granted Patent,no,0,2,18,21,0,G06T15/04;;G06T15/04,G06T15/04,,0,0,,,,EXPIRED
363,DE,D1,DE 69610341 D1,017-479-935-081-366,2000-10-26,2000,DE 69610341 T,1996-01-30,GB 9501832 A,1995-01-31,3-D-Bildertexturierung und -schattierung,,IMAGINATION TECH LTD,FENNEY SIMON J;;OVERLIESE IAN J;;YASSAIE HOSSEIN;;DUNN MARK E;;LEABACK PETER D,,https://lens.org/017-479-935-081-366,Granted Patent,no,0,0,18,21,0,G06T15/04;;G06T15/04,G06T15/04,,0,0,,,,EXPIRED
364,AU,B2,AU 2005/229672 B2,048-738-844-229-351,2007-10-18,2007,AU 2005/229672 A,2005-11-02,US 90535104 A,2004-12-29,Abrasive cutting system and method,,DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;DUNN DOUGLAS W;;HENEBERRY ELIZABETH;;RANUCCI KEVIN J,,https://lens.org/048-738-844-229-351,Granted Patent,no,3,0,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/32,,0,0,,,,INACTIVE
365,WO,A1,WO 2022/046268 A1,095-683-167-667-918,2022-03-03,2022,US 2021/0038805 W,2021-06-24,US 202063071158 P,2020-08-27,MEDICAL DEVICE DIAGNOSTICS AND ALERTING,Methods and systems for medical device diagnostics and reporting. One system including an electronic processor configured to receive a new medical device dataset associated with a medical device. The electronic processor is also configured to determine an operation classification of the medical device using a model utilizing training information. The training information includes a plurality of archived medical device datasets and an associated operation classification for each of the plurality of archived medical device datasets. The electronic processor is also configured determine an operation status of the medical device based on the operation classification. The electronic processor is also configured to generate and provide a notification based on at least the operation status of the medical device.,UNIV NEBRASKA,REDWOOD WILLIAM;;DUNN JEFF;;HESTER RILEY;;TRENT IAN;;WRIGHT ERIC;;MILLER BRAD;;TAUIL ORLY,,https://lens.org/095-683-167-667-918,Patent Application,yes,4,1,2,2,0,A61B2560/0276;;G06F11/3013;;G06F11/3058;;G06F11/3476;;G06F21/554;;G16H40/40,A61B5/276;;G01R31/00;;G01R31/28,,1,0,,,"MAHLER ET AL.: ""Know Your Enemy: Characteristics of Cyber-Attacks on Medical Imaging Devices"", RSNA CONFERENCE, 2017, XP081218798, Retrieved from the Internet <URL:https://arxiv.org/ftp/arxiv/papers/1801/1801.05583.pdf> [retrieved on 20210914]",PENDING
366,EP,B1,EP 0725366 B1,133-090-714-107-294,2000-09-20,2000,EP 96300622 A,1996-01-30,GB 9501832 A,1995-01-31,Texturing and shading 3-D images,,IMAGINATION TECHNOLOGIES LIMIT,FENNEY SIMON J;;OVERLIESE IAN J;;YASSAIE HOSSEIN;;DUNN MARK E;;LEABACK PETER D,IMAGINATION TECHNOLOGIES LIMITED (1999-11-24),https://lens.org/133-090-714-107-294,Granted Patent,yes,3,2,18,21,0,G06T15/04;;G06T15/04,G06T15/04,,0,0,,,,EXPIRED
367,EP,A2,EP 0725366 A2,118-923-079-252-096,1996-08-07,1996,EP 96300622 A,1996-01-30,GB 9501832 A,1995-01-31,Texturing and shading 3-D images,"A 3 dimensional image is textured for display on a screen by firstly receiving data comprising the location of each elementary area (pixel) of the screen and associated image data for that pixel. Texture image data is retrieved from a memory means in dependence on the image data and an appropriate portion of that texture image data is mapped onto the pixel. The number of pixels which share the same associated image data is determined and an incremental change in the mapping of the texture data onto pixels corresponding to a one pixel increment is also determined. For each pixel sharing the same image data as an adjacent pixel the previously derived texture image data for that adjacent pixel is combined with the incremental change in texture image data to thereby derive texture image data for that pixel. An arithmetic division for implementation using hardware or software is performed by firstly storing the reciprocal of each nth value in a range 0 to X where n is greater than 1 and storing the differences between the reciprocals of the intervening n-1 values. A mantissa and an operand for an arithmetic division are received. One of the stored reciprocals is retrieved in response to the most significant part of the received mantissa and a set of differences is retrieved in response to a least significant part of the received mantissa. The differences and the reciprocal are summed and the result is multiplied by the received operand, thereby giving the result of the arithmetic division.",VIDEOLOGIC LTD,FENNEY SIMON J;;OVERLIESE IAN J;;YASSAIE HOSSEIN;;DUNN MARK E;;LEABACK PETER D,IMAGINATION TECHNOLOGIES LIMITED (1999-11-24),https://lens.org/118-923-079-252-096,Patent Application,yes,0,7,18,21,0,G06T15/04;;G06T15/04,G06T15/04,,0,0,,,,EXPIRED
368,ES,T7,ES 2553251 T7,159-641-493-947-194,2018-04-26,2018,ES 11755574 T,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,Sistema de diagnóstico,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN;;SIU ERIC;;NORCOTT ALISON;;DUNN CHRISTOPHER;;JOHNSON IAN;;HUESO ERNESTO;;SOKOLOV RICHARD,,https://lens.org/159-641-493-947-194,Unknown,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61B5/145;;A61B5/15;;A61B5/157;;A61J1/05;;B01L3/00,,0,0,,,,ACTIVE
369,CA,C,CA 2529260 C,047-134-247-479-279,2010-02-16,2010,CA 2529260 A,2005-12-06,US 90535104 A,2004-12-29,ABRASIVE CUTTING SYSTEM AND METHOD,"A high pressure fluid jet system is provided, which is useful for cutting hard material during a surgical procedure. The cutting of hard material is more efficient as the system delivers abrasive solid particles with the high pressure fluid. In an exemplary embodiment, abrasive solid particles can be mixed with a pressurized stream of fluid prior to delivery of the fluid to a nozzle of an application tool. Alternatively, the abrasive solid particles can be entrained in the pressurized fluid stream or the pressurized fluid stream can erode a solid or suspension form of the abrasive particles.",DEPUY MITEK INC,SENGUN MEHMET Z;;HENEBERRY ELIZABETH;;MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/047-134-247-479-279,Granted Patent,no,0,0,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/3203;;B24C5/02,,0,0,,,,INACTIVE
370,CA,A1,CA 2529260 A1,158-017-175-370-021,2006-06-29,2006,CA 2529260 A,2005-12-06,US 90535104 A,2004-12-29,ABRASIVE CUTTING SYSTEM AND METHOD,"A high pressure fluid jet system is provided, which is useful for cutting ha rd material during a surgical procedure. The cutting of hard material is more efficient as the system delivers abrasive solid particles with the high pressure fluid. I n an exemplary embodiment, abrasive solid particles can be mixed with a pressurized stream of fluid prior to delivery of the fluid to a nozzle of an application tool. Alternatively, the abrasive solid particles can be entrained in the pressurized fluid stream or the pressurized fluid stream can erode a solid or suspension form of the abrasiv e particles.",DEPUY MITEK INC,HENEBERRY ELIZABETH;;SENGUN MEHMET Z;;RANUCCI KEVIN J;;MCRURY IAN D;;DUNN DOUGLAS W,,https://lens.org/158-017-175-370-021,Patent Application,no,0,0,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/3203;;B24C5/02,,0,0,,,,INACTIVE
371,GB,B,GB 2338096 B,166-327-431-948-771,2000-02-02,2000,GB 9918186 A,1996-01-31,GB 9918186 A;;GB 9601965 A;;GB 9501832 A,1995-01-31,Texturing and shading of 3D images,,VIDEOLOGIC LTD;;IMAGINATION TECHNOLOGIES LIMIT,FENNY SIMON JAMES;;DUNN MARK EDWARD;;OVERLIESE IAN JAMES;;LEABACK PETER DAVID;;YASSAIE HOSSEIN,,https://lens.org/166-327-431-948-771,Granted Patent,no,1,0,3,21,0,G06T15/04,G06T15/04,G4A AMD           AMD,0,0,,,,EXPIRED
372,EP,A1,EP 1676535 A1,030-299-743-367-362,2006-07-05,2006,EP 05258077 A,2005-12-28,US 90535104 A,2004-12-29,Surgical abrasive cutting system,"A high pressure fluid jet system is provided, which is useful for cutting hard material during a surgical procedure. The cutting of hard material is more efficient as the system delivers abrasive solid particles with the high pressure fluid. In an exemplary embodiment, abrasive solid particles can be mixed with a pressurized stream of fluid prior to delivery of the fluid to a nozzle of an application tool. Alternatively, the abrasive solid particles can be entrained in the pressurized fluid stream or the pressurized fluid stream can erode a solid or suspension form of the abrasive particles.",DEPUY MITEK INC,SENGUN MEHMET Z;;HENEBERRY ELIZABETH;;MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/030-299-743-367-362,Patent Application,yes,24,5,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/16;;A61B17/32,,7,1,017-981-821-130-59X,10.1002/jbm.820221104;;3241012,"PATENT ABSTRACTS OF JAPAN vol. 1998, no. 02 30 January 1998 (1998-01-30);;KEMNITZER; KOHN: ""HANDBOOK OF BIODEGRADABLE POLYMERS"", 1997, HARDWOOD ACADEMIC PRESS, pages: 251 - 272;;COHN; YOUNES, JOURNAL OF BIOMATERIALS RESEARCH, vol. 22, 1988, pages 993 - 1009;;COHN, POLYMER PREPRINTS (ACS DIVISION OF POLYMER CHEMISTRY, vol. 30, no. 1, 1989, pages 498;;ALLCOCK: ""THE ENCYCLOPEDIA OF POLYMER SCIENCE"", vol. 13, 1988, WILEY INTERSCIENCES, JOHN WILEY & SONS, pages: 31 - 41;;VANDORPE: ""HANDBOOK OF BIODEGRADABLE POLYMERS"", 1997, HARDWOOD ACADEMIC PRESS, pages: 161 - 182;;HELLER: ""HANDBOOK OF BIODEGRADABLE POLYMERS"", 1997, HARDWOOD ACADEMIC PRESS, pages: 99 - 118",ACTIVE
373,GB,A,GB 2338096 A,135-714-494-709-730,1999-12-08,1999,GB 9918186 A,1996-01-31,GB 9918186 A;;GB 9601965 A;;GB 9501832 A,1995-01-31,Arithmetic division method,"An arithmetic division for implementation using hardware or software is performed by firstly storing the reciprocal of each nth value in a range 0 to X where n is greater than 1 and storing the differences between the reciprocals of the intervening n-1 values. A mantissa and an operand for an arithmetic division are received. One of the stored reciprocals is retrieved in response to the most significant part of the received mantissa and a set of differences is retrieved in response to a least significant part of the received mantissa. The differences and the reciprocal are summed and the result is multiplied by the received operand, thereby giving the result of the arithmetic division.",VIDEOLOGIC LTD,FENNY SIMON JAMES;;DUNN MARK EDWARD;;OVERLIESE IAN JAMES;;LEABACK PETER DAVID;;YASSAIE HOSSEIN,,https://lens.org/135-714-494-709-730,Patent Application,no,1,0,3,21,0,G06T15/04,G06T15/04,G4A AMD           AMD,0,0,,,,EXPIRED
374,GB,A,GB 2297886 A,192-533-584-565-608,1996-08-14,1996,GB 9601965 A,1996-01-31,GB 9501832 A,1995-01-31,TEXTURING AND SHADING OF 3-D IMAGES,,VIDEOLOGIC LTD,FENNY SIMON JAMES;;DUNN MARK EDWARD;;OVERLIESE IAN JAMES;;LEABACK PETER DAVID;;YASSAIE HOSSEIN,,https://lens.org/192-533-584-565-608,Patent Application,no,3,0,18,21,0,G06T15/04;;G06T15/04,G06T15/04,H4T TBEC          TBEC,0,0,,,,EXPIRED
375,US,B1,US 6313846 B1,094-218-311-434-052,2001-11-06,2001,US 5056498 A,1998-03-30,US 5056498 A;;GB 9501832 A;;US 92895597 A;;US 59364996 A,1995-01-31,Texturing and shading of 3-D images,A three dimensional image is textured for display on a screen by firstly receiving data comprising the location of each elementary area (pixel) of the screen and associated image data for that pixel. Texture image data is retrieved from a memory means in dependence on the image data and an appropriate portion of that texture image data is mapped onto the pixel. The number of pixels which share the same associated image data is determined and an incremental change in the mapping of the texture data onto pixels corresponding to a one pixel increment is also determined. For each pixel sharing the same image data as an adjacent pixel the previously derived texture image data for that adjacent pixel is combined with the incremental change in texture image data to thereby derive texture image data for that pixel.,IMAGINATION TECH LTD,FENNEY SIMON JAMES;;DUNN MARK EDWARD;;OVERLIESE IAN JAMES;;LEABACK PETER DAVID;;YASSAIE HOSSEIN,IMAGINATION TECHNOLOGIES LIMITED (1999-10-27),https://lens.org/094-218-311-434-052,Granted Patent,yes,17,54,18,21,0,G06T15/04;;G06T15/04,G06T15/04,345/552,3,1,177-701-364-923-529,10.1145/964967.801126,"Pyramidal Parametrics, L. Williams, Computer Graphics Lab., vol. 17, No. 3, Jul. 1983 (1 page).;;Foley et al ""Computer Graphics Principles and Practice"" pp. 890-893 (1990).;;Foley et al Computer Graphics Principles and Practice pp 890-893 (1990).",EXPIRED
376,ES,T3,ES 2153077 T3,103-476-231-311-059,2001-02-16,2001,ES 96300622 T,1996-01-30,GB 9501832 A,1995-01-31,TEXTURIZACION Y SOMBREADO DE IMAGENES TRIDIMENSIONALES.,"UNA IMAGEN TRIDIMENSIONAL SE ORGANIZA PARA VISUALIZACION EN UNA PANTALLA EN PRIMER LUGAR RECIBIENDO DATOS QUE COMPRENDEN LA LOCALIZACION DE CADA AREA ELEMENTAL (PIXEL) DE LA PANTALLA Y DATOS DE IMAGEN ASOCIADOS A ESE PIXEL. LOS DATOS DE IMAGEN DE ORGANIZACION SE RECUPERAN DE UN ELEMENTO DE MEMORIA DEPENDIENDO DE LOS DATOS DE IMAGEN Y UNA PORCION APROPIADA DE ESOS DATOS DE IMAGEN DE ORGANIZACION SE REPRESENTA EN EL PIXEL. EL NUMERO DE PIXELS QUE COMPARTE LOS MISMOS DATOS DE IMAGEN ASOCIADA ES DETERMINADO Y UN CAMBIO EN EL INCREMENTO DE LA REPRESENTACION DE LOS DATOS DE ORGANIZACION EN PIXELS CORRESPONDIENTES A UN INCREMENTO DE PIXEL ES TAMBIEN DETERMINADO. PARA CADA PIXEL QUE COMPARTE LOS MISMOS DATOS DE IMAGEN COMO UN PIXEL ADYACENTE LOS DATOS DE IMAGEN DE ORGANIZACION PREVIAMENTE DERIVADOS PARA ESE PIXEL ADYACENTE ES COMBINADO CON EL CAMBIO EN EL INCREMENTO DE LOS DATOS DE IMAGEN DE ORGANIZACION PARA ASI DERIVAR LOS DATOS DE IMAGEN DE ORGANIZACION DE ESE PIXEL. UNA DIVISION ARITMETICA PARAIMPLEMENTACION QUE UTILIZA HARDWARE O SOFTWARE SE LLEVA A CABO EN PRIMER LUGAR ALMACENANDO EL RECIPROCO DE CADA VALOR N EN UN RANGO DE 0 A X DONDE N ES SUPERIOR A 1 Y ALMACENANDO LAS DIFERENCIAS ENTRE LOS RECIPROCOS DE LOS VALORES N-1 QUE INTERVIENEN. SE RECIBEN UNA MANTISA Y UN OPERANDO PARA UNA DIVISION ARITMETICA. UNO DE LOS RECIPROCOS ALMACENADOS ES RECUPERADO EN RESPUESTA A LA PARTE MAS IMPORTANTE DE LA MANTISA RECIBIDA Y UN CONJUNTO DE DIFERENCIAS ES RECUPERADA EN RESPUESTA A UNA PARTE MENOS IMPORTANTE DE LA MANTISA RECIBIDA. LAS DIFERENCIAS Y EL RECIPROCO SE SUMAN Y EL RESULTADO ES MULTIPLICADO POR EL OPERANDO RECIBIDO, PROPORCIONANDO ASI EL RESULTADO DE LA DIVISION ARITMETICA.",IMAGINATION TECH LTD,FENNEY SIMON J;;OVERLIESE IAN J;;YASSAIE HOSSEIN;;DUNN MARK E;;LEABACK PETER D,,https://lens.org/103-476-231-311-059,Granted Patent,no,0,0,18,21,0,G06T15/04;;G06T15/04,G06T15/04,,0,0,,,,EXPIRED
377,AU,A1,AU 2005/229672 A1,151-523-356-296-550,2006-07-13,2006,AU 2005/229672 A,2005-11-02,US 90535104 A,2004-12-29,Abrasive cutting system and method,,DEPUY MITEK INC,MCRURY IAN D;;SENGUN MEHMET Z;;DUNN DOUGLAS W;;HENEBERRY ELIZABETH;;RANUCCI KEVIN J,,https://lens.org/151-523-356-296-550,Patent Application,no,0,0,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/32,,0,0,,,,INACTIVE
378,US,B1,US 6330000 B1,045-516-037-402-864,2001-12-11,2001,US 92895597 A,1997-09-12,US 92895597 A;;GB 9501832 A;;US 59364996 A,1995-01-31,Method and apparatus for performing arithmetic division with a machine,"An arithmetic division for implementation using hardware or software is performed by firstly storing the reciprocal of each nth value in a range 0 to X where n is greater than 1 and storing the differences between the reciprocals of the intervening n-1 values. A mantissa and an operand for an arithmetic division are received. one of the stored reciprocals is retrieved in response to the most significant part of the received mantissa and a set of differences is retrieved in response to a least significant part of the received mantissa. The differences and the reciprocal are summed and the result is multiplied by the received operand, other thereby giving the result of the arithmetic division.",IMAGINATION TECH LTD,FENNEY SIMON JAMES;;DUNN MARK EDWARD;;OVERLIESE IAN JAMES;;LEABACK PETER DAVID;;YASSAIE HOSSEIN,IMAGINATION TECHNOLOGIES LIMITED (1999-10-27),https://lens.org/045-516-037-402-864,Granted Patent,yes,16,47,18,21,0,G06T15/04;;G06T15/04,G06T15/04,345/586;;708/654,2,1,177-701-364-923-529,10.1145/964967.801126,"Pyramidal Parametrics, L. Williams, Computer Graphics Lab., vol. 17, No. 3, Jul. 1983 (1 page).;;Foley et al ""Computer Graphics Principles and Practice"" pp. 890-893 (1990).",EXPIRED
379,DE,D1,DE 602005025192 D1,048-129-647-634-960,2011-01-20,2011,DE 602005025192 T,2005-12-28,US 90535104 A,2004-12-29,Chirurgisches Abrasivstrahlschneidsystem,,DEPUY MITEK INC,SENGUN MEHMET Z;;HENEBERRY ELIZABETH;;MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/048-129-647-634-960,Granted Patent,no,0,0,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/16;;A61B17/32,,0,0,,,,ACTIVE
380,JP,A,JP 2008112468 A,041-079-317-023-174,2008-05-15,2008,JP 2008012767 A,2008-01-23,GB 9501832 A,1995-01-31,TEXTURING AND SHADING OF 3D IMAGE,"<P>PROBLEM TO BE SOLVED: To provide a method for texturing and shading a three-dimensional image for display on a screen. <P>SOLUTION: A three dimensional image is textured for display on a screen by firstly receiving data comprising the location of each elementary area (pixel) of the screen and associated image data for that pixel. Texture image data is retrieved from a memory means in dependence on the image data and an appropriate portion of that texture image data is mapped onto the pixel. The number of pixels which share the same associated image data is determined and an incremental change in the mapping of the texture data onto pixels corresponding to a one pixel increment is also determined. For each pixel sharing the same image data as an adjacent pixel the previously derived texture image data for that adjacent pixel is combined with the incremental change in texture image data to thereby derive texture image data for that pixel. <P>COPYRIGHT: (C)2008,JPO&INPIT",IMAGINATION TECH LTD,FENNEY SIMON JAMES;;DUNN MARK EDWARD;;OVERLIESE IAN JAMES;;LEABACK PETER DAVID;;YASSAIE HOSSEIN,,https://lens.org/041-079-317-023-174,Patent Application,no,0,0,18,21,0,G06T15/04;;G06T15/04,G06T15/04,,0,0,,,,INACTIVE
381,US,A1,US 2011/0118645 A1,144-299-088-868-585,2011-05-19,2011,US 80951808 A,2008-12-12,GB 0725087 A;;GB 2008004115 W,2007-12-21,Wound Dressing Applicator,"A wound dressing applicator ( 10 ) for applying hydrocolloid dressings, compositions for tissue regeneration and the like to a patient's skin. Known wound dressing applicators do not effectively protect against contamination of the wound dressing and/or can be fiddly and difficult to operate and be rendered unusable by unwanted premature separation of the various layers of material adhered to one another. The present applicator comprises a rigid body ( 20 ) having a rigid body enclosure ( 30 ) for receiving a wound dressing, and an ejector ( 40 ) for ejecting the wound dressing from the rigid body enclosure and onto a patient's wound. This enables effective and aseptic handling of a wound dressing and application of the wound dressing onto a patient's wound.",DFB TECHNOLOGY HOLDINGS LLC,DERA IAN;;SCOUTAS DIMITRIOS;;HANNANT MATTHEW;;MAISEY GRAEME;;DUNN PHILIP;;SANDBANK BARRY;;JASSAL SUSHMA,SMITH & NEPHEW INC (2012-12-21);;HEALTHPOINT INTERNATIONAL LLC (2011-12-29),https://lens.org/144-299-088-868-585,Patent Application,yes,13,0,5,6,0,A61F15/001;;A61F15/005;;A61F15/001;;A61F15/001;;A61F15/005;;A61F15/005,A61L15/44;;B65D83/08,602/48;;221/279,0,0,,,,INACTIVE
382,US,B2,US 8425517 B2,093-048-258-336-14X,2013-04-23,2013,US 201113188983 A,2011-07-22,US 201113188983 A;;US 90535104 A,2004-12-29,Abrasive cutting system and method,"A high pressure fluid jet system is provided, which is useful for cutting hard material during a surgical procedure. The cutting of hard material is more efficient as the system delivers abrasive solid particles with the high pressure fluid. A method of effecting cutting during a surgical procedure is also provided. In an exemplary embodiment, a surgical tool that is effective to deliver a pressurized stream of fluid through a nozzle is provided, and the pressurized stream of fluid is delivered through the surgical tool and out of the nozzle to hard material within a patient to effect cutting of the hard material within the patient in a desired pattern. The fluid that cuts the hard material can include a delivery liquid having a plurality of abrasive solid particles that are formed from an organic material. The abrasive solid particles can be entrained in the pressurized fluid stream or the pressurized fluid stream can erode a solid or suspension form of the abrasive particles.",SENGUN MEHMET Z;;HENEBERRY ELIZABETH;;MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W;;DEPUY MITEK INC,SENGUN MEHMET Z;;HENEBERRY ELIZABETH;;MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/093-048-258-336-14X,Granted Patent,yes,41,1,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/00,606/79,6,1,017-981-821-130-59X,10.1002/jbm.820221104;;3241012,"Allcock, The Encyclopedia of Polymer Science, vol. 13, pp. 31-41, Wiley Intersciences, John Wiley & Sons, 1988.;;Cohn and Younes, Journal of Biomaterials Research, vol. 22, pp. 993-1009, 1988.;;Cohn, Polymer Preprints (ACS Division of Polymer Chemistry), vol. 30(1), p. 498, 1989 (e.g., PEO/PLA).;;Heller, Handbook of Biodegradable Polymers, edited by Domb, et al., Hardwood Academic Press, pp. 99-118 (1997).;;Kemnitzer and Kohn, Handbook of Biodegradable Polymers, edited by Domb, et. al., Hardwood Academic Press, pp. 251-272 (1997).;;Vandorpe, et al., Handbook of Biodegradable Polymers, edited by Domb, et al., Hardwood Academic Press, pp. 161-182 (1997).",INACTIVE
383,JP,A,JP 2007213621 A,165-212-015-607-349,2007-08-23,2007,JP 2007140603 A,2007-05-28,GB 9501832 A,1995-01-31,TEXTURING AND SHADING METHOD OF 3-D IMAGE,"<P>PROBLEM TO BE SOLVED: To provide a texturing and shading method of a three-dimensional image such that it is displayed on a screen. <P>SOLUTION: The three-dimensional image is textured for display on the screen by firstly receiving data comprising the location of each elementary area (pixel) of the screen and associated image data for that pixel. Texture image data are retrieved from a memory means in dependence on the image data and an appropriate portion of that texture image data is mapped onto the pixel. The number of pixels which share the same associated image data is determined and an incremental change in the mapping of the texture data onto pixels corresponding to a one pixel increment is also determined. For each pixel sharing the same image data as an adjacent pixel, the previously derived texture image data for that adjacent pixel is combined with the incremental change in texture image data to thereby derive texture image data for that pixel. <P>COPYRIGHT: (C)2007,JPO&INPIT",IMAGINATION TECH LTD,FENNEY SIMON JAMES;;DUNN MARK EDWARD;;OVERLIESE IAN JAMES;;LEABACK PETER DAVID;;YASSAIE HOSSEIN,,https://lens.org/165-212-015-607-349,Patent Application,no,0,0,18,21,0,G06T15/04;;G06T15/04,G06T15/04,,0,0,,,,PENDING
384,US,S,US D0960807 S,070-333-713-136-413,2022-08-16,2022,US 202129765479 F,2021-01-08,US 202129765479 F,2021-01-08,Door for an off-road vehicle,,POLARIS INC,BIYANI AKSHAY A;;DUNN IAN M;;LUTZ DENNIS;;OLSON CHARLES J;;BALTES ALEX M,POLARIS INDUSTRIES INC (2021-01-11),https://lens.org/070-333-713-136-413,Design Right,no,61,3,6,6,0,,,1216;;D12/196,0,0,,,,ACTIVE
385,JP,A,JP 2004103039 A,138-208-114-019-795,2004-04-02,2004,JP 2003389383 A,2003-11-19,GB 9501832 A,1995-01-31,TEXTURE TREATMENT AND SHADING METHOD FOR 3D IMAGE,"<P>PROBLEM TO BE SOLVED: To provide a method for applying a texture treatment to a three-dimensional image and for shading it so as to display it on a screen. <P>SOLUTION: The three-dimensional image is subjected to the texture treatment so as to be displayed on the screen by first receiving data including positions of each picture element area (pixel) on the screen and image data related to the pixel. Texture image data are retrieved from a memory means based on the image data and the appropriate positions for mapping the texture image data on the pixel. The number of pixels sharing the same relating image data is determined, and increment variation of mapping of the texture data on the pixels corresponding to one pixel increment is determined. In the case of each pixel sharing the same image data as adjacent pixel, the texture image data already derived about the adjacent pixel is combined with the incremental change of the texture image data to derive the texture image data for the pixel. <P>COPYRIGHT: (C)2004,JPO",IMAGINATION TECH LTD,FENNEY SIMON JAMES;;DUNN MARK EDWARD;;OVERLIESE IAN JAMES;;LEABACK PETER DAVID;;YASSAIE HOSSEIN,,https://lens.org/138-208-114-019-795,Patent Application,no,0,1,18,21,0,G06T15/04;;G06T15/04,G06T15/04,,0,0,,,,PENDING
386,GB,A,GB 2457870 A,148-573-872-998-900,2009-09-02,2009,GB 0725087 A,2007-12-21,GB 0725087 A,2007-12-21,Wound Dressing Applicator,"The applicator comprises a rigid body 20 having a rigid body enclosure 30 for receiving a wound dressing, and an ejector 40 for ejecting the wound dressing from the rigid body enclosure and onto a patient's wound. This enables effective and aseptic handling of a wound dressing and application of the wound dressing onto a patient's wound. The ejector may be a biased lever coupled to the body. In use the rigid enclosure holds a moist dressing, such as a hydrocolloid dressing, and the ejector breaks a seal between the dressing and the applicator.",INTERCYTEX LTD,DERA IAN;;SCOUTAS DIMITRIOS;;HANNANT MATTHEW;;MAISEY GRAEME;;DUNN PHILIP;;SANDBANK BARRY;;JASSAL SUSHMA,,https://lens.org/148-573-872-998-900,Patent Application,no,2,1,5,6,0,A61F15/001;;A61F15/005;;A61F15/001;;A61F15/001;;A61F15/005;;A61F15/005,A61F15/00,,0,0,,,,DISCONTINUED
387,WO,A1,WO 2009/081096 A1,005-334-823-827-01X,2009-07-02,2009,GB 2008004115 W,2008-12-12,GB 0725087 A,2007-12-21,WOUND DRESSING APPLICATOR,"A wound dressing applicator (10) for applying hydrocolloid dressings, compositions for tissue regeneration and the like to a patient's skin. Known wound dressing applicators do not effectively protect against contamination of the wound dressing and/or can be fiddly and difficult to operate and be rendered unusable by unwanted premature separation of the various layers of material adhered to one another. The present applicator comprises a rigid body (20) having a rigid body enclosure (30) for receiving a wound dressing, and an ejector (40) for ejecting the wound dressing from the rigid body enclosure and onto a patient's wound. This enables effective and aseptic handling of a wound dressing and application of the wound dressing onto a patient's wound.",INTERCYTEX LTD;;DERA IAN;;SCOUTAS DIMITRIOS;;HANNANT MATTHEW;;MAISEY GRAEME;;DUNN PHILIP;;SANDBANK BARRY;;JASSAL SUSHMA,DERA IAN;;SCOUTAS DIMITRIOS;;HANNANT MATTHEW;;MAISEY GRAEME;;DUNN PHILIP;;SANDBANK BARRY;;JASSAL SUSHMA,,https://lens.org/005-334-823-827-01X,Patent Application,yes,7,0,5,6,0,A61F15/001;;A61F15/005;;A61F15/001;;A61F15/001;;A61F15/005;;A61F15/005,A61F15/00,,0,0,,,,PENDING
388,GB,B,GB 2297886 B,034-817-703-866-282,2000-02-02,2000,GB 9601965 A,1996-01-31,GB 9501832 A,1995-01-31,Texturing and shading of 3D images,,VIDEOLOGIC LTD;;IMAGINATION TECHNOLOGIES LIMIT,FENNY SIMON JAMES;;DUNN MARK EDWARD;;OVERLIESE IAN JAMES;;LEABACK PETER DAVID;;YASSAIE HOSSEIN,,https://lens.org/034-817-703-866-282,Granted Patent,no,3,0,18,21,0,G06T15/04;;G06T15/04,G06T15/04,H4T TBEC          TBEC,0,0,,,,EXPIRED
389,US,A1,US 2012/0029519 A1,134-883-932-645-193,2012-02-02,2012,US 201113188983 A,2011-07-22,US 201113188983 A;;US 90535104 A,2004-12-29,ABRASIVE CUTTING SYSTEM AND METHOD,"A high pressure fluid jet system is provided, which is useful for cutting hard material during a surgical procedure. The cutting of hard material is more efficient as the system delivers abrasive solid particles with the high pressure fluid. A method of effecting cutting during a surgical procedure is also provided. In an exemplary embodiment, a surgical tool that is effective to deliver a pressurized stream of fluid through a nozzle is provided, and the pressurized stream of fluid is delivered through the surgical tool and out of the nozzle to hard material within a patient to effect cutting of the hard material within the patient in a desired pattern. The fluid that cuts the hard material can include a delivery liquid having a plurality of abrasive solid particles that are formed from an organic material. The abrasive solid particles can be entrained in the pressurized fluid stream or the pressurized fluid stream can erode a solid or suspension form of the abrasive particles.",SENGUN MEHMET Z;;HENEBERRY ELIZABETH;;MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W,SENGUN MEHMET Z;;HENEBERRY ELIZABETH;;MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W,,https://lens.org/134-883-932-645-193,Patent Application,yes,2,8,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/3203;;A61B17/56,606/79;;606/96,0,0,,,,INACTIVE
390,EP,A3,EP 0725366 A3,177-095-293-306-090,1996-11-06,1996,EP 96300622 A,1996-01-30,GB 9501832 A,1995-01-31,Texturing and shading 3-D images,"A 3 dimensional image is textured for display on a screen by firstly receiving data comprising the location of each elementary area (pixel) of the screen and associated image data for that pixel. Texture image data is retrieved from a memory means in dependence on the image data and an appropriate portion of that texture image data is mapped onto the pixel. The number of pixels which share the same associated image data is determined and an incremental change in the mapping of the texture data onto pixels corresponding to a one pixel increment is also determined. For each pixel sharing the same image data as an adjacent pixel the previously derived texture image data for that adjacent pixel is combined with the incremental change in texture image data to thereby derive texture image data for that pixel. An arithmetic division for implementation using hardware or software is performed by firstly storing the reciprocal of each nth value in a range 0 to X where n is greater than 1 and storing the differences between the reciprocals of the intervening n-1 values. A mantissa and an operand for an arithmetic division are received. One of the stored reciprocals is retrieved in response to the most significant part of the received mantissa and a set of differences is retrieved in response to a least significant part of the received mantissa. The differences and the reciprocal are summed and the result is multiplied by the received operand, thereby giving the result of the arithmetic division.",VIDEOLOGIC LTD,FENNEY SIMON J;;OVERLIESE IAN J;;YASSAIE HOSSEIN;;DUNN MARK E;;LEABACK PETER D,IMAGINATION TECHNOLOGIES LIMITED (1999-11-24),https://lens.org/177-095-293-306-090,Search Report,yes,3,0,18,21,0,G06T15/04;;G06T15/04,G06T15/04,,0,0,,,,EXPIRED
391,US,A1,US 2006/0142773 A1,074-333-399-134-262,2006-06-29,2006,US 90535104 A,2004-12-29,US 90535104 A,2004-12-29,ABRASIVE CUTTING SYSTEM AND METHOD,"A high pressure fluid jet system is provided, which is useful for cutting hard material during a surgical procedure. The cutting of hard material is more efficient as the system delivers abrasive solid particles with the high pressure fluid. In an exemplary embodiment, abrasive solid particles can be mixed with a pressurized stream of fluid prior to delivery of the fluid to a nozzle of an application tool. Alternatively, the abrasive solid particles can be entrained in the pressurized fluid stream or the pressurized fluid stream can erode a solid or suspension form of the abrasive particles.",DEPUY MITEK INC,SENGUN MEHMET Z;;HENEBERRY ELIZABETH;;MCRURY IAN D;;RANUCCI KEVIN J;;DUNN DOUGLAS W,DEPUY MITEK INC (2004-12-21),https://lens.org/074-333-399-134-262,Patent Application,yes,10,4,12,12,0,A61B17/3203;;A61B17/3203;;A61B17/1644;;A61B17/1644;;A61B17/32037;;A61B17/32037;;A61B2017/1648;;A61B2017/1648,A61B17/16,606/79;;606/167,0,0,,,,DISCONTINUED
392,US,B2,US 9303073 B2,000-387-459-511-429,2016-04-05,2016,US 201314078390 A,2013-11-12,US 201314078390 A;;US 201113107796 A;;US 33490110 P,2010-05-14,Chimeric OspA proteins and methods of use thereof,"The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.",BAXALTA INC;;BAXALTA GMBH;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,BAXTER HEALTHCARE SA (2011-05-20);;BAXALTA INCORPORATED (2015-08-11);;BAXALTA GMBH (2015-08-11);;BAXTER INTERNATIONAL INC (2011-05-20);;RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (2012-01-31);;BROOKHAVEN SCIENCE ASSOCIATES LLC (2011-06-10),https://lens.org/000-387-459-511-429,Granted Patent,yes,48,0,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C07K14/20;;A61K39/02,,66,63,056-201-471-905-934;;027-829-588-585-761;;023-730-857-866-719;;104-921-466-213-292;;102-662-593-894-426;;054-732-712-502-061;;010-519-409-512-153;;029-611-134-469-353;;160-840-803-687-381;;029-683-169-457-195;;066-141-497-990-023;;115-303-705-496-498;;025-189-084-402-882;;030-839-409-040-828;;014-935-196-346-195;;096-611-689-245-37X;;012-830-491-824-205;;003-323-279-619-527;;129-466-277-652-523;;072-366-322-919-406;;007-542-078-714-566;;011-820-307-395-282;;023-907-179-348-058;;032-071-991-081-664;;055-792-532-851-126;;081-525-182-466-362;;057-200-638-752-266;;000-150-741-285-140;;006-574-964-805-278;;019-779-601-634-917;;006-742-514-479-110;;106-753-778-592-300;;035-616-782-811-647;;048-564-471-521-204;;003-430-460-951-798;;029-026-124-030-198;;065-101-341-902-59X;;003-448-860-121-684;;060-196-670-596-725;;020-855-322-534-259;;026-944-353-804-488;;030-607-398-087-475;;032-728-154-591-070;;111-109-974-501-414;;101-242-387-154-198;;066-525-457-224-28X;;085-764-009-624-439;;042-204-626-457-327;;048-183-620-015-85X;;062-024-235-743-200;;063-640-832-834-034;;017-216-732-209-839;;053-122-459-007-90X;;115-802-414-738-000;;077-903-001-903-019;;001-147-941-858-547;;017-738-995-123-197;;004-067-735-797-199;;045-094-249-115-990;;068-843-666-295-283;;073-466-339-901-688;;136-216-971-174-99X;;110-082-824-995-005,2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;2388567;;10.1016/0076-6879(90)84268-l;;2447170;;2761388;;10.1111/j.1365-2958.1989.tb00194.x;;10.1006/abio.1996.9982;;9056182;;6263759;;10.1016/0378-1119(81)90008-1;;7516563;;10.1016/s0923-2494(94)80039-1;;9709052;;10.1056/nejm199808203390819;;pmc2192397;;10.1084/jem.183.1.271;;8551231;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1006/jmbi.2000.4119;;11183781;;10.1002/anie.198907161;;10.1128/iai.61.1.81-90.1993;;8418068;;pmc302690;;8961139;;10.1021/js960158a;;9330467;;10.1016/s0264-410x(97)00066-2;;pmc345355;;6204335;;10.1073/pnas.81.13.3998;;10.1128/iai.65.3.882-889.1997;;pmc175064;;9038292;;7639011;;10.1016/0264-410x(94)00027-k;;4705382;;10.1016/0042-6822(73)90341-3;;9685265;;10.1126/science.281.5377.703;;10.1093/dnares/4.4.257;;9405933;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0022-2836(92)90894-p;;1404359;;2410914;;pmc390513;;10.1073/pnas.82.15.5131;;pmc260138;;3019889;;10.1128/iai.54.1.207-212.1986;;2295795;;8556477;;pmc368276;;10.1128/cdli.1.4.406-412.1994;;10.1038/321522a0;;3713831;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;10.1001/jama.1994.03510460056033;;8196120;;10.1001/jama.271.22.1764;;1172191;;10.1038/256495a0;;15935380;;10.1016/j.jmb.2005.04.066;;10.4049/jimmunol.133.6.3001;;6092464;;10603393;;pmc97126;;10.1128/iai.68.1.233-238.2000;;9108020;;pmc20483;;10.1073/pnas.94.8.3584;;pmc173274;;10.1128/iai.63.6.2113-2119.1995;;7768589;;10.1086/338463;;11865439;;pmc335293;;10.1093/nar/17.24.10191;;2690015;;1748994;;10.1016/0022-2836(91)90498-u;;10.1021/ja00897a025;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1016/0022-2836(70)90057-4;;5420325;;10.1016/s0021-9258(18)89400-5;;3838308;;8494350;;10.1146/annurev.pharmtox.33.1.521;;10.1146/annurev.pa.33.040193.002513;;10.4049/jimmunol.166.12.7398;;11390491;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;3127726;;10.1038/332323a0;;10.1006/mcpr.1994.1013;;7935517;;10.1056/nejm199807233390402;;9673299;;10631780;;10.1016/s0167-7799(99)01398-0;;10.1016/0196-8858(81)90046-4;;9673298;;10.1056/nejm199807233390401;;10.1016/0022-2836(86)90385-2;;3537305;;6186024;;10.1126/science.6186024;;2184369;;10.1038/344873a0;;pmc411572;;388439;;10.1073/pnas.76.9.4350;;10.1016/s0264-410x(96)00146-6;;9032890;;10.1126/science.2451287;;2451287;;7500914;;10.1007/bf00221390;;10.1128/jcm.31.2.340-350.1993;;pmc262762;;8432821;;10.1093/protein/13.8.575;;10964987;;2694933;;10.1146/annurev.genet.23.1.289;;10.1146/annurev.ge.23.120189.001445,"Altschul et al., Basic local alignment search tool. J. Mol. Biol., 215:403-10 (1990).;;Batzer et al., Enhanced evolutionary PCR using oligonucleotides with inosine at the 3'-terminus. Nucleic Acid Res., 19:5081 (1991).;;Bayer et al., Protein biotinylation. Meth. Enzym., 184:138-163 (1990).;;Benach et al., A murine IgM monoclonal antibody binds an antigenic determinant in outer surface protein A, an immundominant basic protein of the Lyme disease spirochete. J. Immunol., 140: 265-72 (1988).;;Bergstrom et al., Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Molec. Microbiol. 3:479-86 (1989).;;Bouchon et al., Analysis of the lipidated recombinant outer surface protein A from Borrelia burgdorferi by mass spectrometry. Anal. Biochem., 246: 52-61 (1997).;;Chu et al., SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen. Gene, 13:197-202 (1981).;;Colman et al., Effects of amino acid sequence changes on antibody-antigen interactions. Res. Immunology, 145: 33-6 (1994).;;Correction: A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein a to prevent lyme disease. N. Engl. J. Med., 339:571 (1998).;;de Silva et al., Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med., 183: 271-5 (1996).;;Devereux et al., A comprehensive set of sequence analysis programs for the VAX. Nucl. Acid. Res., 12:387-95 (1984).;;Ding et al., Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. J. Mol. Biol., 302: 1153-64 (2000).;;Engels et al., Gene Synthesis. Angew. Chem. Intl. Ed., 28:716-734 (1989).;;Erdile et al., Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect. Immun., 61: 81-90 (1993).;;Fix, Strategies for delivery of peptides utilizing absorption-enhancing agents. J. Pharm. Sci., 85:1282-5 (1996).;;Francis et al., Protein modification and fusion proteins. Focus on Growth Factors, 3:4-10 (1992).;;Gern et al., Immunization with a polyvalent OspA vaccine protects mice again loxides ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine, 15:1551-7 (1997).;;Geysen et al., Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl. Acad. Sci. USA, 81:3998-4002 (1984).;;Golde et al., Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect. Immun., 65: 882-9 (1997).;;Golde et al., The Lyme disease vaccine candidate outer surface protein a (OspA) in a formulation compatible with human use protects mice against natural tick transmission of b. burgdorferi. Vaccine, 13:435-41 (1995).;;Graham et al., A new technology for the assay of infectivity of human adenovirus 5 DNA. Virology, 52:456-67 (1973).;;Gross et al., Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis, Science, 281: 703-6 (1998).;;Guerdoux-Jamet et. al., Using codon usage to predict genes origin: is the Escherichia coli outer membrane a patchwork of products from different genomes? DNA Res., 4:257-65 (1997).;;Henikoff et al., Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA, 89:10915-9 (1992).;;Hoogenboom et al., By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol., 227:381-8 (1991).;;Houghten et al., General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. USA, 82: 5131-5 (1985).;;Howe et al., Organization of genes encoding two outer membrane proteins of the Lyme disease agent Borrelia burgdorferi within a single transcriptional unit, Infect. Immun. 54:207-12 (1986).;;Jiang et al., Cross-antigenicity between the major surface proteins (ospA and ospB) and other proteins of Borrelia burgdorferi. J. Immunol., 144: 284-9 (1990).;;Jiang et al., Purification of Borrelia burgdorferi outer surface protein A (OspA) and analysis of antibody binding domains. Clin. Diagn. Lab. Immunol., 1:406-12 (1994).;;Jones et al., Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature, 321 :522-5 (1986).;;Karlin et al., Applications and statistics for multiple high-scoring segments in molecular sequences. Proc. Natl. Acad. Sci. USA, 90:5873-7 (1993).;;Keller et al., Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA, 271 :1764 8 (1994).;;Kohler et al., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256:495-7 (1975).;;Koide et al., Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burdorferi OspA. J. Mol. Biol. 350:290-9 (2005).;;Kozbor, A human hybrid myeloma for production of human monoclonal antibodies. J. Immunol., 133:3001-5 (1984).;;Lakey et al., Enhanced production of recombinant Mycobacterium tuberculosis antigens in Escherichia coli by replacement of low-usage codons. Infect. Immun., 68:233-8 (2000).;;Li et al., Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc. Natl. Acad. Sci. U.S.A., 94:3584-9 (1997).;;Lovrich et al., Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect. Immun. 63:2113-9 (1995).;;Luft et al., Approaches toward the directed design of a vaccine against Borrelia burgdorferi. J. Infect. Dis., 185(Suppl. 1): S46-51 (2002).;;Makoff et al., Expression of tetanus toxin fragment C in E. coli: High level expression by removing rare codons. Nucl. Acids Res., 17:10191-202 (1989).;;Marks et al., By-passing immunization: Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol., 222:581-97 (1991).;;Merrifield et al., Solid phase peptide synthesis: The synthesis of a tetrapeptide. J. Am. Chem. Soc., 85:2149-54 (1963).;;Morrison et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA, 81:6851-5 (1985).;;Needleman et al., A general method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mol. Biol., 48:443-53 (1970).;;Ohtsuka et al., An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions. J. Biol. Chem., 260:2605-8 (1985).;;Oliyai et al., Prodrugs of peptides and proteins for improved formulation and delivery. Ann. Rev. Pharmacol. Toxicol., 32:521-44 (1993).;;Pal et al., Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. J. Immunol., 166: 7398-403 (2001).;;Pearson et al., Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA, 85:2444-8 (1988).;;Riechmann et al., Reshaping human antibody for therapy. Nature, 332:323-7 (1988).;;Rossolini et al., Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information. Mol. Cell. Probes, 8:91-8 (1994).;;Sigal et al., A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N. Engl. J. Med., 339:216-22 (1998).;;Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol., 18: 34-9 (2000).;;Smith et al., Comparison of biosequences. Adv. Appl. Math. 2: 482-9 (1981).;;Steere et al., Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme disease vaccine study group. N. Engl. J. Med., 339: 209-15 (1998).;;Studier et al., Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol., 189:113-30 (1986).;;Sutcliffe et al., Antibodies that react with predetermined sites on proteins. Science, 219:660-6 (1983).;;Takahashi et al., Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature, 344:873-5 (1990).;;Towbin, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76:4350-6 (1979).;;Van Hoecke et al., Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 14:1620-6 (1996).;;Verhoeyen et al., Reshaping human antibodies: Grafting an antilysozyme activity. Science, 239:1534-6 (1988).;;Will et al., Sequence analysis of ospA genes shows homogeneity within Borrelia burgdorferi sensu stricto and Borrelia afzelii strains but reveals major subgroups within the Borrelia garinii species. Med. Microbiol. Immunol. 184:73-80, 1995.;;Wilske et al., An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J. Clin. Microbiol., 31:340-50 (1993).;;International Search Report and Written Opinion of the International Searching Authority, PCT/US2011/036525, dated Jul. 12, 2011.;;International Search Report, PCT/US2011/036533, dated Sep. 13, 2011.;;Frankel et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng. 13(8): 575-81 (2000).;;Pakula et al., Genetic analysis of protein stability and function, Ann. Ref. Genet. 23: 289-310 (1989).",ACTIVE
393,US,A1,US 2014/0141030 A1,049-331-507-203-806,2014-05-22,2014,US 201314078390 A,2013-11-12,US 201314078390 A;;US 201113107796 A;;US 33490110 P,2010-05-14,"CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF","The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.",BAXTER INT;;BROOKHAVEN SCIENCE ASS LLC;;UNIV NEW YORK STATE RES FOUND;;BAXTER HEALTHCARE SA,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,BAXTER HEALTHCARE SA (2011-05-20);;BAXALTA INCORPORATED (2015-08-11);;BAXALTA GMBH (2015-08-11);;BAXTER INTERNATIONAL INC (2011-05-20);;RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (2012-01-31);;BROOKHAVEN SCIENCE ASSOCIATES LLC (2011-06-10),https://lens.org/049-331-507-203-806,Patent Application,yes,0,2,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C07K14/20,424/190.1;;530/350,0,0,,,,ACTIVE
394,AU,B2,AU 776695 B2,094-225-550-829-305,2004-09-16,2004,AU 2001/011375 A,2000-10-13,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/094-225-550-829-305,Granted Patent,no,3,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
395,JP,A,JP 2018150386 A,124-255-426-915-453,2018-09-27,2018,JP 2018129896 A,2018-07-09,US 33490110 P,2010-05-14,OspA CHIMERAS AND METHODS OF USE THEREOF IN VACCINES,"PROBLEM TO BE SOLVED: To provide OspA chimeras and methods of use thereof in vaccines.SOLUTION: The invention relates to the development of chimeric OspA molecules for use in novel Lyme vaccine. More specifically, the chimeric OspA molecules comprise a proximal portion from one OspA serotype, together with a distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.SELECTED DRAWING: None",BAXALTA INC;;BAXALTA GMBH;;RES FOUND OF THE STATE UNIV OF NEW YORK;;BROOKHAVEN SCIENCE ASS LLC,BRIAN A CROWE;;LIVEY IAN;;MARIA O'ROURKE;;MICHAEL SCHWENDINGER;;JOHN J DUNN;;BENJAMIN J LUFF,,https://lens.org/124-255-426-915-453,Patent Application,no,0,0,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;A61K31/713;;A61K35/646;;A61K35/76;;A61K39/00;;A61K39/116;;A61K47/54;;A61K48/00;;A61P31/04;;A61P33/00;;A61P37/04,,0,0,,,,DISCONTINUED
396,US,A1,US 2007/0180635 A1,187-879-763-097-528,2007-08-09,2007,US 70192207 A,2007-02-02,GB 0602291 A,2006-02-04,Modular-bridge construction,"Disclosed is a modular bridge, typically for temporary use to enable persons to pass between upper floors of adjacent buildings during fire fighting or disaster relief operations, which can be rapidly assembled and deployed within a confined space and entirely from the “home” side of the gap to be crossed. It comprises a plurality of man-portable box section bridge modules adapted to be connected together end to end and projected in cantilever fashion from one side of the gap to the other. The assembly of modules is supported in and guided through a launch frame, with modules being added to the rear of the assembly and pushed through the frame until the gap is spanned. Removable lever arms of the frame are used to counterbalance the weight of the projected bridge modules during the course of deployment.",QINETIQ LTD,JONES DOUGLAS HUGH;;DUNN IAN JOHN;;MORGAN COLIN PETER;;ARDLEY SCOTT;;STARINK LINDA MARY PATRICIA,QINETIQ LIMITED (2007-01-12),https://lens.org/187-879-763-097-528,Patent Application,yes,11,2,6,6,0,E01D15/133;;E01D2101/40;;E01D15/133;;E01D21/10;;E04G3/18;;E01D15/133;;E01D2101/40,E01D21/00,14/77.1,0,0,,,,INACTIVE
397,HR,A2,HR P20020327 A2,023-793-173-754-909,2004-02-29,2004,HR P20020327 A,2002-04-12,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,ALKYLAMINO SUBSTITED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;WILLIAM HARRIS;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/023-793-173-754-909,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
398,BR,A2,BR 112012029058 A2,037-971-553-359-57X,2020-06-23,2020,BR 112012029058 A,2011-05-13,US 2011/0036533 W;;US 33490110 P,2010-05-14,"molécula de ácido nucleico, vetor, célula hospedeira, processo para produzir um polipeptídeo, composição, polipeptídeo, vacina de combinação, anticorpo ou fragmento do mesmo, e, usos de uma composição, de uma combinação de vacina, e de um anticorpo ou fragmento do mesmo","molécula de ácido nucleico isolado, vetor, célula hospedeira, processo para produzir um polipeptídeo, composição, polipeptídeo isolado, vacina de combinação, métodos para induzir uma resposta imunológica em um indivíduo, e para prevenir ou tratar uma infecção ou doença, e, anticorpo ou fragmento do mesmo. a invenção se refere ao desenvolvimento de moléculas de ospa quimérica para utilização em vacina contra doença de lyme ou borreliose. mais especificamente, as moléculas de ospa quiméricas compreendem a porção proximal de um sorotipo ospa, em conjunto com a porção distal de outro sorotipo ospa, enquanto retendo propriedades antigênicas de ambos os polipeptídeos parentais. as moléculas de ospa quiméricas são distribuídas isoladamente ou em combinação para fornecer proteção contra uma variedade de genoespécies de borrelia.",BAXTER HEALTHCARE SA;;BAXTER INT;;BROOKHAVEN SCIENCE ASS LLC;;THE RESEARCH FOUNDATION OF THE STATE UNIV OF NEW YORK,BENJAMIN J LUFT;;BRIAN A CROWE;;IAN LIVEY;;JOHN J DUNN;;MARIA O'ROURKE;;MICHAEL SCHWENDINGER,"BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) ; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) ; BAXALTA INCORPORATED (US) ; BAXALTA GMBH (CH) (2020-08-11);;BAXTER INTERNATIONAL INC. (US) ; BAXTER HEALTHCARE S.A. (CH) ; BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) ; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) (2020-07-21)",https://lens.org/037-971-553-359-57X,Patent Application,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,0,0,,,,ACTIVE
399,MX,B,MX 340739 B,072-290-247-159-225,2016-07-22,2016,MX 2012013264 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES.,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BROOKHAVEN SCIENCE ASS LLC,BRIAN A CROWE;;IAN LIVEY;;MARIA O'ROURKE;;MICHAEL SCHWENDINGER;;JOHN J DUNN;;BENJAMIN J LUFT,,https://lens.org/072-290-247-159-225,Granted Patent,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/40;;A61K39/116;;C07K14/20;;C12N1/19;;C12N15/63;;C12P21/02,,0,0,,,,ACTIVE
400,US,B2,US 8623376 B2,186-315-572-401-654,2014-01-07,2014,US 201113107796 A,2011-05-13,US 201113107796 A;;US 33490110 P,2010-05-14,"Chimeric OspA genes, proteins, and methods of use thereof","The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.",CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J;;BAXTER INT;;BAXTER HEALTHCARE SA;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,BAXALTA INCORPORATED (2015-11-19);;BROOKHAVER SCIENCE ASSOCIATES (2011-06-10);;THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (2012-01-31);;BAXALTA GMBH (2015-11-19);;BAXTER INTERNATIONAL INC (2011-05-20),https://lens.org/186-315-572-401-654,Granted Patent,yes,42,1,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/40;;A61K39/116;;C07K14/20;;C12N1/19;;C12N15/63;;C12P21/02,424/190.1;;424/234.1;;530/350,64,61,063-640-832-834-034;;029-611-134-469-353;;056-201-471-905-934;;027-829-588-585-761;;023-730-857-866-719;;104-921-466-213-292;;102-662-593-894-426;;054-732-712-502-061;;010-519-409-512-153;;160-840-803-687-381;;029-683-169-457-195;;066-141-497-990-023;;115-303-705-496-498;;025-189-084-402-882;;030-839-409-040-828;;014-935-196-346-195;;096-611-689-245-37X;;012-830-491-824-205;;129-466-277-652-523;;003-323-279-619-527;;072-366-322-919-406;;007-542-078-714-566;;011-820-307-395-282;;023-907-179-348-058;;032-071-991-081-664;;055-792-532-851-126;;081-525-182-466-362;;000-150-741-285-140;;057-200-638-752-266;;006-574-964-805-278;;019-779-601-634-917;;006-742-514-479-110;;106-753-778-592-300;;035-616-782-811-647;;048-564-471-521-204;;003-430-460-951-798;;029-026-124-030-198;;065-101-341-902-59X;;003-448-860-121-684;;060-196-670-596-725;;020-855-322-534-259;;026-944-353-804-488;;030-607-398-087-475;;032-728-154-591-070;;111-109-974-501-414;;101-242-387-154-198;;066-525-457-224-28X;;085-764-009-624-439;;042-204-626-457-327;;048-183-620-015-85X;;062-024-235-743-200;;017-216-732-209-839;;053-122-459-007-90X;;115-802-414-738-000;;077-903-001-903-019;;001-147-941-858-547;;017-738-995-123-197;;004-067-735-797-199;;045-094-249-115-990;;068-843-666-295-283;;073-466-339-901-688,10631780;;10.1016/s0167-7799(99)01398-0;;7516563;;10.1016/s0923-2494(94)80039-1;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;2388567;;10.1016/0076-6879(90)84268-l;;2447170;;2761388;;10.1111/j.1365-2958.1989.tb00194.x;;10.1006/abio.1996.9982;;9056182;;6263759;;10.1016/0378-1119(81)90008-1;;9709052;;10.1056/nejm199808203390819;;pmc2192397;;10.1084/jem.183.1.271;;8551231;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1006/jmbi.2000.4119;;11183781;;10.1002/anie.198907161;;10.1128/iai.61.1.81-90.1993;;8418068;;pmc302690;;8961139;;10.1021/js960158a;;9330467;;10.1016/s0264-410x(97)00066-2;;pmc345355;;6204335;;10.1073/pnas.81.13.3998;;7639011;;10.1016/0264-410x(94)00027-k;;10.1128/iai.65.3.882-889.1997;;pmc175064;;9038292;;4705382;;10.1016/0042-6822(73)90341-3;;9685265;;10.1126/science.281.5377.703;;10.1093/dnares/4.4.257;;9405933;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0022-2836(92)90894-p;;1404359;;2410914;;pmc390513;;10.1073/pnas.82.15.5131;;pmc260138;;3019889;;10.1128/iai.54.1.207-212.1986;;8556477;;pmc368276;;10.1128/cdli.1.4.406-412.1994;;2295795;;10.1038/321522a0;;3713831;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;10.1001/jama.1994.03510460056033;;8196120;;10.1001/jama.271.22.1764;;1172191;;10.1038/256495a0;;15935380;;10.1016/j.jmb.2005.04.066;;10.4049/jimmunol.133.6.3001;;6092464;;10603393;;pmc97126;;10.1128/iai.68.1.233-238.2000;;9108020;;pmc20483;;10.1073/pnas.94.8.3584;;pmc173274;;10.1128/iai.63.6.2113-2119.1995;;7768589;;10.1086/338463;;11865439;;pmc335293;;10.1093/nar/17.24.10191;;2690015;;1748994;;10.1016/0022-2836(91)90498-u;;10.1021/ja00897a025;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1016/0022-2836(70)90057-4;;5420325;;10.1016/s0021-9258(18)89400-5;;3838308;;8494350;;10.1146/annurev.pharmtox.33.1.521;;10.1146/annurev.pa.33.040193.002513;;10.4049/jimmunol.166.12.7398;;11390491;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;3127726;;10.1038/332323a0;;10.1006/mcpr.1994.1013;;7935517;;10.1056/nejm199807233390402;;9673299;;10.1016/0196-8858(81)90046-4;;9673298;;10.1056/nejm199807233390401;;10.1016/0022-2836(86)90385-2;;3537305;;6186024;;10.1126/science.6186024;;2184369;;10.1038/344873a0;;pmc411572;;388439;;10.1073/pnas.76.9.4350;;10.1016/s0264-410x(96)00146-6;;9032890;;10.1126/science.2451287;;2451287;;7500914;;10.1007/bf00221390;;10.1128/jcm.31.2.340-350.1993;;pmc262762;;8432821,"Skolnick et al. (Trends in Biotechnology 18: 34-39, 2000).;;Colman Res. (Immunology, Jan. 1994, vol. 145, pp. 33-36).;;Altschul et al., Basic local alignment search tool. J. Mol. Biol. 215:403-10 (1990).;;Batzer et al., Enhanced evolutionary PCR using oligonucleotides with inosine at the 3'-terminus. Nucleic Acid Res. 19:5081 (1991).;;Bayer et al., Protein biotinylation. Meth. Enzym. 184:138-163 (1990).;;Benach et al., A murine IgM monoclonal antibody binds an antigenic determinant in outer surface protein A, an immundominant basic protein of the Lyme disease spirochete. J. Immunol., 140: 265-72 (1988).;;Bergstrom et al., Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Molec. Microbiol. 3:479-86 (1989).;;Bouchon et al., Analysis of the lipidated recombinant outer surface protein A from Borrelia burgdorferi by mass spectrometry. Anal. Biochem. 246: 52-61 (1997).;;Chu et al., SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen. Gene 13:197-202 (1981).;;Correction: A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein a to prevent lyme disease. N. Engl. J. Med. 339:571 (1998).;;de Silva et al., Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med. 183: 271-5 (1996).;;Devereux et al., A comprehensive set of sequence analysis programs for the VAX. Nucl. Acid. Res. 12:387-95 (1984).;;Ding et al., Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. J. Mol. Biol. 302: 1153-64 (2000).;;Engels et al., Gene Synthesis. Angew. Chem. Intl. Ed. 28:716-734 (1989).;;Erdile et al., Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect. Immun. 61: 81-90 (1993).;;Fix, Strategies for delivery of peptides utilizing absorption-enhancing agents. J. Pharm. Sci. 85:1282-5 (1996).;;Francis et al., Protein modification and fusion proteins. Focus on Growth Factors 3:4-10 (1992).;;Gern et al., Immunization with a polyvalent OspA vaccine protects mice again loxides ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine 15:1551-7 (1997).;;Geysen et al., Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984).;;Golde et al., The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with hman use protects mice against natural tick transmission of B. burgdorferi. Vaccine 13:435-41 (1995).;;Golde et al., Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect. Immun. 65: 882-9 (1997).;;Graham et al., A new technology for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-67 (1973).;;Gross et al., Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281:703-6 (1998).;;Guerdoux-Jamet et. Al., Using codon usage to predict genes origin: is the Escherichia coli outer membrane a patchwork of products from different genomes? DNA Res. 4:257-65 (1997).;;Henikoff et al., Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA 89:10915-9 (1992).;;Hoogenboom et al., By-passing mmunization. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol. 227:381-8 (1991).;;Houghten et al., General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at teh level of individual amino acids. Proc. Natl. Acad. Sci. USA 82: 5131-5 (1985).;;Howe et al., Organization of genes encoding two outer membrane proteins of the Lyme disease agent Borrelia burgdorferi within a single transcriptional unit. Infect. Immun. 54:207-12 (1986).;;Jiang et al., Purification of Borrelia burgdorferi outer surface protein A (OspA) and analysis of antibody binding domains. Clin. Diagn. Lab. Immunol. 1:406-12 (1994).;;Jiang et al., Cross-antigenicity between the major surface proteins (ospA and ospB) and other proteins of Borrelia burgdorferi. J. Immunol. 144: 284-9 (1990).;;Jones et al., Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature 321 :522-5 (1986).;;Karlin et al., Applications and statistics for multiple high-scoring segments in molecular sequences. Proc. Natl. Acad. Sci. USA 90:5873-7 (1993).;;Keller et al., Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 271:1764 8 (1994).;;Kohler et al., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-7 (1975).;;Koide et al., Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burdorferi OspA. J. Mol. Biol. 350:290-9 (2005).;;Kozbor, A human hybrid myeloma for production of human monoclonal antibodies. J. Immunol. 133:3001-5 (1984).;;Lakey et al., Enhanced production of recombinant Mycobacterium tuberculosis antigens in Escherichia coli by replacement of low-usage codons. Infect. Immun. 68:233-8 (2000).;;Li et al., Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc. Natl. Acad. Sci. USA 94:3584-9 (1997).;;Lovrich et al., Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect. Immun. 63:2113-9 (1995).;;Luft et al., Approaches toward the directed design of a vaccine against Borrelia burgdorferi. J. Infect. Dis. 185(Suppl. 1): S46-51 (2002).;;Makoff et al., Expression of tetanus toxin fragment C in E. coli: High level expression by removing rare codons. Nucl. Acids Res. 17:10191-202 (1989).;;Marks et al., By-passing immunization: Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-97 (1991).;;Merrifield et al., Solid phase peptide synthesis: The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85:2149-54 (1963).;;Morrison et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81:6851-5 (1985).;;Needleman et al., A general method applicable to the search for similarities in the amino acid sequqnece of two proteins. J. Mol. Biol. 48:443-53 (1970).;;Ohtsuka et al., An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions. J. Biol. Chem. 260:2605-8 (1985).;;Oliyai et al., Prodrugs of peptides and proteins for improved formulation and delivery. Ann. Rev. Pharmacol. Toxicol. 32:521-44 (1993).;;Pal et al., Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. J. Immunol. 166: 7398-403 (2001).;;Pearson et al., Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA 85:2444-8 (1988).;;Riechmann et al., Reshaping human antibody for therapy. Nature 332:323-7 (1988).;;Rossolini et al., Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information. Mol. Cell. Probes 8:91-8 (1994).;;Sigal et al., A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N. Engl. J. Med. 339:216-22 (1998).;;Smith et al., Comparison of biosequences. Adv. Appl. Math. 2: 482-9 (1981).;;Steere et al., Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme disease vaccine study group. N. Engl. J. Med. 339: 209-15 (1998).;;Studier et al., Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189:113-30 (1986).;;Sutcliffe et al., Antibodies that react with predetermined sites on proteins. Science 219:660-6 (1983).;;Takahashi et al., Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344:873-5 (1990).;;Towbin, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-6 (1979).;;Van Hoecke et al., Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 14:1620-6 (1996).;;Verhoeyen et al., Reshaping human antibodies: Grafting an antilysozyme activity. Science 239:1534-6 (1988).;;Will et al., Sequence analysis of ospA genes shows homogeneity within Borrelia burgdorferi sensu stricto and Borrelia afzelii strains but reveals major subgroups within the Borrelia garinii species. Med. Microbiol. Immunol. 184:73-80 (1995).;;Wilske et al., An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J. Clin. Microbiol. 31:340-50 (1993).;;International Search Report and Written Opinion of the International Searching Authority, PCT/US2011/036533, dated Sep. 23, 2011.;;International Search Report and Written Opinion of the International Searching Authority, PCT/US2011/036525, dated Jul. 20, 2011.",ACTIVE
401,AU,A1,AU 2011/252850 A1,002-949-942-086-64X,2012-11-29,2012,AU 2011/252850 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OspA chimeras and use thereof in vaccines,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",UNIV NEW YORK STATE RES FOUND;;BAXTER HEALTHCARE SA;;BAXTER INT;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW (2016-07-07),https://lens.org/002-949-942-086-64X,Patent Application,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C07K14/20;;A61K39/02,,0,0,,,,ACTIVE
402,ZA,B,ZA 200202603 B,033-420-134-168-852,2003-07-03,2003,ZA 200202603 A,2002-04-03,US 16080499 P,1999-10-21,Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase.,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;HARRIS WILLIAM;;WELCH TERESA ROSANNE;;GOLDSTEIN DAVID MICHAEL;;SMITH IAN EDWARD DAVID,,https://lens.org/033-420-134-168-852,Granted Patent,no,0,0,2,37,0,Y02A50/30,C07D487/04;;A61K/;;A61K31/505;;A61P/;;A61P29/00;;C07D/,,0,0,,,,EXPIRED
403,KR,A,KR 20190027955 A,053-818-100-064-727,2019-03-15,2019,KR 20197006820 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,"본 발명은 라임 질환에 대항 또는 보렐리아증 백신에 사용하기 위한 키메라 OspA 분자의 개발에 관한 것이다. 보다 구체적으로, 상기 키메라 OspA 분자는 또 다른 OspA 혈청형으로부터의 원거리 부분과 함께 하나의 OspA 혈청형으로부터 인접한 부분을 포함하고 모 폴리펩타이드 둘다의 항원성 성질을 보유한다. 상기 키메라 OspA 분자는 다양한 보렐리아 동유전자종으로부터의 보호를 제공하기 위해 단독으로 또는 조합하여 전달된다.",BAXALTA INC;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC;;BAXALTA GMBH,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/053-818-100-064-727,Patent Application,no,3,0,74,74,346,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;A61K39/00;;A61P31/00;;C07K14/20,,0,0,,,,ACTIVE
404,NO,D0,NO 20021783 D0,080-161-823-240-961,2002-04-16,2002,NO 20021783 A,2002-04-16,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,Alkylamino-substituerte bicykliske nitrogen-heterocykler som inhibitorer for P38-protein-kinase,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/080-161-823-240-961,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
405,AU,A,AU 2001/011375 A,105-158-161-815-049,2001-04-30,2001,AU 2001/011375 A,2000-10-13,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/105-158-161-815-049,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
406,YU,A,YU 29202 A,103-447-521-800-296,2004-12-31,2004,YU P29202 A,2000-10-13,US 16080499 P;;US 21371800 P,1999-10-21,ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,"Alkylamino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives of formula (I) are provided wherein R1-R3 are as defined in the application which are useful as inhibitors of p38, along with a process for their manufacture and pharmaceutical preparations containing them.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/103-447-521-800-296,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
407,BR,A,BR 0014973 A,155-904-036-428-520,2002-07-16,2002,BR 0014973 A,2000-10-13,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38,"""HETEROCICLOS DE NITROGêNIO BICìCLICO DE ALQUILAMINO SUBSTITUìDO COMO INIBIDORES DE PROTEìNA QUINASE P38"". Derivados de diidropirimido[4,5-d] pirimidinona de alquilamino substituído da fórmula (I) são proporcionados em que R^ 1^-R^ 3^ são como definidos no pedido que são úteis como inibidores de P38, junto com um processo para sua fabricação e preparações farmacêuticas contendo os mesmos.",HOFFMANN LA ROCHE AG G,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/155-904-036-428-520,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
408,CO,A1,CO 5251408 A1,179-708-709-680-767,2003-02-28,2003,CO 00079670 A,2000-10-19,US 16080499 P;;US 21371800 P,1999-10-21,HETEROCICLOS DE NITROGENO BICICLICOS ALQUILAMINO SUSTITUIDOS,"Un compuesto seleccionado del grupo de compuestos representados por la formula:<EMI FILE=""00079670_1"" ID=""1"" IMF=JPEG >En dondeEl subíndice n es un número entero de 0 a 3; R1 es hidrógeno, alquilo, alquenilo, alquinilo, alquilcarbonilo, cicloalquilo, cicloalquenilo, cicloalquilalquilo, cicloalquilalquenilo, cicloalquilalquinilo y aralquilo;Cada R2 esta independientemente entre sí seleccionado del grupo formado por alquilo, halo, heteroalquilo y vinilo; y R3 es heteroalquilo, heteroalquenilo, heteroalquinilo, heteroalquilcarbonilo, cicloalquilo, heterosubstituido, cicloalquilaquilo heterosubstituido, cicloalquilalquenilo heterosubstituido, cicloalquilalquinilo heterosubstituido, cicloalquilo heteroalquilsubstituido, heterociclilo, heterociclialquilo, arilheteroalquilo, heteroarilheteroalquilo, -(alquileno) -C(O) R31 y - (heteroalquileno) -C(O) R31;En dondeR31 es alquilo, haloalquilo, hidroxilo, alcoxilo, amino, amino monosubstituido, amino, disubstituido, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo y heteroaralquilo; y sus sales farmaceuticamente aceptables.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;ROSANNE WELCH TERESA,,https://lens.org/179-708-709-680-767,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
409,US,A1,US 2016/0235830 A1,178-813-994-134-391,2016-08-18,2016,US 201615049438 A,2016-02-22,US 201615049438 A;;US 201314078390 A;;US 201113107796 A;;US 33490110 P,2010-05-14,"CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF","The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.",BAXALTA INC;;BAXALTA GMBH;;RES FOUND OF THE STATE UNIV OF NEW YORK;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,BAXTER HEALTHCARE SA (2011-05-20);;BAXALTA INCORPORATED (2015-11-19);;BAXALTA GMBH (2015-11-19);;BAXTER INTERNATIONAL INC (2011-05-20);;RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (2012-01-31);;BROOKHAVEN SCIENCE ASSOCIATES LLC (2011-06-10),https://lens.org/178-813-994-134-391,Patent Application,yes,0,0,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,0,0,,,,ACTIVE
410,EP,B1,EP 1226144 B1,192-891-153-906-546,2006-12-27,2006,EP 00972755 A,2000-10-13,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/192-891-153-906-546,Granted Patent,yes,4,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
411,JP,A,JP 2020178719 A,005-470-611-549-552,2020-11-05,2020,JP 2020135857 A,2020-08-11,JP 2018129896 A;;US 33490110 P,2010-05-14,OspA CHIMERAS AND METHODS OF USE THEREOF IN VACCINES,"To provide OspA chimeras and methods of use thereof in vaccines.SOLUTION: The invention relates to the development of chimeric OspA molecules for use in novel Lyme vaccine. More specifically, the chimeric OspA molecules comprise a proximal portion from one OspA serotype, together with a distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.SELECTED DRAWING: None",BAXALTA INC;;BAXALTA GMBH;;RES FOUND OF THE STATE UNIV OF NEW YORK;;BROOKHAVEN SCIENCE ASS LLC,BRIAN A CROWE;;LIVEY IAN;;MARIA O'ROURKE;;MICHAEL SCHWENDINGER;;JOHN J DUNN;;BENJAMIN J LUFF,,https://lens.org/005-470-611-549-552,Patent Application,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C12N15/31;;A61K35/76;;A61K39/02;;A61K39/395;;A61K48/00;;A61P31/04;;C07K14/20;;C07K16/12;;C07K19/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/62;;C12N15/63;;C12P21/08,,0,0,,,,ACTIVE
412,EP,A1,EP 2569008 A1,043-316-975-041-680,2013-03-20,2013,EP 11720967 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,,BAXTER INT;;BAXTER HEALTHCARE SA;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,"BAXALTA GMBH, CH (2021-05-07);;BAXALTA INCORPORATED (2020-04-22);;BAXALTA INCORPORATED; US (2020-04-30);;THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (2020-04-22);;THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY O (2017-11-22);;BAXALTA INCORPORATED, BANNOCKBURN, US (2021-05-07);;BAXALTA GMBH (2020-04-22);;THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF (2016-10-19);;BROOKHAVEN SCIENCE ASSOCIATES LLC, UPTON, US (2021-05-07);;THE RESEARCH FOUNDATION FOR THE STATE UNIVERSI, US (2021-05-07);;BROOKHAVEN SCIENCE ASSOCIATES LLC (2020-04-22)",https://lens.org/043-316-975-041-680,Patent Application,yes,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,0,0,,,,ACTIVE
413,GB,A,GB 2434822 A,049-091-357-372-97X,2007-08-08,2007,GB 0701836 A,2007-01-31,GB 0602291 A,2006-02-04,Modular bridge system,"The modular bridge system, primarily for use by emergency services, military forces to cross gaps in or between buildings etc., comprises a number of man-portable bridge modules 6 adapted to be connected together in liner succession on one side of the gap to be spanned and projected in a cantilevered fashion until the assembly of modules spans the gap. A man-portable apparatus 50, or a number of man-portable components adapted to be assembled for use, are adapted to support and guide the cantilevered assembly of modules as it is projected across the gap. The modules are preferably rectangular box sections, open ended in the longitudinal direction of the bridge, which are formed from fibre-reinforced plastic and which are adapted to be temporarily connected to adjacent modules as they are put into place. The apparatus includes a receiving portion through which modules are fed when the bridge is being extended and from which lever arms 53 extend that to enable one or more people to hold and counter-balance the assembly while it is being put in place. Also claimed is a method of constructing a bridge.",QINETIQ LTD,JONES DOUGLAS HUGH;;DUNN IAN JOHN;;MORGAN COLIN PETER;;ARDLEY SCOTT;;STARINK LINDA MARY PATRICIA,,https://lens.org/049-091-357-372-97X,Patent Application,no,2,6,6,6,0,E01D15/133;;E01D2101/40;;E01D15/133;;E01D21/10;;E04G3/18;;E01D15/133;;E01D2101/40,E01D21/10;;E01D15/133;;E04G3/18,E1G GKN           GKN;;E1S SS            SS,0,0,,,,INACTIVE
414,EP,A1,EP 1339812 A1,054-243-701-920-041,2003-09-03,2003,EP 01996586 A,2001-09-21,EP 01996586 A;;EP 0110944 W;;EP 00124365 A,2000-11-20,CHIRAL PHOTOISOMERIZABLE COMPOUNDS,"The invention relates to chiral photoisomerizable compounds of formula (I) wherein X<SUP>1</SUP>, X<SUP>2</SUP>, X<SUP>3</SUP>, X<SUP>4</SUP>, X<SUP>5 </SUP>and X<SUP>6 </SUP>have the meanings given in claim 1 , to liquid crystalline mixtures and polymers containing them, and to the use of chiral photoisomerizable compounds, liquid crystalline mixtures and polymers containing them in optical and electrooptical devices like liquid crystal displays or projection systems, in optical elements like polarizers, retardation films, compensators, color filters or holographic elements, in liquid crystal pigments and colored films or coatings for decorative or security applications, cosmetic and pharmaceutical compositions, in nonlinear optics and optical information storage.",MERCK PATENT GMBH,VAUGHAN-SPICKERS JULIAN;;DUNN CHRISTOPHER;;HARDING RICHARD;;HASSALL IAN;;JENKINS TONY;;MAY ALISON;;GREENFIELD SIMON,,https://lens.org/054-243-701-920-041,Patent Application,yes,0,0,13,13,0,C09K19/2028;;C09K19/586;;C09K2219/03;;C09K2323/00;;C09K19/58;;C09K19/2028;;C09K2219/03;;C09K19/586;;C09K2323/00,G02B5/30;;C07C69/76;;C07C69/767;;C09K19/20;;C09K19/38;;C09K19/54;;C09K19/58;;G02F1/13;;G02F1/1335,,0,0,,,,EXPIRED
415,CZ,A3,CZ 20021743 A3,052-627-344-577-15X,2002-08-14,2002,CZ 20021743 A,2000-10-13,US 16080499 P;;US 21371800 P,1999-10-21,Bicyclic nitrogen heterocycles substituted with alkylamino group functioning together with the group as P38 protein kinase inhibitors,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/052-627-344-577-15X,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
416,US,B2,US 11305000 B2,073-931-336-005-483,2022-04-19,2022,US 201815875479 A,2018-01-19,US 201815875479 A;;US 201615049438 A;;US 201314078390 A;;US 201113107796 A;;US 33490110 P,2010-05-14,"Chimeric OspA genes, proteins and methods of use thereof","The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.",THE RESEARCH FOUNDATION OF THE STATE UNIV OF NEW YORK;;BAXALTA INC;;BAXALTA GMBH;;BROOKHAVEN SCIENCE ASS LLC;;UNIV NEW YORK STATE RES FOUND,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,BAXTER HEALTHCARE SA (2011-05-20);;BAXALTA INCORPORATED (2015-11-19);;BAXALTA GMBH (2015-11-19);;BAXTER INTERNATIONAL INC (2011-05-20);;RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (2012-01-31);;BROOKHAVEN SCIENCE ASSOCIATES LLC (2011-06-10),https://lens.org/073-931-336-005-483,Granted Patent,yes,57,3,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;A61K39/00;;C07K14/20,,79,68,096-611-689-245-37X;;056-201-471-905-934;;027-829-588-585-761;;023-730-857-866-719;;104-921-466-213-292;;102-662-593-894-426;;054-732-712-502-061;;010-519-409-512-153;;029-611-134-469-353;;160-840-803-687-381;;029-683-169-457-195;;066-141-497-990-023;;115-303-705-496-498;;025-189-084-402-882;;030-839-409-040-828;;014-935-196-346-195;;136-216-971-174-99X;;096-611-689-245-37X;;012-830-491-824-205;;003-323-279-619-527;;129-466-277-652-523;;072-366-322-919-406;;007-542-078-714-566;;011-820-307-395-282;;023-907-179-348-058;;032-071-991-081-664;;055-792-532-851-126;;081-525-182-466-362;;057-200-638-752-266;;000-150-741-285-140;;006-574-964-805-278;;019-779-601-634-917;;006-742-514-479-110;;106-753-778-592-300;;035-616-782-811-647;;048-564-471-521-204;;003-430-460-951-798;;029-026-124-030-198;;065-101-341-902-59X;;003-448-860-121-684;;060-196-670-596-725;;020-855-322-534-259;;026-944-353-804-488;;030-607-398-087-475;;032-728-154-591-070;;111-109-974-501-414;;101-242-387-154-198;;110-082-824-995-005;;066-525-457-224-28X;;085-764-009-624-439;;042-204-626-457-327;;048-183-620-015-85X;;062-024-235-743-200;;063-640-832-834-034;;053-122-459-007-90X;;115-802-414-738-000;;077-903-001-903-019;;001-147-941-858-547;;017-738-995-123-197;;004-067-735-797-199;;045-094-249-115-990;;068-843-666-295-283;;073-466-339-901-688;;052-970-377-033-069;;005-730-274-557-006;;025-106-571-327-924;;015-815-132-309-360;;055-572-145-640-500,9330467;;10.1016/s0264-410x(97)00066-2;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;2388567;;10.1016/0076-6879(90)84268-l;;2447170;;2761388;;10.1111/j.1365-2958.1989.tb00194.x;;10.1006/abio.1996.9982;;9056182;;6263759;;10.1016/0378-1119(81)90008-1;;7516563;;10.1016/s0923-2494(94)80039-1;;9709052;;10.1056/nejm199808203390819;;pmc2192397;;10.1084/jem.183.1.271;;8551231;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1006/jmbi.2000.4119;;11183781;;10.1002/anie.198907161;;10.1128/iai.61.1.81-90.1993;;8418068;;pmc302690;;8961139;;10.1021/js960158a;;10.1093/protein/13.8.575;;10964987;;9330467;;10.1016/s0264-410x(97)00066-2;;pmc345355;;6204335;;10.1073/pnas.81.13.3998;;10.1128/iai.65.3.882-889.1997;;pmc175064;;9038292;;7639011;;10.1016/0264-410x(94)00027-k;;4705382;;10.1016/0042-6822(73)90341-3;;9685265;;10.1126/science.281.5377.703;;10.1093/dnares/4.4.257;;9405933;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0022-2836(92)90894-p;;1404359;;2410914;;pmc390513;;10.1073/pnas.82.15.5131;;pmc260138;;3019889;;10.1128/iai.54.1.207-212.1986;;2295795;;8556477;;pmc368276;;10.1128/cdli.1.4.406-412.1994;;10.1038/321522a0;;3713831;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;10.1001/jama.1994.03510460056033;;8196120;;10.1001/jama.271.22.1764;;1172191;;10.1038/256495a0;;15935380;;10.1016/j.jmb.2005.04.066;;10.4049/jimmunol.133.6.3001;;6092464;;10603393;;pmc97126;;10.1128/iai.68.1.233-238.2000;;9108020;;pmc20483;;10.1073/pnas.94.8.3584;;pmc173274;;10.1128/iai.63.6.2113-2119.1995;;7768589;;10.1086/338463;;11865439;;pmc335293;;10.1093/nar/17.24.10191;;2690015;;1748994;;10.1016/0022-2836(91)90498-u;;10.1021/ja00897a025;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1016/0022-2836(70)90057-4;;5420325;;10.1016/s0021-9258(18)89400-5;;3838308;;8494350;;10.1146/annurev.pharmtox.33.1.521;;10.1146/annurev.pa.33.040193.002513;;2694933;;10.1146/annurev.genet.23.1.289;;10.1146/annurev.ge.23.120189.001445;;10.4049/jimmunol.166.12.7398;;11390491;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;3127726;;10.1038/332323a0;;10.1006/mcpr.1994.1013;;7935517;;10.1056/nejm199807233390402;;9673299;;10631780;;10.1016/s0167-7799(99)01398-0;;9673298;;10.1056/nejm199807233390401;;10.1016/0022-2836(86)90385-2;;3537305;;6186024;;10.1126/science.6186024;;2184369;;10.1038/344873a0;;pmc411572;;388439;;10.1073/pnas.76.9.4350;;10.1016/s0264-410x(96)00146-6;;9032890;;10.1126/science.2451287;;2451287;;7500914;;10.1007/bf00221390;;10.1128/jcm.31.2.340-350.1993;;pmc262762;;8432821;;pmc262748;;10.1128/jcm.31.2.272-278.1993;;8432812;;10.1016/j.vaccine.2015.07.095;;26277070;;pmc47734;;8234271;;10.1073/pnas.90.21.10163;;21217174;;10.1093/cid/ciq118;;10865933,"Aug. 31, 2017 Office Action issued in connection with KR 10-2012-7032560.;;Gem L. et al., “Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii” Vaccine, vol. 15, No. 14, pp. 1551-1557 (1997).;;Altschul et al., Basic local alignment search tool. J. Mal. Biol., 215:403-10 (1990).;;Batzer et al., Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus. D Nucleic Acid Res., 19 :5081 ( 1991).;;Bayer et al., Protein biotinylation. Meth. Enzvm., 184:138-163 (1990).;;Benach et al., A murine IgM monoclonal antibody binds an antigenic determinant in outer surface protein A, an immundominant basic protein of the Lyme disease spirochete. J. Immunol., 140:265-72 (1988).;;Bergstrom et al., Molecular analysis of linear plasmid-encoded major surface proteins, OspA and D OspB, of the Lyme disease spirochaete Borrelia burqdorferi. Malec. Microbial. 3:479-86 (1989).;;Bouchon et al., Analysis of the lipidated recombinant outer surface protein A from Borrelia D burqdorferi by mass spectrometry. Anal. Biochem., 246: 52-61 (1997).;;Chu et al., SV4O DNA transfection of cells in suspension: analysis of efficiency of transcription and D translation of T-antigen. Gene, 13:197-202 (1981).;;Colman et al., Effects of amino acid seguence changes on antibody-antigen interactions. Res. D Immunoloav, 145: 33-6 (1994).;;Correction: A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein a to D prevent lvme disease. N. Ena/. J. Med., 339:571 (1998).;;De Silva et al., Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme D disease vaccine. J. Exo. Med., 183: 271-5 (1996).;;Devereux et al., A comprehensive set of sequence analysis programs for the VAX. Nucl. Acid. D Res., 12:387-95 (1984).;;Ding et al., Structural identification of a key protective B-cell epitope in Lyme disease antigen D OspA. J. Mal. Biol., 302: 1153-64 (2000).;;Engels et al., Gene Synthesis. Angew. Chem. Intl. Ed., 28:716-734 (1989).;;Erdile et al., Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect. Immun., 61: 81-90 (1993).;;Fix, Strategies for delivery of peptides utilizing absorption-enhancing agents. J. Pharm. Sci., 85:1282-5 (1996).;;Francis et al., Protein modification and fusion proteins. Focus on Growth Factors, 3:4-10 (1992).;;Frankel et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 D receptor, Protein Eng. 13(8): 575-81 (2000).;;Gern et al., Immunization with a polyvalent OspA vaccine protects mice again loxides ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine, 15:1551-7 (1997).;;Geysen et al., Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl. Acad. Sci. USA, 81 :3998-4002 (1984).;;Golde et al., Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia bur_qdorferi. Infect. Immun., 65: 882-9 (1997).;;Golde et al., The Lvme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of b. buradorferi. Vaccine, 13:435-41 (1995).;;Graham et al., A new technology for the assay of infectivity of human adenovirus 5 DNA. Virology, 52:456-67 (1973).;;Gross et al., Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis, Science, 281: 703-6 (1998).;;Guerdoux-Jamet et. al., Using codon usage to predict genes origin: is the Escherichia coli outer membrane a patchwork of products from different genomes? DNA Res., 4:257-65 (1997).;;Henikoff et al., Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA, 89:10915-9 (1992).;;Hoogenboom et al., By-passing immunisation. Human antibodies from synthetic repertoires of germ line VH gene segments rearranged in vitro. J. Mal. Biol., 227:381-8 (1991 ).;;Houghten et al., General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at teh level of individual amino acids. Proc. Natl. Acad. Sci. USA, 82: 5131-5 (1985).;;Howe et al., Organization of genes encoding two outer membrane proteins of the Lyme disease agent Borrelia burgdorferi within a single transcriptional unit, Infect. Immun. 54:207-12 (1986).;;International Search Report and Written Opinion of the International Searching Authority, PCT/US2011 /036525, dated Jul. 12, 2011.;;International Search Report, PCT/US2011 /036533, dated Sep. 13, 2011.;;Jiang et al., Cross-antigenicity between the major surface proteins (ospA and ospB) and other proteins of Borrelia burgdorferi. J. Immunol., 144: 284-9 (1990).;;Jiang et al., Purification of Borrelia burgdorferi outer surface protein A (OspA) and analysis of antibody binding domains. Clin. Diagn. Lab. Immunol., 1:406-12 (1994).;;Jones et al., Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature, 321 :522-5 (1986).;;Karlin et al., Applications and statistics for multiple high-scoring segments in molecular sequences. Proc. Natl. Acad. Sci. USA, 90:5873-7 (1993).;;Keller et al., Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA, 271:17648 (1994).;;Kohler et al., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256:495-7 (1975).;;Koide et al., Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fraament of Borrelia burdorferi OspA. J. Mal. Biol. 350:290-9 (2005).;;Kozbor, A human hybrid myeloma for production of human monoclonal antibodies. J. Immunol., 133:3001-5 (1984).;;Lakey et al., Enhanced production of recombinant Mycobacterium tuberculosis antigens in Escherichia coli by replacement of low-usage codons. Infect. Immun., 68:233-8 (2000).;;Li et al., Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc. Natl. Acad. Sci. U.S.A., 94:3584-9 (1997).;;Lovrich et al., Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect. Immun. 63:2113-9 (1995).;;Luft et al., Approaches toward the directed design of a vaccine against Borrelia burgdorferi. J. Infect. Dis., 185 (Suppl.1): S46-51 (2002).;;Makoff et al., Expression of tetanus toxin fragment C in E. coli: High level expression by removing rare codons. Nucl. Acids Res., 17:10191-202 (1989).;;Marks et al., By-passing immunization: Human antibodies from V-gene libraries displayed on phaae. J. Mot. Biol., 222:581-97 (1991).;;Merrifield et al., Solid phase peptide synthesis: The synthesis of a tetrapeptide. J. Am. Chem. Soc., 85:2149-54 (1963).;;Morrison et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA, 81 :6851-5 (1985).;;Needleman et al., A general method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mal. Biol., 48:443-53 (1970).;;Ohtsuka et al., An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions. J. Biol. Chem., 260:2605-8 (1985).;;GenBank : CAA46551.1 (Apr. 18, 2005).;;Oliyai et al., Prodrugs of peptides and proteins for improved formulation and delivery. Ann. Rev. Pharmacol. T oxicol., 32 :521-44 (1993).;;Pakula et al., Genetic analysis of protein stability and function, Ann. Ref. Genet. 23: 289-310 (1989).;;Pal et al., Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. J. Immunol., 166: 7398-403 (2001 ).;;Pearson et al., Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA 85:2444-8 (1988).;;Riechmann et al.,Reshaping human antibody for therapy. Nature, 332:323-7 (1988).;;Rossolini et al., Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information. Mo/. Cell. Probes, 8:91-8 (1994).;;Sigal et al., A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N. En_qf. J. Med., 339:216-22 (1998).;;Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol., 18: 34-9 (2000).;;Smith et al., Comparison of bioseauences. Adv. Aool. Math. 2: 482-9 (1981).;;Steere et al., Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme disease vaccine study group. N. Engl. J. Med., 339: 209-15 (1998).;;Studier et al., Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mot. Biol., 189:113-30 (1986).;;Sutcliffe et al., Antibodies that react with predetermined sites on proteins. Science, 219:660-6 (1983).;;Takahashi et al., Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope D protein in ISCOMs. Nature, 344:873-5 (1990).;;Towbin, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: D procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-6 (1979).;;Van Hoecke et al., Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 14:1620-6 (1996).;;Verhoeyen et al., Reshaping human antibodies: Grafting an antilysozyme activity. Science, 239:1534-6 (1988).;;Will et al., Sequence analysis of ospA genes shows homogeneity within Borrelia burgdorferi sensu stricto and Borrelia afzelii strains but reveals major subgroups within the Borrelia garinii species. Med. Microbial. Immunol. 184:73-80, 1995.;;Wilske et al., An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J. Clin. Microbial., 31:340-50 (1993).;;Sep. 3, 2019 Office Action issued in connection with Brazilian Patent Application No. 1120120273159.;;Burkot et al., “An OspA Antigen-Capture Enzyme-Linked Immunosorbent Assay for Detecting North American Isolates of Borrelia burgdorferi in Larval and Nymphal Ixodes dammini”, Journal of Clinical Microbiology, Feb. 1993, vol. 31, No. 2, pp. 272-278.;;Comstedt et al., “Characterization and optimization of a novel vaccine for protection against Lyme borreliosis”, Vaccine, Vo. 33, pp. 5982-5988 (2015).;;Dykhuizen et al., “Borrelia burgdorferi is clonal: Implications for taxonoby and vaccine development”, Pro. Natl. Acad. Sci., vol. 90, pp. 10163-10167 (Nov. 1993) Evolution.;;First Examination Report issued in Indian Application No. 10517/DELNP/2012 dated Jan. 17, 2020.;;GenBank : CAA59728.1 (Apr. 18, 2005).;;LIVEY IAN; O'ROURKE MARIA; TRAWEGER ANDREAS; SAVIDIS-DACHO HELGA; CROWE BRIAN A; BARRETT P NOEL; YANG XIAOHUA; DUNN JOHN J; LUFT B: ""A New Approach to a Lyme Disease Vaccine"", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL., US, vol. 52, no. Supplement 3, 1 February 2011 (2011-02-01), US , pages S266 - S270, XP008139263, ISSN: 1058-4838, DOI: 10.1093/cid/ciq118;;Partial European Search Report issued in EP Application No. 19 21 7974 dated Jul. 8, 2020.;;Lapp et al., “AAP Issues Recommendations on the Prevention and Treatment of Lyme Disease”, American Family Physician, Jun. 1, 2000;61(11): 3463-3466.;;Korean Office Action dated Mar. 25, 2021 in connection with KR 10-2020-7016104.",ACTIVE
417,GB,B,GB 2383040 B,073-134-220-106-360,2006-03-01,2006,GB 0227108 A,2002-11-20,EP 01127349 A,2001-11-21,"Multiblock compounds comprising hydrocarbon blocks & fluorocarbon, siloxane, or oligo-/poly-(oxaalkylene) block and their use in liquid crystal materials",,MERCK PATENT GMBH,GREENFIELD SIMON;;HARDING RICHARD;;VAUGHAN-SPICKERS JULIAN;;SMITH ASHLEY;;MAY ALISON;;HASSALL IAN;;DUNN CHRISTOPHER,,https://lens.org/073-134-220-106-360,Granted Patent,no,3,0,3,3,0,C07C69/63;;C07C69/65;;C07C69/76;;C07C69/78;;C07C69/92;;C07C233/07;;C07C255/57;;C09K19/54;;C09K19/56;;C09K19/54;;C09K19/56,C07C69/767;;C07C69/63;;C07C69/65;;C07C69/76;;C07C69/773;;C07C69/78;;C07C69/92;;C07C233/07;;C07C255/57;;C09K19/54;;C09K19/56,C2C CAA;;C4X X12           X12TA;;C4X X12TA         X12TA;;U1S S1387;;U1S S1399;;U1S S1427;;U1S S1574;;U1S S1921;;U1S S1985;;U1S S2061;;U1S S2068;;U1S S2234;;U1S S2285,7,0,,,"Chemical Abstracts, abstr no 125:72142 & JP 08076097 A 22.03.1996;;Chemical Abstracts, abstr no 122:80828 & Journal of Materials Chemistry, 1994, Vol. 4(11), pages 1715-1717;;Chemical Abstracts, abstr no 122:162247 & High Performance Polymers, 1994, Vol. 6(2), pages 133-147;;Chemical Abstracts, abstr no 112:208093 & JP 01283258 A 14.11.1989;;Chemical Abstracts, abstr no 98:125615 & JP 57176931 A 30.10.1982;;Chemical Abstracts, abstr no 92:21882 & Zhurnal Obshchei Khimii, 1979, Vol. 49(8), pages 1872-1877;;Chemical Abstracts, abstr no 96:6314 & Adv. Liq. Cryst. Res. Appl., Proc. Liq. Cryst. Conf. Soc. Countries, 3rd (1981), Meeting Date 1979, Vol. 2, pages 1023-1028, Editor(s): Bata, Lajos, Publisher: Pergamon, Oxford, Engl.",EXPIRED
418,AU,A,AU 2002/018190 A,080-043-024-840-998,2002-05-27,2002,AU 2002/018190 A,2001-09-21,EP 00124365 A;;EP 0110944 W,2000-11-20,Chiral photoisomerizable compounds,"The invention relates to chiral photoisomerizable compounds of formula (I) wherein X<SUP>1</SUP>, X<SUP>2</SUP>, X<SUP>3</SUP>, X<SUP>4</SUP>, X<SUP>5 </SUP>and X<SUP>6 </SUP>have the meanings given in claim 1 , to liquid crystalline mixtures and polymers containing them, and to the use of chiral photoisomerizable compounds, liquid crystalline mixtures and polymers containing them in optical and electrooptical devices like liquid crystal displays or projection systems, in optical elements like polarizers, retardation films, compensators, color filters or holographic elements, in liquid crystal pigments and colored films or coatings for decorative or security applications, cosmetic and pharmaceutical compositions, in nonlinear optics and optical information storage.",MERCK PATENT GMBH,VAUGHAN-SPICKERS JULIAN;;DUNN CHRISTOPHER;;HARDING RICHARD;;HASSALL IAN;;JENKINS TONY;;MAY ALISON;;GREENFIELD SIMON,,https://lens.org/080-043-024-840-998,Patent Application,no,0,0,13,13,0,C09K19/2028;;C09K19/586;;C09K2219/03;;C09K2323/00;;C09K19/58;;C09K19/2028;;C09K2219/03;;C09K19/586;;C09K2323/00,G02B5/30;;C07C69/76;;C07C69/767;;C09K19/20;;C09K19/38;;C09K19/54;;C09K19/58;;G02F1/13;;G02F1/1335,,0,0,,,,PENDING
419,DE,D1,DE 60134886 D1,100-824-215-265-047,2008-08-28,2008,DE 60134886 T,2001-09-21,EP 00124365 A;;EP 0110944 W,2000-11-20,CHIRALE PHOTOISOMERISIERBARE VERBINDUNGEN,"The invention relates to chiral photoisomerizable compounds of formula (I) wherein X<SUP>1</SUP>, X<SUP>2</SUP>, X<SUP>3</SUP>, X<SUP>4</SUP>, X<SUP>5 </SUP>and X<SUP>6 </SUP>have the meanings given in claim 1 , to liquid crystalline mixtures and polymers containing them, and to the use of chiral photoisomerizable compounds, liquid crystalline mixtures and polymers containing them in optical and electrooptical devices like liquid crystal displays or projection systems, in optical elements like polarizers, retardation films, compensators, color filters or holographic elements, in liquid crystal pigments and colored films or coatings for decorative or security applications, cosmetic and pharmaceutical compositions, in nonlinear optics and optical information storage.",MERCK PATENT GMBH,VAUGHAN-SPICKERS JULIAN;;DUNN CHRISTOPHER;;HARDING RICHARD;;HASSALL IAN;;JENKINS TONY;;MAY ALISON;;GREENFIELD SIMON,,https://lens.org/100-824-215-265-047,Granted Patent,no,0,0,13,13,0,C09K19/2028;;C09K19/586;;C09K2219/03;;C09K2323/00;;C09K19/58;;C09K19/2028;;C09K2219/03;;C09K19/586;;C09K2323/00,C09K19/58;;G02B5/30;;C07C69/76;;C07C69/767;;C09K19/20;;C09K19/38;;C09K19/54;;G02F1/13;;G02F1/1335,,0,0,,,,EXPIRED
420,WO,A1,WO 2001/029041 A1,057-996-341-914-945,2001-04-26,2001,EP 0010077 W,2000-10-13,US 16080499 P;;US 21371800 P,1999-10-21,ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,"Alkylamino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives of formula (I) are provided wherein R1-R3 are as defined in the application which are useful as inhibitors of p38, along with a process for their manufacture and pharmaceutical preparations containing them.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/057-996-341-914-945,Patent Application,yes,4,68,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,PATENTED
421,EP,B1,EP 1339812 B1,087-623-326-903-996,2008-07-16,2008,EP 01996586 A,2001-09-21,EP 01996586 A;;EP 0110944 W;;EP 00124365 A,2000-11-20,CHIRAL PHOTOISOMERIZABLE COMPOUNDS,"The invention relates to chiral photoisomerizable compounds of formula (I) wherein X<SUP>1</SUP>, X<SUP>2</SUP>, X<SUP>3</SUP>, X<SUP>4</SUP>, X<SUP>5 </SUP>and X<SUP>6 </SUP>have the meanings given in claim 1 , to liquid crystalline mixtures and polymers containing them, and to the use of chiral photoisomerizable compounds, liquid crystalline mixtures and polymers containing them in optical and electrooptical devices like liquid crystal displays or projection systems, in optical elements like polarizers, retardation films, compensators, color filters or holographic elements, in liquid crystal pigments and colored films or coatings for decorative or security applications, cosmetic and pharmaceutical compositions, in nonlinear optics and optical information storage.",MERCK PATENT GMBH,VAUGHAN-SPICKERS JULIAN;;DUNN CHRISTOPHER;;HARDING RICHARD;;HASSALL IAN;;JENKINS TONY;;MAY ALISON;;GREENFIELD SIMON,,https://lens.org/087-623-326-903-996,Granted Patent,yes,1,1,13,13,0,C09K19/2028;;C09K19/586;;C09K2219/03;;C09K2323/00;;C09K19/58;;C09K19/2028;;C09K2219/03;;C09K19/586;;C09K2323/00,C09K19/58;;G02B5/30;;C07C69/76;;C07C69/767;;C09K19/20;;C09K19/38;;C09K19/54;;G02F1/13;;G02F1/1335,,4,0,,,"K. YOKOTA ET AL: ""chirality induction in cyclopolymerization XI. Bulkiness effect of 1,2-diol templateson cyclopolymerizations of bis(4-vinylbenzoate)s with styrene"" POLYMER JOURNAL, vol. 31, no. 11-2, 1999, pages 1037-1040, XP001053658;;S.M. KELLY ET AL: ""Four-unit linking groups V. optically active dopants"" LIQUID CRYSTALS, vol. 11, no. 5, 1992, pages 761-771, XP002192313;;WITTE VAN DE P ET AL: ""MODIFICATION OF THE PITCH OF CHIRAL NEMATIC LIQUID CRYSTALS BY MEANS OF PHOTOISOMERIZATION OF CHIRAL DOPANTS"" LIQUID CRYSTALS, TAYLOR AND FRANCIS LTD, LONDON, GB, vol. 24, no. 6, 1 June 1998 (1998-06-01), pages 819-827, XP000773004 ISSN: 0267-8292 cited in the application;;DEUSSEN H-J ET AL: ""NEW 6,-6-DISUBSTITUTED-BINAPHTHOL DERIVATIVES AS CHIRAL DOPANTS: SYNTHESIS AND TEMPERATURE DEPENDENCE OF MOLECULAR CONFORMATIONS"" LIQUID CRYSTALS, TAYLOR AND FRANCIS LTD, LONDON, GB, vol. 21, no. 3, 1 September 1996 (1996-09-01), pages 327-340, XP000629493 ISSN: 0267-8292 cited in the application",EXPIRED
422,WO,A1,WO 2002/040614 A1,108-126-986-207-024,2002-05-23,2002,EP 0110944 W,2001-09-21,EP 00124365 A,2000-11-20,CHIRAL PHOTOISOMERIZABLE COMPOUNDS,"The invention relates to chiral photoisomerizable compounds of formula (I) wherein X?1, X2, X3, X4, X5 and X6¿ have the meanings given in claim 1, to liquid crystalline mixtures and polymers containing them, and to the use of chiral photoisomerizable compounds, liquid crystalline mixtures and polymers containing them in optical and electrooptical devices like liquid crystal displays or projection systems, inoptical elements like polarizers, retardation films, compensators, colour filters or holographic elements, in liquid crystal pigments and coloured films or coatings for decorative or security applications, cosmetic and pharmaceutical compositions, in nonlinear optics and optical information storage.",MERCK PATENT GMBH;;VAUGHAN SPICKERS JULIAN;;DUNN CHRISTOPHER;;HARDING RICHARD;;HASSALL IAN;;JENKINS TONY;;MAY ALISON;;GREENFIELD SIMON,VAUGHAN-SPICKERS JULIAN;;DUNN CHRISTOPHER;;HARDING RICHARD;;HASSALL IAN;;JENKINS TONY;;MAY ALISON;;GREENFIELD SIMON,,https://lens.org/108-126-986-207-024,Patent Application,yes,1,12,13,13,0,C09K19/2028;;C09K19/586;;C09K2219/03;;C09K2323/00;;C09K19/58;;C09K19/2028;;C09K2219/03;;C09K19/586;;C09K2323/00,G02B5/30;;C07C69/76;;C07C69/767;;C09K19/20;;C09K19/38;;C09K19/54;;C09K19/58;;G02F1/13;;G02F1/1335,,4,4,032-710-801-144-432;;106-636-245-165-485;;028-367-749-113-187;;010-180-958-180-681,10.1295/polymj.31.1037;;10.1080/02678299208029027;;10.1080/026782998206632;;10.1080/02678299608032841,"K. YOKOTA ET AL: ""chirality induction in cyclopolymerization XI. Bulkiness effect of 1,2-diol templateson cyclopolymerizations of bis(4-vinylbenzoate)s with styrene"", POLYMER JOURNAL, vol. 31, no. 11-2, 1999, pages 1037 - 1040, XP001053658;;S.M. KELLY ET AL: ""Four-unit linking groups V. optically active dopants"", LIQUID CRYSTALS, vol. 11, no. 5, 1992, pages 761 - 771, XP002192313;;WITTE VAN DE P ET AL: ""MODIFICATION OF THE PITCH OF CHIRAL NEMATIC LIQUID CRYSTALS BY MEANS OF PHOTOISOMERIZATION OF CHIRAL DOPANTS"", LIQUID CRYSTALS, TAYLOR AND FRANCIS LTD, LONDON, GB, vol. 24, no. 6, 1 June 1998 (1998-06-01), pages 819 - 827, XP000773004, ISSN: 0267-8292;;DEUSSEN H-J ET AL: ""NEW 6,-6-DISUBSTITUTED-BINAPHTHOL DERIVATIVES AS CHIRAL DOPANTS: SYNTHESIS AND TEMPERATURE DEPENDENCE OF MOLECULAR CONFORMATIONS"", LIQUID CRYSTALS, TAYLOR AND FRANCIS LTD, LONDON, GB, vol. 21, no. 3, 1 September 1996 (1996-09-01), pages 327 - 340, XP000629493, ISSN: 0267-8292",PATENTED
423,GB,A,GB 2383040 A,071-439-659-147-34X,2003-06-18,2003,GB 0227108 A,2002-11-20,EP 01127349 A,2001-11-21,"Multiblock compounds comprising hydrocarbon moiety & fluorocarbon, siloxane, or oligo- or poly(oxaalkylene) moiety as an additive in liquid crystal materials","Compounds having a multiblock structure are disclosed which comprise at least one first block, comprising an aliphatic, alicyclic, aromatic or araliphatic hydrocarbon group (""hydrocarbon block""), and at least one second block, comprising a fluorocarbon, siloxane or oliogo- or poly(oxaalkylene) group (""surfactant block"") provided such compounds comprise either at least two hydrocarbon blocks or at least one hydrocarbon block comprising a cyclic group. The compounds may be added to liquid crystal materials (eg polymerisable films) and used to control the orientation of such materials at the material/substrate and/or material/air interface, to promote adhesion between such materials and the substrate and/or subsequent liquid crystals or polymer layers, or to promote wetting of the substrate and/or other layers. In the examples, the surfactant block comprises -(CF 2 ) n - (where n is from 6 to 10) or a 2,3,5,6-tetrafluoro-1,4-phenylene and the hydrocarbon block comprises a branched alkyl group, phenyl or 4-substituted phenyl.",MERCK PATENT GMBH,GREENFIELD SIMON;;HARDING RICHARD;;VAUGHAN-SPICKERS JULIAN;;SMITH ASHLEY;;MAY ALISON;;HASSALL IAN;;DUNN CHRISTOPHER,,https://lens.org/071-439-659-147-34X,Patent Application,no,1,11,3,3,0,C07C69/63;;C07C69/65;;C07C69/76;;C07C69/78;;C07C69/92;;C07C233/07;;C07C255/57;;C09K19/54;;C09K19/56;;C09K19/54;;C09K19/56,C07C69/767;;C07C69/773;;C09K19/54;;C09K19/56,C2C CAA;;C4X X12           X12TA;;C4X X12TA         X12TA;;U1S S1387;;U1S S1399;;U1S S1427;;U1S S1574;;U1S S1921;;U1S S1985;;U1S S2061;;U1S S2068;;U1S S2234;;U1S S2285,7,0,,,"Chemical Abstracts, abstr no 125:72142 & JP 08076097 A 22.03.1996;;Chemical Abstracts, abstr no 122:80828 & Journal of Materials Chemistry, 1994, Vol. 4(11), pages 1715-1717;;Chemical Abstracts, abstr no 122:162247 & High Performance Polymers, 1994, Vol. 6(2), pages 133-147;;Chemical Abstracts, abstr no 112:208093 & JP 01283258 A 14.11.1989;;Chemical Abstracts, abstr no 98:125615 & JP 57176931 A 30.10.1982;;Chemical Abstracts, abstr no 92:21882 & Zhurnal Obshchei Khimii, 1979, Vol. 49(8), pages 1872-1877;;Chemical Abstracts, abstr no 96:6314 & Adv. Liq. Cryst. Res. Appl., Proc. Liq. Cryst. Conf. Soc. Countries, 3rd (1981), Meeting Date 1979, Vol. 2, pages 1023-1028, Editor(s): Bata, Lajos, Publisher: Pergamon, Oxford, Engl.",EXPIRED
424,MX,A,MX 2012013264 A,130-644-154-958-834,2014-12-05,2014,MX 2012013264 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES.,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/130-644-154-958-834,Patent Application,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,0,0,,,,ACTIVE
425,MA,A1,MA 26836 A1,160-885-222-873-222,2004-12-20,2004,MA 26611 A,2002-04-19,US 16080499 P;;US 21371800 P,1999-10-21,HETEROCYCLES AZOTES BICYCLIQUES ALKYLAMINO SUBSTITUES EN TANT QU'INHIBITEURS DE KINASE DE PROTEINE P38.,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;SMITH IAN EDWARD DAVID;;HARRIS WILLIAM;;WELCH TERESA ROSANNE,,https://lens.org/160-885-222-873-222,Granted Patent,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
426,CA,C,CA 2799181 C,197-610-044-609-567,2023-10-24,2023,CA 2799181 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BAXTER INT;;BAXTER HEALTHCARE SA;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/197-610-044-609-567,Granted Patent,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,0,0,,,,PENDING
427,JP,A,JP 2016168057 A,189-430-467-992-635,2016-09-23,2016,JP 2016126608 A,2016-06-27,US 33490110 P,2010-05-14,OspA CHIMERAS AND METHODS OF USE THEREOF IN VACCINES,"PROBLEM TO BE SOLVED: To provide OspA chimeras and methods of use thereof in vaccines.SOLUTION: The invention relates to the development of chimeric OspA molecules for use in novel Lyme vaccine. More specifically, the chimeric OspA molecules comprise a proximal portion from one OspA serotype, together with a distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.SELECTED DRAWING: None",BAXALTA INC;;BAXALTA GMBH;;RES FOUND OF THE STATE UNIV OF NEW YORK;;BROOKHAVEN SCIENCE ASS LLC,BRIAN A CROWE;;LIVEY IAN;;MARIA O'ROURKE;;MICHAEL SCHWENDINGER;;JOHN J DUNN;;BENJAMIN J LUFF,,https://lens.org/189-430-467-992-635,Patent Application,no,0,0,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C12N15/09;;A01K67/027;;A61K31/713;;A61K35/74;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/00;;A61K39/00;;A61K39/295;;A61K48/00;;A61P31/00;;A61P33/00;;C07K14/20;;C07K16/12;;C07K19/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N7/01;;C12P21/02,,0,0,,,,DISCONTINUED
428,US,B1,US 6642241 B1,080-538-723-394-602,2003-11-04,2003,US 69336400 A,2000-10-20,US 69336400 A;;US 21371800 P;;US 16080499 P,1999-10-21,Alkylamino-substituted bicyclic nitrogen heterocycles,"
    Alkylamino-substituted dihydropyrimido4,5-dpyrimidinone derivatives are provided which are useful as inhibitors of p38, along with a process for their manufacture and pharmaceutical preparations containing them. 
",SYNTEX LLC,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,SYNTEX (U.S.A.) LLC (2000-12-21),https://lens.org/080-538-723-394-602,Granted Patent,yes,5,9,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,514/258;;544/256,1,1,007-149-791-139-148,11333350;;10.1097/00002281-200105000-00010,"Graninger et al. Curr. Opin. Rheumatol. 13(3): 209-213,2001.",EXPIRED
429,KR,A,KR 20200084062 A,118-256-072-772-818,2020-07-09,2020,KR 20207018904 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,"본 발명은 라임 질환에 대항 또는 보렐리아증 백신에 사용하기 위한 키메라 OspA 분자의 개발에 관한 것이다. 보다 구체적으로, 상기 키메라 OspA 분자는 또 다른 OspA 혈청형으로부터의 원거리 부분과 함께 하나의 OspA 혈청형으로부터 인접한 부분을 포함하고 모 폴리펩타이드 둘다의 항원성 성질을 보유한다. 상기 키메라 OspA 분자는 다양한 보렐리아 동유전자종으로부터의 보호를 제공하기 위해 단독으로 또는 조합하여 전달된다.",BAXALTA INC;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASSOCIATES LLC;;BAXALTA GMBH,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/118-256-072-772-818,Patent Application,no,3,0,74,74,346,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/00;;A61K39/02;;A61P31/00;;C07K14/20,,0,0,,,,ACTIVE
430,EP,A1,EP 1226144 A1,043-370-807-334-609,2002-07-31,2002,EP 00972755 A,2000-10-13,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/043-370-807-334-609,Patent Application,yes,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
431,PL,T3,PL 2569008 T3,157-943-337-949-682,2021-04-19,2021,PL 11720967 T,2011-05-13,US 33490110 P;;EP 11720967 A;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,,BAXALTA INC;;BAXALTA GMBH;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/157-943-337-949-682,Patent Application,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,0,0,,,,PENDING
432,KR,A,KR 20130133120 A,063-520-729-628-770,2013-12-06,2013,KR 20127032560 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,,BAXTER INT;;BAXTER HEALTHCARE SA;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/063-520-729-628-770,Patent Application,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C07K14/20;;A61K39/02,,0,0,,,,DISCONTINUED
433,NO,L,NO 20021783 L,080-758-139-897-707,2002-04-16,2002,NO 20021783 A,2002-04-16,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,Alkylamino-substituerte bicykliske nitrogen-heterocykler som inhibitorer for P38-protein-kinase,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/080-758-139-897-707,Abstract,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
434,CA,C,CA 2388140 C,190-741-527-133-626,2008-09-02,2008,CA 2388140 A,2000-10-13,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,"Alkylamino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives of formula (I) are provided wherein R1-R3 are as defined in the application which are useful as inhibitors of p38, along with a process for their manufacture and pharmaceutical preparations containing them.",HOFFMANN LA ROCHE,GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;DUNN JAMES PATRICK;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/190-741-527-133-626,Granted Patent,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
435,US,A1,US 2012/0020973 A1,042-536-668-698-592,2012-01-26,2012,US 201113107796 A,2011-05-13,US 201113107796 A;;US 33490110 P,2010-05-14,"CHIMERIC OSPA GENES, PROTEINS, AND METHODS OF USE THEREOF","The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.",CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J;;BAXTER INT;;BROOKHAVEN SCIENCES ASS LLC;;UNIV NEW YORK STATE RES FOUND;;BAXTER HEALTHCARE SA,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,BAXALTA INCORPORATED (2015-11-19);;BROOKHAVER SCIENCE ASSOCIATES (2011-06-10);;THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (2012-01-31);;BAXALTA GMBH (2015-11-19);;BAXTER INTERNATIONAL INC (2011-05-20),https://lens.org/042-536-668-698-592,Patent Application,yes,0,13,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/40;;A61K39/02;;A61K39/116;;A61K39/295;;A61P31/04;;A61P31/14;;A61P37/04;;C07K14/20;;C07K16/12;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/31;;C12N15/63;;C12P21/02,424/139.1;;536/23.7;;435/320.1;;435/69.3;;435/252.33;;435/254.2;;435/348;;435/325;;530/350;;530/387.9;;424/234.1;;424/190.1,2,2,063-640-832-834-034;;029-611-134-469-353,10631780;;10.1016/s0167-7799(99)01398-0;;7516563;;10.1016/s0923-2494(94)80039-1,"Skolnick et al. (Trends in Biotechnology 18: 34-39, 2000);;Colman Res. (Immunology, Jan 1994, Vol. 145, pages 33-36)",ACTIVE
436,US,B2,US 9895434 B2,064-759-084-430-054,2018-02-20,2018,US 201615049438 A,2016-02-22,US 201615049438 A;;US 201314078390 A;;US 201113107796 A;;US 33490110 P,2010-05-14,"Chimeric OspA genes, proteins and methods of use thereof","The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.",BAXALTA INC;;BAXALTA GMBH;;RESEARCH FOUNDATION OF THE STATE UNIV OF NEW YORK;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;OROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,BAXTER HEALTHCARE SA (2011-05-20);;BAXALTA INCORPORATED (2015-11-19);;BAXALTA GMBH (2015-11-19);;BAXTER INTERNATIONAL INC (2011-05-20);;RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (2012-01-31);;BROOKHAVEN SCIENCE ASSOCIATES LLC (2011-06-10),https://lens.org/064-759-084-430-054,Granted Patent,yes,53,0,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C07K14/20;;A61K39/00;;A61K39/02,,68,64,056-201-471-905-934;;027-829-588-585-761;;023-730-857-866-719;;104-921-466-213-292;;102-662-593-894-426;;054-732-712-502-061;;010-519-409-512-153;;029-611-134-469-353;;160-840-803-687-381;;029-683-169-457-195;;066-141-497-990-023;;115-303-705-496-498;;025-189-084-402-882;;030-839-409-040-828;;014-935-196-346-195;;136-216-971-174-99X;;096-611-689-245-37X;;012-830-491-824-205;;003-323-279-619-527;;129-466-277-652-523;;072-366-322-919-406;;007-542-078-714-566;;011-820-307-395-282;;023-907-179-348-058;;032-071-991-081-664;;055-792-532-851-126;;081-525-182-466-362;;057-200-638-752-266;;000-150-741-285-140;;006-574-964-805-278;;019-779-601-634-917;;006-742-514-479-110;;106-753-778-592-300;;035-616-782-811-647;;048-564-471-521-204;;003-430-460-951-798;;029-026-124-030-198;;065-101-341-902-59X;;003-448-860-121-684;;060-196-670-596-725;;020-855-322-534-259;;026-944-353-804-488;;030-607-398-087-475;;032-728-154-591-070;;111-109-974-501-414;;101-242-387-154-198;;110-082-824-995-005;;066-525-457-224-28X;;085-764-009-624-439;;042-204-626-457-327;;048-183-620-015-85X;;062-024-235-743-200;;063-640-832-834-034;;017-216-732-209-839;;053-122-459-007-90X;;115-802-414-738-000;;077-903-001-903-019;;001-147-941-858-547;;017-738-995-123-197;;004-067-735-797-199;;045-094-249-115-990;;068-843-666-295-283;;073-466-339-901-688;;096-611-689-245-37X,2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;2388567;;10.1016/0076-6879(90)84268-l;;2447170;;2761388;;10.1111/j.1365-2958.1989.tb00194.x;;10.1006/abio.1996.9982;;9056182;;6263759;;10.1016/0378-1119(81)90008-1;;7516563;;10.1016/s0923-2494(94)80039-1;;9709052;;10.1056/nejm199808203390819;;pmc2192397;;10.1084/jem.183.1.271;;8551231;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1006/jmbi.2000.4119;;11183781;;10.1002/anie.198907161;;10.1128/iai.61.1.81-90.1993;;8418068;;pmc302690;;8961139;;10.1021/js960158a;;10.1093/protein/13.8.575;;10964987;;9330467;;10.1016/s0264-410x(97)00066-2;;pmc345355;;6204335;;10.1073/pnas.81.13.3998;;10.1128/iai.65.3.882-889.1997;;pmc175064;;9038292;;7639011;;10.1016/0264-410x(94)00027-k;;4705382;;10.1016/0042-6822(73)90341-3;;9685265;;10.1126/science.281.5377.703;;10.1093/dnares/4.4.257;;9405933;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0022-2836(92)90894-p;;1404359;;2410914;;pmc390513;;10.1073/pnas.82.15.5131;;pmc260138;;3019889;;10.1128/iai.54.1.207-212.1986;;2295795;;8556477;;pmc368276;;10.1128/cdli.1.4.406-412.1994;;10.1038/321522a0;;3713831;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;10.1001/jama.1994.03510460056033;;8196120;;10.1001/jama.271.22.1764;;1172191;;10.1038/256495a0;;15935380;;10.1016/j.jmb.2005.04.066;;10.4049/jimmunol.133.6.3001;;6092464;;10603393;;pmc97126;;10.1128/iai.68.1.233-238.2000;;9108020;;pmc20483;;10.1073/pnas.94.8.3584;;pmc173274;;10.1128/iai.63.6.2113-2119.1995;;7768589;;10.1086/338463;;11865439;;pmc335293;;10.1093/nar/17.24.10191;;2690015;;1748994;;10.1016/0022-2836(91)90498-u;;10.1021/ja00897a025;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1016/0022-2836(70)90057-4;;5420325;;10.1016/s0021-9258(18)89400-5;;3838308;;8494350;;10.1146/annurev.pharmtox.33.1.521;;10.1146/annurev.pa.33.040193.002513;;2694933;;10.1146/annurev.genet.23.1.289;;10.1146/annurev.ge.23.120189.001445;;10.4049/jimmunol.166.12.7398;;11390491;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;3127726;;10.1038/332323a0;;10.1006/mcpr.1994.1013;;7935517;;10.1056/nejm199807233390402;;9673299;;10631780;;10.1016/s0167-7799(99)01398-0;;10.1016/0196-8858(81)90046-4;;9673298;;10.1056/nejm199807233390401;;10.1016/0022-2836(86)90385-2;;3537305;;6186024;;10.1126/science.6186024;;2184369;;10.1038/344873a0;;pmc411572;;388439;;10.1073/pnas.76.9.4350;;10.1016/s0264-410x(96)00146-6;;9032890;;10.1126/science.2451287;;2451287;;7500914;;10.1007/bf00221390;;10.1128/jcm.31.2.340-350.1993;;pmc262762;;8432821;;9330467;;10.1016/s0264-410x(97)00066-2,"Altschul et al., Basic local alignment search tool. J. Mol. Biol., 215:403-10 (1990).;;Batzer et al., Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus. Nucleic Acid Res., 19:5081 (1991).;;Bayer et al., Protein biotinylation. Meth. Enzym., 184:138-163 (1990).;;Benach et al., A murine IgM monoclonal antibody binds an antigenic determinant in outer surface protein A, an immundominant basic protein of the Lyme disease spirochete. J. Immunol., 140:265-72 (1988).;;Bergstrom et al., Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Molec. Microbiol. 3:479-86 (1989).;;Bouchon et al., Analysis of the lipidated recombinant outer surface protein A from Borrelia burgdorferi by mass spectrometry. Anal. Biochem., 246: 52-61 (1997).;;Chu et al., SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen. Gene, 13:197-202 (1981).;;Colman et al., Effects of amino acid sequence changes on antibody-antigen interactions. Res. Immunology, 145: 33-6 (1994).;;Correction: A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein a to prevent lyme disease. N. Engl. J. Med., 339:571 (1998).;;de Silva et al., Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med., 183: 271-5 (1996).;;Devereux et al., A comprehensive set of sequence analysis programs for the VAX. Nucl. Acid. Res., 12:387-95 (1984).;;Ding et al., Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. J. Mol. Biol., 302: 1153-64 (2000).;;Engels et al., Gene Synthesis. Angew. Chem. Intl. Ed., 28:716-734 (1989).;;Erdile et al., Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect. Immun., 61: 81-90 (1993).;;Fix, Strategies for delivery of peptides utilizing absorption-enhancing agents. J. Pharm. Sci., 85:1282-5 (1996).;;Francis et al., Protein modification and fusion proteins. Focus on Growth Factors, 3:4-10 (1992).;;Frankel et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng. 13(8): 575-81 (2000).;;Gern et al., Immunization with a polyvalent OspA vaccine protects mice again loxides ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine, 15:1551-7 (1997).;;Geysen et al., Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl. Acad. Sci. USA, 81:3998-4002 (1984).;;Golde et al., Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect. Immun., 65: 882-9 (1997).;;Golde et al., The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Vaccine, 13:435-41 (1995).;;Graham et al., A new technology for the assay of infectivity of human adenovirus 5 DNA. Virology, 52:456-67 (1973).;;Gross et al., Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis, Science, 281: 703-6 (1998).;;Guerdoux-Jamet et. al., Using codon usage to predict genes origin: is the Escherichia coli outer membrane a patchwork of products from different genomes? DNA Res., 4:257-65 (1997).;;Henikoff et al., Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA, 89:10915-9 (1992).;;Hoogenboom et al., By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol., 227:381-8 (1991).;;Houghten et al., General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at teh level of individual amino acids. Proc. Natl. Acad. Sci. USA, 82: 5131-5 (1985).;;Howe et al., Organization of genes encoding two outer membrane proteins of the Lyme disease agent Borrelia burgdorferi within a single transcriptional unit, Infect. Immun. 54:207-12 (1986).;;International Search Report and Written Opinion of the International Searching Authority, PCT/US2011/036525, dated Jul. 12, 2011.;;International Search Report, PCT/US2011/036533, dated Sep. 13, 2011.;;Jiang et al., Cross-antigenicity between the major surface proteins (ospA and ospB) and other proteins of Borrelia burgdorferi. J. Immunol., 144: 284-9 (1990).;;Jiang et al., Purification of Borrelia burgdorferi outer surface protein A (OspA) and analysis of antibody binding domains. Clin. Diagn. Lab. Immunol., 1:406-12 (1994).;;Jones et al., Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature, 321:522-5 (1986).;;Karlin et al., Applications and statistics for multiple high-scoring segments in molecular sequences. Proc. Natl. Acad. Sci. USA, 90:5873-7 (1993).;;Keller et al., Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA, 271:1764 8 (1994).;;Kohler et al., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256:495-7 (1975).;;Koide et al., Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burdorferi OspA. J. Mol. Biol. 350:290-9 (2005).;;Kozbor, A human hybrid myeloma for production of human monoclonal antibodies. J. Immunol., 133:3001-5 (1984).;;Lakey et al., Enhanced production of recombinant Mycobacterium tuberculosis antigens in Escherichia coli by replacement of low-usage codons. Infect. Immun., 68:233-8 (2000).;;Li et al., Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc. Natl. Acad. Sci. U.S.A., 94:3584-9 (1997).;;Lovrich et al., Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect. Immun. 63:2113-9 (1995).;;Luft et al., Approaches toward the directed design of a vaccine against Borrelia burgdorferi. J. Infect. Dis., 185(Suppl. 1): S46-51 (2002).;;Makoff et al., Expression of tetanus toxin fragment C in E. coli: High level expression by removing rare codons. Nucl. Acids Res., 17:10191-202 (1989).;;Marks et al., By-passing immunization: Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol., 222:581-97 (1991).;;Merrifield et al., Solid phase peptide synthesis: The synthesis of a tetrapeptide. J. Am. Chem. Soc., 85:2149-54 (1963).;;Morrison et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA, 81:6851-5 (1985).;;Needleman et al., A general method applicable to the search for similarities in the amino acid sequqnece of two proteins. J. Mol. Biol., 48:443-53 (1970).;;Ohtsuka et al., An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions. J. Biol. Chem., 260:2605-8 (1985).;;Oliyai et al., Prodrugs of peptides and proteins for improved formulation and delivery. Ann. Rev. Pharmacol. Toxicol., 32:521-44 (1993).;;Pakula et al., Genetic analysis of protein stability and function, Ann. Ref. Genet. 23: 289-310 (1989).;;Pal et al., Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. J. Immunol., 166: 7398-403 (2001).;;Pearson et al., Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA 85:2444-8 (1988).;;Riechmann et al.,Reshaping human antibody for therapy. Nature, 332:323-7 (1988).;;Rossolini et al., Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information. Mol. Cell. Probes, 8:91-8 (1994).;;Sigal et al., A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N. Engl. J. Med., 339:216-22 (1998).;;Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol., 18: 34-9 (2000).;;Smith et al., Comparison of biosequences. Adv. Appl. Math. 2:482-9 (1981).;;Steere et al., Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme disease vaccine study group. N. Engl. J. Med., 339: 209-15 (1998).;;Studier et al., Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol., 189:113-30 (1986).;;Sutcliffe et al., Antibodies that react with predetermined sites on proteins. Science, 219:660-6 (1983).;;Takahashi et al., Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature, 344:873-5 (1990).;;Towbin, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-6 (1979).;;Van Hoecke et al., Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 14:1620-6 (1996).;;Verhoeyen et al., Reshaping human antibodies: Grafting an antilysozyme activity. Science, 239:1534-6 (1988).;;Will et al., Sequence analysis of ospA genes shows homogeneity within Borrelia burgdorferi sensu stricto and Borrelia afzelii strains but reveals major subgroups within the Borrelia garinii species. Med. Microbiol. Immunol. 184:73-80, 1995.;;Wilske et al., An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J. Clin. Microbiol., 31:340-50 (1993).;;Gern L. et al., “Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii” Vaccine, vol. 15, No. 14, pp. 1551-1557 (1997).;;Aug. 31, 2017 Office Action issued in connection with KR 10-2012-7032560.",ACTIVE
437,GB,B,GB 2434822 B,097-708-534-019-623,2009-08-19,2009,GB 0701836 A,2007-01-31,GB 0602291 A,2006-02-04,Modular bridge construction,,QINETIQ LTD,JONES DOUGLAS HUGH;;DUNN IAN JOHN;;MORGAN COLIN PETER;;ARDLEY SCOTT;;STARINK LINDA MARY PATRICIA,,https://lens.org/097-708-534-019-623,Granted Patent,no,3,0,6,6,0,E01D15/133;;E01D2101/40;;E01D15/133;;E01D21/10;;E04G3/18;;E01D15/133;;E01D2101/40,E01D15/133;;E01D21/10;;E04G3/18,,0,0,,,,INACTIVE
438,CA,A1,CA 2388140 A1,124-733-632-245-263,2001-04-26,2001,CA 2388140 A,2000-10-13,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,"Alkylamino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives of formula (I) are provided wherein R1-R3 are as defined in the application whi ch are useful as inhibitors of p38, along with a process for their manufacture and pharmaceutical preparations containing them.",HOFFMANN LA ROCHE,HARRIS WILLIAM;;GOLDSTEIN DAVID MICHAEL;;DUNN JAMES PATRICK;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/124-733-632-245-263,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
439,TR,T2,TR 200201058 T2,175-271-417-951-348,2002-07-22,2002,TR 200201058 T,2000-10-13,US 16080499 P;;US 21371800 P,1999-10-21,"P38 protein kinaz inhibitörleri olarak, alkilaminoyla ornatılmış bisiklik, azotlu heterosikller","R -R kökleri isbu patent müracaatinda tanimlandiklari gibi olmak üzere, asagidaki (I) formülüne sahip, p38 inhibitörleri olarak yararli, alkilamino ile ornatilmis dihidropirimido[4,5-d]pirimidinon türevleri: Formül (1) ve bunlarin yani sira, bunlarin imal edilmelerine yönelik bir proses ve bunlari içeren ilaç preparatlari saglanmistir.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHEAL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAWID;;WELCH TERESA ROSANNE,,https://lens.org/175-271-417-951-348,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
440,CN,A,CN 107641151 A,176-718-821-415-488,2018-01-30,2018,CN 201710853809 A,2011-05-13,US 33490110 P;;CN 201180033682 A,2010-05-14,OspA chimeras and use thereof in vaccines,"The invention relates to OSPA chimeras and use thereof in vaccines, more specifically, the invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BAXALTA INC;;BAXALTA GMBH;;RESEARCH FOUNDATION OF THE STATE UNIV OF NEW YORK;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/176-718-821-415-488,Patent Application,no,8,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C07K14/20;;A61K39/02;;A61K39/116;;A61P31/04;;C12N15/31,,2,1,075-861-209-465-702,25185574;;pmc4248771;;10.1128/cvi.00406-14,"NINA WRESSNIGG: ""A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato."", 《CLINICAL AND VACCINE IMMUNOLOGY》;;汪桂清: ""莱姆病疫苗研制进展"", 《国外医学.预防.诊断.治疗用生物制品分册》",ACTIVE
441,AT,T1,AT E401383 T1,070-419-934-520-66X,2008-08-15,2008,AT 01996586 T,2001-09-21,EP 00124365 A,2000-11-20,CHIRALE PHOTOISOMERISIERBARE VERBINDUNGEN,"The invention relates to chiral photoisomerizable compounds of formula (I) wherein X<SUP>1</SUP>, X<SUP>2</SUP>, X<SUP>3</SUP>, X<SUP>4</SUP>, X<SUP>5 </SUP>and X<SUP>6 </SUP>have the meanings given in claim 1 , to liquid crystalline mixtures and polymers containing them, and to the use of chiral photoisomerizable compounds, liquid crystalline mixtures and polymers containing them in optical and electrooptical devices like liquid crystal displays or projection systems, in optical elements like polarizers, retardation films, compensators, color filters or holographic elements, in liquid crystal pigments and colored films or coatings for decorative or security applications, cosmetic and pharmaceutical compositions, in nonlinear optics and optical information storage.",MERCK PATENT GMBH,VAUGHAN-SPICKERS JULIAN;;DUNN CHRISTOPHER;;HARDING RICHARD;;HASSALL IAN;;JENKINS TONY;;MAY ALISON;;GREENFIELD SIMON,,https://lens.org/070-419-934-520-66X,Granted Patent,no,0,0,13,13,0,C09K19/2028;;C09K19/586;;C09K2219/03;;C09K2323/00;;C09K19/58;;C09K19/2028;;C09K2219/03;;C09K19/586;;C09K2323/00,G02B5/30;;C07C69/76;;C07C69/767;;C09K19/20;;C09K19/38;;C09K19/54;;C09K19/58;;G02F1/13;;G02F1/1335,,0,0,,,,EXPIRED
442,UY,A1,UY 26410 A1,112-307-075-396-95X,2001-04-30,2001,UY 26410 A,2000-10-20,UY 26410 A,2000-10-20,HETEROCICLOS BICICLONITROGENADOS ALQUILAMINO SUSTITUIDOS,"Se proporcionan derivados de la dihidropirimido (4,5-d) pirimidinona alquilamino-substituidos, de fórmula (I) en donde R1-R3 son como se ha definido en la solicitud, los cuales son de utilidad como inhibidores del p38, juntamente con un procedimiento para su obtención, y preparaciones farmacéuticas que los contienen.",HOFFMANN LA ROCHE,GOLDSTEIN DAVID MICHAEL;;SMITH IAN EDWARD DAVID;;DUNN JAMES PATRICK;;WELCH TERESA ROSANNE;;HARRIS WILLIAM,,https://lens.org/112-307-075-396-95X,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
443,PE,A1,PE 20010760 A1,163-842-781-179-084,2001-07-21,2001,PE 0011062000 A,2000-10-17,US 16080499 P;;US 21371800 P,1999-10-21,"DERIVADOS DE DIHIDROPIRIMIDO[4,5]PIRIMIDINONA ALQUILAMINO SUSTITUIDOS COMO INHIBIDORES DE QUINASAS p38","SE REFIERE A DERIVADOS DE DIHIDRO-PIRIMIDO[4,5]PIRIMIDINONA ALQUILAMINO SUSTITUIDOS DE FORMULA I, DONDE n ES 0-3; R1 ES H, ALQUILO, ALQUENILO, ALQUINILO, ALQUILCARBONILO, CICLOALQUILO, ENTRE OTROS; R2 ES ALQUILO, HALO, HETEROALQUILO, VINILO; R3 ES HETEROALQUILO, HETEROALQUILENO, HETEROALQUILINILO, HETEROALQUILCARBONILO, ALQUILENO-COR31, ENTRE OTROS; R31 ES ALQUILO, HALOALQUILO, OH, ALCOXILO, AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 3-(2-CLORO-FENIL)-1-ETOXICARBONILMETIL-7-ISOPROPILAMINO-3,4-DIHDIRO-PIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA, 3-82-CLORO-FENIL)-1-CARBOXIMETIL-7-ISOPROPILAMINO-3,4-DIHDIRO-PIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA, 3-(2-CLORO-FENIL)-1-(2-METOXIETIL)-7-ISOPROPILAMINO-3,4-DIHIDRO-PIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN INHIBIDOR DE LA QUINASA p38 Y PUEDE SER UTIL PARA ELT RATAMIETNO DE ARTRITIS, ENFERMEAD DE CROHN, SINDROME DEL INTESTINO IRRITABLE, SINDROME DEL DOLOR RESPIRATORIO, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;WELCH TERESA ROSANNE;;SMITH IAN EDWARD DAVID;;HARRIS WILLIAM,,https://lens.org/163-842-781-179-084,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
444,BR,B1,BR 112012029058 B1,002-652-797-754-551,2022-03-29,2022,BR 112012029058 A,2011-05-13,US 2011/0036533 W;;US 33490110 P,2010-05-14,"Molécula de ácido nucleico, vetor, microrganismo transgênico, processo para produzir um polipeptídeo, composição, polipeptídeo, composição imunogênica, composição de vacina, vacina de combinação, e, uso de uma composição","molécula de ácido nucleico isolado, vetor, célula hospedeira, processo para produzir um polipeptídeo, composição, polipeptídeo isolado, vacina de combinação, métodos para induzir uma resposta imunológica em um indivíduo, e para prevenir ou tratar uma infecção ou doença, e, anticorpo ou fragmento do mesmo. a invenção se refere ao desenvolvimento de moléculas de ospa quimérica para utilização em vacina contra doença de lyme ou borreliose. mais especificamente, as moléculas de ospa quiméricas compreendem a porção proximal de um sorotipo ospa, em conjunto com a porção distal de outro sorotipo ospa, enquanto retendo propriedades antigênicas de ambos os polipeptídeos parentais. as moléculas de ospa quiméricas são distribuídas isoladamente ou em combinação para fornecer proteção contra uma variedade de genoespécies de borrelia.",BAXALTA GMBH;;BAXALTA INC;;BAXTER HEALTHCARE SA;;BAXTER INT;;BROOKHAVEN SCIENCE ASS LLC;;UNIV NEW YORK STATE RES FOUND;;THE RESEARCH FOUNDATION OF THE STATE UNIV OF NEW YORK,BENJAMIN J LUFT;;BRIAN A CROWE;;LIVEY IAN;;JOHN J DUNN;;SCHWENDINGER MICHAEL;;O'ROURKE MARIA,"BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) ; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) ; BAXALTA INCORPORATED (US) ; BAXALTA GMBH (CH) (2020-08-11);;BAXTER INTERNATIONAL INC. (US) ; BAXTER HEALTHCARE S.A. (CH) ; BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) ; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) (2020-07-21)",https://lens.org/002-652-797-754-551,Granted Patent,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,0,0,,,,ACTIVE
445,KR,A,KR 20180082633 A,023-578-383-402-651,2018-07-18,2018,KR 20187019612 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,"본 발명은 라임 질환에 대항 또는 보렐리아증 백신에 사용하기 위한 키메라 OspA 분자의 개발에 관한 것이다. 보다 구체적으로, 상기 키메라 OspA 분자는 또 다른 OspA 혈청형으로부터의 원거리 부분과 함께 하나의 OspA 혈청형으로부터 인접한 부분을 포함하고 모 폴리펩타이드 둘다의 항원성 성질을 보유한다. 상기 키메라 OspA 분자는 다양한 보렐리아 동유전자종으로부터의 보호를 제공하기 위해 단독으로 또는 조합하여 전달된다.",BAXALTA INC;;BAXALTA GMBH;;BROOKHAVEN SCIENCE ASS LLC;;UNIV NEW YORK STATE RES FOUND,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/023-578-383-402-651,Patent Application,no,0,0,74,74,346,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;A61K39/00;;A61P31/00;;C07K14/20,,0,0,,,,DISCONTINUED
446,US,A1,US 2018/0296656 A1,074-826-564-818-541,2018-10-18,2018,US 201815875479 A,2018-01-19,US 201815875479 A;;US 201615049438 A;;US 201314078390 A;;US 201113107796 A;;US 33490110 P,2010-05-14,"CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF","The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.",BROOKHAVEN SCIENCE ASS LLC;;RESEARCH FOUNDATION OF THE STATE UNIV OF NEW YORK;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,BAXTER HEALTHCARE SA (2011-05-20);;BAXALTA INCORPORATED (2015-11-19);;BAXALTA GMBH (2015-11-19);;BAXTER INTERNATIONAL INC (2011-05-20);;RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (2012-01-31);;BROOKHAVEN SCIENCE ASSOCIATES LLC (2011-06-10),https://lens.org/074-826-564-818-541,Patent Application,yes,0,1,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;A61K39/00;;C07K14/20,,0,0,,,,ACTIVE
447,AU,B2,AU 2011/252850 B2,162-528-929-748-22X,2016-03-17,2016,AU 2011/252850 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OspA chimeras and use thereof in vaccines,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BAXALTA GMBH;;BAXALTA INC;;BROOKHAVEN SCIENCE ASSOCIATES LLC;;UNIV NEW YORK STATE RES FOUND,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW (2016-07-07),https://lens.org/162-528-929-748-22X,Granted Patent,no,1,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C07K14/20;;A61K39/02,,0,0,,,,ACTIVE
448,CN,A,CN 103118701 A,182-381-943-699-841,2013-05-22,2013,CN 201180033682 A,2011-05-13,US 2011/0036533 W;;US 33490110 P,2010-05-14,OSPA chimeras and use thereof in vaccines,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BAXTER INT;;BAXTER HEALTHCARE SA;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCES ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/182-381-943-699-841,Patent Application,no,3,7,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,0,0,,,,ACTIVE
449,AT,T1,AT E349447 T1,057-923-409-098-01X,2007-01-15,2007,AT 00972755 T,2000-10-13,US 16080499 P;;US 21371800 P,1999-10-21,ALKYLAMINO-SUBSTITUIERTE BICYCLISCHE HETEROCYCLEN ALS P38 PROTEIN KINASE INHIBITOREN,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/057-923-409-098-01X,Granted Patent,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
450,ES,T3,ES 2277858 T3,064-619-212-118-969,2007-08-01,2007,ES 00972755 T,2000-10-13,US 16080499 P;;US 21371800 P,1999-10-21,HETEROCICLOS DE NITROGENO BICICLICOS ALQUILAMINO SUSTITUIDOS COMO INHIBIDORES DE PROTEINA KINASA P38.,"Un compuesto seleccionado del grupo de compuestos representados por la fórmula: en donde el subíndice n es un número entero 1 o 2; R1 es hidrógeno, alquilo C1-C6, alquenilo, cicloalquilo C3-C6, R3 es hidroxi-alquilo C1-C6, alcoxi-alqulo C1-C6, -(alquileno C1-C6)-C(O)R31, 2-(N-piperidinil)etilo o 2-(N-2-pirrolidinonil))etilo; y R31 es hidroxilo, etoxilo, amino, metilamino, dime- tilamino, metilo o etilo; y sus sales farmacéuticamente aceptables.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/064-619-212-118-969,Granted Patent,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
451,WO,A1,WO 2011/143623 A1,117-487-224-669-652,2011-11-17,2011,US 2011/0036533 W,2011-05-13,US 33490110 P,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BAXTER INT;;BAXTER HEALTHCARE SA;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCES ASS LLC;;CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/117-487-224-669-652,Patent Application,yes,23,18,74,74,173,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,75,45,096-611-689-245-37X;;053-122-459-007-90X;;062-024-235-743-200;;160-840-803-687-381;;054-732-712-502-061;;030-839-409-040-828;;029-026-124-030-198;;096-611-689-245-37X;;073-466-339-901-688;;029-683-169-457-195;;066-525-457-224-28X;;003-323-279-619-527;;115-303-705-496-498;;027-829-588-585-761;;111-109-974-501-414;;048-183-620-015-85X;;016-338-497-443-009;;032-728-154-591-070;;085-764-009-624-439;;056-201-471-905-934;;019-779-601-634-917;;072-366-322-919-406;;010-519-409-512-153;;000-150-741-285-140;;006-742-514-479-110;;066-141-497-990-023;;023-907-179-348-058;;032-728-154-591-070;;012-830-491-824-205;;077-903-001-903-019;;025-189-084-402-882;;060-196-670-596-725;;003-430-460-951-798;;026-944-353-804-488;;001-147-941-858-547;;106-753-778-592-300;;006-574-964-805-278;;042-204-626-457-327;;045-094-249-115-990;;032-071-991-081-664;;020-855-322-534-259;;014-935-196-346-195;;101-242-387-154-198;;057-200-638-752-266;;115-802-414-738-000,9330467;;10.1016/s0264-410x(97)00066-2;;9673298;;10.1056/nejm199807233390401;;10.1056/nejm199807233390402;;9673299;;9709052;;10.1056/nejm199808203390819;;10.1006/abio.1996.9982;;9056182;;10.1128/iai.61.1.81-90.1993;;8418068;;pmc302690;;9108020;;pmc20483;;10.1073/pnas.94.8.3584;;9330467;;10.1016/s0264-410x(97)00066-2;;10.1128/jcm.31.2.340-350.1993;;pmc262762;;8432821;;pmc2192397;;10.1084/jem.183.1.271;;8551231;;10.4049/jimmunol.166.12.7398;;11390491;;10.1128/iai.65.3.882-889.1997;;pmc175064;;9038292;;10.1006/jmbi.2000.4119;;11183781;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;10.1016/s0021-9258(18)89400-5;;3838308;;10.1006/mcpr.1994.1013;;7935517;;10.1016/0092-8674(87)90322-9;;3621342;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;4705382;;10.1016/0042-6822(73)90341-3;;6263759;;10.1016/0378-1119(81)90008-1;;8556477;;pmc368276;;10.1128/cdli.1.4.406-412.1994;;10.1001/jama.1994.03510460056033;;8196120;;10.1001/jama.271.22.1764;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0022-2836(70)90057-4;;5420325;;pmc345355;;6204335;;10.1073/pnas.81.13.3998;;6186024;;10.1126/science.6186024;;10.1002/anie.198907161;;pmc335293;;10.1093/nar/17.24.10191;;2690015;;10603393;;pmc97126;;10.1128/iai.68.1.233-238.2000;;10.1021/ja00897a025;;2184369;;10.1038/344873a0;;1172191;;10.1038/256495a0;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;10.1016/0022-2836(92)90894-p;;1404359;;1748994;;10.1016/0022-2836(91)90498-u;;8961139;;10.1021/js960158a;;8494350;;10.1146/annurev.pharmtox.33.1.521;;10.1146/annurev.pa.33.040193.002513;;2295795;;10.1016/0022-2836(86)90385-2;;3537305,"GERN L ET AL: ""Immunization with a polyvalent OspA vaccine protects mice against Ioxides ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii"", VACCINE, ELSEVIER LTD, GB, vol. 15, no. 14, 1 October 1997 (1997-10-01), pages 1551 - 1557, XP004090340, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(97)00066-2;;STEERE ET AL., N. ENGL. J. MED., vol. 339, 1998, pages 209 - 15;;SIGAL ET AL., N. ENGL. J. MED., vol. 339, 1998, pages 216 - 22;;N. ENGL. J. MED., vol. 339, 1998, pages 571;;BOUCHON ET AL., ANAL. BIOCHEM., vol. 246, 1997, pages 52 - 61;;ERDILE ET AL., INFECT. IMMUN., vol. 61, 1993, pages 81 - 90;;LI ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 94, 1997, pages 3584 - 9;;GERN ET AL., VACCINE, vol. 15, 1997, pages 1551 - 7;;WILSKE ET AL., J. CLIN. MICROBIOL., vol. 31, 1993, pages 340 - 50;;SILVA ET AL., J. EXP. MED., vol. 183, 1996, pages 271 - 5;;PAL ET AL., J. IMMUNOL., vol. 166, 2001, pages 7398 - 403;;GOLDE ET AL., INFECT. IMMUN., vol. 65, 1997, pages 882 - 9;;DING ET AL., J. MOL. BIOL., vol. 302, 2000, pages 1153 - 64;;LUFT ET AL., J INFECT DIS., vol. 185, no. 1, 2002, pages S46 - 51;;SINGLETON ET AL.: ""DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY(2d ed."", 1994;;WALKER: ""THE CAMBRIDGE DICTIONARY OF SCIENCE AND TECHNOLOGY"", 1988;;R. RIEGER, ET AL.: ""THE GLOSSARY OF GENETICS, 5TH ED.,"", 1991, SPRINGER VERLAG;;HALE, MARHAM, THE HARPER COLLINS DICTIONARY OF BIOLOGY, 1991;;BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081;;OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608;;ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98;;CREIGHTON, PROTEINS, 1984;;""Remington's Pharmaceutical Sciences"", 1980;;REECK ET AL., CELL, vol. 50, 1987, pages 667;;SMITH ET AL., ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 443;;PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;KARLIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5787;;GRAHAM ET AL., VIROLOGY, vol. 52, 1973, pages 456;;SAMBROOK ET AL.: ""Molecular Cloning, a Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORIES;;DAVIS ET AL.: ""Basic Methods in Molecular Biology"", 1986, ELSEVIER;;CHU ET AL., GENE, vol. 13, 1981, pages 197;;JIANG ET AL., CLIN. DIAGN. LAB. IMMUNOL., vol. 1, 1994, pages 406 - 12;;KELLER ET AL., JAMA, vol. 271, 1994, pages 1764 1768;;DEVEREUX ET AL., NUCL. ACID. RES., vol. 12, 1984, pages 387;;ALTSCHUL ET AL.: ""BLAST Manual"", 1990, NCB/NLM/NIH BETHESDA;;DAYHOFF ET AL., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, vol. 5, no. 3, 1978;;HENIKOFF ET AL., PROC. NATL. ACAD. SCI USA, vol. 89, 1992, pages 10915 - 10919;;NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 443 - 453;;KYTE ET AL., J. MOL. BIOL., vol. 157, 1982, pages 105 - 131;;GEYSEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 3998 - 4002;;SUTCLIFFE ET AL., SCIENCE, vol. 219, 1983, pages 660 - 666;;TOBIN, PROC. NATL. ACAD. SCI. USA, vol. 76, 1979, pages 4350 - 4356;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR;;""Current Protocols in Molecular Biology"", 1994, GREEN PUBLISHERS INC. AND WILEY AND SONS;;ENGELS ET AL., ANGEW. CHEM. INTL. ED., vol. 28, 1989, pages 716 - 734;;MAKOFF ET AL., NUCLEIC ACIDS RES., vol. 17, 1989, pages 10191 - 202;;LAKEY ET AL., INFECT. IMMUN., vol. 68, 2000, pages 233 - 8;;D.V. GOEDDEL: ""Meth. Enz."", vol. 1.185, 1990, ACADEMIC PRESS INC.;;SAMBROOK, FRITSCH, MANIATIS: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;MANIATIS ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY;;""Current Protocols in Molecular Biology"", 1993, JOHN WILEY & SONS;;MERRIFIELD ET AL., J. AM. CHEM. SOC., vol. 85, 1963, pages 2149;;HOUGHTEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 5132;;STEWART, YOUNG: ""Solid Phase Peptide Synthesis"", 1984, PIERCE CHEMICAL CO.;;FRANCIS ET AL., FOCUS ON GROWTH FACTORS, vol. 3, 1992, pages 4 - 10;;TAKAHASHI ET AL., NATURE, vol. 344, 1990, pages 873 - 875;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497;;J. IMMUNOL., vol. 133, 1984, pages 3001;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 51 - 63;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1985, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;HOOGENBOOM ET AL., J. MOL. BIOL., vol. 227, 1991, pages 381;;MARKS, J. MOL. BIOL., vol. 222, 1991, pages 581;;SOLA: ""Monoclonal Antibodies: A Manual of Techniques"", 1987, CRC PRESS, INC., pages: 147 - 158;;BAYER ET AL., METH. ENZYM., vol. 184, 1990, pages 138 - 163;;""Remington's Pharmaceutical Science, 15th ed.,"", 1980, MACK PUBLISHING COMPANY;;FIX, J. PHARM. SCI., vol. 85, 1996, pages 1282 - 1285;;OLIYAI ET AL., ANN. REV. PHARMACOL. TOXICOL., vol. 32, 1993, pages 521 - 544;;""Remington's Pharmaceutical Sciences, 18th Ed."", 1990, MACK PUBLISHING CO., pages: 1435 - 1712;;JIANG ET AL., J. IMMUNOL., vol. 144, 1990, pages 284 - 9;;STUDIER ET AL., J. MOL. BIOL., vol. 189, 1986, pages 113 - 30",PENDING
452,CA,A1,CA 2799181 A1,178-893-460-853-677,2011-11-17,2011,CA 2799181 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BAXTER INT;;BAXTER HEALTHCARE SA;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIN J,,https://lens.org/178-893-460-853-677,Patent Application,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,0,0,,,,PENDING
453,EC,A,EC SP003739 A,191-254-613-397-407,2001-05-23,2001,EC SP003739 A,2000-10-20,EC SP003739 A,2000-10-20,HETEROCICLICOS DE NITROGENO BICICLICOS ALQUILAMINO,"Se proporcionan derivados de la dihidropirimido [4, 5-d] pirimidinona alquilamino-sustituidos, de fórmula (I) En donde R1 ¿ R3 son como se ha definido en la solicitud, los cuales son de utilidad como inhibidores del p38, juntamente con un procedimiento para su obtención, y preparaciones farmacéuticas que los contienen.",,HARRIS WILLIAM;;GOLDSTEIN DAVID MICHAEL;;SMITH IAN EDWARD DAVID;;DUNN JAMES PATRICK;;WELCH TERESA ROSANNE,,https://lens.org/191-254-613-397-407,Patent Application,no,0,0,1,1,0,,A61K31/50;;C07D487/02,,0,0,,,,PENDING
454,US,A1,US 2023/0290493 A1,007-736-725-188-140,2023-09-14,2023,US 202118007217 A,2021-06-24,US 202118007217 A;;US 202063071158 P;;US 2021/0038805 W,2020-08-27,MEDICAL DEVICE DIAGNOSTICS AND ALERTING,Methods and systems for medical device diagnostics and reporting. One system including an electronic processor configured to receive a new medical device dataset associated with a medical device. The electronic processor is also configured to determine an operation classification of the medical device using a model utilizing training information. The training information includes a plurality of archived medical device datasets and an associated operation classification for each of the plurality of archived medical device datasets. The electronic processor is also configured determine an operation status of the medical device based on the operation classification. The electronic processor is also configured to generate and provide a notification based on at least the operation status of the medical device.,UNIV NEBRASKA,REDWOOD WILLIAM OWEN;;DUNN JEFF;;HESTER RILEY;;TRENT IAN;;WRIGHT ERIC;;MILLER BRAD;;TAUIL ORLY,BOARD OF REGENTS OF THE UNIVERSITY OF (2021-06-24),https://lens.org/007-736-725-188-140,Patent Application,yes,0,0,2,2,0,A61B2560/0276;;G06F11/3013;;G06F11/3058;;G06F11/3476;;G06F21/554;;G16H40/40,G16H40/40,,0,0,,,,PENDING
455,US,B2,US 7694374 B2,037-059-252-346-518,2010-04-13,2010,US 70192207 A,2007-02-02,GB 0602291 A,2006-02-04,Modular-bridge construction,"Disclosed is a modular bridge, typically for temporary use to enable persons to pass between upper floors of adjacent buildings during fire fighting or disaster relief operations, which can be rapidly assembled and deployed within a confined space and entirely from the “home” side of the gap to be crossed. It comprises a plurality of man-portable box section bridge modules adapted to be connected together end to end and projected in cantilever fashion from one side of the gap to the other. The assembly of modules is supported in and guided through a launch frame, with modules being added to the rear of the assembly and pushed through the frame until the gap is spanned. Removable lever arms of the frame are used to counterbalance the weight of the projected bridge modules during the course of deployment.",QINETIQ LTD,JONES DOUGLAS HUGH;;DUNN IAN JOHN;;MORGAN COLIN PETER;;ARDLEY SCOTT;;STARINK LINDA MARY PATRICIA,QINETIQ LIMITED (2007-01-12),https://lens.org/037-059-252-346-518,Granted Patent,yes,15,6,6,6,0,E01D15/133;;E01D2101/40;;E01D15/133;;E01D21/10;;E04G3/18;;E01D15/133;;E01D2101/40,E01D15/12,14/2.4;;14/69.5;;14/77.1;;182/116;;182/119,1,0,,,English Abstract of DE 20 2005 000 646 provided by EPODOC/EPO.,INACTIVE
456,HK,A1,HK 1051040 A1,180-378-535-722-803,2003-07-18,2003,HK 03103209 A,2003-05-06,EP 0010077 W;;US 16080499 P;;US 21371800 P,1999-10-21,Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase.,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/180-378-535-722-803,Patent Application,no,0,0,35,37,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/04;;A61P19/02;;A61P29/00;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
457,WO,A1,WO 2008/028251 A1,072-025-803-884-667,2008-03-13,2008,AU 2007/001330 W,2007-09-07,AU 2006/904919 A;;AU 2006/906743 A,2006-09-07,"DNA-BINDING PROTEIN, NUCLEOPROTEIN COMPLEX AND METHOD OF USE","The invention provides an isolated nucloprotein complex comprising a mammalian Ifi202 protein and foreign double stranded DNA, which complexes may be involved in intracellular recognition of, and cellular activation by, foreign double stranded DNA, such as vira or bacterial DNA, transfected plasmid DNA or extranuclear DNA fragments. Also provided are methods of identifying, designing or screening modulators of nucleoprotein complex formation and/or downstream signaling normally activated by mammalian Ifi202 protein upon binding double stranded DNA. Modulation of this binding interaction, and/or subsequent intracellular signalling pathways may improve cell transfection efficiency or treat diseases or conditions responsive to modulation of this binding interaction. Modulation of the induction of type I interferons in response to double stranded DNA may assist in treating diseases and/or conditions including cancers responsive to type I interferons, autoimmune diseases, inflammatory diseases and/or viral infections.",INFLAMAC PTY LTD;;STACEY KATRYN J;;ROBERTS TARA L;;ROSS IAN L;;HUME DAVID A;;IDRIS ADI;;DUNN JASMYN,STACEY KATRYN J;;ROBERTS TARA L;;ROSS IAN L;;HUME DAVID A;;IDRIS ADI;;DUNN JASMYN,,https://lens.org/072-025-803-884-667,Patent Application,yes,0,4,1,1,0,A61K38/00;;C07K14/47;;G01N33/6866;;G01N33/6875;;G01N2800/104,C07K2/00;;A61K38/17;;C07K4/12;;C07K14/435,,14,11,044-391-055-556-485;;081-911-680-583-380;;060-039-439-165-464;;102-077-639-715-810;;102-045-615-435-64X;;035-582-703-354-554;;012-943-565-598-804;;021-600-283-297-394;;081-344-059-598-324;;038-120-343-927-664;;063-659-693-268-254,10.1006/bbrc.1995.2269;;7545391;;8619867;;10.1006/bbrc.1996.0607;;7536752;;10.1002/jcb.240570106;;9642285;;10.1074/jbc.273.27.17172;;10.1089/jir.1993.13.43;;8454910;;10.1038/sj.onc.1204005;;11146555;;9766636;;10.1002/jlb.64.4.546;;10.1038/sj.onc.1204844;;11687962;;10.1016/s1386-6532(99)90405-5;;10.1023/a:1026391715071;;14618084;;10.1074/jbc.m410542200;;15572361,"DAWSON M.J. ET AL.: ""The interferon-inducible autoantigen, ifi 16"", BIOCHEM BIOPHYS RES COMM, vol. 214, no. 1, 5 September 1995 (1995-09-05), pages 152 - 162;;CHOUBEY D. ET AL.: ""The inerferon-inducible growth-inhibitory p202 protein: dna binding properties and identification of a dna binding domain"", BIOCHEM BIOPHYS RES COMM, vol. 221, no. 2, 16 April 1996 (1996-04-16), pages 396 - 401;;DAWSON M.J. ET AL.: ""IFI 16 Gene Encodes a Nuclear Protein Whose Expression Is Induced by Interferons in Human Myeloid Leukemia Cell Lines"", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 57, no. 1, January 1995 (1995-01-01), pages 39 - 51;;DATABASE CAPLUS [online] XU ZHONG-YI ET AL., Database accession no. (2006:1103812);;JOHNSTONE R.W. ET AL.: ""The human interferon-inducible protein IFI 16, is a repressor of transcription"", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 27, 3 July 1998 (1998-07-03), pages 17172 - 17177;;CHOUBEY D. ET AL.: ""Interferon action: cytoplasmic and nuclear localization of the interferon-inducible 52-kD protein that is encoded by the Ifi 200 gene from the gene 200 cluster"", JOURNAL OF INTERFERON RESEARCH, vol. 13, no. 1, February 1993 (1993-02-01), pages 43 - 52;;GARIGLIO M. ET AL.: ""Analysis of the role of the interferon-inducible gene IFI16 that links interferon to apoptosis in HPV-related carcinogenesis"", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 22, no. SUPPL. 1, 2002, pages S-73;;YAN D.-H. ET AL.: ""Anti-tumour Activities of p202"", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 8, no. SUPPL. 1, 2001, pages S-86;;JOHNSTONE R.W. ET AL.: ""Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16"", ONCOGENE, vol. 19, no. 52, 7 December 2000 (2000-12-07), pages 6033 - 6042;;DAWSON M.J. ET AL.: ""The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and marked down-regulated in other myeloid precursor populations"", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 64, no. 4, October 1998 (1998-10-01), pages 546 - 554;;XIN H. ET AL.: ""p202, an interferon-inducible negative regulato of cell growth, is a target of the adenovirus E1A protein"", ONCOGENE, vol. 20, no. 47, 18 October 2001 (2001-10-18), pages 6828 - 6839;;GARIGLIO M. ET AL.: ""Mouse cytomegalovirus (MCMV) replication strictly depends on the interferon-inducible Ifi200 genes"", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 19, no. SUPPL. 1, September 1999 (1999-09-01), pages S-68;;MASAYA F. ET AL.: ""Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpes virus interacts with human myeloid cell nuclear differentiation antigen induced by interferon alpha"", VIRUS GENES, vol. 27, no. 3, December 2003 (2003-12-01), pages 237 - 247;;KIM E.-J. ET AL.: ""IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 6, 11 February 2005 (2005-02-11), pages 4913 - 4920",PENDING
458,EP,A3,EP 3705133 A3,092-834-184-748-193,2021-01-06,2021,EP 19217974 A,2011-05-13,US 33490110 P;;EP 11720967 A;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BAXALTA INC;;BAXALTA GMBH;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;DR LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIIN J,,https://lens.org/092-834-184-748-193,Search Report,yes,3,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,1,1,015-815-132-309-360,21217174;;10.1093/cid/ciq118,"LIVEY IAN ET AL: ""A New Approach to a Lyme Disease Vaccine"", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 52, no. Supplement 3, 1 February 2011 (2011-02-01), pages S266 - S270, XP008139263, ISSN: 1058-4838, Retrieved from the Internet <URL:http://www.journals.uchicago.edu/CID/home.html> DOI: 10.1093/CID/CIQ118",PENDING
459,AU,B2,AU 2010/317659 B2,136-523-698-937-81X,2014-01-23,2014,AU 2010/317659 A,2010-11-11,US 26025309 P;;AU 2010/001504 W,2009-11-11,Clinical syringe,"A replaceable needle assembly is provided for a retractable syringe comprising a barrel and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. A mounting member is removably mountable to the barrel by way of a screw-thread connection and a needle mount is removably coupled to the mounting member. A needle is mounted to the needle mount. The barrel comprises a needle mount retainer that comprises a plurality of fingers that engage the retractable needle mount to prevent inadvertent retraction. The plunger comprises a collapsible seal which maximizes the efficiency of fluid delivery prior to the plunger engaging the retractable needle mount for retraction. An initially compressed spring decompresses to drive retraction of the plunger and the engaged needle mount. A lock formed between the plunger and barrel prevents further use of the plunger after retraction.",UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,,https://lens.org/136-523-698-937-81X,Granted Patent,no,3,0,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/32;;A61M5/315,,0,0,,,,INACTIVE
460,US,A1,US 2013/0060202 A1,144-254-688-833-643,2013-03-07,2013,US 201013508690 A,2010-11-11,US 201013508690 A;;US 26025309 P;;AU 2010/001504 W,2009-11-11,Clinical Syringe with Replaceable Retractable Needle,"A replaceable needle assembly is provided for a retractable syringe comprising a barrel and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. A mounting member is removably mountable to the barrel by way of a screw-thread connection and a needle mount is removably coupled to the mounting member. A needle is mounted to the needle mount. The barrel comprises a needle mount retainer that comprises a plurality of fingers that engage the retractable needle mount to prevent inadvertent retraction. The plunger comprises a collapsible seal which maximizes the efficiency of fluid delivery prior to the plunger engaging the retractable needle mount for retraction. An initially compressed spring decompresses to drive retraction of the plunger and the engaged needle mount. A lock formed between the plunger and barrel prevents further use of the plunger after retraction.",THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER;;UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,UNITRACT SYRINGE PTY LTD (2012-10-31);;UNL HOLDINGS LLC (2017-07-24),https://lens.org/144-254-688-833-643,Patent Application,yes,7,29,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/34;;A61M5/315;;B23P11/00,604/220;;604/218;;604/222;;29/428,0,0,,,,ACTIVE
461,US,B2,US 10358430 B2,042-774-793-573-098,2019-07-23,2019,US 201715686949 A,2017-08-25,US 201715686949 A,2017-08-25,"Oligomeric (TH)FP, production and uses therefor","A method for the isolation of oligomeric 2, 2-difurylpropane (DTHFP) suitable for use on an industrial scale. A method can include using oligomeric 2, 2-difurylpropane, in particular, its use can be as a polar modifier for butadiene and styrene butadiene polymerization so is to produce rubber. Utilizing the material as an alternative to DTHFP in rubber production avoids subsequent leaching of the DTHFP into the environment as the oligomeric 2, 2-difurylpropane (DTHFP) gives rise to much lower levels of leaching.",SWAN THOMAS & CO LTD,PEARCE IAN STUART;;DUNN DAVID;;SUTTON HOWARD WINSTON TYRRELL;;DALY JOHN ING CHUAN;;GRANT SIMON JONATHON,,https://lens.org/042-774-793-573-098,Granted Patent,yes,8,0,2,2,0,C07D307/36;;C07D307/36;;C07D307/06;;C07D307/06;;C07D307/12;;C07D307/12;;C07D307/40;;C07D307/40;;C08F36/06;;C08F36/06,C07D307/36;;C07D307/06;;C08F36/06,,0,0,,,,ACTIVE
462,US,B2,US 9254365 B2,174-652-347-060-752,2016-02-09,2016,US 201013508690 A,2010-11-11,US 201013508690 A;;US 26025309 P;;AU 2010/001504 W,2009-11-11,Clinical syringe with replaceable retractable needle,"A replaceable needle assembly is provided for a retractable syringe comprising a barrel and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. A mounting member is removably mountable to the barrel by way of a screw-thread connection and a needle mount is removably coupled to the mounting member. A needle is mounted to the needle mount. The barrel comprises a needle mount retainer that comprises a plurality of fingers that engage the retractable needle mount to prevent inadvertent retraction. The plunger comprises a collapsible seal which maximizes the efficiency of fluid delivery prior to the plunger engaging the retractable needle mount for retraction. An initially compressed spring decompresses to drive retraction of the plunger and the engaged needle mount. A lock formed between the plunger and barrel prevents further use of the plunger after retraction.",THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER;;UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,UNITRACT SYRINGE PTY LTD (2012-10-31);;UNL HOLDINGS LLC (2017-07-24),https://lens.org/174-652-347-060-752,Granted Patent,yes,17,2,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/32,,1,0,,,"Australian Patent Office, International Search Report in International Patent Application No. PCT/AU2010/00154 (Feb. 10, 2011).",ACTIVE
463,US,S,US D0623740 S,028-800-938-383-877,2010-09-14,2010,US 32006708 F,2008-06-19,EM 08518780000 F;;GB 0725087 A,2007-12-21,Wound dressing applicator,,DFB TECHNOLOGY HOLDINGS LLC,HARRIS CHRISTOPHER;;DERA IAN;;SCOUTAS DIMITRIOS;;HANNANT MATTHEW;;MAISEY GRAEME;;DUNN PHILIP;;SANDBANK BARRY;;JASSAL SUSHMA,SMITH & NEPHEW INC (2012-12-21);;HEALTHPOINT INTERNATIONAL LLC (2011-12-29);;INTERCYTEX LIMITED (2008-08-27),https://lens.org/028-800-938-383-877,Design Right,no,0,7,1,6,0,,,2402;;D24/133;;D24/145,0,0,,,,ACTIVE
464,AU,A1,AU 2010/317659 A1,062-197-786-676-230,2012-06-21,2012,AU 2010/317659 A,2010-11-11,US 26025309 P;;AU 2010/001504 W,2009-11-11,Clinical syringe,"A replaceable needle assembly is provided for a retractable syringe comprising a barrel and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. A mounting member is removably mountable to the barrel by way of a screw-thread connection and a needle mount is removably coupled to the mounting member. A needle is mounted to the needle mount. The barrel comprises a needle mount retainer that comprises a plurality of fingers that engage the retractable needle mount to prevent inadvertent retraction. The plunger comprises a collapsible seal which maximizes the efficiency of fluid delivery prior to the plunger engaging the retractable needle mount for retraction. An initially compressed spring decompresses to drive retraction of the plunger and the engaged needle mount. A lock formed between the plunger and barrel prevents further use of the plunger after retraction.",UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,,https://lens.org/062-197-786-676-230,Patent Application,no,0,0,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/32;;A61M5/315,,0,0,,,,INACTIVE
465,EP,A2,EP 3705133 A2,096-260-647-623-756,2020-09-09,2020,EP 19217974 A,2011-05-13,US 33490110 P;;EP 11720967 A;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,"The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.",BAXALTA INC;;BAXALTA GMBH;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;DR LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J;;LUFT BENJAMIIN J,,https://lens.org/096-260-647-623-756,Patent Application,yes,20,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,57,39,054-732-712-502-061;;030-839-409-040-828;;029-026-124-030-198;;096-611-689-245-37X;;073-466-339-901-688;;029-683-169-457-195;;066-525-457-224-28X;;003-323-279-619-527;;115-303-705-496-498;;048-183-620-015-85X;;085-764-009-624-439;;027-829-588-585-761;;111-109-974-501-414;;016-338-497-443-009;;032-728-154-591-070;;056-201-471-905-934;;019-779-601-634-917;;072-366-322-919-406;;025-189-084-402-882;;006-574-964-805-278;;010-519-409-512-153;;000-150-741-285-140;;006-742-514-479-110;;066-141-497-990-023;;023-907-179-348-058;;012-830-491-824-205;;077-903-001-903-019;;101-242-387-154-198;;060-196-670-596-725;;003-430-460-951-798;;001-147-941-858-547;;026-944-353-804-488;;048-564-471-521-204;;106-753-778-592-300;;042-204-626-457-327;;045-094-249-115-990;;020-855-322-534-259;;014-935-196-346-195;;115-802-414-738-000,10.1006/abio.1996.9982;;9056182;;10.1128/iai.61.1.81-90.1993;;8418068;;pmc302690;;9108020;;pmc20483;;10.1073/pnas.94.8.3584;;9330467;;10.1016/s0264-410x(97)00066-2;;10.1128/jcm.31.2.340-350.1993;;pmc262762;;8432821;;pmc2192397;;10.1084/jem.183.1.271;;8551231;;10.4049/jimmunol.166.12.7398;;11390491;;10.1128/iai.65.3.882-889.1997;;pmc175064;;9038292;;10.1006/jmbi.2000.4119;;11183781;;10.1006/mcpr.1994.1013;;7935517;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;10.1016/s0021-9258(18)89400-5;;3838308;;10.1016/0092-8674(87)90322-9;;3621342;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;4705382;;10.1016/0042-6822(73)90341-3;;10.1002/anie.198907161;;10.1038/321522a0;;3713831;;6263759;;10.1016/0378-1119(81)90008-1;;8556477;;pmc368276;;10.1128/cdli.1.4.406-412.1994;;10.1001/jama.1994.03510460056033;;8196120;;10.1001/jama.271.22.1764;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;pmc345355;;6204335;;10.1073/pnas.81.13.3998;;6186024;;10.1126/science.6186024;;8494350;;10.1146/annurev.pharmtox.33.1.521;;10.1146/annurev.pa.33.040193.002513;;pmc335293;;10.1093/nar/17.24.10191;;2690015;;10603393;;pmc97126;;10.1128/iai.68.1.233-238.2000;;2184369;;10.1038/344873a0;;10.1021/ja00897a025;;10.4049/jimmunol.133.6.3001;;6092464;;1172191;;10.1038/256495a0;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;1748994;;10.1016/0022-2836(91)90498-u;;8961139;;10.1021/js960158a;;10.1016/0022-2836(86)90385-2;;3537305,"STEERE ET AL., N. ENGL. J. MED., vol. 339, 1998, pages 571 - 22;;BOUCHON ET AL., ANAL. BIOCHEM., vol. 246, 1997, pages 52 - 61;;ERDILE ET AL., INFECT. IMMUN., vol. 61, 1993, pages 81 - 90;;LI ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 94, 1997, pages 3584 - 9;;GERN ET AL., VACCINE, vol. 15, 1997, pages 1551 - 7;;WILSKE ET AL., J. CLIN. MICROBIOL., vol. 31, 1993, pages 340 - 50;;DE SILVA ET AL., J. EXP. MED., vol. 183, 1996, pages 271 - 5;;PAL ET AL., J. IMMUNOL., vol. 166, 2001, pages 7398 - 403;;GOLDE ET AL., INFECT. IMMUN., vol. 65, 1997, pages 882 - 9;;DING ET AL., J. MOL. BIOL., vol. 302, 2000, pages 1153 - 64;;LUFT ET AL., J INFECT DIS., vol. 185, no. 1, 2002, pages 46 - 51;;ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98;;PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444;;BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081;;OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608;;REMINGTON'S PHARMACEUTICAL SCIENCES, 1980;;REECK ET AL., CELL, vol. 50, 1987, pages 667;;SMITH ET AL., ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 443 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;KARLIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5787;;GRAHAM ET AL., VIROLOGY, vol. 52, 1973, pages 456;;ENGELS ET AL., ANGEW. CHEM. INTL. ED., vol. 28, 1989, pages 716 - 734;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;CHU ET AL., GENE, vol. 13, 1981, pages 197;;JIANG ET AL., CLIN. DIAGN. LAB. IMMUNOL., vol. 1, 1994, pages 406 - 12;;KELLER ET AL., JAMA, vol. 271, 1994, pages 1764;;DEVEREUX ET AL., NUCL. ACID. RES., vol. 12, 1984, pages 387;;DAYHOFF ET AL., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, vol. 5, no. 3, 1978;;HENIKOFF ET AL., PROC. NATL. ACAD. SCI USA, vol. 89, 1992, pages 10915 - 10919;;""Program Manual, Wisconsin Package"", September 1997;;KYTE ET AL., J. MOL. BIOL., vol. 157, 1982, pages 105 - 131;;GEYSEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 3998 - 4002;;SUTCLIFFE ET AL., SCIENCE, vol. 219, 1983, pages 660 - 666;;TOBIN, PROC. NATL. ACAD. SCI. USA, vol. 76, 1979, pages 4350 - 4356;;OLIYAI ET AL., ANN. REV. PHARMACOL. TOXICOL., vol. 32, 1993, pages 521 - 544;;MAKOFF ET AL., NUCLEIC ACIDS RES., vol. 17, 1989, pages 10191 - 202;;LAKEY ET AL., INFECT. IMMUN., vol. 68, 2000, pages 233 - 8;;TAKAHASHI ET AL., NATURE, vol. 344, 1990, pages 873 - 875;;SAMBROOKFRITSCHMANIATIS: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;MERRIFIELD ET AL., J. AM. CHEM. SOC., vol. 85, 1963, pages 2149;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1985, pages 6851 - 6855;;KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;;FRANCIS ET AL., FOCUS ON GROWTH FACTORS, vol. 3, 1992, pages 4 - 10;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 147 - 158;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;HOOGENBOOM ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581;;BAYER ET AL., METH. ENZYM., vol. 184, 1990, pages 138 - 163;;""Remington's Pharmaceutical Science"", 1980, MACK PUBLISHING COMPANY;;FIX, J. PHARM. SCI., vol. 85, 1996, pages 1282 - 1285;;JIANG ET AL., J. IMMUNOL., vol. 144, 1990, pages 1435 - 1712;;""GenBank"", Database accession no. AF095940;;""Database"", Database accession no. embIX85441;;""Genbank"", Database accession no. X80256;;STUDIER ET AL., J. MOL. BIOL., vol. 189, 1986, pages 113 - 30",PENDING
466,AU,B2,AU 2010/317660 B2,119-743-096-398-36X,2013-11-21,2013,AU 2010/317660 A,2010-11-11,US 26025209 P;;AU 2010/001505 W,2009-11-11,Vaccination syringe,"A replaceable needle assembly is provided for a retractable, prefilled syringe comprising a barrel having a mounting member and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. The replaceable needle assembly comprises a needle fitted to a retractable needle mount and a needle retainer. The needle mount is removably, screw-threadedly mountable to the mounting member of the barrel. The needle retainer comprises a plurality of fingers that releasably engage the retractable needle to thereby prevent inadvertent retraction of the retractable needle before engagement by the plunger. The plunger comprises a plunger seal comprising an outer member and an inner member that engages the needle for spring-driven retraction. At the end of retraction, a lock is formed between the plunger and barrel to prevent re-use of the syringe.",UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,,https://lens.org/119-743-096-398-36X,Granted Patent,no,2,0,29,29,0,A61M5/3234;;A61M5/3234;;A61M5/502;;A61M2005/3231;;A61M2005/3231;;A61M2005/3241;;A61M2005/3241;;A61M2005/5033;;A61M2202/30;;Y10T29/49826;;Y10T29/49826,A61M5/32,,0,0,,,,INACTIVE
467,US,S,US D0987547 S,125-502-838-155-122,2023-05-30,2023,US 35002190 F,2021-12-06,US 35002190 F,2021-12-06,Roof for vehicle,,POLARIS INC,MAZOUR SCOTT T;;HOLROYD JAMES A J;;CHRISTENSEN CARL D;;UTTER BRIAN T;;DUNN IAN M,POLARIS INDUSTRIES INC (2021-09-29),https://lens.org/125-502-838-155-122,Design Right,no,99,1,1,1,0,,,1216;;D12/404,14,0,,,"Examiner's Report issued by the Canadian Intellectual Property Office, dated Feb. 6, 2018, for corresponding Canadian Patent Application No. 171376; 3 pages.;;Examiner's Report issued by the Canadian Intellectual Property Office, dated Jul. 11, 2018, for corresponding Canadian Patent Application No. 171376; 1 page.;;Examiner's Report issued by the Canadian Intellectual Property Office, dated Jun. 15, 2017, for related Canadian patent application No. 171376; 9 pages.;;Madstad Stinger Roof System for the Polaris Slingshot, downloaded from the Internet on May 17, 2016; http://www.madstad.com/s.nl/sc.7/category.17020/.f, 3 pages.;;MadStad Stiuger Roof-Polaris Slingshot Forum, dated Oct. 24, 2015, www.slingshotforums.com; 11 pages.;;New KTM X-Bow GT4 Coupe Breaks Cover, www.dailysportscar.com, Apr. 3, 2015; 5 pages.;;Polaris Slingshot Panoramic Roof Top by Fab Factory, www.slingmods.com, copyright 2016; 7 pages, Jan. 1.;;Polaris Slingshot Panoramic Roof Top by Fab Factory, www.slingmods.com/polaris-slingshot-panoramic-top; copyright 2016, 8 pages, Jan. 1.;;Slinglines Slingshot-Roof Enclosure for Polaris, www.slinglines.com, copyright 2016; 5 pages, Jan. 1.;;Slingshot Only, Bullet Speed V Back Top for the Polaris Slingshot, downloaded from the Internet on May 17, 2016; http://slingshotonly.com/polaris-slingshot-accessories/polaris-slingshot-bullet-speed-v-back-top/, 5 pages.;;Twist Custom Tops—Twist Dynamics, downloaded from the Internet on May 17, 2016; http://twis.mybigcommerce.com/twist-custom-tops/, 2 pages.;;Twist Dynamics, copyright 2015, www.twistdynamics.com; 2 pages, Jan. 1.;;Twist Gullwing (Pre-Order)—Twist Dynamics, downloaded from the Internet on May 17, 2016; http://twist.mybigcommerce.com/twist-gullwing-pre-order/, 2 pages.;;Slingshade, available at https://web.archive.org/web/20191229040519/https://slingshot.polaris.com/en-us/shop/accessories/functional/slingshade/; 10 pages; available on at least Dec. 29, 2019.",ACTIVE
468,US,B2,US 8722962 B2,167-231-952-699-176,2014-05-13,2014,US 80951808 A,2008-12-12,GB 0725087 A;;GB 2008004115 W,2007-12-21,Wound dressing applicator,"A wound dressing applicator ( 10 ) for applying hydrocolloid dressings, compositions for tissue regeneration and the like to a patient's skin. Known wound dressing applicators do not effectively protect against contamination of the wound dressing and/or can be fiddly and difficult to operate and be rendered unusable by unwanted premature separation of the various layers of material adhered to one another. The present applicator comprises a rigid body ( 20 ) having a rigid body enclosure ( 30 ) for receiving a wound dressing, and an ejector ( 40 ) for ejecting the wound dressing from the rigid body enclosure and onto a patient's wound. This enables effective and aseptic handling of a wound dressing and application of the wound dressing onto a patient's wound.",DERA IAN;;SCOUTAS DIMITRIOS;;HANNANT MATTHEW;;MAISEY GRAEME;;DUNN PHILLIP MICHAEL;;SANDBANK BARRY;;JASSAL SUSHMA RANI;;SMITH & NEPHEW INC,DERA IAN;;SCOUTAS DIMITRIOS;;HANNANT MATTHEW;;MAISEY GRAEME;;DUNN PHILLIP MICHAEL;;SANDBANK BARRY;;JASSAL SUSHMA RANI,SMITH & NEPHEW INC (2012-12-21);;HEALTHPOINT INTERNATIONAL LLC (2011-12-29),https://lens.org/167-231-952-699-176,Granted Patent,yes,16,4,5,6,0,A61F15/001;;A61F15/005;;A61F15/001;;A61F15/001;;A61F15/005;;A61F15/005,A61F13/00,602/48;;221/74,2,0,,,"Office Communication, issued in Great Britain application No. GB0725087.1, dated Mar. 19, 2008.;;PCT International Preliminary Report on Patentability, issued in International application No. PCT/GB2008/004115, mailed Jun. 22, 2010.",INACTIVE
469,NZ,A,NZ 600455 A,155-263-863-330-669,2013-06-28,2013,NZ 60045510 A,2010-11-11,US 26025309 P;;AU 2010/001504 W,2009-11-11,Retractable clinical syringe with a replaceable needle assembly,"600455 A replaceable needle assembly is provided for a retractable syringe (10) comprising a barrel (11) and a plunger (20), whereby the retractable needle (30) can be replaced by a user without affecting the retraction mechanism. A mounting member (40) is removably mountable to the barrel (11) by way of a screw-thread connection and a needle mount is removably coupled to the mounting member (40). A needle (30) is mounted to the needle mount (34). The barrel (11) comprises a needle mount retainer (60) that comprises a plurality of fingers that engage the retractable needle mount (34) to prevent inadvertent retraction. The plunger (20) comprises a collapsible seal (80) which maximizes the efficiency of fluid delivery prior to the plunger (20) engaging the retractable needle mount (34) for retraction. An initially compressed spring decompresses to drive retraction of the plunger (20) and the engaged needle mount (34). A lock formed between the plunger (20) and barrel (11) prevents further use of the plunger after retraction.",UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,,https://lens.org/155-263-863-330-669,Patent Application,no,0,0,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/32;;A61M5/315,,0,0,,,,DISCONTINUED
470,CN,A,CN 102695533 A,196-674-298-005-532,2012-09-26,2012,CN 201080050897 A,2010-11-11,AU 2010/001504 W;;US 26025309 P,2009-11-11,Clinical syringe,"A replaceable needle assembly is provided for a retractable syringe comprising a barrel and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. A mounting member is removably mountable to the barrel by way of a screw-thread connection and a needle mount is removably coupled to the mounting member. A needle is mounted to the needle mount. The barrel comprises a needle mount retainer that comprises a plurality of fingers that engage the retractable needle mount to prevent inadvertent retraction. The plunger comprises a collapsible seal which maximizes the efficiency of fluid delivery prior to the plunger engaging the retractable needle mount for retraction. An initially compressed spring decompresses to drive retraction of the plunger and the engaged needle mount. A lock formed between the plunger and barrel prevents further use of the plunger after retraction.",UNITRACT SYRINGE PTY LTD,STEPHEN THORLEY CRAIG;;HERMES KAAL JOSEPH;;IAN JOHNSON;;ANDREW READE;;ERIC SIU;;RICHARD SOKOLOV;;CHRISTOPHER DUNN,,https://lens.org/196-674-298-005-532,Patent Application,no,3,5,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/32;;A61M5/315,,0,0,,,,INACTIVE
471,WO,A3,WO 2020/212760 A3,144-048-407-079-14X,2021-02-25,2021,IB 2020000312 W,2020-04-16,US 202062966482 P;;US 201962835975 P,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/ infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK;;DUNN JONATHAN,,https://lens.org/144-048-407-079-14X,Search Report,yes,3,0,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,A61K31/7042;;A61K31/70;;A61K31/7052;;A61P27/02;;C07D405/14;;C07D413/14,,0,0,,,,PENDING
472,WO,A2,WO 2020/212760 A2,167-847-962-970-332,2020-10-22,2020,IB 2020000312 W,2020-04-16,US 202062966482 P;;US 201962835975 P,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/ infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK;;DUNN JONATHAN,,https://lens.org/167-847-962-970-332,Patent Application,yes,0,4,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,C07H17/08,,0,0,,,,PENDING
473,CA,C,CA 2780168 C,155-892-940-051-455,2018-10-09,2018,CA 2780168 A,2010-11-11,US 26025309 P;;AU 2010/001504 W,2009-11-11,CLINICAL SYRINGE,"A replaceable needle assembly is provided for a retractable syringe comprising a barrel and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. A mounting member is removably mountable to the barrel by way of a screw-thread connection and a needle mount is removably coupled to the mounting member. A needle is mounted to the needle mount. The barrel comprises a needle mount retainer that comprises a plurality of fingers that engage the retractable needle mount to prevent inadvertent retraction. The plunger comprises a collapsible seal which maximizes the efficiency of fluid delivery prior to the plunger engaging the retractable needle mount for retraction. An initially compressed spring decompresses to drive retraction of the plunger and the engaged needle mount. A lock formed between the plunger and barrel prevents further use of the plunger after retraction.",UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,,https://lens.org/155-892-940-051-455,Granted Patent,no,0,0,15,15,0,A61M2005/323;;A61M5/3234;;Y10T29/49826;;Y10T29/49826;;A61M5/3221;;A61M2005/323;;A61M5/3234,A61M5/32;;A61M5/315,,0,0,,,,INACTIVE
474,AT,T1,AT E165968 T1,185-413-487-891-954,1998-05-15,1998,AT 95911437 T,1995-03-20,GB 9409211 A;;GB 9501629 A;;GB 9504426 A,1994-05-10,HEBEVORRICHTUNG FÜR BEHINDERTE,"PCT No. PCT/GB95/00606 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/30400 PCT Pub. Date Nov. 16, 1995The invalid hoist comprises a mobile chassis 10, a lifting column 11 upstanding from the chassis and a lifting arm 12 supported by the lifting column. The chassis comprises a main portion 13 extending transversely of the hoist and two side members 14 which are movable between a first in-use position in which they project forwardly from the main portion, and a second storage position in which they extend parallel or substantially parallel to the lifting column. Side members 14 are also pivotable about a vertical axis, allowing them to spread away from one another at their forward ends. Releasable means 22 may be provided for holding the lifting arm in an operative position and for releasing the lifting arm to allow it to pivot into a storage position alongside the lifting column. Alternatively, an extendible, retractable device may be connected between the lifting arm and the lifting column at positions remote from the pivot axis between the lifting arm and the lifting column so that the lifting arm can be moved between an operative position and a storage position alongside the lifting column.",ARJO LTD,DUNN ROBERT;;GILL MICHAEL GEORGE;;WEST WINDS PRESTBURY;;GREAVES JOHN;;LEES RICHARD IAN;;SOMERTON BRUCE EDWARD,,https://lens.org/185-413-487-891-954,Granted Patent,no,0,0,38,40,0,A61G7/1017;;A61G7/1046;;A61G7/1061;;A61G7/1067;;A61G7/1074;;A61G7/1076;;A61G7/1074;;A61G7/1061;;A61G7/1076;;A61G7/1067;;A61G7/1017;;A61G7/1046,A61G7/10,,0,0,,,,DISCONTINUED
475,SI,T1,SI 2569008 T1,053-151-063-991-229,2020-02-28,2020,SI 201131835 T,2011-05-13,US 33490110 P;;US 2011/0036533 W;;EP 11720967 A,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,,BAXALTA INC;;BAXALTA GMBH;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J (DECEASED);;LUFT BENJAMIN J,,https://lens.org/053-151-063-991-229,Granted Patent,no,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,C07K14/00;;A61K39/00,,0,0,,,,ACTIVE
476,EP,B1,EP 2569008 B1,084-391-710-227-989,2019-12-25,2019,EP 11720967 A,2011-05-13,US 33490110 P;;US 2011/0036533 W,2010-05-14,OSPA CHIMERAS AND USE THEREOF IN VACCINES,,BAXALTA INC;;BAXALTA GMBH;;UNIV NEW YORK STATE RES FOUND;;BROOKHAVEN SCIENCE ASS LLC,CROWE BRIAN A;;LIVEY IAN;;O'ROURKE MARIA;;SCHWENDINGER MICHAEL;;DUNN JOHN J (DECEASED);;LUFT BENJAMIN J,"BAXALTA GMBH, CH (2021-05-07);;BAXALTA INCORPORATED (2020-04-22);;BAXALTA INCORPORATED; US (2020-04-30);;THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (2020-04-22);;THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY O (2017-11-22);;BAXALTA INCORPORATED, BANNOCKBURN, US (2021-05-07);;BAXALTA GMBH (2020-04-22);;THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF (2016-10-19);;BROOKHAVEN SCIENCE ASSOCIATES LLC, UPTON, US (2021-05-07);;THE RESEARCH FOUNDATION FOR THE STATE UNIVERSI, US (2021-05-07);;BROOKHAVEN SCIENCE ASSOCIATES LLC (2020-04-22)",https://lens.org/084-391-710-227-989,Granted Patent,yes,0,0,74,74,0,A61K39/0225;;C07K14/20;;A61P31/00;;A61P31/04;;A61P31/14;;A61P33/00;;A61P33/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K14/20;;A61P31/00;;A61K39/0225;;A61K2039/575;;A61K2039/6018;;A61K2039/70;;A61K39/0225;;C07K14/20;;Y02A50/30;;A61K39/0225;;C07K14/20;;A61K2039/575;;A61K2039/6018;;A61K2039/70,A61K39/02;;C07K14/20,,1,0,,,"""DNA Vaccines. Methods and Protocols. Second Edition"", 2006, METHODS IN MOLECULAR MEDICINE HUMANA PRESS INC, 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SERIES : METHODS IN MOLECULAR MEDICINE (ISSN 1543-1894(PRINT)), Totowa, New Jersey, ISSN: null, article SHEN, H. AND BRANDSMA, J.L.",ACTIVE
477,EP,A1,EP 2498843 A1,007-791-330-719-05X,2012-09-19,2012,EP 10829351 A,2010-11-11,US 26025309 P;;AU 2010/001504 W,2009-11-11,CLINICAL SYRINGE,,UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,UNL HOLDINGS LLC (2017-09-27),https://lens.org/007-791-330-719-05X,Patent Application,yes,0,0,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/32,,0,0,,,,DISCONTINUED
478,DE,T2,DE 60033307 T2,143-897-109-194-975,2007-07-12,2007,DE 60033307 T,2000-10-13,US 16080399 P;;US 21374300 P;;EP 0010088 W,1999-10-21,HETEROALKYLAMINO-SUBSTITUIERTE BICYCLISCHE STICKSTOFFHETEROCYCLEN ALS P38-PROTEINKINASE-INHIBITOREN,,HOFFMANN LA ROCHE,DUNN PATRICK;;FISHER EMERSON;;GOLDSTEIN MICHAEL;;HARRIS WILLIAM;;BILL HUW;;SMITH IAN EDWARD DAVID;;WELCH ROSANNE,,https://lens.org/143-897-109-194-975,Granted Patent,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00,,0,0,,,,EXPIRED
479,DE,D1,DE 60033307 D1,150-673-246-484-320,2007-03-22,2007,DE 60033307 T,2000-10-13,US 16080399 P;;US 21374300 P;;EP 0010088 W,1999-10-21,HETEROALKYLAMINO-SUBSTITUIERTE BICYCLISCHE STICKSTOFFHETEROCYCLEN,,HOFFMANN LA ROCHE,DUNN PATRICK;;FISHER EMERSON;;GOLDSTEIN MICHAEL;;HARRIS WILLIAM;;BILL HUW;;SMITH IAN EDWARD DAVID;;WELCH ROSANNE,,https://lens.org/150-673-246-484-320,Granted Patent,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00,,0,0,,,,EXPIRED
480,ZA,B,ZA 201204048 B,052-163-988-988-39X,2013-02-27,2013,ZA 201204048 A,2012-06-04,US 26025309 P;;AU 2010/001504 W,2009-11-11,CLINICAL SYRINGE,,UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,,https://lens.org/052-163-988-988-39X,Granted Patent,no,0,0,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M/,,0,0,,,,ACTIVE
481,US,A1,US 2019/0062291 A1,132-651-684-113-626,2019-02-28,2019,US 201715686949 A,2017-08-25,US 201715686949 A,2017-08-25,"Oligomeric (TH)FP, production and uses therefor","A method for the isolation of oligomeric 2, 2-difurylpropane (DTHFP) suitable for use on an industrial scale. A method can include using oligomeric 2, 2-difurylpropane, in particular, its use can be as a polar modifier for butadiene and styrene butadiene polymerisation so is to produce rubber. Utilising the material as an alternative to DTHFP in rubber production avoids subsequent leaching of the DTHFP into the environment as the oligomeric 2, 2-difurylpropane (DTHFP) gives rise to much lower levels of leaching.",SWAN THOMAS & CO LTD,PEARCE IAN STUART;;DUNN DAVID;;SUTTON HOWARD WINSTON TYRRELL;;DALY JOHN ING CHUAN;;GRANT SIMON JONATHON,,https://lens.org/132-651-684-113-626,Patent Application,yes,1,0,2,2,0,C07D307/36;;C07D307/36;;C07D307/06;;C07D307/06;;C07D307/12;;C07D307/12;;C07D307/40;;C07D307/40;;C08F36/06;;C08F36/06,C07D307/36;;C07D307/06;;C08F36/06,,0,0,,,,ACTIVE
482,WO,A1,WO 2011/057334 A1,150-524-411-580-406,2011-05-19,2011,AU 2010/001504 W,2010-11-11,US 26025309 P,2009-11-11,CLINICAL SYRINGE,"A replaceable needle assembly is provided for a retractable syringe comprising a barrel and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. A mounting member is removably mountable to the barrel by way of a screw-thread connection and a needle mount is removably coupled to the mounting member. A needle is mounted to the needle mount. The barrel comprises a needle mount retainer that comprises a plurality of fingers that engage the retractable needle mount to prevent inadvertent retraction. The plunger comprises a collapsible seal which maximizes the efficiency of fluid delivery prior to the plunger engaging the retractable needle mount for retraction. An initially compressed spring decompresses to drive retraction of the plunger and the engaged needle mount. A lock formed between the plunger and barrel prevents further use of the plunger after retraction.",UNITRACT SYRINGE PTY LTD;;THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,,https://lens.org/150-524-411-580-406,Patent Application,yes,12,6,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/32;;A61M5/315,,1,0,,,See also references of EP 2498843A4,PENDING
483,EP,A4,EP 2498843 A4,141-417-996-535-079,2013-10-09,2013,EP 10829351 A,2010-11-11,US 26025309 P;;AU 2010/001504 W,2009-11-11,CLINICAL SYRINGE,,UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,UNL HOLDINGS LLC (2017-09-27),https://lens.org/141-417-996-535-079,Search Report,no,2,0,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/32,,1,0,,,See also references of WO 2011057334A1,DISCONTINUED
484,AU,A1,AU 2010/317660 A1,141-081-821-223-317,2012-06-21,2012,AU 2010/317660 A,2010-11-11,US 26025209 P;;AU 2010/001505 W,2009-11-11,Vaccination syringe,"A replaceable needle assembly is provided for a retractable, prefilled syringe comprising a barrel having a mounting member and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. The replaceable needle assembly comprises a needle fitted to a retractable needle mount and a needle retainer. The needle mount is removably, screw-threadedly mountable to the mounting member of the barrel. The needle retainer comprises a plurality of fingers that releasably engage the retractable needle to thereby prevent inadvertent retraction of the retractable needle before engagement by the plunger. The plunger comprises a plunger seal comprising an outer member and an inner member that engages the needle for spring-driven retraction. At the end of retraction, a lock is formed between the plunger and barrel to prevent re-use of the syringe.",UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,,https://lens.org/141-081-821-223-317,Patent Application,no,0,0,29,29,0,A61M5/3234;;A61M5/3234;;A61M5/502;;A61M2005/3231;;A61M2005/3231;;A61M2005/3241;;A61M2005/3241;;A61M2005/5033;;A61M2202/30;;Y10T29/49826;;Y10T29/49826,A61M5/32,,0,0,,,,INACTIVE
485,CA,A1,CA 2780168 A1,189-039-142-659-47X,2011-05-19,2011,CA 2780168 A,2010-11-11,US 26025309 P;;AU 2010/001504 W,2009-11-11,CLINICAL SYRINGE,"A replaceable needle assembly is provided for a retractable syringe comprising a barrel and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. A mounting member is removably mountable to the barrel by way of a screw-thread connection and a needle mount is removably coupled to the mounting member. A needle is mounted to the needle mount. The barrel comprises a needle mount retainer that comprises a plurality of fingers that engage the retractable needle mount to prevent inadvertent retraction. The plunger comprises a collapsible seal which maximizes the efficiency of fluid delivery prior to the plunger engaging the retractable needle mount for retraction. An initially compressed spring decompresses to drive retraction of the plunger and the engaged needle mount. A lock formed between the plunger and barrel prevents further use of the plunger after retraction.",UNITRACT SYRINGE PTY LTD,THORLEY CRAIG STEPHEN;;KAAL JOSEPH HERMES;;JOHNSON IAN;;READE ANDREW;;SIU ERIC;;SOKOLOV RICHARD;;DUNN CHRISTOPHER,,https://lens.org/189-039-142-659-47X,Patent Application,no,0,0,15,15,0,A61M5/3234;;A61M5/3234;;A61M5/3221;;A61M2005/323;;A61M2005/323;;Y10T29/49826;;Y10T29/49826,A61M5/32;;A61M5/315,,0,0,,,,INACTIVE
486,US,B2,US 11643429 B2,107-596-531-415-951,2023-05-09,2023,US 202117222821 A,2021-04-05,US 202117222821 A;;IB 2020000312 W;;US 202062966482 P;;US 201962835975 P,2019-04-18,Compounds and methods for the treatment of ocular disorders,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN,DOMAINEX LTD (2021-05-04);;AZURA OPHTHALMICS LTD (2021-05-04);;BCP3 PTY LIMITED (2021-05-04),https://lens.org/107-596-531-415-951,Granted Patent,yes,23,0,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,C07H17/00;;A61K9/00;;A61P27/04;;C07H17/08,,19,16,037-396-919-462-769;;039-638-656-437-378;;027-766-748-249-199;;020-870-855-859-609;;090-991-982-963-361;;007-364-858-655-289;;121-114-378-458-21X;;027-488-422-889-594;;006-519-925-085-122;;073-352-788-052-508;;094-813-021-617-631;;001-718-978-242-312;;003-334-491-119-371;;030-234-441-646-238;;074-730-080-706-256;;018-859-478-183-391,30005585;;10.1080/02713683.2018.1500611;;pmc6881093;;10.1111/j.1365-2133.2007.07864.x;;17488405;;10.1007/978-3-540-69375-8_54;;10.1167/iovs.03-1055;;15161821;;10.1167/iovs.04-1326;;16043849;;10.1002/jps.2600660104;;833720;;11867577;;10.1007/bf02518337;;10.1016/s0040-4020(01)89131-6;;pmc3072159;;10.1167/iovs.10-6997c;;21450915;;pmc3072157;;10.1167/iovs.10-6997;;21450913;;10.1167/iovs.10-6997a;;10.4049/jimmunol.176.7.3950;;16547229;;15364229;;10.1016/j.ajo.2004.04.052;;10.1016/s1542-0124(12)70085-x;;17508120;;10.1167/iovs.10-6997e;;pmc3072161;;21450917;;10.2147/opth.s33182;;24043929;;pmc3772773,"Postnikoff, C. et al “Leukocyte distribution in the open eye tears . . . ” Curr. Eye Res., voll 43, No. 10, pp. 1253-1259. (Year: 2018).;;Ulrich, C. et al “Treatment of multiple actinic keratoses with topical diclofenac . . . ” Br. J. Dermatol., vol. 156, suppl. 3, pp. 40-42. (Year : 2007).;;CN 1837225A machine translation. (Year: 2006).;;Alikhan, A. et al “Keratolytic Treatment” in Pathogenesis and Treatment of Acne and Rosacea, C. Zouboulis etal (eds.), Springer-Verlag, Berlin, pp. 397-414. (Year: 2014).;;Barabino et al. Animal Models of Dry Eye: A Critical Assessment of Opportunities and Limitations. Invest. Ophthalmol. Vis. Sci. 45:1641-1646 (2004).;;Barabino et al. The Controlled-Environment Chamber: A New Mouse Model of Dry Eye. Invest. Ophthalmol. Vis. Sci. 46:2766-2771 (2005).;;Berge et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (Jan. 1977).;;Dursun et al. A Mouse Model of Keratoconjunctivitis Sicca. Invest. Ophthalmol. Vis. Sci. 43:632-638 (2002).;;Evans. Synthesis of radiolabeled compounds. J Radioanal Chem 64(1-2):9-32 (1981).;;Kabalka et al. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates. Tetrahedron 45(21):6601-6621 (1989).;;Knop et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. IOVS 52(4):1938-1978 (2011).;;Nichols et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest. Ophthalmol. Vis. Sci. 52(4):1922-1929 (2011).;;Niederkorn et al. Desiccating Stress Induces T Cell-Mediated Sjogren's Syndrome-like Lacrimal Keratoconjunctivitis. J. Immunol. 176:3950-3957 (2006).;;PCT/IB2020/000312 International Invitation to Pay Additional Fees dated Oct. 29, 2020.;;PCT/IB2020/000312 International Search Report and Written Opinion dated Jan. 15, 2021.;;Pflugfelder et al. A Randomized, Double-Masked, Placebo-Controlled, Multicenter Comparison of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, and Placebo for Treatment of Keratoconjunctivitis Sicca in Patients With Delayed Tear Clearance. Am J Ophthalmol 138:444-57 (2004).;;Pflugfelder et al. International Dry Eye Workshop, 2007. Management and Therapy of Dry Eye Disease: Report of the Management and Therapy Subcommittee of the International Dry Eye Workshop. Ocul Surf 5:163-178 (2007).;;Schaumberg et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on the Epidemiology of, and Associated Risk Factors for, MGD. Invest. Ophthalmol. Vis. Sci. 52(4):1994-2005 (2011).;;Qiao et al. Emerging treatment options for meibomian gland dysfunction. Clinical Ophthalmology 7:1797-1803 (2013).",ACTIVE
487,US,A1,US 2007/0265450 A1,010-500-334-017-990,2007-11-15,2007,US 78290207 A,2007-07-25,US 78290207 A;;US 83884304 A;;US 75764104 A;;US 4349802 A;;US 67000500 A;;US 26647199 A;;US 26629899 P;;US 15519798 P,1998-03-13,"NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.",AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,HILPERT THOMAS H E;;FLEMMING HANS-WOLFRAM;;STOLZ-DUNN SANDRA K;;EVANS JONATHAN C;;TOMLINSON IAN A,,https://lens.org/010-500-334-017-990,Patent Application,yes,25,0,6,8,0,C07D211/32;;C07D211/32;;C07D211/22;;C07D211/22,C07D213/04;;A61K31/445;;C07D211/04;;C07D211/20;;C07D211/22;;C07D211/32,546/250;;546/343,0,0,,,,DISCONTINUED
488,US,A1,US 2021/0230205 A1,053-600-852-331-873,2021-07-29,2021,US 202117222821 A,2021-04-05,US 202117222821 A;;IB 2020000312 W;;US 202062966482 P;;US 201962835975 P,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN,DOMAINEX LTD (2021-05-04);;AZURA OPHTHALMICS LTD (2021-05-04);;BCP3 PTY LIMITED (2021-05-04),https://lens.org/053-600-852-331-873,Patent Application,yes,0,0,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,A61K9/00;;C07H17/00;;A61P27/04,,0,0,,,,ACTIVE
489,US,A1,US 2023/0348517 A1,102-718-638-801-124,2023-11-02,2023,US 202318117759 A,2023-03-06,US 202318117759 A;;US 202117222821 A;;IB 2020000312 W;;US 202062966482 P;;US 201962835975 P,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN,DOMAINEX LTD (2021-05-04);;AZURA OPHTHALMICS LTD (2021-05-04);;BCP3 PTY LIMITED (2021-05-04),https://lens.org/102-718-638-801-124,Patent Application,yes,0,0,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,C07H17/00;;A61K9/00;;A61P27/04;;C07H17/08,,0,0,,,,PENDING
490,US,A1,US 2004/0210061 A1,162-622-257-376-136,2004-10-21,2004,US 83884304 A,2004-05-04,US 83884304 A;;US 4349802 A;;US 67000500 A;;US 26647199 A;;US 75764104 A;;US 26629899 P;;US 15519798 P,1998-03-13,"Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol","
    The present invention provides various processes for the preparation of (R)--(2,3-dimethoxyphenyl)-1-2-(4-fluorophenyl)ethyl-4-piperidinemethanol. These processes may be characterized by the following scheme: 
",AVENTIS PHARMA INC;;AVENTIS PHARMA GMBH,HILPERT THOMAS HEINZ EDUARD;;FLEMMING HANS-WOLFRAM;;STOLZ-DUNN SANDRA K;;EVANS JONATHAN C;;TOMLINSON IAN A,THE DOW CHEMICAL COMPANY (1999-02-08);;AVENTIS PHARMACEUTICALS INC (1999-02-10);;AVENTIS PHARMA DEUTSCHLAND GMBH (1999-02-10),https://lens.org/162-622-257-376-136,Patent Application,yes,25,0,6,8,0,C07D211/32;;C07D211/32;;C07D211/22;;C07D211/22,A61K31/445;;C07D211/20;;C07D211/22;;C07D211/32,546/339,0,0,,,,DISCONTINUED
491,US,B1,US 6665674 B1,028-489-775-008-642,2003-12-16,2003,US 49604900 A,2000-02-02,US 49604900 A,2000-02-02,Framework for open directory operation extensibility,"
    Methods and apparatus are provided for processing messages for access to information stored in an open directory. A Lightweight Directory Access Protocol (LDAP) LDAP Validation Proxy (LVP) is used to intercept LDAP request messages intended for the directory, validates the LDAP requests according to a schema description and optionally provides side-effects. The schema validation and LDAP message processing is modularized according to object classes representing the data stored in the directory and according to services provided. The schema is enforced by validating LDAP messages. This modularization provides a controlled message processing granularity and enables multi-threaded concurrent processing of multiple LDAP messages. The LVP has the capability of generating LDAP requests in processing LDAP messages. The LVP also intercepts and processes LDAP responses issued by a directory and intended for clients. 
",NORTEL NETWORKS LTD,BUCHANAN JAMES H;;GIBSON ROBERT T;;DUNN BRUCE E;;CONNELL BRIAN D;;MACFARLANE IAN A;;MILLER SCOTT E,NORTEL NETWORKS LIMITED (2000-01-26),https://lens.org/028-489-775-008-642,Granted Patent,yes,7,88,1,1,0,H04L63/123;;H04L2101/622;;H04L61/4523;;H04L63/123;;H04L61/4523;;H04L2101/622,H04L29/06;;H04L29/12,707/10;;707/103;;709/203;;709/315,1,0,,,"Cheng et al., Directory-Enabled Network Management Framework For Battlefield Networks, Military Communications Conf. Proceedings, IEEE, p. 1171-1175 vol. 2, Oct. 1999.",EXPIRED
492,AT,T1,AT E276332 T1,083-112-987-906-174,2004-10-15,2004,AT 02007978 T,2002-04-10,EP 01110189 A;;EP 01116737 A,2001-05-08,POLYMERISIERBARES FLÜSSIGKRISTALLMATERIAL,"The invention relates to a polymerizable liquid crystal material containing at least one polymerizable surface-active compound, its use for the preparation of anisotropic polymer films, and the use of the liquid crystal material and the polymer films in optical and electrooptical devices, and for decorative and security applications.",MERCK PATENT GMBH,DUNN CHRISTOPHER J;;GREENFIELD SIMON;;HARDING RICHARD;;HASSALL IAN VICTOR EDWARD;;MAY ALISON LINDA;;VAUGHAN-SPICKERS JULIAN FREDER,,https://lens.org/083-112-987-906-174,Granted Patent,no,0,0,9,11,0,C09K19/2007;;C09K19/38;;C09K19/3852;;C09K19/46;;C09K2019/0448;;C09K2019/3095;;C09K2323/03;;C09K2323/02;;C09K2323/031;;C09K2323/00;;C09K19/52;;C09K19/2007;;C09K19/3852;;C09K2019/3095;;C09K2019/0448;;C09K19/38;;C09K19/46;;C09K2323/00;;C09K2323/02;;C09K2323/03;;C09K2323/031,G02B5/30;;C08F2/24;;C08F20/28;;C09K19/20;;C09K19/38;;C09K19/46;;C09K19/52;;G02F1/13,,0,0,,,,DISCONTINUED
493,US,B2,US 7029728 B2,166-305-696-790-001,2006-04-18,2006,US 13542502 A,2002-05-01,EP 01110189 A;;EP 01116737 A,2001-05-08,Polymerizable liquid crystal material,"The invention relates to a polymerizable liquid crystal material containing at least one polymerizable surface-active compound, its use for the preparation of anisotropic polymer films, and the use of the liquid crystal material and the polymer films in optical and electrooptical devices, and for decorative and security applications.",MERCK PATENT GMBH,DUNN CHRISTOPHER J;;GREENFIELD SIMON;;HARDING RICHARD;;HASSALL IAN VICTOR EDWARD;;MAY ALISON LINDA;;VAUGHAN-SPICKERS JULIAN FREDER,MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (2002-04-25),https://lens.org/166-305-696-790-001,Granted Patent,yes,8,21,9,11,0,C09K19/2007;;C09K19/38;;C09K19/3852;;C09K19/46;;C09K2019/0448;;C09K2019/3095;;C09K2323/03;;C09K2323/02;;C09K2323/031;;C09K2323/00;;C09K19/52;;C09K19/2007;;C09K19/3852;;C09K2019/3095;;C09K2019/0448;;C09K19/38;;C09K19/46;;C09K2323/00;;C09K2323/02;;C09K2323/03;;C09K2323/031,C09K19/38;;C08F2/24;;G02B5/30;;C08F20/28;;C09K19/20;;C09K19/46;;C09K19/52;;C09K19/54;;G02F1/13,428/1.1;;428/1.2;;428/1.3;;428/1.31;;252/299.01;;252/299.5,0,0,,,,EXPIRED
494,ES,T3,ES 2280247 T3,153-135-244-042-490,2007-09-16,2007,ES 00967864 T,2000-10-13,US 16080399 P;;US 21374300 P,1999-10-21,HETEROCICLOS DE NITROGENO BICICLICOS HETEROALQUILAMINO SUSTITUIDOS COMO INHIBIDORES DE PROTEINAS DE QUINASA P38.,"Un compuesto seleccionado entre un grupo de compuestos que se ajustan a la **fórmula**, en la que el subíndice n es un número entero de 1 o 2; R1 es acilo, heteroalquilo, arilheteroalquilo eventualmente sustituido, heteroalquenilo, heteroalquinilo, heteroalquilcarbonilo, cicloalquilo heterosustituido, cicloalquilalquilo heterosustituido, cicloalquilalquenilo heterosustituido, cicloalquilalquinilo heterosustituido, cicloalquilo heteroalquilsustituido, heterociclilo eventualmente sustituido, heterociclilalquilo eventualmente sustituido, heterocicliespirocicloalquilo eventualmente sustituido, -(alquilen)-C(O)-R11 o -(heteroalquilen)-C(O)-R11; y un esereoisómero individual, un mezcla racémica o no racémica de estereoisómeros, o una sal respectiva farmacéuticamente aceptable.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;BILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID,,https://lens.org/153-135-244-042-490,Granted Patent,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00,,0,0,,,,EXPIRED
495,EP,A1,EP 1256617 A1,038-556-640-496-351,2002-11-13,2002,EP 02007978 A,2002-04-10,EP 02007978 A;;EP 01110189 A;;EP 01116737 A,2001-05-08,Polymerizable liquid crystal material,"The invention relates to a polymerizable liquid crystal material comprising at least one polymerizable surface-active compound, its use for the preparation of anisotropic polymer films, and the use of the liquid crystal material and the polymer films in optical and electrooptical devices, for decorative and security applications.",MERCK PATENT GMBH,DUNN CHRISTOPHER J;;GREENFIELD SIMON;;HARDING RICHARD;;HASSALL IAN VICTOR EDWARD;;MAY ALISON LINDA;;VAUGHAN-SPICKERS JULIAN FREDER,,https://lens.org/038-556-640-496-351,Patent Application,yes,9,18,2,11,0,C09K19/54;;C09K19/2007;;C09K19/38;;C09K19/3852;;C09K19/46;;C09K2019/0448;;C09K2019/3095;;C09K2019/528,C09K19/20;;C09K19/38;;C09K19/46;;C09K19/54,,0,0,,,,EXPIRED
496,US,A1,US 2003/0085377 A1,041-859-571-071-427,2003-05-08,2003,US 13542502 A,2002-05-01,EP 01110189 A;;EP 01116737 A,2001-05-08,Polymerizable liquid crystal material,"
   The invention relates to a polymerizable liquid crystal material containing at least one polymerizable surface-active compound, its use for the preparation of anisotropic polymer films, and the use of the liquid crystal material and the polymer films in optical and electrooptical devices, and for decorative and security applications. 
",MERCK PAPTENTGMBH,DUNN CHRISTOPHER J;;GREENFIELD SIMON;;HARDING RICHARD;;VICTOR EDWARD HASSALL IAN;;MAY ALISON LINDA;;FREDERICK SAMUEL VAUGHAN-SPICK,MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (2002-04-25),https://lens.org/041-859-571-071-427,Patent Application,yes,6,27,9,11,0,C09K19/2007;;C09K19/38;;C09K19/3852;;C09K19/46;;C09K2019/0448;;C09K2019/3095;;C09K2323/03;;C09K2323/02;;C09K2323/031;;C09K2323/00;;C09K19/52;;C09K19/2007;;C09K19/3852;;C09K2019/3095;;C09K2019/0448;;C09K19/38;;C09K19/46;;C09K2323/00;;C09K2323/02;;C09K2323/03;;C09K2323/031,C08F2/24;;C08F20/28;;C09K19/20;;C09K19/38;;C09K19/46;;C09K19/52;;G02F1/13;;G02B5/30,252/299.01;;252/299.61;;252/299.62;;252/299.63;;252/299.64;;252/299.66;;252/299.67,0,0,,,,EXPIRED
497,TW,B,TW I295314 B,112-584-758-975-905,2008-04-01,2008,TW 91106627 A,2002-04-02,TW 91106627 A,2002-04-02,Polymerizable liquid crystal material,,MERCK PATENT GMBH,DUNN CHRISTOPHER J;;GREENFIELD SIMON;;HARDING RICHARD;;HASSALL IAN V E;;MAY ALISON;;VAUGHAN-SPICKERS JULIAN F S,,https://lens.org/112-584-758-975-905,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
498,US,S,US D0971793 S,130-732-497-724-861,2022-12-06,2022,US 201929684633 F,2019-03-22,US 201929684633 F,2019-03-22,Two-wheeled vehicle,,INDIAN MOTORCYCLE INTERNATIONAL LLC;;INDIAN MOTORCYCLE INTERANTIONAL LLC,DUNN IAN M;;O'HALLORAN JEFFREY M;;QUADE NEIL P;;DOORNINK WILLIAM H;;SONG MICHAEL M;;SCHUHMACHER KORY J,INDIAN MOTORCYCLE INTERNATIONAL LLC (2019-06-25),https://lens.org/130-732-497-724-861,Design Right,no,52,1,1,1,0,,,1211;;D12/114,6,0,,,"Zig Wheels, Indian Chieftain Dark Horse—Road Test Review, posted Apr. 25, 2017, [online], [visited Jun. 21, 2021]. Internet, <URL: https://www.zigwheels.com/reviews-advice/reviews/indian-chieftain-dark-horse-road-test-review/27856/> (Year: 2017).;;Zig Wheels, Three New Indian Bikes Confirmed in Leaked Document, posted May 4, 2019, [online], [visited Jun. 21, 2021]. Internet, <URL: https://www.zigwheels.com/news-features/news/new-1770cc-indian-motorcycles-bagger-to-be-called-raptor-leaked-doc-reveals-more-details/33735/> (Year: 2019).;;International Preliminary Report on Patentability issued by the International Preliminary Examining Authority, dated Jun. 10, 2021, for International Patent Application No. PCT/US2020/023159; 31 pages.;;International Search Report and Written Opinion issued by the International Searching Authority, dated Sep. 23, 2020, for International Patent Application No. PCT/US2020/023159; 21 pages.;;Zig Wheels, Indian Chieftain Dark Horse - Road Test Review, posted 04/25/2017, [online], [visited 06/21/2021]. Internet, <URL: https://www.zigwheels.com/reviews-advice/reviews/indian-chieftain-dark-horse-road-test-review/27856/> (Year: 2017);;Zig Wheels, Three New Indian Bikes Confirmed in Leaked Document, posted 05/04/2019, [online], [visited 06/21/2021]. Internet, <URL: https://www.zigwheels.com/news-features/news/new-1770cc-indian-motorcycles-bagger-to-be-called-raptor-leaked-doc-reveals-more-details/33735/> (Year: 2019)",ACTIVE
499,DE,D1,DE 60201213 D1,034-387-006-614-701,2004-10-21,2004,DE 60201213 T,2002-04-10,EP 01110189 A;;EP 01116737 A,2001-05-08,Polymerisierbares Flüssigkristallmaterial,"The invention relates to a polymerizable liquid crystal material containing at least one polymerizable surface-active compound, its use for the preparation of anisotropic polymer films, and the use of the liquid crystal material and the polymer films in optical and electrooptical devices, and for decorative and security applications.",MERCK PATENT GMBH,DUNN CHRISTOPHER J;;GREENFIELD SIMON;;HARDING RICHARD;;HASSALL IAN VICTOR EDWARD;;MAY ALISON LINDA;;VAUGHAN-SPICKERS JULIAN FREDER,,https://lens.org/034-387-006-614-701,Granted Patent,no,0,0,9,11,0,C09K19/2007;;C09K19/38;;C09K19/3852;;C09K19/46;;C09K2019/0448;;C09K2019/3095;;C09K2323/03;;C09K2323/02;;C09K2323/031;;C09K2323/00;;C09K19/52;;C09K19/2007;;C09K19/3852;;C09K2019/3095;;C09K2019/0448;;C09K19/38;;C09K19/46;;C09K2323/00;;C09K2323/02;;C09K2323/03;;C09K2323/031,G02B5/30;;C08F2/24;;C08F20/28;;C09K19/20;;C09K19/38;;C09K19/46;;C09K19/52;;G02F1/13,,0,0,,,,EXPIRED
500,JP,A,JP 2003105030 A,050-598-019-823-596,2003-04-09,2003,JP 2002132291 A,2002-05-08,EP 01110189 A;;EP 01116737 A,2001-05-08,POLYMERIZABLE LIQUID CRYSTAL SUBSTANCE,"PROBLEM TO BE SOLVED: To provide a polymerizable liquid crystal substance for producing a polymeric film having plane orientation without having the conventional defects. SOLUTION: The polymerizable liquid crystal substance comprises at least one polymerizable surface active agent. This substance is used in producing an anisotropic polymeric film, and the liquid crystal substance and the polymeric film are used in the decorative and security applications in optical and electro- optical devices.",MERCK PATENT GMBH,DUNN CHRISTOPHER J;;SIMON GREENFIELD;;HARDING RICHARD;;HASSALL IAN VICTOR EDWARD;;MAY ALISON LINDA;;VAUGHAN-SPICKERS JULIAN FREDER,,https://lens.org/050-598-019-823-596,Patent Application,no,0,39,9,11,0,C09K19/2007;;C09K19/38;;C09K19/3852;;C09K19/46;;C09K2019/0448;;C09K2019/3095;;C09K2323/03;;C09K2323/02;;C09K2323/031;;C09K2323/00;;C09K19/52;;C09K19/2007;;C09K19/3852;;C09K2019/3095;;C09K2019/0448;;C09K19/38;;C09K19/46;;C09K2323/00;;C09K2323/02;;C09K2323/03;;C09K2323/031,C08F2/24;;C08F20/28;;C09K19/20;;C09K19/38;;C09K19/46;;G02B5/30;;C09K19/52;;G02F1/13,,0,0,,,,PENDING
501,TW,A,TW 200305636 A,096-437-620-795-313,2003-11-01,2003,TW 92108556 A,2003-04-14,EP 02008230 A,2002-04-18,Polymerisable compounds comprising a cinnamic acid group and an acetylene group,"The invention relates to new polymerisable mesogenic or liquid crystalline compounds comprising a cinnamic acid and an acetylene group, to polymerisable mesogenic or liquid crystalline mixtures and anisotropic polymers prepared thereof, and to the use of the new compounds and the mixtures and polymers prepared thereof in optical and electrooptical devices, adhesives, synthetic resins with anisotropic mechanical properties, cosmetics, diagnostics, liquid crystal pigments, decorative and security applications, nonlinear optics, optical information storage, electronic devices like organic field effect transistors (FET or OFET), electroluminescent devices, or as chiral dopants.",MERCK PATENT GMBH,GREENFIELD SIMON;;HARDING RICHARD;;VAUGHAN-SPICKERS JULIAN F S;;SMITH ASHLEY;;HASSALL IAN V E;;DUNN CHRISTOPHER J,,https://lens.org/096-437-620-795-313,Patent of Addition,no,0,2,6,6,0,C07C69/734;;C07C69/736;;C07D213/55;;C09B69/109;;C09K19/18;;C07D213/55;;C09K19/0403;;C09K19/3405;;C09K19/3444;;C09K19/3461;;C09K19/3491;;C09K19/3497;;C09K2019/0407;;C09K2019/0444;;C09K2019/0448;;C09K2019/0459;;C09K2219/03,G02B5/30;;C07C69/017;;C07C69/734;;C07D213/55;;C08F20/10;;C09K19/04;;C09K19/18;;C09K19/20;;C09K19/28;;C09K19/32;;C09K19/34;;C09K19/38;;G02F1/13;;G02F1/1335;;H01L51/05;;H01L51/30,,0,0,,,,PENDING
502,US,B2,US 7122227 B2,166-564-300-611-609,2006-10-17,2006,US 43201503 A,2003-05-19,EP 00124365 A;;EP 0110944 W,2000-11-20,Chiral photoisomerizable compounds,"The invention relates to chiral photoisomerizable compounds of formula (I) wherein X 1 , X 2 , X 3 , X 4 , X 5 and X 6 have the meanings given in claim 1 , to liquid crystalline mixtures and polymers containing them, and to the use of chiral photoisomerizable compounds, liquid crystalline mixtures and polymers containing them in optical and electrooptical devices like liquid crystal displays or projection systems, in optical elements like polarizers, retardation films, compensators, color filters or holographic elements, in liquid crystal pigments and colored films or coatings for decorative or security applications, cosmetic and pharmaceutical compositions, in nonlinear optics and optical information storage.",MERCK PATENT GMBH,VAUGHN-SPICKERS JULIAN;;GREENFIELD SIMON;;HASSALL IAN VICTOR EDWARD;;DUNN CHRISTOPHER J;;HARDING RICHARD;;JENKINS TONY;;MAY ALISON,MERCK PATENT GMBH (2003-05-06),https://lens.org/166-564-300-611-609,Granted Patent,yes,8,18,13,13,0,C09K19/2028;;C09K19/586;;C09K2219/03;;C09K2323/00;;C09K19/58;;C09K19/2028;;C09K2219/03;;C09K19/586;;C09K2323/00,C09K19/38;;G02B5/30;;C07C69/76;;C07C69/767;;C09K19/20;;C09K19/52;;C09K19/54;;C09K19/58;;G02F1/13;;G02F1/1335,428/1.1;;252/299.01;;252/299.2;;252/299.61;;252/299.62;;252/299.63;;252/299.64;;252/299.65;;252/299.66;;252/299.67;;560/76;;560/85,8,7,043-051-376-226-690;;057-876-402-807-638;;069-265-329-389-03X;;032-710-801-144-432;;106-636-245-165-485;;028-367-749-113-187;;010-180-958-180-681,10.1021/ma000346u;;10.1080/026782901462346;;10.1080/02678290210156678;;10.1295/polymj.31.1037;;10.1080/02678299208029027;;10.1080/026782998206632;;10.1080/02678299608032841,"Yun, Y-K; Ko, D-H; Jin, J-I; Kang, Y.S.; Zin, W-C; Jo, B-W. ""Synthesis and Characterization fo New Chiral Side Chain Liquid Crystalline Polyoxetanes"", Macromolecules 2000, 33, 6653-6663 (web published Aug. 10, 2000).;;Hattori, H.; Uryu, T., ""Photochromic chiral liquid crystalline systems containing spiro-oxazine with a chiral substituent I. Synthesis and characterization of compounds"", Liquid Crystals, 2001, vol. 28, No. 1, pp. 25-34.;;Ritter, O.M.S; Merlo, A.A.; Pereira, F.V.; Da Silveira, N.P.; Geissler, E.; Zukerman-Schpector, J. ""Synthesis and characterization of new chiral liquid crystalline polyacrylates from L-isoleucine"", Liquid Crystals, 2002, No. 9, 1187-1200.;;English translation of Yusuke et al.;;K. Yokota et al., ""Chirality induction in cyclopolymerization XI. Bulkiness effect of 1,2-diol templateson cyclopolymerations of bis(4-vinylbenzoate)s with styrene,"" Polymer Journal, 1999, pp. 1037-1040, vol. 31, No. 11-2, XP001053658, Scheme 1, Compound 1e.;;S. M. Kelly et al., ""Four-unit linking groups V. optically active dopants,"" Liquid Crystals, 1992, pp. 761-771, vol. 11, No. 5, XP002192313, table 3.;;Witte Van De P et al., ""Modification of the pitch of chiral nematic liquid crystals by means of photisomerization of chiral dopants,"" Liquid Crystals, Jun. 1, 1998, pp. 819-827, vol. 24, No. 6, XP000773004, ISSN: 0267-8292, cited in the application, the whole document, Taylor and Francis Ltd, London, GB.;;Deussenn H-J et al., ""New 6,-6-disubstituted-binaphthol derivatives as chiral dopants: Synthesis and temperature dependence of molecular conformations,"" Liquid Crystals, Sep. 1, 1996, p. 327-340, vol. 21, No. 3, XP000629493, ISSN: 0267-8292, cited in the application, the whole document, Taylor and Francis Ltd, London, GB.",EXPIRED
503,JP,A,JP 2009041023 A,184-495-879-105-882,2009-02-26,2009,JP 2008224872 A,2008-09-02,EP 01110189 A;;EP 01116737 A,2001-05-08,POLYMERIZABLE LIQUID CRYSTAL MATERIAL,"<P>PROBLEM TO BE SOLVED: To provide a polymerizable liquid crystal material for the preparation of polymer films which do not have the prior art disadvantages and have plane orientation. <P>SOLUTION: The invention relates to a polymerizable liquid crystal material containing at least one polymerizable surface-active compound, its use for the preparation of anisotropic polymer films, and the use of the liquid crystal material and the polymer films in optical and electrooptical devices, and for decorative and security applications. <P>COPYRIGHT: (C)2009,JPO&INPIT",MERCK PATENT GMBH,DUNN CHRISTOPHER J;;SIMON GREENFIELD;;HARDING RICHARD;;HASSALL IAN VICTOR EDWARD;;MAY ALISON LINDA;;VAUGHAN-SPICKERS JULIAN FREDER,,https://lens.org/184-495-879-105-882,Patent Application,no,5,3,9,11,0,C09K19/2007;;C09K19/38;;C09K19/3852;;C09K19/46;;C09K2019/0448;;C09K2019/3095;;C09K2323/03;;C09K2323/02;;C09K2323/031;;C09K2323/00;;C09K19/52;;C09K19/2007;;C09K19/3852;;C09K2019/3095;;C09K2019/0448;;C09K19/38;;C09K19/46;;C09K2323/00;;C09K2323/02;;C09K2323/03;;C09K2323/031,C08F228/02;;C08F2/24;;G02B5/30;;C08F20/28;;C08J5/18;;C09K19/20;;C09K19/38;;C09K19/46;;C09K19/52;;C09K19/54;;G02F1/13;;G02F1/1335;;G02F1/13363;;G02F1/1337,,0,0,,,,PENDING
504,EP,B1,EP 1256617 B1,054-934-037-226-862,2004-09-15,2004,EP 02007978 A,2002-04-10,EP 02007978 A;;EP 01110189 A;;EP 01116737 A,2001-05-08,Polymerizable liquid crystal material,,MERCK PATENT GMBH,DUNN CHRISTOPHER J;;GREENFIELD SIMON;;HARDING RICHARD;;HASSALL IAN VICTOR EDWARD;;MAY ALISON LINDA;;VAUGHAN-SPICKERS JULIAN FREDER,,https://lens.org/054-934-037-226-862,Granted Patent,yes,9,1,2,11,0,C09K19/54;;C09K19/2007;;C09K19/38;;C09K19/3852;;C09K19/46;;C09K2019/0448;;C09K2019/3095;;C09K2019/528,C09K19/20;;C09K19/38;;C09K19/46;;C09K19/54,,0,0,,,,EXPIRED
505,DE,T2,DE 60201213 T2,183-158-232-442-868,2005-09-29,2005,DE 60201213 T,2002-04-10,EP 01110189 A;;EP 01116737 A,2001-05-08,Polymerisierbares Flüssigkristallmaterial,"The invention relates to a polymerizable liquid crystal material containing at least one polymerizable surface-active compound, its use for the preparation of anisotropic polymer films, and the use of the liquid crystal material and the polymer films in optical and electrooptical devices, and for decorative and security applications.",MERCK PATENT GMBH,DUNN CHRISTOPHER J;;GREENFIELD SIMON;;HARDING RICHARD;;HASSALL IAN VICTOR EDWARD;;MAY ALISON LINDA;;VAUGHAN-SPICKERS JULIAN FREDER,,https://lens.org/183-158-232-442-868,Granted Patent,no,0,0,9,11,0,C09K19/2007;;C09K19/38;;C09K19/3852;;C09K19/46;;C09K2019/0448;;C09K2019/3095;;C09K2323/03;;C09K2323/02;;C09K2323/031;;C09K2323/00;;C09K19/52;;C09K19/2007;;C09K19/3852;;C09K2019/3095;;C09K2019/0448;;C09K19/38;;C09K19/46;;C09K2323/00;;C09K2323/02;;C09K2323/03;;C09K2323/031,G02B5/30;;C08F2/24;;C08F20/28;;C09K19/20;;C09K19/38;;C09K19/46;;C09K19/52;;G02F1/13,,0,0,,,,EXPIRED
506,AU,A1,AU 2011/229159 A1,048-186-721-452-948,2012-08-16,2012,AU 2011/229159 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W;;AU 2011/229159 A,2010-03-19,Diagnostic system,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,ATOMO DIAGNOSTICS LIMITED (2022-03-17),https://lens.org/048-186-721-452-948,Patent Application,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61J1/05,,0,0,,,,ACTIVE
507,DE,T5,DE 112019004889 T5,192-732-045-243-062,2021-06-24,2021,DE 112019004889 T,2019-09-24,US 201862738066 P;;US 2019/0052587 W,2018-09-28,Recheneffiziente Modellauswahl,"In verschiedenen Implementierungen vermisst eine Vorrichtung eine Szene und präsentiert innerhalb der Szene eine Umgebung der synthetisierten Realität (SR-Umgebung), die ein oder mehrere Assets einschließt, die sich im Laufe der Zeit entwickeln (z. B. Position oder Alter ändern). Das Modellieren einer solchen SR-Umgebung auf verschiedenen Zeitskalen kann insbesondere beim Modellieren der SR-Umgebung über größere Zeitskalen hinweg rechenintensiv sein. Dementsprechend werden in verschiedenen Implementierungen unterschiedliche Modelle verwendet, um den Umgebungszustand der SR-Umgebung zu bestimmen, wenn die SR-Umgebung mit unterschiedlichen Zeitskalen präsentiert wird.",APPLE INC,MORGAN BO;;DRUMMOND MARK E;;MEIER PETER;;DUNN CAMERON J;;RUSSELL JOHN CHRISTOPHER;;SIVAPURAPU SIVA CHANDRA;;RICHTER IAN M,,https://lens.org/192-732-045-243-062,Patent Application,no,0,0,12,12,0,A63F2300/60;;G06F3/011;;A63F2300/60;;G06F3/011;;G06F3/011;;A63F2300/60;;A63F13/55;;G06F40/14;;G06F3/011;;G06T19/006,G06T13/20,,0,0,,,,PENDING
508,SG,A1,SG 184077 A1,058-900-420-228-035,2012-10-30,2012,SG 2012068318 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/058-900-420-228-035,Patent Application,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,,,0,0,,,,PENDING
509,DE,A1,DE 2327210 A1,078-376-030-686-652,1974-08-01,1974,DE 2327210 A,1973-05-28,US 32726873 A,1973-01-29,SPIELZEUGNAEHMASCHINE UND VERFAHREN ZUR HERSTELLUNG VON NAEHTEN,,MATTEL INC,DUNN RALPH;;AYTON IAN FREDERIC;;CANE ALBERT;;COLLINS HAROLD BERNARD;;LEWIS J STEPHEN;;MORRIS JOSEPH PAUL;;SHAPERO WALLACE HENRY,,https://lens.org/078-376-030-686-652,Patent Application,no,0,0,10,10,0,D05B81/00;;Y10T156/1724;;Y10T156/1798;;Y10T156/1724;;Y10T156/1798;;D05B81/00,D05B23/00;;A63H33/30;;D05B81/00,,0,0,,,,EXPIRED
510,AU,C1,AU 2011/229159 C1,085-107-130-880-32X,2018-01-04,2018,AU 2011/229159 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W;;AU 2011/229159 A,2010-03-19,Diagnostic system,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,ATOMO DIAGNOSTICS LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,ATOMO DIAGNOSTICS LIMITED (2022-03-17),https://lens.org/085-107-130-880-32X,Amended Patent,no,9,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61J1/05,,0,0,,,,ACTIVE
511,WO,A2,WO 2020/221794 A2,164-389-341-297-654,2020-11-05,2020,EP 2020061862 W,2020-04-29,US 201962841888 P,2019-05-02,BIOPROCESSING SYSTEM AND CONSUMABLE BAG FOR A BIOPROCESSING SYSTEM,"A bioreactor system, includes a base platform, a lid received atop the base platform and defining an interior space for receiving a bioprocessing bag, and a tubing management system supporting a tubing array a distance above the base platform and providing a means for quickly connecting and/or disconnecting a fluid supply line.",GLOBAL LIFE SCIENCES SOLUTIONS USA LLC;;GE HEALTHCARE BIO SCIENCES AB,PARZIALE MICHELLE;;SAUKKONEN HANNA-LEENA;;MILLER MICHAEL;;DUNN CHRISTOPHER;;MELLACE KENNETH;;STEGNER ELIZABETH;;STANKOWSKI RALPH;;DARISSE IAN;;BENOIT KEITH,,https://lens.org/164-389-341-297-654,Patent Application,yes,0,3,5,5,0,C12M23/14;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M41/48;;B01D46/0001;;B01D46/521;;B01D46/543;;G06K19/07758;;B01D2275/206;;C12M23/14;;C12M23/40;;C12M23/42;;C12M41/48;;C12M29/10;;C12M29/04;;C12M23/14;;C12M23/28;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M29/10;;C12M29/20;;C12M41/48;;G06K19/07758,C12M1/00;;C12M1/36;;C12M3/00,,0,0,,,,PENDING
512,US,A1,US 2017/0001192 A1,012-016-806-376-165,2017-01-05,2017,US 201615083839 A,2016-03-29,US 201615083839 A;;AU 2010/901175 A;;AU 2010/904615 A;;US 201313838145 A;;US 201313635903 A;;AU 2011/000315 W;;AU 2011/001321 W,2010-03-19,INTEGRATED TESTING DEVICE,"An integrated testing device and method are disclosed. The device includes an integral reservoir for a test fluid, and an actuator, so that the test fluid can be dispensed to facilitate the test.",KELLY JOHN MICHAEL;;SUI ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD;;ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SUI ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,ATOMO DIAGNOSTICS PTY LIMITED (2013-02-08),https://lens.org/012-016-806-376-165,Patent Application,yes,1,4,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,B01L3/00;;A61B5/15;;A61B5/151;;A61B5/157,,0,0,,,,ACTIVE
513,US,A1,US 2004/0026660 A1,074-241-220-567-925,2004-02-12,2004,US 43201503 A,2003-05-19,EP 00124365 A;;EP 0110944 W,2000-11-20,Chiral photoisomerizable compounds,"
    The invention relates to chiral photoisomerizable compounds of formula (I) wherein X ¹ , X ² , X ³ , X ⁴ , X ⁵ and X ⁶ have the meanings given in claim 1 , to liquid crystalline mixtures and polymers containing them, and to the use of chiral photoisomerizable compounds, liquid crystalline mixtures and polymers containing them in optical and electrooptical devices like liquid crystal displays or projection systems, in optical elements like polarizers, retardation films, compensators, colour filters or holographic elements, in liquid crystal pigments and coloured films or coatings for decorative or security applications, cosmetic and pharmaceutical compositions, in nonlinear optics and optical information storage. 
",VAUGHAN-SPICKERS JULIAN;;GREENFIELD SIMON;;HASSALL IAN VICTOR EDWARD;;DUNN CHRISTOPHER J.;;HARDING RICHARD;;JENKINS TONY;;MAY ALISON LINDA,VAUGHAN-SPICKERS JULIAN;;GREENFIELD SIMON;;HASSALL IAN VICTOR EDWARD;;DUNN CHRISTOPHER J;;HARDING RICHARD;;JENKINS TONY;;MAY ALISON LINDA,MERCK PATENT GMBH (2003-05-06),https://lens.org/074-241-220-567-925,Patent Application,yes,6,10,13,13,0,C09K19/2028;;C09K19/586;;C09K2219/03;;C09K2323/00;;C09K19/58;;C09K19/2028;;C09K2219/03;;C09K19/586;;C09K2323/00,G02B5/30;;C07C69/76;;C07C69/767;;C09K19/20;;C09K19/38;;C09K19/54;;C09K19/58;;G02F1/13;;G02F1/1335,252/299.01;;252/299.61;;252/299.62;;252/299.63;;428/1.1,0,0,,,,EXPIRED
514,CN,A,CN 103002805 A,100-317-273-111-728,2013-03-27,2013,CN 201180024714 A,2011-03-18,AU 2011/000315 W;;AU 2010/901175 A,2010-03-19,Diagnostic system,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/100-317-273-111-728,Patent Application,no,8,5,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61J1/05,,0,0,,,,ACTIVE
515,PL,T3,PL 2547259 T3,148-540-625-150-098,2016-04-29,2016,PL 11755574 T,2011-03-18,AU 2010/901175 A;;EP 11755574 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/148-540-625-150-098,Patent Application,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61B5/145;;A61B5/15;;A61B5/157;;A61J1/05;;B01L3/00,,0,0,,,,PENDING
516,US,A1,US 2022/0213420 A1,143-347-118-678-836,2022-07-07,2022,US 202017607105 A,2020-04-29,US 202017607105 A;;US 201962841888 P;;EP 2020061862 W,2019-05-02,BIOPROCESSING SYSTEM AND CONSUMABLE BAG FOR A BIOPROCESSING SYSTEM,"A bioreactor system, includes a base platform, a lid received atop the base platform and defining an interior space for receiving a bioprocessing bag, and a tubing management system supporting a tubing array a distance above the base platform and providing a means for quickly connecting and/or disconnecting a fluid supply line.",GLOBAL LIFE SCIENCES SOLUTIONS USA LLC,PARZIALE MICHELLE;;SAUKKONEN HANNA-LEENA;;MILLER MICHAEL;;DUNN CHRISTOPHER;;MELLACE KENNETH;;STEGNER ELIZABETH;;STANKOWSKI RALPH;;DARISSE IAN;;BENOIT KEITH,GLOBAL LIFE SCIENCES SOLUTIONS USA LLC (2020-04-14),https://lens.org/143-347-118-678-836,Patent Application,yes,0,0,5,5,0,C12M23/14;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M41/48;;B01D46/0001;;B01D46/521;;B01D46/543;;G06K19/07758;;B01D2275/206;;C12M23/14;;C12M23/40;;C12M23/42;;C12M41/48;;C12M29/10;;C12M29/04;;C12M23/14;;C12M23/28;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M29/10;;C12M29/20;;C12M41/48;;G06K19/07758,C12M1/00;;C12M1/36;;C12M3/00,,0,0,,,,PENDING
517,EP,A4,EP 2547259 A4,067-829-934-030-103,2014-03-12,2014,EP 11755574 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/067-829-934-030-103,Search Report,no,5,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61B5/145;;A61B5/15;;A61B5/157;;A61J1/05;;B01L3/00,,1,0,,,See also references of WO 2011113114A1,ACTIVE
518,HU,T2,HU E026294 T2,092-396-158-800-886,2016-05-30,2016,HU E11755574 A,2011-03-18,AU 2010/901175 A,2010-03-19,DIAGNOSTIC SYSTEM,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/092-396-158-800-886,Amended Patent,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/15;;A61J1/05;;B01L3/00,,0,0,,,,PENDING
519,CN,A,CN 114007625 A,126-749-808-842-811,2022-02-01,2022,CN 202080044806 A,2020-04-16,US 201962835975 P;;US 202062966482 P;;IB 2020000312 W,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/ infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK;;DUNN JONATHAN;;ROBERT M BURKE,,https://lens.org/126-749-808-842-811,Patent Application,no,8,0,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,A61K31/70;;A61K31/7042;;A61K31/7052;;A61P27/02;;C07D405/14;;C07D413/14,,1,0,,,"JING QIAO 等: ""E merging treatment options for meibomian gland dysfunction"", 《CLINICAL OPHTHALMOLOGY》, vol. 7, pages 1797 - 1803",PENDING
520,WO,A3,WO 2020/221794 A3,040-651-942-855-855,2020-12-03,2020,EP 2020061862 W,2020-04-29,US 201962841888 P,2019-05-02,BIOPROCESSING SYSTEM AND CONSUMABLE BAG FOR A BIOPROCESSING SYSTEM,"A bioreactor system, includes a base platform, a lid received atop the base platform and defining an interior space for receiving a bioprocessing bag, and a tubing management system supporting a tubing array a distance above the base platform and providing a means for quickly connecting and/or disconnecting a fluid supply line.",GLOBAL LIFE SCIENCES SOLUTIONS USA LLC;;GE HEALTHCARE BIO SCIENCES AB,PARZIALE MICHELLE;;SAUKKONEN HANNA-LEENA;;MILLER MICHAEL;;DUNN CHRISTOPHER;;MELLACE KENNETH;;STEGNER ELIZABETH;;STANKOWSKI RALPH;;DARISSE IAN;;BENOIT KEITH,,https://lens.org/040-651-942-855-855,Search Report,yes,5,0,5,5,0,C12M23/14;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M41/48;;B01D46/0001;;B01D46/521;;B01D46/543;;G06K19/07758;;B01D2275/206;;C12M23/14;;C12M23/40;;C12M23/42;;C12M41/48;;C12M29/10;;C12M29/04;;C12M23/14;;C12M23/28;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M29/10;;C12M29/20;;C12M41/48;;G06K19/07758,C12M1/00;;C12M1/36;;C12M3/00,,0,0,,,,PENDING
521,US,B2,US 10525463 B2,182-292-830-514-922,2020-01-07,2020,US 201615083839 A,2016-03-29,US 201615083839 A;;AU 2010/901175 A;;AU 2010/904615 A;;US 201313838145 A;;US 201313635903 A;;AU 2011/000315 W;;AU 2011/001321 W,2010-03-19,Integrated testing device,"An integrated testing device and method are disclosed. The device includes an integral reservoir for a test fluid, and an actuator, so that the test fluid can be dispensed to facilitate the test.",ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,ATOMO DIAGNOSTICS PTY LIMITED (2013-02-08),https://lens.org/182-292-830-514-922,Granted Patent,yes,35,1,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,B01L3/00;;A61B5/145;;A61B5/15;;A61B5/151;;A61B5/157,,4,0,,,"International Search Report dated Dec. 20, 2011 in International Application No. PCT/AU2011/001321, International Filing Date Oct. 17, 2011. (4 pages).;;International Preliminary Report on Patentability dated Jul. 30, 2012 in International Application No. PCT/AU2011/000315, International Filing Date Mar. 18, 2011. (12 pages).;;International Search Report dated Jun. 14, 2011 in International Application No. PCT/AU2011/000315, International Filing Date Mar. 18, 2011. (7 pages).;;Supplementary Partial European Search Report dated Jan. 31, 2014 in EP Application No. 11 75 5574. (7 pages).",ACTIVE
522,KR,A,KR 20130057985 A,186-437-890-491-419,2013-06-03,2013,KR 20127027179 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/186-437-890-491-419,Patent Application,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61B5/157,,0,0,,,,ACTIVE
523,US,B2,US 9295987 B2,052-183-891-738-51X,2016-03-29,2016,US 201313838145 A,2013-03-15,US 201313838145 A;;AU 2010/901175 A;;AU 2010/904615 A;;US 201313635903 A;;AU 2011/000315 W;;AU 2011/001321 W,2010-03-19,Integrated testing device,"An integrated testing device and method are disclosed. The device includes an integral reservoir for a test fluid, and an actuator, so that the test fluid can be dispensed to facilitate the test.",KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD;;ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,ATOMO DIAGNOSTICS PTY LIMITED (2013-02-08),https://lens.org/052-183-891-738-51X,Granted Patent,yes,35,1,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,B01L3/00;;A61B5/145;;A61B5/15;;A61B5/151;;A61B5/157,,4,0,,,"International Search Report mailed on Dec. 20, 2011 in International Application No. PCT/AU2011/001321, International Filing Date Oct. 17, 2011. (4 pages).;;International Preliminary Report on Patentability mailed on Jul. 30, 2012 in International Application No. PCT/AU2011/000315, International Filing Date Mar. 18, 2011. (12 pages).;;International Search Report mailed on Jun. 14, 2011 in International Application No. PCT/AU2011/000315, International Filing Date Mar. 18, 2011. (7 pages).;;Supplementary Partial European Search Report mailed on Jan. 31, 2014 in EP Application No. 11 75 5574. (7 pages).",ACTIVE
524,ZA,B,ZA 201304196 B,105-901-301-751-859,2015-10-28,2015,ZA 201304196 A,2013-06-07,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,,ATOMO DIAGNOSTICS PTY LTD,HUESO ERNESTO MONIS;;DUNN CHRISTOPHER DAVID;;NORCOTT ALISON RUTH;;SIU ERIC;;JOHNSON IAN FREDERICK;;KELLY JOHN MICHAEL;;SOKOLOV RICHARD,,https://lens.org/105-901-301-751-859,Granted Patent,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,,,0,0,,,,ACTIVE
525,WO,A1,WO 2020/219643 A1,129-054-861-542-111,2020-10-29,2020,US 2020/0029472 W,2020-04-23,US 201962837253 P,2019-04-23,TRAINING A MODEL WITH HUMAN-INTUITIVE INPUTS,"In one implementation, a method of generating environment states is performed by a device including one or more processors and non-transitory memory. The method includes displaying a computer-generated reality (CGR) environment including an asset associated with a neural network model and having a plurality of asset states. The method includes receiving a user input indicative of a training request. The method includes selecting, based on the user input, a training focus indicating one or more of the plurality of asset states. The method includes generating a set of training data including a plurality of training instances weighted according to the training focus. The method includes training the neural network model on the set of training data.",APPLE INC,DRUMMOND MARK;;MEIER PETER;;MORGAN BO;;DUNN CAMERON J;;RUSSELL JOHN CHRISTOPHER;;RICHTER IAN M;;SIVAPURAPU SIVA CHANDRA MOULI,,https://lens.org/129-054-861-542-111,Patent Application,yes,3,0,2,2,0,G06F3/04815;;G06T19/006;;G06F3/011;;G06N3/006;;G06N3/08;;G06N20/00;;G10L15/22;;G10L15/26;;G06V20/40;;G06F18/40;;G06F3/04815,G06F3/01;;G06F3/0481;;G06N3/00;;G06T19/00,,1,1,067-850-393-508-499,10.1016/s0097-8493(01)00151-0,"MIRANDA F R ET AL: ""An artificial life approach for the animation of cognitive characters"", COMPUTERS AND GRAPHICS, ELSEVIER, GB, vol. 25, no. 6, 1 December 2001 (2001-12-01), pages 955 - 964, XP027289237, ISSN: 0097-8493, [retrieved on 20011201]",PENDING
526,WO,A1,WO 2011/113114 A1,019-686-734-367-223,2011-09-22,2011,AU 2011/000315 W,2011-03-18,AU 2010/901175 A,2010-03-19,DIAGNOSTIC SYSTEM,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,ATOMO DIAGNOSTICS PTY LTD;;KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/019-686-734-367-223,Patent Application,yes,11,5,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61J1/05,,1,0,,,See also references of EP 2547259A4,PENDING
527,CA,A,CA 999511 A,023-168-142-882-218,1976-11-09,1976,CA 168700 A,1973-04-13,US 32726873 A,1973-01-29,SEWING MACHINE TOY AND METHOD OF USING SAME,,MATTEL INC,DUNN RALPH;;AYTON IAN F;;CANE ALBERT;;COLLINS HAROLD B;;LEWIS J STEPHEN;;MORRIS JOSEPH P;;SHAPERO WALLACE H,,https://lens.org/023-168-142-882-218,Granted Patent,no,0,0,10,10,0,D05B81/00;;Y10T156/1724;;Y10T156/1798;;Y10T156/1724;;Y10T156/1798;;D05B81/00,D05B23/00;;A63H33/30;;D05B81/00,154-73,0,0,,,,EXPIRED
528,US,A1,US 2013/0323123 A1,131-500-212-592-433,2013-12-05,2013,US 201313838145 A,2013-03-15,US 201313838145 A;;AU 2010/901175 A;;AU 2010/904615 A;;US 201313635903 A;;AU 2011/000315 W;;AU 2011/001321 W,2010-03-19,INTEGRATED TESTING DEVICE,"An integrated testing device and method are disclosed. The device includes an integral reservoir for a test fluid, and an actuator, so that the test fluid can be dispensed to facilitate the test.",KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD;;ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,ATOMO DIAGNOSTICS PTY LIMITED (2013-02-08),https://lens.org/131-500-212-592-433,Patent Application,yes,2,1,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,B01L3/00,422/68.1,0,0,,,,ACTIVE
529,MY,A,MY 174486 A,015-213-221-218-155,2020-04-22,2020,MY PI2012004126 A,2011-03-18,AU 2010/901175 A,2010-03-19,DIAGNOSTIC SYSTEM,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/015-213-221-218-155,Granted Patent,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,,,0,0,,,,ACTIVE
530,EP,B3,EP 2547259 B3,132-086-877-472-108,2018-03-21,2018,EP 11755574 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/132-086-877-472-108,Amended Patent,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61B5/145;;A61B5/15;;A61B5/157;;A61J1/05;;B01L3/00,,0,0,,,,ACTIVE
531,NZ,A,NZ 602912 A,034-553-544-428-771,2014-07-25,2014,NZ 60291211 A,2011-03-18,AU 2011/000315 W;;AU 2010/901175 A,2010-03-19,Diagnostic system,"Disclosed is a composite diagnostic system (140) for performing diagnostics on bodily fluids of humans and animals. The system (140) comprises a test component (162), device (142), internal reservoir (159) and fluid delivery actuator (160). The device (142) comprises a bodily fluid collection point (156) which is positioned on the exterior of the device (142) for collection of a bodily fluid. The collection point (156) is arranged so that the bodily fluid entering the collection point (156) contacts the test component (162). The internal reservoir (159) is adapted to contain a fluid. Actuation of the fluid delivery actuator (160) causes the fluid to be released from the internal reservoir (159) and contact the test component (162).",ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/034-553-544-428-771,Patent Application,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61J1/05;;G01N1/00;;G01N33/48,,0,0,,,,DISCONTINUED
532,BR,B1,BR 112012023562 B1,083-200-435-211-622,2021-07-06,2021,BR 112012023562 A,2011-03-18,AU 2011/000315 W;;AU 2010/901175 A,2010-03-19,sistema compósito de diagnóstico descartável,"sistema compósito de diagnóstico. a presente invenção trata de um sistema compósito de diagnóstico que compreende um membro de suporte que tem um elemento de penetração de membrana; um ponto de coleta de fluido corporal posicionado para coleta de um fluido corporal liberado pela aplicação do elemento de penetração de membrana a um corpo de usuário; um material de teste posicionado no membro de suporte de tal forma que, em uso, o fluido corporal é colocado em contato com o material de teste.",ATOMO DIAGNOSTICS PTY LTD,ALISON RUTH NORCOTT;;CHRISTOPHER DAVID DUNN;;ERIC SIU;;ERNESTO MONIS HUESO;;IAN FREDERICK JOHNSON;;JOHN MICHAEL KELLY;;RICHARD SOKOLOV,,https://lens.org/083-200-435-211-622,Granted Patent,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61J1/05;;A61B5/151,,0,0,,,,ACTIVE
533,EP,A1,EP 2547259 A1,085-916-281-878-024,2013-01-23,2013,EP 11755574 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/085-916-281-878-024,Patent Application,yes,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61B5/145;;A61B5/15;;A61B5/157;;A61J1/05;;B01L3/00,,0,0,,,,ACTIVE
534,PT,E,PT 2547259 E,180-788-686-560-364,2015-12-01,2015,PT 11755574 T,2011-03-18,AU 2010/901175 A,2010-03-19,DIAGNOSTIC SYSTEM,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/180-788-686-560-364,Granted Patent,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,,,0,0,,,,ACTIVE
535,AU,B2,AU 2011/229159 B2,005-292-048-376-269,2012-12-13,2012,AU 2011/229159 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W;;AU 2011/229159 A,2010-03-19,Diagnostic system,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,ATOMO DIAGNOSTICS LIMITED (2022-03-17),https://lens.org/005-292-048-376-269,Granted Patent,no,9,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61J1/05,,0,0,,,,ACTIVE
536,EP,B1,EP 2547259 B1,031-606-024-139-80X,2015-08-19,2015,EP 11755574 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/031-606-024-139-80X,Granted Patent,yes,14,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61B5/145;;A61B5/15;;A61B5/157;;A61J1/05;;B01L3/00,,0,0,,,,ACTIVE
537,CA,A1,CA 2793554 A1,009-415-562-004-313,2011-09-22,2011,CA 2793554 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/009-415-562-004-313,Patent Application,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61J1/05,,0,0,,,,ACTIVE
538,BR,A2,BR 112012023562 A2,123-175-540-673-519,2016-08-02,2016,BR 112012023562 A,2011-03-18,AU 2011/000315 W;;AU 2010/901175 A,2010-03-19,sistema de diagnóstico,"sistema de diagnóstico. a presente invenção refere-se trata-se de um sistema de diagnóstico de compósito que compreende um membro de suporte que tem um elemento de penetração de membrana; um ponto de coleta de fluido corporal posicionado para coleta de um fluido corporal liberado pela liberado pela aplicado do elemento de penetração de membrana a um corpo de usuário; um material de teste posicionado no membro de suporte de tal forma que, em uso, o fluido corporal é colocado em contato com o material de teste.",ATOMO DIAGNOSTICS PTY LTD,NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;SIU ERIC;;HUESO ERNESTO MONIS;;JOHNSON IAN FREDERICK;;KELLY JOHN MICHAEL;;SOKOLOV RICHARD,,https://lens.org/123-175-540-673-519,Patent Application,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61J1/05;;A61B5/151,,0,0,,,,ACTIVE
539,CN,B,CN 103002805 B,050-028-605-119-900,2015-05-27,2015,CN 201180024714 A,2011-03-18,AU 2011/000315 W;;AU 2010/901175 A,2010-03-19,Diagnostic system,,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/050-028-605-119-900,Granted Patent,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61J1/05,,0,0,,,,ACTIVE
540,CA,C,CA 2793554 C,135-637-944-277-431,2018-04-03,2018,CA 2793554 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,BODILY FLUID DIAGNOSTIC SYSTEM,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,ATOMO DIAGNOSTICS PTY LTD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,,https://lens.org/135-637-944-277-431,Granted Patent,no,0,0,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/151;;A61J1/05,,0,0,,,,ACTIVE
541,US,A1,US 2013/0131479 A1,152-308-310-209-700,2013-05-23,2013,US 201113635903 A,2011-03-18,AU 2010/901175 A;;AU 2011/000315 W,2010-03-19,DIAGNOSTIC SYSTEM,A composite diagnostic system comprising a support member having a membrane penetration element; a bodily fluid collection point positioned for collection of a bodily fluid released by application of the membrane penetration element to a user's body; a test material positioned in the support member such that in use the bodily fluid is brought into contact with the test material.,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,KELLY JOHN MICHAEL;;SIU ERIC;;NORCOTT ALISON RUTH;;DUNN CHRISTOPHER DAVID;;JOHNSON IAN FREDERICK;;HUESO ERNESTO MONIS;;SOKOLOV RICHARD,ATOMO DIAGNOSTICS PTY LIMITED (2014-02-19),https://lens.org/152-308-310-209-700,Patent Application,yes,4,3,34,34,0,A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150503;;A61B5/150549;;A61B5/150618;;A61B5/150717;;A61B5/150755;;A61B5/150824;;A61B5/15111;;A61B5/15113;;A61B5/15117;;A61B5/15144;;A61B5/157;;A61B5/150343;;A61B5/150358;;A61B5/1411;;A61B5/14532;;A61B5/150022;;A61B5/150305;;A61B5/150343;;A61B5/150412;;A61B5/150549;;A61B5/15186;;A61B5/157;;A61B2562/0295;;A61B5/151;;A61J1/05;;A61B5/14532;;A61B2562/0295;;A61B5/150022;;A61B5/150305;;A61B5/150412;;A61B5/150618;;A61B5/150755;;A61B5/15113;;A61B5/15117;;A61B5/15111;;A61B5/150549;;A61B5/150824;;A61B5/15144;;A61B5/150717;;A61B5/150503;;A61B5/1411;;A61B5/15186;;A61B5/157;;A61B5/145;;A61B5/150343;;A61B5/150358;;A61B5/151;;A61B5/15192;;B01L3/502;;B01L3/5023;;B01L2200/0605;;B01L2200/16;;B01L2300/14;;B01L2400/0475,A61B5/157;;A61B5/145;;A61B5/15;;A61B5/151,600/367;;600/583;;600/309,0,0,,,,DISCONTINUED
542,CN,A,CN 112740280 A,107-078-952-286-334,2021-04-30,2021,CN 201980062386 A,2019-09-24,US 201862738066 P;;US 2019/0052587 W,2018-09-28,COMPUTATIONALLY EFFICIENT MODEL SELECTION,"In various implementations, a device surveys a scene and presents, within the scene, a synthesized reality (SR) environment including one or more assets that evolve over time (e.g., change location or age). Modeling such an SR environment at various timescales can be computationally intensive, particularly when modeling the SR environment over larger timescales. Accordingly, in various implementations, different models are used to determine the environment state of the SR environment when presenting the SR environment at different timescales.",APPLE INC,MORGAN BO;;DRUMMOND MARK E;;MEIER PETER;;DUNN CAMERON J;;RUSSELL JOHN CHRISTOPHER;;SIVAPURAPU SIVA CHANDRA MOULI;;RICHTER IAN M,,https://lens.org/107-078-952-286-334,Patent Application,no,0,0,12,12,0,A63F2300/60;;G06F3/011;;A63F2300/60;;G06F3/011;;G06F3/011;;A63F2300/60;;A63F13/55;;G06F40/14;;G06F3/011;;G06T19/006,G06T13/40;;G06F3/01;;G06N3/00;;G06T13/60;;G09B9/00,,0,0,,,,PENDING
543,WO,A2,WO 2022/084738 A2,119-129-301-379-054,2022-04-28,2022,IB 2021000707 W,2021-10-20,US 202163170988 P;;US 202063094793 P,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT;;GLEESON MARC;;STEWART MARK;;DUNN JONATHAN;;NICHOLLS ALEXANDER,,https://lens.org/119-129-301-379-054,Patent Application,yes,0,2,9,10,0,A61P17/00;;A61P27/02;;C07H17/00;;A61P27/02;;A61P17/00;;C07H17/00;;C07H17/00;;A61K31/7042;;A61K9/0048;;A61P17/00;;A61P27/02,,,0,0,,,,PENDING
544,AU,A1,AU 2021/365530 A1,179-046-654-458-754,2023-06-15,2023,AU 2021/365530 A,2021-10-20,US 202063094808 P;;IB 2021000708 W,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,BOSWORTH CHARLES;;STEWART MARK;;BARASH HILA;;CHAPMAN NICHOLAS;;BURK ROBERT;;HOLMES IAN;;GLEESON MARC;;ALSTER YAIR;;RAFAELI OMER;;DUNN JONATHAN,,https://lens.org/179-046-654-458-754,Patent Application,no,0,0,10,10,0,A61P27/02;;C07D405/06;;A61K9/08;;A61K9/0048;;C07D409/14;;C07D417/14;;A61P17/00;;A61P27/02;;C07D405/06;;A61P17/00;;C07D409/14;;C07D417/14;;A61K9/0048;;A61K9/08;;C07D405/06;;A61K31/4725;;A61K9/0048;;A61P17/00;;A61P27/02;;C07D409/14;;C07D417/14;;A61P27/02;;A61K9/0048;;A61K9/08;;C07D405/06;;C07D405/14;;C07D409/14;;C07D417/14,A61K31/472;;A61K31/4725;;A61P27/02;;C07D217/02;;C07D217/04;;C07D405/06,,0,0,,,,PENDING
545,KR,A,KR 20210154214 A,174-725-351-016-855,2021-12-20,2021,KR 20217037540 A,2020-04-16,US 201962835975 P;;US 202062966482 P;;IB 2020000312 W,2019-04-18,안구 질병의 치료를 위한 화합물 및 방법,"마이봄샘 기능장애, 안검염, 안구건조증 및 눈의 전방 표면의 다른 염증성/감염 질환을 포함하는 안구 표면 질병의 치료를 위한 조성물 및 방법이 본원에 기재된다. 상기 조성물 및 방법은 각질용해 활성, 및 항염증성 또는 다른 바람직한 활성을 증명하는 각질용해 컨쥬게이트를 포함한다. 상기 조성물의 눈, 안구 표면 또는 주변 영역에 대한 국소 투여는 안구 표면 질병으로 고통 받는 환자에게 치료적 이득을 제공한다.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;BURK ROBERT M,,https://lens.org/174-725-351-016-855,Patent Application,no,0,1,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,C07H17/08;;A61K9/00;;A61K31/7048;;A61P27/02,,0,0,,,,PENDING
546,CN,A,CN 113728087 A,013-425-780-018-784,2021-11-30,2021,CN 202080032746 A,2020-04-29,US 201962841888 P;;EP 2020061862 W,2019-05-02,BIOPROCESSING SYSTEM AND CONSUMABLE BAG FOR A BIOPROCESSING SYSTEM,"A bioreactor system, includes a base platform, a lid received atop the base platform and defining an interior space for receiving a bioprocessing bag, and a tubing management system supporting a tubing array a distance above the base platform and providing a means for quickly connecting and/or disconnecting a fluid supply line.",GLOBAL LIFE SCIENCES SOLUTIONS USA LLC,PARZIALE MICHELLE;;SAUKKONEN HANNA-LEENA;;MILLER MICHAEL;;DUNN CHRISTOPHER;;MELLACE KENNETH J;;STEGNER ELIZABETH;;STANKOWSKI RALPH;;DARISSE IAN;;BENOIT KEITH,,https://lens.org/013-425-780-018-784,Patent Application,no,3,0,5,5,0,C12M23/14;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M41/48;;B01D46/0001;;B01D46/521;;B01D46/543;;G06K19/07758;;B01D2275/206;;C12M23/14;;C12M23/40;;C12M23/42;;C12M41/48;;C12M29/10;;C12M29/04;;C12M23/14;;C12M23/28;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M29/10;;C12M29/20;;C12M41/48;;G06K19/07758,C12M3/00;;B01D46/00;;B01D46/52;;B01D46/54;;C12M1/04;;C12M1/12;;C12M1/36;;C12M3/06;;G06K19/077,,0,0,,,,PENDING
547,KR,A,KR 20210046781 A,022-641-193-560-731,2021-04-28,2021,KR 20217009111 A,2019-09-24,US 201862738066 P;;US 2019/0052587 W,2018-09-28,계산 효율적인 모델 선택,"다양한 구현예들에서, 디바이스는 장면을 조사하고, 시간 경과에 따라 진화하는 (예를 들어, 위치 또는 나이가 변경됨) 하나 이상의 에셋들을 포함하는 합성 현실(SR) 환경을, 장면 내에 제시한다. 다양한 타임스케일들에서의 그러한 SR 환경을 모델링하는 것은 계산 집약적일 수 있는데, 특히 더 긴 타임스케일들에 걸쳐 SR 환경을 모델링할 때 그러할 수 있다. 따라서, 다양한 구현예들에서, 상이한 타임스케일들에서의 SR 환경을 제시할 때 SR 환경의 환경 상태를 결정하는 데 상이한 모델들이 사용된다.",APPLE INC,MORGAN BO;;DRUMMOND MARK E;;MEIER PETER;;DUNN CAMERON J;;RUSSELL JOHN CHRISTOPHER;;SIVAPURAPU SIVA CHANDRA MOULI;;RICHTER IAN M,,https://lens.org/022-641-193-560-731,Patent Application,no,0,0,12,12,0,A63F2300/60;;G06F3/011;;A63F2300/60;;G06F3/011;;G06F3/011;;A63F2300/60;;A63F13/55;;G06F40/14;;G06F3/011;;G06T19/006,G06F3/01,,2,0,,,"M.S. et. al., ""A Decentralized Parallelization-in-Time Approach with Parareal,"" Cornell Univ., 2015.06.16., XP080811409.;;ChemEngTutor, ""Simulink Basics Part 7"", Youtube, 2016.08.08., [url: https://www.youtube.com/watch?v=k1yOu-64ITw&t=80s], [검색:2023.06.20.]",ACTIVE
548,AU,A9,AU 2021/365530 A9,072-955-761-699-535,2024-02-08,2024,AU 2021/365530 A,2021-10-20,US 202063094808 P;;IB 2021000708 W,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,BOSWORTH CHARLES;;STEWART MARK;;BARASH HILA;;CHAPMAN NICHOLAS;;BURK ROBERT;;HOLMES IAN;;GLEESON MARC;;ALSTER YAIR;;RAFAELI OMER;;DUNN JONATHAN,,https://lens.org/072-955-761-699-535,Patent Application,no,0,0,10,10,0,A61P27/02;;C07D405/06;;A61K9/08;;A61K9/0048;;C07D409/14;;C07D417/14;;A61P17/00;;A61P27/02;;C07D405/06;;A61P17/00;;C07D409/14;;C07D417/14;;A61K9/0048;;A61K9/08;;C07D405/06;;A61K31/4725;;A61K9/0048;;A61P17/00;;A61P27/02;;C07D409/14;;C07D417/14;;A61P27/02;;A61K9/0048;;A61K9/08;;C07D405/06;;C07D405/14;;C07D409/14;;C07D417/14,A61K31/472;;A61K31/4725;;A61P27/02;;C07D217/02;;C07D217/04;;C07D405/06,,0,0,,,,PENDING
549,AU,A1,AU 2020/259997 A1,166-011-163-815-671,2021-11-25,2021,AU 2020/259997 A,2020-04-16,US 202062966482 P;;US 201962835975 P;;IB 2020000312 W,2019-04-18,Compounds and methods for the treatment of ocular disorders,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/ infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;BURK ROBERT M,,https://lens.org/166-011-163-815-671,Patent Application,no,0,0,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,A61K31/70;;A61K31/7042;;A61K31/7052;;A61P27/02;;C07D405/14;;C07D413/14,,0,0,,,,PENDING
550,AU,A1,AU 2021/363702 A1,030-193-175-580-740,2023-06-15,2023,AU 2021/363702 A,2021-10-20,US 202163170988 P;;US 202063094793 P;;IB 2021000707 W,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT;;GLEESON MARC;;STEWART MARK;;DUNN JONATHAN;;NICHOLLS ALEXANDER,,https://lens.org/030-193-175-580-740,Patent Application,no,0,0,9,10,0,A61P17/00;;A61P27/02;;C07H17/00;;A61P27/02;;A61P17/00;;C07H17/00;;C07H17/00;;A61K31/7042;;A61K9/0048;;A61P17/00;;A61P27/02,A61P17/00;;A61P27/02;;C07D413/14,,0,0,,,,PENDING
551,US,B2,US 11699270 B2,058-159-316-030-986,2023-07-11,2023,US 202217740052 A,2022-05-09,US 202217740052 A;;US 202117203393 A;;US 2019/0052587 W;;US 201862738066 P,2018-09-28,Computationally efficient model selection,"In various implementations, a device surveys a scene and presents, within the scene, a extended reality (XR) environment including one or more assets that evolve over time (e.g., change location or age). Modeling such an XR environment at various timescales can be computationally intensive, particularly when modeling the XR environment over larger timescales. Accordingly, in various implementations, different models are used to determine the environment state of the XR environment when presenting the XR environment at different timescales.",APPLE INC,MORGAN BO;;DRUMMOND MARK E;;MEIER PETER;;DUNN CAMERON J;;RUSSELL JOHN CHRISTOPHER;;SIVAPURAPU SIVA CHANDRA MOULI;;RICHTER IAN M,,https://lens.org/058-159-316-030-986,Granted Patent,yes,7,0,12,12,0,A63F2300/60;;G06F3/011;;A63F2300/60;;G06F3/011;;G06F3/011;;A63F2300/60;;A63F13/55;;G06F40/14;;G06F3/011;;G06T19/006,G06T19/00;;A63F13/55;;G06F3/01;;G06F40/14,,4,0,,,"International Search Report and Written Opinion dated Dec. 9, 2019, International Application No. PCT/US2019/052587, pp. 1-14.;;ChemEngtTutor, “Simulink Basics Part 7—Changing Model Configuration Parameters,” YouTube, Aug. 9, 2016, Retrieved from the Internet on Dec. 2, 2019: https://www.youtube.com/watch?v=k1yOu-64ITw, 1 Page.;;Martin Schreiber et al., “A Decentralized Parallelization-in-Time Approach with Parareal,” arXiv preprint arXiv:1506.05157, 2015, pp. 1-6.;;IPPI First Examination Report dated Mar. 8, 2022, Indian Patent Application No. 202117012582, pp. 1-7.",ACTIVE
552,US,A1,US 2021/0201594 A1,083-925-969-474-927,2021-07-01,2021,US 202117203393 A,2021-03-16,US 202117203393 A;;US 2019/0052587 W;;US 201862738066 P,2018-09-28,COMPUTATIONALLY EFFICIENT MODEL SELECTION,"In various implementations, a device surveys a scene and presents, within the scene, a extended reality (XR) environment including one or more assets that evolve over time (e.g., change location or age). Modeling such an XR environment at various timescales can be computationally intensive, particularly when modeling the XR environment over larger timescales. Accordingly, in various implementations, different models are used to determine the environment state of the XR environment when presenting the XR environment at different timescales.",APPLE INC,MORGAN BO;;DRUMMOND MARK E;;MEIER PETER;;DUNN CAMERON J;;RUSSELL JOHN CHRISTOPHER;;SIVAPURAPU SIVA CHANDRA MOULI;;RICHTER IAN M,,https://lens.org/083-925-969-474-927,Patent Application,yes,0,1,12,12,0,A63F2300/60;;G06F3/011;;A63F2300/60;;G06F3/011;;G06F3/011;;A63F2300/60;;A63F13/55;;G06F40/14;;G06F3/011;;G06T19/006,G06T19/00;;A63F13/55;;G06F3/01;;G06F40/14,,0,0,,,,ACTIVE
553,US,B2,US 11373377 B2,072-739-868-503-970,2022-06-28,2022,US 202117203393 A,2021-03-16,US 202117203393 A;;US 2019/0052587 W;;US 201862738066 P,2018-09-28,Computationally efficient model selection,"In various implementations, a device surveys a scene and presents, within the scene, a extended reality (XR) environment including one or more assets that evolve over time (e.g., change location or age). Modeling such an XR environment at various timescales can be computationally intensive, particularly when modeling the XR environment over larger timescales. Accordingly, in various implementations, different models are used to determine the environment state of the XR environment when presenting the XR environment at different timescales.",APPLE INC,MORGAN BO;;DRUMMOND MARK E;;MEIER PETER;;DUNN CAMERON J;;RUSSELL JOHN CHRISTOPHER;;SIVAPURAPU SIVA CHANDRA MOULI;;RICHTER IAN M,,https://lens.org/072-739-868-503-970,Granted Patent,yes,5,2,12,12,0,A63F2300/60;;G06F3/011;;A63F2300/60;;G06F3/011;;G06F3/011;;A63F2300/60;;A63F13/55;;G06F40/14;;G06F3/011;;G06T19/006,G06T19/00;;A63F13/55;;G06F3/01;;G06F40/14,,4,0,,,"IPPI First Examination Report dated Mar. 8, 2022, Indian Patent Application No. 202117012582, pp. 1-7.;;International Search Report and Written Opinion dated Dec. 9, 2019, International Application No. PCT/US2019/052587, pp. 1-14.;;ChemEngTutor, “Simulink Basics Part 7—Changing Model Configuration Parameters,” YouTube, Aug. 9, 2016, Retrieved from the Internet on Dec. 2, 2019: https://www.youtube.com/watch?v=k1yOu-64ITw, 1 Page.;;Martin Schreiber et al., “A Decentralized Parallelization-in-Time Approach with Parareal,” arXiv preprint arXiv:1506.05157, 2015, pp. 1-6.",ACTIVE
554,EP,A2,EP 3963044 A2,161-543-447-166-904,2022-03-09,2022,EP 20724432 A,2020-04-29,US 201962841888 P;;EP 2020061862 W,2019-05-02,BIOPROCESSING SYSTEM AND CONSUMABLE BAG FOR A BIOPROCESSING SYSTEM,,GLOBAL LIFE SCIENCES SOLUTIONS USA LLC,PARZIALE MICHELLE;;SAUKKONEN HANNA-LEENA;;MILLER MICHAEL;;DUNN CHRISTOPHER;;MELLACE KENNETH J;;STEGNER ELIZABETH;;STANKOWSKI RALPH;;DARISSE IAN;;BENOIT KEITH,,https://lens.org/161-543-447-166-904,Patent Application,yes,0,0,5,5,0,C12M23/14;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M41/48;;B01D46/0001;;B01D46/521;;B01D46/543;;G06K19/07758;;B01D2275/206;;C12M23/14;;C12M23/40;;C12M23/42;;C12M41/48;;C12M29/10;;C12M29/04;;C12M23/14;;C12M23/28;;C12M23/38;;C12M23/40;;C12M23/42;;C12M23/48;;C12M29/04;;C12M29/10;;C12M29/20;;C12M41/48;;G06K19/07758,C12M1/00;;C12M1/36;;C12M3/00,,0,0,,,,PENDING
555,GB,A,GB 2592136 A,113-820-327-411-831,2021-08-18,2021,GB 202104028 A,2019-09-24,US 2019/0052587 W;;US 201862738066 P,2018-09-28,Computationally efficient model selection,"In various implementations, a device surveys a scene and presents, within the scene, a synthesized reality (SR) environment including one or more assets that evolve over time (e.g., change location or age). Modeling such an SR environment at various timescales can be computationally intensive, particularly when modeling the SR environment over larger timescales. Accordingly, in various implementations, different models are used to determine the environment state of the SR environment when presenting the SR environment at different timescales.",APPLE INC,BO MORGAN;;MARK E DRUMMOND;;PETER MEIER;;CAMERON J DUNN;;JOHN CHRISTOPHER RUSSELL;;SIVA CHANDRA MOULI SIVAPURAPU;;IAN M RICHTER,,https://lens.org/113-820-327-411-831,Patent Application,no,0,0,12,12,0,A63F2300/60;;G06F3/011;;A63F2300/60;;G06F3/011;;G06F3/011;;A63F2300/60;;A63F13/55;;G06F40/14;;G06F3/011;;G06T19/006,G06T13/40;;G06F3/01;;G06T13/60,,2,0,,,"ChemEngTutor: ""Simulink Basics Part 7 - Changing Model Configuration Parameters"", YouTube, 8 August 2016 (2016-08-08), page 1, Retrieved from the Internet: URL:https://www.youtube.com/watch?v=k1y0u-64ITw&feature=youtu.be&t=80 [retrieved on 2019-12-02] t=0:03 t=0:51 t=1:20 t=1:25;;MARTIN SCHREIBER ET AL: ""A Decentralized Parallelization-in-Time Approach with Paraeal"", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 16 June 2015 (2015-06-16), page 3, left-hand column, paragraph 3",ACTIVE
556,EP,A2,EP 3955937 A2,022-550-849-871-863,2022-02-23,2022,EP 20790702 A,2020-04-16,US 201962835975 P;;US 202062966482 P;;IB 2020000312 W,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,,AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;BURK ROBERT M,AZURA OPHTHALMICS LTD (2023-05-03),https://lens.org/022-550-849-871-863,Patent Application,yes,0,0,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,A61K31/70;;A61K31/7042;;A61K31/7052;;A61P27/02;;C07D405/14;;C07D413/14,,0,0,,,,PENDING
557,EP,A4,EP 3955937 A4,184-295-794-899-664,2023-01-18,2023,EP 20790702 A,2020-04-16,US 201962835975 P;;US 202062966482 P;;IB 2020000312 W,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,,AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;BURK ROBERT M,AZURA OPHTHALMICS LTD (2023-05-03),https://lens.org/184-295-794-899-664,Search Report,no,6,0,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,A61K31/70;;A61K31/7042;;A61K31/7052;;A61P27/02;;C07D405/14;;C07D413/14,,1,1,018-859-478-183-391,10.2147/opth.s33182;;24043929;;pmc3772773,"XIAO-MING YAN ET AL: ""Emerging treatment options for meibomian gland dysfunction"", CLINICAL OPHTHALMOLOGY, 1 September 2013 (2013-09-01), pages 1797, XP055294421, DOI: 10.2147/OPTH.S33182",PENDING
558,WO,A1,WO 2022/084739 A1,029-707-219-900-268,2022-04-28,2022,IB 2021000708 W,2021-10-20,US 202063094808 P,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,BOSWORTH CHARLES;;STEWART MARK;;BARASH HILA;;CHAPMAN NICHOLAS;;BURK ROBERT;;HOLMES IAN;;GLEESON MARC;;ALSTER YAIR;;RAFAELI OMER;;DUNN JONATHAN,,https://lens.org/029-707-219-900-268,Patent Application,yes,4,0,10,10,0,A61P27/02;;C07D405/06;;A61K9/08;;A61K9/0048;;C07D409/14;;C07D417/14;;A61P17/00;;A61P27/02;;C07D405/06;;A61P17/00;;C07D409/14;;C07D417/14;;A61K9/0048;;A61K9/08;;C07D405/06;;A61K31/4725;;A61K9/0048;;A61P17/00;;A61P27/02;;C07D409/14;;C07D417/14;;A61P27/02;;A61K9/0048;;A61K9/08;;C07D405/06;;C07D405/14;;C07D409/14;;C07D417/14,A61K31/472;;A61K31/4725;;A61P27/02;;C07D217/02;;C07D217/04;;C07D405/06,,0,0,,,,PENDING
559,DE,D1,DE 69330513 D1,060-996-653-455-563,2001-09-06,2001,DE 69330513 T,1993-03-22,AU PL146492 A;;AU PL146592 A;;AU 1915/093001 W,1992-03-20,GEGENSTANDS-ÜBERWACHUNGSYSTEM,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes(2).",COMMW SCIENT IND RES ORG,AUTY WILLIAM;;CORKE IAN;;DUNN ALEXANDER;;MACINTYRE BARRY;;MILLS CHARLES;;SIMONS FRANCIS;;JENSEN JOHN;;KNIGHT LAVIS;;PIERCE STUART;;BALAKUMAR PONNAMPALAM,,https://lens.org/060-996-653-455-563,Granted Patent,no,0,0,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,0,0,,,,EXPIRED
560,WO,A3,WO 2022/084738 A3,092-652-330-275-631,2022-06-30,2022,IB 2021000707 W,2021-10-20,US 202163170988 P;;US 202063094793 P,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT;;GLEESON MARC;;STEWART MARK;;DUNN JONATHAN;;NICHOLLS ALEXANDER,,https://lens.org/092-652-330-275-631,Search Report,yes,2,0,9,10,0,A61P17/00;;A61P27/02;;C07H17/00;;A61P27/02;;A61P17/00;;C07H17/00;;C07H17/00;;A61K31/7042;;A61K9/0048;;A61P17/00;;A61P27/02,A61P27/02;;A61P17/00;;C07D413/14,,2,0,,,"DATABASE PUBCHEM SUBSTANCE 17 March 2015 (2015-03-17), ""PUBCHEM SUBSTANCE RECORD SID 244662985"", XP055952884, retrieved from NCBI Database accession no. 244662985;;DATABASE PUBCHEM SUBSTANCE 17 March 2015 (2015-03-17), ""PUBCHEM SUBSTANCE RECORD SID 244881306"", XP055952885, retrieved from NCBI Database accession no. 244881306",PENDING
561,GB,B,GB 2592136 B,113-897-384-302-418,2022-12-14,2022,GB 202104028 A,2019-09-24,US 2019/0052587 W;;US 201862738066 P,2018-09-28,Computationally efficient model selection,,APPLE INC,BO MORGAN;;MARK E DRUMMOND;;PETER MEIER;;CAMERON J DUNN;;JOHN CHRISTOPHER RUSSELL;;SIVA CHANDRA MOULI SIVAPURAPU;;IAN M RICHTER,,https://lens.org/113-897-384-302-418,Granted Patent,no,0,0,12,12,0,A63F2300/60;;G06F3/011;;A63F2300/60;;G06F3/011;;G06F3/011;;A63F2300/60;;A63F13/55;;G06F40/14;;G06F3/011;;G06T19/006,G06F3/01;;G06T13/40;;G06T13/60,,2,0,,,"ChemEngTutor: ""Simulink Basics Part 7 - Changing Model Configuration Parameters"", YouTube, 8 August 2016 (2016-08-08), page 1, Retrieved from the Internet: URL:https://www.youtube.com/watch?v=k1y0u-64ITw&feature=youtu.be&t=80 [retrieved on 2019-12-02] t=0:03 t=0:51 t=1:20 t=1:25;;MARTIN SCHREIBER ET AL: ""A Decentralized Parallelization-in-Time Approach with Paraeal"", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 16 June 2015 (2015-06-16), page 3, left-hand column, paragraph 3",ACTIVE
562,AU,A9,AU 2021/363702 A9,136-830-256-993-101,2024-02-08,2024,AU 2021/363702 A,2021-10-20,US 202163170988 P;;US 202063094793 P;;IB 2021000707 W,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT;;GLEESON MARC;;STEWART MARK;;DUNN JONATHAN;;NICHOLLS ALEXANDER,,https://lens.org/136-830-256-993-101,Patent Application,no,0,0,9,10,0,A61P17/00;;A61P27/02;;C07H17/00;;A61P27/02;;A61P17/00;;C07H17/00;;C07H17/00;;A61K31/7042;;A61K9/0048;;A61P17/00;;A61P27/02,A61P17/00;;A61P27/02;;C07D413/14,,0,0,,,,PENDING
563,US,A1,US 2022/0270335 A1,178-664-257-832-353,2022-08-25,2022,US 202217740052 A,2022-05-09,US 202217740052 A;;US 202117203393 A;;US 2019/0052587 W;;US 201862738066 P,2018-09-28,COMPUTATIONALLY EFFICIENT MODEL SELECTION,"In various implementations, a device surveys a scene and presents, within the scene, a extended reality (XR) environment including one or more assets that evolve over time (e.g., change location or age). Modeling such an XR environment at various timescales can be computationally intensive, particularly when modeling the XR environment over larger timescales. Accordingly, in various implementations, different models are used to determine the environment state of the XR environment when presenting the XR environment at different timescales.",APPLE INC,MORGAN BO;;DRUMMOND MARK E;;MEIER PETER;;DUNN CAMERON J;;RUSSELL JOHN CHRISTOPHER;;SIVAPURAPU SIVA CHANDRA MOULI;;RICHTER IAN M,,https://lens.org/178-664-257-832-353,Patent Application,yes,2,0,12,12,0,A63F2300/60;;G06F3/011;;A63F2300/60;;G06F3/011;;G06F3/011;;A63F2300/60;;A63F13/55;;G06F40/14;;G06F3/011;;G06T19/006,G06T19/00;;A63F13/55;;G06F3/01;;G06F40/14,,0,0,,,,ACTIVE
564,CA,A1,CA 3136369 A1,089-052-178-630-936,2020-10-22,2020,CA 3136369 A,2020-04-16,US 201962835975 P;;US 202062966482 P;;IB 2020000312 W,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/ infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;BURK ROBERT M,,https://lens.org/089-052-178-630-936,Patent Application,no,0,0,13,13,0,C07H17/08;;C07H17/00;;A61K9/0048;;A61P27/04;;C07H17/08;;C07H17/08;;A61K9/0051;;A61K31/7048;;A61P27/02;;A61P27/04;;A61K9/0048;;C07H17/00;;C07H17/08,A61K31/70;;A61K31/7042;;A61K31/7052;;A61P27/02;;C07D405/14;;C07D413/14,,0,0,,,,PENDING
565,NZ,A,NZ 518119 A,145-299-883-338-715,2004-02-27,2004,NZ 51811900 A,2000-10-13,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase,"The invention provides compounds represented by formula (I) in which R1, R2, R3, R4, and n are as defined in the application; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The compounds are p38 inhibitors and may be used in the treatment of arthritis, Crohn's disease, irritable bowel syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease, osteoporosis, or Alzheimer's disease.",F,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;OLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHERHUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/145-299-883-338-715,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
566,AU,B2,AU 671106 B2,198-580-735-643-758,1996-08-15,1996,AU 1993/037402 A,1993-03-22,AU PL146492 A;;AU PL146592 A;;AU 1915/093001 W,1992-03-20,An object monitoring system,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes(2).",COMMW SCIENT IND RES ORG;;TELSTRA CORP LTD,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (2001-02-15),https://lens.org/198-580-735-643-758,Granted Patent,no,3,0,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,0,0,,,,EXPIRED
567,US,A,US 5809161 A,055-821-835-994-271,1998-09-15,1998,US 3598793 A,1993-03-22,AU PL146492 A;;AU PL146592 A,1992-03-20,Vehicle monitoring system,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes(2).",COMMW SCIENT IND RES ORG;;TELSTRA CORP LTD,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,TELSTRA CORPORATION LIMITED (1993-04-13);;AUSTRALIAN AND OVERSEAS TELECOMMUNICATIONS CORPORATION LIMITED (1993-04-13);;COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (1993-04-13);;COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION(A BODY CORPORATE ESTABLISHED UNDER THE SCIENCE AND INDUSTRY RESEARCH ACT 1949 CARRYING ON SCIENTIFIC AND INDUSTRIAL RESEARCH) (1993-04-20),https://lens.org/055-821-835-994-271,Granted Patent,yes,51,655,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,382/104;;382/103;;340/937;;348/149,2,0,,,"International Search Report received Dec. 6, 1993.;;New Zealand Search Report for Patent Application No. 249799 mailed May 29, 1996.",EXPIRED
568,EP,A1,EP 0631683 A1,026-241-125-257-047,1995-01-04,1995,EP 93906382 A,1993-03-22,AU 1915/093001 W;;AU PL146492 A;;AU PL146592 A,1992-03-20,AN OBJECT MONITORING SYSTEM.,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes(2).",COMMW SCIENT IND RES ORG;;TELSTRA CORP LTD,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (2001-03-21),https://lens.org/026-241-125-257-047,Patent Application,yes,0,4,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,7,0,,,"""M25 VIDEO SURVEY JUNCTIONS 15 - 16"", FINAL REPORT M25 VIDEO SURVEY JUNCTION 15-16, XX, XX, 1 February 1991 (1991-02-01), XX, pages A/B + 01 - 37, XP002933401;;Letter ref: 1E/SM199/DJR/WMV to Dr. A.Rawlins, SERC, dated 15th January 1992;;""TRAVERS MORGAN ENGINEERING"", LETTER TRAVERS MORGAN ENGINEERING, XX, XX, 21 February 1992 (1992-02-21), XX, pages COMPLETE, XP002933403;;Agenda for 2nd April 1992 Department of Transport meeting;;Internal Memo ref: GJH/T/SCT, dated 3rd April 1992;;Letter from the Department of Transport dated 20 January 1993;;Letter ref: GJH/T/SCT to Mr. John Dinner, dated 7th September 1993",EXPIRED
569,AU,A,AU 1993/037402 A,156-577-332-466-151,1993-10-21,1993,AU 1993/037402 A,1993-03-22,AU PL146492 A;;AU PL146592 A;;AU 1915/093001 W,1992-03-20,An object monitoring system,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes(2).",COMMW SCIENT IND RES ORG;;TELSTRA CORP LTD,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (2001-02-15),https://lens.org/156-577-332-466-151,Patent Application,no,0,0,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,0,0,,,,EXPIRED
570,AT,T1,AT E203844 T1,173-732-483-835-034,2001-08-15,2001,AT 93906382 T,1993-03-22,AU PL146492 A;;AU PL146592 A;;AU 1915/093001 W,1992-03-20,GEGENSTANDS-ÜBERWACHUNGSYSTEM,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes(2).",COMMW SCIENT IND RES ORG,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,,https://lens.org/173-732-483-835-034,Granted Patent,no,0,0,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,0,0,,,,DISCONTINUED
571,EP,B1,EP 0631683 B1,136-287-914-795-819,2001-08-01,2001,EP 93906382 A,1993-03-22,AU 1915/093001 W;;AU PL146492 A;;AU PL146592 A,1992-03-20,AN OBJECT MONITORING SYSTEM,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes(2).",COMMW SCIENT IND RES ORG,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (2001-03-21),https://lens.org/136-287-914-795-819,Granted Patent,yes,8,6,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,3,0,,,"Derwent Abstract Accession No. 86-168438/26, Class T07; & SU,A,1193716 (PROMAVTOMATIKA) 23 November 1985 (23.11.85), Abstract.;;PATENT ABSTRACTS OF JAPAN, P-1190, page 97; & JP,A,03 022 099 (MATSUSHITA ELECTRIC IND CO LTD) 30 January 1991 (30.01.91), Abstract.;;PATENT ABSTRACTS OF JAPAN, P-888, page 135; & JP,A,01 061 899 (MITSUBISHI ELECTRIC CORP) 8 March 1989 (08.03.89), Abstract.",EXPIRED
572,EP,A4,EP 0631683 A4,120-176-439-385-745,1996-04-17,1996,EP 93906382 A,1993-03-22,AU 1915/093001 W;;AU PL146492 A;;AU PL146592 A,1992-03-20,AN OBJECT MONITORING SYSTEM.,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes(2).",COMMW SCIENT IND RES ORG;;TELSTRA CORP LTD,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (2001-03-21),https://lens.org/120-176-439-385-745,Search Report,no,0,0,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,1,0,,,No further relevant documents disclosed,EXPIRED
573,WO,A1,WO 1993/019441 A1,079-155-025-485-554,1993-09-30,1993,AU 1915/093001 W,1993-03-22,AU PL146492 A;;AU PL146592 A,1992-03-20,AN OBJECT MONITORING SYSTEM,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes (2).",COMMW SCIENT IND RES ORG;;TELSTRA CORP LTD,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,,https://lens.org/079-155-025-485-554,Patent Application,yes,8,40,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,3,0,,,"Derwent Abstract Accession No. 86-168438/26, Class T07; & SU,A,1193716 (PROMAVTOMATIKA) 23 November 1985 (23.11.85), Abstract.;;PATENT ABSTRACTS OF JAPAN, P-1190, page 97; & JP,A,03 022 099 (MATSUSHITA ELECTRIC IND CO LTD) 30 January 1991 (30.01.91), Abstract.;;PATENT ABSTRACTS OF JAPAN, P-888, page 135; & JP,A,01 061 899 (MITSUBISHI ELECTRIC CORP) 8 March 1989 (08.03.89), Abstract.",PATENTED
574,NZ,A,NZ 249799 A,040-778-124-874-390,1996-11-26,1996,NZ 24979993 A,1993-03-23,AU PL146492 A;;AU PL146592 A,1992-03-20,TRAFFIC CAMERA MONITORS VEHICLE MOVEMENT AND PREDICTS WHEN VEHICLE WILL BE IN POSITION TO ACQUIRE IMAGE,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes(2).",COMMW SCIENT IND RES ORG;;TELSTRA CORP LTD,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,,https://lens.org/040-778-124-874-390,Patent Application,no,0,1,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,0,0,,,,DISCONTINUED
575,NZ,A,NZ 299442 A,087-808-646-719-769,1998-04-27,1998,NZ 29944293 A,1993-03-23,AU PL146492 A;;AU PL146592 A;;NZ 24979993 A,1992-03-20,OBJECT MONITORING SYSTEM FOR VEHICLES USING A CAMERA TO MONITOR A MOVING VEHICLE AND ACQUIRE IMAGES,,COMMW SCIENT IND RES ORG;;TELSTRA CORP LTD,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,,https://lens.org/087-808-646-719-769,Patent Application,no,0,1,1,14,0,,G08G1/00;;G08G1/054,,0,0,,,,DISCONTINUED
576,CA,C,CA 2132515 C,043-478-002-424-791,2006-01-31,2006,CA 2132515 A,1993-03-22,AU PL146492 A;;AU PL146592 A;;AU 1915/093001 W,1992-03-20,AN OBJECT MONITORING SYSTEM,"An object monitoring system includes a camera node (2) for monitoring moveme nt of an object (18) to determine as acquisition time when an image of the obje ct (18) is to be acquired and acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) fro m other vehicles over a multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nodes (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can exact extract vehicle identifying data, such as licence plate details, and obtain information on vehicle travel between nodes (2).",COMMW SCIENT IND RES ORG;;TELSTRA CORP LTD,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,,https://lens.org/043-478-002-424-791,Granted Patent,no,0,4,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G08G1/017;;G01P3/38;;G06K9/60;;G06K9/78;;G06K9/80;;G06T5/00;;G06T7/20;;G08G1/04;;G08G1/054,,0,0,,,,EXPIRED
577,CA,A1,CA 2132515 A1,119-883-651-944-943,1993-09-21,1993,CA 2132515 A,1993-03-22,AU PL146492 A;;AU PL146592 A;;AU 1915/093001 W,1992-03-20,AN OBJECT MONITORING SYSTEM,"An object monitoring system includes a camera node (2) for monitoring movement of an object (18) to determine an acquisition time when an image of the object (18) is to be acquired acquiring the image at the predetermined time. The system includes a camera (6) which is able to monitor moving objects (18), and image processing circuitry (10), responsive to the camera (6), which is able to detect a predetermined moving object (18) from other moving and static objects. From the image acquired, information identifying the object (18) can be automatically extracted. The system is particularly suited to monitoring and discriminating large vehicles (18) from other vehicles over multi-lane roadway, and acquiring high resolution images of the large vehicles (18) at a predetermined acquisition point (22). Image data acquired by a plurality of camera nones (2) can be sent over a digital telecommunications network (45) to a central image processing system (42) which can extract vehicle identifying d data, such as licence plate details, and obtain information ion on vehicle travel between nodes (2).",,AUTY GLEN WILLIAM;;CORKE PETER IAN;;DUNN PAUL ALEXANDER;;MACINTYRE IAN BARRY;;MILLS DENNIS CHARLES;;SIMONS BENJAMIN FRANCIS;;JENSEN MURRAY JOHN;;KNIGHT RODNEY LAVIS;;PIERCE DAVID STUART;;BALAKUMAR PONNAMPALAM,,https://lens.org/119-883-651-944-943,Patent Application,no,0,1,13,14,0,G01P3/38;;G06T2207/10016;;G06T2207/30261;;G08G1/017;;G08G1/04;;G08G1/054;;G06T7/11;;G06T7/174;;G06T7/254;;G06V20/54;;G06V10/255;;G06V20/625;;G01P3/38;;G08G1/054;;G08G1/017;;G08G1/04;;G06T2207/30261;;G06T2207/10016;;G06T7/174;;G06T7/254;;G06T7/11;;G06V10/255;;G06V20/54;;G06V20/625,G01P3/38;;G06T5/00;;G06T7/20;;G08G1/017;;G08G1/04;;G08G1/054,,0,0,,,,EXPIRED
578,ZA,B,ZA 200202540 B,140-914-218-959-773,2003-06-30,2003,ZA 200202540 A,2002-03-28,US 16080399 P,1999-10-21,Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase.,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HILL CHRISTOPHER HUW;;WELCH TERESA ROSANNE;;FISHER LAWRENCE EMERSON;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID,,https://lens.org/140-914-218-959-773,Granted Patent,no,0,0,1,38,0,,A61K/;;A61P/;;C07D/,,0,0,,,,EXPIRED
579,BR,A,BR 0015243 A,065-612-395-914-697,2002-07-16,2002,BR 0015243 A,2000-10-13,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,Heterociclos de nitrogênio bicìclico substituìdos por heteroalquilamino como inibidores da proteìna cinase p38,"""HETEROCICLOS DE NITROGêNIO BICìCLICO SUBSTITUìDOS POR HETEROALQUILAMINO COMO INIBIDORES DA PROTEìNA CINASE P38"". A invenção fornece compostos representados pela fórmula (I) em que R^ 1^, R^ 2^, R^ 3^, R^ 4^, e n são como definidos no pedido; e isómeros individuais, misturas racêmicas ou não racêmicas de isómeros, e sais farmaceuticamente aceitáveis destes. Os compostos são inibidores de p38 e podem ser usados no tratamento de artrite, doença de Crohn, síndrome do intestino sensível, síndrome da angústia respiratória do adulto, doença pulmonar obstrutiva crónica, osteoporose, ou doença de Alzheimer.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/065-612-395-914-697,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
580,CA,C,CA 2388142 C,123-199-007-263-040,2008-12-09,2008,CA 2388142 A,2000-10-13,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,"The invention provides compounds represented by formula (I) in which R1, R2, R3, R4, and n are as defined in the application; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The compounds are p38 inhibitors and may be used in the treatment of arthritis, Crohn's disease, irritable bowel syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease, osteoporosis, or Alzheimer's disease.",HOFFMANN LA ROCHE,HARRIS WILLIAM;;WELCH TERESA ROSANNE;;HILL CHRISTOPHER HUW;;DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;SMITH IAN EDWARD DAVID,,https://lens.org/123-199-007-263-040,Granted Patent,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00,,0,0,,,,EXPIRED
581,NO,D0,NO 20021781 D0,088-097-148-776-224,2002-04-16,2002,NO 20021781 A,2002-04-16,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,Heteroalkylamino-substituerte bicykliske nitrogenheterocykler som inhibitorer for P38-proteinkinase,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/088-097-148-776-224,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
582,TR,T2,TR 200201057 T2,032-029-577-973-190,2002-09-23,2002,TR 200201057 T,2000-10-13,US 16080399 P;;US 21374300 P,1999-10-21,P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları.,"Bulus, R1, R2, R3, R4 ve n'nin basvuruda tanimlandigi gibi oldugu formül (1) ile temsil edilen bilesikler; ve ayri ayri izomerler, izomerlerin rasemik olmayan karisimlarini, ve bunlarin farmasötik olarak kabul gören tuzlarini saglar. Bilesikler, p38 önleyicidirler ve arterit, Crohn hastaligi, tahris olabilir barsak sendromu, yetiskin solunum zorlugu sendromu, kronik engelleyici akciger hastaligi, osteoporoz veya Alzheimer hastaliginin tedavisinde kullanilabilir.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHEAL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERASE ROSANNE,,https://lens.org/032-029-577-973-190,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
583,YU,A,YU 29102 A,006-540-290-461-476,2004-12-31,2004,YU P29102 A,2000-10-13,US 16080399 P;;US 21374300 P,1999-10-21,HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,"The invention provides compounds represented by formula (I) in which R1, R2, R3, R4, and n are as defined in the application; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The compounds are p38 inhibitors and may be used in the treatment of arthritis, Crohn's disease, irritable bowel syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease, osteoporosis, or Alzheimer's disease.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICAHEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/006-540-290-461-476,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
584,UY,A1,UY 26411 A1,174-033-026-086-625,2001-04-30,2001,UY 26411 A,2000-10-20,UY 26411 A,2000-10-20,HETEROCICLOS BICICLONITROGENADOS HETEROALQUIL AMINO SUSTITUIDOS,"Esta invención proporciona compuestos que se ajustan a la fórmula: (I) en la que R1, R2, R3, R4 y n tienen los significados definidos en la aplicación; y los isómeros individuales, mezclas racémicas o no racémicass de isómeros, y las sales farmacéuticamente aceptables de los mismos. Estos compuestos son inhibidores de p38 y pueden utilizarse en el tratamiento de la artritis, enfermedad de Crohn, síndrome de irritación intestinal, síndrome de insuficiencia respiratoria en adultos, enfermedad pulmonar obstructiva crónica, osteoporosis o enfermedad de Alzheimer.",HOFFMANN LA ROCHE,GOLDSTEIN DAVID MICHAEL;;SMITH IAN EDWARD DAVID;;DUNN JAMES PATRICK;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;FISCHER LAWRENCE EMERSON;;WELCH TERESA ROSANNE,,https://lens.org/174-033-026-086-625,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
585,US,B1,US 6451804 B1,178-695-813-207-199,2002-09-17,2002,US 69333700 A,2000-10-20,US 69333700 A;;US 21374300 P;;US 16080399 P,1999-10-21,Heteroalkylamino-substituted bicyclic nitrogen heterocycles,"
    The invention provides compounds represented by the formula: 

    wherein R ^{ 1 } , R ^{ 2 } , R ^{ 3 } , R ^{ 4 } , and n are as defined in the Summary of the Invention; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof. 
",SYNTEX LLC,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,SYNTEX (U.S.A.) LLC (2000-12-21),https://lens.org/178-695-813-207-199,Granted Patent,yes,5,33,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,514/262.1;;544/6;;544/256;;544/230,0,0,,,,EXPIRED
586,EP,A1,EP 1228070 A1,061-538-825-216-410,2002-08-07,2002,EP 00967864 A,2000-10-13,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;BILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/061-538-825-216-410,Patent Application,yes,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
587,HR,A2,HR P20020328 A2,065-617-678-128-197,2004-02-29,2004,HR P20020328 A,2002-04-12,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,HETEROALKYLAMINO-SUBSTITED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;WILLIAM HARRIS;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/065-617-678-128-197,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
588,AU,B2,AU 776250 B2,083-428-090-532-383,2004-09-02,2004,AU 2000/077873 A,2000-10-13,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/083-428-090-532-383,Granted Patent,no,2,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
589,HK,A1,HK 1051039 A1,031-907-455-908-198,2003-07-18,2003,HK 03103208 A,2003-05-06,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase.,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/031-907-455-908-198,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
590,WO,A1,WO 2001/029042 A1,163-186-057-058-537,2001-04-26,2001,EP 0010088 W,2000-10-13,US 16080399 P;;US 21374300 P,1999-10-21,HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,"The invention provides compounds represented by formula (I) in which R?1, R2, R3, R4¿, and n are as defined in the application; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The compounds are p38 inhibitors and may be used in the treatment of arthritis, Crohn's disease, irritable bowel syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease, osteoporosis, or Alzheimer's disease.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/163-186-057-058-537,Patent Application,yes,4,88,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PATENTED
591,CA,A1,CA 2388142 A1,012-816-041-220-075,2001-04-26,2001,CA 2388142 A,2000-10-13,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,"The invention provides compounds represented by formula (I) in which R1, R2, R3, R4, and n are as defined in the application; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The compounds are p38 inhibitors and may be used in the treatment of arthritis, Crohn's disease, irritable bowel syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease, osteoporosis, or Alzheimer's disease.",HOFFMANN LA ROCHE,HARRIS WILLIAM;;FISHER LAWRENCE EMERSON;;DUNN JAMES PATRICK;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE;;GOLDSTEIN DAVID MICHAEL,,https://lens.org/012-816-041-220-075,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
592,PE,A1,PE 20010758 A1,192-442-371-629-176,2001-07-21,2001,PE 0011042000 A,2000-10-17,US 16080399 P;;US 21374300 P,1999-10-21,"DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA SUSTITUIDOS POR HETEROALQUILO COMO INHIBIDORES DE QUINASAS p38","SE REFIERE A DERIVADOS DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA SUSTITUIDOS CON HETEROARILO, DONDE R1 ES ACILO, HETEROALQUILO, ARILHETEROALQUILO, ARILHETEROALQUILO, (ALQUILEN)-CO-R11, ENTRE OTROS; R11 ES ALQUILO, HALOALQUILO, AMINO, CICLOALQUILO; R2 ES ALQUILO, HALOGENO, HETEROALQUILO, VINILO; R3 ES H, ALQUILO, HETEROALQUILO, ARILO, ARALQUILO, ALQUILEN-COR31, ENTRE OTROS; R31 ES ALQUILO, HALOALQUILO, OH, ALCOXI, ENTRE OTROS; R4 ES H, ALQUILO, (ALQUILEN)-COR31. SON COMPUESTOS PREFERIDOS 3-(2-CLOROFENIL)-7-(TRANS-4-HIDROXICICLOHEXILAMINO)-3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)ONA, 3-(2-CLOROFENIL)-7-(TETRAHIDROPIRAN-4-ILAMINO]-3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN INHIBIDOR DE LA QUINASA p38 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ARTRITIS, ENFERMEDAD DE CROHN, SINDROME DE IRRITACION INTESTINAL, SINDROME DE INSUFICIENCIA RESPIRATORIA, OSTEOPOROSIS, ALZHEIMER",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;WELCH TERESA ROSANNE;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;HARRIS WILLIAM,,https://lens.org/192-442-371-629-176,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
593,EP,B1,EP 1228070 B1,066-666-544-040-584,2007-02-07,2007,EP 00967864 A,2000-10-13,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;BILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/066-666-544-040-584,Granted Patent,yes,4,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/505;;A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00,,0,0,,,,EXPIRED
594,MA,A1,MA 26837 A1,123-439-845-442-216,2004-12-20,2004,MA 26612 A,2002-04-19,US 16080399 P;;US 21374300 P,1999-10-21,HETEROCYCLES AZOTES BICYCLIQUES HETEROALKY-LAMINO SUBSTITUES EN TANT QU'INHIBITEURS DE KINASE DE PROTEINE P38.,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE;;FISHER LAWRENCE EMERSON;;HILL CHRISTOPHER HUW,,https://lens.org/123-439-845-442-216,Granted Patent,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
595,AU,A,AU 2000/077873 A,042-397-246-484-335,2001-04-30,2001,AU 2000/077873 A,2000-10-13,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38protein kinase,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/042-397-246-484-335,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
596,NO,L,NO 20021781 L,044-753-266-452-729,2002-04-18,2002,NO 20021781 A,2002-04-16,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,Heteroalkylamino-substituerte bicykliske nitrogenheterocykler som inhibitorer for P38-proteinkinase,"Oppfinnelsen tilveiebringer forbindelser representert ved formelen (I) hvor R ,2,og n er som definert i søknaden; og individuelle isomerer, racemiske eller ikke-racemiske blandinger av isomerer og farmasøytisk akseptable salter derav. Forbindelsene er p38-inhibitorer og kan anvendes ved behandling av artritt, Crohn's sykdom, irritert-tarm-syndrom, voksen åndenødssyndrom, kronisk obstruktiv pulmonal sykdom, osteoporose eller Alzheimers sykdom.",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/044-753-266-452-729,Abstract,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
597,US,A1,US 2004/0246236 A1,162-572-102-128-928,2004-12-09,2004,US 45305403 A,2003-06-02,US 45305403 A,2003-06-02,REMOTE CONTROL FOR ELECTRONIC WHITEBOARD,"
Abstract of the Disclosure

    A remote controllable electronic whiteboard system and method of operating the remote controllable electronic whiteboard system are provided. An exemplary remote controllable electronic whiteboard system includes an electronic whiteboard in communication with a remote control device. Methods of operating the electronic whiteboard system including the use of a remote control device are also provided. 
",GREENSTEEL INC,HILDEBRANDT PETER;;WATSON JAMES D;;HOFMANN NEAL A;;ASSARAF A JOEL;;DUNN MICHAEL H;;HUTCHINSON IAN G;;DRAUDT GREGG;;MILLEN SAM,POLYVISION CORPORATION (2004-01-02);;GREENSTEEL INC (2003-10-29),https://lens.org/162-572-102-128-928,Patent Application,yes,19,33,7,7,0,G06F3/038;;G06F3/038;;G06F3/041;;G06F3/0488;;G06F3/0488;;G08C17/02;;G08C17/02;;G08C23/04;;G08C23/04,G06F3/038;;G06F3/041;;G08C17/02;;G08C23/04;;G09G5/00,345/169,0,0,,,,PENDING
598,CZ,A3,CZ 20021744 A3,196-907-468-667-542,2002-08-14,2002,CZ 20021744 A,2000-10-13,US 16080399 P;;US 21374300 P,1999-10-21,Bicyclic nitrogen heterocycles substituted with heteroalkylamino group functioning as P38 protein kinase inhibitors,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/196-907-468-667-542,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
599,AT,T1,AT E353329 T1,199-561-382-158-687,2007-02-15,2007,AT 00967864 T,2000-10-13,US 16080399 P;;US 21374300 P,1999-10-21,HETEROALKYLAMINO-SUBSTITUIERTE BICYCLISCHE STICKSTOFFHETEROCYCLEN,,HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM;;BILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/199-561-382-158-687,Granted Patent,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
600,US,S,US D0751188 S,025-405-699-078-55X,2016-03-08,2016,US 201329451049 F,2013-03-27,US 201329451049 F,2013-03-27,Patient interface,,RESMED LTD;;RESMES LTD,SKIPPER CHRISTOPHER SCOTT;;GRAY STEPHEN;;HUNG ANDREW;;BURNHAM ROBERT THOMAS;;AMARASINGHE AMAL SHIRLEY;;MATTHEWS IAN JAMES;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA,RESMED PTY LTD (2013-04-04),https://lens.org/025-405-699-078-55X,Design Right,no,0,44,24,24,0,,,2902;;D24/110.4,0,0,,,,ACTIVE
601,CA,A1,CA 3137583 A1,073-958-483-636-250,2020-10-22,2020,CA 3137583 A,2020-04-16,US 201962835963 P;;IB 2020000288 W,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti- inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;BURK ROBERT M;;CHAPMAN NICHOLAS,,https://lens.org/073-958-483-636-250,Patent Application,no,0,0,3,14,0,A61P43/00;;A61P27/02;;C07D405/06;;C07D409/14;;C07D211/62;;A61K47/545,A61K31/472;;A61K31/47;;A61P43/00;;C07D217/00;;C07D217/06;;C07D217/12,,0,0,,,,PENDING
602,US,B2,US 11634411 B2,003-224-746-069-234,2023-04-25,2023,US 202017112371 A,2020-12-04,US 202017112371 A;;US 202016904036 A;;IB 2020000288 W;;US 201962835963 P,2019-04-18,Compounds and methods for the treatment of ocular disorders,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;BURK ROBERT M;;DUNN JONATHAN;;CHAPMAN NICHOLAS,DOMAINEX LTD (2020-07-28);;AZURA OPHTHALMICS LTD (2020-06-23);;BCP3 PTY LIMITED (2020-06-24),https://lens.org/003-224-746-069-234,Granted Patent,yes,36,0,11,14,0,C07D405/14;;C07D405/06;;C07D409/14;;A61P27/02;;A61K47/545;;A61P43/00;;C07D211/62;;C07D405/06;;C07D211/62;;A61K47/545;;A61P27/02;;C07D409/14;;A61P43/00;;C07D405/06;;A61K31/4725;;A61K31/445;;A61K9/0048;;A61P27/02;;A61P17/00;;C07D409/14;;C07D211/34;;C07D405/06;;A61P27/02;;C07D409/14;;C07D405/14,C07D405/06;;A61P27/02;;C07D405/14;;C07D409/14,,30,21,099-960-763-749-627;;020-870-855-859-609;;090-991-982-963-361;;007-364-858-655-289;;121-114-378-458-21X;;027-488-422-889-594;;006-519-925-085-122;;015-154-901-178-524;;016-192-796-868-999;;094-813-021-617-631;;001-718-978-242-312;;003-334-491-119-371;;030-234-441-646-238;;066-371-099-307-130;;032-610-338-117-484;;074-730-080-706-256;;030-237-906-192-920;;073-352-788-052-508;;007-877-542-945-654;;086-535-204-937-112;;093-811-571-643-302,23215539;;pmc3601677;;10.1089/jop.2012.0200;;10.1167/iovs.03-1055;;15161821;;10.1167/iovs.04-1326;;16043849;;10.1002/jps.2600660104;;833720;;11867577;;10.1007/bf02518337;;10.1016/s0040-4020(01)89131-6;;10.1167/iovs.15-17249;;26348638;;pmc4566400;;10.1007/978-0-387-49785-3_20;;pmc3072157;;10.1167/iovs.10-6997;;21450913;;10.1167/iovs.10-6997a;;10.4049/jimmunol.176.7.3950;;16547229;;15364229;;10.1016/j.ajo.2004.04.052;;10.1016/s1542-0124(12)70085-x;;17508120;;18219308;;10.1038/nrd2468;;16918513;;10.1111/j.1398-9995.2006.01146.x;;10.1167/iovs.10-6997e;;pmc3072161;;21450917;;26058030;;10.1097/icu.0000000000000165;;pmc3072159;;10.1167/iovs.10-6997c;;21450915;;10.1097/ico.0b013e318239aaea;;22222996;;10.1016/j.ajo.2011.11.003;;22330307;;24900456;;pmc4025648;;10.1021/ml2002482,"Tilley, J.W. “Identification of N-acyl 4-(3-pyridonyl) phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists.” Bioorganic & medicinal chemistry letters 23.4 (2013): 1036-1040.;;Cholkar, K., “Novel strategies for anterior segment ocular drug delivery.” Journal of ocular pharmacology and therapeutics 29.2 (2013): 106-123.;;Barabino et al. Animal Models of Dry Eye: A Critical Assessment of Opportunities and Limitations. Invest. Ophthalmol. Vis. Sci. 45:1641-1646 (2004).;;Barabino et al. The Controlled-Environment Chamber: A New Mouse Model of Dry Eye. Invest. Ophthalmol. Vis. Sci. 46:2766-2771 (2005).;;Berge et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (Jan. 1977).;;Dursun et al. A Mouse Model of Keratoconjunctivitis Sicca. Invest. Ophthalmol. Vis. Sci. 43:632-638 (2002).;;Evans. Synthesis of radiolabeled compounds. J Radioanal Chem 64(1-2):9-32 (1981).;;Kabalka et al. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates. Tetrahedron 45(21):6601-6621 (1989).;;Krauss et al. Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model. Invest. Ophthalmol. Vis. Sci. 56(10):5888-5895 (2015).;;Maag. Prodrugs of carboxylic acids. Prodrugs. Springer, New York, NY (pp. 703-729) (2007):.;;Nichols et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest. Ophthalmol. Vis. Sci. 52(4):1922-1929 (2011).;;Niederkorn et al. Desiccating Stress Induces T Cell-Mediated Sjögren's Syndrome-like Lacrimal Keratoconjunctivitis. J. Immunol. 176:3950-3957 (2006).;;PCT/IB2020/000288 International Search Report and Written Opinion dated Sep. 10, 2020.;;PCT/IB2020/000288 Invitation to Pay Additional Fees dated Jul. 16, 2020.;;Pflugfelder et al. A Randomized, Double-Masked, Placebo-Controlled, Multicenter Comparison of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, and Placebo for Treatment of Keratoconjunctivitis Sicca in Patients With Delayed Tear Clearance. Am J Ophthalmol 138:444-57 (2004).;;Pflugfelder et al. International Dry Eye Workshop, 2007. Management and Therapy of Dry Eye Disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop. Ocul Surf 5:163-178 (2007).;;Rautio et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 7(3):255-270 (2008).;;Ravensberg et al. The Effect of a Single Inhaled Dose of a VLA-4 Antagonist on Allergen-Induced Airway Responses and Airway Inflammation in Patients With Asthma. Allergy 61:1097-1103 (2006).;;Schaumberg et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on the Epidemiology Of, and Associated Risk Factors For, MGD. Invest. Ophthalmol. Vis. Sci. 52(4):1994-2005 (2011).;;PCT/IB2021/000707 International Search Report and Written Opinion dated May 16, 2022.;;PCT/IB2021/000707 Invitation to Pay Additional Fees dated Feb. 23, 2022.;;Pub Chem SID 244662985 (Mar. 17, 2015).;;Pub Chem SID 244881306 (Mar. 17, 2015).;;Blackie et al. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation. Curr Opin Ophthalmol 26(4):306-13 (2015).;;Knop et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. IOVS 52(4):1938-1978 (2011).;;Lane et al. A New System, the LipiFlow, for the Treatment of Meibomian Gland Dysfunction. Cornea 31(4):396-404 (2012).;;U.S. Appl. No. 17/222,802 dated Aug. 25, 2021.;;U.S. Appl. No. 17/222,802 dated Dec. 13, 2021.;;Semba et al. A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study of a Novel Integrin Antagonist (SAR 1118) for the Treatment of Dry Eye. American Journal Of Ophthalmology 153(6):1050-1060 (2012).;;Zhong et al. Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS medicinal chemistry letters 3(3):203-206 (2012) (Including Supporting Information).",ACTIVE
603,US,A1,US 2021/0107899 A1,179-345-666-136-509,2021-04-15,2021,US 202017112371 A,2020-12-04,US 202017112371 A;;US 202016904036 A;;IB 2020000288 W;;US 201962835963 P,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;BURK ROBERT M;;DUNN JONATHAN;;CHAPMAN NICHOLAS,DOMAINEX LTD (2020-07-28);;AZURA OPHTHALMICS LTD (2020-06-23);;BCP3 PTY LIMITED (2020-06-24),https://lens.org/179-345-666-136-509,Patent Application,yes,0,0,11,14,0,C07D405/14;;C07D405/06;;C07D409/14;;A61P27/02;;A61K47/545;;A61P43/00;;C07D211/62;;C07D405/06;;C07D211/62;;A61K47/545;;A61P27/02;;C07D409/14;;A61P43/00;;C07D405/06;;A61K31/4725;;A61K31/445;;A61K9/0048;;A61P27/02;;A61P17/00;;C07D409/14;;C07D211/34;;C07D405/06;;A61P27/02;;C07D409/14;;C07D405/14,C07D405/06;;A61P27/02;;C07D405/14;;C07D409/14,,2,1,099-960-763-749-627,23215539;;pmc3601677;;10.1089/jop.2012.0200,"Tilley, J.W. ""Identification of N-acyl 4-(3-pyridonyl) phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists."" Bioorganic & medicinal chemistry letters 23.4 (2013): 1036-1040.;;Cholkar, K., ""Novel strategies for anterior segment ocular drug delivery."" Journal of ocular pharmacology and therapeutics 29.2 (2013): 106-123.",ACTIVE
604,EP,A4,EP 3955926 A4,038-619-450-792-382,2022-11-30,2022,EP 20791787 A,2020-04-16,US 201962835963 P;;IB 2020000288 W,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,,AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;BURK ROBERT M;;DUNN JONATHAN;;CHAPMAN NICHOLAS,AZURA OPHTHALMICS LTD (2023-05-03),https://lens.org/038-619-450-792-382,Search Report,no,1,0,11,14,0,C07D405/14;;C07D405/06;;C07D409/14;;A61P27/02;;A61K47/545;;A61P43/00;;C07D211/62;;C07D405/06;;C07D211/62;;A61K47/545;;A61P27/02;;C07D409/14;;A61P43/00;;C07D405/06;;A61K31/4725;;A61K31/445;;A61K9/0048;;A61P27/02;;A61P17/00;;C07D409/14;;C07D211/34;;C07D405/06;;A61P27/02;;C07D409/14;;C07D405/14,A61K31/472;;A61K31/47;;A61K47/54;;A61P27/02;;A61P43/00;;C07D211/62;;C07D217/00;;C07D217/06;;C07D217/12;;C07D405/06;;C07D405/14;;C07D409/14,,2,2,086-535-204-937-112;;093-811-571-643-302,10.1016/j.ajo.2011.11.003;;22330307;;24900456;;pmc4025648;;10.1021/ml2002482,"CHARLES P. SEMBA ET AL: ""A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study of a Novel Integrin Antagonist (SAR 1118) for the Treatment of Dry Eye"", AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 153, no. 6, 1 June 2012 (2012-06-01), pages 1050 - 1060.e1, XP055115168, ISSN: 0002-9394, DOI: 10.1016/j.ajo.2011.11.003;;MIN ZHONG ET AL: ""Supporting information: Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye"", ACS MEDICINAL CHEMISTRY LETTERS, 8 March 2012 (2012-03-08), United States, pages 203 - 206, XP055570585, Retrieved from the Internet <URL:https://pubs.acs.org/doi/suppl/10.1021/ml2002482/suppl_file/ml2002482_si_001.pdf> [retrieved on 20190318], DOI: 10.1021/ml2002482",PENDING
605,CA,A1,CA 2527889 A1,075-514-835-060-060,2004-12-16,2004,CA 2527889 A,2004-06-01,US 45305403 A;;US 2004/0017384 W,2003-06-02,REMOTE CONTROL FOR ELECTRONIC WHITEBOARD,A remote controllable electronic whiteboard system (100) and method of operating the remote controllable electronic whiteboard system (100) are provided. An exemplary remote controllable electronic whiteboard system (100 ) includes an electronic whiteboard (105) in communication with a remote contr ol device (130). Methods of operating the electronic whiteboard system (100) including the use of a remote control device (130) are also provided.</SDOAB >,POLYVISION CORP,MILLEN SAM;;ASSARAF A JOEL;;DUNN MICHAEL H;;WATSON JAMES D;;HOFMANN NEAL A;;HUTCHINSON IAN G;;HILDEBRANDT PETER W;;DRAUDT GREGG,,https://lens.org/075-514-835-060-060,Patent Application,no,0,0,7,7,0,G06F3/038;;G06F3/038;;G06F3/041;;G06F3/0488;;G06F3/0488;;G08C17/02;;G08C17/02;;G08C23/04;;G08C23/04,G06F3/038;;G06F3/041;;G08C17/02;;G08C23/04;;G09G5/00,,0,0,,,,DISCONTINUED
606,AU,A1,AU 2020/259996 A1,111-552-670-841-352,2021-11-25,2021,AU 2020/259996 A,2020-04-16,US 201962835963 P;;IB 2020000288 W,2019-04-18,Compounds and methods for the treatment of ocular disorders,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti- inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;BURK ROBERT M;;DUNN JONATHAN;;CHAPMAN NICHOLAS,,https://lens.org/111-552-670-841-352,Patent Application,no,0,0,3,14,0,A61P43/00;;A61P27/02;;C07D405/06;;C07D409/14;;C07D211/62;;A61K47/545,A61K31/472;;A61K31/47;;A61P43/00;;C07D217/00;;C07D217/06;;C07D217/12,,0,0,,,,PENDING
607,AU,A1,AU 2004/246667 A1,131-465-461-787-046,2004-12-16,2004,AU 2004/246667 A,2004-06-01,US 45305403 A;;US 2004/0017384 W,2003-06-02,Remote control for electronic whiteboard,,POLYVISION CORP,HILDEBRANDT PETER W;;DRAUDT GREGG;;HOFMANN NEAL A;;ASSARAF A JOEL;;HUTCHINSON IAN G;;MILLEN SAM;;WATSON JAMES D;;DUNN MICHAEL H,,https://lens.org/131-465-461-787-046,Patent Application,no,0,0,7,7,0,G06F3/038;;G06F3/038;;G06F3/041;;G06F3/0488;;G06F3/0488;;G08C17/02;;G08C17/02;;G08C23/04;;G08C23/04,G06F3/038;;G06F3/041;;G08C17/02;;G08C23/04;;G09G5/00,,0,0,,,,DISCONTINUED
608,KR,A,KR 20220003555 A,184-096-645-709-431,2022-01-10,2022,KR 20217037591 A,2020-04-16,US 201962835963 P;;IB 2020000288 W,2019-04-18,안구 장애의 치료를 위한 화합물 및 방법,"본원에는 마이봄샘 기능장애, 안검염, 안구 건조증 및 눈의 전방 표면의 기타 염증성 및/또는 감염성 질환을 포함하는 안구 표면 장애의 치료를 위한 조성물 및 방법이 기재되어 있다. 상기 조성물 및 방법은 각질용해 활성, 및 항염증성 또는 기타 바람직한 활성을 나타내는 각질용해 접합체를 포함한다. 눈꺼풀 가장자리 또는 주변 영역에 대한 상기 조성물의 국소 투여는 안구 표면 장애를 앓고 있는 환자에게 치료적 이점을 제공한다.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;BURK ROBERT M;;DUNN JONATHAN;;CHAPMAN NICHOLAS,,https://lens.org/184-096-645-709-431,Patent Application,no,0,0,11,14,0,C07D405/14;;C07D405/06;;C07D409/14;;A61P27/02;;A61K47/545;;A61P43/00;;C07D211/62;;C07D405/06;;C07D211/62;;A61K47/545;;A61P27/02;;C07D409/14;;A61P43/00;;C07D405/06;;A61K31/4725;;A61K31/445;;A61K9/0048;;A61P27/02;;A61P17/00;;C07D409/14;;C07D211/34;;C07D405/06;;A61P27/02;;C07D409/14;;C07D405/14,C07D405/06;;A61K9/00;;A61K31/445;;A61K31/4725;;A61P17/00;;A61P27/02;;C07D211/34;;C07D409/14,,0,0,,,,PENDING
609,HU,A2,HU P0203564 A2,182-307-071-764-451,2003-02-28,2003,HU P0203564 A,2000-10-13,EP 0010088 W;;US 16080399 P;;US 21374300 P,1999-10-21,"HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINEASE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","A találmány (I) általános képletű vegyületekre (mely képletben R1, R2,R3, R4 és n jelentése az alábbiakban megadott), egyedi izomerjeikre,az izomerek racém vagy nem racém keverékeire és e vegyületekgyógyászatilag alkalmas sóira vonatkozik, továbbá a találmány kiterjeda vegyületek előállítási eljárására és a vegyületeket tartalmazógyógyszerkészítményekre. A találmány szerinti vegyületek p38inhibitorok és arthritis, Crohn-féle betegség, ingerlésesbélszindróma, felnőtt légzési depressziós szindróma, krónikuselzáródásos tüdőbetegség, osteoporosis vagy Alzheimer-betegségkezelésére alkalmazhatók. n értéke 0-3; R1 jelentése acilcsoport,heteroalkil-csoport, adott esetben helyettesített aril-heteroalkil-,heteroalkenil-, heteroalkinil-, heteroalkil-karbonil-,heterohelyettesített cikloalkil-, heterohelyettesítettcikloalkilalkil-, heterohelyettesített cikloalkil-alkenil-,heterohelyettesített cikloalkil-alkinil-, heteroalkil-helyettesítettcikloalkil-, adott esetben helyettesített heterociklikus, adottesetben helyettesített heterociklikus alkil-, adott esetbenheterociklikus-spiro-cikloalkil-csoport, -(alkilén)-C(O)-R11 vagy -(heteroalkilén)-C(O)-R11 csoport; R11 jelentése alkil-, halogén-alkil-, amino-, egyszeresen vagy kétszeresen helyettesített amino-,adott esetben helyettesített cikloalkil-, adott esetben helyettesítettcikloalkil-alkil-, adott esetben helyettesített aril-, adott esetbenhelyettesített aralkil-, adott esetben helyettesített heteroaril-,adott esetben helyettesített heteroaralkil-, hidroxil- vagyalkoxicsoport; R2 jelentése egymástól függetlenül alkilcsoport,halogénatom, heteroalkil- vagy vinilcsoport; R3 jelentésehidrogénatom, alkil-, heteroalkil-, adott esetben helyettesítettaril-, adott esetben helyettesített aralkil-, adott esetbenhelyettesített heteroaril-, adott esetben helyettesítettheteroaralkil-, adott esetben helyettesített cikloalkil-,cikloalkenil-, adott esetben helyettesített cikloalkil-alkil-,halogén-alkil-, ciano-alkil-, heterohelyettesített cikloalkil-,heterohelyettesített cikloalkil-alkil-, heteroalkil-helyettesítettcikloalkil-, adott esetben helyettesített heterociklikus, adottesetben helyettesített heterociklikus alkil-, -(alkilén)-C(O)R31 vagy-(heteroalkilén)-C(O)R31 csoport; R31 jelentése alkil-, halogén-alkil-, hidroxil-, alkoxi-, amino-, egyszeresen vagy kétszeresenhelyettesített amino-, adott esetben helyettesített cikloalkil-, adottesetben helyettesített cikloalkil-alkil-, adott esetben helyettesítettaril-, adott esetben helyettesített aralkil-, adott esetbenhelyettesített heteroaril- vagy adott esetben helyettesítettheteroaralkil-csoport; és R4 jelentése hidrogénatom, alkilcsoport vagy-(alkilén)-COR31 csoport] Ó",HOFFMANN LA ROCHE,DUNN JAMES PATRICK;;FISHER LAWRENCE EMERSON;;GOLDSTEIN DAVID MICHAEL;;HARRIS WILLIAM S;;HILL CHRISTOPHER HUW;;SMITH IAN EDWARD DAVID;;WELCH TERESA ROSANNE,,https://lens.org/182-307-071-764-451,Patent Application,no,0,0,37,38,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P3/10;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/02;;A61P7/08;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P11/16;;A61P13/12;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P25/00;;A61P25/04;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/16;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
610,US,A1,US 2023/0357207 A1,028-525-596-099-142,2023-11-09,2023,US 202318119248 A,2023-03-08,US 202318119248 A;;US 202017112371 A;;US 202016904036 A;;IB 2020000288 W;;US 201962835963 P,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;BURK ROBERT M;;DUNN JONATHAN;;CHAPMAN NICHOLAS,DOMAINEX LTD (2020-07-28);;AZURA OPHTHALMICS LTD (2020-06-23);;BCP3 PTY LIMITED (2020-06-24),https://lens.org/028-525-596-099-142,Patent Application,yes,0,0,11,14,0,C07D405/14;;C07D405/06;;C07D409/14;;A61P27/02;;A61K47/545;;A61P43/00;;C07D211/62;;C07D405/06;;C07D211/62;;A61K47/545;;A61P27/02;;C07D409/14;;A61P43/00;;C07D405/06;;A61K31/4725;;A61K31/445;;A61K9/0048;;A61P27/02;;A61P17/00;;C07D409/14;;C07D211/34;;C07D405/06;;A61P27/02;;C07D409/14;;C07D405/14,C07D405/06;;A61P27/02;;C07D405/14;;C07D409/14,,0,0,,,,PENDING
611,TW,S,TW D167585 S,026-081-217-423-428,2015-05-01,2015,TW 102306360 F,2013-09-26,US 201329451049 F,2013-03-27,PART OF PATIENT INTERFACE,【物品用途】;一種病患連接裝置之部分，係指一種套設於使用者頭部以供給空氣的病患連接裝置之部分。;【設計說明】;本設計係有關一種病患連接裝置之部分，尤指一種具有如附圖所示之形狀者。由本設計的整體觀之，其包含有一主體，一管件，一護套，以及一繩帶。該主體呈類似一三角形。該主體具有一通道，一三角形開口，一圓形開口，一連接該三角形開口與該圓形開口的三角形通道，以及一設置於該主體的凹陷。該管件包含有一環形管體，以及一相對該環形管體並以一傾斜角度延伸的彎管。該護套具有一呈類似三角形的框架，二矩形翼片，一設置於該矩形翼片的孔洞，以及二鈎狀片。該繩帶具有四呈片狀的帶體，以及一呈片狀並連接該繩帶的環狀帶體。;本案圖式所揭露之虛線部分為本案不主張設計之部分。此外，參考圖1~7中非輪廓線的部分為陰影線，不同形式的陰影線可代表不同材質。;綜上所述，本設計具有流線型的外觀，具有簡潔乾淨的視覺觀感，深具美感並富有實用價值。,瑞思邁有限公司;;RESMED LTD,SKIPPER CHRISTOPHER SCOTT;;AMARASINGHE AMAL SHIRLEY;;BURNHAM ROBERT THOMAS;;DUNN JESSICA LEA;;FORMICA JUSTIN JOHN;;GRAY STEPHEN;;HUNG ANDREW;;MATTHEWS IAN JAMES,,https://lens.org/026-081-217-423-428,Design Right,no,0,0,24,24,0,,,24-04,0,0,,,,ACTIVE
612,EP,A1,EP 3955926 A1,022-430-613-734-276,2022-02-23,2022,EP 20791787 A,2020-04-16,US 201962835963 P;;IB 2020000288 W,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,,AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;BURK ROBERT M;;DUNN JONATHAN;;CHAPMAN NICHOLAS,AZURA OPHTHALMICS LTD (2023-05-03),https://lens.org/022-430-613-734-276,Patent Application,yes,0,0,11,14,0,C07D405/14;;C07D405/06;;C07D409/14;;A61P27/02;;A61K47/545;;A61P43/00;;C07D211/62;;C07D405/06;;C07D211/62;;A61K47/545;;A61P27/02;;C07D409/14;;A61P43/00;;C07D405/06;;A61K31/4725;;A61K31/445;;A61K9/0048;;A61P27/02;;A61P17/00;;C07D409/14;;C07D211/34;;C07D405/06;;A61P27/02;;C07D409/14;;C07D405/14,A61K31/472;;A61K31/47;;A61P43/00;;C07D217/00;;C07D217/06;;C07D217/12,,0,0,,,,PENDING
613,US,A1,US 2020/0331896 A1,139-731-868-485-154,2020-10-22,2020,US 202016904036 A,2020-06-17,US 202016904036 A;;IB 2020000288 W;;US 201962835963 P,2019-04-18,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;BURK ROBERT M;;DUNN JONATHAN;;CHAPMAN NICHOLAS,DOMAINEX LTD (2020-07-28);;AZURA OPHTHALMICS LTD (2020-06-23);;BCP3 PTY LIMITED (2020-06-24),https://lens.org/139-731-868-485-154,Patent Application,yes,0,2,11,14,0,C07D405/14;;C07D405/06;;C07D409/14;;A61P27/02;;A61K47/545;;A61P43/00;;C07D211/62;;C07D405/06;;C07D211/62;;A61K47/545;;A61P27/02;;C07D409/14;;A61P43/00;;C07D405/06;;A61K31/4725;;A61K31/445;;A61K9/0048;;A61P27/02;;A61P17/00;;C07D409/14;;C07D211/34;;C07D405/06;;A61P27/02;;C07D409/14;;C07D405/14,C07D405/06;;A61P27/02;;C07D405/14;;C07D409/14,,0,0,,,,ACTIVE
614,US,B2,US 10875845 B2,002-345-748-120-018,2020-12-29,2020,US 202016904036 A,2020-06-17,US 202016904036 A;;IB 2020000288 W;;US 201962835963 P,2019-04-18,Compounds and methods for the treatment of ocular disorders,"Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;GLEESON MARC;;STEWART MARK RICHARD;;BURK ROBERT M;;DUNN JONATHAN;;CHAPMAN NICHOLAS,DOMAINEX LTD (2020-07-28);;AZURA OPHTHALMICS LTD (2020-06-23);;BCP3 PTY LIMITED (2020-06-24),https://lens.org/002-345-748-120-018,Granted Patent,yes,23,2,11,14,0,C07D405/14;;C07D405/06;;C07D409/14;;A61P27/02;;A61K47/545;;A61P43/00;;C07D211/62;;C07D405/06;;C07D211/62;;A61K47/545;;A61P27/02;;C07D409/14;;A61P43/00;;C07D405/06;;A61K31/4725;;A61K31/445;;A61K9/0048;;A61P27/02;;A61P17/00;;C07D409/14;;C07D211/34;;C07D405/06;;A61P27/02;;C07D409/14;;C07D405/14,C07D405/06;;A61P27/02;;C07D405/14;;C07D409/14,,17,15,016-192-796-868-999;;066-371-099-307-130;;020-870-855-859-609;;090-991-982-963-361;;007-364-858-655-289;;121-114-378-458-21X;;027-488-422-889-594;;006-519-925-085-122;;015-154-901-178-524;;094-813-021-617-631;;001-718-978-242-312;;003-334-491-119-371;;030-234-441-646-238;;032-610-338-117-484;;074-730-080-706-256,10.1007/978-0-387-49785-3_20;;18219308;;10.1038/nrd2468;;10.1167/iovs.03-1055;;15161821;;10.1167/iovs.04-1326;;16043849;;10.1002/jps.2600660104;;833720;;11867577;;10.1007/bf02518337;;10.1016/s0040-4020(01)89131-6;;10.1167/iovs.15-17249;;26348638;;pmc4566400;;pmc3072157;;10.1167/iovs.10-6997;;21450913;;10.1167/iovs.10-6997a;;10.4049/jimmunol.176.7.3950;;16547229;;15364229;;10.1016/j.ajo.2004.04.052;;10.1016/s1542-0124(12)70085-x;;17508120;;16918513;;10.1111/j.1398-9995.2006.01146.x;;10.1167/iovs.10-6997e;;pmc3072161;;21450917,"Maag, H. “Prodrugs of carboxylic acids.” Prodrugs. Springer, New York, NY( 2007):703-729.;;Rautio, J. “Prodrugs: design and clinical applications.” Nature Reviews Drug Discovery 7.3 (2008): 255-270.;;Barabino et al. Animal Models of Dry Eye: A Critical Assessment of Opportunities and Limitations. Invest. Ophthalmol. Vis. Sci. 45:1641-1646 (2004).;;Barabino et al. The Controlled-Environment Chamber: A New Mouse Model of Dry Eye. Invest. Ophthalmol. Vis. Sci. 46:2766-2771 (2005).;;Berge et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (Jan. 1977).;;Dursun et al. A Mouse Model of Keratoconjunctivitis Sicca. Invest. Ophthalmol. Vis. Sci. 43:632-638 (2002).;;Evans. Synthesis of radiolabeled compounds. J Radioanal Chem 64(1-2):9-32 (1981).;;Kabalka et al. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates. Tetrahedron 45(21):6601-6621 (1989).;;Krauss et al. Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model. Invest. Ophthalmol. Vis. Sci. 56(10):5888-5895 (2015).;;Nichols et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest. Ophthalmol. Vis. Sci. 52(4):1922-1929 (2011).;;Niederkorn et al. Desiccating Stress Induces T Cell-Mediated Sjögren's Syndrome-like Lacrimal Keratoconjunctivitis. J. Immunol. 176:3950-3957 (2006).;;Pflugfelder et al. A Randomized, Double-Masked, Placebo-Controlled, Multicenter Comparison of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, and Placebo for Treatment of Keratoconjunctivitis Sicca in Patients With Delayed Tear Clearance. Am J Ophthalmol 138:444-57 (2004).;;Pflugfelder et al. International Dry Eye WorkShop, 2007. Management and Therapy of Dry Eye Disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop. Ocul Surf 5:163-178 (2007).;;Ravensberg et al. The Effect of a Single Inhaled Dose of a VLA-4 Antagonist on Allergen-Induced Airway Responses and Airway Inflammation in Patients With Asthma. Allergy 61:1097-1103 (2006).;;Schaumberg et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on the Epidemiology of, and Associated Risk Factors for, MGD. Invest. Ophthalmol. Vis. Sci. 52(4):1994-2005 (2011).;;PCT/IB2020/000288 International Search Report and Written Opinion dated Sep. 10, 2020.;;PCT/IB2020/000288 Invitation to Pay Additional Fees dated Jul. 16, 2020.",ACTIVE
615,WO,A2,WO 2004/109497 A2,010-204-797-029-473,2004-12-16,2004,US 2004/0017384 W,2004-06-01,US 45305403 A,2003-06-02,REMOTE CONTROL FOR ELECTRONIC WHITEBOARD,A remote controllable electronic whiteboard system (100) and method of operating the remote controllable electronic whiteboard system (100) are provided. An exemplary remote controllable electronic whiteboard system (100) includes an electronic whiteboard (105) in communication with a remote control device (130). Methods of operating the electronic whiteboard system (100) including the use of a remote control device (130) are also provided.,POLYVISION CORP;;HILDEBRANDT PETER W;;WATSON JAMES D;;HOFMANN NEAL A;;ASSARAF A JOEL;;DUNN MICHAEL H;;HUTCHINSON IAN G;;DRAUDT GREGG;;MILLEN SAM,HILDEBRANDT PETER W;;WATSON JAMES D;;HOFMANN NEAL A;;ASSARAF A JOEL;;DUNN MICHAEL H;;HUTCHINSON IAN G;;DRAUDT GREGG;;MILLEN SAM,,https://lens.org/010-204-797-029-473,Patent Application,yes,0,1,7,7,0,G06F3/038;;G06F3/038;;G06F3/041;;G06F3/0488;;G06F3/0488;;G08C17/02;;G08C17/02;;G08C23/04;;G08C23/04,G06F3/038;;G06F3/041;;G08C17/02;;G08C23/04;;G09G5/00,,0,0,,,,PENDING
616,EP,A2,EP 1634158 A2,114-290-831-862-915,2006-03-15,2006,EP 04754075 A,2004-06-01,US 2004/0017384 W;;US 45305403 A,2003-06-02,REMOTE CONTROL FOR ELECTRONIC WHITEBOARD,,POLYVISION CORP,HILDEBRANDT PETER W;;WATSON JAMES D;;HOFMANN NEAL A;;ASSARAF A JOEL;;DUNN MICHAEL H;;HUTCHINSON IAN G;;DRAUDT GREGG;;MILLEN SAM,,https://lens.org/114-290-831-862-915,Patent Application,yes,0,0,7,7,0,G06F3/038;;G06F3/0488;;G08C17/02;;G08C23/04;;G06F3/038;;G08C17/02;;G08C23/04;;G06F3/041;;G06F3/0488,G06F3/038;;G06F3/041;;G08C17/02;;G08C23/04;;G09G5/00,,0,0,,,,DISCONTINUED
617,US,S,US D0987808 S,058-636-726-339-803,2023-05-30,2023,US 201929700678 F,2019-08-05,US 201929700678 F;;US 201729631231 F;;US 201729609731 F;;US 201629577378 F;;US 201529538127 F;;US 201329451049 F,2013-03-27,Shroud module for a patient interface,,RESMED PTY LTD,SKIPPER CHRISTOPHER SCOTT;;GRAY STEPHEN;;HUNG ANDREW;;BURNHAM ROBERT THOMAS;;AMARASINGHE AMAL SHIRLEY;;MATTHEWS IAN JAMES;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA,RESMED PTY LTD (2013-04-04),https://lens.org/058-636-726-339-803,Design Right,no,83,0,24,24,0,,,2902;;D24/110.1;;D24/110.3,1,0,,,"Gray et al., U.S. Appl. No. 29/631,231, filed Dec. 28, 2017 for “Elbow Module Fora Patient Interface,” (parent application).",ACTIVE
618,WO,A3,WO 2004/109497 A3,072-160-533-821-421,2005-03-17,2005,US 2004/0017384 W,2004-06-01,US 45305403 A,2003-06-02,REMOTE CONTROL FOR ELECTRONIC WHITEBOARD,A remote controllable electronic whiteboard system (100) and method of operating the remote controllable electronic whiteboard system (100) are provided. An exemplary remote controllable electronic whiteboard system (100) includes an electronic whiteboard (105) in communication with a remote control device (130). Methods of operating the electronic whiteboard system (100) including the use of a remote control device (130) are also provided.,POLYVISION CORP;;HILDEBRANDT PETER W;;WATSON JAMES D;;HOFMANN NEAL A;;ASSARAF A JOEL;;DUNN MICHAEL H;;HUTCHINSON IAN G;;DRAUDT GREGG;;MILLEN SAM,HILDEBRANDT PETER W;;WATSON JAMES D;;HOFMANN NEAL A;;ASSARAF A JOEL;;DUNN MICHAEL H;;HUTCHINSON IAN G;;DRAUDT GREGG;;MILLEN SAM,,https://lens.org/072-160-533-821-421,Search Report,yes,6,0,7,7,0,G06F3/038;;G06F3/038;;G06F3/041;;G06F3/0488;;G06F3/0488;;G08C17/02;;G08C17/02;;G08C23/04;;G08C23/04,G06F3/038;;G06F3/041;;G08C17/02;;G08C23/04;;G09G5/00,,0,0,,,,PENDING
619,CN,A,CN 116635032 A,088-821-288-803-25X,2023-08-22,2023,CN 202180086872 A,2021-10-20,US 202063094808 P;;IB 2021000708 W,2020-10-21,Compounds and methods for treating ocular conditions,"Described herein are compositions and methods for treating or preventing ocular surface conditions, including meibomian gland dysfunction, blepharitis, dry eye disease, and other inflammatory and/or infectious diseases of the anterior surface of the eye. The compositions and methods include keratinolytic conjugates that exhibit keratinolytic activity and anti-inflammatory activity or other desired activity. Topical application of the composition to the edge or surrounding area of the eyelid provides a therapeutic benefit for patients with ocular surface conditions.",AZURA OPHTHALMOLOGY LTD,BOSWORTH CHARLES;;STEWART MARK RICHARD;;BARASH SHEILA;;CHAPMAN NICHOLAS ANDREW;;BURKE ROBERT M;;HOLMES IAN;;GLEESON MARK;;ALSTER YAIR;;LAFARI OMER;;DUNN JONATHAN,,https://lens.org/088-821-288-803-25X,Patent Application,no,0,0,10,10,0,A61P27/02;;C07D405/06;;A61K9/08;;A61K9/0048;;C07D409/14;;C07D417/14;;A61P17/00;;A61P27/02;;C07D405/06;;A61P17/00;;C07D409/14;;C07D417/14;;A61K9/0048;;A61K9/08;;C07D405/06;;A61K31/4725;;A61K9/0048;;A61P17/00;;A61P27/02;;C07D409/14;;C07D417/14;;A61P27/02;;A61K9/0048;;A61K9/08;;C07D405/06;;C07D405/14;;C07D409/14;;C07D417/14,A61K31/4725,,0,0,,,,PENDING
620,CA,A1,CA 3196146 A1,014-889-201-685-120,2022-04-28,2022,CA 3196146 A,2021-10-20,US 202063094808 P;;IB 2021000708 W,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,BOSWORTH CHARLES;;STEWART MARK RICHARD;;BARASH HILA;;CHAPMAN NICHOLAS ANDREW;;BURK ROBERT M;;HOLMES IAN;;GLEESON MARC;;ALSTER YAIR;;RAFAELI OMER;;DUNN JONATHAN,,https://lens.org/014-889-201-685-120,Patent Application,no,0,0,10,10,0,A61P27/02;;C07D405/06;;A61K9/08;;A61K9/0048;;C07D409/14;;C07D417/14;;A61P17/00;;A61P27/02;;C07D405/06;;A61P17/00;;C07D409/14;;C07D417/14;;A61K9/0048;;A61K9/08;;C07D405/06;;A61K31/4725;;A61K9/0048;;A61P17/00;;A61P27/02;;C07D409/14;;C07D417/14;;A61P27/02;;A61K9/0048;;A61K9/08;;C07D405/06;;C07D405/14;;C07D409/14;;C07D417/14,A61K31/4725;;A61P27/02;;C07D217/02;;C07D217/04;;C07D405/06,,0,0,,,,PENDING
621,US,A1,US 2023/0399317 A1,062-366-832-001-440,2023-12-14,2023,US 202118033055 A,2021-10-20,US 202118033055 A;;US 202063094808 P;;IB 2021000708 W,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,BOSWORTH CHARLES;;STEWART MARK RICHARD;;BARASH HILA;;CHAPMAN NICHOLAS ANDREW;;BURK ROBERT M;;HOLMES IAN;;GLEESON MARC;;ALSTER YAIR;;RAFAELI OMER;;DUNN JONATHAN,DOMAINEX LTD (2023-06-28);;AZURA OPHTHALMICS LTD (2023-06-02);;BCP3 PTY LIMITED (2023-07-11),https://lens.org/062-366-832-001-440,Patent Application,yes,0,0,10,10,0,A61P27/02;;C07D405/06;;A61K9/08;;A61K9/0048;;C07D409/14;;C07D417/14;;A61P17/00;;A61P27/02;;C07D405/06;;A61P17/00;;C07D409/14;;C07D417/14;;A61K9/0048;;A61K9/08;;C07D405/06;;A61K31/4725;;A61K9/0048;;A61P17/00;;A61P27/02;;C07D409/14;;C07D417/14;;A61P27/02;;A61K9/0048;;A61K9/08;;C07D405/06;;C07D405/14;;C07D409/14;;C07D417/14,C07D405/06;;A61K9/00;;A61K9/08;;A61P27/02;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,PENDING
622,EP,A1,EP 4232034 A1,114-990-585-620-618,2023-08-30,2023,EP 21882227 A,2021-10-20,US 202063094808 P;;IB 2021000708 W,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,,AZURA OPHTHALMICS LTD,BOSWORTH CHARLES;;STEWART MARK RICHARD;;BARASH HILA;;CHAPMAN NICHOLAS ANDREW;;BURK ROBERT M;;HOLMES IAN;;GLEESON MARC;;ALSTER YAIR;;RAFAELI OMER;;DUNN JONATHAN,,https://lens.org/114-990-585-620-618,Patent Application,yes,0,0,10,10,0,A61P27/02;;C07D405/06;;A61K9/08;;A61K9/0048;;C07D409/14;;C07D417/14;;A61P17/00;;A61P27/02;;C07D405/06;;A61P17/00;;C07D409/14;;C07D417/14;;A61K9/0048;;A61K9/08;;C07D405/06;;A61K31/4725;;A61K9/0048;;A61P17/00;;A61P27/02;;C07D409/14;;C07D417/14;;A61P27/02;;A61K9/0048;;A61K9/08;;C07D405/06;;C07D405/14;;C07D409/14;;C07D417/14,A61K31/472;;A61K31/4725;;A61P27/02;;C07D217/02;;C07D217/04;;C07D405/06,,0,0,,,,PENDING
623,US,A1,US 2022/0332748 A1,162-701-603-089-371,2022-10-20,2022,US 202117222802 A,2021-04-05,US 202117222802 A,2021-04-05,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT M;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;NICHOLLS ALEXANDER JAMES,,https://lens.org/162-701-603-089-371,Patent Application,yes,1,0,3,3,0,C07H17/08;;A61P27/00;;A61K9/08;;A61K9/0048;;A61K9/0048;;C07H17/08,C07H17/08;;A61K9/00,,0,0,,,,ACTIVE
624,KR,A,KR 20230110516 A,153-896-566-070-116,2023-07-24,2023,KR 20237016473 A,2021-10-20,US 202063094808 P;;IB 2021000708 W,2020-10-21,눈 장애의 치료를 위한 화합물 및 방법,"본원에서 마이봄샘 기능 장애, 안검염, 안구 건조증 및 눈(들)의 전방 표면의 기타 염증성 및/또는 감염성 질환을 포함한 눈 표면 장애의 치료 또는 예방을 위한 조성물 및 방법이 기재된다. 상기 조성물 및 방법은 각질용해 활성, 및 항염증 또는 기타 바람직한 활성을 나타내는 각질용해 접합체를 포함한다. 상기 조성물을 눈꺼풀 가장자리 또는 주변 영역에 국소 투여하여 눈 표면 장애를 앓고 있는 환자에게 치료적 이점을 제공한다.",AZURA OPHTHALMICS LTD,BOSWORTH CHARLES;;STEWART MARK RICHARD;;BARASH HILA;;CHAPMAN NICHOLAS ANDREW;;BURK ROBERT M;;HOLMES IAN;;GLEESON MARC;;ALSTER YAIR;;RAFAELI OMER;;DUNN JONATHAN,,https://lens.org/153-896-566-070-116,Patent Application,no,0,0,10,10,0,A61P27/02;;C07D405/06;;A61K9/08;;A61K9/0048;;C07D409/14;;C07D417/14;;A61P17/00;;A61P27/02;;C07D405/06;;A61P17/00;;C07D409/14;;C07D417/14;;A61K9/0048;;A61K9/08;;C07D405/06;;A61K31/4725;;A61K9/0048;;A61P17/00;;A61P27/02;;C07D409/14;;C07D417/14;;A61P27/02;;A61K9/0048;;A61K9/08;;C07D405/06;;C07D405/14;;C07D409/14;;C07D417/14,C07D405/06;;A61K9/00;;A61K31/4725;;A61P17/00;;A61P27/02;;C07D409/14;;C07D417/14,,0,0,,,,PENDING
625,KR,A,KR 20230110515 A,157-477-290-722-070,2023-07-24,2023,KR 20237016470 A,2021-10-20,US 202063094793 P;;US 202163170988 P;;IB 2021000707 W,2020-10-21,눈 장애의 치료를 위한 화합물 및 방법,"본원에서 마이봄샘 기능 장애, 안검염, 안구 건조증 및 눈(들)의 전방 표면의 기타 염증성 및/또는 감염성 질환을 포함한 눈 표면 장애의 치료 또는 예방을 위한 조성물 및 방법이 기재된다. 상기 조성물 및 방법은 각질용해 활성, 및 항염증 또는 기타 바람직한 활성을 나타내는 각질용해 접합체를 포함한다. 상기 조성물을 눈꺼풀 가장자리 또는 주변 영역에 국소 투여하여 눈 표면 장애를 앓고 있는 환자에게 치료적 이점을 제공한다.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT M;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;NICHOLLS ALEXANDER JAMES,,https://lens.org/157-477-290-722-070,Patent Application,no,0,0,9,10,0,A61P17/00;;A61P27/02;;C07H17/00;;A61P27/02;;A61P17/00;;C07H17/00;;C07H17/00;;A61K31/7042;;A61K9/0048;;A61P17/00;;A61P27/02,A61K9/00;;C07H17/00;;A61K31/7042;;A61P17/00;;A61P27/02,,0,0,,,,PENDING
626,EP,A2,EP 4232149 A2,052-756-609-806-757,2023-08-30,2023,EP 21882226 A,2021-10-20,US 202063094793 P;;US 202163170988 P;;IB 2021000707 W,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,,AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT M;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;NICHOLLS ALEXANDER JAMES,,https://lens.org/052-756-609-806-757,Patent Application,yes,0,0,9,10,0,A61P17/00;;A61P27/02;;C07H17/00;;A61P27/02;;A61P17/00;;C07H17/00;;C07H17/00;;A61K31/7042;;A61K9/0048;;A61P17/00;;A61P27/02,A61P17/00;;A61P27/02;;C07D413/14,,0,0,,,,PENDING
627,CA,A1,CA 3196145 A1,004-431-603-290-730,2022-04-28,2022,CA 3196145 A,2021-10-20,US 202063094793 P;;US 202163170988 P;;IB 2021000707 W,2020-10-21,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT M;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;NICHOLLS ALEXANDER JAMES,,https://lens.org/004-431-603-290-730,Patent Application,no,0,0,9,10,0,A61P17/00;;A61P27/02;;C07H17/00;;A61P27/02;;A61P17/00;;C07H17/00;;C07H17/00;;A61K31/7042;;A61K9/0048;;A61P17/00;;A61P27/02,A61P27/02;;C07D413/14,,0,0,,,,PENDING
628,CN,A,CN 116940570 A,011-590-720-554-119,2023-10-24,2023,CN 202180086926 A,2021-10-20,US 202163170988 P;;IB 2021000707 W,2021-04-05,Compounds and methods for treating ocular conditions,"Described herein are compositions and methods for treating or preventing ocular surface conditions, including meibomian gland dysfunction, blepharitis, dry eye disease, and other inflammatory and/or infectious diseases of the anterior surface of the eye. The compositions and methods include keratinolytic conjugates that exhibit keratinolytic activity and anti-inflammatory activity or other desired activity. Topical application of the composition to the edge or surrounding area of the eyelid provides a therapeutic benefit for patients with ocular surface conditions.",AZURA OPHTHALMOLOGY LTD,HOLMES IAN;;ALSTER YAIR;;BARASH SHEILA;;BOSWORTH CHARLES;;LAFARI OMER;;BURKE ROBERT M;;GLEESON MARK;;STEWART MARK RICHARD;;DUNN JONATHAN;;NICHOLS ALEXANDER JAMES,,https://lens.org/011-590-720-554-119,Patent Application,no,0,0,1,10,0,,C07D413/14;;A61K31/7042;;A61P17/00;;A61P27/02;;C07H17/00,,0,0,,,,PENDING
629,US,B1,US 11459351 B1,178-838-529-829-981,2022-10-04,2022,US 202117222802 A,2021-04-05,US 202117222802 A,2021-04-05,Compounds and methods for the treatment of ocular disorders,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT M;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;NICHOLLS ALEXANDER JAMES,DOMAINEX LTD (2021-06-01);;AZURA OPHTHALMICS LTD (2021-05-26);;BCP3 PTY LIMITED (2021-06-15),https://lens.org/178-838-529-829-981,Granted Patent,yes,32,1,3,3,0,C07H17/08;;A61P27/00;;A61K9/08;;A61K9/0048;;A61K9/0048;;C07H17/08,C07H17/08;;A61K9/00,,23,18,020-870-855-859-609;;090-991-982-963-361;;007-364-858-655-289;;121-114-378-458-21X;;027-488-422-889-594;;006-519-925-085-122;;073-352-788-052-508;;015-154-901-178-524;;016-192-796-868-999;;094-813-021-617-631;;001-718-978-242-312;;003-334-491-119-371;;030-234-441-646-238;;066-371-099-307-130;;032-610-338-117-484;;074-730-080-706-256;;030-237-906-192-920;;007-877-542-945-654,10.1167/iovs.03-1055;;15161821;;10.1167/iovs.04-1326;;16043849;;10.1002/jps.2600660104;;833720;;11867577;;10.1007/bf02518337;;10.1016/s0040-4020(01)89131-6;;pmc3072159;;10.1167/iovs.10-6997c;;21450915;;10.1167/iovs.15-17249;;26348638;;pmc4566400;;10.1007/978-0-387-49785-3_20;;pmc3072157;;10.1167/iovs.10-6997;;21450913;;10.1167/iovs.10-6997a;;10.4049/jimmunol.176.7.3950;;16547229;;15364229;;10.1016/j.ajo.2004.04.052;;10.1016/s1542-0124(12)70085-x;;17508120;;18219308;;10.1038/nrd2468;;16918513;;10.1111/j.1398-9995.2006.01146.x;;10.1167/iovs.10-6997e;;pmc3072161;;21450917;;26058030;;10.1097/icu.0000000000000165;;10.1097/ico.0b013e318239aaea;;22222996,"Barabino et al. Animal Models of Dry Eye: A Critical Assessment of Opportunities and Limitations. Invest. Ophthalmol. Vis. Sci. 45:1641-1646 (2004).;;Barabino et al. The Controlled-Environment Chamber: A New Mouse Model of Dry Eye. Invest. Ophthalmol. Vis. Sci. 46:2766-2771 (2005).;;Berge et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (Jan. 1977).;;Co-pending U.S. Appl. No. 17/112,371, inventors Holmes; Ian et al., filed Dec. 4, 2020.;;Dursun et al. A Mouse Model of Keratoconjunctivitis Sicca. Invest. Ophthalmol. Vis. Sci. 43:632-638 (2002).;;Evans. Synthesis of radiolabeled compounds. J Radioanal Chem 64(1-2):9-32 (1981).;;Kabalka et al. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates. Tetrahedron 45(21):6601-6621 (1989).;;Knop et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. IOVS 52(4):1938-1978 (2011).;;Krauss et al. Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model. Invest. Ophthalmol. Vis. Sci. 56(10):5888-5895 (2015).;;Maag. Prodrugs of carboxylic acids. Prodrugs. Springer, New York, NY (pp. 703-729) (2007).;;Nichols et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest. Ophthalmol. Vis. Sci. 52(4):1922-1929 (2011).;;Niederkorn et al. Desiccating Stress Induces T Cell-Mediated Sjögren's Syndrome-like Lacrimal Keratoconjunctivitis. J. Immunol. 176:3950-3957 (2006).;;PCT/IB2020/000288 International Search Report and Written Opinion dated Sep. 10, 2020.;;PCT/IB2020/000288 Invitation to Pay Additional Fees dated Jul. 16, 2020.;;Pflugfelder et al. A Randomized, Double-Masked, Placebo-Controlled, Multicenter Comparison of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, and Placebo for Treatment of Keratoconjunctivitis Sicca in Patients With Delayed Tear Clearance. Am J Ophthalmol 138:444-57 (2004).;;Pflugfelder et al. International Dry Eye Workshop, 2007. Management and Therapy of Dry Eye Disease: Report of the Management and Therapy Subcommittee of the International Dry Eye Workshop. Ocul Surf 5:163-178 (2007).;;Rautio et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 7(3):255-270 (2008).;;Ravensberg et al. The Effect of a Single Inhaled Dose of a VLA-4 Antagonist on Allergen-Induced Airway Responses and Airway Inflammation in Patients With Asthma. Allergy 61:1097-1103 (2006).;;Schaumberg et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on the Epidemiology of, and Associated Risk Factors for, MGD. Invest. Ophthalmol. Vis. Sci. 52(4):1994-2005 (2011).;;Blackie et al. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation. Curr Opin Ophthalmol 26(4):306-13 (2015).;;Lane et al. A New System, the LipiFlow, for the Treatment of Meibomian Gland Dysfunction. Cornea 31(4):396-404 (2012).;;PCT/IB2021/000707 International Search Report and Written Opinion dated May 16, 2022.;;Pub Chem SID 244881306 (Mar. 17, 2015).",ACTIVE
630,CN,A,CN 111670073 A,126-173-809-477-730,2020-09-15,2020,CN 201980010891 A,2019-02-01,US 201862625572 P;;CA 2019050130 W,2018-02-02,"Automated laboratory system and related systems, methods, and devices","An automated laboratory system (10) includes a vertical shelving system (12) including a frame (16) and at least one shelf (20) movably mounted to the frame (16) such that the at least one shelf (20)is movable relative to the frame (16) between a docked position and an undocked position, the at least one shelf (20) being configured to carry at least one instrument (300, 302, 304, 306, 308, 310, 312). The system (10) also includes a robotic device (14) proximate the vertical shelving system (12) and being configured to access the at least one instrument (300, 302, 304, 306, 308, 310, 312) carried by the at least one shelf (20).",THERMO CRS LTD,WITTCHEN JONATHAN;;DARNEL GARY;;RIFF MICHAEL PAUL;;JOHNSON STEPHEN WAYNE;;MULYK DEAN S;;GARNER MARK MICHAEL;;DUNN-DUFAULT ROBERT;;YATES IAN;;HAAS HANSJOERG WERNER,,https://lens.org/126-173-809-477-730,Patent Application,no,6,0,7,7,0,G01N35/04;;G01N2035/0425;;G01N2035/0465;;B01L9/02;;G01N35/00712;;B01L2200/028;;B01L2200/021;;B01L2200/087;;G01N2035/0465;;G01N2035/0425;;G01N35/04;;B25J9/1694;;B65G1/127;;B65G2201/02;;G01N35/0099,B01L9/00;;A47B46/00;;A47B81/00,,0,0,,,,ACTIVE
631,US,B2,US 11136190 B2,198-340-651-382-658,2021-10-05,2021,US 201916265225 A,2019-02-01,US 201916265225 A;;US 201862625572 P,2018-02-02,"Automated laboratory system and related systems, methods, and devices","An automated laboratory system includes a vertical shelving system including a frame and at least one shelf movably mounted to the frame such that the at least one shelf is movable relative to the frame between a docked position and an undocked position, the at least one shelf being configured to carry at least one instrument. The system also includes a robotic device proximate the vertical shelving system and being configured to access the at least one instrument carried by the at least one shelf.",THERMO CRS LTD,WITTCHEN JONATHAN;;DARNEL GARY;;RIFF MICHAEL PAUL;;JOHNSON STEPHEN WAYNE;;MULYK DEAN S;;GARNER MARK MICHAEL;;DUNN-DUFAULT ROBERT;;YATES IAN;;HAAS HANSJOERG WERNER,THERMO CRS LTD (2019-02-19),https://lens.org/198-340-651-382-658,Granted Patent,yes,20,0,7,7,0,G01N35/04;;G01N2035/0425;;G01N2035/0465;;B01L9/02;;G01N35/00712;;B01L2200/028;;B01L2200/021;;B01L2200/087;;G01N2035/0465;;G01N2035/0425;;G01N35/04;;B25J9/1694;;B65G1/127;;B65G2201/02;;G01N35/0099,B65G1/127;;B25J9/16;;G01N35/00;;G01N35/04,,3,0,,,"The International Bureau of WIPO, International Preliminary Report On Patentability, International Application No. PCT/CA2019/050130, dated Aug. 13, 2020 (8 pages).;;International Search Authority, Canadian Intellectual Property Office, International Search Report and Written Opinion issued in corresponding PCT Application No. PCT/CA2019/050130, dated Apr. 17, 2019 (11 pages).;;Highres Biosolutions, CoLAB Flex Mobile, Modular Lab Automation, www.highresbio.com, 2018.",ACTIVE
632,WO,A3,WO 2023/067387 A3,006-665-250-713-252,2023-06-29,2023,IB 2022000609 W,2022-10-19,US 202163257855 P,2021-10-20,COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders. Ocular surface disorders include ocular allergy, dry eye disease, ocular manifestation of graft versus host disease and other inflammatory and/or infectious diseases of the (e.g., anterior) surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate immunological, keratolytic, anti-inflammatory, and/or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT;;GLEESON MARC;;STEWART MARK;;DUNN JONATHAN;;KATSINA SOULTANA;;PILEGGI ELISA;;NICHOLLS ALEXANDER,,https://lens.org/006-665-250-713-252,Search Report,yes,2,0,2,2,0,C07D487/04;;C07D339/04;;A61P27/02;;C07J33/002;;C07J41/0094;;C07J3/005;;C07J41/0038;;C07J43/003,C07C255/46;;A61P17/00;;A61P27/02,,1,0,,,"DATABASE PUBCHEM SUBSTANCE ANONYMOUS : ""SCHEMBL20742838"", XP093077659, retrieved from PUBCHEM",PENDING
633,US,A1,US 2022/0332749 A1,174-114-054-689-225,2022-10-20,2022,US 202217841383 A,2022-06-15,US 202217841383 A;;US 202117222802 A,2021-04-05,COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;EPSTEIN-BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT M;;GLEESON MARC;;STEWART MARK RICHARD;;DUNN JONATHAN;;NICHOLLS ALEXANDER JAMES,DOMAINEX LTD (2021-06-01);;AZURA OPHTHALMICS LTD (2021-05-26);;BCP3 PTY LIMITED (2021-06-15),https://lens.org/174-114-054-689-225,Patent Application,yes,0,1,3,3,0,C07H17/08;;A61P27/00;;A61K9/08;;A61K9/0048;;A61K9/0048;;C07H17/08,C07H17/08;;A61K9/00,,0,0,,,,PENDING
634,EP,A1,EP 3746226 A1,162-842-098-332-471,2020-12-09,2020,EP 19747409 A,2019-02-01,US 201862625572 P;;CA 2019050130 W,2018-02-02,"AUTOMATED LABORATORY SYSTEM AND RELATED SYSTEMS, METHODS, AND DEVICES",,THERMO CRS LTD,WITTCHEN JONATHAN;;DARNEL GARY;;RIFF MICHAEL PAUL;;JOHNSON STEPHEN WAYNE;;MULYK DEAN S;;GARNER MARK MICHAEL;;DUNN-DUFAULT ROBERT;;YATES IAN;;HAAS HANSJOERG WERNER,,https://lens.org/162-842-098-332-471,Patent Application,yes,0,0,7,7,0,G01N35/04;;G01N2035/0425;;G01N2035/0465;;B01L9/02;;G01N35/00712;;B01L2200/028;;B01L2200/021;;B01L2200/087;;G01N2035/0465;;G01N2035/0425;;G01N35/04;;B25J9/1694;;B65G1/127;;B65G2201/02;;G01N35/0099,B01L9/00;;A47B46/00;;A47B81/00,,0,0,,,,PENDING
635,WO,A1,WO 2019/148288 A1,033-941-630-659-590,2019-08-08,2019,CA 2019050130 W,2019-02-01,US 201862625572 P,2018-02-02,"AUTOMATED LABORATORY SYSTEM AND RELATED SYSTEMS, METHODS, AND DEVICES","An automated laboratory system (10) includes a vertical shelving system (12) including a frame (16) and at least one shelf (20) movably mounted to the frame (16) such that the at least one shelf (20) is movable relative to the frame (16) between a docked position and an undocked position, the at least one shelf (20) being configured to carry at least one instrument (300, 302, 304, 306, 308, 310, 312). The system (10) also includes a robotic device (14) proximate the vertical shelving system (12) and being configured to access the at least one instrument (300, 302, 304, 306, 308, 310, 312) carried by the at least one shelf (20).",THERMO CRS LTD,WITTCHEN JONATHAN;;DARNEL GARY;;RIFF MICHAEL PAUL;;JOHNSON STEPHEN WAYNE;;MULYK DEAN S;;GARNER MARK MICHAEL;;DUNN-DUFAULT ROBERT;;YATES IAN;;HAAS HANSJOERG WERNER,,https://lens.org/033-941-630-659-590,Patent Application,yes,2,0,7,7,0,G01N35/04;;G01N2035/0425;;G01N2035/0465;;B01L9/02;;G01N35/00712;;B01L2200/028;;B01L2200/021;;B01L2200/087;;G01N2035/0465;;G01N2035/0425;;G01N35/04;;B25J9/1694;;B65G1/127;;B65G2201/02;;G01N35/0099,B01L9/00;;A47B46/00;;A47B81/00,,1,0,,,See also references of EP 3746226A4,PENDING
636,WO,A2,WO 2023/067387 A2,093-867-098-672-468,2023-04-27,2023,IB 2022000609 W,2022-10-19,US 202163257855 P,2021-10-20,COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS,"Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders. Ocular surface disorders include ocular allergy, dry eye disease, ocular manifestation of graft versus host disease and other inflammatory and/or infectious diseases of the (e.g., anterior) surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate immunological, keratolytic, anti-inflammatory, and/or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.",AZURA OPHTHALMICS LTD,HOLMES IAN;;ALSTER YAIR;;BARASH HILA;;BOSWORTH CHARLES;;RAFAELI OMER;;BURK ROBERT;;GLEESON MARC;;STEWART MARK;;DUNN JONATHAN;;KATSINA SOULTANA;;PILEGGI ELISA;;NICHOLLS ALEXANDER,,https://lens.org/093-867-098-672-468,Patent Application,yes,0,0,2,2,0,C07D487/04;;C07D339/04;;A61P27/02;;C07J33/002;;C07J41/0094;;C07J3/005;;C07J41/0038;;C07J43/003,C07D487/04;;A61K31/519,,0,0,,,,PENDING
637,US,A1,US 2009/0227798 A1,032-861-091-100-619,2009-09-10,2009,US 40376809 A,2009-03-13,US 40376809 A;;US 11438105 A;;US 83884304 A;;US 75764104 A;;US 4349802 A;;US 67000500 A;;US 26647199 A;;US 26629899 P;;US 15519798 P,1998-03-13,"NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by the following scheme:",SANOFI AVENTIS DEUTSCHLAND;;AVENTIS PHARMA INC,LAUX WOLFGANG;;GUILLAMOT GERARD;;LASKOVICS FREDERICK M;;KING CHI-HSIN R;;HITT JAMES E;;STOLZ-DUNN SANDRA K;;TOMLINSON IAN A;;KOEK JOHANNES NICOLAAS,AVENTIS HOLDINGS INC (2001-12-28);;SYNCOM B.V (2005-06-13);;THE DOW CHEMICAL COMPANY (2005-06-10);;AVENTIS PHARMACEUTICALS INC (2005-06-02);;SANOFI-AVENTIS DEUTSCHLAND GMBH (2005-07-25);;HMR PHARMA INC (2001-12-28),https://lens.org/032-861-091-100-619,Patent Application,yes,26,0,2,8,0,C07D211/22;;C07D211/32;;C07D211/22;;C07D211/32,A61K31/445;;C07D211/32;;C07D211/20;;C07D211/22,546/226;;546/241,0,0,,,,DISCONTINUED
638,EP,A4,EP 3746226 A4,065-467-090-888-004,2021-11-10,2021,EP 19747409 A,2019-02-01,US 201862625572 P;;CA 2019050130 W,2018-02-02,"AUTOMATED LABORATORY SYSTEM AND RELATED SYSTEMS, METHODS, AND DEVICES",,THERMO CRS LTD,WITTCHEN JONATHAN;;DARNEL GARY;;RIFF MICHAEL PAUL;;JOHNSON STEPHEN WAYNE;;MULYK DEAN S;;GARNER MARK MICHAEL;;DUNN-DUFAULT ROBERT;;YATES IAN;;HAAS HANSJOERG WERNER,,https://lens.org/065-467-090-888-004,Search Report,no,3,0,7,7,0,G01N35/04;;G01N2035/0425;;G01N2035/0465;;B01L9/02;;G01N35/00712;;B01L2200/028;;B01L2200/021;;B01L2200/087;;G01N2035/0465;;G01N2035/0425;;G01N35/04;;B25J9/1694;;B65G1/127;;B65G2201/02;;G01N35/0099,B01L9/02;;G01N35/00;;G01N35/04,,1,0,,,See also references of WO 2019148288A1,PENDING
639,US,A1,US 2005/0261341 A1,192-119-352-973-692,2005-11-24,2005,US 11438105 A,2005-04-26,US 11438105 A;;US 83884304 A;;US 75764104 A;;US 4349802 A;;US 67000500 A;;US 26647199 A;;US 26629899 P;;US 15519798 P,1998-03-13,"Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol","The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by the following scheme:",AVENTIS PHARMA GMBH,LAUX WOLFGANG;;GUILLAMOT GERARD;;LASKOVICS FREDERICK M;;KING CHI-HSIN R;;HITT JAMES E;;STOLZ-DUNN SANDRA K;;TOMLINSON IAN A;;KOEK JOHANNES N,SYNCOM B.V (2006-06-13);;THE DOW CHEMICAL COMPANY (2005-06-10);;AVENTIS PHARMACEUTICALS INC (2005-06-02);;SANOFI-AVENTIS DEUTSCHLAND GMBH (2005-07-25),https://lens.org/192-119-352-973-692,Patent Application,yes,0,6,2,8,0,C07D211/22;;C07D211/32;;C07D211/22;;C07D211/32,A61K31/445;;C07D211/20;;C07D211/22,514/317;;546/236,0,0,,,,DISCONTINUED
640,US,A1,US 2019/0241363 A1,021-255-846-680-270,2019-08-08,2019,US 201916265225 A,2019-02-01,US 201916265225 A;;US 201862625572 P,2018-02-02,"AUTOMATED LABORATORY SYSTEM AND RELATED SYSTEMS, METHODS, AND DEVICES","An automated laboratory system includes a vertical shelving system including a frame and at least one shelf movably mounted to the frame such that the at least one shelf is movable relative to the frame between a docked position and an undocked position, the at least one shelf being configured to carry at least one instrument. The system also includes a robotic device proximate the vertical shelving system and being configured to access the at least one instrument carried by the at least one shelf.",THERMO CRS LTD,WITTCHEN JONATHAN;;DARNEL GARY;;RIFF MICHAEL PAUL;;JOHNSON STEPHEN WAYNE;;MULYK DEAN S;;GARNER MARK MICHAEL;;DUNN-DUFAULT ROBERT;;YATES IAN;;HAAS HANSJOERG WERNER,THERMO CRS LTD (2019-02-19),https://lens.org/021-255-846-680-270,Patent Application,yes,0,0,7,7,0,G01N35/04;;G01N2035/0425;;G01N2035/0465;;B01L9/02;;G01N35/00712;;B01L2200/028;;B01L2200/021;;B01L2200/087;;G01N2035/0465;;G01N2035/0425;;G01N35/04;;B25J9/1694;;B65G1/127;;B65G2201/02;;G01N35/0099,B65G1/127;;B25J9/16,,0,0,,,,ACTIVE
641,WO,A3,WO 2006/001985 A3,003-278-079-182-201,2006-06-22,2006,US 2005/0019780 W,2005-06-06,US 57709504 P,2004-06-04,INTERACTIVE COMMUNICATION SYSTEMS,"The present invention includes interactive communication systems that incorporate several beneficial embodiments including an interactive tray system, an electronic presentation messaging system, an interactive podium, and a key drive system. The interactive tray system enables a single, transferable interactive unit to be fastened to a communication medium, turning into a fully interactive medium. The electronic presentation messaging system enables the e-mailing of presentations and notes to and from components of the interactive communication system. The interactive podium increases conventional podium mobility, enabling both the presenter, and podium, to move and be moved about the room without attention to wired connections. The key drive system replaces the conventional Y-connector of the key drive technology by effectively integrating the key drive in the device, thus only having one connector, and eliminating the need to change connectors from the key drive, to the USB connector, upon software driver loading.",POLYVISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,,https://lens.org/003-278-079-182-201,Search Report,yes,10,0,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/033;;G06F3/042;;G09G5/00,,6,0,,,"PATENT ABSTRACTS OF JAPAN vol. 2002, no. 02 2 April 2002 (2002-04-02);;PATENT ABSTRACTS OF JAPAN vol. 2000, no. 21 3 August 2001 (2001-08-03);;PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05);;""Walk-and-Talk presentation series whiteboard"", 1 October 2003, POLYVISION, XP002368937;;J. SISKO, T. STEVENS: ""POLYVISION BREAKS BARRIERS TO INTERATIVE WHITEBOARD ADOPTION WITH NEW PRODUCT LINE"", 22 October 2003, XP002368938;;""POLYVISION BREAKS BARRIERS TO ELECTRONIC WHITEBOARD ADOPTION"", 4 June 2003, POLYVISION, XP002368939",PENDING
642,AU,B2,AU 2005/332017 B2,135-828-246-487-580,2010-06-17,2010,AU 2005/332017 A,2005-06-06,US 57709504 P;;US 2005/0019780 W,2004-06-04,Interactive communication systems,,POLYVISION CORP,HILDEBRANDT PETER W;;ASHFORD LOUIS;;WATSON JAMES D;;HOFMANN NEAL A;;ANDERSON BRENT W;;HUTCHINSON IAN G;;MEISSNER RICHARD;;WILSON SCOTT E;;DUNN MICHAEL H,,https://lens.org/135-828-246-487-580,Granted Patent,no,7,0,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/033;;G06F3/042;;G09G5/00,,0,0,,,,INACTIVE
643,US,A1,US 2010/0275132 A1,040-715-834-453-357,2010-10-28,2010,US 83092410 A,2010-07-06,US 83092410 A;;US 14690105 A;;US 57709504 P,2004-06-04,INTERACTIVE COMMUNICATION SYSTEMS,"The present invention includes interactive communication systems that incorporate several beneficial embodiments including an interactive tray system, an electronic presentation messaging system, an interactive podium, and a key drive system. The interactive tray system enables a single, transferable interactive unit to be fastened to a communication medium, turning into a fully interactive medium. The electronic presentation messaging system enables the e-mailing of presentations and notes to and from components of the interactive communication system. The interactive podium increases conventional podium mobility, enabling both the presenter, and podium, to move and be moved about the room without attention to wired connections. The key drive system replaces the conventional Y-connector of the key drive technology by effectively integrating the key drive in the device, thus only having one connector, and eliminating the need to change connectors from the key drive, to the USB connector, upon software driver loading.",POLYVISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,POLYVISION CORPORATION (2005-08-02);;STEELCASE INC (2014-02-10),https://lens.org/040-715-834-453-357,Patent Application,no,63,6,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/041;;G06F3/01;;G06F3/042;;G06F15/16;;G09G5/00,715/752;;345/173,0,0,,,,INACTIVE
644,US,B1,US 7427983 B1,009-471-944-964-674,2008-09-23,2008,US 44933603 A,2003-05-30,US 44933603 A;;US 38505902 P;;US 38511402 P;;US 38506202 P;;US 38506002 P;;US 38506102 P,2002-06-02,Visual communication system,A visual communication system that is suitable for use in connection with a display surface is disclosed. The system includes a camera or other data-capturing device that can be remotely positioned from the display surface. A control unit receives image data from the camera or data-capturing device and processes the image data to create an electronic image of the display surface.,STEELCASE DEV CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WILSON SCOTT E;;WILLIAMS GUY L;;MINTZ JAKE;;BROWN STEPHEN G;;COTE MARIE;;MICHALSKI JAMES E;;DUNN MICHAEL H,STEELCASE DEVELOPMENT CORPORATION (2003-09-24);;STEELCASE INC (2014-02-10),https://lens.org/009-471-944-964-674,Granted Patent,yes,108,42,3,3,0,H04N1/00127;;H04N1/00127;;H04N1/00347;;H04N1/00347;;H04N1/00493;;H04N1/00493;;H04N1/00496;;H04N1/00496;;H04N2101/00;;H04N2101/00;;H04N2201/0041;;H04N2201/0041;;H04N2201/0044;;H04N2201/0044;;H04N2201/0049;;H04N2201/0049;;H04N2201/0055;;H04N2201/0055;;H04N2201/0063;;H04N2201/0063;;H04N2201/0082;;H04N2201/0082;;H04N2201/0084;;H04N2201/0084;;H04N2201/0087;;H04N2201/0087,G06F3/042,345/175;;345/173;;345/174;;178/18.01;;178/18.03;;178/18.06,1,0,,,"""Hawkeye 480C and Hawkeye CAM,"" Smart Technologies (Oct. 1, 2000).",EXPIRED
645,AU,A1,AU 2005/332017 A1,066-302-847-910-324,2007-01-04,2007,AU 2005/332017 A,2005-06-06,US 57709504 P;;US 2005/0019780 W,2004-06-04,Interactive communication systems,,POLYVISION CORP,HILDEBRANDT PETER W;;ASHFORD LOUIS;;WATSON JAMES D;;HOFMANN NEAL A;;ANDERSON BRENT W;;HUTCHINSON IAN G;;MEISSNER RICHARD;;WILSON SCOTT E;;DUNN MICHAEL H,,https://lens.org/066-302-847-910-324,Patent Application,no,0,0,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/033;;G06F3/042;;G09G5/00,,0,0,,,,INACTIVE
646,EP,A1,EP 2042973 A1,025-869-562-456-818,2009-04-01,2009,EP 08020514 A,2005-06-06,EP 05731611 A;;US 57709504 P,2004-06-04,Interactive communication system,"The present invention includes interactive communication systems (200) that incorporate several beneficial embodiments including an interactive tray system (250), an electronic presentation messaging system, an interactive podium, and a key drive system. The interactive tray system (250) enables a single, transferable interactive unit to be fastened to a communication medium, turning into a fully interactive medium. The electronic presentation messaging system enables the e-mailing of presentations and notes to and from components of the interactive communication system (200). The interactive podium increases conventional podium mobility, enabling both the presenter, and podium, to move and be moved about the room without attention to wired connections. The key drive system replaces the conventional Y-connector of the key drive technology by effectively integrating the key drive in the device, thus only having one connector, and eliminating the need to change connectors from the key drive, to the USB connector, upon software driver loading.
",POLYVISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEIL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,,https://lens.org/025-869-562-456-818,Patent Application,yes,7,0,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/042;;G09G5/00,,3,0,,,"PATENT ABSTRACTS OF JAPAN vol. 2002, no. 02 2 April 2002 (2002-04-02);;PATENT ABSTRACTS OF JAPAN vol. 2000, no. 21 3 August 2001 (2001-08-03);;PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05)",DISCONTINUED
647,US,B2,US 8723815 B2,080-004-270-282-053,2014-05-13,2014,US 83092410 A,2010-07-06,US 83092410 A;;US 14690105 A;;US 57709504 P,2004-06-04,Interactive communication systems,"The present invention includes interactive communication systems that incorporate several beneficial embodiments including an interactive tray system, an electronic presentation messaging system, an interactive podium, and a key drive system. The interactive tray system enables a single, transferable interactive unit to be fastened to a communication medium, turning into a fully interactive medium. The electronic presentation messaging system enables the e-mailing of presentations and notes to and from components of the interactive communication system. The interactive podium increases conventional podium mobility, enabling both the presenter, and podium, to move and be moved about the room without attention to wired connections. The key drive system replaces the conventional Y-connector of the key drive technology by effectively integrating the key drive in the device, thus only having one connector, and eliminating the need to change connectors from the key drive, to the USB connector, upon software driver loading.",HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD;;STEELCASE INC,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,POLYVISION CORPORATION (2005-08-02);;STEELCASE INC (2014-02-10),https://lens.org/080-004-270-282-053,Granted Patent,yes,70,2,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/042;;G06F3/041;;G09G5/00,345/173;;341/171;;715/752,7,0,,,"Invitation to Pay Additional Fees, Annex to form PCT/ISA/206, Communication Relating to the Results of the Partial International Search for related Application No. PCT/US2005/019780 dated Dec. 15, 2005.;;International Search Report and Written Opinion for related PCT Application No. PCT/US2005019780 dated Mar. 24, 2006.;;""Polyvision Breaks Barriers to Electronic Whiteboard Adoption"", Retrieved from the Internet, URL: www.polyvision.com/news/press/060403.asp, pp. 1-2, dated Jun. 4, 2003.;;""Walk-and Talk Presentation Series Whiteboard"" Installation Guide, Retrieved from the Internet, URL: www.polyvision.com/media/support/guides/w-t-install-web.pdf, pp. 1-28, dated Oct. 1, 2003.;;Sisko, J. et al., ""Polyvision Breaks Barriers to Electronic Whiteboard Adoption with New Product Line, Walk-and-Talk Makes Interactive Whiteboards Easy to Use with Remote Control and PolyKey Technology"", Retrieved from the Internet, URL: www.nsba.org/t+12003/press/polyvision.pdf, pp. 1-3, dated Oct. 22, 2003.;;EP Communication for related Application No. EP08020514 dated Nov. 2, 2009.;;Notice of Reasons for Rejection dated Nov. 17, 2010 issued by the Japanese Patent Office for related Japanese Application No. 2007-515672.",INACTIVE
648,EP,A2,EP 1759267 A2,036-084-475-813-708,2007-03-07,2007,EP 05731611 A,2005-06-06,US 2005/0019780 W;;US 57709504 P,2004-06-04,INTERACTIVE COMMUNICATION SYSTEMS,,POLYVISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,,https://lens.org/036-084-475-813-708,Patent Application,yes,0,0,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/033;;G06F3/042;;G09G5/00,,0,0,,,,DISCONTINUED
649,US,A1,US 2009/0146965 A1,078-575-200-593-531,2009-06-11,2009,US 19164808 A,2008-08-14,US 19164808 A;;US 14690105 A;;US 57709504 P,2004-06-04,INTERACTIVE COMMUNICATION SYSTEM HAVING AN INTEGRATED KEY DRIVE SYSTEM,"A device and method of connecting an interactive communication system to a processing device. The device is a cable system that includes first and second ends. The first end of the cable system has a leg connector, while the second end of the connector system has first and second arm connectors. The method implements the cable system to load or run software onto the processing device, and includes connecting the leg connector to an interactive communication system; connecting the first arm connector having a memory device to the processing device, wherein the memory device includes predetermined software; loading/running the software on the processing device; disconnecting the first arm connector having the memory device from the processing device; and connecting a second arm connector to the processing device.",POLYVISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,POLYVISION CORPORATION (2009-01-26);;STEELCASE INC (2014-02-10),https://lens.org/078-575-200-593-531,Patent Application,yes,67,5,2,16,0,G06Q10/10;;G06Q10/10;;G09G5/006;;G09G5/006;;G09G2370/16;;G09G2370/16,G06F3/041;;G06F3/00;;G06F15/16,345/173;;710/62;;709/206,6,6,037-211-646-992-073;;013-820-433-706-881;;013-820-433-706-881;;015-163-991-712-122;;040-521-852-655-387;;040-451-373-125-652,10.1109/iedm.1996.553149;;10.1109/isce.2004.1375986;;10.1109/isce.2004.1375986;;10.1109/jlt.1986.1074875;;10.1109/20.133593;;10.1049/ree.1981.0050,T.Ohnakado et al.; Novel Self-limiting Program Scheme Utilizing N-channel Select Transistors in P-channel DINOR Flash Memory; 1996 IEEE; 4 pages;;S.I. Sudharsanan et al.; Software Architecture of a Digital Media Hub; 2004 IEEE; pp. 447-451;;S.I. Sudharsanan et al.; Software Architecture of a Digital Media Hub; 2004 IEEE; pp. 447-451;;PETER KAISER et al.; Fiber cables for public communications state of the art technologies and the future; 1986 IEEE; pp. 1157-1166;;G.H. Morgan et al.; WINDING MANDREL DESIGN FOR THE WIDE CABLE ssc DIPOLE; 1991 IEEE; pp. 1981-1984;;M. H. REEVE; Optical fibre cables; 1981 IEEE; 6 pages,INACTIVE
650,WO,A2,WO 2006/001985 A2,168-748-821-630-601,2006-01-05,2006,US 2005/0019780 W,2005-06-06,US 57709504 P,2004-06-04,INTERACTIVE COMMUNICATION SYSTEMS,"The present invention includes interactive communication systems that incorporate several beneficial embodiments including an interactive tray system, an electronic presentation messaging system, an interactive podium, and a key drive system. The interactive tray system enables a single, transferable interactive unit to be fastened to a communication medium, turning into a fully interactive medium. The electronic presentation messaging system enables the e-mailing of presentations and notes to and from components of the interactive communication system. The interactive podium increases conventional podium mobility, enabling both the presenter, and podium, to move and be moved about the room without attention to wired connections. The key drive system replaces the conventional Y-connector of the key drive technology by effectively integrating the key drive in the device, thus only having one connector, and eliminating the need to change connectors from the key drive, to the USB connector, upon software driver loading.",POLYVISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,,https://lens.org/168-748-821-630-601,Patent Application,yes,0,2,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/042;;G09G5/00,,0,0,,,,PENDING
651,US,B2,US 9027015 B2,119-771-798-542-731,2015-05-05,2015,US 19164808 A,2008-08-14,US 19164808 A;;US 14690105 A;;US 57709504 P,2004-06-04,Interactive communication system having an integrated key drive system,"A device and method of connecting an interactive communication system to a processing device. The device is a cable system that includes first and second ends. The first end of the cable system has a leg connector, while the second end of the connector system has first and second arm connectors. The method implements the cable system to load or run software onto the processing device, and includes connecting the leg connector to an interactive communication system; connecting the first arm connector having a memory device to the processing device, wherein the memory device includes predetermined software; loading/running the software on the processing device; disconnecting the first arm connector having the memory device from the processing device; and connecting a second arm connector to the processing device.",HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD;;STEELCASE INC,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,POLYVISION CORPORATION (2009-01-26);;STEELCASE INC (2014-02-10),https://lens.org/119-771-798-542-731,Granted Patent,yes,75,2,2,16,0,G06Q10/10;;G06Q10/10;;G09G5/006;;G09G5/006;;G09G2370/16;;G09G2370/16,G06F9/445;;G06F3/00;;G06Q10/10;;G09G5/00,717/174;;710/1;;710/8;;717/178,14,5,037-211-646-992-073;;013-820-433-706-881;;015-163-991-712-122;;040-521-852-655-387;;040-451-373-125-652,10.1109/iedm.1996.553149;;10.1109/isce.2004.1375986;;10.1109/jlt.1986.1074875;;10.1109/20.133593;;10.1049/ree.1981.0050,"Mimio Accessories.;;T. Ohnakado et al.; Novel Self-limiting Program Scheme Utilizing N-channel Select Transistors in P-channel DINOR Flash Memory; 1996 IEEE; 4 pages; .;;S.I. Sudharsanan et al.; Software Architecture of a Digital Media Hub; 2004 IEEE; pp. 447-451; .;;Peter Kaiser et al.; Fiber cables for public communications state of the art technologies and the future; 1986 IEEE; pp. 1157-1166; .;;G.H. Morgan et al.; Winding Mandrel Design for the Wide Cable ssc Dipole; 1991 IEEE; pp. 1981-1984; .;;M. H. Reeve; Optical fibre cables; 1981 IEEE; 6 pages; .;;""Walk-and-Talk Presentation Series Whiteboard"", Oct. 1, 2003, Polyvision, XP002368937, Retrieved from http://www.polyvision.com/media/support/guides/W-T-Install-web.pdf>, (retrieved Feb. 21, 2006), pp. 5, 12-14.;;J. Sisko et al., ""Polyvision Breaks Barriers to Interactive Whiteboard Adoption With New Product Line"", Oct. 22, 2003, XP002368938, Retrieved from http://www.nsba.org/t+12003/press/Polyvision.pdf>, retrieved Feb. 21, 2006.;;""Polyvision Breaks Barriers to Electronic Whiteboard Adoption"", Jun. 4, 2003, Polyvision, XP002368939, Retrieved from www. polyvision.com/news/press/060403.asp>, Retrieved Feb. 21, 2006.;;International Search Report and Written Opinion for PCT Patent Application No. PCT/US2005/019780 dated Mar. 24, 2006.;;Invitation to Pay Additional Fees (3 pgs.), 2005.;;Annex to Form PCT/ISA/206, Communication Relating to the Results of the Partial International Search (3 pgs.), 2009.;;Communication pursuant to Article 94(3) EPC issued by the European Patent Office on Aug. 26, 2010 for related European Application No. 08020514.9.;;Notice of Reasons for Rejection dated Nov. 17, 2010 issued by the Japanese Patent Office for related Japanese Application No. 2007-515672.",INACTIVE
652,US,B2,US 7750892 B2,182-782-795-264-084,2010-07-06,2010,US 14690105 A,2005-06-06,US 14690105 A;;US 57709504 P,2004-06-04,Portable interactive communication systems,"The present invention includes interactive communication systems that incorporate several beneficial embodiments including an interactive tray system, an electronic presentation messaging system, an interactive podium, and a key drive system. The interactive tray system enables a single, transferable interactive unit to be fastened to a communication medium, turning into a fully interactive medium. The electronic presentation messaging system enables the e-mailing of presentations and notes to and from components of the interactive communication system. The interactive podium increases conventional podium mobility, enabling both the presenter, and podium, to move and be moved about the room without attention to wired connections. The key drive system replaces the conventional Y-connector of the key drive technology by effectively integrating the key drive in the device, thus only having one connector, and eliminating the need to change connectors from the key drive, to the USB connector, upon software driver loading.",POLYVISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,POLYVISION CORPORATION (2005-01-31),https://lens.org/182-782-795-264-084,Granted Patent,yes,60,2,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/042;;G06F3/041;;G09G5/00,345/173;;341/31,8,0,,,"Mimio Accessories.;;Invitation To Pay Additional Fees (3 pgs.).;;Annex to Form PCT/ISA/206, Communication Relating to the Results of the Partial International Search (3 pgs.).;;""Walk-and-Talk Presentation Series Whiteboard"", (Online), October 1, 2003, Polyvision, XP002368937, Retrieved from the Internet: URL:http://www.polyvision.com/media/support/guides/W-T-Install-web.pdf>, (retrieved on Feb. 21, 2006), pp. 5, 12-14.;;J. Sisko, T. Stevens : ""Polyvision Breaks Barriers to Interactive Whiteboard Adoption With New Product Line"", (Online), October 22, 2003, XP002368938, Retrieved from the Internet: URL:http://www.nsba.org/t+12003/press/Polyvision.pdf>, retrieved on Feb. 21, 2006.;;""Polyvision Breaks Barriers to Electronic Whiteboard Adoption"", (Online), June 4, 2003, Polyvision, XP002368939, Retrieved from the Internet: URL:www.polyvision.com/news/press/060403.asp>, Retrieved on Feb. 21, 2006.;;International Search Report and Written Opinion for PCT Patent Application No. PCT/US2005019780, dated Mar. 24, 2006.;;EP Communication dated Nov. 2, 2009 from European Application No. EP08020514.9.",INACTIVE
653,US,B2,US 8179382 B2,055-321-954-620-44X,2012-05-15,2012,US 19185808 A,2008-08-14,US 19185808 A;;US 44933603 A,2003-05-30,Visual communication system,A visual communication system that is suitable for use in connection with a display surface is disclosed. The system includes a camera or other data-capturing device that can be remotely positioned from the display surface. A control unit receives image data from the camera or data-capturing device and processes the image data to create an electronic image of the display surface.,HILDEBRANDT PETER W;;DUNN MICHAEL H;;HUTCHINSON IAN G;;WILSON SCOTT E;;WILLIAMS GUY L;;MINTZ JAKE;;BROWN STEPHEN L;;COTE MARIE;;MICHALSKI JAMES L;;STEELCASE DEV CORP,HILDEBRANDT PETER W;;DUNN MICHAEL H;;HUTCHINSON IAN G;;WILSON SCOTT E;;WILLIAMS GUY L;;MINTZ JAKE;;BROWN STEPHEN L;;COTE MARIE;;MICHALSKI JAMES L,,https://lens.org/055-321-954-620-44X,Granted Patent,yes,100,2,3,3,0,H04N1/00127;;H04N1/00127;;H04N1/00347;;H04N1/00347;;H04N1/00493;;H04N1/00493;;H04N1/00496;;H04N1/00496;;H04N2101/00;;H04N2101/00;;H04N2201/0041;;H04N2201/0041;;H04N2201/0044;;H04N2201/0044;;H04N2201/0049;;H04N2201/0049;;H04N2201/0055;;H04N2201/0055;;H04N2201/0063;;H04N2201/0063;;H04N2201/0082;;H04N2201/0082;;H04N2201/0084;;H04N2201/0084;;H04N2201/0087;;H04N2201/0087,G06F3/042,345/175;;345/174;;178/18.01;;178/18.06,1,0,,,"""Hawkeye 480C and Hawkeye CAM,"" SMART Technologies (Oct. 1, 2000).",INACTIVE
654,CA,A1,CA 2568596 A1,149-100-611-500-381,2006-01-05,2006,CA 2568596 A,2005-06-06,US 57709504 P;;US 2005/0019780 W,2004-06-04,INTERACTIVE COMMUNICATION SYSTEMS,,POLYVISION CORP,WILSON SCOTT E;;ANDERSON BRENT W;;DUNN MICHAEL H;;HOFMANN NEAL A;;HILDEBRANDT PETER W;;ASHFORD LOUIS;;WATSON JAMES D;;HUTCHINSON IAN G;;MEISSNER RICHARD,,https://lens.org/149-100-611-500-381,Patent Application,no,0,0,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/033;;G06F3/042;;G09G5/00,,0,0,,,,DISCONTINUED
655,US,A1,US 2008/0297595 A1,155-518-419-249-639,2008-12-04,2008,US 19185808 A,2008-08-14,US 19185808 A;;US 44933603 A,2003-05-30,VISUAL COMMUNICATION SYSTEM,A visual communication system that is suitable for use in connection with a display surface is disclosed. The system includes a camera or other data-capturing device that can be remotely positioned from the display surface. A control unit receives image data from the camera or data-capturing device and processes the image data to create an electronic image of the display surface.,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WILSON SCOTT E;;WILLIAMS GUY L;;MINTZ JAKE;;BROWN STEPHEN G;;COTE MARIE;;MICHALSKI JAMES E;;DUNN MICHAEL H,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WILSON SCOTT E;;WILLIAMS GUY L;;MINTZ JAKE;;BROWN STEPHEN G;;COTE MARIE;;MICHALSKI JAMES E;;DUNN MICHAEL H,,https://lens.org/155-518-419-249-639,Patent Application,yes,99,5,3,3,0,H04N1/00127;;H04N1/00127;;H04N1/00347;;H04N1/00347;;H04N1/00493;;H04N1/00493;;H04N1/00496;;H04N1/00496;;H04N2101/00;;H04N2101/00;;H04N2201/0041;;H04N2201/0041;;H04N2201/0044;;H04N2201/0044;;H04N2201/0049;;H04N2201/0049;;H04N2201/0055;;H04N2201/0055;;H04N2201/0063;;H04N2201/0063;;H04N2201/0082;;H04N2201/0082;;H04N2201/0084;;H04N2201/0084;;H04N2201/0087;;H04N2201/0087,H04N7/18;;G09G5/00;;H04N7/04,348/61;;345/156;;358/483;;X348E07085,0,0,,,,EXPIRED
656,US,A1,US 2005/0280636 A1,007-859-572-295-665,2005-12-22,2005,US 14690105 A,2005-06-06,US 14690105 A;;US 57709504 P,2004-06-04,Interactive communication systems,"The present invention includes interactive communication systems that incorporate several beneficial embodiments including an interactive tray system, an electronic presentation messaging system, an interactive podium, and a key drive system. The interactive tray system enables a single, transferable interactive unit to be fastened to a communication medium, turning into a fully interactive medium. The electronic presentation messaging system enables the e-mailing of presentations and notes to and from components of the interactive communication system. The interactive podium increases conventional podium mobility, enabling both the presenter, and podium, to move and be moved about the room without attention to wired connections. The key drive system replaces the conventional Y-connector of the key drive technology by effectively integrating the key drive in the device, thus only having one connector, and eliminating the need to change connectors from the key drive, to the USB connector, upon software driver loading.",POLYVISION CORP,HILDEBRANDT PETER W;;HUTCHINSON IAN G;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,POLYVISION CORPORATION (2005-01-31),https://lens.org/007-859-572-295-665,Patent Application,yes,56,26,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/042;;G09G5/00,345/173,0,0,,,,INACTIVE
657,MX,A,MX PA06013950 A,103-413-230-590-748,2007-03-15,2007,MX PA06013950 A,2005-06-06,US 57709504 P;;US 2005/0019780 W,2004-06-04,ADAPTIVE READ AND READ-AFTER-WRITE FOR CARBON NANOTUBE RECORDERS.,"A method and apparatus for adaptive read and read-after-write for carbon nanotube recorders is described. In one embodiment, the invention is an apparatus, utilizing carbon nanotubes (CNTs) to read and write data, and deflecting the emissions of such CNTs precisely in the process. In an alternate embodiment, the invention is a method of locating CNTs for purposes of reading and writing data on a disk, using a rough location and feedback to refine the location into a precise location for the track, both for a group of heads and for individual heads within the group. Location may include both physical movement of the heads and deflection of emissions of the heads.",POLYVISION CORP,HUTCHINSON IAN G;;HILDEBRANDT PETER W;;WATSON JAMES D;;DUNN MICHAEL H;;HOFMANN NEAL A;;WILSON SCOTT E;;ANDERSON BRENT W;;ASHFORD LOUIS;;MEISSNER RICHARD,,https://lens.org/103-413-230-590-748,Patent Application,no,0,0,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/00;;G06F3/042;;G09G5/00,,0,0,,,,DISCONTINUED
658,AU,A8,AU 2005/332017 A8,184-483-931-987-010,2008-08-14,2008,AU 2005/332017 A,2005-06-06,US 57709504 P;;US 2005/0019780 W,2004-06-04,Interactive communication systems,,POLYVISION CORP,HILDEBRANDT PETER W;;ASHFORD LOUIS;;WATSON JAMES D;;HOFMANN NEAL A;;ANDERSON BRENT W;;HUTCHINSON IAN G;;MEISSNER RICHARD;;WILSON SCOTT E;;DUNN MICHAEL H,,https://lens.org/184-483-931-987-010,Patent Application,no,0,0,14,16,0,G06F1/1605;;G06F3/0428;;G06F3/043;;G06F3/0428;;G06F1/1605;;G06F3/043,G06F3/033;;G06F3/042;;G09G5/00,,0,0,,,,INACTIVE
659,WO,A1,WO 2012/167327 A1,030-427-743-194-960,2012-12-13,2012,AU 2012/000667 W,2012-06-08,US 201161457810 P;;US 201261635351 P,2011-06-08,AIR DELIVERY CONDUIT,"An air delivery conduit (620) includes first (621) and second (622) conduit portions that cooperate to form the conduit, each conduit portion including an inner layer of a film laminate (650) that forms an interior surface of the conduit and an outer layer of a textile (655) that forms an exterior surface of the conduit.",RESMED LTD;;OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIO;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIO;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,,https://lens.org/030-427-743-194-960,Patent Application,yes,8,17,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/06;;A62B9/00,,1,0,,,See also references of EP 2717954A4,PENDING
660,EP,A1,EP 2717954 A1,112-000-134-874-928,2014-04-16,2014,EP 12796616 A,2012-06-08,US 201161457810 P;;US 201261635351 P;;AU 2012/000667 W,2011-06-08,AIR DELIVERY CONDUIT,,RESMED LTD,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIO;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,RESMED PTY LTD (2019-07-10),https://lens.org/112-000-134-874-928,Patent Application,yes,0,6,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/06;;A62B9/00;;F16L11/02;;F24F13/02,,0,0,,,,ACTIVE
661,EP,A4,EP 2717954 A4,107-541-450-099-522,2015-04-01,2015,EP 12796616 A,2012-06-08,US 201161457810 P;;US 201261635351 P;;AU 2012/000667 W,2011-06-08,AIR DELIVERY CONDUIT,,RESMED LTD,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIO;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,RESMED PTY LTD (2019-07-10),https://lens.org/107-541-450-099-522,Search Report,no,13,0,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/06;;A62B9/00;;F16L11/02;;F24F13/02,,1,0,,,See also references of WO 2012167327A1,ACTIVE
662,EP,B1,EP 2717954 B1,017-623-058-514-310,2020-09-30,2020,EP 12796616 A,2012-06-08,US 201161457810 P;;US 201261635351 P;;AU 2012/000667 W,2011-06-08,AIR DELIVERY CONDUIT,,RESMED PTY LTD,SWIFT LANCE IAN;;OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIO;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI,RESMED PTY LTD (2019-07-10),https://lens.org/017-623-058-514-310,Granted Patent,yes,21,0,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/06;;A61M16/08,,0,0,,,,ACTIVE
663,US,A1,US 2022/0355060 A1,024-392-876-058-917,2022-11-10,2022,US 202217869957 A,2022-07-21,US 202217869957 A;;US 201916355150 A;;US 201715669173 A;;US 201314124878 A;;AU 2012/000667 W;;US 201161457810 P;;US 201261635351 P,2011-06-08,AIR DELIVERY CONDUIT,"An air delivery conduit includes first and second conduit portions that cooperate to form the conduit, each conduit portion including an inner layer of a film laminate that forms an interior surface of the conduit and an outer layer of a textile that forms an exterior surface of the conduit.",RESMED PTY LTD,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIA;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,RESMED PTY LTD (2012-07-23),https://lens.org/024-392-876-058-917,Patent Application,yes,8,0,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/08;;A61M16/00;;A61M16/06,,0,0,,,,PENDING
664,US,B2,US 9731090 B2,175-807-021-565-670,2017-08-15,2017,US 201214124878 A,2012-06-08,US 201214124878 A;;US 201161457810 P;;US 201261635351 P;;AU 2012/000667 W,2011-06-08,Air delivery conduit,"An air delivery conduit ( 620 ) includes first ( 621 ) and second ( 622 ) conduit portions that cooperate to form the conduit, each conduit portion including an inner layer of a film laminate ( 650 ) that forms an interior surface of the conduit and an outer layer of a textile ( 655 ) that forms an exterior surface of the conduit.",OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIA;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN;;RESMED LTD,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIA;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,RESMED PTY LTD (2012-07-23),https://lens.org/175-807-021-565-670,Granted Patent,yes,19,12,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/08;;A61M16/00;;A61M16/06,,3,0,,,"International Search Report issued for PCT/AU2012/000667 on Oct. 4, 2012.;;Hydrospace, NIRI, The Nonwovens Innovation & Research Institute, http://www.nonwovens-innovation.com/hydrospace.html, May 3, 2011, 1 page.;;Extended European Search Report dated Feb. 27, 2015 issued in corresponding European Application No. 12796616.6 (10 pages).",ACTIVE
665,US,B2,US 6713627 B2,150-385-591-453-633,2004-03-30,2004,US 4349802 A,2002-01-11,US 4349802 A;;US 67000500 A;;US 26647199 A;;US 26629899 P;;US 15519798 P,1998-03-13,"Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol","
    The present invention provides various processes for the preparation of (R)--(2,3-dimethoxyphenyl)-1-2-(4-fluorophenyl)ethyl-4-piperidinemethanol. These processes may be characterized by the following scheme: 
",AVENTIS PHARMA INC,DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;HILPERT THOMAS HEINZ EDUARD;;KOEK JOHANNES NICOLAAS;;LASKOVICS FREDERICK M;;STOLZ-DUNN SANDRA K;;TOMLINSON IAN A,AVENTIS HOLDINGS INC (2001-12-28);;MARION MERRELL S.A (1999-02-08);;SYNCOM B.V (1999-02-09);;DOW CHEMICAL COMPANY THE (1999-02-08);;AVENTISUB II INC (2008-12-31);;AVENTIS PHARMACEUTICALS INC (1999-12-13);;AVENTIS PHARMA DEUTSCHLAND GMBH (1999-02-10),https://lens.org/150-385-591-453-633,Granted Patent,yes,41,1,6,8,0,C07D211/32;;C07D211/32;;C07D211/22;;C07D211/22,A61K31/445;;C07D211/20;;C07D211/22;;C07D211/32,546/241;;546/240;;514/317,11,5,189-748-148-589-38X;;082-212-859-841-769;;131-268-337-121-519;;022-138-021-142-447;;066-193-295-374-147,10.1016/s0957-4166(00)80136-6;;10.1021/jm00174a007;;2258899;;10.1007/bf00562664;;1233237;;1360026;;10.1021/jm00101a012;;10.1016/0960-894x(96)00148-5,"Chi-Hsin R. King et al., Immobilization of Substrates in Enzyme-Catalyzed Hydrolysis, Tetrahedron: Asymmetry vol. 4, No. 5 pp. 943-946 1993.;;Doepke, W. Schwertner et al., The resolution of racemates of the .beta. -receptor blocking agent propranolol, Pharmazie, 1990, vol. 45, pp. 673-675 (Chem. Abs. 114: 101,311).;;Efange, S.M.N. et al., Flexible N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Analogues; Synthesis and Monoamine Oxidase Catalyzed Bioactivation, J. Med. Chem. pp. 3133-3138, vol. 33, 1990.;;Herbert A. Lieberman et al., Pharmaceutical Dosage Forms, Marcel Dekker, Inc. 1989 vol. 2.;;Jounela A.J. et al., Effect of Particle Size on The Bioavailability of Digoxin , (EMBASE 1976084536) (1975).;;Paul J. Gilligan et al., Novel Piperidine o Receptor Ligands as Potential Antipsychotic Drugs, J. Med. Chem. 1992, vol. 35, pp. 4344-4361.;;Sauter, Fritz et al., Synthesis of Substituted Phenyl Pyridinyl and Phenyl Pyrimidinyl ketones, Journal Chem. Research 1977, vol. 7, pp. 186 (English Abstract).;;Sauter, Fritz, Synthese Substituierter Pheny-pyridinyl- und Phenyl-pyrimidinyl-methanone, J. Chem Research, (M), 1997, vol. 186; pp. 2001-2009.;;Timothy P. Burkholder et al., Identification and Chemical Synthesis of MDL 105,212, a Non-Peptide Tachykinin Antagonist with High Affinity for NK1 and NK2 Receptors, Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 8, pp. 951-956 1996.;;Villari A. et al., Methods for the Particle-Size Analysis of Pharmaceutical Powders I, (BIOSIS 06098131) (1987).;;Computer Optimization for the Formulation of Controlled Release Theophylline Tablet Made of Micronized Low-substituted Hydroxypropylcellulose and Methylcellulose, 1999 pp.",EXPIRED
666,US,B2,US 10279138 B2,017-020-887-235-13X,2019-05-07,2019,US 201715669173 A,2017-08-04,US 201715669173 A;;US 201314124878 A;;AU 2012/000667 W;;US 201161457810 P;;US 201261635351 P,2011-06-08,Air delivery conduit,"An air delivery conduit includes first and second conduit portions that cooperate to form the conduit, each conduit portion including an inner layer of a film laminate that forms an interior surface of the conduit and an outer layer of a textile that forms an exterior surface of the conduit.",RESMED LTD,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIO;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,RESMED PTY LTD (2012-07-23),https://lens.org/017-020-887-235-13X,Granted Patent,yes,27,15,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/06;;A61M16/00;;A61M16/08,,4,0,,,"International Search Report issued for PCT/AU2012/000667 dated Oct. 4, 2012.;;Hydrospace, NIRI, The Nonwovens Innovation & Research Institute, http://www.nonwovens-innovation.com/hydrospace.html, May 3, 2011, 1 page.;;Extended European Search Report dated Feb. 27, 2015 issued in corresponding European Application No. 12796616.6 (10 pages).;;A Communication Pursuant to Article 94(3) dated Sep. 8, 2017, in a corresponding European Application No. 12 796 161.6 (5 pages).",ACTIVE
667,US,A1,US 2014/0102456 A1,011-871-181-990-683,2014-04-17,2014,US 201214124878 A,2012-06-08,US 201214124878 A;;US 201161457810 P;;US 201261635351 P;;AU 2012/000667 W,2011-06-08,AIR DELIVERY CONDUIT,"An air delivery conduit ( 620 ) includes first ( 621 ) and second ( 622 ) conduit portions that cooperate to form the conduit, each conduit portion including an inner layer of a film laminate ( 650 ) that forms an interior surface of the conduit and an outer layer of a textile ( 655 ) that forms an exterior surface of the conduit.",OVIZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIA;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN;;RESMED LTD,OVIZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIA;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,RESMED PTY LTD (2012-07-23),https://lens.org/011-871-181-990-683,Patent Application,yes,4,57,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/06;;A61M16/00,128/205.25;;29/428,0,0,,,,ACTIVE
668,US,A1,US 2002/0151717 A1,059-567-137-124-134,2002-10-17,2002,US 4349802 A,2002-01-11,US 4349802 A;;US 67000500 A;;US 26647199 A;;US 26629899 P;;US 15519798 P,1998-03-13,"Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol","
    The present invention provides various processes for the preparation of (R)--(2,3-dimethoxyphenyl)-1-2-(4-fluorophenyl)ethyl-4-piperidinemethanol. These processes may be characterized by the following scheme: 
",DAUGS EDWARD D.;;EVANS JONATHAN C.;;FLEMMING HANS-WOLFRAM;;HILPERT THOMAS HEINZ EDUARD;;KOEK JOHANNES NICOLAAS;;LASKOVICS FREDERICK M.;;STOLZ-DUNN SANDRA K.;;TOMLINSON IAN A.,DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;HILPERT THOMAS HEINZ EDUARD;;KOEK JOHANNES NICOLAAS;;LASKOVICS FREDERICK M;;STOLZ-DUNN SANDRA K;;TOMLINSON IAN A,AVENTIS HOLDINGS INC (2001-12-28);;MARION MERRELL S.A (1999-02-08);;SYNCOM B.V (1999-02-09);;DOW CHEMICAL COMPANY THE (1999-02-08);;AVENTISUB II INC (2008-12-31);;AVENTIS PHARMACEUTICALS INC (1999-12-13);;AVENTIS PHARMA DEUTSCHLAND GMBH (1999-02-10),https://lens.org/059-567-137-124-134,Patent Application,yes,0,3,6,8,0,C07D211/32;;C07D211/32;;C07D211/22;;C07D211/22,A61K31/445;;C07D211/20;;C07D211/22;;C07D211/32,546/232;;546/339,0,0,,,,EXPIRED
669,US,B2,US 11395898 B2,173-654-416-225-235,2022-07-26,2022,US 201916355150 A,2019-03-15,US 201916355150 A;;US 201715669173 A;;US 201314124878 A;;AU 2012/000667 W;;US 201161457810 P;;US 201261635351 P,2011-06-08,Air delivery conduit,"An air delivery conduit includes first and second conduit portions that cooperate to form the conduit, each conduit portion including an inner layer of a film laminate that forms an interior surface of the conduit and an outer layer of a textile that forms an exterior surface of the conduit.",RESMED LTD;;RESMED PTY LTD,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIA;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,RESMED PTY LTD (2012-07-23),https://lens.org/173-654-416-225-235,Granted Patent,yes,33,1,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/08;;A61M16/00;;A61M16/06,,5,0,,,"International Search Report issued for PCT/AU2012/000667 dated Oct. 4, 2012.;;Hydrospace, NIRI, The Nonwovens Innovation & Research Institute, http://www.nonwovens-innovation.com/hydrospace.html, May 3, 2011, 1 page.;;Extended European Search Report dated Feb. 27, 2015 issued in corresponding European Application No. 12796616.6 (10 pages).;;A Communication Pursuant to Article 94(3) dated Sep. 8, 2017, in a corresponding European Application No. 12 796 161.6 (5 pages).;;EP Search Report dated Apr. 14, 2021 in corresponding EP Application 20198992.8 (7 pages).",ACTIVE
670,US,A1,US 2019/0209799 A1,197-786-432-553-20X,2019-07-11,2019,US 201916355150 A,2019-03-15,US 201916355150 A;;US 201715669173 A;;US 201314124878 A;;AU 2012/000667 W;;US 201161457810 P;;US 201261635351 P,2011-06-08,AIR DELIVERY CONDUIT,"An air delivery conduit includes first and second conduit portions that cooperate to form the conduit, each conduit portion including an inner layer of a film laminate that forms an interior surface of the conduit and an outer layer of a textile that forms an exterior surface of the conduit.",RESMED LTD,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIA;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,RESMED PTY LTD (2012-07-23),https://lens.org/197-786-432-553-20X,Patent Application,yes,0,6,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/08;;A61M16/00;;A61M16/06,,0,0,,,,ACTIVE
671,US,A1,US 2017/0333662 A1,061-263-073-757-950,2017-11-23,2017,US 201715669173 A,2017-08-04,US 201715669173 A;;US 201314124878 A;;AU 2012/000667 W;;US 201161457810 P;;US 201261635351 P,2011-06-08,AIR DELIVERY CONDUIT,"An air delivery conduit includes first and second conduit portions that cooperate to form the conduit, each conduit portion including an inner layer of a film laminate that forms an interior surface of the conduit and an outer layer of a textile that forms an exterior surface of the conduit.",RESMED LTD,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIO;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,RESMED PTY LTD (2012-07-23),https://lens.org/061-263-073-757-950,Patent Application,yes,3,23,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/08;;A61M16/06,,0,0,,,,ACTIVE
672,EP,A1,EP 3827864 A1,131-868-042-717-04X,2021-06-02,2021,EP 20198992 A,2012-06-08,US 201161457810 P;;US 201261635351 P;;EP 12796616 A;;AU 2012/000667 W,2011-06-08,AIR DELIVERY CONDUIT,"The present disclosure relates to a mask assembly for delivering a supply of pressurized gas to a patient for treatment of sleep disordered breathing, the mask assembly comprising: a patient interface configured to form a seal with the patient's face to deliver the supply of gas to the patient during treatment; an air delivery conduit configured to, in use, extend along at least one side of the patient's face between the patient's eye and ear to deliver the supply of gas to the patient interface and to at least partially support the patient interface in a desired position on the patient's face, the air delivery conduit including: first and second conduit portions that cooperate to form a tubular conduit, wherein each conduit portion includes an inner sealing layer that forms an air impermeable interior surface of the conduit and an outer layer of a textile that forms an exterior surface of the conduit, and wherein the first and second conduit portions are thermoformed to create complimentary shapes that cooperate to form the conduit.",RESMED PTY LTD,OVZINSKY GRANT MILTON;;FORMICA JUSTIN JOHN;;DUNN JESSICA LEA;;DAVIDSON AARON SAMUEL;;ORMROD JOSEPH SAMUEL;;ROMAGNOLI JOSE IGNACIO;;RUMMERY GERARD MICHAEL;;STUEBIGER KAI;;SWIFT LANCE IAN,,https://lens.org/131-868-042-717-04X,Patent Application,yes,4,0,12,12,0,A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;Y10T29/49826;;A61M16/0683;;A61M16/0875;;Y10T29/49826;;A61M2207/00;;A61M2205/0238;;A61M2205/0266;;A61M16/06;;A61M16/0816;;A61M2205/42;;A61M2210/0618;;A61M16/0672;;A61M16/0683;;A61M16/0875;;A61M16/0066;;A61M16/0666;;A61M16/0605;;A61M2205/02,A61M16/06;;A62B9/00;;F16L11/02;;F24F13/02,,0,0,,,,PENDING
673,US,A1,US 2018/0350296 A1,197-934-193-452-090,2018-12-06,2018,US 201815874799 A,2018-01-18,US 201815874799 A;;US 201762556376 P;;US 201762514939 P,2017-06-04,LONG-TERM HISTORY OF DISPLAY INTENSITIES,"A data processing system can store a long-term history of pixel luminance values in a secure memory and use those values to create burn-in compensation values that are used to mitigate burn-in effect on a display. The long-term history can be updated over time with new, accumulated pixel luminance values.",APPLE INC,THOMPSON ROSS;;COTE GUY;;TANN CHRISTOPHER P;;HAUCK JERROLD V;;HENDRY IAN C;;HEPPOLETTE VANESSA C;;MACHALEK ADAM J;;DUNN ALAN M;;SAZEGARI ALI;;LINDBERG LARS M;;SPENCE ARTHUR L,APPLE INC (2017-11-15),https://lens.org/197-934-193-452-090,Patent Application,yes,5,18,9,9,0,G09G3/32;;G09G2320/0285;;G09G2320/043;;G09G2320/048;;G09G2330/026;;G06F9/451;;G09G2320/046;;G09G2358/00;;G06F9/4401;;G09G3/2003;;G09G3/006;;G09G2320/046;;G09G2320/066;;G09G2358/00;;G09G2300/0847;;G09G2354/00;;G06F9/451;;G09G3/32;;G09G2320/0285;;G09G2320/043;;G09G2320/048;;G09G2330/026;;G09G2320/0233;;G06F3/0622;;G06F3/0623;;G06F3/0652;;G06F3/0656;;G06F3/0673;;G09G3/3208;;G06F3/0643;;G06F3/0644;;G06F3/0647;;G06F3/067;;G06F9/4401,G09G3/3208;;G06F3/06;;G06F9/4401,,0,0,,,,ACTIVE
674,US,B2,US 10699622 B2,069-970-813-125-742,2020-06-30,2020,US 201815874799 A,2018-01-18,US 201815874799 A;;US 201762556376 P;;US 201762514939 P,2017-06-04,Long-term history of display intensities,"A data processing system can store a long-term history of pixel luminance values in a secure memory and use those values to create burn-in compensation values that are used to mitigate burn-in effect on a display. The long-term history can be updated over time with new, accumulated pixel luminance values.",APPLE INC,THOMPSON ROSS;;COTE GUY;;TANN CHRISTOPHER P;;HAUCK JERROLD V;;HENDRY IAN C;;HEPPOLETTE VANESSA C;;MACHALEK ADAM J;;DUNN ALAN M;;SAZEGARI ALI;;LINDBERG LARS M;;SPENCE ARTHUR L,APPLE INC (2017-11-15),https://lens.org/069-970-813-125-742,Granted Patent,yes,21,2,9,9,0,G09G3/32;;G09G2320/0285;;G09G2320/043;;G09G2320/048;;G09G2330/026;;G06F9/451;;G09G2320/046;;G09G2358/00;;G06F9/4401;;G09G3/2003;;G09G3/006;;G09G2320/046;;G09G2320/066;;G09G2358/00;;G09G2300/0847;;G09G2354/00;;G06F9/451;;G09G3/32;;G09G2320/0285;;G09G2320/043;;G09G2320/048;;G09G2330/026;;G09G2320/0233;;G06F3/0622;;G06F3/0623;;G06F3/0652;;G06F3/0656;;G06F3/0673;;G09G3/3208;;G06F3/0643;;G06F3/0644;;G06F3/0647;;G06F3/067;;G06F9/4401,G09G3/20;;G06F3/06;;G06F9/4401;;G06F9/451;;G09G3/00;;G09G3/32;;G09G3/3208,,4,1,030-403-488-845-474,10.1002/jsid.401,"PCT International Search Report and the Written Opinion of the International Searching Authority for PCT/US2018/015485 dated Jul. 9, 2018.;;P. Volkert, X. Jiang, and C. Xu, “Characterization and Compensation of OLED Aging in a Digital AMOLED System,” J. Soc. Info. Display, vol. 23, Issue 12, pp. 570-579 (Dec. 2015), DOI:10.1002/jsid.401.;;PCT Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for PCT/US2018/015485 dated Apr. 24, 2018.;;PCT International Preliminary Report on Patentability for PCT/US2018/015485 dated Dec. 19, 2019, 30 pages.",ACTIVE
675,TW,A,TW 201831460 A,061-359-089-115-166,2018-09-01,2018,TW 106141134 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P,2016-11-28,Heteroarylphenoxy benzamide KAPPA opioid ligands,"The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid ([kappa]-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.",PFIZER,ARORA KAPILDEV KASHMIRILAL;;DUNN MATTHEW FRANCIS;;BRODNEY MICHAEL AARON;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/061-359-089-115-166,Patent of Addition,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D401/04;;A61K31/4155;;A61K31/4192;;A61K31/433;;A61K31/454;;A61K31/5377;;A61P25/00;;C07D403/04;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
676,CA,A1,CA 3045242 A1,197-221-880-561-715,2018-05-31,2018,CA 3045242 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,"The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compound s or s al ts, an d thei r uses for treating kappa opioid (?-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.",PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/197-221-880-561-715,Patent Application,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,PENDING
677,EP,B1,EP 3544972 B1,111-449-663-058-815,2023-04-26,2023,EP 17818281 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,PFIZER INC. (2023-05-24),https://lens.org/111-449-663-058-815,Granted Patent,yes,2,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
678,US,B2,US 10316021 B2,171-731-226-507-980,2019-06-11,2019,US 201715820679 A,2017-11-22,US 201715820679 A;;US 201762585016 P;;US 201762576435 P;;US 201662426980 P,2016-11-28,Heteroarylphenoxy benzamide kappa opioid ligands,"The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R 1 , R 2 , R 3 , R 4 , R 9 , X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.",PFIZER,KABLAOUI NATASHA MARIAM;;GREEN MICHAEL ERIC;;MONTGOMERY JUSTIN IAN;;BRODNEY MICHAEL AARON;;VERHOEST PATRICK ROBERT;;KAUFFMAN GREGORY WAYNE;;RANKIC DANICA ANTONIA;;MENTE SCOT RICHARD;;ROGERS BRUCE NELSEN;;ARORA KAPILDEV KASHMIRILAL;;DUNN MATTHEW FRANCIS,,https://lens.org/171-731-226-507-980,Granted Patent,yes,25,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,A61P25/00;;C07D403/04;;C07D231/20;;C07D413/04;;C07D417/04,,25,23,045-443-768-762-017;;020-514-852-962-060;;031-465-074-322-606;;127-146-137-741-940;;161-797-547-749-365;;079-335-658-708-672;;055-122-599-670-386;;032-158-870-681-93X;;009-167-659-599-683;;034-329-320-010-097;;096-062-641-684-497;;121-512-435-537-242;;118-907-665-065-269;;031-587-595-173-365;;002-804-087-361-059;;126-424-785-841-094;;050-061-272-649-958;;060-603-818-409-62X;;075-570-882-329-612;;117-807-497-887-591;;071-801-324-109-930;;063-776-546-226-073;;071-057-310-358-693,10.1016/j.brainres.2009.08.062;;pmc2819621;;19716811;;pmc3685470;;10.1016/j.tins.2012.05.005;;22709632;;23360448;;pmc3612131;;10.1021/jm301783x;;10.1002/cmdc.201402142;;24981721;;pmc5588862;;pmc3055513;;10.1038/npp.2010.137;;21116263;;pmc3749293;;10.1016/j.biopsych.2013.03.014;;23611261;;pmc4258993;;10.3389/fpsyt.2014.00170;;25538632;;24619932;;10.1002/jcph.286;;pmc3594542;;10.1016/j.tins.2012.11.002;;23219016;;21958337;;10.1021/jm200789r;;pmc3747596;;10.1371/journal.pone.0070701;;23976952;;10.1177/0269881113504017;;24048097;;pmc4368892;;10.1093/ijnp/pyu036;;25637376;;24071566;;10.1016/j.neuropharm.2013.09.021;;10.1016/j.bmcl.2014.03.040;;24690494;;pmc3682153;;23446450;;10.1038/npp.2013.58;;22437504;;pmc3356457;;10.1038/nature10939;;pmc3775344;;23353688;;10.2967/jnumed.112.109512;;pmc5824998;;10.2967/jnumed.112.118877;;23918735;;25565277;;pmc4394387;;10.1021/ja512115s;;10.1038/jcbfm.2014.150;;25182664;;pmc4269759;;10.2967/jnumed.114.147975;;25593119;;pmc4322754;;pmc4826283;;10.2967/jnumed.114.138701;;24854795,"Bruchas, M.R., et al., “The Dynorphin-Kappa Opioid System as a Modulator of Stress-induced and Pro-addictive Behaviors”, Brain Research, Feb. 16, 2010, pp. 44-55, vol. 1314.;;Butelman, Eduardo, R., et al., “k-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addictions”, Trends in Neurosciences, Oct. 2012, pp. 587-596, 35(10).;;Carroll, F. Ivy, et al., “The Development of k Opioid Receptor Antagonists”, Journal of Medicinal Chemistry, Mar. 28, 2013, pp. 2178-2195, 56(6).;;Carroll, F. Ivy, et al., “The Discovery and Development of the N-Substituted trans-3,4-Dimethyl-4-(3′-hydroxyphenyl)piperidine Class of Pure Opioid Receptor Antagonists”, ChemMedChem, 2014, pp. 1638-1654, vol. 9.;;Chavkin, Charles, “The Therapeutic Potential of k-Opioids for Treatment of Pain and Addiction”, Neuropsychopharmacology Reviews, Jan. 2011, pp. 369-370, 36(1).;;Cueva, Juan Pablo, et al., “C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors”, Journal of Medicinal Chemistry, May 28, 2015, pp. 4242-4249, 58(10).;;Kissler, Jessica L., et al., “The One-Two Punch of Alcoholism: Role of Central Amygdala Dynorphins/Kappa-Opioid Receptors”, Biological Psychiatry, May 15, 2014, pp. 774-782, 75(10).;;Lalanne, Laurence, et al., “The kappa opioid receptor: from addiction to depression, and back”, Frontiers in Psychiatry, Dec. 8, 2014, pp. 1-17, vol. 5, article 170.;;Lowe, Stephen L., et al., “Safety, Tolerability, and Pharmacokinetic Evaluation of Single- and Multiple-Ascending Doses of a Novel Kappa Opioid Receptor Antagonist LY2456302 and Drug Interaction With Ethanol in Healthy Subjects”, Journal of Clinical Pharmacology, 2014, pp. 968-978, 54(9).;;Lutz, Pierre-Eric, et al., “Opioid receptors: distinct roles in mood disorders”, Trends in Neurosciences, Mar. 2013, pp. 195-206, 36(3).;;Mitch, Charles H., et al., “Discovery of Aminobenzyloxyarylamides as k Opioid Receptor Selective Antagonists: Application to Preclinical Development of a k Opioid Receptor Antagonist Receptor Occupancy Tracer”, Journal of Medicinal Chemistry, Dec. 8, 2011, pp. 8000-8012,54(23).;;Munro, Thomas A., et al., “Selective Opioid Antagonists nor-BNI, GNTI and JDTic Have Low Affinities for Non-Opioid Receptors and Transporters”, PLOS One, Aug. 2013, pp. 1-9, 8(8).;;Nutt, David J., “The role of the opioid system in alcohol depenence”, Journal of Psychopharmacology, 2014, pp. 8-22, 28(1).;;Rorick-Kehn, Linda M., et al., “Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human” International Journal of Neuropsychopharmacology, Feb. 2015, pp. 1-11, 18(2).;;Rorick-Kehn, Linda M., et al., “LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders”, Neuropharmacology, 2014, pp. 131-144, vol. 77.;;Urbano, Mariangela, et al., “Antagonists of the kappa opioid receptor”, Bioorganic & Medicinal Chemistry Letters, 2014, pp. 2021-2032, vol. 24.;;Van't Veer, Ashlee, et al., “Ablation of Kappa-Opioid Receptors from Brain Dopamine Neurons has Anxiolytic-Like Effects and Enhances Cocaine-Induced Plasticity”, Neuropsychopharmacology, 2013, pp. 1585-1597, 38(8).;;Wu, Huixian, et al., “Structure of the human kappa opioid receptor in complex with JDTic”, Nature, May 17, 2012, pp. 327-332, 485(7398).;;Zheng, Ming-Qiang, et al., “Synthesis and Evaluation of 11C-LY2795050 as a k-Opioid Receptor Antagonist Radiotracer for PET Imaging”, Journal of Nuclear Medicine, Jan. 25, 2013, pp. 455-463, vol. 54.;;Kim, Su Jin, et al., “Determination of the in vivo selectivity of a new kappa-opioid receptor antagonist PET tracer 11C-LY2795050 in the rhesus monkey”, Journal of Nuclear Medicine, 2013, pp. 1668-1674, 54(9).;;Lee, Hong, et al., “Virtually Instantaneous, Room-Temperature [11C]-Cyanation Using Biaryl Phosphine Pd(0) Complexes” Journal of the American Chemical Society, 2015, pp. 648-651, 137(2).;;Naganawa, Mika, et al., “Kinetic modeling of 11C-LY2795050, a novel antagonist radiotracer for PET imaging of the kappa opioid receptor in humans”, Journal of Cerebral Blood Flow & Metabolism, 2014, pp. 1818-1825, 34(11).;;Naganawa, Mika, et al., “Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer fro the k opioid receptor”, Journal of Nuclear Medicine, 2015, pp. 243-248, 56(2).;;Zheng, Ming-Qiang, et al., “An improved antagonist radiotracer for the K-opioid receptor: synthesis and characterization of 11C-LY2459989”, Journal of Nuclear Medicine, 2014, pp. 1185-1191, 55(7).;;International Patent Application No. PCT/IB2017/057418, filed Nov. 27, 2017; International Search Report and Written Opinion dated Mar. 21, 2018, 12 pages.",ACTIVE
679,TW,B,TW I720272 B,069-031-067-982-623,2021-03-01,2021,TW 106141134 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P,2016-11-28,Heteroarylphenoxy benzamide kappa opioid ligands,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;DUNN MATTHEW FRANCIS;;BRODNEY MICHAEL AARON;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/069-031-067-982-623,Granted Patent,no,1,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,,,0,0,,,,ACTIVE
680,MX,A,MX 2019006220 A,172-934-433-981-518,2019-10-07,2019,MX 2019006220 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS.,"The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compound s or s al ts, an d thei r uses for treating kappa opioid (?-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.",PFIZER,JUSTIN IAN MONTGOMERY;;GREGORY WAYNE KAUFFMAN;;DANICA ANTONIA RANKIC;;MICHAEL AARON BRODNEY;;BRUCE NELSEN ROGERS;;PATRICK ROBERT VERHOEST;;KAPILDEV KASHMIRILAL ARORA;;MATTHEW FRANCIS DUNN;;MICHAEL ERIC GREEN;;NATASHA MARIAM KABLAOUI;;SCOT RICHARD MENTE,,https://lens.org/172-934-433-981-518,Patent Application,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,PENDING
681,FI,T3,FI 3544972 T3,181-641-410-081-098,2023-06-02,2023,FI 17818281 T,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/181-641-410-081-098,Unknown,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,PENDING
682,EP,B8,EP 3544972 B8,088-353-370-955-653,2023-06-07,2023,EP 17818281 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,PFIZER INC. (2023-05-24),https://lens.org/088-353-370-955-653,Amended Patent,yes,2,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
683,PH,A1,PH 12019501172 A1,102-716-920-829-527,2019-12-11,2019,PH 12019501172 A,2019-05-28,US 201762576435 P;;US 201762585016 P;;US 201662426980 P;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,"The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compound s or s al ts, an d thei r uses for treating kappa opioid (?-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.",PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/102-716-920-829-527,Patent Application,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D403/04;;C07D413/04;;C07D417/04,,0,0,,,,PENDING
684,ES,T3,ES 2947293 T3,179-358-506-261-979,2023-08-04,2023,ES 17818281 T,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,Ligandos opioides kappa de heteroarilfenoxi benzamida,"La presente invención proporciona compuestos de Fórmula I: y sales farmacéuticamente aceptables de los mismos en donde las variables R1, R2, R3, R4, R9, X, myn son como se definen aquí; procesos para la elaboración de; intermedios utilizados en la preparación de; y composiciones que contienen tales compuestos o sales, y sus usos para tratar trastornos asociados con opioides kappa (opioide κ) que incluyen, por ejemplo, un trastorno neurológico o un trastorno psiquiátrico tal como un trastorno neurocognitivo, trastorno por abuso de sustancias, trastorno depresivo , trastorno de ansiedad, trastorno relacionado con traumas y factores estresantes y trastornos alimentarios y alimentarios. (Traducción automática con Google Translate, sin valor legal)",PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/179-358-506-261-979,Granted Patent,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
685,EP,A1,EP 3544972 A1,003-089-883-943-793,2019-10-02,2019,EP 17818281 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,PFIZER INC. (2023-05-24),https://lens.org/003-089-883-943-793,Patent Application,yes,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
686,AU,B2,AU 2017/365123 B2,057-111-905-994-40X,2022-02-17,2022,AU 2017/365123 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,Heteroarylphenoxy benzamide kappa opioid ligands,The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/057-111-905-994-40X,Granted Patent,no,2,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
687,AU,A1,AU 2017/365123 A1,104-228-074-731-554,2019-07-11,2019,AU 2017/365123 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,Heteroarylphenoxy benzamide kappa opioid ligands,The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/104-228-074-731-554,Patent Application,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
688,HR,T1,HR P20230518 T1,113-831-079-656-517,2023-08-04,2023,HR P20230518 T,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;EP 17818281 A;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/113-831-079-656-517,Granted Patent,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
689,US,A1,US 2018/0148432 A1,118-171-082-270-35X,2018-05-31,2018,US 201715820679 A,2017-11-22,US 201715820679 A;;US 201762585016 P;;US 201762576435 P;;US 201662426980 P,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,"The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R 1 , R 2 , R 3 , R 4 , R 9 , X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.",PFIZER,KABLAOUI NATASHA MARIAM;;GREEN MICHAEL ERIC;;MONTGOMERY JUSTIN IAN;;BRODNEY MICHAEL AARON;;VERHOEST PATRICK ROBERT;;KAUFFMAN GREGORY WAYNE;;RANKIC DANICA ANTONIA;;MENTE SCOT RICHARD;;ROGERS BRUCE NELSEN;;ARORA KAPILDEV KASHMIRILAL;;DUNN MATTHEW FRANCIS,,https://lens.org/118-171-082-270-35X,Patent Application,yes,0,3,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61P25/00;;C07D231/20;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
690,PL,T3,PL 3544972 T3,180-655-413-879-258,2023-07-24,2023,PL 17818281 T,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/180-655-413-879-258,Patent Application,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,PENDING
691,CN,A,CN 110234638 A,131-925-203-640-281,2019-09-13,2019,CN 201780084763 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,"The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (kappa-opioid) associated disorders including, e.g.,a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.",PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/131-925-203-640-281,Patent Application,no,2,2,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
692,DK,T3,DK 3544972 T3,146-291-311-356-66X,2023-05-30,2023,DK 17818281 T,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W,2016-11-28,Heteroarylphenoxy-benzamid kappa opioid ligander,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/146-291-311-356-66X,Granted Patent,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
693,DE,C3,DE 2327210 C3,037-692-806-111-504,1978-09-14,1978,DE 2327210 A,1973-05-28,US 32726873 A,1973-01-29,DE 2327210 C3,,"MATTEL, INC., HAWTHORNE, CALIF. (V.ST.A.)","DUNN, RALPH, LOS ANGELES;;AYTON, IAN FREDERIC, PALOS VERDES ESTATES;;CANE, ALBERT, LOS ANGELES;;COLLINS, HAROLD BERNARD, HAWTHORNE;;LEWIS, J. STEPHEN, PACIFIC PALISADES;;MORRIS, JOSEPH PAUL, HUNTINGTON BEACH;;SHAPERO, WALLACE HENRY, EL TORO",,https://lens.org/037-692-806-111-504,Granted Patent,no,0,0,10,10,0,D05B81/00;;Y10T156/1724;;Y10T156/1798;;Y10T156/1724;;Y10T156/1798;;D05B81/00,D05B23/00;;A63H33/30;;D05B81/00,,0,0,,,,EXPIRED
694,RS,B1,RS 64258 B1,126-476-747-638-33X,2023-07-31,2023,RS P20230453 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P;;IB 2017057418 W;;EP 17818281 A,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/126-476-747-638-33X,Granted Patent,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,A61K31/4155;;C07D403/04;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,ACTIVE
695,WO,A1,WO 2018/096510 A1,009-161-893-947-079,2018-05-31,2018,IB 2017057418 W,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,"The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R 1 , R 2 , R 3 , R 4 , R 9 , X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compound s or s al ts, an d thei r uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.",PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/009-161-893-947-079,Patent Application,yes,12,3,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61K31/4155;;A61K31/433;;A61K31/5375;;A61P25/00;;C07D413/04;;C07D417/04,,63,41,050-061-272-649-958;;045-443-768-762-017;;055-122-599-670-386;;079-335-658-708-672;;002-804-087-361-059;;096-062-641-684-497;;034-329-320-010-097;;118-907-665-065-269;;051-637-894-718-95X;;051-637-894-718-95X;;001-937-515-622-810;;002-202-467-783-116;;000-596-381-077-992;;031-902-506-698-766;;099-062-849-468-207;;031-026-904-928-320;;099-062-849-468-207;;031-026-904-928-320;;011-442-064-707-046;;023-389-021-125-842;;066-205-459-219-430;;084-264-172-869-906;;035-351-410-043-949;;034-329-320-010-097;;001-464-735-149-618;;013-191-959-161-514;;042-943-703-432-22X;;029-017-293-705-876;;044-483-019-439-642;;009-358-369-753-779;;055-137-034-632-210;;099-980-138-090-052;;068-221-734-555-993;;060-112-387-564-129;;167-008-445-298-720;;010-167-061-289-758;;051-504-865-990-218;;066-205-459-219-430;;074-486-653-055-437;;062-638-881-901-919;;035-351-410-043-949,22437504;;pmc3356457;;10.1038/nature10939;;10.1016/j.brainres.2009.08.062;;pmc2819621;;19716811;;pmc4258993;;10.3389/fpsyt.2014.00170;;25538632;;pmc3749293;;10.1016/j.biopsych.2013.03.014;;23611261;;10.1016/j.bmcl.2014.03.040;;24690494;;pmc3747596;;10.1371/journal.pone.0070701;;23976952;;21958337;;10.1021/jm200789r;;pmc4368892;;10.1093/ijnp/pyu036;;25637376;;1151699;;10.1002/jps.2600640805;;1151699;;10.1002/jps.2600640805;;10.1517/13543776.11.6.981;;10.1021/js990154g;;10514338;;10.1107/s0021889802022112;;10.1107/s002188980600731x;;10.1107/s0021889808042726;;19461838;;10.1107/s0021889807059870;;pmc2467520;;10.1107/s0021889808042726;;19461838;;10.1107/s0021889807059870;;pmc2467520;;10.1002/anie.201504775;;26371961;;pmc4629799;;12054962;;10.1021/jo011184i;;22942318;;10.1124/dmd.112.047233;;10.1093/toxsci/kfm052;;17361016;;10.1124/dmd.109.027888;;19546239;;21958337;;10.1021/jm200789r;;10.1016/j.bmcl.2010.06.129;;20655216;;20576494;;10.1016/j.toxlet.2010.05.016;;10.1016/j.bmcl.2014.04.039;;24794102;;10.1021/tx300091x;;22646477;;10.1093/toxsci/kfv152;;26206150;;26091267;;10.1038/nrd4609;;10.1007/978-3-642-00663-0_1;;20020257;;10.1002/hep.27206;;24799086;;pmc4382850;;25889215;;10.1186/s12916-015-0310-y;;16638925;;10.1093/toxsci/kfj208;;19359406;;10.1124/dmd.109.026716;;21540107;;10.1016/j.ejps.2011.04.008;;10.1124/dmd.110.037911;;21383203;;22942318;;10.1124/dmd.112.047233;;10.1124/dmd.106.012633;;17093004;;19356071;;10.2174/187231208783478407;;10.1124/dmd.109.027888;;19546239,"WU, H. ET AL.: ""Structure of the human kappa opioid receptor in complex with JDTic"", NATURE, vol. 485, no. 7398, 2012, pages 327 - 332;;BRUCHAS, M.R. ET AL.: ""The Dynorphin-Kappa Opioid System as a Modulator of Stress-induced and Pro-addictive Behaviors"", BRAIN RES., 16 February 2010 (2010-02-16);;LALANNE, L. ET AL.: ""The kappa opioid receptor: from addiction to depression, and back"", FRONTIERS IN PSYCHIATRY, vol. 5, 2014, pages 170;;KISSLER, J.L. ET AL.: ""The One-Two Punch of Alcoholism: Role of Central Amygdala Dynorphins/ Kappa-Opioid Receptors"", BIOL. PSYCHIATRY, vol. 75, 2014, pages 774 - 782, XP028646567, DOI: doi:10.1016/j.biopsych.2013.03.014;;URBANO, M. ET AL.: ""Antagonists of the kappa opioid receptor"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, 2014, pages 2021 - 2032;;MUNRO, T.A. ET AL.: ""Selective K Opioid Antagonists nor-BNI, GNTI and JDTic Have Low Affinities for Non-Opioid Receptors and Transporters"", PLOS ONE, vol. 8, no. 8, 2013, pages e70701;;MITCH, C.H. ET AL.: ""Discovery of Aminobenzyloxyarylamides as K Opioid Receptor Selective Antagonists: Application to Preclinical Development of a K Opioid Receptor Antagonist Receptor Occupancy Tracer"", J. MED. CHEM., vol. 54, 2011, pages 8000 - 8012, XP055469683, DOI: doi:10.1021/jm200789r;;RORICK- KEHN, L.M. ET AL.: ""Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human"", INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, pages 1 - 11;;HALEBLIAN, J. PHARM. SCI., vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288;;O. ALMARSSON; M. J. ZAWOROTKO, CHEM. COMMUN., vol. 17, 2004, pages 1889 - 1896;;J. K. HALEBLIAN, J. PHARM. SCI., vol. 64, 1975, pages 1269 - 1288;;N. H. HARTSHORNE; A. STUART: ""Crystals and the Polarizing Microscope"", 1970;;T. HIGUCHI; V. STELLA: ""Pro-drugs as Novel Delivery Systems"", ACS SYMPOSIUM SERIES, vol. 14;;""Bioreversible Carriers in Drug Design"", 1987, PERGAMON PRESS;;H. BUNDGAARD: ""Design of Prodrugs"", 1985, ELSEVIER;;""COMPENDIUM OF ORGANIC SYNTHETIC METHODS"", vol. I-XIII, WILEY-INTERSCIENCE;;T. W. GREENE: ""Protective Groups in Organic Chemistry"", 1981, JOHN WILEY & SONS;;T. W. GREENE; P. G. M. WUTS: ""Protective Groups in Organic Chemistry"", 1991, JOHN WILEY & SONS;;T. W. GREENE; P. G. M. WUTS: ""Protective Groups in Organic Chemistry"", 1999, JOHN WILEY & SONS;;T. W. GREENE; P. G. M. WUTS: ""Protective Groups in Organic Chemistry"", 2007, JOHN WILEY & SONS;;""Compendium of Organic Synthetic Methods"", vol. I-XII, WILEY-INTERSCIENCE;;E. L. ELIEL; S. H. WILEN: ""Stereochemistry of Organic Compounds"", 1994, WILEY;;""Remington's Pharmaceutical Sciences"", 1995, MACK PUBLISHING COMPANY;;LIANG; CHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 11, 2001, pages 981 - 986;;H. LIEBERMAN; L. LACHMAN: ""Pharmaceutical Dosage Forms: Tablets"", vol. 1, 1980, MARCEL DEKKER;;VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, vol. 25, no. 2, 2001, pages 1 - 14;;FINNIN; MORGAN, J. PHARM. SCI., vol. 88, 1999, pages 955 - 958;;SHELXTL, BRUKER AXS, 1997;;A. L. SPEK, J. APPL. CRYST., vol. 36, 2003, pages 7 - 13;;C. F. MACRAE; P. R. EDINGTON; P. MCCABE; E. PIDCOCK; G. P. SHIELDS; R. TAYLOR; M. TOWLER; J. VAN DE STREEK, J. APPL. CRYST., vol. 39, 2006, pages 453 - 457;;O. V. DOLOMANOV; L. J. BOURHIS; R. J. GILDEA; J. A. K. HOWARD; H. PUSCHMANN, J. APPL. CRYST., vol. 42, 2009, pages 339 - 341;;R. W. W. HOOFT; L. H. STRAVER; A. L. SPEK, J. APPL. CRYST., vol. 41, 2008, pages 96 - 103;;H. D. FLACK, ACTA CRYST., vol. A39, 1983, pages 867 - 881;;BRUKER AXS, 1997;;A.L. SPEK, J. APPL. CRYST., vol. 36, 2003, pages 7 - 13;;C.F. MACRAE; P.R. EDINGTON; P. MCCABE; E. PIDCOCK; G.P. SHIELDS; R. TAYLOR; M. TOWLER; J. VAN DE STREEK, J. APPL. CRYST., vol. 39, 2006, pages 453 - 457;;DOLOMANOV, O.V.; BOURHIS, L.J.; GILDEA, R.J.; HOWARD, J.A.K.; PUSCHMANN, H., J. APPL. CRYST., vol. 42, 2009, pages 339 - 341;;R.W.W. HOOFT ET AL., J. APPL. CRYST., vol. 41, 2008, pages 96 - 103;;H.D. FLACK, ACTA CRYST., vol. A39, 1983, pages 867 - 881;;K. J. FRANKOWSKI ET AL., ANGEW. CHEM., INT. ED., vol. 54, 2015, pages 10555 - 10558;;S. HANESSIAN ET AL., J. ORG. CHEM., vol. 67, 2002, pages 4261 - 4274;;YATES P; ENG H; DI L; OBACH RS, DRUG METAB DISPOS, vol. 40, 2012, pages 2289 - 96;;MARROQUIN ET AL., TOXICOLOGICAL SCIENCES, vol. 97, no. 2, 2007, pages 539 - 547;;HYNES ET AL., TOXICOLOGICAL SCIENCES, vol. 91, no. 1, 2006, pages 186 - 200;;HAY ET AL., DRUG METABOLISM AND DISPOSITION, vol. 37, no. 9, 2009, pages 1864 - 1870;;MITCH ET AL., J. MED. CHEM., vol. 54, 2011, pages 8000 - 8012;;N. GREEN ET AL.: ""Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies"", BMCL, vol. 5308, 2010;;J. BENBOW ET AL.: ""Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies"", TOXICOLOGY LETTERS, 2010, pages 175, XP027147945;;F. SHAH ET AL.: ""Chemotypes sensitivity and predictivity of in vivo outcomes for cytotoxic assays in THLE and HepG3 cell lines"", BMCL, 2014, pages 2753;;R. A. THOMPSON ET AL.: ""In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs"", CHEMICAL RESEARCH IN TOXICOLOGY, 2012, pages 1616;;F. SHAH ET AL.: ""Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays"", TOXICOLOGY SCIENCES, vol. 147, no. 2, 2015, pages 500;;M. WARING ET AL.: ""An analysis of the attrition of drug candidates from four major pharmaceutical companies"", NATURE REVIEWS DRUG DISCOVERY, 2015, pages 475;;M HOLT; C JU: ""Drug induced livery injury, Handb"", EXP. PHARMACOL., 2010, pages 3;;M ALEO ET AL.: ""Human Drug-Induced Liver Injury Severity Is Highly Associated with Dual Inhibition of Liver Mitochondrial Function and Bile Salt Export Pump"", HEPATOLOGY, vol. 60, no. 3, 2014;;G MORRIS; M BERK: ""The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders"", BMC MEDICINE, vol. 13, 2015, pages 68, XP021220407, DOI: doi:10.1186/s12916-015-0310-y;;J HYNES ET AL.: ""Investigation of Drug-Induced Mitochondrial Toxicity Using Flourescence_Based Oxygen-Sensitive Probes"", TOXICOLOGICAL SCIENCES, vol. 91, no. 1, 2006, pages 186 - 200;;S. W. GRIMM ET AL.: ""The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America"", DRUG METABOLISM AND DEPOSITION, vol. 37, no. 7, 2009, pages 1355;;K. ROWLAND YEO ET AL.: ""Prediction of Time-Dependent CYP3A4 Drug-Drug interactions by Physiologically Based Pharmacokinetic Modelling: Impact of Inactivation Parameters and Enzyme Turnover"", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 43, no. 3, 2011, pages 160;;A. ZIMMERLIN ET AL.: ""CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs"", DRUG METABOLISM AND DEPOSITION, vol. 39, no. 6, 2011, pages 1039;;P. YATES ET AL.: ""Statistical Methods for Analysis of Time-Dependent Inhibition of Cytochrome P450 Enzymes"", DRUG METABOLISM AND DEPOSITION, vol. 40, no. 12, 2012, pages 2289;;OBACH, R. S.; WALSKY, R. L.; VENKATAKRISHNAN, K.: ""Mechanism Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug Drug Interactions"", DRUG METAB. DISPOS., vol. 35, 2007, pages 246 - 55;;BERRY L.; ZHAO, Z.: ""An Examination of IC50 and IC50-Shift Experiments in Assessing Time-Dependent Inhibition of CYP3A4, CYP2D6 and CYP2C9 in Human Liver Microsomes"", DRUG METABOLISM LETTERS, vol. 2, 2008, pages 51 - 59;;HAY T.; JONES R.; BEAUMONT K.; KEMP M.: ""Modulation of the partition coefficient between octanol and buffer at pH 7.4 and pKa to achieve the optimum balance of blood clearance and volume of distribution for a series of tetrahydropyran histamine type 3 receptor antagonists"", DRUG METAB. DISPOS., vol. 37, no. 9, 2009, pages 1864 - 1870",PENDING
696,HU,T2,HU E061945 T2,045-288-342-935-040,2023-09-28,2023,HU E17818281 A,2017-11-27,US 201662426980 P;;US 201762576435 P;;US 201762585016 P,2016-11-28,HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS,,PFIZER,ARORA KAPILDEV KASHMIRILAL;;BRODNEY MICHAEL AARON;;DUNN MATTHEW FRANCIS;;GREEN MICHAEL ERIC;;KABLAOUI NATASHA MARIAM;;KAUFFMAN GREGORY WAYNE;;MENTE SCOT RICHARD;;MONTGOMERY JUSTIN IAN;;RANKIC DANICA ANTONIA;;ROGERS BRUCE NELSEN;;VERHOEST PATRICK ROBERT,,https://lens.org/045-288-342-935-040,Amended Patent,no,0,0,27,27,0,A61P25/00;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04;;C07D403/04;;C07D417/04;;C07D413/04;;C07D231/20;;A61P25/00;;C07B2200/13;;C07D231/20;;C07D403/04;;C07D413/04;;C07D417/04,C07D403/04;;A61P25/00;;C07D413/04;;C07D417/04,,0,0,,,,PENDING
697,US,B2,US 7110437 B2,186-360-665-258-052,2006-09-19,2006,US 9988902 A,2002-03-14,US 9988902 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for direct memory access and buffering of digital signals for multiple user detection,"The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a digital signal processor (“DSP”) that processes user waveforms. The DSP has an associated memory and an associated direct memory access (“DMA”) controller that controls access to that memory. A programmable logic device (“PLD”) is coupled to the DMA controller and configures it to move data relating to user waveform characteristics from the memory to a buffer external to the DSP.",MERCURY COMP SYSTEMS INC,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/186-360-665-258-052,Granted Patent,yes,103,27,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,G06F12/00;;G06F13/28;;H04B1/707,375/147;;710/22;;711/212,0,0,,,,ACTIVE
698,WO,A2,WO 2002/073230 A2,135-376-680-387-334,2002-09-19,2002,US 0207783 W,2002-03-14,US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,WIRELESS COMMUNICATIONS METHODS AND SYSTEMS FOR SHORT-CODE AND OTHER SPREAD SPECTRUM WAVEFORM PROCESSING,"The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, 'gamma matrix') that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, 'R-matrix') that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third processing element produces estimates of the user transmitted symbols as a function of the R-matrix.",MERCURY COMP SYSTEMS INC,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,,https://lens.org/135-376-680-387-334,Patent Application,yes,0,0,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/707,,0,0,,,,PENDING
699,US,B2,US 7453922 B2,004-898-178-542-202,2008-11-18,2008,US 9991202 A,2002-03-14,US 9991202 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communication systems and methods for contiguously addressable memory enabled multiple processor based multiple user detection,"The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, “gamma matrix”) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, “R-matrix”) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third procesing element produces estimates of the user transmitted symbols as a function of the R-matrix.",MERCURY COMP SYSTEMS INC,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/004-898-178-542-202,Granted Patent,yes,111,11,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/707;;H04B1/00,375/148;;375/262;;375/341;;375/148;;375/316,1,0,,,"Harvey et. al., ""DMA Fundamentals on various PC platforms"" National Instruments Apr. 1991.",ACTIVE
700,US,A1,US 2003/0231702 A1,069-677-738-493-154,2003-12-18,2003,US 29117602 A,2002-11-08,US 29117602 A;;US 9987902 A;;US 9988302 A;;US 9991202 A;;US 9954502 A;;US 9991802 A;;US 9989902 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for cache enabled multiple processor based multiple user detection,"
   The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, gamma matrix) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, R-matrix) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third processing element produces estimates of the user transmitted symbols as a function of the R-matrix. 
",OATES JOHN H.;;IMPERIALI STEVEN R.;;FUCHS ALDEN J.;;JACQUES KATHLEEN J.;;GREENE JONATHAN E.;;JENKINS WILLIAM J.;;LAUGINIGER FRANK P.;;MAJCHRZAK DAVID E.;;CANTRELL PAUL E.;;CIFRIC MIRZA;;DUNN IAN N.;;VINSKUS MICHAEL J.,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/069-677-738-493-154,Patent Application,yes,63,67,2,35,0,H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B1/7105;;H04B2201/70707;;H04B2201/70711;;H04B1/71075;;H04B1/7115,H04B1/707,375/148;;X37515,0,0,,,,EXPIRED
701,US,A1,US 2003/0202559 A1,035-947-860-556-132,2003-10-30,2003,US 9954502 A,2002-03-14,US 9954502 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for nonvolatile storage of operating parameters for multiple processor based multiple user detection,"
   The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, gamma matrix) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, R-matrix) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third procesing element produces estimates of the user transmitted symbols as a function of the R-matrix. 
",OATES JOHN H.;;IMPERIALI STEVEN R.;;FUCHS ALDEN J.;;JACQUES KATHLEEN J.;;GREENE JONATHAN E.;;CANTRELL PAUL E.;;LAUGINIGER FRANK P.;;MAJCHRZAK DAVID E.;;CIFRIC MIRZA;;JENKINS WILLIAM J.;;DUNN IAN N.;;VINSKUS MICHAEL J.,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;CANTRELL PAUL E;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CIFRIC MIRZA;;JENKINS WILLIAM J;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/035-947-860-556-132,Patent Application,yes,77,29,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/707,37513,0,0,,,,EXPIRED
702,WO,A3,WO 2002/073230 A3,022-576-318-930-583,2002-12-27,2002,US 0207783 W,2002-03-14,US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,WIRELESS COMMUNICATIONS METHODS AND SYSTEMS FOR SHORT-CODE AND OTHER SPREAD SPECTRUM WAVEFORM PROCESSING,"The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, 'gamma matrix') that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, 'R-matrix') that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third processing element produces estimates of the user transmitted symbols as a function of the R-matrix.",MERCURY COMP SYSTEMS INC,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,,https://lens.org/022-576-318-930-583,Search Report,yes,1,0,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/707,,0,0,,,,PENDING
703,US,B2,US 7110440 B2,026-270-359-529-431,2006-09-19,2006,US 9988302 A,2002-03-14,US 9988302 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for multiple processor based multiple user detection,"The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, “gamma matrix”) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, “R-matrix”) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third procesing element produces estimates of the user transmitted symbols as a function of the R-matrix.",MERCURY COMP SYSTEMS INC,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/026-270-359-529-431,Granted Patent,yes,103,10,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/707;;H04B7/216,375/148;;375/144;;375/147,0,0,,,,EXPIRED
704,US,B2,US 7210062 B2,026-469-892-811-943,2007-04-24,2007,US 9954502 A,2002-03-14,US 9954502 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for nonvolatile storage of operating parameters for multiple processor based multiple user detection,"The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, “gamma matrix”) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, “R-matrix”) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third procesing element produces estimates of the user transmitted symbols as a function of the R-matrix.",MERCURY COMP SYSTEMS INC,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/026-469-892-811-943,Granted Patent,yes,118,10,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,G06F11/00;;H04B1/707,714/15;;714/47,3,0,,,"VITA Mercury Computer Systems, RACEWay Interlink-Data Link and Physical Layers, Nov. 1998, VITA Mercury Computer Systems, Rev. 1.6.5, p. vii.;;Lockheed Sanders, Inc, Hughes Aircraft, Motorola, ISX Corporation; RASSP Architecture Guide, Jan. 5, 1995, Rev. B, pp. 25 and 81.;;Microsoft Corporation, Microsoft Computer Dictionary, 2002, Microsoft Press, Fifth Edition, pp. 326 and 419.",EXPIRED
705,US,A1,US 2003/0191887 A1,143-832-962-966-71X,2003-10-09,2003,US 9988902 A,2002-03-14,US 9988902 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for direct memory access and buffering of digital signals for multiple user detection,"
   The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, gamma matrix) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, R-matrix) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third processing element produces estimates of the user transmitted symbols as a function of the R-matrix. 
",OATES JOHN H.;;IMPERIALI STEVEN R.;;FUCHS ALDEN J.;;JACQUES KATHLEEN J.;;GREENE JONATHAN E.;;JENKINS WILLIAM J.;;LAUGINIGER FRANK P.;;MAJCHRZAK DAVID E.;;CANTRELL PAUL E.;;CIFRIC MIRZA;;DUNN IAN N.;;VINSKUS MICHAEL J.,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/143-832-962-966-71X,Patent Application,yes,60,43,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/707,711/104,0,0,,,,EXPIRED
706,US,B2,US 7376175 B2,162-661-927-562-264,2008-05-20,2008,US 29117602 A,2002-11-08,US 29117602 A;;US 9987902 A;;US 9988302 A;;US 9991202 A;;US 9954502 A;;US 9991802 A;;US 9989902 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for cache enabled multiple processor based multiple user detection,"The invention provides methods and apparatus for multiple user detection (MUD) processing. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, “gamma matrix”) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, “R-matrix”) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third processing element produces estimates of the user transmitted symbols as a function of the R-matrix.",MERCURY COMP SYSTEMS INC,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIZRA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/162-661-927-562-264,Granted Patent,yes,105,8,2,35,0,H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B1/7105;;H04B2201/70707;;H04B2201/70711;;H04B1/71075;;H04B1/7115,H04B1/00;;G06F12/00;;G06F13/00;;H03K9/00;;H04B1/707;;H04L27/00,375/147;;375/148;;375/316;;711/118;;711/149;;71/22,1,0,,,"TI ""TMS 320C62xx CPU and Instruction Set Refernce Guide"" 1997, Texas Instruments.",ACTIVE
707,US,A1,US 2003/0128739 A1,104-974-995-963-629,2003-07-10,2003,US 9991802 A,2002-03-14,US 9991802 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for multiple operating system multiple user detection,"
   The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, gamma matrix) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, R-matrix) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third procesing element produces estimates of the user transmitted symbols as a function of the R-matrix. 
",OATES JOHN H.;;IMPERIALI STEVEN R.;;FUCHS ALDEN J.;;JACQUES KATHLEEN J.;;GREENE JONATHAN E.;;JENKINS WILLIAM J.;;LAUGINIGER FRANK P.;;MAJCHRZAK DAVID E.;;CANTRELL PAUL E.;;CIFRIC MIRZA;;DUNN IAN N.;;VINSKUS MICHAEL J.,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY COMPUTERS SYSTEMS INC (2002-05-28);;MERCURY SYSTEMS INC (2012-11-05),https://lens.org/104-974-995-963-629,Patent Application,yes,73,32,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/707,37513,0,0,,,,EXPIRED
708,US,A1,US 2003/0198197 A1,139-018-729-828-635,2003-10-23,2003,US 9991202 A,2002-03-14,US 9991202 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communication systems and methods for contiguously addressable memory enabled multiple processor based multiple user detection,"
   The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, gamma matrix) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, R-matrix) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third procesing element produces estimates of the user transmitted symbols as a function of the R-matrix. 
",OATES JOHN H.;;LAUGINIGER FRANK P.;;IMPERIALI STEVEN R.;;MAJCHRZAK DAVID E.;;FUCHS ALDEN J.;;CANTRELL PAUL E.;;JACQUES KATHLEEN J.;;CIFRIC MIRZA;;GREENE JONATHAN E.;;DUNN IAN N.;;JENKINS WILLIAM J.;;VINSKUS MICHAEL J.,OATES JOHN H;;LAUGINIGER FRANK P;;IMPERIALI STEVEN R;;MAJCHRZAK DAVID E;;FUCHS ALDEN J;;CANTRELL PAUL E;;JACQUES KATHLEEN J;;CIFRIC MIRZA;;GREENE JONATHAN E;;DUNN IAN N;;JENKINS WILLIAM J;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/139-018-729-828-635,Patent Application,yes,78,25,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/707,37032;;375/148,0,0,,,,EXPIRED
709,US,A1,US 2003/0202566 A1,166-454-701-377-887,2003-10-30,2003,US 9988302 A,2002-03-14,US 9988302 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for multiple processor based multiple user detection,"
   The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, gamma matrix) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, R-matrix) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third procesing element produces estimates of the user transmitted symbols as a function of the R-matrix. 
",OATES JOHN H.;;IMPERIALI STEVEN R.;;FUCHS ALDEN J.;;JACQUES KATHLEEN J.;;GREENE JONATHAN E.;;JENKINS WILLIAM J.;;LAUGINIGER FRANK P.;;MAJCHRZAK DAVID E.;;CANTRELL PAUL E.;;CIFRIC MIRZA;;DUNN IAN N.;;VINSKUS MICHAEL J.,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY SYSTEMS INC (2002-05-28),https://lens.org/166-454-701-377-887,Patent Application,yes,4,30,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/707,375/148;;X37515,0,0,,,,EXPIRED
710,US,B2,US 7327780 B2,000-651-730-415-283,2008-02-05,2008,US 9991802 A,2002-03-14,US 9991802 A;;US 27584601 P;;US 28960001 P;;US 29506001 P,2001-03-14,Wireless communications systems and methods for multiple operating system multiple user detection,"The invention provides methods and apparatus for multiple user detection (MUD) processing that have application, for example, in improving the capacity CDMA and other wireless base stations. One aspect of the invention provides a multiprocessor, multiuser detection system for detecting user transmitted symbols in CDMA short-code spectrum waveforms. A first processing element generates a matrix (hereinafter, “gamma matrix”) that represents a correlation between a short-code associated with one user and those associated with one or more other users. A set of second processing elements generates, e.g., from the gamma matrix, a matrix (hereinafter, “R-matrix”) that represents cross-correlations among user waveforms based on their amplitudes and time lags. A third processing element produces estimates of the user transmitted symbols as a function of the R-matrix.",MERCURY COMP SYSTEMS INC,OATES JOHN H;;IMPERIALI STEVEN R;;FUCHS ALDEN J;;JACQUES KATHLEEN J;;GREENE JONATHAN E;;JENKINS WILLIAM J;;LAUGINIGER FRANK P;;MAJCHRZAK DAVID E;;CANTRELL PAUL E;;CIFRIC MIRZA;;DUNN IAN N;;VINSKUS MICHAEL J,MERCURY COMPUTERS SYSTEMS INC (2002-05-28);;MERCURY SYSTEMS INC (2012-11-05),https://lens.org/000-651-730-415-283,Granted Patent,yes,108,11,33,35,0,H04B1/707;;H04B1/7093;;H04B1/7105;;H04B1/71052;;H04B1/71075;;H04B1/7115;;H04B2201/70707;;H04B2201/70711;;H04B1/71052;;H04B2201/70707;;H04B1/7105;;H04B1/71075;;H04B1/7093;;H04B1/7115;;H04B1/707;;H04B2201/70711,H04B1/00;;H04B1/707,375/150;;375/136;;375/137;;375/142;;375/143;;375/144;;375/147;;375/148;;375/149;;375/151;;375/152,0,0,,,,INACTIVE
711,WO,A1,WO 2018/226262 A1,155-171-349-291-494,2018-12-13,2018,US 2018/0015485 W,2018-01-26,US 201762514939 P;;US 201762556376 P;;US 201815874791 A;;US 201815874799 A;;US 201815874816 A;;US 201815874821 A,2017-06-04,LONG-TERM HISTORY OF DISPLAY INTENSITIES,"A data processing system can store a long-term history of pixel luminance values in a secure memory and use those values to create burn-in compensation values that are used to mitigate burn-in effect on a display. The long-term history can be updated over time with new, accumulated pixel luminance values.",APPLE INC,COTE GUY;;DRZAIC PAUL S;;DUNN ALAN M;;GUILLOU JEAN-PIERRE;;HAUCK JERROLD V;;HENDRY IAN C;;HEPPOLETTE VANESSA C;;KOH TAE-WOOK;;LINDBERG LARS M;;MACHALEK ADAM J;;SAZEGARI ALI;;SPENCE ARTHUR L;;TANN CHRISTOPHER P;;THOMPSON ROSS;;ZHANG YIFAN,,https://lens.org/155-171-349-291-494,Patent Application,yes,11,1,9,9,0,G09G3/32;;G09G2320/0285;;G09G2320/043;;G09G2320/048;;G09G2330/026;;G06F9/451;;G09G2320/046;;G09G2358/00;;G06F9/4401;;G09G3/2003;;G09G3/006;;G09G2320/046;;G09G2320/066;;G09G2358/00;;G09G2300/0847;;G09G2354/00;;G06F9/451;;G09G3/32;;G09G2320/0285;;G09G2320/043;;G09G2320/048;;G09G2330/026;;G09G2320/0233;;G06F3/0622;;G06F3/0623;;G06F3/0652;;G06F3/0656;;G06F3/0673;;G09G3/3208;;G06F3/0643;;G06F3/0644;;G06F3/0647;;G06F3/067;;G06F9/4401,G09G3/32,,1,1,030-403-488-845-474,10.1002/jsid.401,"P. VOLKERT; X. JIANG; C. XU: ""Characterization and Compensation of OLED Aging in a Digital AMOLED System"", J. SOC. INFO. DISPLAY, vol. 23, no. 12, December 2015 (2015-12-01), pages 570 - 579",PENDING
712,HK,A1,HK 1042484 A1,017-185-581-719-233,2002-08-16,2002,HK 02103493 A,2002-05-08,US 25071899 A;;US 4225198 A;;US 9905332 W,1998-03-13,"Processes for the preparation of (r)-a-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)-4-piperidinemethanol",,AVENTIS PHARMA INC,ALAN BINA;;EDWARD DAUGS;;JONATHAN EVANS;;HANS-WOLFRAM FLEMMING;;GERARD GUILLAMOT;;ROBERT HAWTRONE;;THOMAS HILPERT;;JAMES HITT;;CHI-HSIN KING;;JOHANNES KOEK;;FREDERICK LASKOVICS;;JOHN LEFLER;;ALEXEY MARGOLION;;SHARON MINISH;;THOMAS ORTYL;;LIAN RAJEWSKI;;MARVIN SACK;;PAUL SKULTETY;;SANDRA STOLTZ-DUNN;;ALONZO TIGNER;;IAN TOMLINSON,,https://lens.org/017-185-581-719-233,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D/;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
713,EP,A2,EP 1636688 A2,035-003-243-727-137,2006-03-22,2006,EP 04753739 A,2004-06-01,US 2004/0016975 W;;US 45217803 A,2003-06-02,ELECTRONIC WHITEBOARD,,POLY VISION CORP,HILDEBRANDT PETER W;;GILLESPIE SCOTT PAUL;;DEAKIN LYNDA ALISON;;WILSON SCOTT E;;HUTCHINSON IAN G;;PRACHAR TIMOTHY J;;WATSON JAMES D;;DUNN MICHAEL H;;WILLIAMS GUY L;;ADLER ARI T;;PATRON TONY P;;SENATORE STEPHEN J;;MACDONALD PETER S;;DESMOND MATTHEW A;;HICKS GRAHAM MACDONALD;;GILMORE DAVID;;WEGENER KATRIN;;RAGAN JEANNE M;;ENDERS THOMAS FRANZ;;MACINTOSH ERIC ALLAN,,https://lens.org/035-003-243-727-137,Patent Application,yes,0,0,8,8,0,G06F21/84;;G06F21/84,G06F3/033;;G06F21/00;;G09G5/00;;H04N1/00;;H04N1/21,,0,0,,,,DISCONTINUED
714,NO,B1,NO 317981 B1,078-966-252-876-144,2005-01-17,2005,NO 20004545 A,2000-09-12,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"Fremgangsmate for fremstilling av (R)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol, mellomprodukter for bruk ved fremstilling av denne forbindelse og fremgangsmpter for fremstilling av noen av disse mellomprodukter",,AVENTIS PHARMA GMBH;;AVENTIS PHARMA INC,TOMLINSON IAN A;;SKULTETY PAUL F;;EVANS JONATHAN CHARLES;;MARGOLIN ALEXEY LEONID;;STOLZ-DUNN SANDRA KAYE;;FLEMMING HANS-WOLFRAM;;HITT JAMES E;;LEFLER JOHN ROBERT;;MINISH SHARON KAY;;BINA ALAN G;;DAUGS EDWARD D;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J,,https://lens.org/078-966-252-876-144,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
715,CA,A1,CA 2528306 A1,066-775-679-803-764,2004-12-16,2004,CA 2528306 A,2004-06-01,US 45217803 A;;US 2004/0016975 W,2003-06-02,ELECTRONIC WHITEBOARD,"A method and apparatus for use with a whiteboard and an archive memory, the whiteboard having a surface for displaying images, the method for grouping presented images together for storage in the archive memory and password protecting the image groups in separate session files where a password is subsequently required to access the session file images.",POLY VISION CORP,BOURN DOUGLAS R;;PATRON TONY P;;ZEH MARK A;;HILDEBRANDT PETER W;;HUTCHINSON IAN G;;MACDONALD PETER S;;SENATORE STEPHEN J;;GILLESPIE SCOTT PAUL;;MACINTOSH ERIC ALLAN;;ADLER ARI T;;WILSON SCOTT E;;PRACHAR TIMOTHY J;;HICKS GRAHAM MACDONALD;;DESMOND MATTHEW A;;ENDERS THOMAS FRANZ;;DEAKIN LYNDA ALISON;;RAGAN JEANNE M;;DUNN MICHAEL H;;GILMORE DAVID;;WILLIAMS GUY L;;WEGENER KATRIN;;WATSON JAMES D,,https://lens.org/066-775-679-803-764,Patent Application,no,0,0,8,8,0,G06F21/84;;G06F21/84,H04N1/21;;G06F3/033;;G06F21/00;;G09G5/00;;H04N1/00,,0,0,,,,DISCONTINUED
716,DZ,A1,DZ 2742 A1,024-624-025-729-970,2003-09-08,2003,DZ 990043 A,1999-03-10,US 4225198 A;;US 25071899 A,1998-03-13,"Nouveaux procédés pour la préparation de (r)-beta-(2,3-diméthoxy phényl)-1-Ä2-(4-fluorophényl)éthylÜ-4-pipéridineméthanol.",,HOECHST MARION ROUSSEL INC;;HOECHST MARION ROUSSEL DE GMBH,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS W;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOLINSON IAN A,,https://lens.org/024-624-025-729-970,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
717,WO,A3,WO 1999/046245 A3,147-299-369-423-83X,1999-09-16,1999,US US9905332,1999-03-11,"US 09/0/042,251;;US 09/2/050,718",1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMACEUTICALS INC.;;HOECHST MARION ROUSSEL DEUTSCHLAND GMBH,"BINA, Alan, G.;;DAUGS, Edward, D.;;EVANS, Jonathan, C.;;FLEMMING, Hans-Wolfram;;GUILLAMOT, Gerard;;HAWTHORNE, Robert, A.;;HILPERT, Thomas, H., E.;;HITT, James, E.;;KING, Chi-Hsin, R.;;KOEK, Johannes, N.;;LASKOVICS, Frederick, M.;;LEFLER, John, R.;;MARGOLIN, Alexey, L.;;MINISH, Sharon, K.;;ORTYL, Thomas, T.;;RAJEWSKI, Lian, G.;;SACK, Marvin, J.;;SKULTETY, Paul, F.;;STOLZ-DUNN, Sandra, K.;;TIGNER, Alonzo, L.;;TOMLINSON, Ian, A.",,https://lens.org/147-299-369-423-83X,Search Report,yes,0,0,1,1,0,,C07D211/22;;C07D211/32,,0,0,,,,UNKNOWN
718,CA,C,CA 2322501 C,170-443-867-287-33X,2006-05-09,2006,CA 2322501 A,1999-03-11,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-.ALPHA.-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",HOECHST MARION ROUSSEL DE GMBH;;AVENTIS PHARMA INC,HILPERT THOMAS H E;;HITT JAMES E;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;LASKOVICS FREDERICK M;;MINISH SHARON K;;KING CHI-HSIN R;;KOEK JOHANNES N;;TOMLINSON IAN A;;DAUGS EDWARD D;;FLEMMING HANS-WOLFRAM;;EVANS JONATHAN C;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;TIGNER ALONZO L;;STOLZ-DUNN SANDRA K;;SKULTETY PAUL F;;BINA ALAN G;;MARGOLIN ALEXEY L;;LEFLER JOHN R,,https://lens.org/170-443-867-287-33X,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
719,HK,B,HK 1042484 B,092-881-230-898-275,2008-05-02,2008,HK 02103493 A,2002-05-08,US 25071899 A;;US 4225198 A;;US 9905332 W,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL",,AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN M;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLTZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/092-881-230-898-275,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D/;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
720,SI,T1,SI 1192134 T1,049-306-634-714-17X,2008-02-29,2008,SI 9930992 T,1999-03-11,US 4225198 A;;US 25071899 A;;US 9905332 W;;EP 99911318 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4 PIPERIDINEMETHANOL",,AVENTIS PHARMA INC;;HOECHST MARION ROUSSEL DE GMBH,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN M;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLTZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/049-306-634-714-17X,Granted Patent,no,0,0,1,64,0,C07D211/22;;C07D211/32,C07D211/00;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
721,KR,A,KR 20060002034 A,132-223-816-152-280,2006-01-06,2006,KR 20057024567 A,2005-12-22,US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-alpha-(2,3- dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/132-223-816-152-280,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,INACTIVE
722,CA,A1,CA 2493559 A1,152-093-377-952-27X,1999-09-16,1999,CA 2493559 A,1999-03-11,CA 2322501 A;;US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-.ALPHA.-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMA INC;;HOECHST MARION ROUSSEL DE GMBH,TOMLINSON IAN A;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;TIGNER ALONZO L;;KOEK JAHANNES N;;LASKOVICS FREDERICK M;;EVANS JONATHAN C;;HAWTHORNE ROBERT A;;BINA ALAN G;;GUILLAMOT GERARD;;DAUGS EDWARD D;;HITT JAMES E;;FLEMMING HANS-WOLFRAM;;KING CHI-HSIN R;;LEFLER JOHN R;;ORTYL THOMAS T;;MINISH SHARON K;;MARGOLIN ALEXEY L;;HILPERT THOMAS H;;RAJEWSKI LIAN G;;SACK MARYIN J,,https://lens.org/152-093-377-952-27X,Patent Application,no,0,0,4,64,0,,C07D211/22;;C07D213/30,,0,0,,,,DISCONTINUED
723,CA,A1,CA 2493173 A1,098-253-117-340-027,1999-09-16,1999,CA 2493173 A,1999-03-11,CA 2322501 A;;US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-.ALPHA.-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMA INC;;HOECHST MARION ROUSSEL DE GMBH,MINISH SHARON K;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;ORTYL THOMAS T;;STOLZ-DUNN SANDRA K;;BINA ALAN G;;TIGNER ALONZO L;;TOMLINSON IAN A;;SKULTETY PAUL F;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;RAJEWSKI LIAN G;;HITT JAMES E;;SACK MARYIN J;;GUILLAMOT GERHARD;;KING CHI-HSIN R,,https://lens.org/098-253-117-340-027,Patent Application,no,0,0,4,64,0,,C07D211/22;;C07D213/30,,0,0,,,,DISCONTINUED
724,WO,A2,WO 1999/046245 A2,126-595-529-588-807,1999-09-16,1999,US 9905332 W,1999-03-11,US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)- alpha - (2,3-DIMETHOXYPHENYL)- 1-[2-(4- FLUOROPHENYL)ETHYL]- 4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)- alpha -(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",HOECHST MARION ROUSSEL INC;;HOECHST MARION ROUSSEL DE GMBH,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/126-595-529-588-807,Patent Application,no,0,6,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,PATENTED
725,CA,A1,CA 2322501 A1,012-306-939-083-791,1999-09-16,1999,CA 2322501 A,1999-03-11,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-.ALPHA.- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R).alpha.-(2,3-dimethoxyphenyl)-1-¢2-(fluorophenyl)ethyl!-4-piperidinemethanol. These processes may be characterized by scheme (A).",HOECHST MARION ROUSSEL DE GMBH;;AVENTIS PHARMA INC,GUILLAMOT GERARD;;SKULTETY PAUL F;;HITT JAMES E;;TIGNER ALONZO L;;STOLZ-DUNN SANDRA K;;FLEMMING HANS-WOLFRAM;;EVANS JONATHAN C;;TOMLINSON IAN A;;MARGOLIN ALEXEY L;;SACK MARVIN J;;LEFLER JOHN R;;DAUGS EDWARD D;;MINISH SHARON K;;BINA ALAN G;;RAJEWSKI LIAN G;;LASKOVICS FREDERICK M;;ORTYL THOMAS T;;HILPERT THOMAS H E;;KOEK JOHANNES N;;KING CHI-HSIN R;;HAWTHORNE ROBERT A,,https://lens.org/012-306-939-083-791,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
726,US,A1,US 2011/0083109 A1,054-025-446-262-399,2011-04-07,2011,US 96399010 A,2010-12-09,US 96399010 A;;US 45217803 A;;US 38498202 P;;US 38513902 P;;US 38498402 P;;US 38497702 P,2002-06-02,Electronic Whiteboard,"A method and apparatus for use with an electronic display system including a display surface wherein the system is capable of identifying a touch location on at least a portion of the display surface of a contact with the display surface, the display surface having a display area, the method for moving a cursor icon about at least a portion of the display area and comprising the steps of identifying first and second areas within the display area having first and second area surfaces, respectively, sensing a touch location on the first area surface and presenting a cursor icon on the second area surface as a function of the touch location on the first area surface.",HILDEBRANDT PETER W;;GILLESPIE SCOTT PAUL;;DEAKIN LYNDA ALISON;;WILSON SCOTT E;;HUTCHINSON IAN G;;PRACHAR TIMOTHY J;;WATSON JAMES D;;DUNN MICHAEL H;;WILLIAMS GUY L;;ADLER ARI T;;PATRON TONY P;;SENATORE STEPHEN J;;MACDONALD PETER S;;DESMOND MATTHEW A;;HICKS GRAHAM MACDONALD;;GILMORE DAVID;;WEGENER KATRIN;;RAGAN JEANNE M;;ENDERS THOMAS FRANZ;;BOURN DOUGLAS R;;MACINTOSH ERIC ALLAN;;ZEH MARK A,HILDEBRANDT PETER W;;GILLESPIE SCOTT PAUL;;DEAKIN LYNDA ALISON;;WILSON SCOTT E;;HUTCHINSON IAN G;;PRACHAR TIMOTHY J;;WATSON JAMES D;;DUNN MICHAEL H;;WILLIAMS GUY L;;ADLER ARI T;;PATRON TONY P;;SENATORE STEPHEN J;;MACDONALD PETER S;;DESMOND MATTHEW A;;HICKS GRAHAM MACDONALD;;GILMORE DAVID;;WEGENER KATRIN;;RAGAN JEANNE M;;ENDERS THOMAS FRANZ;;BOURN DOUGLAS R;;MACINTOSH ERIC ALLAN;;ZEH MARK A,STEELCASE INC (2014-02-10),https://lens.org/054-025-446-262-399,Patent Application,yes,9,50,8,8,0,G06F21/84;;G06F21/84,G06F3/033;;G06F3/048;;G06F3/041;;G06F21/00;;G09G5/00;;H04N1/00;;H04N1/21,715/862;;345/173,0,0,,,,DISCONTINUED
727,NZ,A,NZ 506807 A,085-355-096-468-974,2003-03-28,2003,NZ 50680799 A,1999-03-11,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"Processes for the preparation of (R)-alpha-(2,3- dimethoxyphenyl)-1-[2-(4- fluorophenyl)ethyl]-4- piperidinemethanol","A process for preparing (R)-a-(2,3-dimethoxyphenyl)-1- [2-(fluorophenyl)ethyl]-4-piperidinemethanol of formula (3) is depicted in scheme A. This compound can be used to treat schizophrenia, anxiety, variant angina, anorexia nervosa, Raynaud's phenomenon, intermittent claudication, coronary or peripheral vasospasms, fibromyalgia, cardiac arrhythmia's, thrombotic illness. The compound (R)-a-(2,3-dimethoxyphenyl)-4- piperidinemethanol has the formula (I); the compound 4-[1- oxo-1-(2,3-dimethoxyphenyl)methyl]-N-2-(4-fluorophen-1-oxo- ethyl)piperidine has the formula (4); the compound (R)-a- (2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol, (2S,3S)-(+)-di-(p-anisoyl)tartaric acid salt has the formula (3a) and .the compound 4-[1-hydroxy-1- (2,3-dimethoxyphenyl)methyl]-N-2-(4-fluorophen-1-oxo- ethyl)piperidine has the formula (20).",AVENTIS PHARMA INC,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;LEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERTA;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;OEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;ARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;AJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/085-355-096-468-974,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,PENDING
728,PT,E,PT 1192134 E,052-260-156-534-621,2007-11-13,2007,PT 99911318 T,1999-03-11,US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL",,SANOFI AVENTIS DEUTSCHLAND;;AVENTIS PHARMA INC,MARGOLIN ALEXEY L;;EVANS JONATHAN C;;MINISH SHARON K;;FLEMMING HANS-WOLFRAM;;SKULTETY PAUL F;;BINA ALAN G;;DAUGS EDWARD D;;GUILLAMOT GERARD;;HAWTORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN M;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;STOLTZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/052-260-156-534-621,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
729,AU,B2,AU 755436 B2,084-063-650-851-778,2002-12-12,2002,AU 1999/029988 A,1999-03-11,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"Processes for the preparation of (R)-alpha- (2,3-dimethoxyphenyl)- 1-Ý2-(4- fluorophenyl)ethyl¨- 4-piperidinemethanol",,AVENTIS PHARMA INC;;AVENTIS PHARMA GMBH,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,"AVENTIS PHARMACEUTICALS INC, AVENTIS PHARMA DEUTSC (2002-12-05)",https://lens.org/084-063-650-851-778,Granted Patent,no,2,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,1,1,022-138-021-142-447,1360026;;10.1021/jm00101a012,"J.MED.CHEM.,1992, 35(23), 4344-61",EXPIRED
730,ZA,B,ZA 991907 B,184-260-011-966-972,1999-09-13,1999,ZA 991907 A,1999-03-09,US 4225198 A,1998-03-13,"Novel processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.",,HOECHST MARION ROUSSEL INC;;HOECHST MARION ROUSELL DEUTSCH,BINA ALAN G;;FLEMMING HANDS-WOLFRAM;;HILPERT THOMAS H E;;KOEK JOHANNES N;;LEFLER JOHN R;;MINISH SHARON K;;SACK MARVIN J;;TIGNER ALONZO L;;DAUGS EDWARD D;;GUILLAMOT GERARD;;HITT JAMES E;;LASKOVICS FREDERICK M;;MARGOLIN ALEXEY L;;ORTYL THOMAS T;;SKULTETY PAUL F;;TOMLINSON IAN A;;EVANS JONATHAN C;;HAWTHORNE ROBERT A;;KING CHI-HSIN R;;RAJEWSKI LIAN G;;STOLZ-DUNN SANDRA K,,https://lens.org/184-260-011-966-972,Granted Patent,no,0,0,3,64,0,,A61K/;;C07D/,,0,0,,,,EXPIRED
731,KR,A,KR 20060002036 A,182-829-375-577-717,2006-01-06,2006,KR 20057024569 A,2005-12-22,US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-alpha-(2,3- dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/182-829-375-577-717,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,INACTIVE
732,DE,D1,DE 69937162 D1,103-895-148-038-81X,2007-10-31,2007,DE 69937162 T,1999-03-11,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"VERFAHREN ZUR HERSTELLUNG VON (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINMETHANOL",,AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G.;;DAUGS EDWARD D;;EVANS JONATHAN C.;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTORNE ROBERT A;;HILPERT THOMAS H.E.;;HITT JAMES E.;;KING CHI-HSIN R.;;KOEK JOHANNES N.;;LASKOVICS FREDERICK M;;LEFLER JOHN M.;;MARGOLIN ALEXEY L.;;MINISH SHARON K;;ORTYL THOMAS T.;;RAJEWSKI LIAN G.;;SACK MARVIN J.;;SKULTETY PAUL F.;;STOLTZ-DUNN SANDRA K.;;TIGNER ALONZO L.;;TOMLINSON IAN A.,,https://lens.org/103-895-148-038-81X,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
733,NO,L,NO 20004545 L,149-118-439-425-521,2000-11-13,2000,NO 20004545 A,2000-09-12,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol",,AVENTIS PHARMA INC;;HOECHST MARION ROUSSEL DE GMBH,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN CHARLES;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN ROBERT;;MARGOLIN ALEXEY LEONID;;MINISH SHARON KAY;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA KAYE;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/149-118-439-425-521,Abstract,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
734,AU,A1,AU 2004/246630 A1,013-813-951-683-290,2004-12-16,2004,AU 2004/246630 A,2004-06-01,US 45217803 A;;US 2004/0016975 W,2003-06-02,Electronic whiteboard,,POLY VISION CORP,GILLESPIE SCOTT PAUL;;GILMORE DAVID;;ENDERS THOMAS FRANZ;;WATSON JAMES D;;BOURN DOUGLAS R;;MACINTOSH ERIC ALLAN;;HUTCHINSON IAN G;;ADLER ARI T;;HILDEBRANDT PETER W;;DESMOND MATTHEW A;;PRACHAR TIMOTHY J;;DUNN MICHAEL H;;PATRON TONY P;;SENATORE STEPHEN J;;WEGENER KATRIN;;WILSON SCOTT E;;MACDONALD PETER S;;HICKS GRAHAM MACDONALD;;RAGAN JEANNE M;;WILLIAMS GUY L;;ZEH MARK A;;DEAKIN LYNDA ALISON,,https://lens.org/013-813-951-683-290,Patent Application,no,0,0,8,8,0,G06F21/84;;G06F21/84,H04N1/21;;G06F3/033;;G06F21/00;;G09G5/00;;H04N1/00,,0,0,,,,DISCONTINUED
735,KR,A,KR 20060002037 A,122-228-210-039-603,2006-01-06,2006,KR 20057024570 A,2005-12-22,US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-alpha-(2,3- dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/122-228-210-039-603,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,INACTIVE
736,TN,A1,TN SN99035 A1,045-536-919-123-996,2005-11-10,2005,TN SN99035 A,1999-03-11,US 4225198 A;;US 25071899 A,1998-03-13,"NOUVEAUX PROCEDES POUR LA PREPARATION DE (R) - α - ( 2,3 DIMETHOXYPHENYL) -1 - [ 2 - (4 - FLUOROPHENYL) ETHYL] - 4 - PIPERIDINEMETHANOL","LA PRESENTE INVENTION MET A DISPOSITION DIVERS PROCEDES POUR LA PREPARATION DE (R) – α - (2,3 - DIMETHOXYPHENYL)- 1 - [2 - (4 - FLUOROPHENYL) ETHYL] - 4 - PIPERIDINEMETHANOL. CES PROCEDES PEUVENT ETRE CARACTERISES PAR LE SCHEMA SUIVANT",HOECHST MARION ROUSSEL INC;;HOECHST MARION ROUSSEL DE GMBH,KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERIC M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;TIGNER ALONZO L;;THOMLINSON IAN A,,https://lens.org/045-536-919-123-996,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,PENDING
737,WO,A2,WO 2004/109496 A2,049-855-534-267-976,2004-12-16,2004,US 2004/0016975 W,2004-06-01,US 45217803 A,2003-06-02,ELECTRONIC WHITEBOARD,"A method and apparatus for use with a whiteboard and an archive memory, the whiteboard having a surface for displaying images, the method for grouping presented images together for storage in the archive memory and password protecting the image groups in separate session files where a password is subsequently required to access the session file images.",POLY VISION CORP;;HILDEBRANDT PETER W;;GILLESPIE SCOTT PAUL;;DEAKIN LYNDA ALISON;;WILSON SCOTT E;;HUTCHINSON IAN G;;PRACHAR TIMOTHY J;;WATSON JAMES D;;DUNN MICHAEL H;;WILLIAMS GUY L;;ADLER ARI T;;PATRON TONY P;;SENATORE STEPHEN J;;MACDONALD PETER S;;DESMOND MATTHEW A;;HICKS GRAHAM MACDONALD;;GILMORE DAVID;;WEGENER KATRIN;;RAGAN JEANNE M;;ENDERS THOMAS FRANZ;;BOURN DOUGLAS R;;MACINTOSH ERIC ALLAN;;ZEH MARK A,HILDEBRANDT PETER W;;GILLESPIE SCOTT PAUL;;DEAKIN LYNDA ALISON;;WILSON SCOTT E;;HUTCHINSON IAN G;;PRACHAR TIMOTHY J;;WATSON JAMES D;;DUNN MICHAEL H;;WILLIAMS GUY L;;ADLER ARI T;;PATRON TONY P;;SENATORE STEPHEN J;;MACDONALD PETER S;;DESMOND MATTHEW A;;HICKS GRAHAM MACDONALD;;GILMORE DAVID;;WEGENER KATRIN;;RAGAN JEANNE M;;ENDERS THOMAS FRANZ;;BOURN DOUGLAS R;;MACINTOSH ERIC ALLAN;;ZEH MARK A,,https://lens.org/049-855-534-267-976,Patent Application,yes,0,11,8,8,0,G06F21/84;;G06F21/84,G06F3/033;;G06F21/00;;G09G5/00;;H04N1/00;;H04N1/21,,0,0,,,,PENDING
738,WO,A3,WO 2004/109496 A3,102-605-625-757-135,2005-03-24,2005,US 2004/0016975 W,2004-06-01,US 45217803 A,2003-06-02,ELECTRONIC WHITEBOARD,"A method and apparatus for use with a whiteboard and an archive memory, the whiteboard having a surface for displaying images, the method for grouping presented images together for storage in the archive memory and password protecting the image groups in separate session files where a password is subsequently required to access the session file images.",POLY VISION CORP;;HILDEBRANDT PETER W;;GILLESPIE SCOTT PAUL;;DEAKIN LYNDA ALISON;;WILSON SCOTT E;;HUTCHINSON IAN G;;PRACHAR TIMOTHY J;;WATSON JAMES D;;DUNN MICHAEL H;;WILLIAMS GUY L;;ADLER ARI T;;PATRON TONY P;;SENATORE STEPHEN J;;MACDONALD PETER S;;DESMOND MATTHEW A;;HICKS GRAHAM MACDONALD;;GILMORE DAVID;;WEGENER KATRIN;;RAGAN JEANNE M;;ENDERS THOMAS FRANZ;;BOURN DOUGLAS R;;MACINTOSH ERIC ALLAN;;ZEH MARK A,HILDEBRANDT PETER W;;GILLESPIE SCOTT PAUL;;DEAKIN LYNDA ALISON;;WILSON SCOTT E;;HUTCHINSON IAN G;;PRACHAR TIMOTHY J;;WATSON JAMES D;;DUNN MICHAEL H;;WILLIAMS GUY L;;ADLER ARI T;;PATRON TONY P;;SENATORE STEPHEN J;;MACDONALD PETER S;;DESMOND MATTHEW A;;HICKS GRAHAM MACDONALD;;GILMORE DAVID;;WEGENER KATRIN;;RAGAN JEANNE M;;ENDERS THOMAS FRANZ;;BOURN DOUGLAS R;;MACINTOSH ERIC ALLAN;;ZEH MARK A,,https://lens.org/102-605-625-757-135,Search Report,yes,5,0,8,8,0,G06F21/84;;G06F21/84,G06F3/033;;G06F21/00;;G09G5/00;;H04N1/00;;H04N1/21,,0,0,,,,PENDING
739,AT,T1,AT E373639 T1,168-806-670-307-083,2007-10-15,2007,AT 99911318 T,1999-03-11,US 4225198 A;;US 25071899 A,1998-03-13,"VERFAHREN ZUR HERSTELLUNG VON (R)-G(A)-(2,3- DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4- PIPERIDINMETHANOL",,AVENTIS PHARMA INC,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN M;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLTZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/168-806-670-307-083,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
740,CA,A1,CA 2492600 A1,097-233-916-210-304,1999-09-16,1999,CA 2492600 A,1999-03-11,CA 2322501 A;;US 4225198 A;;US 25071899 A,1998-03-13,"PROCESS FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4 -FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",HOECHST MARION ROUSSEL DE GMBH;;AVENTIS PHARMA INC,DAUGS EDWARD D;;ORTYL THOMAS T;;KING CHI-HSIN R;;RAJEWSKI LIAN G;;TOMLINSON IAN A;;HITT JAMES E;;KOEK JAHANNES N;;SACK MARYIN J;;LASKOVICS FREDERICK M;;TIGNER ALONZO L;;HILPERT THOMAS H E;;MINISH SHARON K;;STOLZ-DUNN SANDRA K;;HAWTHORNE ROBERT A;;MARGOLIN ALEXEY L;;LEFLER JOHN R;;FLEMMING HANS-WOLFRAM;;EVANS JONATHAN C;;SKULTETY PAUL F;;BINA ALAN G;;GUILLAMOT GERARD,,https://lens.org/097-233-916-210-304,Patent Application,no,0,0,4,64,0,,C07D211/22;;C07D213/30,,0,0,,,,DISCONTINUED
741,NO,D0,NO 20004545 D0,105-095-194-080-32X,2000-09-12,2000,NO 20004545 A,2000-09-12,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol",,AVENTIS PHARMA INC;;HOECHST MARION ROUSSEL DE GMBH,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN CHARLES;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN ROBERT;;MARGOLIN ALEXEY LEONID;;MINISH SHARON KAY;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA KAYE;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/105-095-194-080-32X,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
742,DK,T3,DK 1192134 T3,186-222-403-670-981,2007-11-26,2007,DK 99911318 T,1999-03-11,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"Fremgangsmåde til fremstilling af (R)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinmethanol",,AVENTIS PHARMA INC;;HOECHST MARION ROUSSEL DE GMBH,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;LASKOVICS FREDERICK M;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLTZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A;;KING CHI-HSIN R;;KOEK JOHANNES N;;LEFLER JOHN M;;MARGOLIN ALEXEY L,,https://lens.org/186-222-403-670-981,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
743,WO,A3,WO 1999/046245 A3,060-509-142-834-747,1999-10-21,1999,US 9905332 W,1999-03-11,US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)- alpha - (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",HOECHST MARION ROUSSEL INC;;HOECHST MARION ROUSSEL DE GMBH,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/060-509-142-834-747,Search Report,yes,6,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,2,2,022-138-021-142-447;;189-748-148-589-38X,1360026;;10.1021/jm00101a012;;10.1016/s0957-4166(00)80136-6,"GILLIGAN ET AL: ""Novel Piperidine sigma Receptor Ligands as Potential Antipsychotc Drugs"", J.MED.CHEM, vol. 35, no. 23, 1992, pages 4344 - 4361, XP002106858;;KING ET AL: ""Immobilization of Substrates in Enzyme-Catalysed Hydrolysis"", TETRAHEDRON:ASYMMETRY, vol. 4, no. 5, 1993, pages 943 - 946, XP002113290",PATENTED
744,KR,A,KR 20060002039 A,116-419-935-511-949,2006-01-06,2006,KR 20057024573 A,2005-12-22,US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-alpha-(2,3- dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/116-419-935-511-949,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,INACTIVE
745,JP,A,JP 2010143925 A,090-144-412-801-259,2010-07-01,2010,JP 2009296809 A,2009-12-28,US 4225198 A;;US 25071899 A,1998-03-13,"METHOD FOR PRODUCING (R)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","<P>PROBLEM TO BE SOLVED: To provide various methods for producing (R)-α-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. <P>SOLUTION: There are provided various methods for the production comprising, reacting an (R)-α-(2,3-dimethoxyphenyl)-4-piperidinemethanol with a 4-fluorophenylethyl alkylating agent, reacting 4-[1-oxo-1-(2,3-dimethoxyphenyl)methyl]-N-2-(4-fluorofen-1-oxo-ethyl)piperidine with a chiral reducing agent, or a selective enzymatic hydrolysis of α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol butyric acid ester. <P>COPYRIGHT: (C)2010,JPO&INPIT",AVENTIS HOLDINGS INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLTZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/090-144-412-801-259,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;C07B61/00;;C07D211/30;;C07D211/32;;C07D213/00;;C07D213/50;;C12P41/00,,0,0,,,,DISCONTINUED
746,DE,T2,DE 69937162 T2,140-180-537-741-413,2008-06-12,2008,DE 69937162 T,1999-03-11,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"Verfahren zur Herstellung von (R)-alpha-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinmethanol",,AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G.;;DAUGS EDWARD D;;EVANS JONATHAN C.;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTORNE ROBERT A;;HILPERT THOMAS H.E.;;HITT JAMES E.;;KING CHI-HSIN R.;;KOEK JOHANNES N.;;LASKOVICS FREDERICK M;;LEFLER JOHN M.;;MARGOLIN ALEXEY L.;;MINISH SHARON K;;ORTYL THOMAS T.;;RAJEWSKI LIAN G.;;SACK MARVIN J.;;SKULTETY PAUL F.;;STOLTZ-DUNN SANDRA K.;;TIGNER ALONZO L.;;TOMLINSON IAN A.,,https://lens.org/140-180-537-741-413,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
747,CA,A1,CA 2493546 A1,146-750-358-418-012,1999-09-16,1999,CA 2493546 A,1999-03-11,CA 2322501 A;;US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-.ALPHA.-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL","The present invention provides various processes for the preparation of (R)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMA INC;;HOECHST MARION ROUSSEL DE GMBH,HAWTHORNE ROBERT A;;DAUGS EDWARD D;;BINA ALAN G;;GUILLAMOT GERARD;;KING CHI-HSIN R;;HITT JAMES E;;HILPERT THOMAS H E;;KOEK JAHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;EVANS JONATHAN C;;RAJEWSKI LIAN G;;SACK MARYIN J;;TIGNER ALONZO L;;TOMLINSON IAN A;;ORTYL THOMAS T;;FLEMMING HANS-WOLFRAM;;MINISH SHARON K;;MARGOLIN ALEXEY L,,https://lens.org/146-750-358-418-012,Patent Application,no,0,0,4,64,0,,C07D211/22;;C07D213/30,,0,0,,,,DISCONTINUED
748,US,A1,US 2004/0070616 A1,192-132-678-343-531,2004-04-15,2004,US 45217803 A,2003-06-02,US 45217803 A;;US 38498202 P;;US 38513902 P;;US 38498402 P;;US 38497702 P,2002-06-02,Electronic whiteboard,"
   A method and apparatus for use with a whiteboard and an archive memory, the whiteboard having a surface for displaying images, the method for grouping presented images together for storage in the archive memory and password protecting the image groups in separate session files where a password is subsequently required to access the session file images. 
",HILDEBRANDT PETER W.;;GILLESPIE SCOTT PAUL;;DEAKIN LYNDA ALISON;;WILSON SCOTT E.;;HUTCHINSON IAN G.;;PRACHAR TIMOTHY J.;;WATSON JAMES D.;;DUNN MICHAEL H.;;WILLIAMS GUY L.;;ADLER ARI T.;;PATRON TONY P.;;SENATORE STEPHEN J.;;MACDONALD PETER S.;;DESMOND MATTHEW A.;;HICKS GRAHAM MACDONALD;;GILMORE DAVID;;WEGENER KATRIN;;RAGAN JEANNE M.;;ENDERS THOMAS FRANZ;;BOURN DOUGLAS R.;;MACINTOSH ERIC ALLAN;;ZEH MARK A.,HILDEBRANDT PETER W;;GILLESPIE SCOTT PAUL;;DEAKIN LYNDA ALISON;;WILSON SCOTT E;;HUTCHINSON IAN G;;PRACHAR TIMOTHY J;;WATSON JAMES D;;DUNN MICHAEL H;;WILLIAMS GUY L;;ADLER ARI T;;PATRON TONY P;;SENATORE STEPHEN J;;MACDONALD PETER S;;DESMOND MATTHEW A;;HICKS GRAHAM MACDONALD;;GILMORE DAVID;;WEGENER KATRIN;;RAGAN JEANNE M;;ENDERS THOMAS FRANZ;;BOURN DOUGLAS R;;MACINTOSH ERIC ALLAN;;ZEH MARK A,POLY VISION CORPORATION (2003-09-22),https://lens.org/192-132-678-343-531,Patent Application,yes,99,88,8,8,0,G06F21/84;;G06F21/84,G06F3/033;;G06F21/00;;G09G5/00;;H04N1/00;;H04N1/21,345/764,0,0,,,,DISCONTINUED
749,HU,A2,HU P0400889 A2,080-963-395-251-350,2004-08-30,2004,HU P0400889 A,1999-03-11,US 4225198 A;;US 25071899 A;;US 9905332 W,1998-03-13,"PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUND","A találmány (3) képletű (R)-a-(2,3-dimetoxi-fenil)-1-[2-(4-fluor-fenil)-etil]-4-piperidin-metanol előállítására alkalmas újeljárásokra, az új eljárások közbenső termékeire, azok előállítására,speciális részecskeméretű (R)-a-(2,3-dimetoxi-fenil)-1-[2-(4-fluorfenil)-etil]-4-piperidin-metanol előállítására és az ilyenvegyületet tartalmazó gyógyászati készítményekre vonatkozik. Ó",AVENTIS PHARMA GMBH;;AVENTIS PHARMA INC,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI-HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/080-963-395-251-350,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,DISCONTINUED
750,KR,A,KR 20060002038 A,027-016-594-825-233,2006-01-06,2006,KR 20057024572 A,2005-12-22,US 4225198 A;;US 25071899 A,1998-03-13,"(R)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL, PROCESSES FOR THE PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME","The present invention provides various processes for the preparation of (R)-alpha-(2,3- dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/027-016-594-825-233,Patent Application,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,INACTIVE
751,KR,A,KR 20060002035 A,086-193-755-866-042,2006-01-06,2006,KR 20057024568 A,2005-12-22,US 4225198 A;;US 25071899 A,1998-03-13,"PROCESSES FOR THE PREPARATION OF 4-[1-HYDROXY-1-(2,3-DIMETHOXYPHENYL)METHYL]PIPERIDINE","The present invention provides various processes for the preparation of (R)-alpha-(2,3- dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).",AVENTIS PHARMA INC;;SANOFI AVENTIS DEUTSCHLAND,BINA ALAN G;;DAUGS EDWARD D;;EVANS JONATHAN C;;FLEMMING HANS WOLFRAM;;GUILLAMOT GERARD;;HAWTHORNE ROBERT A;;HILPERT THOMAS H E;;HITT JAMES E;;KING CHI HSIN R;;KOEK JOHANNES N;;LASKOVICS FREDERICK M;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;ORTYL THOMAS T;;RAJEWSKI LIAN G;;SACK MARVIN J;;SKULTETY PAUL F;;STOLZ DUNN SANDRA K;;TIGNER ALONZO L;;TOMLINSON IAN A,,https://lens.org/086-193-755-866-042,Patent Application,no,0,2,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,C07D211/22;;A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,INACTIVE
752,MA,A1,MA 25515 A1,019-701-772-268-587,2002-10-01,2002,MA 25491 A,1999-03-10,US 4225198 A;;US 25071899 A,1998-03-13,"NOUVEAUX PROCEDES POUR LA PREPARATION DE (R)- ALPHA-(2,3-DIMETHOXYPHENYL)-1[2-(4-FLUOROPHENYL) ETRYL]-4-PIPERIDINEMETHANOL",,TIGNER ALONZO L;;HOECHST MARION ROUSSEL DE GMBH,BINA ALAN G;;EVANS JONATHAN C;;FLEMMING HANS-WOLFRAM;;GUILLAMOT GERARD;;HILPERT THOMAS H E;;HITT JAMES E;;KOEK JOHANNES N;;LEFLER JOHN R;;MARGOLIN ALEXEY L;;MINISH SHARON K;;RAJEWSKI LIAN G;;SKULTETY PAUL F;;STOLZ-DUNN SANDRA K;;TOMLINSON IAN A;;DAUGS EDWARD D;;HAWTHORNE ROBERT A;;KING CHI-HSIN R;;LASKOVICS FREDERICK M;;ORTYL THOMAS T;;SACK MARVIN J;;TIGNER ALONZO L;;HOECHST MARION ROUSSEL DEUTSCH,,https://lens.org/019-701-772-268-587,Granted Patent,no,0,0,55,64,0,C07D211/22;;C07D211/32;;A61P1/14;;A61P11/04;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/06;;A61P9/08;;A61P9/10;;C07D211/22;;C07D211/34;;A61K31/445,A61K9/20;;A61K31/4409;;A61K31/445;;A61K47/04;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/14;;A61P7/02;;A61P9/06;;A61P9/08;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/18;;A61P25/22;;C07D211/22;;C07D211/32;;C07D213/00;;C07D213/50,,0,0,,,,EXPIRED
